0000950170-24-09621310-Q Kezar Life Sciences, Inc. 2024081320240813161054161055161055 0 0000950170-24-096213 10-Q 77 20240630 20240813 20240813 Kezar Life Sciences, Inc. 0001645666 2834 473366145 DE 1231 10-Q 34 001-38542 241201533 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 10-Q 1 kzr-20240630.htm 10-Q 10-Q 0001645666Q2false--12-3100016456662024-01-012024-03-3100016456662023-12-310001645666kzr:EverestLicenseAgreementMemberus-gaap:RoyaltyMember2024-01-012024-06-300001645666srt:ChiefExecutiveOfficerMember2024-04-012024-06-300001645666kzr:RestrictedStockUnitsSubjectToFutureVestingMember2024-04-012024-06-300001645666kzr:EverestLicenseAgreementMember2024-01-012024-06-300001645666us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-3000016456662023-04-012023-06-300001645666us-gaap:CommonStockMember2024-01-012024-03-3100016456666us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001645666us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001645666kzr:CowenAndCompanyLimitedLiabilityCompanyMemberkzr:AtTheMarketAgreementMember2024-06-300001645666us-gaap:ComputerEquipmentMember2023-12-310001645666us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666us-gaap:CommonStockMember2024-06-300001645666srt:MinimumMember2024-01-012024-06-300001645666us-gaap:RetainedEarningsMember2024-04-012024-06-300001645666kzr:OxfordFinanceLLCMemberkzr:TrancheOneMemberkzr:LoanAndSecurityAgreementMember2021-11-300001645666us-gaap:ComputerEquipmentMember2024-06-300001645666us-gaap:FairValueMeasurementsRecurringMember2023-12-310001645666us-gaap:EmployeeSeveranceMember2022-12-310001645666kzr:OxfordFinanceLLCMemberkzr:LoanAndSecurityAgreementMember2023-01-012023-06-300001645666us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666kzr:CowenAndCompanyLimitedLiabilityCompanyMemberkzr:AtTheMarketAgreementMember2021-12-012024-06-300001645666us-gaap:AdditionalPaidInCapitalMember2022-12-310001645666us-gaap:CommonStockMember2023-03-310001645666kzr:SouthSanFranciscoCaliforniaMember2022-11-010001645666kzr:TwoThousandFifteenEquityIncentivePlanMember2024-06-300001645666us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001645666us-gaap:AdditionalPaidInCapitalMember2023-12-310001645666us-gaap:FurnitureLaboratoryAndOfficeEquipmentMember2024-06-300001645666srt:MinimumMember2024-04-012024-06-300001645666us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666us-gaap:EmployeeStockOptionMember2024-04-012024-06-300001645666us-gaap:RetainedEarningsMember2023-01-012023-03-310001645666us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001645666kzr:EverestLicenseAgreementMember2023-09-012023-09-300001645666us-gaap:RestrictedStockUnitsRSUMemberkzr:TwoThousandEighteenEquityIncentivePlanMember2024-01-012024-06-300001645666us-gaap:CommonStockMember2024-03-310001645666us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001645666us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001645666kzr:AssetImpairmentMember2023-12-310001645666kzr:OxfordFinanceLLCMemberkzr:LoanAndSecurityAgreementMembersrt:MaximumMember2021-11-012021-11-300001645666us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001645666kzr:OxfordFinanceLLCMemberkzr:LoanAndSecurityAgreementMember2023-04-012023-06-300001645666us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001645666us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001645666us-gaap:DomesticCountryMember2024-01-012024-06-300001645666us-gaap:CommonStockMemberkzr:TwoThousandEighteenEquityIncentivePlanMember2024-06-3000016456662024-08-090001645666us-gaap:CommercialPaperMember2024-06-300001645666us-gaap:RetainedEarningsMember2022-12-310001645666kzr:OxfordFinanceLLCMemberkzr:LoanAndSecurityAgreementMember2021-11-300001645666us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001645666kzr:AssetImpairmentMember2024-06-300001645666us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666us-gaap:EmployeeSeveranceMember2024-04-012024-06-300001645666kzr:EverestLicenseAgreementMember2024-06-300001645666us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666us-gaap:EmployeeSeveranceMember2023-01-012023-12-310001645666kzr:AssetImpairmentMember2023-01-012023-12-310001645666us-gaap:RetainedEarningsMember2024-03-3100016456662023-01-012023-06-300001645666us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001645666us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666kzr:EverestLicenseAgreementMember2023-10-012023-10-310001645666us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001645666us-gaap:AdditionalPaidInCapitalMember2023-03-310001645666us-gaap:RestrictedStockUnitsRSUMemberkzr:TwoThousandEighteenEquityIncentivePlanMember2023-12-310001645666us-gaap:RetainedEarningsMember2023-03-310001645666us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberkzr:OxfordFinanceLLCMember2024-01-012024-06-300001645666kzr:AssetImpairmentMember2024-04-012024-06-3000016456662023-07-242024-06-300001645666us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666us-gaap:CommonStockMember2024-04-012024-06-300001645666us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001645666us-gaap:CommonStockMember2022-12-3100016456662023-06-3000016456662023-03-310001645666srt:MaximumMember2024-01-012024-06-300001645666us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666us-gaap:EmployeeSeveranceMember2024-03-310001645666us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-06-3000016456662023-04-300001645666us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001645666us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001645666us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001645666kzr:CowenAndCompanyLimitedLiabilityCompanyMemberkzr:AtTheMarketAgreementMembersrt:MaximumMember2021-12-012021-12-310001645666us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001645666kzr:EverestLicenseAgreementMemberkzr:DevelopmentRegulatoryAndCommercialMilestonesMember2024-01-012024-06-300001645666us-gaap:CommonStockMemberkzr:TwoThousandEighteenEquityIncentivePlanMember2024-01-012024-06-300001645666kzr:TwoThousandTwentyTwoStockIncentivePlanMember2024-06-300001645666srt:ChiefExecutiveOfficerMember2023-11-072023-11-070001645666us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001645666us-gaap:EmployeeStockOptionMember2023-04-012023-06-300001645666kzr:TwoThousandEighteenPlanMember2023-07-242024-06-300001645666us-gaap:BaseRateMemberkzr:OxfordFinanceLLCMemberkzr:LoanAndSecurityAgreementMemberkzr:EqualToSumOfAMember2021-11-012021-11-300001645666srt:MaximumMember2023-04-012023-06-300001645666us-gaap:AdditionalPaidInCapitalMember2024-03-310001645666us-gaap:LeaseholdImprovementsMember2023-12-310001645666us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001645666us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001645666us-gaap:EmployeeSeveranceMember2024-01-012024-03-310001645666us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001645666us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001645666us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001645666srt:MinimumMember2023-01-012023-06-300001645666us-gaap:LeaseholdImprovementsMember2024-06-300001645666us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-3000016456662024-04-012024-06-300001645666us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666kzr:OxfordFinanceLLCMemberkzr:EqualToSumOfBMemberkzr:LoanAndSecurityAgreementMember2021-11-012021-11-300001645666us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001645666kzr:EverestLicenseAgreementMember2023-10-310001645666us-gaap:CommercialPaperMember2023-12-310001645666kzr:RestrictedStockUnitsSubjectToFutureVestingMember2024-01-012024-06-3000016456662023-01-012023-03-310001645666us-gaap:RetainedEarningsMember2024-01-012024-03-3100016456662024-01-012024-06-300001645666kzr:AssetImpairmentMember2024-03-310001645666kzr:TwoThousandEighteenPlanMember2023-07-240001645666us-gaap:RetainedEarningsMember2023-04-012023-06-300001645666kzr:FurnitureLaboratoryAndOfficeEquipmentMember2023-12-310001645666us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666kzr:UnderwrittenPublicOfferingMember2022-12-310001645666us-gaap:EmployeeSeveranceMember2023-12-310001645666us-gaap:CorporateDebtSecuritiesMember2024-06-300001645666us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001645666us-gaap:CommonStockMember2023-04-012023-06-300001645666us-gaap:CommonStockMemberkzr:TwoThousandEighteenEmployeeStockPurchasePlanMember2024-01-012024-06-300001645666us-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666kzr:AssetImpairmentMember2024-01-012024-03-310001645666us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666us-gaap:CommonStockMemberkzr:TwoThousandEighteenEmployeeStockPurchasePlanMember2024-06-300001645666us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001645666us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001645666kzr:RestrictedStockUnitsSubjectToFutureVestingMember2023-04-012023-06-300001645666kzr:OxfordFinanceLLCMemberkzr:LoanAndSecurityAgreementMember2021-11-012021-11-300001645666srt:MaximumMemberkzr:TwoThousandFifteenEquityIncentivePlanMember2024-01-012024-06-300001645666kzr:RestrictedStockUnitsSubjectToFutureVestingMember2023-01-012023-06-300001645666srt:MaximumMember2023-01-012023-06-300001645666us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001645666us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001645666us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666kzr:AtTheMarketAgreementMember2024-01-012024-06-300001645666kzr:TwoThousandEighteenEquityIncentivePlanMember2024-06-300001645666kzr:TwoThousandEighteenPlanMember2023-07-242023-07-240001645666us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001645666kzr:AssetImpairmentMember2022-12-310001645666us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666us-gaap:CommonStockMemberkzr:TwoThousandEighteenEmployeeStockPurchasePlanMember2018-06-300001645666us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666kzr:EverestLicenseAgreementMemberkzr:CollaborationRevenueMember2023-07-012023-09-300001645666us-gaap:EmployeeSeveranceMember2024-06-300001645666kzr:TwoThousandFifteenEquityIncentivePlanMember2024-01-012024-06-300001645666srt:MinimumMember2023-04-012023-06-300001645666us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001645666kzr:OxfordFinanceLLCMembersrt:MinimumMemberkzr:LoanAndSecurityAgreementMember2021-11-012021-11-3000016456662023-01-012023-12-310001645666us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001645666us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666us-gaap:CommonStockMember2023-01-012023-03-310001645666us-gaap:EmployeeStockOptionMember2024-06-300001645666us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001645666us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001645666us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001645666us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001645666kzr:AtTheMarketAgreementMemberkzr:CowenAndCompanyLimitedLiabilityCompanyMember2021-12-012021-12-3100016456662024-03-310001645666us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666us-gaap:RetainedEarningsMember2024-06-300001645666us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001645666us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001645666us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001645666us-gaap:USTreasurySecuritiesMember2024-06-300001645666us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300001645666srt:MaximumMember2024-04-012024-06-300001645666us-gaap:ForeignCountryMember2024-01-012024-06-300001645666us-gaap:CommonStockMemberkzr:TwoThousandEighteenEmployeeStockPurchasePlanMember2024-01-010001645666kzr:OxfordFinanceLLCMemberkzr:LoanAndSecurityAgreementMember2024-04-012024-06-300001645666kzr:TwoThousandEighteenEquityIncentivePlanMember2024-01-012024-06-300001645666us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001645666us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001645666kzr:SouthSanFranciscoCaliforniaMember2024-01-012024-06-3000016456662022-12-310001645666kzr:EmployeeStockPurchasePlanMember2024-01-012024-06-300001645666us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001645666kzr:EverestLicenseAgreementMember2024-04-012024-06-300001645666kzr:OxfordFinanceLLCMemberkzr:LoanAndSecurityAgreementMember2024-01-012024-06-300001645666srt:ChiefExecutiveOfficerMember2024-01-012024-06-300001645666us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001645666us-gaap:AdditionalPaidInCapitalMember2023-06-300001645666us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001645666us-gaap:CommonStockMemberkzr:TwoThousandEighteenEmployeeStockPurchasePlanMembersrt:MaximumMember2024-01-012024-06-300001645666us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001645666us-gaap:RestrictedStockUnitsRSUMemberkzr:TwoThousandEighteenEquityIncentivePlanMember2024-06-300001645666us-gaap:CommonStockMembersrt:MaximumMemberkzr:TwoThousandEighteenEquityIncentivePlanMemberkzr:IncentiveStockOptionsMember2024-06-300001645666us-gaap:AdditionalPaidInCapitalMember2024-06-300001645666kzr:TwoThousandEighteenEquityIncentivePlanMember2024-04-012024-06-300001645666us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001645666us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001645666us-gaap:CommonStockMember2023-12-310001645666us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-3000016456662024-06-300001645666us-gaap:RetainedEarningsMember2023-06-300001645666us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-

310001645666us-gaap:CommonStockMembersrt:MaximumMemberkzr:TwoThousandEighteenEquityIncentivePlanMember2024-06-300001645666us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001645666us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001645666us-gaap:RetainedEarningsMember2023-12-310001645666us-gaap:USTreasurySecuritiesMember2023-12-310001645666us-gaap:CommonStockMember2023-06-30xbrli:pureiso4217:USDxbrli:sharesxbrli:shareskzr:Tranchekzr:Segmentiso4217:USD Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Â FORM 10-Q Â (Mark One) â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38542 Â Kezar Life Sciences, Inc. (Exact Name of Registrant as Specified in its Charter) Â Â Delaware 47-3366145 (State or other jurisdiction ofincorporation or organization) (I.R.S. EmployerIdentification No.) 4000 Shoreline Court, Suite 300 South San Francisco, CA, 94080 (650) 822-5600 (Address, including zip code, and telephone number, including area code, of registrantâ€™s principal executive offices) Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Trading symbol Name of each exchange on which registered Common Stock, $0.001 par value KZR The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜ Accelerated filer â˜ Non-accelerated filer â˜’ Smaller reporting company â˜’ Emerging growth company Â â˜ Â Â Â Â Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ As of August 9, 2024, the registrant had 72,962,220 shares of common stock, $0.001 par value per share, outstanding. Â Â Â Â Table of Contents Â Page PART I. FINANCIAL INFORMATION Item 1. Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations 2 Condensed Consolidated Statements of Comprehensive Loss 3 Â Condensed Consolidated Statement of Stockholdersâ€™ Equity 4 Condensed Consolidated Statements of Cash Flows 5 Notes to Unaudited Condensed Consolidated Financial Statements 6 Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3. Quantitative and Qualitative Disclosures About Market Risk 27 Item 4. Controls and Procedures 27 PART II. OTHER INFORMATION Item 1. Legal Proceedings 28 Item 1A. Risk Factors 28 Item 6. Exhibits 67 Â Â Â Â Â i Â SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the â€œSecurities Actâ€), and Section 21E of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), that involve substantial risks and uncertainties. In some cases, you can identify these statements by forward-looking words such as â€œbelieve,â€ â€œmay,â€ â€œwill,â€ â€œestimate,â€ â€œcontinue,â€ â€œanticipate,â€ â€œintend,â€ â€œcould,â€ â€œshould,â€ â€œwould,â€ â€œpotential,â€ â€œproject,â€ â€œplan,â€ â€œexpect,â€ â€œseek,â€ â€œtargetâ€ or similar expressions, or the negative or plural of these words or expressions. These forward-looking statements include statements concerning the following: Â â€¢our plans to develop and commercialize our product candidates; â€¢the initiation, timing, progress and expected results of our current and future clinical trials and our research and development programs; â€¢our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; â€¢our ability to maintain and establish collaborations or strategic relationships or obtain additional funding; â€¢the timing and likelihood of obtaining regulatory approval of our current and future product candidates; â€¢the potential milestone and royalty payments under certain of our license agreements; â€¢our expectations regarding the potential market size and the rate and degree of market acceptance of such product candidates; â€¢our ability to fund our working capital requirements and expectations regarding the sufficiency of our capital resources; â€¢the implementation of our business model and strategic plans for our business and product candidates; â€¢the scope of protection we are able to establish and maintain for intellectual property rights and the duration of our patent rights covering our product candidates; â€¢developments or disputes concerning our intellectual property or other proprietary rights; â€¢the scalability and commercial viability of our manufacturing methods and processes; â€¢our expectations regarding government and third-party payor coverage and reimbursement; â€¢our ability to compete in the markets for our product candidates; â€¢general economic, political, and market conditions and overall fluctuations in the financial markets in the United States and abroad, including as a result of bank failures, public health crisis or geopolitical tensions; â€¢the impact of government laws and regulations; â€¢developments relating to our competitors and our industry; and â€¢other factors that may impact our financial results. These statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industryâ€™s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in greater detail under the heading â€œRisk Factorsâ€ and elsewhere in this report. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we are under no duty to update or revise any of the forward-looking statements in this report, whether as a result of new information, future events or otherwise, after the date of this report. Unless the context otherwise requires, the terms â€œKezar,â€ â€œKezar Life Sciences,â€ â€œthe Company,â€ â€œwe,â€ â€œus,â€ â€œourâ€ and similar references in this Quarterly Report on Form 10-Q refer to Kezar Life Sciences, Inc. and our wholly owned Australian subsidiary, Kezar Life Sciences Australia Pty Ltd. Â Â Â Â ii Â PART Iâ”FINANCIAL INFORMATION Item 1. Financial Statements. KEZAR LIFE SCIENCES, INC. Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) Â Â June 30, 2024 Â Â December 31, 2023 Â Â Â (Unaudited) Â Â Â Â Assets Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Cash and cash equivalents Â $ 28,276 Â Â $ 35,493 Â Marketable securities Â Â 135,906 Â Â Â 165,879 Â Prepaid expenses and other current assets Â Â 3,435 Â Â Â 5,578 Â Total current assets Â Â 167,617 Â Â Â 206,950 Â Property and equipment, net Â Â 3,391 Â Â Â 3,912 Â Operating lease right-of-use asset Â Â 2,391 Â Â Â 4,778 Â Other assets Â Â 6,522 Â Â Â 5,595 Â Total assets Â $ 179,921 Â Â $ 221,235 Â Liabilities and Stockholders' Equity Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Accounts payable Â $ 2,263 Â Â $ 8,251 Â Accrued and other current liabilities Â Â 9,363 Â Â Â 6,481 Â Operating lease liabilities, current Â Â 3,260 Â Â Â 3,012 Â Debt, current Â Â 2,609 Â Â Â â€” Â Total current liabilities Â Â 17,495 Â Â Â 17,744 Â Operating lease liabilities, noncurrent Â Â 4,152 Â Â Â 5,852 Â Debt, noncurrent Â Â 7,589 Â Â Â 10,069 Â Total liabilities Â Â 29,236 Â Â Â 33,665 Â Stockholders' equity: Â Â Â Â Â Â Common stock, $0.001Â par value, 250,000,000Â and 250,000,000Â shares Â Â authorized as of June 30, 2024 (unaudited) and December 31, 2023, respectively; Â Â 72,887,538Â and 72,779,077Â shares issued and outstanding as of Â Â June 30, 2024 (unaudited) and December 31, 2023, respectively Â Â 73 Â Â Â 73 Â Preferred stock, $0.001Â par value, 10,000,000Â shares authorized; zeroÂ shares issuedÂ Â Â and outstanding as of June 30, 2024 (unaudited) and December 31, 2023 Â Â â€” Â Â Â â€” Â Additional paid-in capital Â Â 544,965 Â Â Â 538,390 Â Accumulated other comprehensive loss Â Â (385) Â Â (130) Accumulated deficit Â Â (393,968) Â Â (350,763) Total stockholders' equity Â Â 150,685 Â Â Â 187,570 Â Total liabilities and stockholders' equity Â $ 179,921 Â Â $ 221,235 Â Â See accompanying notes to the unaudited condensed consolidated financial statements Â Â 1 Â KEZAR LIFE SCIENCES, INC. Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except share and per share amounts) Â Â Three Months Ended Â Â Six Months Ended Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â $ 16,298 Â Â $ 20,999 Â Â $ 33,470 Â Â $ 39,317 Â General and administrative Â Â 5,603 Â Â Â 5,785 Â Â Â 12,142 Â Â Â 11,991 Â Restructuring and impairment charges Â Â 1,482 Â Â Â â€” Â Â Â 1,482 Â Â Â â€” Â Total operating expenses Â Â 23,383 Â Â Â 26,784 Â Â Â 47,094 Â Â Â 51,308 Â Loss from operations Â Â (23,383) Â Â (26,784) Â Â (47,094) Â Â (51,308) Interest income Â Â 2,237 Â Â Â 2,861 Â Â Â 4,690 Â Â Â 5,556 Â Interest expense Â Â (401) Â Â (385) Â Â (801) Â Â (755) Net loss Â $ (21,547) Â $ (24,308) Â $ (43,205) Â $ (46,507) Net loss per common share, basic and diluted Â $ (0.30) Â $ (0.34) Â $ (0.59) Â $ (0.64) Weighted-average shares used to compute net loss per commonÂ Â Â share, basic and diluted Â Â 72,845,869 Â Â Â 72,461,850 Â Â Â 72,822,890 Â Â Â 72,395,410 Â Â See accompanying notes to the unaudited condensed consolidated financial statements Â 2 Â KEZAR LIFE SCIENCES, INC. Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (In thousands) Â Â Three Months Ended Â Â Six Months Ended Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net loss Â $ (21,547) Â $ (24,308) Â $ (43,205) Â $ (46,507) Other comprehensive income (loss): Â Â Â Â Â Â Â Â Â Â Â Â Foreign currency translation adjustments Â Â 14 Â Â Â (5) Â Â (15) Â Â (17) Unrealized (loss) gain on marketable securities Â Â (44) Â Â (302) Â Â (240) Â Â 110 Â Total other comprehensive (loss) income, net of tax Â Â (30) Â Â (307) Â Â (255) Â Â 93 Â Comprehensive loss Â $ (21,577) Â $ (24,615) Â $ (43,460) Â $ (46,414) Â See accompanying notes to the unaudited condensed consolidated financial statements Â 3 Â KEZAR LIFE SCIENCES, INC. Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (In thousands, except share amounts) Â Â Â COMMON STOCK Â Â ADDITIONALPAID-IN Â Â ACCUMULATEDOTHERCOMPREHENSIVE Â Â ACCUMULATED Â Â TOTALSTOCKHOLDERS' Â Â Â SHARES Â Â AMOUNTS Â Â CAPITAL Â Â LOSS Â Â DEFICIT Â Â EQUITY Â Balance at December 31, 2023 Â Â 72,779,077 Â Â $ 73 Â Â $ 538,390 Â Â $ (130) Â $ (350,763) Â $ 187,570 Â Issuance of common stock under employee stock incentive plans Â Â 22,282 Â Â Â Â Â â€” Â Â Â Â Â â€” Â Â Â Â Â â€” Â Â Â Â Â â€” Â Stock-based compensation expense Â Â â€” Â Â Â Â Â â€” Â Â Â 3,434 Â Â Â Â Â â€” Â Â Â â€” Â Â Â 3,434 Â Other comprehensive loss Â Â â€” Â Â Â Â Â â€” Â Â Â â€” Â Â Â (225) Â Â Â â€” Â Â Â (225) Net loss Â Â â€” Â Â Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (21,658) Â Â (21,658) Balance as of March 31, 2024 Â Â 72,801,359 Â Â $ 73 Â Â $ 541,824 Â Â $ (355) Â $ (372,421) Â $ 169,121 Â Issuance of common stock under employee stock incentive plans Â Â 86,179 Â Â Â Â Â â€” Â Â Â Â Â â€” Â Â Â Â Â â€” Â Â Â Â Â â€” Â Stock-based compensation expense Â Â â€” Â Â Â Â Â â€” Â Â Â 3,085 Â Â Â Â Â â€” Â Â Â â€” Â Â Â 3,085 Â Other comprehensive loss Â Â â€” Â Â Â Â Â â€” Â Â Â â€” Â Â Â (30) Â Â Â â€” Â Â Â (30) Net loss Â Â â€” Â Â Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (21,547) Â Â (21,547) Balance as of June 30, 2024 Â Â 72,887,538 Â Â $ 73 Â Â $ 544,965 Â Â $ (385) Â $ (393,968) Â $ 150,685 Â Â Â Â Â Â Â Â Â Â Â Â

Life Sciences Australia Pty Ltd., which is a proprietary company limited by shares. All intercompany balances and transactions have been eliminated upon consolidation.The condensed consolidated balance sheet as of December 31, 2023 has been derived from the audited consolidated financial statements at that date but does not include all information and footnotes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements included in the Annual Report.Unaudited Condensed Consolidated Financial StatementsThe accompanying financial information as of June 30, 2024 is unaudited. The interim condensed consolidated financial statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that our management considers Â 6 Â necessary for the fair statement of the results of operations for the interim periods covered and of our financial condition at the date of the interim balance sheet. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report.Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such judgments, estimates and assumptions include the valuation of marketable securities, impairment of long-lived assets, determining the fair-value of stock-based compensation, and evaluating the progress to completion of external research and development costs. Management bases its estimates on historical experience and on various other market-specific relevant assumptions that management believes to be reasonable under the circumstances. Actual results may differ from those estimates.Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its judgments, estimates and assumptions or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Companyâ€™s condensed consolidated financial statements.Recently Issued Accounting PronouncementsIn December 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update No. 2023-09 Income Taxes (Topic 740) â€“ Improvements to Income Tax Disclosures (â€œASU 2023-09â€), which requires entities to disclose specific categories in the income tax rate reconciliation annually and provide additional information for reconciling items that meet a qualitative threshold. ASU 2023-09 also requires that entities disclose annually additional information about income taxes paid and disaggregated information for certain items. ASU 2023-09 is effective for the Company beginning on January 1, 2025. The Company is currently evaluating the impact of the adoption of ASU 2023-09 on its financial position, results of operations and cash flows. In November 2023, the FASB issued Accounting Standards Update No. 2023-07 Segment Reporting (Topic 280) â€“ Improvements to Reportable Segment Disclosures (â€œASU 2023-07â€), which requires entities to disclose incremental segment information on an annual and interim basis. ASU 2023-07 requires entities with a single reportable segment to provide all the disclosures required by the amendments in ASU 2023-07 and all existing segment disclosures in Segment Reporting (Topic 280). ASU 2023-07 is effective for the Company beginning with the Form 10-K for the year ending December 31, 2024. The Company is currently evaluating the effect of adopting the update on its related disclosures. There have been no other recent accounting pronouncements, changes in accounting pronouncements or recently adopted accounting guidance that are expected to have a material impact on the Companyâ€™s condensed consolidated financial statements upon adoption. 3. Fair Value MeasurementsFinancial assets and liabilities are recorded at fair value. The carrying amount of certain financial instruments, including cash equivalents, other current assets, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. Assets and liabilities recorded at fair value on a recurring basis in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:Level 1: Quoted prices in active markets for identical assets or liabilities.Â 7 Â Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Companyâ€™s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are required to be recognized or disclosed at fair value in the financial statements. The Company determines the fair value of Level 1 assets using quoted prices in active markets for identical assets. The Company reviews trading activity and pricing for Level 2 investments as of each measurement date. Level 2 inputs, which are obtained from various third-party data providers, represent quoted prices for similar assets in active markets and were derived from observable market data, or, if not directly observable, were derived from or corroborated by other observable market data.In certain cases, where there is limited activity or less transparency around inputs to valuation, securities are classified as Level 3 within the valuation hierarchy. The Company did not have any financial assets or liabilities measured using Level 3 inputs as of June 30, 2024 or December 31, 2023.The following table summarizes the Companyâ€™s financial assets measured at fair value on a recurring basis and classified under the appropriate level of the fair value hierarchy as described above (in thousands):Â Â Â June 30, 2024Â Â Â Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Financial Assets: Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury money market funds Â $ 28,158 Â Â $ 28,158 Â Â $ â€” Â Â $ â€” Â Marketable securities: Â Â Â Â Â Â Â Â Â Â Â Â Certificate of deposit Â Â 533 Â Â Â â€” Â Â Â 533 Â Â Â â€” Â U.S. Treasury securities Â Â 51,889 Â Â Â 51,889 Â Â Â â€” Â Â Â â€” Â Commercial paper Â Â 65,494 Â Â Â â€” Â Â Â 65,494 Â Â Â â€” Â Corporate debt securities Â Â 10,990 Â Â Â â€” Â Â Â 10,990 Â Â Â â€” Â U.S. government agency bonds Â Â 7,000 Â Â Â â€” Â Â Â 7,000 Â Â Â â€” Â Total Â $ 164,064 Â Â $ 80,047 Â Â $ 84,017 Â Â $ â€” Â Â Â Â December 31, 2023Â Â Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Financial Assets: Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury money market funds Â $ 35,349 Â Â $ 35,349 Â Â $ â€” Â Â $ â€” Â Marketable securities: Â Â Â Â Â Â Â Â Â Â Â Â Certificate of deposit Â Â 544 Â Â Â â€” Â Â Â 544 Â Â Â â€” Â U.S. Treasury securities Â Â 54,175 Â Â Â 54,175 Â Â Â â€” Â Â Â â€” Â Commercial paper Â Â 65,070 Â Â Â â€” Â Â Â 65,070 Â Â Â â€” Â U.S. government agency bonds Â Â 46,090 Â Â Â â€” Â Â Â 46,090 Â Â Â â€” Â Total Â $ 201,228 Â Â $ 89,524 Â Â $ 111,704 Â Â $ â€” Â Â Nonrecurring Fair Value Measurements The right-of-use (â€œROUâ€) asset associated with Suite 400 of the Company's headquarters in South San Francisco, California, is a separate asset group measured at fair value on a nonrecurring basis as of December 31, 2023 due to an impairment recognized on the ROU asset at that date (see Note 6). The fair value of this asset group calculated as the present value of the estimated future cash flows of sublease income attributable to the ROU asset associated with Suite 400, was classified in Level 3 of the fair value hierarchy. When calculating the present value of the estimated future cash flows, sublease income was estimated to increase at a rate of 3.5% per year, and the cash flows were discounted using a rate of 13.3%. In June 2024, the Company recognized an additional $1.5 million Â 8 Â impairment charge in relation to Suite 400 to write off the net book value of the ROU asset as of June 30, 2024 as the estimated future cash flow from sublease income is zero due to current market conditions. 4. Available-for-Sale SecuritiesThe following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in the Companyâ€™s condensed consolidated balance sheets (in thousands):Â Â Â June 30, 2024Â Â Â Â AmortizedCost Â Â UnrealizedGains Â Â UnrealizedLosses Â Â FairValue Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury money market funds Â $ 28,158 Â Â $ â€” Â Â $ â€” Â Â $ 28,158 Â Marketable securities: Â Â Â Â Â Â Â Â Â Â Â Â Certificate of deposit Â Â 533 Â Â Â â€” Â Â Â â€” Â Â Â 533 Â U.S. Treasury securities Â Â 51,926 Â Â Â â€” Â Â Â (37) Â Â 51,889 Â Commercial paper Â Â 65,572 Â Â Â 3 Â Â Â (81) Â Â 65,494 Â Corporate debt securities Â Â 10,994 Â Â Â 1 Â Â Â (5) Â Â 10,990 Â U.S. government agency bonds Â Â 7,005 Â Â Â â€” Â Â Â (5) Â Â 7,000 Â Total Â $ 164,188 Â Â $ 4 Â Â $ (128) Â $ 164,064 Â Cash Â Â Â Â Â Â Â Â Â Â 118 Â Total cash, cash equivalent and marketable securities Â Â Â Â Â Â Â Â Â Â $ 164,182 Â Â Â Â December 31, 2023 Â Â Â AmortizedCost Â Â UnrealizedGains Â Â UnrealizedLosses Â Â FairValue Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury money market funds Â $ 35,349 Â Â $ â€” Â Â $ â€” Â Â $ 35,349 Â Marketable securities: Â Â Â Â Â Â Â Â Â Â Â Â Certificate of deposit Â Â 544 Â Â Â â€” Â Â Â â€” Â Â Â 544 Â U.S. Treasury securities Â Â 54,066 Â Â Â 151 Â Â Â (42) Â Â 54,175 Â Commercial paper Â Â 65,038 Â Â Â 41 Â Â Â (9) Â Â 65,070 Â U.S. government agency bonds Â Â 46,115 Â Â Â 27 Â Â Â (52) Â Â 46,090 Â Total Â $ 201,112 Â Â $ 219 Â Â $ (103) Â $ 201,228 Â Cash Â Â Â Â Â Â Â Â Â Â 144 Â Total cash, cash equivalent and marketable securities Â Â Â Â Â Â Â Â Â Â $ 201,372 Â The Company has not recognized an allowance for credit losses on any securities in an unrealized loss position as of June 30, 2024 and December 31, 2023. The following tables display additional information regarding gross unrealized losses and fair value by major security type for available-for-sale securities in an unrealized loss position as of June 30, 2024 and December 31, 2023 (in thousands): Â Â June 30, 2024Â Â Â Less than 12 consecutive months Â Â Â Fair Value Â Â Unrealized Losses Â U.S. Treasury securities Â $ 48,463 Â Â $ (37) Commercial paper Â Â 47,574 Â Â Â (81) Corporate debt securities Â Â 7,814 Â Â Â (5) U.S. government agency bonds Â Â 7,000 Â Â Â (5) Total Â $ 110,851 Â Â $ (128) Â Â Â December 31, 2023Â Â Â Less than 12 consecutive months Â Â Â Fair Value Â Â Unrealized Losses Â U.S. Treasury securities Â $ 16,261 Â Â $ (42) Commercial paper Â Â 20,789 Â Â Â (9) U.S. government agency bonds Â Â 39,052 Â Â Â (52) Total Â $ 76,102 Â Â $ (103) Â Â 9 Â The Company believes that the individual unrealized losses represent temporary declines primarily resulting from interest rate changes and intends to hold these marketable securities to their maturities. The Company currently does not intend to sell these securities prior to maturity, and it is not more likely than not that the Company will be required to sell these securities before recovery of their amortized cost basis, which may be at maturity. The Company evaluated securities with unrealized losses to determine whether such losses, if any, were due to credit-related factors and determined that there were no credit-related losses to be recognized as of June 30, 2024. There were no sales of available-for-sale securities in any of the periods presented.As of June 30, 2024, the amortized cost and estimated fair value of the Companyâ€™s available-for-sale securities by contractual maturity are shown below (in thousands): Â Â Amortized Â Â Estimated Â Available-for-sale securities maturing in: Â Cost Â Â Fair Value Â One year or less Â $ 164,188 Â Â $ 164,064 Â Total available-for-sale securities Â $ 164,188 Â Â $ 164,064 Â Â 5. Balance Sheet Components Prepaid Expenses and Other Current AssetsPrepaid expenses and other current assets consisted of the following (in thousands): Â Â June 30,2024 Â Â December 31,2023 Â Receivable from Everest, current (Note 10) Â $ 1,312 Â Â $ 1,596 Â Advance for clinical-related costs, current Â Â 773 Â Â Â 1,818 Â Licenses, dues and subscriptions Â Â 662 Â Â Â 506 Â Insurance Â Â 104 Â Â Â 712 Â Interest receivable Â Â 374 Â Â Â 695 Â Others Â Â 210 Â Â Â 251 Â Total prepaid expenses and other current assets Â $ 3,435 Â Â $ 5,578 Â Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): Â Â June 30,2024 Â Â December 31,2023 Â Leasehold improvements Â $ 3,488 Â Â $ 3,488 Â Furniture, laboratory and office equipment Â Â 5,559 Â Â Â 5,559 Â Computer equipment Â Â 285 Â Â Â 285 Â Total property and equipment Â Â 9,332 Â Â Â 9,332 Â Less: accumulated depreciation and amortization Â Â (5,941) Â Â (5,420) Property and equipment, net Â $ 3,391 Â Â $ 3,912 Â Depreciation expense was $0.3 million and $0.5 million for each of the three and six months ended June 30, 2024, respectively, compared to $0.2 million and $0.5 million for the three and six months ended June 30, 2023, respectively.Other AssetsOther assets consisted of the following (in thousands): Â Â June 30,2024 Â Â December 31,2023 Â Advance for clinical related costs, noncurrent Â $ 4,670 Â Â $ 4,787 Â Unbilled receivable from Everest, noncurrent (Note 10) Â Â 1,099 Â Â Â â€” Â Deposits for operating lease Â Â 674 Â Â Â 674 Â Other Â Â 79 Â Â Â 134 Â Total other assets Â $ 6,522 Â Â $ 5,595 Â Â Â 10 Â Accrued and Other Current Liabilities Accrued liabilities consisted of the following (in thousands): Â Â June 30,2024 Â Â December 31,2023 Â Accrued clinical costs Â $ 5,909 Â Â $ 1,801 Â Accrued employee-related costs Â Â 1,802 Â Â Â 3,708 Â Accrued preclinical and research costs Â Â 1,532 Â Â Â 756 Â Accrued professional services Â Â 55 Â Â Â 110 Â Others Â Â 65 Â Â Â 106 Â Total accrued liabilities Â $ 9,363 Â Â $ 6,481 Â Â 6. LeaseIn November 2022, the Company entered into an amendment to the lease agreement for its corporate headquarters in South San Francisco, California, which expanded the leased premises in the same building as its corporate headquarters and extended the lease term of the original premises to be coterminous with the expansion premises to July 31, 2026. The transaction was treated as a lease modification as of the effective date and resulted in the recognition of approximately $8.0 million in new lease liabilities and ROU assets. In December 2023, the Company committed to a plan to sublease Suite 400 of its corporate headquarters in connection with a workforce reduction (see Note 14) and evaluated the recoverability of ROU asset by comparing the carrying amount of the asset to future net undiscounted cash flows associated with the asset. The ROU asset is considered to be impaired if the carrying amount of the assets exceeds the fair value of the assets. Consequently, the Company recognized a $2.7 million impairment charge in 2023. In June 2024, the Company recognized an additional $1.5 million impairment charge in relation to Suite 400 to write off the net book value of the ROU asset as of June 30, 2024 as the estimated future cash flow from sublease income is zero due to current market conditions.Information related to the Companyâ€™s lease liabilities were as follows (in thousands): Â Â Three months ended June 30, 2024Â Â Â Six months ended June 30, 2024Â Â Cash paid for operating lease liabilities Â $ 741 Â Â Â $ 1,452 Â Â Operating lease costs Â Â 655 Â Â Â 1,322 Â Â Variable lease costs Â Â 467 Â Â Â 916 Â Â Â Â Â Â Â Â Maturities of lease liabilities as of June 30, 2024 were as follows: Â Â Â Â Â Â Â Â Less than 12 months Â Â Â Â $ 3,957 Â 13 - 24 months Â Â Â Â Â Â 4,095 Â 25 - 36 months Â Â Â Â Â Â 347 Â Total undiscounted lease payments Â Â Â Â Â Â 8,399 Â Less: imputed interest Â Â Â Â Â Â (987) Total lease liabilities Â Â Â Â Â $ 7,412 Â Â Â Â Â Â Â Â Â Operating lease liabilities, current Â Â Â Â Â $ 3,260 Â Operating lease liabilities, noncurrent Â Â Â Â Â Â 4,152 Â Total operating lease liabilities Â Â Â Â Â $ 7,412 Â Â 7. DebtIn November 2021, the Company entered into a loan agreement (the â€œLoan Agreementâ€) with Oxford Finance, LLC (â€œOxford Financeâ€), which provided the Company up to $50.0 million in borrowing capacity across five potential tranches (each a â€œTerm Loan,â€ and collectively â€œTerm Loansâ€). The initial tranche of $10.0 million was funded at the closing of the Loan Agreement. The remaining tranches were dependent on achieving certain clinical trial milestones, and the Company declined these remaining tranches in borrowing capacity available to it under the Loan Agreement. The loan facility is secured by all assets except intellectual property, which is subject to a negative pledge, and will mature on November 1, 2026 (the â€œMaturity Dateâ€). There are no warrants or financial covenants associated with the Loan Agreement.Until June 30, 2023, the Term Loans bore interest at a floating per annum rate (based on the actual number of days elapsed divided by a year of 360 days) equal to the sum of (a) the greater of (i) 30-day U.S. LIBOR rate reported in the Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue and (ii) 0.08%, plus (b) 7.87%. A Â 11 Â LIBOR transition event occurred effective July 1, 2023 and Oxford Finance subsequently replaced the LIBOR rate with the 1-month CME term SOFR plus 0.1%. The rate change did not require contract remeasurement at the effective date of the change or a reassessment of any previous accounting determinations pertaining to the facility. The rate change did not have a material impact on the Companyâ€™s financial statements. The Company is required to make monthly interest-only payments prior to the amortization date of January 1, 2025, subject to a potential one-year extension upon satisfaction of certain conditions. All unpaid principal and accrued and unpaid interest with respect to each Term Loan is due and payable in full on the Maturity Date. The Company has the option to prepay the outstanding balance prior to maturity, subject to a prepayment fee of 1.0% to 2.0% depending upon when the prepayment occurs. Upon repayment of the Term Loans, the Company is required to make a final payment fee to the lenders equal to 6.5% of the original principal amount of the Term Loans funded which will be accrued by charges to interest expense over the term of the loans using the effective interest method.The Loan Agreement also includes subjective acceleration clauses that permit the lenders to accelerate the Maturity Date under certain circumstances, including, but not limited to, material adverse effects on a Companyâ€™s financial status or otherwise. As of June 30, 2024, the Company is in compliance with all covenants in the Loan Agreement.Interest expense was $0.4 million and $0.8 million for the three and six months ended June 30, 2024, respectively, compared to $0.4 million and $0.8 million for the three and six months ended June 30, 2023, respectively. The initial effective interest rate on the Term Loans, including the amortization of the debt discount and issuance costs, and accretion of the final payment, was 11%. The components of the long-term debt balance are as follows: Â Â June 30,2024 Â Â December 31,2023 Â Principal loan balance Â $ 10,000 Â Â $ 10,000 Â Unamortized debt discount and issuance costs Â Â (189) Â Â (243) Cumulative accretion of final fee Â Â 387 Â Â Â 312 Â Â Â $ 10,198 Â Â $ 10,069 Â Â Â Â Â Â Â Â

Debt, current Â $ 2,609 Â Â $ â€” Â Debt, noncurrent Â Â 7,589 Â Â Â 10,069 Â Debt, net Â $ 10,198 Â Â $ 10,069 Â As of June 30, 2024, the estimated future principal payments due were as follows: Years Ending December 31, Â Â Â 2024 Â $ â€” Â 2025 Â Â 5,217 Â 2026 Â Â 4,783 Â Total Â $ 10,000 Â Â 8. Pre-Funded WarrantsIn connection with the Companyâ€™s previous underwritten public offerings, the Company issued pre-funded warrants to purchase an aggregate of 3,793,706 shares of the Companyâ€™s common stock. Each pre-funded warrant entitled the holder to purchase shares of common stock at an exercise price of $0.001 per share and expired 20 years from the date of issuance. These warrants were recorded as a component of stockholdersâ€™ equity within additional paid-in capital. The warrant holders exercised all the shares of outstanding pre-funded warrants in 2023 at an exercise price of $0.001 per share. As of June 30, 2024, there were no pre-funded warrants outstanding. 9. Stock-Based CompensationStock Incentive Plans2022 Inducement PlanIn April 2022, the Company adopted the Kezar Life Sciences, Inc. 2022 Inducement Plan (the â€œInducement Planâ€), which is a non-stockholder approved stock plan adopted pursuant to the â€œinducement exceptionâ€ provided under Nasdaq Listing Rule 5635(c)(4), for the award of nonstatutory stock options (â€œNSOsâ€), restricted stock units (â€œRSUsâ€) and other equity awards as permitted by the Inducement Plan (collectively, â€œInducement Awardsâ€) to persons not previously an employee or director of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company (â€œEligible Recipientsâ€). Under the Inducement Plan, the Company may grant up to 3,000,000 shares of Common Stock in Â 12 Â the form of Inducement Awards to Eligible Recipients in compliance with the requirements of Nasdaq Listing Rule 5635(c)(4). Awards must be approved by either a majority of the Companyâ€™s independent directors or the Companyâ€™s independent compensation committee. Consultants and directors are not eligible to received grants under the Inducement Plan. As of June 30, 2024, options to purchase 1,247,708 shares of common stock were outstanding and 1,752,292 shares were available for future issuance under the Inducement Plan.2018 Equity Incentive PlanIn June 2018, the Companyâ€™s board of directors adopted and the stockholders approved the 2018 Equity Incentive Plan (the â€œ2018 Planâ€), which became effective as of June 20, 2018, at which point no further grants could be made under the 2015 Equity Incentive Plan (the â€œ2015 Planâ€) described below. Under the 2018 Plan, the Company may grant incentive stock options (â€œISOsâ€), NSOs, stock appreciation rights, restricted stock awards, RSUs and other stock-based awards. As of June 30, 2024, options to purchase 12,645,480 shares of common stock and 185,416 RSUs were outstanding, and 2,843,990 shares were available for future issuance under the 2018 Plan.Initially, subject to adjustment as provided in the 2018 Plan, the aggregate number of shares of the Companyâ€™s common stock authorized for issuance pursuant to stock awards under the 2018 Plan was 4,000,000 shares, which is the sum of (i) 1,600,692 shares plus (ii) the number of shares reserved and available for issuance under the 2015 Plan at the time the 2018 Plan became effective and (iii) the number of shares subject to stock options or other stock awards granted under the 2015 Plan that expire, terminate are forfeited or otherwise not issued, or are withheld to satisfy a tax withholding obligation in connection with an award or to satisfy a purchase or exercise price of an award (such as upon the expiration or termination of a stock award prior to vesting). The number of shares of the Companyâ€™s common stock reserved for issuance under the 2018 Plan automatically increases on January 1 of each year, beginning on January 1, 2019 and continuing through and including January 1, 2028, by 5% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the Companyâ€™s board of directors prior to such increase. The maximum number of shares that may be issued upon the exercise of ISOs under the 2018 Plan is 12,500,000 shares.2015 Equity Incentive PlanThe 2015 Plan provided for the granting of ISOs and NSOs to employees, directors and consultants at the discretion of the Companyâ€™s board of directors. The 2015 Plan was terminated as to future awards in June 2018, although it continues to govern the terms of options that remain outstanding under the 2015 Plan.No additional stock awards will be granted under the 2015 Plan, and all outstanding stock awards granted under the 2015 Plan that are repurchased, forfeited, expire or are cancelled will become available for grant under the 2018 Plan in accordance with its terms.Options granted under the 2015 Plan expire no later than 10 years from the date of grant. Options granted under the 2015 Plan vest over periods determined by the Companyâ€™s board of directors, generally over four years. The 2015 Plan allows for early exercise of certain options prior to vesting. Upon termination of employment, the unvested shares are subject to repurchase at the original exercise price. As of June 30, 2024, options to purchase 1,363,394 shares of common stock were outstanding under the 2015 Plan.2018 Employee Stock Purchase PlanIn June 2018, the Companyâ€™s board of directors adopted and the stockholders approved the 2018 Employee Stock Purchase Plan (the â€œESPPâ€), which became effective as of June 20, 2018. The ESPP is intended to qualify as an â€œemployee stock purchase planâ€ within the meaning of Section 423 of the U.S. Internal Revenue Code of 1986, as amended. The number of shares of common stock initially reserved for issuance under the ESPP was 200,000 shares. The ESPP provides for an annual increase on January 1 of each year, beginning on January 1, 2019 and continuing through and including January 1, 2028, equal to the lesser of (i) 1% of the shares of common stock outstanding on the last day of the prior fiscal year or (ii) 375,000 shares, or a lesser number of shares determined by the Companyâ€™s board of directors prior to such increase. In December 2023, the Companyâ€™s board of directors acted such that there was no increase of the number of shares of common stock reserved for issuance under the ESPP as of January 1, 2024. As of June 30, 2024, 676,129 shares of common stock had been issued under the ESPP and 657,095 shares remained available for future issuance under the ESPP.Â 13 Â The price per share of common stock to be paid by an ESPP participant on the applicable purchase date of an offering period shall be equal to 85% of the lesser of the fair market value of a share of common stock on (i) the applicable offering date or (ii) the applicable purchase date. The Companyâ€™s board of directors authorized an initial six-month offering period beginning on November 16, 2018 and ending on May 15, 2019. The Companyâ€™s board of directors has subsequently authorized additional six-month offering periods, with the most recent offering period beginning on May 16, 2024.Option RepricingIn July 2023, the Compensation Committee of the Companyâ€™s board of directors approved a stock option repricing (the â€œOption Repricingâ€) in which the exercise price of certain outstanding options to purchase shares of the Companyâ€™s common stock under the 2018 Plan was reduced to $2.28 per share, the closing price of the Common Stock on July 24, 2023. Outstanding options that were granted under the 2015 Plan and the Inducement Plan were not included in the Option Repricing. The Option Repricing included options granted pursuant to the 2018 Plan that were held by, among others, members of the Companyâ€™s board of the directors (other than options granted in June 2023) and the Companyâ€™s named executive officers and principal financial officer.As a result of the Option Repricing, 9,904,755 shares of vested and unvested stock options outstanding as of July 24, 2023, with original exercise prices ranging from $2.44 to $22.85 per share, were repriced to $2.28 per share. The total incremental fair value to be recognized as a result of the repricing was approximately $4.7 million on the date of Option Repricing, of which $3.0 million related to the vested option shares had been recognized as stock-based compensation expense and $0.6 million related to the unvested option shares subsequently cancelled due to termination as of June 30, 2024. As of June 30, 2024, there was $1.1 million remaining related to the unvested option shares which will be amortized over the remaining requisite service periods through the end of 2026. Stock Option ActivityThe following table summarizes activity under the Companyâ€™s stock option plans and related information (in thousands, except share and per share amounts): Â Â Number ofOptionsOutstanding Â Â WeightedAverageExercise Price Â Â WeightedAverageRemainingContractualTerm (Years) Â Â AggregateIntrinsic Value Â Outstanding as of December 31, 2023 Â Â 13,110,717 Â Â $ 2.60 Â Â Â 7.1 Â Â $ 118 Â Options granted Â Â 3,541,000 Â Â $ 0.90 Â Â Â Â Â Â Â Â Options cancelled/forfeited Â Â (1,395,135) Â $ 2.84 Â Â Â Â Â Â Â Outstanding as of June 30, 2024 Â Â 15,256,582 Â Â $ 2.18 Â Â Â 7.2 Â Â $ â€” Â Vested and exercisable as of June 30, 2024 Â Â 8,334,868 Â Â $ 2.58 Â Â Â 5.7 Â Â $ â€” Â Â The weighted average grant date fair value of options granted during the three and six months ended June 30, 2024 was $0.54 and $0.67 per share, respectively. There were no options exercised during the six months ended June 30, 2024. The aggregate intrinsic value is calculated as the difference between the exercise price and the estimated fair value of the Companyâ€™s common stock at the date of exercise.Restricted Stock Units ActivityThere were no RSUs granted during the six months ended June 30, 2024. One-third of each RSU granted vests annually following the vesting commencement dates, over a vesting period of three years. RSUs are awards that entitle the holder to receive freely tradable shares of the Company's common stock upon vesting and are not forfeitable once fully vested. The valuations for these RSUs were based on the closing prices of the Company's common stock on the grant dates and recognized as stock-based compensation expenses over the respective vesting terms. Â Â Number of RSUs Outstanding Â Â Weighted Average Grant-Date Fair Price Â Outstanding as of December 31, 2023 Â Â 219,609 Â Â $ 9.20 Â RSUs vested Â Â (22,282) Â $ 9.63 Â RSUs forfeited Â Â (11,911) Â $ 9.26 Â Outstanding as of June 30, 2024 Â Â 185,416 Â Â $ 9.14 Â Â Â 14 Â Stock-Based Compensation ExpenseTotal stock-based compensation expense recognized by function was as follows (in thousands):Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 915 Â Â $ 2,013 Â Â $ 1,971 Â Â $ 4,281 Â General and administrative Â Â 2,170 Â Â Â 2,007 Â Â Â 4,548 Â Â Â 4,002 Â Total stock-based compensation expense Â $ 3,085 Â Â $ 4,020 Â Â $ 6,519 Â Â $ 8,283 Â Â As of June 30, 2024, the unrecognized stock-based compensation cost related to outstanding unvested stock options and RSUs that are expected to vest was $20.0 million with an estimated weighted average amortization period of 2.7 years.Â The fair value of the stock options granted is calculated using the Black-Scholes option-pricing model with the following range of assumptions: Â Â Three Months Ended June 30, Â Six Months Ended June 30, Â Â Â 2024 Â 2023 Â 2024 Â 2023 Â Expected term (years) Â 5.5Â - 6.1 Â 5.5Â - 6.1 Â 5.5 - 6.1 Â 5.5 - 6.1 Â Expected volatility Â 86.8Â - 87.7 % 88.0Â - 88.3 % 86.8Â - 87.9 % 87.8Â - 88.3 % Risk-free interest rate Â 4.3Â - 4.6 % 3.5Â - 3.9 % 4.0Â - 4.6 % 3.5Â - 4.3 % Expected dividend yield Â â€” Â â€” Â â€” Â â€” Â The expected term of options granted represents the period of time that options granted are expected to be outstanding and was determined by calculating the midpoint between the date of vesting and the contractual life of each option. The expected term of the ESPP rights is equal to the six-month look-back period. Since inception until March 2024, the volatility of the Companyâ€™s stock price was based on the weighted average of the historical volatility of the Company's stock price and that of a peer group of public companies over the expected term due to the Company's limited public trading history of its common stock. The peer group was selected on the basis of operational and economic similarity with the Companyâ€™s principal business operations. Effective as of the quarter-ended June 30, 2024, the expected volatility is based on the daily historical volatility of the Companyâ€™s common stock covering the estimated expected term. The risk-free interest rate for the expected term of the options is based on the U.S. Treasury yield curve with a maturity equal to the expected term in effect at the time of grant. The Company has not paid, and does not anticipate paying, cash dividends on its shares of common stock; therefore, the expected dividend yield is zero. Â 10. Everest CollaborationIn September 2023, the Company entered into a Collaboration and License Agreement (the â€œEverest License Agreementâ€) with Everest pursuant to which, among other things, the Company granted to Everest an exclusive license to develop and commercialize one or more products containing the Companyâ€™s proprietary compound, zetomipzomib (the â€œProductsâ€), in the licensed field in the Greater China region (Mainland China, Taiwan, Hong Kong and Macau), South Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam and the Philippines (the â€œTerritoryâ€). The licensed field includes all uses other than the diagnosis or treatment in humans of cancerous or pre-cancerous diseases or conditions. During the PALIZADE trial, Everest will contribute their local regulatory and clinical trial expertise and will be responsible for study costs in the Territory. Everest Medicines Limited is also a party to the Everest License Agreement solely for limited purposes, including to guarantee the performance by Everest of its obligations under the Everest License Agreement.Under the terms of the Everest License Agreement, the Company received a one-time, irrecoverable, non-refundable and non-creditable upfront payment of $7.0 million in October 2023 and is entitled to receive certain variable payments for manufacturing supply services and milestone payments upon achievement of certain development, regulatory and commercial milestone events, for total potential milestone payments of up to $125.5 million. In addition, Everest will pay to the Company tiered royalties on the net sales of the Products in the Territory during the term of the Everest License Agreement ranging from the single digit to the low-teens, subject to certain reductions for patent expiration, generic competition and payments for licenses to third-party patents. The term of the Everest License Agreement will continue on a market-by-market basis until expiration of the relevant royalty term of the Products, unless terminated earlier. Everest has the right to terminate the Everest License Agreement for convenience following completion, suspension or termination of the PALIZADE clinical trial. The Company may terminate the Everest License Agreement if Everest challenges the Companyâ€™s patents or fails to perform any development or commercialization activities for a continuous period of more than twelve (12) months, subject to certain exceptions. In addition, either party may terminate the Everest License Agreement Â 15 Â for the other partyâ€™s uncured breach or insolvency, and the Everest License Agreement will automatically terminate in the event of termination of the Companyâ€™s exclusive license agreement with Onyx Therapeutics, Inc.Under the terms of the Everest License Agreement, at the election of Everest, the Company may manufacture and provide clinical supply to Everest to use in development and commercialization in the Territory at the fully burdened manufacturing cost plus specified margins, as defined within the Everest License Agreement. Certain of these provisions were determined to be options to acquire additional goods or services at a price that approximates the stand-alone selling price for that good or service and therefore do not represent material rights, or separate performance obligations, within the context of the Everest License Agreement. The Company evaluated the Everest License Agreement and determined it was within the scope of ASC 606. The transaction price was determined to consist of the upfront payment of $7.0 million.License of Intellectual Property. The license to the Companyâ€™s intellectual property and associated know-how represents a distinct performance obligation. The license and associated know-how was transferred to Everest in the third quarter of 2023 to satisfy this performance obligation. The Company allocated the full transaction price to the license of the Companyâ€™s intellectual property and accordingly recognized collaboration revenue of $7.0 million in 2023.Milestone Payments. The potential development, regulatory and commercial milestone payments are paid upon achievement of certain milestones as defined in the Everest License Agreement. It was determined that their achievement is highly dependent on factors outside of the Companyâ€™s control. These payments have been fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods and, as such, have been excluded from the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint and, if necessary, adjust its estimate of the overall transaction price. As of June 30, 2024, the Company has not recognized any revenue associated with development, regulatory and commercial milestones.Royalties. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Everest and, therefore, have also been excluded from the transaction price. No royalty revenue was recognized as of June 30, 2024. In July 2024, the Company amended the Everest License Agreement to modify a development milestone and adjust certain payment terms relating to Everestâ€™s responsibility for PALIZADE study costs in the Territory. As of June 30, 2024, the Company had a receivable of $1.3 million, representing the billed amounts related to Everest's share of the Territory-specific direct costs and pro rata portion of indirect costs incurred to conduct PALIZADE study under the Everest License Agreement, and a noncurrent unbilled receivable of $1.1 million representing reimbursement for payment is yet to be billed or due. The receivable amount was included in prepaid expenses and other current assets and the unbilled receivable was included in other assets in the Companyâ€™s Condensed Consolidated Balance Sheet. In connection with the cost-sharing arrangement with Everest, $1.6 million and $2.4 million was recognized as contra research and development expense for each of the three and six months ended June 30, 2024, respectively. Â 11. Income TaxesNo provision for income taxes was recorded for the three and six months ended June 30, 2024 and 2023, respectively. Deferred tax assets generated from the Companyâ€™s net operating losses have been fully reserved, as the Company believes it is not more likely than not that the benefit will be realized. Effective January 1, 2022, under the Tax Cuts and Jobs Act, for tax purposes the Company is required to capitalize and subsequently amortize all R&D expenditures over five years for research activities conducted in the U.S. and over fifteen years for research activities conducted outside of the U.S. Given the significant loss and credit carryforwards in the U.S., the Company does not anticipate having a change in valuation allowance assertion.In March 2020, the Coronavirus Aid, Relief and Economic Security (â€œCARESâ€) Act was signed into law. The CARES Act included several tax changes as part of its economic package. These changes principally related to expanded net operating loss carryback periods, increases to interest deductibility limitations, and accelerated alternative minimum tax refunds. The CARES Act enacted the Employee Retention Credit (â€œERCâ€) to incentivize companies to retain employees, which was subsequently modified by extension of the CARES Act. Under the provisions of the CARES Act and its subsequent extension, the Company was eligible for ERCs, subject to certain criteria. During the six months ended June 30, 2023, the Company received refunds of approximately $1.4 million related to ERCs that offset the related payroll expenses in the respective operating costs and expenses line item in the condensed consolidated statements of operations. During the six months ended June 30, 2024, no refund related to ERCs was received by the Company. Â 16 Â 12. Net Loss Per ShareNet Loss Per Share The following table sets forth the calculation of basic and diluted net loss per share during the periods presented (in thousands, except share and per share data): Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Numerator: Â Â Â Â Â Â Â Â Â Â Â Â Net loss Â $ (21,547) Â $ (24,308) Â $ (43,205) Â $ (46,507) Denominator: Â Â Â Â Â Â Â Â Â Â Â Â Weighted-average shares of common stock outstanding Â Â 72,845,869 Â Â Â 72,461,850 Â Â Â 72,822,890 Â Â Â 72,395,410 Â Net loss per share, basic and diluted Â $ (0.30) Â $ (0.34) Â $ (0.59) Â $ (0.64) Â Basic net loss per common share is calculated by dividing net loss by the

weighted-average number of shares of common stock and pre-funded warrants outstanding during the period, without consideration of common share equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock, pre-funded warrants and common share equivalents outstanding for the period. The pre-funded warrants were included in the computation of basic and diluted net loss per common share as the exercise price was negligible and the pre-funded warrants were fully vested and exercisable. Common share equivalents are only included in the calculation of diluted net loss per common share when their effect is dilutive.Potential dilutive securities, which include, vested and unvested options to purchase common stock and RSUs subject to future vesting have been excluded from the computation of diluted net loss per share as the effect is antidilutive. Therefore, the denominator used to calculate both basic and diluted net loss per common share is the same in all periods presented.The following outstanding shares of common stock equivalents were excluded from the computation of the diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Â Â Â Three and Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Stock options to purchase common stock Â Â 15,256,582 Â Â Â 12,962,005 Â Restricted stock units subject to future vesting Â Â 185,416 Â Â Â 433,611 Â Total Â Â 15,441,998 Â Â Â 13,395,616 Â Â 13. Related Party Transactions In connection with the resignation of John Fowler from his role as Chief Executive Officer, the Company and Mr. Fowler entered into a Separation and Consulting Agreement, effective as of November 7, 2023 (the â€œFowler Agreementâ€), pursuant to which Mr. Fowler provides consulting services to the Company at a rate of $5,000 per month for one year ending November 7, 2024. Pursuant to the Fowler Agreement, the Company recognized $15,000 and $30,000 of compensation expense within general and administrative expenses in the Condensed Consolidated Statement of Operations during the three and six months ended June 30, 2024, respectively. Â 14. 2023 Restructuring and Impairment ChargesIn October 2023, the Company announced a strategic restructuring and workforce reduction to prioritize its clinical-stage assets, extend its cash runway and reduce its total workforce. All employees affected by the workforce reduction separated from the company by December 31, 2023. In connection with the workforce reduction, the Company committed to a plan to sublease Suite 400 of its corporate headquarters which resulted in an impairment to the ROU asset and certain property and equipment no longer utilized under current or expected future operations.The Company recognized cumulative restructuring charges of $6.2 million, comprised primarily of one-time employee termination benefits and long-lived assets impairment costs during the year ended December 31, 2023. The Company recognized an additional $1.5 million impairment charge in relation to Suite 400 to write off the net book value of the ROU asset as of June 30, 2024. The unpaid severance and related benefit costs included in accrued liabilities in the Condensed Consolidated Balance Sheets were $0.2 million and $1.4 million as of June 30, 2024 and December 31, 2023, respectively. The Company expects that substantially all of the remaining accrued restructuring liabilities will be paid in cash over next four months.Â Â 17 Â The following table illustrates the accrual activities and payments relating to restructuring and impairment charges (in thousands):Â Â Â Severance and related benefit costs Â Â Asset impairments Â Â Total Â Balance as of January 1, 2023 Â $ â€” Â Â $ â€” Â Â $ â€” Â Restructuring charges Â Â 3,279 Â Â Â 2,908 Â Â Â 6,187 Â Cash payments made Â Â (1,858) Â Â â€” Â Â Â (1,858) Non-cash charges Â Â â€” Â Â Â (2,908) Â Â (2,908) Balance as of December 31, 2023 Â $ 1,421 Â Â $ â€” Â Â $ 1,421 Â Cash payments made Â Â (775) Â Â â€” Â Â Â (775) Balance as of March 31, 2024 Â $ 646 Â Â $ â€” Â Â $ 646 Â Restructuring charges Â Â (67) Â Â 1,549 Â Â Â 1,482 Â Cash payments made Â Â (344) Â Â â€” Â Â Â (344) Non-cash charges Â Â â€” Â Â Â (1,549) Â Â (1,549) Balance as of June 30, 2024 Â $ 235 Â Â $ â€” Â Â $ 235 Â Â Â 18 Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations. You should read the following managementâ€™s discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q, and with our audited consolidated financial statements and related notes thereto for the year ended December 31, 2023 included in our Annual Report on Form 10-K, as filed with the U.S. Securities and Exchange Commission, or the SEC, on March 14, 2024, or the Annual Report. Overview We are a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. We believe therapies that inhibit multiple drivers of disease by targeting fundamental upstream control processes within the cell have the potential for profound therapeutic benefit in a number of difficult-to-treat diseases. To that end, we are advancing two drug development programs that harness different regulators of cellular function: the first targets the immunoproteasome which is responsible for protein degradation in cells of the immune system and drives many key aspects of immune cell function, and the second targets the Sec61 translocon, which is located on the endoplasmic reticulum and represents the beginning of the protein secretion pathway. Targeting these fundamental regulators of cellular function offers an attractive approach to treating many diseases. Our lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase 1a testing in healthy volunteers and a Phase 1b/2 clinical trial in patients with systemic lupus erythematosus, or SLE, with or without lupus nephritis, or LN (the MISSION trial). We are conducting PALIZADE, a global, placebo-controlled, double-blind Phase 2b clinical trial evaluating zetomipzomib in patients with LN. In addition, we are leveraging the broad therapeutic potential of zetomipzomib in other severe autoimmune diseases of high unmet medical need. PORTOLA is a placebo-controlled, double-blind Phase 2a clinical trial evaluating zetomipzomib in patients with autoimmune hepatitis, or AIH. We are also continuing to explore development opportunities for zetomipzomib in patients with SLE. In August 2024, we announced completion of enrollment in our PORTOLA trial, and we expect to report topline data from this trial in the first half of 2025. Based on clinical data generated to date with zetomipzomib, we believe that zetomipzomib has the potential to address multiple chronic immune-mediated diseases. We believe that the immunoproteasome is a validated target for the treatment of a wide variety of immune-mediated diseases given its ability to regulate multiple drivers of the inflammatory disease process. Many inflammatory disorders are currently treated one cytokine or cell type at a time, but the immunoproteasome affects a broad spectrum of immune regulators. We have seen encouraging clinical activity and biomarker data in the SLE and LN patients who received zetomipzomib in our MISSION trial. The safety and tolerability profiles of zetomipzomib have been favorable and consistent with the needs for a long-term therapy. Our oncology product candidate, KZR-261, is a small molecule agent being studied in an open-label Phase 1 clinical study designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types. KZR-261 was discovered from our novel research platform targeting the Sec61 translocon and the protein secretion pathway. KZR-261 has demonstrated broad anti-tumor activity in preclinical models of both solid and hematologic malignancies by targeting multiple pathways driving tumor growth and survival. In August 2024, we announced that we have stopped enrollment in the KZR-261 open-label Phase 1 clinical study, and we are reallocating clinical resources toward development of zetomipzomib in AIH and LN. No objective responses have been observed to date in the KZR-261 study. We plan to report data from the trial at a medical conference following completion of the study. Since the commencement of our operations, we have devoted substantially all of our resources to performing research and development activities in support of our product development efforts, hiring personnel, raising capital to support and expand such activities and providing general and administrative support for these operations. We do not have any products approved for sale and have not generated any revenue from product sales. We have funded our operations to date primarily from the issuance and sale of convertible preferred stock, public offerings of common stock and pre-funded warrants to purchase common stock, and debt. We acquired exclusive worldwide rights to zetomipzomib pursuant to a license agreement, or the Onyx License Agreement, with Onyx Therapeutics, Inc., or Onyx, a wholly owned subsidiary of Amgen, Inc. Since our inception, we have incurred significant operating losses. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates and programs. Our net losses were $101.9 million and $43.2 million for the year ended December 31, 2023 and the six months ended June 30, 2024, respectively, and we expect to continue to incur significant losses for the foreseeable future. As of June 30, 2024, we had an accumulated deficit of $394.0 million. We anticipate that a substantial portion of our capital resources Â 19 Â and efforts in the foreseeable future will be focused on completing the necessary development, obtaining regulatory approval and preparing for potential commercialization of our product candidates. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. Our net losses may fluctuate significantly from period to period, depending on the timing of our planned clinical trials and expenditures on other research and development activities. We expect our expenses will increase substantially over time as we: â€¢continue the ongoing and planned development of zetomipzomib; â€¢seek to develop additional product candidates, including preclinical studies and clinical trials for such product candidates; â€¢maintain, protect and expand our portfolio of intellectual property rights, including patents, trade secrets and know-how; â€¢seek marketing approvals for zetomipzomib and any future product candidates that successfully complete clinical trials; â€¢establish a sales, marketing, manufacturing and distribution infrastructure to commercialize any product candidate for which we may obtain marketing approval; â€¢continue to build a portfolio of product candidates through the acquisition or in-license of drugs, product candidates or technologies; â€¢implement operational, financial, management and compliance systems; and â€¢attract, hire and retain additional administrative, clinical, regulatory and scientific personnel. Our Pipeline The following table sets forth the status of our product candidates and discovery programs: Â m Financial Operations Overview Collaboration Revenue We have no products approved for commercial sales and, to date, have not generated any revenue from the sale of products, and we do not expect to generate any revenue from the sale of products in the near future. Our revenue to date has been generated from the upfront payment pursuant to our collaboration with Everest under the Everest License Agreement. Collaboration revenue consists of revenue received from upfront, milestone and contingent payments received from the strategic partner. We recognize collaboration revenue when the performance obligation is satisfied. In addition to receiving an upfront payment, we may also be entitled to milestones and other contingent payments upon achieving predefined objectives. If a milestone is considered probable of being reached, and if it is probable that a significant revenue reversal would not occur, the associated milestone amount would also be included in the transaction price. Â 20 Â We expect that any collaboration revenue we generate from our current collaboration and license agreement, and from any future collaboration partners, will fluctuate as a result of the timing and amount of upfront, milestones and other collaboration agreement payments and other factors. Research and Development Expenses Research and development expenses consist primarily of costs incurred for the development of our product candidates, which include: â€¢employee-related expenses, which include salaries, benefits and stock-based compensation; â€¢fees paid to consultants for services directly related to our product development and regulatory effort; â€¢expenses incurred under agreements with third-party contract organizations, investigative clinical trial sites and consultants that conduct research and development activities on our behalf; â€¢costs associated with preclinical studies and clinical trials; â€¢costs associated with technology and intellectual property licenses; â€¢the costs related to production of clinical supplies; and â€¢facilities and other allocated expenses, which include expenses for rent and facility-related costs and supplies. We expense all research and development costs in the periods in which they are incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors, collaborators and third-party service providers. The following table summarizes our research and development expenses incurred during the respective periods (in millions): Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (unaudited) Â Â (unaudited) Â Research and development expenses by program: Â Â Â Â Â Â Â Â Â Â Â Â Â Zetomipzomib Â $ 12.9 Â Â $ 12.5 Â Â $ 26.7 Â Â $ 24.0 Â KZR-261 Â Â 3.4 Â Â Â 4.4 Â Â Â 6.5 Â Â Â 7.7 Â Protein Secretion Â Â â€” Â Â Â 4.1 Â Â Â 0.3 Â Â Â 7.6 Â Total research and development expenses Â $ 16.3 Â Â $ 21.0 Â Â $ 33.5 Â Â $ 39.3 Â Â We expect our research and development expenses to increase substantially for the foreseeable future as our product candidates advance into later stages of development. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates. General and Administrative Expenses Our general and administrative expenses consist primarily of personnel costs, allocated facilities costs and expenses for outside professional services, including legal, human resource, information technology and audit services. Personnel costs consist of salaries, benefits and stock-based compensation. We will incur additional expenses as we increase the size of our administrative function to support the growth of our business. Restructuring and Impairment Charges In October 2023, we announced a strategic restructuring and workforce reduction (the â€œWorkforce Reductionâ€) to prioritize our clinical-stage assets and extend our cash runway, reducing our workforce by approximately 40%. All employees affected by the Workforce Reduction separated from the Company by December 31, 2023. In connection with the Workforce Reduction, we committed to a plan to sublease the vacated floor in our leased office facility, which resulted in an impairment to the right-of-use (â€œROUâ€) asset and certain property and equipment no longer utilized under current or expected future operations. We recognize an impairment loss when the total estimated future cash flows expected to result from the use of the asset and its eventual disposition are Â 21 Â less than the carrying amount. See Note 14 to our condensed consolidated financial statements for additional information on the restructuring and impairment charges. Interest Income Our interest income consists of interest income earned on our cash, cash equivalents and marketable securities. Interest Expense Our interest expense is related to our debt facility. A portion of the interest expense is non-cash expense relating to the accretion of the final payment fees and amortization of debt discount and debt issuance costs associated with our Loan Agreement with Oxford Finance entered into in November 2021. Results of Operations Comparison of the Three Months Ended June 30, 2024 and 2023 Â Â Â Three Months Ended June 30, Â Â Â Â (dollars in millions) Â 2024 Â Â 2023 Â Â $ Change Â Operating expenses: Â Â Â Â Â Â Â Â Â Research and development Â $ 16.3 Â Â $ 21.0 Â Â $ (4.7) General and administrative Â Â 5.6 Â Â Â 5.8 Â Â Â (0.2) Restructuring and impairment charges Â Â 1.5 Â Â Â â€” Â Â Â 1.5 Â Total operating expenses Â Â 23.4 Â Â Â 26.8 Â Â Â (3.4) Loss from operations Â Â (23.4) Â Â (26.8) Â Â 3.4 Â Interest income Â Â 2.3 Â Â Â 2.9 Â Â (0.6) Interest expense Â Â (0.4) Â Â (0.4) Â Â â€” Â Net loss Â $ (21.5) Â $ (24.3) Â $ 2.8 Â Research and Development Expenses Research and development expenses decreased by $4.7 million for the three months ended June 30, 2024, compared to the three months ended June 30, 2023. The decrease was primarily due to our October 2023 strategic restructuring to prioritize clinical-stage programs, reduce our headcount and pause early-stage research and discovery activities that resulted in a decrease of $3.7 million in stock-based compensation and personnel-related expenses, a decrease of $2.1 million in research and pre-clinical expenses, a decrease of $0.4 million in facility-related expenses, a decrease of $0.2 million in consulting expenses, and a decrease in $0.4 million in manufacturing expenses related to the timing of drug manufacturing runs, offset by an increase of $2.1 million in clinical expenses primarily related to increased activities for the PALIZADE and PORTOLA trials. General and Administrative Expenses General and administrative expenses decreased by $0.2 million for the three months ended June 30, 2024, compared to the three months ended June 30, 2023. The decrease was mainly due to a decrease in legal and professional services. Restructuring and Impairment Charges Restructuring and impairment charges increased by $1.5 million for the three months ended June 30, 2024, compared to the three months ended June 30, 2023. The increase was primarily related to the ROU asset impairment charge related to the vacated floor in our leased office facility as the estimated future cash flow from sublease income is zero due to current market conditions. Interest Income Interest income decreased by $0.6 million for the three months ended June 30, 2024, compared to the three months ended June 30, 2023. The decrease was primarily due to the decrease in the balance of cash equivalent and marketable securities. Interest Expense Interest expense was $0.4 million for the three months ended June 30, 2024, compared to $0.4 million for the three months ended June 30, 2023. The interest expense was composed of the contractual coupon interest expense, the amortization of the debt discount and issuance costs and the accretion of the final payment fee associated with the Loan Agreement with Oxford Finance. Â 22 Â Comparison of the Six Months Ended June 30, 2024 and 2023 Â Â Â Six Months Ended June 30, Â Â Â Â (dollars in millions) Â 2024 Â Â 2023 Â Â $ Change Â Operating expenses: Â Â Â Â Â Â Â Â Â Research and development Â $ 33.5 Â Â $ 39.3 Â Â $ (5.8) General and administrative Â Â 12.1 Â Â Â 12.0 Â Â Â 0.1 Â Restructuring and impairment charges Â Â 1.5 Â Â Â â€” Â Â Â 1.5 Â Total operating expenses Â Â 47.1 Â Â Â 51.3 Â Â Â (4.2) Loss from operations Â Â (47.1) Â Â (51.3) Â Â 4.2 Â Interest income Â Â 4.7 Â Â Â 5.6 Â Â Â (0.9) Interest expense Â Â (0.8) Â Â (0.8) Â Â â€” Â Net loss Â $ (43.2) Â $ (46.5) Â $ 3.3 Â Research and Development Expenses Research and development expenses decreased by $5.8 million for the six months ended June 30, 2024, compared to the six months ended June 30, 2023. The decrease was primarily due to our October 2023 strategic restructuring to prioritize clinical-stage programs, reduce our headcount and pause early-stage research and discovery activities. As the result of the restructuring, a decrease of $6.0 million in stock-based compensation and personnel-related expenses, a decrease of $3.5 million in research and pre-clinical expenses and a decrease of $0.7 million in facility-related expenses, offset by an increase of $4.4 million in clinical expenses primarily related to increased activities for the PALIZADE and PORTOLA trials. General and Administrative Expenses General and administrative expenses increased by $0.1 million for the six months ended June 30, 2024, compared to the six months ended June 30, 2023. The increase was due to an increase of $0.5 million in stock-based compensation and an increase of $0.4 million in payroll expense as a result of the Employee Retention Credit refunds under the CARES Acts received during the six months ended June 30, 2023 compared to none during the six months ended June 30, 2024, offset by a

decrease of $0.6 million in legal and professional services and a decrease of $0.2 million in consulting expenses. Restructuring and Impairment Charges Restructuring and impairment charges increased by $1.5 million for the six months ended June 30, 2024, compared to the six months ended June 30, 2023. The increase was primarily related to the ROU asset impairment charge related to the vacated floor in our leased office facility as the estimated future cash flow from sublease income is zero due to current market conditions. Interest Income Interest income decreased by $0.9 million for the six months ended June 30, 2024, compared to the six months ended June 30, 2023. The decrease was primarily due to the decrease in the balance of cash equivalent and marketable securities. Interest Expense Interest expense was $0.8 million for the six months ended June 30, 2024, compared to $0.8 million for the six months ended June 30, 2023. The interest expense was composed of the contractual coupon interest expense, the amortization of the debt discount and issuance costs and the accretion of the final payment fee associated with the Loan Agreement with Oxford Finance. Liquidity and Capital Resources Overview As of June 30, 2024, we had $164.2 million in cash, cash equivalents and marketable securities. As of June 30, 2024, our cash equivalents and marketable securities had an average maturity of approximately five months and the longest maturity was 12 months. We have incurred operating losses and experienced negative operating cash flows since our inception and anticipate that we will continue to incur losses for at least the foreseeable future. Our net loss was $43.2 million for the six months ended June 30, 2024, and we had an accumulated deficit of $394.0 million as of June 30, 2024. We believe that our cash, cash equivalents and marketable securities as of June 30, 2024 will be sufficient to meet our projected operating requirements through at least the next 12 months from the date these financial statements were issued. We have based this Â 23 Â estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. At-the-Market Offering Program In December 2021, we entered into a Sales Agreement, or the ATM Agreement, with Cowen and Company, LLC, or Cowen, pursuant to which we can offer and sell, from time to time at our sole discretion, through Cowen, as our sales agent, shares of common stock having an aggregate offering price of up to $200.0 million. Any shares of common stock sold will be issued pursuant to our shelf registration statement on Form S-3 (File No. 333-261774). We will pay Cowen a commission up to 3.0% of the gross sales proceeds of any shares of common stock sold through Cowen under the ATM Agreement and also have provided Cowen with indemnification and contribution rights. As of June 30, 2024, we have sold an aggregate of 11,986,003 shares of our common stock for gross proceeds of approximately $131.7 million at a weighted average purchase price of $10.98 per share pursuant to the ATM Agreement. As of June 30, 2024, approximately $68.3 million remains available under the ATM Agreement. No shares were sold under the ATM Agreement during the six months ended June 30, 2024. Debt Facility In November 2021, we entered into the Loan Agreement with Oxford Finance, which provides up to $50.0 million in borrowing capacity across five potential tranches. The initial tranche of $10.0 million was funded at the closing of the Loan Agreement. The remaining tranches were dependent on achieving certain clinical trial milestones. As of June 30, 2024, we declined these tranches in borrowing capacity available to us under the Loan Agreement. Until June 30, 2023, the Loan Agreement bore interest at a floating per annum rate (based on the actual number of days elapsed divided by a year of 360 days) equal to the sum of (a) the greater of (i) the 30-day U.S. LIBOR rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue and (ii) 0.08%, plus (b) 7.87%. We are required to make monthly interest-only payments prior to the amortization date of January 1, 2025, subject to a potential one-year extension upon satisfaction of certain conditions. The loan facility is secured by all assets except intellectual property, which is subject to a negative pledge, and will mature on November 1, 2026. There are no warrants or financial covenants associated with the Loan Agreement. A LIBOR transition event occurred effective July 1, 2023 and Oxford Finance revised the Loan Agreement to replace the LIBOR rate with the 1-month CME term SOFR plus 0.1%. The rate change did not require contract remeasurement at the effective date of the change or a reassessment of any previous accounting determinations pertaining to the facility. The rate change did not have a material impact on the Companyâ€™s financial statements. Funding Requirements We believe that our available cash, cash equivalents and short-term investments are sufficient to fund existing and planned cash requirements for the next 12 months. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research and development services, clinical costs, legal and other regulatory expenses and general overhead costs. We have based our estimates on assumptions that may prove to be incorrect, and we could use our capital resources sooner than we currently expect. Our future funding requirements will depend on many factors, including the following: â€¢the progress, timing, scope, results and costs of our clinical trials and preclinical studies for our product candidates, including the ability to enroll patients in a timely manner for our clinical trials; â€¢the costs of obtaining clinical and commercial supplies for zetomipzomib, KZR-261 and any other product candidates we may identify and develop; â€¢the cost, timing and outcomes of regulatory approvals; â€¢the extent to which we may acquire or in-license other product candidates and technologies; â€¢the cost of attracting, hiring and retaining qualified personnel; â€¢our ability to successfully commercialize any product candidates for which we obtain regulatory approval; and â€¢the cost of preparing, filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights. Further, our operating plan may change, and we may need additional funds to meet operational needs and capital requirements for clinical trials and other research and development expenditures. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical studies. Â 24 Â Our material cash requirements as of June 30, 2024 primarily relate to the maturities of principal obligations under our Term Loan and operating leases for office space and equipment. As of June 30, 2024, we have $7.3 million payable within 12 months. Refer to Notes 6 and 7 to our condensed consolidated financial statements for additional information. Our expected material cash requirements do not include any potential contingent payments upon the achievement by us of clinical, regulatory and commercial events, as applicable, or royalty payments that we may be required to make under license agreements we have entered into or may enter into with various entities pursuant to which we have in-licensed certain intellectual property, including our Onyx License Agreement. Under the Onyx License Agreement, we are obligated to pay Onyx milestone payments of up to $167.5 million in the aggregate upon the achievement of certain development, regulatory and sales milestones. We excluded the contingent payments given that the timing and amount (if any) of any such payments cannot be reasonably estimated at this time. We also have no material non-cancellable purchase commitments with service providers, as we have generally contracted on a cancellable, purchase order basis. We will require additional financing to fund working capital and pay our obligations. We may pursue financing opportunities through a combination of equity offerings, debt financings and additional funding from license and collaboration agreements. Except for any obligations of Everest to reimburse us for research and development expenses or to make milestone or royalty payments under the Everest License Agreement, we have no committed external sources of funding. There can be no assurance that we will be successful in acquiring additional funding at levels sufficient to fund our operations or on terms favorable to us or at all. Funding may not be available to us on acceptable terms, or at all. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of or suspend one or more of our preclinical studies, clinical trials, research and development programs or commercialization efforts. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, collaborations and other licensing arrangements. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Cash Flows The following summarizes our cash flows for the periods indicated: Â Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â (dollars in millions) Â (unaudited) Â Net cash used in operating activities Â $ (39.9) Â $ (42.5) Net cash provided by investing activities Â $ 32.6 Â Â $ 29.6 Â Net cash provided by financing activities Â $ 0.1 Â Â $ 0.5 Â Â Cash Flows from Operating Activities During the six months ended June 30, 2024, cash used in operating activities was $39.9 million, which consisted of a net loss of $43.2 million and a net change of $2.5 million in our net operating assets and liabilities, adjusted by non-cash charges of $5.8 million. The non-cash charges consisted of $6.5 million for stock-based compensation expense, $1.5 million for the impairment loss of ROU asset, $0.5 million for depreciation and amortization, and $0.1 million of non-cash interest expense, offset by $2.9 million of amortization of premium and discounts on marketable securities. The change in our net operating assets and liabilities was primarily due to a decrease of $1.2 million in prepaid expenses, other current assets and other assets, a decrease of $0.6 million in operating lease asset and liabilities, and a decrease of $3.1 million in accounts payable and accrued liabilities due to increased clinical expenditures. During the six months ended June 30, 2023, cash used in operating activities was $42.5 million, which consisted of a net loss of $46.5 million and a net change of $1.3 million in our net operating assets and liabilities, adjusted by non-cash charges of $5.4 million. The non-cash charges consisted of $8.3 million for stock-based compensation expense, $0.5 million for depreciation, and $0.1 million of non-cash interest expense, offset by $3.5 million of amortization of premium and discounts on marketable securities. The change in our net operating assets and liabilities was primarily due to an increase of $3.7 million in prepaid expenses and other current assets driven by the start-up clinical activities related to the PALIZADE trial, and a decrease of $0.1 million in operating lease asset and liabilities, offset by an increase of $2.5 million in accounts payable and accrued liabilities due to increased clinical expenditures. Cash Flows from Investing Activities Net cash provided by investing activities was $32.6 million for the six months ended June 30, 2024, primarily relating to the maturities of marketable securities exceeding purchases of such marketable securities. Â 25 Â Net cash provided by investing activities was $29.6 million for the six months ended June 30, 2023, primarily relating to the maturities of marketable securities exceeding purchases of such marketable securities. Payments for the purchases of property and equipment were $1.7 million during the six months ended June 30, 2023. Cash Flows from Financing Activities Net cash provided by financing activities for the six months ended June 30, 2024 was $0.1 million, primarily from the issuance of common stock pursuant to our employee equity plans. Net cash provided by financing activities for the six months ended June 30, 2023 was $0.5 million, primarily from the issuance of common stock pursuant to our employee equity plans. Critical Accounting Estimates Our managementâ€™s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of these financial statements requires us to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. There have been no other material changes to our critical accounting judgments and estimates from those described under â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ in our Annual Report. Status as a Smaller Reporting Company We are a smaller reporting company as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act. As a result, we may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as (i) our voting and non-voting common stock held by nonaffiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter. Â 26 Â Item 3. Quantitative and Qualitative Disclosures About Market Risk. The primary objectives of our investment activities are to ensure liquidity and to preserve capital. The market risk inherent in our financial instruments and in our financial position reflects the potential losses arising from adverse changes in interest rates and concentration of credit risk. We had cash, cash equivalents and marketable securities of $164.2 million as of June 30, 2024, which consisted of bank deposits, highly liquid U.S. Treasury money market funds, U.S. Treasury securities, commercial paper, corporate debt securities and U.S. agency bonds. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. As of June 30, 2024, our cash equivalents and marketable securities had an average maturity of approximately 5 months and the longest maturity was 12 months. Due to the short-term duration and the lower risk profile of our cash equivalents and marketable securities, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents and marketable securities. We have the ability to hold our cash equivalents and marketable securities until maturity, and we therefore do not expect a change in market interest rates to affect our operating results or cash flows to any significant degree. Our investment portfolio consists of investment grade securities diversified amongst security types, industries, and issuers. We maintain cash, cash equivalents, and investments with multiple financial institutions that we believe are financially sound and have minimal credit risk exposure, although at times our balances may exceed the applicable insurance coverage limits. We monitor and manage the overall counterparty credit risk exposure of our cash balances to individual financial institutions on an ongoing basis. All our securities are held in custody by a recognized financial institution. Our policy limits the amount of credit exposure to a maximum of 10% to any one issuer, except for the U.S. Treasury, Federal Agencies, or Government Money Market Funds, and we believe no significant concentration risk exists with respect to these investments. Approximately $0.7 million of our cash, cash equivalents and marketable securities balance was located in Australia as of June 30, 2024. Our expenses, except those related to our Australian operations, are generally denominated in U.S. dollars. For our operations in Australia, the majority of the expenses are denominated in Australian dollars. To date, we have not had a formal hedging program with respect to foreign currency. A 10% increase or decrease in current exchange rates would not have a material effect on our consolidated financial results. Item 4. Controls and Procedures. Evaluation of Disclosure Controls and Procedures. We maintain â€œdisclosure controls and procedures,â€ as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported, within the time periods specified in the SECâ€™s rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2024. Based upon the evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level. Changes in Internal Control over Financial Reporting. There have been no changes in our internal control over financial reporting during our most recent fiscal quarter that materially affected or are reasonably likely to materially affect our internal control over financial reporting. Â 27 Â PART IIâ€”OTHER INFORMATION Item 1. Legal Proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have an adverse effect on our business, operating results or financial condition. Item 1A. Risk Factors. An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following information about these risks, together with the other information appearing elsewhere in this Quarterly Report on Form 10-Q, including our financial statements and related notes hereto, before deciding to invest in our common stock. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment. We cannot assure you that any of the events discussed below will not occur. Summary of Selected Risks Associated with our Business Our business is subject to numerous risks and uncertainties, including those discussed at length in the section titled â€œRisk Factors.â€ These risks include, among others, the following: â€¢We have incurred significant operating losses since inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability. â€¢We have a limited operating history and have never generated revenue from product sales, which may make it difficult to evaluate the success of our business to date and to assess our future viability. â€¢We will require substantial additional capital to finance our operations, which may not be available on acceptable terms, if at all. Failure to obtain this necessary capital when needed may force us to delay, reduce or terminate certain of our product development programs or other operations. â€¢Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish proprietary rights. â€¢Our future success is substantially dependent on the successful clinical development, regulatory approval and commercialization of zetomipzomib and KZR-261, as well as any future product candidates. â€¢We may explore strategic collaborations, which would require us to relinquish important rights to and control over the development and commercialization of our product candidates to any future collaborators. â€¢Success in preclinical studies or earlier clinical trials may not be indicative of future clinical trial results, and we cannot assure you that any clinical trials will lead to results sufficient for the necessary regulatory approvals. â€¢Clinical trials are very expensive, time consuming and difficult to design and implement. â€¢Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be

delayed, made more difficult or rendered impossible by multiple factors outside our control. â€¢We may encounter substantial delays or difficulties in enrolling and retaining patients in our clinical trials. â€¢The manufacture of our product candidates is complex and uncertain, and until we develop a validated manufacturing process, we may encounter difficulties in supplying our planned and future clinical trials. If we encounter such difficulties, or fail to meet quality standards, our ability to meet clinical timelines and expand our development strategy could be impacted. â€¢Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval. â€¢We may not be able to obtain or maintain orphan drug designations or exclusivity for our product candidates, which could limit the potential profitability of our product candidates. Â 28 Â â€¢Even if our product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success. â€¢We face substantial competition, which may result in others developing or commercializing drugs before or more successfully than us. â€¢We are dependent upon Everest for the further development and commercialization of zetomipzomib in the greater China region, South Korea and certain Southeast Asian countries. â€¢Our relationships with customers, physicians, and third-party payors may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, transparency laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. â€¢We rely on third parties to manufacture clinical supplies of our product candidates and to conduct, supervise and monitor our clinical trials and preclinical studies. If those third parties perform in an unsatisfactory manner, it may harm our business. â€¢Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. If we breach our exclusive license agreement with Onyx Therapeutics, Inc., we could lose the ability to continue the development and commercialization of zetomipzomib. â€¢If we are unable to obtain and maintain patent protection for zetomipzomib, KZR-261 or any future product candidate, if the scope of patent protection is not sufficiently broad, or if our patents are insufficient to protect our product candidates for an adequate amount of time, we may not be able to compete effectively in our markets. â€¢Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. â€¢We are highly dependent on the services of our executive officers, and if we are not able to retain these members of our management team or recruit and retain additional management, clinical and scientific personnel, our business will be harmed. â€¢If securities or industry analysts do not publish research or reports, or publish unfavorable research or reports, about our business or our market, our stock price and trading volume could decline. â€¢Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and share price. Â Risks Related to Our Financial Position and Capital Needs We have incurred significant operating losses since inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability. Since inception in February 2015, we have incurred significant operating losses. Our net loss was $101.9 million for the year ended December 31, 2023 and $43.2 million for the six months ended June 30, 2024. As of June 30, 2024, we had an accumulated deficit of $394.0 million. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. Since inception, we have devoted substantially all of our efforts to research and preclinical and clinical development of our product candidates, as well as to expanding our management team and infrastructure. It could be several years, if ever, before we have a commercialized drug. The net losses we incur may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if, and as, we: â€¢continue the ongoing and planned development of zetomipzomib, KZR-261 and future product candidates from our protein secretion program; â€¢seek to discover and develop additional product candidates, including preclinical studies and clinical trials for such product candidates; â€¢maintain, protect and expand our portfolio of intellectual property rights, including patents, trade secrets and know-how; â€¢seek marketing approvals for zetomipzomib, KZR-261 and any future product candidates that successfully complete clinical trials; Â 29 Â â€¢establish a sales, marketing, manufacturing and distribution infrastructure to commercialize any product candidate for which we may obtain marketing approval; â€¢continue to build a portfolio of product candidates through the acquisition or in-license of drugs, product candidates or technologies; â€¢implement operational, financial, management and compliance systems; and â€¢attract, hire and retain additional administrative, clinical, regulatory and scientific personnel. In addition, because of the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to accurately predict the timing or amount of increased expenses and when, or if, we will be able to achieve profitability. Our expenses could increase, and profitability could be further delayed if we decide to or are required by regulatory authorities to perform studies or trials in addition to those currently expected or if there are any delays in the initiation, enrollment or completion of any planned or future preclinical studies or clinical trials of our current and future product candidates. Even if we complete the development and regulatory processes necessary to obtain marketing approval, we anticipate incurring significant costs associated with launching and commercializing zetomipzomib, KZR-261 and any future product candidates. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of the Company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. We have a limited operating history and have never generated revenue from product sales, which may make it difficult to evaluate the success of our business to date and to assess our future viability. We are a clinical-stage company and our operations to date have been largely focused on raising capital and conducting preclinical and clinical development of zetomipzomib and KZR-261. As an organization, we have not yet demonstrated an ability to successfully complete clinical development, obtain regulatory approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization of our product candidates. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history. Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with any future collaborative partners, to successfully complete the development of and obtain the regulatory approvals necessary to commercialize zetomipzomib, KZR-261 and any future product candidates. We do not anticipate generating revenue from product sales for the next several years, if ever. Our ability to generate revenue from product sales depends heavily on our, or any future collaboratorsâ€™, success in: â€¢timely and successfully completing preclinical and clinical development of zetomipzomib, KZR-261 and any future product candidates; â€¢obtaining regulatory approvals for zetomipzomib, KZR-261 and any future product candidates for which we successfully complete clinical trials; â€¢launching and commercializing any product candidates for which we obtain regulatory approval by establishing a sales force, marketing and distribution infrastructure or, alternatively, collaborating with a commercialization partner; â€¢qualifying for and obtaining coverage and adequate reimbursement by government and third-party payors for any product candidates for which we obtain regulatory approval, both in the United States and internationally; â€¢developing, validating and maintaining commercially viable, sustainable, scalable, reproducible and transferable manufacturing processes for zetomipzomib, a self-administered dual-chamber system for administering zetomipzomib and any future product candidates that are compliant with current good manufacturing practices, or cGMP; â€¢establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate amount and quality of starting materials, drug substance, drug product and drug delivery devices and services to support clinical development, as well as the market demand for zetomipzomib, KZR-261 and any future product candidates, if approved; â€¢obtaining market acceptance, if and when approved, of zetomipzomib, KZR-261 or any future product candidate as a viable treatment option by physicians, patients, third-party payors and others in the medical community; â€¢effectively addressing any competing technological and market developments; â€¢implementing additional internal systems and infrastructure, as needed; Â 30 Â â€¢negotiating favorable terms in any collaboration, licensing, spin-off or other arrangements into which we may enter and performing our obligations pursuant to such arrangements; â€¢maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; and â€¢securing appropriate pricing in the United States and internationally. We expect our financial condition and operating results to continue to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. We may need to eventually transition from a company with a research and development focus to a company capable of undertaking commercial activities. We may encounter unforeseen expenses, difficulties, complications and delays and may not be successful in such a transition. We will require substantial additional capital to finance our operations, which may not be available on acceptable terms, if at all. Failure to obtain this necessary capital when needed may force us to delay, reduce or terminate certain of our product development programs or other operations. Our operations have consumed substantial amounts of cash since our inception. We expect our expenses to increase in connection with our ongoing and planned activities, particularly as we continue to develop and potentially commercialize our product candidates, in addition to costs associated with the acquisition or in-licensing of any additional product candidates we may pursue. Our expenses could increase beyond expectations if the U.S. Food and Drug Administration, or FDA, or comparable foreign regulatory authorities require us to perform clinical and other studies in addition to those that we currently anticipate. In addition, if we obtain marketing approval for our product candidates, we expect to incur significant expenses related to sales, marketing, manufacturing and distribution. As of June 30, 2024, we had cash, cash equivalents and marketable securities of $164.2 million. We believe that our cash, cash equivalents and marketable securities as of June 30, 2024 will fund our current operating plans through at least the next 12 months from the date the financial statements were issued. However, our operating plan may change as a result of many factors currently unknown to us, including as a result of the macroeconomic uncertainties and geopolitical tensions, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, third-party funding, marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. If the adverse global economic conditions, including higher inflation rates and changes in interest rates, persist or worsen, we could experience an inability to access additional capital or engage in strategic transactions on terms reasonable to us, or at all. We do not currently have any commitments for future funding other than reimbursement, milestone and royalty payments we may receive under our Everest License Agreement, and we may not receive any further funds under that agreement. In any event, we will require substantial additional capital to develop a delivery system for zetomipzomib, conduct additional clinical trials, seek regulatory approval and commence commercialization of zetomipzomib, KZR-261 or any future product candidates. Even if we believe we have sufficient capital for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. Any additional capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize zetomipzomib, KZR-261 and any future product candidates. If we do not raise additional capital in sufficient amounts, or on terms acceptable to us, we may be prevented from pursuing discovery, development and commercialization efforts, which will harm our business, operating results and prospects. Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish proprietary rights. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through public or private equity or debt financings, third-party funding, marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. We do not have any committed external source of funds. In December 2021, we entered into Sales Agreement, or the ATM Agreement, with Cowen and Company, LLC, for an at-the-market offering program that allows us to sell up to an aggregate of $200 million of our common stock. As of June 30, 2024, approximately $68.3 million remains available under the at-the-market offering program. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. In addition, we may issue equity or debt securities as consideration for obtaining rights to additional compounds. Debt and equity financings, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as redeeming our shares, making investments, incurring additional debt, making capital expenditures, declaring dividends or placing limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that Â 31 Â could negatively impact our ability to conduct our business. For example, our obligations under the Loan Agreement are secured by a security interest in all of our assets, other than our intellectual property which is subject to a negative pledge. In addition, the Loan Agreement contains customary covenants that, subject to specific exceptions, restrict our ability to, among other things, declare dividends or redeem or repurchase equity interests, incur additional liens, make loans and investments, incur additional indebtedness, engage in mergers, acquisitions and asset sales, transact with affiliates, undergo a change in control, add or change business locations, or engage in businesses that are not related to its existing business. In addition, if we raise additional capital through future collaborations, strategic alliances or third-party licensing arrangements, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. For example, in September 2023, we entered into a collaboration and license agreement with Everest granting it an exclusive license to develop and commercialize zetomipzomib in the greater China region, South Korea and certain Southeast Asian countries in exchange for an upfront payment and potential milestone and royalty payments. If we are unable to raise additional capital when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise develop and market ourselves. The terms of the Loan Agreement with Oxford Finance place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business. In November 2021, we entered into a Loan Agreement with Oxford Finance that provided us with up to $50.0 million of borrowing capacity across five potential tranches. The initial tranche of $10.0 million was funded at the closing of the Loan Agreement, and we declined the remaining tranches in borrowing capacity available to us. Our overall leverage and certain obligations and affirmative and negative covenants contained in the related documentation could adversely affect our financial health and business and future operations by limiting our ability to, among other things, satisfy our obligations under the Loan Agreement, refinance our debt on terms acceptable to us or at all, plan for and adjust to changing business, industry and market conditions, use our available cash flow to fund future acquisitions and make dividend payments, and obtain additional financing for working capital, to fund growth or for general corporate purposes, even when necessary to maintain adequate liquidity. If we default under the Loan Agreement, Oxford Finance may accelerate all of our repayment obligations and exercise all of their rights and remedies under the Loan Agreement and applicable law, potentially requiring us to renegotiate our agreement on terms less favorable to us. Further, if we are liquidated, the lendersâ€™ right to repayment would be senior to the rights of the holders of our common stock to receive any proceeds from the liquidation. Oxford Finance could declare a default upon the occurrence of an event of default, including events that they interpret as a material adverse change as defined in the Loan Agreement, payment defaults or breaches of certain affirmative and negative covenants, thereby requiring us to repay the loan immediately. Any declaration by Oxford Finance of an event of default could significantly harm our business and prospects and could cause the price of our common stock to decline. Additionally, if we raise any additional debt financing, the terms of such additional debt could further restrict our operating and financial flexibility. We are required and expect to make significant payments in connection with our license agreement with Onyx Therapeutics, Inc., or Onyx, for zetomipzomib. We acquired rights to zetomipzomib, pursuant to an exclusive license agreement with Onyx, or the Onyx License Agreement. Under the Onyx License Agreement, we are subject to significant obligations, including payment obligations triggered upon achievement of specified milestones and royalties on licensed product sales. We have paid $5.0 million in milestone payments to date under the Onyx License Agreement, and we are obligated to pay Onyx additional milestone payments of up to $167.5 million in the aggregate upon the achievement of certain development, regulatory and sales milestones. In addition, we are obligated to pay Onyx tiered royalties based on net sales of zetomipzomib. If these payments become due, we may not have sufficient funds available to meet our obligations and our development efforts may be harmed. Our ability to use net operating losses and certain other tax attributes to offset future taxable income may be subject to limitation. Our net operating loss, or NOL, carryforwards could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. Our NOLs generated in tax years beginning on or prior to December 31, 2017 are permitted to be carried forward for only 20 years under applicable U.S. tax law. Our federal NOLs generated in tax years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of current year taxable income. It is uncertain if and to what extent various states will conform to federal law with respect to the limitations on the use of NOLs. In addition, under Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an â€œownership change,â€ its ability to use its pre-change NOL carryforwards and other pre-change Â 32 Â tax attributes (such as research tax credits) to offset its post-change income may be limited. A Section 382 â€œownership changeâ€ generally occurs if one or more stockholders or groups of stockholders who own at least 5% of our stock increase their ownership by more than 50 percentage points (by value) over their lowest ownership percentage over a rolling three-year period. We may have experienced ownership changes in the past and may experience ownership changes in the future as a result of shifts in our stock ownership (some of which are outside our control). As a result, if we earn net taxable

income, our ability to use our pre-change NOLs to offset such taxable income may be subject to limitations. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. Consequently, even if we achieve profitability, we may not be able to utilize a material portion of our NOL carryforwards and certain other tax attributes, which could have a material adverse effect on cash flow and results of operations. Changes in tax laws or regulations could materially adversely affect our company. The tax regimes to which we are subject or under which we operate are unsettled and may be subject to significant change. The issuance of additional guidance related to existing or future tax laws, or changes to tax laws or regulations proposed or implemented by the current or a future U.S. presidential administration, Congress, or taxing authorities in other jurisdictions, including jurisdictions outside of the United States, could materially affect our tax obligations and effective tax rate. To the extent that such changes have a negative impact on us, our suppliers, manufacturers, or our customers, including as a result of related uncertainty, these changes may adversely impact our business, financial condition, results of operations, and cash flows. The amount of taxes we pay in different jurisdictions depends on the application of the tax laws of various jurisdictions, including the United States, to our international business activities, tax rates, new or revised tax laws, or interpretations of tax laws and policies, and our ability to operate our business in a manner consistent with our corporate structure and intercompany arrangements. The taxing authorities of the jurisdictions in which we operate may challenge our methodologies for pricing intercompany transactions pursuant to our intercompany arrangements or disagree with our determinations as to the income and expenses attributable to specific jurisdictions. If such a challenge or disagreement were to occur, and our position was not sustained, we could be required to pay additional taxes, interest, and penalties, which could result in one-time tax charges, higher effective tax rates, reduced cash flows, and lower overall profitability of our operations. Our financial statements could fail to reflect adequate reserves to cover such a contingency. Similarly, a taxing authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a â€œpermanent establishmentâ€ under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions. Risks Related to the Development and Commercialization of Our Product Candidates Our future success is substantially dependent on the successful clinical development, regulatory approval and commercialization of zetomipzomib and KZR-261. If we are not able to obtain required regulatory approvals, we will not be able to commercialize our product candidates, and our ability to generate revenue will be adversely affected. The time required to obtain approval or other marketing authorizations by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations and the type and amount of clinical data necessary to gain approval may change during the course of a product candidateâ€™s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate, and it is possible that neither our current product candidates, nor any product candidates we may seek to develop in the future, will ever obtain regulatory approval. Neither we nor any future collaborator is permitted to market zetomipzomib or KZR-261 in the United States or abroad until we receive regulatory approval from the FDA or the applicable foreign regulatory authority. Prior to obtaining approval to commercialize our product candidates in the United States or abroad, we must demonstrate with substantial evidence from well controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. Results from clinical trials and preclinical studies can be interpreted in different ways. Even if we believe the clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and comparable foreign regulatory authorities. The FDA may also require us to conduct additional clinical trials or nonclinical studies for our product candidates either prior to or post-approval, or it may object to the design of our clinical trials and other elements of our clinical development programs. In addition, the FDA typically refers applications for novel drugs to an advisory committee comprising outside experts. The FDA is not bound by the recommendation of the advisory committee, but it considers such recommendation when making its decision. Of the large number of product candidates in development, only a small percentage are successfully approved by the FDA or a comparable foreign regulatory authority and are commercialized. The lengthy approval or marketing authorization process as well as Â 33 Â the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval or marketing authorization to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects. We have invested a significant portion of our time and limited financial and management resources in the development of zetomipzomib and KZR-261. Our business is dependent on our ability to successfully complete development of, obtain regulatory approval for, and, if approved, successfully commercialize zetomipzomib and KZR-261 in a timely manner. Our resource allocation decisions may cause us to fail to capitalize on profitable market opportunities for our product candidates. Even if we eventually complete clinical testing and receive approval of a new drug application, or NDA, or foreign marketing application for zetomipzomib, KZR-261 or any future product candidates, the FDA or the comparable foreign regulatory authorities may grant approval or other marketing authorization contingent on the performance of costly additional clinical trials, including post-market clinical trials. The FDA or the comparable foreign regulatory authorities also may approve or authorize for marketing a product candidate for a more limited indication or patient population than we originally request, and the FDA or comparable foreign regulatory authorities may not approve or authorize the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable regulatory approval or other marketing authorization would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects. In addition, the FDA and comparable foreign regulatory authorities may change their policies, adopt additional regulations or revise existing regulations or take other actions, which may prevent or delay approval of our future products under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained. In addition, we could also experience delays in the timing of our interactions with regulatory authorities due to absenteeism by governmental employees, inability to conduct planned physical inspections related to regulatory approval, which could delay anticipated approval decisions and otherwise delay or limit our ability to make planned regulatory submissions or obtain new product approvals. Even if we receive regulatory approval to market any of our product candidates, we cannot assure you that any such product candidate will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. Furthermore, even if we obtain regulatory approval for any of our product candidates, we will still need to develop a commercial organization, establish a commercially viable pricing structure and obtain approval for adequate reimbursement from third-party and government payors. If we are unable to successfully commercialize zetomipzomib, KZR-261 and any future product candidates, we may not be able to generate sufficient revenue to continue our business. Clinical trials are very expensive, time consuming and difficult to design and implement. Our product candidates will require clinical testing before we are prepared to submit an NDA for regulatory approval. The clinical trial process is expensive, time consuming, difficult to design and implement, and subject to uncertainty. We estimate that the successful completion of clinical trials of our product candidates will take several years to complete. We cannot predict with any certainty if or when we might submit an NDA for regulatory approval for any of our product candidates or whether any such NDA will be approved by the FDA. Human clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. For instance, the FDA may not agree with our proposed endpoints for any future clinical trial of our product candidates, which may delay the commencement of our clinical trials. We may design the inclusion and exclusion criteria for trial participation too narrowly, which would make it difficult to find and enroll patients for our clinical trials. In addition, we may not succeed in developing and validating disease-relevant clinical endpoints based on insights regarding biological pathways for the disorders we are studying. Failure can occur at any stage, and we could encounter problems that cause us to suspend, abandon or repeat clinical trials. PALIZADE is a global, placebo-controlled, double-blind Phase 2b clinical trial evaluating zetomipzomib in patients with LN. As an organization, we have not previously conducted a clinical trial to the scale of the PALIZADE trial. We have engaged and intend to use a single contract research organization, or CRO, to manage the PALIZADE trial, and although we will oversee their performance and maintain certain regulatory responsibilities, the ultimate success of initiating, enrolling and completing this trial, and ensuring regulatory and quality compliance across several countries, will depend significantly on the CRO's performance, in addition to several other third-party service providers and clinical trial vendors in the United States and worldwide. We are conducting the PALIZADE trial in several countries where we have not previously engaged with local regulatory authorities nor performed clinical trials. The process and timelines required to obtain approval from foreign regulatory authorities is unpredictable and may depend upon numerous factors and their substantial discretion. The inability to obtain and maintain regulatory approval for the conduct of the PALIZADE trial outside the United States may impact the timelines and completion of the PALIZADE trial. If the market opportunities for zetomipzomib and KZR-261 are smaller than we believe they are, our business may suffer. Â 34 Â We currently focus our drug development of zetomipzomib on treatments of immune-mediated diseases, including lupus nephritis and autoimmune hepatitis. Our eligible patient population and pricing estimates may differ significantly from the actual market addressable by our product candidates. Our projections of both the number of people who have these disorders, as well as the subset of people with these disorders who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, patient foundations or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these disorders. Our Phase 1 trial of KZR-261 is designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, and we have not yet selected the tumor types or patient populations for the next stages of clinical development. The number of eligible patients for either product candidate may turn out to be lower than expected. Likewise, the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with our product candidates. If the market opportunities for our product candidates are smaller than we estimate, our business and results of operations could be adversely affected. Due to the significant resources required for clinical development, we are required to make strategic decisions for the development of our product candidates. We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on other opportunities that may be more profitable or for which there may be a greater likelihood of success. The development of zetomipzomib and KZR-261 requires significant capital investment. Due to the significant resources required for clinical development, we must focus our research and development efforts on specific indications and decide which development opportunities to pursue and advance for each program. For example, in August 2024, we stopped enrollment in the dose expansion portion of the KZR-261 Phase 1 clinical study to reallocate our clinical resources toward development of zetomipzomib. Our decisions concerning the allocation of development, management and financial resources may not lead to the development of viable commercial products and may divert resources away from better opportunities. If we do not accurately evaluate the viability, development costs and commercial potential of our product candidates, we may fail to capitalize on profitable market opportunities, forego or delay opportunities to pursue other product candidates or other indications that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to product candidates through strategic transactions, including collaboration, licensing or other royalty arrangements, asset sales, and spin-offs, in cases in which it would have been more advantageous for us to retain ownership and sole development and commercialization rights to such product candidates. We may explore strategic collaborations, which would require us to relinquish important rights to and control over the development and commercialization of our product candidates to any future collaborators. Over time, our business strategy may include entering into product development collaborations, including strategic collaborations with major biotechnology or pharmaceutical companies. For example, in September 2023, we entered into a collaboration and license agreement with Everest granting it exclusive license to develop and commercialize zetomipzomib in the greater China region, South Korea and certain Southeast Asian countries in exchange for an upfront payment and potential milestone and royalty payments. We cannot predict what form such a strategic collaboration might take. We face significant competition in seeking appropriate strategic collaborators, and the negotiation process can be complicated and time consuming. Even if we are successful in our efforts to establish new development collaborations, the terms of such collaborations may not be favorable to us. Entering into future collaborations could subject us to a number of risks, including: â€¢we may be required to relinquish important rights to and control over the development and commercialization of our product candidates; â€¢we may be required to undertake the expenditure of substantial operational, financial and management resources; â€¢we may be required to issue equity securities that would dilute our stockholdersâ€™ percentage ownership of our company; â€¢we may be required to assume substantial actual or contingent liabilities; â€¢we may not be able to control the amount and timing of resources that our strategic collaborators devote to the development or commercialization of our product candidates; â€¢strategic collaborators may select indications or design clinical trials in a way that may be less successful or slower than if we were doing so; â€¢strategic collaborators may delay clinical trials, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing; â€¢strategic collaborators may not pursue further development and commercialization of products resulting from the strategic collaboration arrangement or may elect to discontinue research and development programs; â€¢strategic collaborators may not commit adequate resources to the marketing and distribution of our product candidates, limiting our potential revenues from these products; Â 35 Â â€¢disputes may arise between us and our strategic collaborators that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts managementâ€™s attention and consumes resources; â€¢strategic collaborators may experience financial difficulties; â€¢strategic collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation; â€¢business combinations or significant changes in a strategic collaboratorâ€™s business strategy may adversely affect a strategic collaboratorâ€™s willingness or ability to complete its obligations under any arrangement; â€¢strategic collaborators could decide to move forward with a competing product candidate developed either independently or in collaboration with others, including our competitors; and â€¢strategic collaborators could terminate the arrangement or allow it to expire, which would delay the development and may increase the cost of developing our product candidates. Success in preclinical studies or earlier clinical trials may not be indicative of future clinical trial results, and we cannot assure you that any clinical trials will lead to results sufficient for the necessary regulatory approvals. Success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Preclinical tests and early clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side effects of product candidates at various doses and schedules. Success in preclinical studies and earlier clinical trials does not ensure that later trials designed to test efficacy will be successful, nor does it predict final results. Our product candidates may fail to show the desired safety and efficacy in clinical development despite positive results in preclinical studies or having successfully advanced through earlier clinical trials. For example, in May 2022, we reported topline data from our PRESIDIO Phase 2 clinical trial of zetomipzomib in patients with dermatomyositis and polymyositis, in which zetomipzomib did not demonstrate significant differentiation from placebo. In addition, the design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. As an organization, we have limited experience designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, we may experience regulatory delays or rejections as a result of many factors, including changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations and prospects. Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be delayed, made more difficult or rendered impossible by multiple factors outside our control. Identifying and qualifying patients to participate in our clinical trials is critical to our success. We are developing zetomipzomib to address several autoimmune diseases with high degrees of unmet medical need, including lupus nephritis and autoimmune hepatitis. If the actual number of patients with these disorders is smaller than we anticipate, or if these patients are unwilling to participate in a clinical trial, we may encounter difficulties in enrolling patients in our clinical trials, thereby delaying or preventing development and approval of our product candidates. Even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. Patient enrollment and retention in clinical trials depends on many factors, including the size of the patient population, the nature of the trial protocol, the existing body of safety and efficacy data, the number and nature of competing treatments and ongoing clinical trials of competing therapies for the same indication, the proximity of patients to clinical sites, our ability to provide zetomipzomib for at-home administration, and the eligibility criteria for the trial. Because our focus includes

rare disorders, there are limited patient pools from which to draw in order to complete our clinical trials in a timely and cost-effective manner. Furthermore, our efforts to build relationships with patient communities may not succeed, which could result in delays in patient enrollment in our clinical trials. In addition, any negative results we may report in clinical trials of our product candidate may make it difficult or impossible to recruit and retain patients in other clinical trials of that same product candidate. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our product candidates or could render further development impossible. For example, political instability or disruption in a geographic region where we are conducting trials, regardless of cause, including public health crises, war, terrorism, social unrest and political changes, could delay or prevent patients from enrolling or from receiving treatment in accordance with the protocol and the required timelines, which could delay our clinical trials, or prevent us from completing our clinical trials at all. Any inability to timely and successfully complete clinical development will increase our costs, slow our development plans and impair our ability to generate revenue from our product candidates. In addition, we may be reliant on CROs and clinical trial sites to ensure proper and timely Â 36 Â conduct of our clinical trials and, while we intend to enter into agreements governing their services, we will be limited in our ability to compel their actual performance. We may encounter substantial delays or difficulties in our clinical trials. We may not commercialize, market, promote or sell any product candidate without obtaining marketing approval from the FDA or a comparable foreign regulatory authority, and we may never receive such approvals. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans and will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. A failure of one or more clinical trials can occur at any stage of testing. For example, in May 2022, we reported topline data from our PRESIDIO Phase 2 clinical trial of zetomipzomib in patients with dermatomyositis and polymyositis, in which zetomipzomib did not demonstrate significant differentiation from placebo. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. Moreover, circumstances may arise that could result in suspending or terminating our ongoing clinical trials. As an example, some patients included in the Phase 2 portion of our MISSION clinical trial were located in Ukraine and Russia at the time of the February 2022 Russian invasion of Ukraine. The closure of sites, the inability to screen and enroll new patients or any premature discontinuation of treatment by patients already enrolled in our trial could result in the need to enroll additional patients, which would be costly and could delay our anticipated timeline for the completion of the trial. Any inability to timely and successfully complete clinical development will increase our costs, slow our development plans and impair our ability to generate revenue from our product candidates. We have experienced and may in the future experience numerous unforeseen events that may prevent the timely and successful completion of our clinical trials, or result in the termination of such clinical trials prior to their completion, including: â€¢failure to recruit suitable patients to participate in a clinical trial, enrollment in these clinical trials may be slower than we anticipate, and participants may drop out during the course of these trials at a higher rate than we anticipate; â€¢delays in manufacturing, testing, releasing, validating and shipping stable quantities of our product candidates and placebo for our clinical trial sites; â€¢delays in reaching a consensus with the FDA and foreign regulatory authorities on the design of our clinical trials; â€¢the number of patients required for clinical trials to produce statistically meaningful data may be larger than we anticipate; â€¢the costs of clinical trials of our product candidates may be greater than we anticipate, which may be more likely as a result of increased price inflation worldwide; â€¢occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits; â€¢imposition of a clinical hold by regulatory authorities as a result of a serious adverse event, concerns with a class of product candidates or after an inspection of our clinical trial operations, trial sites or manufacturing facilities; â€¢regulators or institutional review boards or IRBs, may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site, or may otherwise suspend our clinical trials at any time if it appears we are or our collaborators are failing to conduct a trial in accordance with regulatory requirements; â€¢delays in identifying and recruiting suitable clinical investigators or reaching agreement on acceptable terms with prospective clinical trial sites; â€¢clinical trials of our product candidates may produce negative or inconclusive results, such as the topline data from our PRESIDIO Phase 2 clinical trial of zetomipzomib in patients with dermatomyositis and polymyositis, in which zetomipzomib did not demonstrate significant differentiation from placebo; â€¢failure to perform our clinical trials in accordance with current Good Clinical Practice, or cGCP, or regulations required by the FDA or foreign regulatory authorities; â€¢changes in regulatory requirements and guidance or other unforeseen regulatory developments that require amending or submitting new clinical protocols; â€¢we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs; or Â 37 Â â€¢business interruptions resulting from geo-political actions, war, terrorism, natural disasters or public health crises. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates, if approved, or allow our competitors to bring competing drugs to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional testing to bridge our modified product candidate to earlier versions. Additionally, if the results of our clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates, we may: â€¢be delayed in obtaining marketing approval, if at all; â€¢obtain approval for indications or patient populations that are not as broad as intended or desired; â€¢obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; â€¢be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; â€¢have regulatory authorities withdraw, or suspend, their approval of the drug or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy, or REMS; â€¢be subject to the addition of labeling statements, such as warnings or contraindications; â€¢be sued or held liable for harm causes to patients; or â€¢experience damage to our reputation. Further, we, the FDA, comparable foreign regulatory authorities, or an IRB may suspend our clinical trials at any time if it appears that we or our collaborators are failing to conduct a trial in accordance with regulatory requirements, including cGCP, that we are exposing participants to unacceptable health risks, or if the FDA finds deficiencies in our INDs, or the conduct of these trials. Therefore, we cannot predict with any certainty the schedule for commencement and completion of clinical trials. If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of our product candidates could be negatively impacted, and our ability to generate revenues from our product candidates may be delayed. The manufacture of our product candidates is complex and uncertain, and until we develop a validated manufacturing process, we may encounter difficulties in supplying our planned and future clinical trials. If we encounter such difficulties, or fail to meet quality standards, our ability to meet clinical timelines and expand our development strategy could be impacted. The processes involved in manufacturing the active drug substance and finished drug product of zetomipzomib and KZR-261 are complex, expensive, highly regulated and subject to multiple risks and uncertainties. As product candidates are developed through early to late-stage clinical trials and then to approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are modified along the way to optimize the scale, process and results. Any changes to the manufacturing processes carry the risk that they will not achieve these intended objectives, or that the product candidates may not meet the rigorous quality standards necessary for use in our clinical trials. We are continuing to manufacture zetomipzomib and placebo in support of our PALIZADE and PORTOLA trials. However, if planned or future manufacturing of zetomipzomib fails to meet the quality standards for use in our clinical trials, or the active drug substance does not meet our quality specifications, it could impact our timelines and limit our development strategy. In addition, our contract manufacturing organizations, or CMOs, may be unable to successfully increase the manufacturing scale for our product candidates in a timely or cost-effective manner and may experience delays due to limited manufacturing capacity. In addition, quality issues may arise during manufacturing activities. If our CMOs are unable to successfully manufacture our product candidates in sufficient quantity in a timely manner, our planned clinical trials may be delayed or modified and we may also be unable to fulfill our obligations under the Everest License Agreement, allowing Everest to terminate its collaboration or other potential adverse consequences as provided in the Everest License Agreement. Our product candidates have been involved, and may be involved in the future, in investigator-initiated clinical trials, and we have limited or no control over the conduct of such trials. Zetomipzomib has been involved in an investigator-initiated clinical trial, and our product candidates may be involved in investigator-initiated clinical trials in the future. Investigator-initiated clinical trials pose similar risks as those set forth elsewhere in this â€œRisk Â 38 Â Factorâ€ section relating to our own internal clinical trials. However, while investigator-initiated clinical trials may provide us with clinical data that can inform our development strategy, we are not the sponsors of such trials, and therefore, we do not control the protocols, administration, quality or conduct of these trials, including follow-up with patients and ongoing data collection. Despite this lack of control, negative results in investigator-initiated clinical trials could have a material adverse effect on our business and prospects and the perception of our product candidates. Interim topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. From time to time, we may publish interim topline or preliminary data from our clinical trials. Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available, particularly from our open-label studies. Preliminary or topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. Preliminary or topline data may include, for example, data regarding a small percentage of the patients enrolled in a clinical trial, and such preliminary data should not be viewed as an indication, belief or guarantee that other patients enrolled in such clinical trial will achieve similar results or that the preliminary results from such patients will be maintained. As a result, interim and preliminary data may not be statistically significant and should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data may cause the trading price of our common stock to fluctuate significantly and could significantly harm our business prospects. Zetomipzomib is being developed as a lyophilized formulation which could adversely affect market acceptance if patients are required to reconstitute zetomipzomib themselves prior to injection. We are developing zetomipzomib as a lyophilized product candidate, meaning that it will be freeze-dried and must be reconstituted with water prior to patient administration. While lyophilized products are common in the drug industry, this method for administering zetomipzomib could adversely affect market acceptance and make it more difficult to conduct clinical trials of zetomipzomib. In our current trials, zetomipzomib is reconstituted in the hospital pharmacy prior to patient administration or reconstituted and self-administered by the patient at home. Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval. During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries, discomforts and other adverse events, to their doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. Regulatory authorities may draw different conclusions or require additional testing to confirm these determinations, if they occur. In addition, it is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by subjects or patients. Many times, side effects are only detectable after investigational drugs are tested in large-scale pivotal trials or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that zetomipzomib, KZR-261 or any future product candidates has side effects or causes serious or life-threatening side effects, the development of the product candidate may fail or be delayed, or, if the product candidate has received regulatory approval, such approval may be revoked, which would harm our business, prospects, operating results and financial condition. Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed and our ability to generate revenue through their sale may be delayed or eliminated. Any of these occurrences may harm our business, financial condition and prospects significantly. Additionally, if any of our product candidates receive marketing approval, the FDA could require us to include a black box warning in our label or adopt a REMS to ensure that the benefits outweigh the risks, which may include, among other things, a Medication Guide outlining the risks of the drug for distribution to patients and a communication plan to healthcare practitioners. Furthermore, if we or others identify undesirable side effects caused by our product candidates during development or after obtaining U.S. regulatory approval, several potentially significant negative consequences could result, including: â€¢regulatory authorities may not permit us to initiate our studies or could put them on hold; â€¢regulatory authorities may not approve, or may withdraw, their approval of the product; â€¢regulatory authorities may require us to recall the product; â€¢regulatory authorities may add new limitations for distribution and marketing of the product; Â 39 Â â€¢regulatory authorities may require the addition of warnings in the product label or narrowing of the indication in the product label; â€¢we may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients; â€¢we may be required to change the way the product is administered or modify the product in some other way; â€¢we may be required to implement a REMS program; â€¢the FDA may require us to conduct additional clinical trials or costly post-marketing testing and surveillance to monitor the safety or efficacy of the product; â€¢we could be sued and held liable for harm caused to patients; and â€¢our reputation may suffer. Any of the above events resulting from undesirable side effects or other previously unknown problems could prevent us from achieving or maintaining market acceptance of the affected product candidate, if approved. In addition, these events could substantially increase the costs of commercializing our product candidates and could significantly harm our business, prospects, financial condition and results of operations. We may not be able to obtain or maintain orphan drug designations or exclusivity for our product candidates, which could limit the potential profitability of our product candidates. Regulatory authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000, there is no reasonable expectation that sales of the drug in the United States will be sufficient to offset the costs of developing and making the drug available in the United States. If a drug with an orphan drug designation subsequently receives the first marketing approval for use in the rare disease or condition for which it was designated, then the sponsor is eligible for a seven-year period of marketing during which the FDA may not approve another sponsorâ€™s marketing application for a drug with the same active moiety and intended for the same use or indication as the approved orphan drug, except in limited circumstances, such as if a subsequent sponsor demonstrates its product is clinically superior. During a sponsorâ€™s orphan drug exclusivity period, however, competitors may receive approval for drugs with different active moieties for the same indication as the approved orphan drug, or for drugs with the same active moiety as the approved orphan drug, but for different indications. Further, if a designated orphan drug receives marketing approval for an indication broader than the rare disease or condition for which it received orphan drug designation, it may not be entitled to exclusivity. We intend to pursue orphan drug designation for zetomipzomib in the treatment of autoimmune hepatitis and any other rare immune-mediated disease indications we pursue for development. Obtaining orphan drug designation in additional indications and other jurisdictions may be difficult, and we may not be successful in doing so. The exclusivity for our orphan drug designations, and for any other designations that we may obtain in the future, may not effectively protect the drug from the competition of different drugs for the same condition, which could have already been approved or could be approved before or during the exclusivity period. Additionally, after an orphan drug is approved, the FDA could subsequently approve another application for the same drug for the same indication if the FDA concludes that the later drug is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusive marketing rights in the United States also may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. The failure to obtain an orphan drug designation for any product candidates we may develop, the inability to maintain that designation for the duration of the applicable period, or the inability to obtain or maintain orphan drug exclusivity could reduce our ability to make sufficient sales of the applicable product candidate to balance our expenses incurred to develop it, which would have a negative impact on our operational results and financial condition. Even if we obtain and maintain approval for our product candidates from the FDA, we may never obtain approval for our product candidates outside of the United States, which would limit our market opportunities and could harm our business. Approval of a product candidate in the United States by the FDA does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. Sales of zetomipzomib and KZR-261 outside of the United States will be subject to foreign regulatory requirements governing clinical trials and marketing

approval. Even if the FDA grants marketing approval for a product candidate, comparable foreign regulatory authorities also must approve the manufacturing and marketing of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and more onerous than, those in the United States, including additional preclinical studies or clinical trials. In many countries outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale Â 40 Â in that country. In some cases, the price that we intend to charge for any product candidates, if approved, is also subject to approval. Obtaining approval for zetomipzomib and KZR-261 in the European Union from the European Commission following the opinion of the European Medicines Agency, if we choose to submit a marketing authorization application there, would be a lengthy and expensive process. Even if a product candidate is approved, the FDA or the European Commission, as the case may be, may limit the indications for which the drug may be marketed, require extensive warnings on the drug labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of zetomipzomib, KZR-261 and any future product candidates in certain countries. Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Also, regulatory approval for our product candidates may be withdrawn. If we fail to comply with the regulatory requirements, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business, financial condition, results of operations and prospects could be harmed. Even if we obtain regulatory approval for any of our product candidates, they will remain subject to ongoing regulatory oversight. Even if we obtain regulatory approvals for our product candidates, such approvals will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information. For example, the FDA strictly regulates the promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the productâ€™s approved labeling. Additionally, any regulatory approvals that we receive for our product candidates may also be subject to a REMS, limitations on the approved indicated uses for which the drug may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 trials, and surveillance to monitor the quality, safety and efficacy of the drug. Such regulatory requirements may differ from country to country depending on where we have received regulatory approval. In addition, drug manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and comparable foreign regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the NDA or foreign marketing application. If we, or a regulatory authority, discover previously unknown problems with a drug, such as adverse events of unanticipated severity or frequency, or problems with the facility where the drug is manufactured or if a regulatory authority disagrees with the promotion, marketing or labeling of that drug, a regulatory authority may impose restrictions relative to that drug, the manufacturing facility or us, including requesting a recall or requiring withdrawal of the drug from the market or suspension of manufacturing. If we fail to comply with applicable regulatory requirements following approval of any of our product candidates, a regulatory authority may: â€¢issue an untitled letter or warning letter asserting that we are in violation of the law; â€¢seek an injunction or impose administrative, civil or criminal penalties or monetary fines; â€¢suspend or withdraw regulatory approval; â€¢suspend any ongoing clinical trials; â€¢refuse to approve a pending NDA or comparable foreign marketing application or any supplements thereto submitted by us or our partners; â€¢restrict the marketing or manufacturing of the drug; â€¢seize or detain the drug or otherwise require the withdrawal of the drug from the market; â€¢refuse to permit the import or export of product candidates; or â€¢refuse to allow us to enter into supply contracts, including government contracts. Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and harm our business, financial condition, results of operations and prospects. The FDAâ€™s and comparable foreign regulatory authoritiesâ€™ policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations. Â 41 Â In addition, we cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. Even if our product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success. Even if our product candidates receive marketing approval, they may fail to gain market acceptance by physicians, patients, third-party payors and others in the medical community. If they do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of zetomipzomib, KZR-261 and any future product candidates, if approved for commercial sale, will depend on a number of factors, including but not limited to: â€¢the efficacy and potential advantages compared to alternative treatments and therapies; â€¢the effectiveness of sales and marketing efforts; â€¢the strength of our relationships with patient communities; â€¢the cost of treatment in relation to alternative treatments and therapies, including any similar generic treatments; â€¢our ability to offer such drug for sale at competitive prices; â€¢the convenience and ease of administration compared to alternative treatments and therapies; â€¢the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; â€¢the strength of marketing and distribution support; â€¢the availability of third-party coverage and adequate reimbursement; â€¢the prevalence and severity of any side effects; and â€¢any restrictions on the use of the drug together with other medications. Our efforts to educate physicians, patients, third-party payors and others in the medical community on the benefits of our product candidates may require significant resources and may never be successful. Such efforts may require more resources than are typically required due to the complexity and uniqueness of our product candidates. Because we expect sales of our product candidates, if approved, to generate substantially all of our revenues for the foreseeable future, the failure of our product candidates to find market acceptance would harm our business. In addition, if we enter into a strategic collaboration regarding any of our product candidates, our rights to receive milestone payments and royalties related to such product candidates will depend on our collaboratorsâ€™ abilities to achieve market acceptance of those product candidates. We are dependent upon our collaboration with Everest to further develop and commercialize zetomipzomib in the Greater China region, South Korea and select Southeast Asian countries. If we or Everest fail to perform as expected, the potential for us to generate future revenues under the collaboration could be significantly reduced, the development and commercialization of zetomipzomib may be substantially delayed, and our business could be adversely affected. In September 2023, we entered into the Everest License Agreement granting Everest an exclusive license to develop and commercialize zetomipzomib in the greater China region, South Korea, and select Southeast Asian countries. Under the terms of the Everest License Agreement, we received an initial upfront payment of $7.0 million and are entitled to receive milestone payments upon achievement of certain development, regulatory and commercial milestone events, for total potential milestone payments of up to $125.5 million. In addition, Everest will pay to the Company tiered royalties on the net sales of zetomipzomib in the Territory during the term of the Everest License Agreement ranging from the single digit to the low-teens, subject to certain reductions. Everest will be responsible for, at its own cost, and is required to use commercially reasonable efforts to, develop and commercialize zetomipzomib in the licensed territory. In addition, we will collaborate with Everest on the PALIZADE trial, where Everest will have primary responsibility for clinical development and regulatory activities in the licensed territory and will reimburse the Company for clinical trial costs incurred in the licensed territory. Everest will also have the opportunity to participate in the Companyâ€™s future global clinical trials involving zetomipzomib. The Company has agreed to supply zetomipzomib to Everest during the term of the Everest License Agreement, subject to Everestâ€™s option to manufacture zetomipzomib for its own use in the licensed territory following completion of the PALIZADE trial. There can be no assurance that the parties will achieve any of the regulatory, development or sales milestones, or that we will receive any future milestone or royalty payments under the Everest License Agreement. Everestâ€™s activities may be influenced by, among other things, the efforts and allocation of resources by Everest, which we cannot control. If Everest does not perform in the manner we Â 42 Â expect or fulfill its responsibilities in a timely manner, or at all, the clinical development, manufacturing, regulatory approval, and commercialization efforts related to zetomipzomib could be substantially delayed. In addition, our collaboration with Everest may be unsuccessful due to other factors, including, without limitation, the following: â€¢Everest may terminate the agreement for convenience following completion, suspension or termination of the PALIZADE trial; â€¢Everest may change the focus of its development and commercialization efforts or prioritize other programs more highly and, accordingly, reduce the efforts and resources allocated to zetomipzomib; â€¢Everest may, within its commercially reasonable discretion, choose not to develop and commercialize zetomipzomib in any part of the licensed territory or for one or more indications, if at all; and â€¢If Everest is acquired during the term of our collaboration, the acquirer may have competing programs or different strategic priorities that could cause it to reduce its commitment to our collaboration or to terminate the collaboration. Â The actions of Everest and any other current or future licensees could adversely affect our business. We currently exclusively license zetomipzomib to Everest to develop and commercialize zetomipzomib in the greater China region, South Korea and select Southeast Asian countries. It is possible that any clinical trials conducted by Everest or any other current or future licensees in its respective licensed territories could have negative results, which in turn could have a material adverse effect on the development and commercialization of zetomipzomib in the United States and the rest of the world. In addition, we will depend on Everest or any other current or future licensee to comply with all applicable laws relative to the development and commercialization of zetomipzomib in its respective licensed territories. If Everest were to violate, or was alleged to have violated, any laws or regulations during the performance of its obligations to us, it is possible we could suffer financial and reputational harm or other negative outcomes, including possible legal consequences. In addition, in the event of any termination, breach or expiration of the Everest License Agreement, we may be required to devote additional efforts and to incur additional costs associated with pursuing the development and commercialization of zetomipzomib in the greater China region, South Korea and select Southeast Asian countries. We face substantial competition, which may result in others developing or commercializing drugs before or more successfully than us. The development and commercialization of new drugs is highly competitive. We face competition from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell drugs or are pursuing the development of product candidates for the treatment of the indications that we are pursuing. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. More established companies may have a competitive advantage over us due to their greater size, resources and institutional experience. In particular, these companies have greater experience and expertise in securing reimbursement, government contracts and relationships with key opinion leaders, conducting testing and clinical trials, obtaining and maintaining regulatory approvals and distribution relationships to market products and marketing approved drugs. These companies also have significantly greater research and marketing capabilities than we do. If we are not able to compete effectively against existing and potential competitors, our business and financial condition may be harmed. As a result of these factors, our competitors may obtain regulatory approval of their drugs before we are able to, which may limit our ability to develop or commercialize our product candidates. Our competitors may also develop therapies that are safer, more effective, more widely accepted or less expensive than ours, or may be more successful than we are in manufacturing and marketing their drugs. These advantages could render our product candidates obsolete or non-competitive before we can recover the costs of such product candidatesâ€™ development and commercialization. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific, medical, management and commercial personnel, establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be successful in commercializing such product candidates, if and when they are approved. Â 43 Â To successfully commercialize any product candidate that may result from our development programs, we will need to build out our sales and marketing capabilities, either on our own or with others. The establishment and development of our own commercial team or the establishment of a contract sales force to market any product candidate we may develop will be expensive and time-consuming and could delay any drug launch. Moreover, we cannot be certain that we will be able to successfully develop this capability. We may seek to enter into collaborations with other entities to utilize their established marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. If any current or future collaborators do not commit sufficient resources to commercialize our product candidates, or we are unable to develop the necessary capabilities on our own, we may be unable to generate sufficient revenue to sustain our business. We compete with many companies that currently have extensive, experienced and well-funded marketing and sales operations to recruit, hire, train and retain marketing and sales personnel. We will likely also face competition if we seek third parties to assist us with the sales and marketing efforts of our product candidates. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies. If we seek to commercialize our product candidates outside of the United States, a variety of risks associated with international operations could harm our business. If we seek to commercialize our product candidates outside of the United States, we expect that we will be subject to additional risks including: â€¢different regulatory requirements for approval of therapies in foreign countries; â€¢reduced protection for intellectual property rights; â€¢unexpected changes in tariffs, trade barriers and regulatory requirements; â€¢economic weakness, including inflation, or political instability in particular foreign economies and markets; â€¢compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; â€¢foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country; â€¢foreign reimbursement, pricing and insurance regimes; â€¢workforce uncertainty in countries where labor unrest is more common than in the United States; â€¢production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and â€¢business interruptions resulting from geopolitical actions, war, terrorism, natural disasters and public health epidemics. We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor and other legal requirements imposed by many of the individual countries in and outside of Europe with which we will need to comply. Many biopharmaceutical companies have found the process of marketing their own products in foreign countries to be very challenging. Coverage and adequate reimbursement may not be available for zetomipzomib or KZR-261, which could make it difficult for us to sell profitably, if approved. Market acceptance and sales of any product candidates that we commercialize, if approved, will depend in part on the extent to which coverage and reimbursement for these drugs and related treatments will be available from third-party payors, including government health administration authorities, managed care organizations and other private health insurers. Third-party payors decide which therapies they will pay for and establish reimbursement levels. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a payor-by-payor basis. One third-party payorâ€™s determination to provide coverage for a drug does not assure that other payors will also provide coverage, and adequate reimbursement, for the drug. Additionally, a third-party payorâ€™s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Each third-party payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier of its formulary it will be placed. The position on a third-party payorâ€™s list of covered drugs, or formulary, generally determines the co-payment that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products. Â 44 Â Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be available for any drug that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage and reimbursement may impact the demand for, or the price of, any drug for which we obtain marketing approval. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize zetomipzomib, KZR-261 or any future product candidates that we develop. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies

and reimbursement rates may be implemented in the future. Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop. We face an inherent risk of product liability exposure related to the testing of our product candidates in clinical trials, both within and outside of the United States, and may face an even greater risk if we commercialize any product candidate that we may develop. If we cannot successfully defend ourselves against claims that any such product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: â€¢decreased demand for any product candidate that we may develop; â€¢loss of revenue; â€¢substantial monetary awards to trial participants or patients; â€¢significant time and costs to defend the related litigation; â€¢withdrawal of clinical trial participants; â€¢increased insurance costs; â€¢the inability to commercialize any product candidate that we may develop; and â€¢injury to our reputation and significant negative media attention. Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as we advance through clinical development and if we are able to successfully commercialize any product candidate. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Risks Related to Regulatory Compliance Our relationships with customers, physicians, and third-party payors may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, transparency laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. Healthcare providers, including physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors may subject us to various federal and state fraud and abuse laws and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims laws and the law commonly referred to as the Physician Payments Sunshine Act and regulations. These laws will impact, among other things, our clinical research, proposed sales, marketing and educational programs. In addition, we may be subject to patient privacy laws by both the federal government and the states in which we conduct or may conduct our business. The laws that will affect our operations include, but are not limited to: â€¢the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for the purchase, recommendation, leasing or furnishing of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers, formulary managers and others, on the other hand. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it to have committed a violation; â€¢federal civil and criminal false claims laws, including, without limitation, the federal civil False Claims Act, and civil monetary penalty laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other government payors that are false or Â 45 Â fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. Federal Anti-Kickback Statute violations and certain marketing practices, including off-label promotion, implicate the federal civil False Claims Act; â€¢the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal civil and criminal statutes that prohibit, among other things, a person from knowingly and willfully executing, or attempting to execute, a scheme or artifice to defraud any healthcare benefit program, or making false or fraudulent statements to defraud any healthcare benefit program, regardless of the payor (e.g., public or private); â€¢HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information on health plans, health care clearinghouses and certain healthcare providers, known as covered entities, and their respective business associates and their subcontractors that perform certain services involving the use or disclosure of individually identifiable health information; â€¢federal transparency laws, including the federal Physician Payments Sunshine Act, that require certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Childrenâ€™s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare & Medicaid Services, or CMS, information related to: (i) payments or other â€œtransfers of valueâ€ made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals; and (ii) ownership and investment interests held by physicians and their immediate family members; and â€¢state and foreign law equivalents of each of the above federal laws, state laws that require manufacturers to report information related to payments and other "transfers of value" to physicians and other healthcare providers, marketing expenditures, or drug pricing, state laws that require pharmaceutical companies to comply with the pharmaceutical industryâ€™s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and state and local laws that require the registration of pharmaceutical sales representatives, or that otherwise restrict payments that may be made to healthcare providers; as well as state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations. The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our managementâ€™s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements. Healthcare legislative reform measures may have a negative impact on our business and results of operations. In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In March 2010, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Â 46 Â Act of 2010, or collectively the PPACA, was passed, which substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The PPACA, among other things: (i) addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; (ii) increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations; (iii) established annual fees and taxes on manufacturers of certain branded prescription drugs; (iv) expanded the availability of lower pricing under the 340B drug pricing program by adding new entities to the program; and (v) established a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturerâ€™s outpatient drugs to be covered under Medicare Part D. Since its passage, there have been varied executive, judicial and Congressional challenges to certain provisions of the PPACA. In addition, Congress has considered, and may consider in the future, legislation to repeal or repeal and replace all or part of the PPACA. While Congress has not passed any comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the PPACA have been signed into law. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the PPACA is unconstitutional in its entirety because the â€œindividual mandateâ€ was repealed by Congress. Further, prior to the U.S. Supreme Court ruling, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the PPACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the PPACA. It is possible that the PPACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the PPACA and our business. Other legislative changes have been proposed and adopted since the PPACA was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013, and due to subsequent legislative amendments to the statute, will remain in effect through 2032 unless additional congressional action is taken. On March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drugâ€™s average manufacturer price, for single source and innovator multiple source drugs, effective January 1, 2024. The American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. More recently, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or the IRA, into law, which included a number of significant drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services, or HHS, that would require pharmaceutical manufacturers to charge a negotiated â€œmaximum fair priceâ€ for certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements on manufacturers under Medicare Parts B and D to penalize price increases that outpace inflation, and a redesign of the Part D benefit, as part of which manufacturers are required to provide discounts on Part D drugs and Part D beneficiariesâ€™ annual out-of-pocket spending will be capped at $2,000 beginning in 2025, although the Medicare drug price negotiation program is currently subject to legal challenges. The U.S. Department of Health and Human Services has and will continue to issue and update guidance as these programs are implemented. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although they may be the Medicare drug price negotiation program is currently subject to legal challenges. It is unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. In response to the Biden administrationâ€™s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. Additional changes that may affect our business include the expansion of new programs such as Medicare payment for performance initiatives for physicians under the Medicare Access and CHIP Reauthorization Act of 2015, which introduced a merit-based incentive bonus program for Medicare physicians, also referred to as the Quality Payment Program. The Quality Payment Program consists of two payment tracks that eligible clinicians can participate in: Advanced Alternative Payment Models and the Merit-Based Incentive Payment System. Under both the Advanced Alternative Payment Models and the Merit-Based Incentive Payment System, performance data collected each performance year will affect Medicare payments in later years, including potentially reducing payments. Â 47 Â Also, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which have resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Additionally, based on a recent executive order, the Biden administration expressed its intent to pursue certain policy initiatives to reduce drug prices and directed HHS to submit a report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. It is unclear whether these this executive order or similar policy initiatives will be implemented in the future. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We expect that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved drug. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private third-party payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Risks Related to Our Dependence on Third Parties We will rely on third parties to manufacture clinical and commercial supplies of zetomipzomib, KZR-261 and any future product candidates. We do not own or operate facilities for drug manufacturing, testing, storage or distribution. We are dependent on third parties to manufacture the clinical supplies of our product candidates. Moreover, under the Everest License Agreement, we have committed to providing Everest with supply of zetomipzomib for the development and commercialization of zetomipzomib in the greater China region, South Korea and certain Southeast Asian countries, which we will have to source from third-party manufacturers. Any significant delay in the supply of a product candidate or raw material components for an ongoing clinical trial due to the need to replace a third-party CMO could considerably delay the completion of our clinical trials or cause us to breach our obligations under the Everest License Agreement. We are completely dependent on our CMOs for compliance with cGMP for manufacture of both active drug substances and finished drug products. If our CMOs cannot successfully manufacture active drug substances and finished drug product that conform to our specifications and the strict regulatory requirements of the FDA and comparable foreign regulatory authorities, we will not be able to secure or maintain regulatory approval for our product candidates. In addition, we have no control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our timelines and ability to develop, obtain regulatory approval for or market our product candidates, if approved. For any activities conducted in China, we are exposed to the increased possibility of supply disruptions and higher costs in the event of changes in the policies of the U.S. or Chinese governments, political unrest or unstable economic conditions including sanctions on China or any of our China-based suppliers. Our manufacturing costs could also increase as a result of future appreciation of the local currency in China or increased labor costs if the demand for skilled laborers increases and/or the availability of skilled labor declines in China. In addition, certain Chinese biotechnology companies may become subject to trade restrictions, sanctions, other regulatory requirements, or proposed legislation by the U.S. government, which could restrict or even prohibit our ability to work with such entities, thereby potentially disrupting the supply of material to us. For example, the recently proposed BIOSECURE Act introduced in the U.S. House of Representatives, and a substantially similar bill in the U.S. Senate, target U.S. government contracts, grants, and loans for entities that use equipment and services from certain named Chinese biotechnology companies and authorizes the U.S. government to include additional Chinese biotechnology companies of concern. If these bills become law, or similar laws are passed, they would have the potential to severely restrict the ability of companies to work with certain Chinese biotechnology companies of concern without losing the ability to contract with, or otherwise receive funding

from, the U.S. government. Such disruption could have adverse effects on the development of our product candidates and our business operations. The facilities used by our CMOs to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit an NDA for any of our product candidates. We also expect to rely on third-party manufacturers to supply us with sufficient quantities of our product candidates to be used, if approved, for commercialization. Our reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured product candidates ourselves, including: â€¢inability to meet our product specifications and quality requirements consistently; Â 48 Â â€¢delay or inability to procure or expand sufficient manufacturing capacity; â€¢issues related to scale-up of manufacturing; â€¢costs and validation of new equipment and facilities required for scale-up; â€¢our third-party manufacturers may not be able to execute our manufacturing procedures and other logistical support requirements appropriately; â€¢our third-party manufacturers may fail to comply with cGMP and other inspections by the FDA or comparable foreign regulatory authorities; â€¢our inability to negotiate manufacturing agreements with third parties under commercially reasonable terms, if at all; â€¢breach, termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us; â€¢reliance on single sources for drug components; â€¢lack of qualified backup suppliers for those components that are currently purchased from a sole or single source supplier; â€¢our third-party manufacturers may not devote sufficient resources to our product candidates; â€¢we may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our product candidates; â€¢operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier; and â€¢carrier disruptions or increased costs that are beyond our control. Any of these events could lead to clinical trial delays, failure to obtain regulatory approval or impact our ability to successfully commercialize our current or any future product candidates once approved. Some of these events could be the basis for FDA action, including injunction, request for recall, seizure, or total or partial suspension of production. We rely on third parties to conduct, supervise and monitor our clinical trials and preclinical studies, and if those third parties perform in an unsatisfactory manner, it may harm our business. We do not currently have the ability to independently conduct clinical trials. We intend to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and we expect to have limited influence over their actual performance. We rely upon CROs to monitor and manage data for our clinical programs. We expect to control only certain aspects of our CROsâ€™ activities. Nevertheless, we will be responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. For example, we have engaged and intend to use a single CRO to manage the PALIZADE trial, and although we will oversee their performance and maintain certain regulatory responsibilities, the ultimate success of initiating, enrolling and completing this trial, and ensuring regulatory and quality compliance across several countries, will depend significantly on the CROâ€™s performance. We and our CROs are required to comply with the good laboratory practices and good clinical practices, or GCP, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities in the form of International Council for Harmonisation guidelines for any of our product candidates that are in preclinical and clinical development, respectively. The regulatory authorities enforce GCP through periodic inspections of trial sponsors, principal investigators and clinical trial sites. Although we rely on CROs to conduct GCP-compliant clinical trials, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities. If we or our CROs fail to comply with GCP, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. Accordingly, if our CROs fail to comply with these regulations, we may be required to repeat clinical trials, which would delay the regulatory approval process. Our reliance on third parties to conduct clinical trials results in less direct control over the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with CROs and other third parties can be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. In addition, such parties may: â€¢have staffing difficulties; â€¢fail to comply with contractual obligations; Â 49 Â â€¢not devote sufficient time and resources to our clinical trials; â€¢experience regulatory compliance issues; or â€¢undergo changes in priorities or become financially distressed. These factors may materially adversely affect the timelines of our clinical trials and may subject us to unexpected cost increases that are beyond our control. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, fail to comply with regulatory requirements, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, the product candidate being developed. As a result, our financial results and commercial prospects would be harmed, our costs could increase, and our ability to generate revenue from the product candidate could be delayed. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities which could compete with recruitment of our clinical trials. If our relationship with any of these CROs terminates, we may be delayed in entering into new arrangements with alternative CROs or unable to do so on commercially reasonable terms. Changing CROs during an ongoing clinical trial involves substantial cost, requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can negatively impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a negative impact on our business, financial condition and prospects. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our product candidates. Risks Related to Our Intellectual Property Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. If we breach the Onyx License Agreement, we could lose the ability to continue the development and commercialization of zetomipzomib. The licensing of intellectual property is of critical importance to our business and to our current and future product candidates, and we expect to enter into additional such agreements in the future. In particular, our immunoproteasome program, including zetomipzomib, is dependent on the Onyx License Agreement. Pursuant to the Onyx License Agreement, Onyx granted us an exclusive license under certain patent rights, and a non-exclusive license to certain know-how, in each case controlled by Onyx, to develop, manufacture and commercialize certain types of compounds, including zetomipzomib, that are selective inhibitors of the immunoproteasome for any and all uses, other than those related to the diagnosis or treatment in humans of cancerous or pre-cancerous diseases or conditions, including those related to hematological diseases or conditions. The licensed compounds, including zetomipzomib, are selective for the immunoproteasome and therefore are not known or believed, based on scientific literature and the Companyâ€™s own research and development activities, to have any application in cancer or pre-cancerous conditions. However, notwithstanding these known characteristics of the licensed compounds, Onyx retains all rights under the licensed intellectual property rights that are not granted to the Company, and therefore Onyx retains rights under such intellectual property rights to develop and commercialize the licensed compounds in connection with the diagnosis or treatment in humans of cancerous or pre-cancerous diseases or conditions, including those related to hematological diseases or conditions, and also has the rights to transfer these rights to a third-party. If Onyx or its licensee develops and commercializes any of the licensed compounds in cancer or pre-cancerous indications that are commercially interchangeable with our product candidates, including zetomipzomib, sales by Onyx or its licensee of such compounds for cancer and pre-cancerous indications could result in the threat of off-label use in our licensed field, potentially diminishing our sales of the applicable licensed compounds in our licensed field. The Onyx License Agreement may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. Specifically, under the Onyx License Agreement, Onyx has a right of first negotiation under certain circumstances to obtain a license or a similar transfer of rights, if we are seeking to out-license rights to develop and/or commercialize certain licensed products. Â 50 Â Disputes may arise between us and any of these counterparties regarding intellectual property rights that are subject to such agreements, including, but not limited to: â€¢the scope of rights granted under the agreement and other interpretation-related issues; â€¢whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the agreement; â€¢our right to sublicense patent and other rights to third parties; â€¢our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; â€¢the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; â€¢our right to transfer or assign our license; and â€¢the effects of termination. These or other disputes over intellectual property that we have licensed, or will license or acquire in the future, may prevent or impair our ability to maintain our current arrangements on acceptable terms or may impair the value of the arrangement to us. Any such dispute could have an adverse effect on our business. If we fail to meet our obligations under these agreements in any material respect, the counterparty may have the right to terminate the respective agreement. Any uncured, material breach under a license could result in our loss of exclusive rights and may lead to a complete termination of our product development and any commercialization efforts for each of our product candidates. While we would expect to exercise all rights and remedies available to us, including seeking to cure any breach by us, and otherwise seek to preserve our rights under the technology licensed to or acquired by us, we may not be able to do so in a timely manner, at an acceptable cost or at all. Furthermore, certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. If we are unable to obtain and maintain patent protection for zetomipzomib, KZR-261 or any future product candidates, or if the scope of the patent protection obtained is not sufficiently broad, or if our patents are insufficient to protect our product candidates for an adequate amount of time, we may not be able to compete effectively in our markets. We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our development programs and product candidates. Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to zetomipzomib, KZR-261 and any future product candidates. We seek to protect our proprietary position by, among other methods, filing patent applications in the United States and abroad related to our current and future research programs and product candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We file patent applications directed to our product candidates in an effort to establish intellectual property positions directed to their compositions of matter as well as uses of these product candidates in the treatment of diseases. Our intellectual property includes patents and patent applications that we own as well as patents and patent applications that we in-license. For example, we have a field-specific exclusive license under the Onyx License Agreement to certain patents and patent applications relating to zetomipzomib. We or our licensors have not pursued or maintained, and may not pursue or maintain in the future, patent protection for our product candidates in every country or territory in which we may sell our products, if approved. In addition, we cannot be sure that any of our pending patent applications will issue or that, if issued, they have or will issue in a form that will be advantageous to us. The United States Patent and Trademark Office, or the USPTO, international patent offices or judicial bodies may deny or significantly narrow claims made under our patent applications and our issued patents may be successfully challenged, may be designed around, or may otherwise be of insufficient scope to provide us with protection for our commercial products. It is possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, patent prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the USPTO may be significantly narrowed by the time they issue, if issued at all. The claims of our issued patents or patent applications when issued may not cover our current or future product candidates, or even if such patents provide coverage, the Â 51 Â coverage obtained may not provide any competitive advantage. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our current or any future product candidates in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our current or any future product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates or companion diagnostic that we may develop. Further, if we encounter delays in clinical trials or regulatory approvals, the period of time during which we could market our product candidates under patent protection would be reduced. If the patent applications we hold or have in-licensed with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for zetomipzomib, KZR-261 or any future product candidates, it could dissuade companies from collaborating with us to develop and commercialize product candidates and future drugs and threaten our ability to commercialize, future drugs. Any such outcome could have a negative effect on our business. The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Furthermore, other parties may have developed or may develop technologies that may be related or competitive to our own, and such parties may have filed or may file patent applications, or may have received or may receive patents, claiming inventions that may overlap or conflict with those claimed in our patent applications or issued patents. Publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after the initial filing. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions until such publication dates have passed. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or drugs, in whole or in part, or which effectively prevent others from commercializing competitive technologies and drugs. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to the United States patent law. These include provisions that affect the way patent applications are prosecuted and may affect the scope, strength and enforceability of our patent rights or the nature of proceedings that may be brought by or against us related to our patent rights. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could harm our business and financial condition. Moreover, we may be subject to a third-party pre-issuance submission of prior art to the USPTO or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or drugs and compete directly with us without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize zetomipzomib, KZR-261 or any future product candidates. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. For example, we may be subject to a third-party submission of prior art to the USPTO challenging the priority of an invention claimed within one of our patents, which submissions may also be made prior to a patentâ€™s issuance, precluding the granting of any of our pending patent applications. An adverse determination in any such challenges may result in

loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and drugs, or limit the duration of the patent protection of our technology and drugs. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years from the earliest filing date of a non-provisional patent application. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Upon the expiration of patent protection for zetomipzomib, KZR-261 or any future product candidates, we may be open to competition from generic versions of such drugs. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting our product candidates might expire before or shortly after such candidates are commercialized. As a Â 52 Â result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours. Even if they are unchallenged, our patents may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. For example, a third-party may develop a competitive drug that is structurally similar to one or more of our product candidates but that has a different composition that falls outside the scope of our patent protection. If the patent protection provided by our patents is not sufficiently broad to impede such competition, or if the breadth, strength or term (including any extensions or adjustments) of protection provided by our patents is successfully challenged, our ability to successfully commercialize our product candidates could be negatively affected, which would harm our business. Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. Given the amount of time required for the development, testing and regulatory review of new product candidates such as zetomipzomib and KZR-261, patents protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved indication, or any additional indications approved during the period of extension. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their drug earlier than might otherwise be the case. Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and applications will have to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned and licensed patents and applications and any patent rights we may own or license in the future. We rely on our outside counsel or our licensing partners to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our products or technologies, we may not be able to stop a competitor from marketing products that are the same as or similar to our product candidates, which would have a material adverse effect on our business. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could harm our business. In addition, if we fail to apply for applicable patent term extensions or adjustments, we will have a more limited time during which we can enforce our granted patents. In addition, if we are responsible for patent prosecution and maintenance of patent rights in-licensed to us, any of the foregoing could expose us to liability to the applicable patent owner. Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business. Our commercial success depends, in part, upon our ability and the ability of our future collaborators to develop, manufacture, market and sell zetomipzomib and KZR-261 without infringing the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to zetomipzomib, KZR-261 and any future product candidates and technology, including interference proceedings, post grant review and inter partes review before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we Â 53 Â believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could have a negative impact on our ability to commercialize zetomipzomib, KZR-261 or any future product candidates. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Moreover, given the vast number of patents in our field of technology, we cannot be certain that we do not infringe existing patents or that we will not infringe patents that may be granted in the future. Many companies and research institutions have filed, and continue to file, patent applications related to selective immunoproteasome inhibitors and protein secretion inhibitors. Some of these patent applications have already been allowed or issued, and others may issue in the future. While we may decide to initiate proceedings to challenge the validity of these or other patents in the future, we may be unsuccessful, and courts or patent offices in the United States and abroad could uphold the validity of any such patent. Furthermore, because patent applications can take many years to issue and may be confidential for 18 months or more after filing, and because pending patent claims can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use or sale of our product candidates. Regardless of when filed, we may fail to identify relevant third-party patents or patent applications, or we may incorrectly conclude that a third-party patent is invalid or not infringed by our product candidates or activities. If a patent holder believes our product candidate infringes its patent, the patent holder may sue us even if we have received patent protection for our technology. Moreover, we may face patent infringement claims from non-practicing entities that have no relevant drug revenue and against whom our own patent portfolio may thus have no deterrent effect. If a patent infringement suit were threatened or brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the drug or product candidate that is the subject of the actual or threatened suit. If we are found to infringe a third partyâ€™s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our product candidate(s) and technology. Under any such license, we would most likely be required to pay various types of fees, milestones, royalties or other amounts. Moreover, we may not be able to obtain any required license on commercially reasonable terms or at all. The licensing or acquisition of third-party intellectual property rights is a competitive area, and more established companies may also pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations and prospects. Furthermore, even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidate. In addition, we could be found liable for monetary damages, including treble damages and attorneysâ€™ fees, if we are found to have willfully infringed a patent or other intellectual property right. We may be required to indemnify collaborators or contractors against such claims. A finding of infringement could prevent us from manufacturing and commercializing our product candidates or force us to cease some or all of our business operations, which could materially harm our business. Even if we are successful in defending against such claims, litigation can be expensive and time consuming and would divert managementâ€™s attention from our core business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects. We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful. Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time consuming and is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring counter claims against us such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made Â 54 Â a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, inter partes review, or post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is or will be no invalidating prior art, of which we and the patent examiner were unaware during prosecution. For the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates. Such a loss of patent protection could harm our business. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license, and such a license may not be on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. The United States has recently enacted and implemented wide ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce patents that we have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. In addition to seeking patent protection for our product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, our competitors may independently develop knowledge, methods and know-how equivalent to our trade secrets. Competitors could purchase our products and replicate some or all of the competitive advantages we derive from our development efforts for technologies on which we do not have patent protection. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. Â 55 Â We also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach. In addition, our confidential information may otherwise become known or be independently discovered by competitors, in which case we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. Since we rely on third parties to develop and manufacture zetomipzomib and KZR-261, and if we collaborate with third parties for the development of our research programs or product candidates, we must, at times, share trade secrets with them. We may also conduct collaborative research and development programs that may require us to share trade secrets and proprietary know how. We seek to protect our proprietary information by entering into agreements containing confidentiality obligations and ownership provisions relating to intellectual property prior to disclosing proprietary information

or beginning research projects with third-party collaborators. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, sharing trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, the unauthorized disclosure or use of our confidential information could have an adverse effect on our business and results of operations. In addition, these agreements typically restrict the ability of our collaborators, advisors, employees, investigators, contractors and consultants to publish data potentially relating to our trade secrets. Despite our efforts to protect our trade secrets, we may not be able to prevent the unauthorized disclosure or use of our technical know-how or other trade secrets by the parties to these agreements. Moreover, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our confidential information or proprietary technology and processes. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, advisors, employees, investigators, contractors and consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. Moreover, if confidential information that is licensed or disclosed to us by our partners, collaborators, or others is inadvertently disclosed or subject to a breach or violation, we may be exposed to liability to the owner of that confidential information. Enforcing a claim that a third-party illegally obtained and is using our trade secrets, like patent litigation, is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business. Filing, prosecuting and defending patents covering zetomipzomib, KZR-261 and any future product candidates throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection but where patent enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued or licensed patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. Intellectual property rights do not necessarily address all potential threats to our business. The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business. The following examples are illustrative: â€¢others may be able to make compounds or formulations that are similar to our product candidates but that are not covered by the claims of any patents, should they issue, that we own or control; â€¢we or any strategic partners might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or control; â€¢we might not have been the first to file patent applications covering certain of our inventions; â€¢others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; Â 56 Â â€¢it is possible that our pending patent applications will not lead to issued patents; â€¢issued patents that we own or control may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges; â€¢our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights and then use the information learned from such activities to develop competitive drugs for sale in our major commercial markets; â€¢we may not develop additional proprietary technologies that are patentable; and â€¢the patents of others may prevent us from fully exploiting our product candidates or technologies. Risks Related to Our Business Operations, Employee Matters and Managing Growth We are highly dependent on the services of our executive officers, and if we are not able to retain these members of our management team or recruit and retain additional management, clinical and scientific personnel, our business will be harmed. Recruiting and retaining senior executives, qualified scientific and clinical personnel and, if we progress the development of any of our product candidates, commercialization, manufacturing and sales and marketing personnel, will be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Additionally, we do not currently maintain â€œkey personâ€ life insurance on the lives of our executives or any of our employees. Replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize our product candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. If we are unable to continue to attract and retain high-quality personnel, our ability to pursue our growth strategy will be limited. Further, our Workforce Reduction announced in October 2023 may make retention of our current personnel both more important and more challenging. This Workforce Reduction resulted in the loss of certain longer-term employees, the loss of institutional knowledge and expertise and the reallocation and combination of certain roles and responsibilities across the organization, all of which could adversely affect our operations. Â We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations. As the clinical development of our product candidates progresses, we also expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of research, drug development, medical affairs, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. This could be a particular challenge as a result of the Workforce Reduction announced in October 2023. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. We are subject to stringent and changing U.S. and foreign laws, regulations and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; and other adverse business consequences. In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit and share personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, and sensitive third-party data. As a result of our data processing activities, we are or may become subject to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other obligations relating to data privacy and security. Â 57 Â In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, and consumer protection laws. For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information. If we become subject to new data privacy laws, at the state level, the risk of enforcement action against us could increase because we may become subject to additional obligations, and the number of individuals or entities that can initiate actions against us may increase (including individuals, via a private right of action, and state actors). In addition, data privacy and security laws have been proposed at the federal, state, and local levels in recent years, which could further complicate compliance efforts. Additionally, in the past few years, numerous U.S. statesâ€”including California, Virginia, Colorado, Connecticut, and Utahâ€”have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future. These developments may further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties upon whom we rely. Outside the United States, an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, the European Unionâ€™s General Data Protection Regulation, or EU GDPR and the United Kingdomâ€™s GDPR, or UK GDPR impose strict requirements for processing the personal data of individuals located, respectively within the European Economic Area, or EEA and the United Kingdom, or UK. For example, under GDPR, government regulators may impose temporary or definitive bans on data processing, as well as fines of up to 20 million euros under the EU GDPR or 17.5 million pounds sterling under the UK GDPR, or, in each case, 4% of annual global revenue, whichever is greater. Further, companies may face private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests. In Canada, the Personal Information Protection and Electronic Documents Act and various related provincial laws, as well as Canadaâ€™s Anti-Spam Legislation, may apply to our operations. In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows. Although there are various mechanisms that may be used in some cases to lawfully transfer personal data to the United States or other countries, these mechanisms are subject to legal challenges and may not be available to us. An inability or material limitation on our ability to transfer personal data to the United States or other countries could materially impact our business operations. In the ordinary course of business, we may transfer personal data from Europe and other jurisdictions to the United States or other countries. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the EEA and the UK have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA standard contractual clauses, the UKâ€™s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activist groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers out of Europe for allegedly violating the EU GDPRâ€™s cross-border data transfer limitations. We are also bound by contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. For example, certain privacy laws, such as GDPR and the CCPA, require our customers to impose specific contractual restrictions on their service providers. We publish privacy policies, marketing materials and other statements, such as compliance with certain certifications or self-regulatory principles, regarding data privacy and security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators or other adverse consequences. Our obligations related to data privacy and security are quickly changing and are becoming increasingly stringent, and creating uncertainty. These obligations may be subject to differing applications and interpretations, which may be inconsistent or in conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources, including, Â 58 Â without limitation, financial and time-related resources. These obligations may necessitate changes to our information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail, or be perceived to have failed, to do so which could negatively impact our business operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation, including class-related claims and mass arbitration demands; additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations, including clinical trials; inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring of our operations. Significant disruptions of our, or our contractors' or vendors', information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to us. In the ordinary course of our business, we and the third parties upon which we rely process proprietary, confidential, and sensitive data, including personal data (such as health-related data), intellectual property, and trade secrets (collectively, sensitive information). Cyberattacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive information and information technology systems, and those of the third parties upon which we rely. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer â€œhackers,â€ threat actors, â€œhacktivists,â€ organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including cyber-attacks that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services. We and the third parties upon which we rely may be subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential stuffing), personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, and other similar threats. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, ability to provide our products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers and devices outside our premises or network, including working at home, while in transit and in public locations. Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entitiesâ€™ systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program. In addition, our reliance on third-party service providers could introduce new cybersecurity risks and vulnerabilities, including supply-chain attacks, and other threats to our business operations. We rely on third-party service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation, cloud-based infrastructure, data center facilities, encryption and authentication technology,

employee email, content delivery to customers, and other functions. We also rely on third-party service providers to provide other products, services, parts, or otherwise to operate our business. Our ability to monitor these third partiesâ€™ information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third partiesâ€™ infrastructure in our supply chain or our third-party partnersâ€™ supply chains have not been compromised. Â 59 Â While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We take steps designed to detect, mitigate, and remediate vulnerabilities in our information systems (such as our hardware and/or software, including that of third parties upon which we rely). Further, we may experience delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities. We may not, however, detect and remediate all such vulnerabilities including on a timely basis. Vulnerabilities could be exploited and result in a security incident. Any of the previously identified or similar threats could cause a security incident that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive data or our information technology systems, or those of the third parties upon whom we rely. A security incident could disrupt our ability (and that of third parties upon whom we rely) to conduct our business. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. We may expend significant resources or modify our business activities (including our clinical trial activities) in an effort to protect against security incidents. Additionally, certain data privacy and security obligations may require us to implement and maintain specific security measures, industry-standard or reasonable security measures to protect our information technology systems and data. While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosures or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. These consequences may include government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may negatively impact our ability to grow and operate our business. Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. Additionally, we cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims. In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading. We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in other jurisdictions, provide accurate information to the FDA and comparable foreign regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or comparable foreign regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations, any of which could have a negative impact on our business, financial condition, results of operations and prospects. If we engage in future acquisitions or strategic collaborations, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks. Â 60 Â From time to time, we may evaluate various acquisitions and strategic collaborations, including licensing or acquiring complementary drugs, intellectual property rights, technologies or businesses, as deemed appropriate to carry out our business plan. Any potential acquisition or strategic partnership may entail numerous risks, including: â€¢increased operating expenses and cash requirements; â€¢the assumption of additional indebtedness or contingent liabilities; â€¢assimilation of operations, intellectual property and drugs of an acquired company, including difficulties associated with integrating new personnel; â€¢the diversion of our managementâ€™s attention from our existing drug programs and initiatives in pursuing such a strategic partnership, merger or acquisition; â€¢retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships; â€¢risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing drugs or product candidates and regulatory approvals; and â€¢our inability to generate revenue from acquired technology and/or drugs sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs. In addition, if we engage in future acquisitions or strategic partnerships, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities, and this inability could impair our ability to grow or obtain access to technology or drugs that may be important to the development of our business. Risks Related to Ownership of Our Common Stock and Other General Matters The market price of our common stock may be volatile and fluctuate substantially, and you could lose all or part of your investment. The market price of our common stock has at times experienced price volatility and may continue to be volatile. For example, during 2023, the closing price of our common stock on The Nasdaq Global Select Market ranged from $7.31 per share to $0.72 per share. The stock market in general and the market for biopharmaceutical and pharmaceutical companies in particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies, which has resulted in decreased stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. Broad market and industry factors, including potentially worsening economic conditions, including higher inflation rates and changes in interest rates, and other adverse effects or developments, may negatively affect the market price of our common stock, regardless of our actual operating performance. As a result of this volatility, you may not be able to sell your common stock at or above the price paid for the shares. In addition to the factors discussed in this â€œRisk Factorsâ€ section, the market price for our common stock may be influenced by the following: â€¢the commencement, enrollment or results of our planned or future clinical trials of zetomipzomib, KZR-261 and any future product candidates; â€¢the clinical or commercial success of competitive drugs, therapies or technologies; â€¢regulatory or legal developments in the United States and other countries; â€¢disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain and maintain patent protection for our technologies; â€¢negative or inconclusive results from our clinical trials, such as the May 2022 topline data from the PRESIDIO Phase 2 clinical trial; â€¢failure or discontinuation of any of our clinical development or research programs; â€¢the recruitment or departure of key personnel; â€¢the level of expenses related to our product candidates and clinical development or research programs; â€¢our ability to discover, develop and broaden our pipeline beyond our current product candidates; â€¢commencement or termination of collaborations for our research and development programs; Â 61 Â â€¢actual or anticipated changes in estimates as to financial results or development timelines; â€¢changes in estimates or recommendations by securities analysts, if any, that cover our stock; â€¢our inability to obtain or delays in manufacturing adequate supply for our clinical trials or the inability to do so at acceptable costs; â€¢significant lawsuits, including patent or stockholder litigation or products liability claims; â€¢variations in our financial results or those of companies that are perceived to be similar to us; â€¢announcement, expectation or completion of additional financing efforts; â€¢changes in the structure of healthcare payment systems; â€¢market conditions in the pharmaceutical and biotechnology sectors; â€¢general economic, political, and market conditions and overall fluctuations in the financial markets in the United States and abroad, including as a result of bank failures, public health crises or geopolitical tensions; and â€¢investorsâ€™ general perception of us and our business. These and other market and industry factors may cause the market price and demand for our common stock to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from selling their shares at or above the price paid for the shares and may otherwise negatively affect the liquidity of our common stock. Some companies that have experienced volatility in the trading price of their shares have been the subject of securities class action litigation. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our business practices. Defending against litigation is costly and time-consuming, and could divert our managementâ€™s attention and our resources. Furthermore, during the course of litigation, there could be negative public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a negative effect on the market price of our common stock. If securities or industry analysts do not publish research or reports, or publish unfavorable research or reports, about our business or our market, our stock price and trading volume could decline. The trading market for our common stock will be influenced by the research and reports that industry or financial analysts publish about us or our business. Equity research analysts may discontinue research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. We do not have any control over the analysts or the content and opinions included in their reports. The price of our shares could decline if one or more equity research analysts downgrade our shares or issue other unfavorable commentary or research about us. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our shares could decrease, which in turn could cause the trading price or trading volume of our common stock to decline. Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and share price. The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in inflation rates, changes in interest rates and uncertainty about economic stability. For example, the Russia-Ukraine war and the Israel-Hamas war created volatility in the global capital markets and may have further global economic consequences, including disruptions of the global supply chain and energy markets. Any such volatility and disruptions may have adverse consequences on us or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of recent bank failures, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. A severe or prolonged global economic downturn could result in a variety of risks to our business. For example, inflation rates, particularly in the United States, have increased recently to levels not seen in years, and increased inflation may result in increases in our operating costs (including our labor costs), reduced liquidity and limits on our ability to access credit or otherwise raise capital on acceptable terms, if at all. In addition, the U.S. Federal Reserve has raised, and may again raise, interest rates in response to concerns about inflation, which coupled with reduced government spending and volatility in financial markets may have the effect of further increasing economic uncertainty and heightening these risks. A weak or declining economy could also strain our suppliers and Â 62 Â manufacturers, possibly resulting in supply and clinical trial disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. Our common stock is thinly traded and our stockholders may be unable to sell their shares quickly or at market price. Although we have had periods of high-volume daily trading in our common stock, generally our stock is thinly traded. As a consequence of this lack of liquidity, the trading of relatively small quantities of shares by our stockholders may disproportionately influence the price of those shares in either direction. Our common stock price could, for example, decline significantly as a result of sales of a large number of shares of our common stock on the market without commensurate demand, as compared to a seasoned issuer that could better absorb those sales without adverse impact on its share price, or from the perception that these sales could occur. Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions. Based upon our shares of our common stock outstanding as of June 30, 2024, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock do, in the aggregate, beneficially own shares representing approximately 33% of our outstanding common stock. If our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock acted together, they may be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. The concentration of voting power and transfer restrictions could delay or prevent an acquisition of our company on terms that other stockholders may desire or result in the management of our company in ways with which other stockholders disagree. Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain. You should not rely on an investment in our common stock to provide dividend income. We have never declared or paid cash dividends on our capital stock. Furthermore, our ability to pay cash dividends is currently restricted by the terms of the Loan Agreement. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. We are a â€œsmaller reporting company,â€ and the reduced disclosure requirements applicable to such companies may make our common stock less attractive to investors. We are a smaller reporting company as defined in the Securities Exchange Act of 1934, as amended. We take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as (i) our voting and non-voting common stock held by nonaffiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter. We will continue to incur increased costs as a public company, and our management will be required to devote substantial time to new compliance initiatives. As a public company, we have incurred and will continue to incur significant legal, accounting, insurance and other expenses that we did not incur as a private company, including costs associated with public company reporting requirements. We also have incurred and will continue to incur costs associated with the Sarbanes-Oxley Act and related rules implemented by the SEC and The Nasdaq Stock Market. Our management and other personnel will need to devote a substantial amount of time to compliance with these laws and regulations. These requirements have increased and will continue to increase our legal, accounting, external audit and financial compliance costs and have made and will continue to make some activities more time consuming and costly. The Sarbanes-Oxley Act requires, among other things, that we assess and document the effectiveness of our internal control over financial reporting annually and the effectiveness of our disclosure controls and procedures quarterly. In particular, Section 404(a) of the Sarbanes-Oxley Act, or Section 404(a), requires us to perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting. Section 404(b) of Sarbanes-Oxley Act, or Section 404(b), also requires our independent registered public accounting firm to attest to the effectiveness of our internal control over financial reporting. Our compliance with applicable provisions of Section 404 will require that we incur substantial accounting expense and expend significant management time on compliance-related issues as we implement and maintain corporate governance practices and comply with reporting requirements. However, while we remain a smaller reporting Â 63 Â company that is not an accelerated filer, we will not be required to include an

attestation report on internal control over financial reporting issued by our independent registered public accounting firm. Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions: â€¢establish a classified board of directors such that not all members of the board are elected at one time; â€¢allow the authorized number of our directors to be changed only by resolution of our board of directors; â€¢limit the manner in which stockholders can remove directors from the board; â€¢establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors; â€¢require that stockholder actions must be affected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent; â€¢limit who may call stockholder meetings; â€¢authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a stockholder rights plan, or so-called â€œpoison pill,â€ that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and â€¢require the approval of the holders of at least 66 2â„3% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws. Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for our common stock, including transactions that may be in your best interests. These provisions may also prevent changes in our management or limit the price that investors are willing to pay for our stock. Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholdersâ€™ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: â€¢any derivative action or proceeding brought on our behalf; â€¢any action asserting a breach of fiduciary duty; â€¢any action asserting a claim against us or any of our directors, officers, employees or agents arising under the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws; â€¢any action or proceeding to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws; and â€¢any action asserting a claim against us or any of our directors, officers, employees or agents that is governed by the internal-affairs doctrine. Â 64 Â This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions. These exclusive-forum provisions may limit a stockholderâ€™s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business. Â 65 Â Item 5. Other Information. Insider Trading Arrangements During the fiscal quarter ended June 30, 2024, none of our directors or officers (as defined in Rule 16a-1(f)) adopted, modified or terminated a â€œRule 10b5-1 trading arrangementâ€ or a â€œnon-Rule 10b5-1 trading arrangement,â€ as those terms are defined in Item 408 of Regulation S-K. Â 66 Â Item 6. Exhibits. Â ExhibitNumber Description 3.1 Amended and Restated Certificate of Incorporation of the Company (incorporated herein by reference to Exhibit 3.1 to the Companyâ€™s Current Report on Form 8-K (File No. 001-38542), filed with the SEC on June 26, 2018). 3.2 Â Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company (incorporated herein by reference to Exhibit 3.1 to the Companyâ€™s Current Report on Form 8-K (File No. 001-38542), filed with the SEC on June 16, 2023). 3.3 Amended and Restated Bylaws of the Company (incorporated herein by reference to Exhibit 3.2 to the Companyâ€™s Current Report on Form 8-K (File No. 001-38542), filed with the SEC on June 26, 2018). 10.1â€ Â Amendment No. 1 to Collaboration and License Agreement by and between the Company and Everest Medicines II (HK) Limited, dated as of July 2, 2024. 31.1 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1* Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL Document. 101.SCH Â Inline XBRL Taxonomy Extension Schema Document With Embedded Linkbase Documents. 104 Â Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibit 101). Â * Furnished herewith and not deemed to be â€œfiledâ€ for purposes of Section 18 of the Exchange Act, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act (whether made before or after the date of this Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing. â€ Certain information has been omitted from this document in accordance with Regulation S-K, Item 601(b)(10). Â 67 Â SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Kezar Life Sciences, Inc.(Registrant) Date: August 13, 2024 By: Â /s/ Christopher Kirk, Ph.D. Christopher Kirk, Ph.D. Chief Executive Officer(Principal Executive Officer) Â Date: August 13, 2024 By: Â /s/ Marc Belsky Marc Belsky Chief Financial Officer and Secretary(Principal Financial and Accounting Officer) Â Â 68 EX-10.1 2 kzr-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1Â Execution VersionÂ Certain identified information has been excluded from the exhibit because it is both not material and is the type that the Registrant treats as private or confidential. Triple asterisks [***] denote exclusions.Â AMENDMENT NO. 1 TO COLLABORATION AND LICENSE AGREEMENT This AMENDMENT NO. 1 TO COLLABORATION AND LICENSE AGREEMENT (this â€œAmendmentâ€) is entered into as of July 2, 2024 (the â€œFirst Amendment Effective Dateâ€), by and between KEZAR LIFE SCIENCES, INC., a Delaware corporation having an address at 4000 Shoreline Court, Suite 300, South San Francisco, CA 94080 (â€œKezarâ€), EVEREST MEDICINES II (HK) LIMITED, a Hong Kong company with limited liability having an address at Unit 417 4/F, Lippo Centre Tower Two, No.89 Queensway Admiralty, HK (â€œEverestâ€), and solely for purposes of Section 4 (Acknowledgement of Guarantee) of this Amendment, EVEREST MEDICINES LIMITED, a Cayman Islands company with limited liability having an address at PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands (â€œGuarantorâ€). Kezar, Everest and Guarantor are sometimes referred to herein individually as a â€œPartyâ€ and collectively as the â€œPartiesâ€. RECITALS WHEREAS, Kezar, Everest and, solely for certain purposes as set forth therein, Guarantor, are parties to that certain Collaboration and License Agreement, dated as of September 20, 2023 (the â€œAgreementâ€); and WHEREAS, the Parties desire to amend or modify certain terms of the Agreement. NOW THEREFORE, in consideration of the premises and the mutual promises and covenants contained in this Amendment, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows: 1.Definitions. Capitalized terms that are used but not defined herein shall have the meanings ascribed to such terms in the Agreement. 2.Amendments to the Agreement. Section 3.2.2(c) of the Agreement is hereby deleted in its entirety and replaced with the following: â€œ(c) [***]â€ 3.Palizade Cost Sharing. In connection with the cost sharing obligations of the Parties under Section 5.3.4 (Cost Sharing) of the Agreement with respect to the Palizade Trial, Kezar and Everest hereby agree that the terms set forth on Annex A attached hereto shall apply. This Section 3 (Palizade Cost Sharing) of the Amendment, including the terms set forth on Annex A, shall survive the expiration or termination of the Agreement with respect to any payment obligations accruing hereunder before such expiration or termination. 4.Acknowledgement of Guarantee. Guarantor hereby acknowledges that the guarantee contemplated by Section 15.6 (Guarantee) of the Agreement shall include the guarantee of payment and performance with respect to all of Everestâ€™s obligations hereunder. Â Â Â 5.Miscellaneous. This Amendment is made in accordance with Section 15.1 (Entire Agreement; Amendment) of the Agreement. Except as expressly set forth in this Amendment, the Agreement shall remain unmodified and in full force and effect, and the provisions of Article 15 (Miscellaneous) of the Agreement shall apply mutatis mutandis to this Amendment, together with the Annex attached hereto, and to the Agreement as modified by this Amendment, taken together as a single agreement, reflecting the terms therein as modified hereby. In the event of a conflict between the terms of this Amendment, including the Annex attached hereto, and the Agreement, the terms of this Amendment shall control. 6.Counterparts. This Amendment may be executed in counterparts by a single Party, each of which when taken together shall constitute one and the same agreement. Counterparts may be delivered via electronic mail, including Adobeâ„¢ Portable Document Format (PDF) or any electronic signature complying with the U.S. Federal ESIGN Act of 2000, and any counterpart so delivered will be deemed to be original signatures, will be valid and binding upon the Parties, and, upon delivery, will constitute due execution of this Amendment. [signature page follows] Â -2- Â IN WITNESS WHEREOF, the Parties have executed this Amendment as of the First Amendment Effective Date. Â kezar LIFE SCIENCES, INC.Â EVEREST MEDICINES II (HK) LIMITED By: /s/ Christopher Kirk, Ph.D.Name: Christopher Kirk, Ph.D.Title: Chief Executive Officer By: /s/ Yongqing LuoName: Yongqing LUOTitle: Chief Executive Officer Â Â Â IN WITNESS WHEREOF, Guarantor, solely for purposes of Section 4 (Acknowledgement of Guarantee), has executed this Amendment as of the First Amendment Effective Date. Â EVEREST MEDICINES LIMITEDÂ By: /s/ Yongqing LuoName: Yongqing LUOTitle: Chief Executive Officer Â Â Â Annex APalizade Cost Sharing Â [***] Â EX-31.1 3 kzr-ex31_1.htm EX-31.1 EX-31.1 Â Exhibit 31.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Christopher Kirk, Ph.D., certify that: 1.I have reviewed this Quarterly Report on Form 10-Q of Kezar Life Sciences, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Â Date: August 13, 2024 By: Â /s/ Christopher Kirk, Ph.D. Christopher Kirk, Ph.D. Chief Executive Officer(Principal Executive Officer) Â Â EX-31.2 4 kzr-ex31_2.htm EX-31.2 EX-31.2 Â Exhibit 31.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Marc Belsky, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q of Kezar Life Sciences, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Â Date: August 13, 2024 By: Â /s/ Marc Belsky Marc Belsky Chief Financial Officer(Principal Financial Officer) Â Â EX-32.1 5 kzr-ex32_1.htm EX-32.1 EX-32.1 Â Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Â§1350), Christopher Kirk, Ph.D., Chief Executive Officer of Kezar Life Sciences, Inc. (the â€œCompanyâ€), and Marc Belsky, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge: (1)The Companyâ€™s Quarterly Report on Form 10-Q for the period ended June 30, 2024, to which this Certification is attached as Exhibit 32.1 (the â€œPeriodic Reportâ€), fully complies with the requirements of Section 13(a) or Section 15(d) of

the Exchange Act; and (2)The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the company. Date: August 13, 2024 Â Â Â /s/ Christopher Kirk, Ph.D. Â Â /s/ Marc Belsky Christopher Kirk, Ph.D. Â Marc Belsky Chief Executive Officer Â Chief Financial Officer (Principal Executive Officer) Â (Principal Financial Officer) Â Â GRAPHIC 6 img40159629_0.jpg GRAPHIC begin 644 img40159629_0.jpg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~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

M'.U!C)|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|K[5$J,XJXG%HZ@\ WOTH\Y_WZ5D26J*]^<_]|*\.?^]^E %JBJOG/_ 'OTH\Y_[WZ4 M 6J*]^<_]|*\.?^]^E %]JFG_ZJ;_KO)_Z$:?SG.Q?I3(R8@P3@,Q8_4G)H M NT55\Y_[WZ4><_]|* +5%5?.?^]^E'G/\ WOTH M455\Y_[WZ4><_]|* M+5%5?.?^]^E'G/\ WOTH M455\Y_[WZ4><_]|* +5%5?.?^]^E'G/\ WOTH M455\Y_[WZ4><_]|* +5%5?.?^]^E'G/\ WOTH M455\Y_[WZ4><_]|* M+5%5?.?^]^E'G/\ WOTH M455\Y_[WZ4><_]|* +5%5?.?^]^E'G/\ WOTH M455\Y_[WZ4><_]|* M+5%5?.?^]^E'G/\ WOTH M455\Y_[WZ4><_]|* +

A<'B#_GSTS_OU)_\71]3JA]= MI'M=%>*?\+@\0?\ /GIG_?]3_P"+H_X7!X@_Y\|_ P"_4G_Q='U.J'UVD>UT M5XI_PN#Q!_SYZ9_WZD_^+H_X7!X@_P"?/3/^_4G_ ,71]3JA]=I'M=%>*?\ M"X/$'_/GIG_?]3_XNC_A<'B#_GSTS_OU)_\ %T?4ZH?7:1[717BG_"X/$'_/ MGIG_ 'ZD_P#BZ/\ A<'B#_GSTS_OU)_\71]3JA]=I'M=%>*?\+@\0?\ /GIG M_?
]3_P"+H_X7!X@_Y\|_ P"_4G_Q='U.J'UVD>UT5XI_PN#Q!_SYZ9_WZD_^ M+H_X7!X@_P"?/3/^_4G_ ,71]3JA]=I'M=%>*?\ "X/$'_/GIG_?]3_XNC_A<'B#_GSTS_OU)_\ %T?4ZH? 7:1[717BG_"X/$'_/GIG_ 'ZD_P#BZ/\ A<'B M#_GSTS_OU)_\71]3JA]=I'M=%>*?\+@\0?\ /GIG_?]3_P"+H_X7!X@_Y\|_
M_P" 4G_Q='U.J'UVD>UT5XI_PN#Q!_SYZ9_WZD_^+H_X7!X@_P"?/3/^_4G_ M ,71]3JA]=I'M=%>*?\ "X/$'_/GIG_?]3_XNC_A<'B#_GSTS_OU)_\ %T?4 MZH?7:1[717BG_"X/$'_/GIG_ 'ZD_P#BZ/\ A<'B#_GSTS_OU)_\71]3JA]= MI'L$_P#R$K3_ '9/Y"K=>'O\6M>>>.4VFF[HP0!Y;XY_X'[5+_PN#Q!_SYZ9 M_P!^I/\ XNCZG5#Z[2/:Z*\4_P"%P>(/^?/3/^_4G_Q=' "X/$' #YZ9_WZ MD_\ BZ/]=4/KM(]KHKQ3_A<'B#_GSTS_ +]2?_%T?\+@\0?\^>F?]^I/_BZ/ MJ=4/KM(]KHKQ3_A<'B#_)\|_[]2?\ Q=' _N#Q!_SYZ9_WZD_^+H^IU0^ MNTCVNBO%/^%P>(/^?/3/^_4G_P 71_PN#Q!_SYZ9_P!^I/\ XNCZG5#Z[2/: MZ*\4_P"%P>(/^?/3/^_4G_Q=' "X/$'_ #YZ9_WZD_\ BZ/]=4/KM(]KHKQ3 M_A<'B#_GSTS_ +]2?_%T?\+@\0?\^>F?]^I/_BZ/]=4/KM(]KHKQ3_A<'B# _M)\|_[]2?\ Q=' _N#Q!_SYZ9_WZD_^+H^IU0^NTCVNBO%/^%P>(/^?/3/ M^_4G_P 71_PN#Q!_SYZ9_P!^I/\ XNCZG5#Z[2/:Z*\4_P"%P>(/^?/3/^_4G_Q=' "X/$'_ #YZ9_WZD_^+H^IU0^NTCVNBO%/^%P>(/^?/3/^_4G_P 71_PN#Q!_SYZ9 M_P!^I/\ XNCZG5#Z[2/:Z*\4_P"%P>(/^?/3/^_4G_Q=' "X/$'_ #YZ9_WZ MD_\ BZ/]=4/KM(]KHKQ3_A<'B#_GSTS_ +]2?_%T?\+@\0?\^>F?]^I/_BZ/ MJ=4/KM(]@U7_)!-W_UQ;^56ZV/N/BUKUS;R0/:::%D4J2(WS@\,#J7_ (7! MX@_Y\|_ [I2?_%T?4ZH? 7:1[717BG_"X/$'_#YZ9_WZD_\ BZ/^%P>(/^?/ M3/\ OU)_\71]3JA]=I'M=%>*?\+@\0?\^>F?]^I/_BZ/^%P>(/\ GSTS_OU) M_P#%T?4ZH?7:1[717BJ?&'7@WSV6FD>@1Q_[/6UI? QA@ED6/4]/,)_UL+;P M/JO7\LTI82JE>Q4<72;M<]0HJA9ZI!]%K'=6DT@KF:L=*= MRQ15?SV!1Y[>@H L457\]O04>>WH* +%%5_/;T%'GMZ"@"Q15?SV!1Y[>@H L457\]O04>>W MH* +%%5_/;T%'GMZ"@"Q15?SV!1Y[>@H L54T__%4W_7>3_P"!~/\ /;T% M1PGR%8+R&=G.?4G-
%RBJ_GMZ"CSV!!0!8HJOY[>@H\]O04 6**K^>WH*//; MT% %BBJ_GMZ"CSV!!0!8HJOY[>@H\]O04 6**K^>WH*//;T% %BBJ_GMZ"CS MV!!0!8HJOY[>@H\]O04 6**K^>WH*//;T% %BBJ_GMZ"CSV!!0!8HJOY[>@H M\]O04 6**K^>WH*//;T% %BBJ_GMZ"CSV!!0!8HJOY[>@I1<>]_E0!/51O\ MD+Q_|<'_ /0EJRKJXX-5F_Y"\?\ UP?_ -
"6@"W113)IHK>%YII$BB0;G=V" MJH]23TH <0&4@]#Q7$QV>O:18'1/^$?M-;TU6/DR(<(F$SD!U<')'MZ5V4MU M;PVQN99XH[<+N,KN H'KGIBGQR)-&LD3J\;@,K*A!H XD>%K^#P]J\<= MM:17>]2(K068"QPQ9"D#.,D+N)]S5SQAX;;5(-.D@L$OTLBP-BTYA$BD <,. MA&!UXZUUE% '"Z#X1>V^V7D6D6^BW3V[Q6P6ZDGD1F!&YFW;<=. ,^]83>#M M2GL8K;_A%;:MS7^T7K7HE>8:AN903P3R>3TR*I7HH YB73=0N?$.L1R6FVQ MO;)8(KQ9AF/"GY=G7.6)SI5RMIX%D=XK.?PG9Q%"%EOWU&1T<#JRQJP:)"1
M7J).!DI*KVNH65]YGV2[@N/+.U_)D#[3Z'!XH RI*TR6WU_4[R6'RX2D-O:_ M,#^[1>>^?O$]?2G^(]+NM2L87L)8X[ZTG6X@,F=A9<_*V.Q!(K9JDVL:8EY] MD;4K-;G./),ZA\^FW.:
,!IO%FLH+*738]%B8@37:W8EV8L&+(H)8^OWCW]*VZ* ..;0]2GT#[-):XFO=4^T7: MF13Y<7F;NN>?E51@9ZUL65A<#Q3]>HW$6V-HHH+9MP.Y "S'V^8]_2MFF&6- M2P9U!5=SG H/4^W!_*@#B[!0-6N?#-PH@W75S]#75S:&;9YT6X@1[P<#Y0O? MM5;0?#5W#XIL=0;P[;Z3:0QR#9'F"<8]\UWL,T5Q"DT,B21.-R MNC JP[01UIS*KJ58 J1@@C@B@"GI-
]+J.G)'3%UFU>9I(9FO1&\:L<[&WYSC.!CM74HBQHJ(%[%" "JHP /04 MZ@#B3X8U1-&;::+-=0&HKJ*V<9Q""!CR\^N.<], G5V"VUS7=5LKG5["+3;. MR?SDMQ.)GEEP0"2.
!D^^:ZFFAU9F56!*G# 'H>O- ' M8^+$T34])MM+MT: M>65VO6NE)F$CG.U>H.#U8!|Z\5MFPOI/Q+I1M[$3Z?;V1MO-\Y5,)XR=IY:(M51QZUO7=]:6$:R7EU!;HS;5::0("?0$]ZGH Y2VTK4[:P)>6R0?\36[$SN@D M48>1C_%G' /KVKI;2W6TLH+9/N0QK&/H!BIJCAN(;E"\$T7>$?$YTB86=VQ-E(W7_GDO[_3U_.O
M4%974,I#*1D$'((KP]%TI6>Q[|"LJL;K<6BBBL#8***** "L_6]332-(GO& M+(N$4G[S'@#\ZT*\3^-- QZQ<1F.X7$'R*V#GL![5C:KK5YKX$5M Z6T2EU4MCJ2:X)[MW,:
MLS$(NT9K0L]1F*?91/(L+GYE4]:]6.&4/>ZG@2%&)Q;IL4OU(SW]II* M+?ZK"K;1$AWR, 0*.230Z<%^\:*4DES=30T[Q%+;SE;E2\3<,">W>MZ#29=>
MA^P6TULVV/S;9B2"1^N#ZU>FTRWUFV\NYL!%+&2OF*=I&.A4CJ#6I\/]'@LW MN[D.OF+^Z2,.&*+UR3ZD_P JXJ]92CHK,SPZCBJRC)>I5M/AM*^FO%>ZAY<[
M,"/)7(&/7/6NE\+>&SX;LYH6NS_2P=&E)2BM40R MVEM*:LDMO%)(GW6= 2/H:FHH! *BBB@ HHHH **** "D9@JEF(R M2>U+7">+O$PE\S3+)\Q)I ?O?[(]O6KITW-
V0&5XHUXZO?>7"Q^R0G$8_O' M^]_A6#24M>G&*BK(I#E4NX502Q. !W->K>'=(71|+2)@//?YY3[^GX5S\S0 M3-,NJ7"_NT/IE3_$W][Z#^2TKO:X\34N^5 V%%%%.0Q-
LD"N#L;T/H:Q=7\56.FC362YM)([VX6/S#.H58^=S^X&,9Z9 M- &_15:YU&QLX$GNKVW@A?[LDLJK?0D\U'>7G_$HFN[*YM.(B\4TS_N>G!9 MA_#]* +M%4O[2M((4^UWMI')Y(F?]Z -O +#)^[D]:'U?3(X(9WU&T6&%EC\TB255(3.-W)Z9XS4;ZOID<$,[ZC M:+#.<12-.H60_P"R\<_A0!=H](W, N5MC-&)V4NL6X;BHXR!UQ[U&^H648N# M)>6Z"WQYY:0#RL]-W/'XT
6:*JQ:G87%T]K#?6TEPGWH64E4NOU .:+O4[#3R M@O;VVMB_W?.E5-WTR>: +5%(K!E#*05(R"P16=X@U"72M OK^!4:6"(NH<$ MJ2/7!%
&E15=)V;3UN"!O,6_';,,U1'5FU#PU::I>F&%I8O,D(.U%_,\#\: M -:BJ]]%E]$;265W!>N9"#@[>>>>. M* +U%0W5Y:V,7FW=S#;QI-\KA!^9J%-6T^6QEO(;ZUEMH@2\]3*47'JP.!0!
MSU M&QU%&>RO+>Y53AC!*K@'W?: +-%5K^]ATW3Y[VX;;# A=CI#^M5XK^6VT$ZA MJBQPND332HF<(.3M]R!QGN>PZ4 :-%<]X3U^ZUNUN$U"".WOH&4O$F<;'4,A
MY)Z@_I4L&LW$NK:]:,D7EZ>D;1$ Y;>F>U '245!9 MW<-_90W=N^^&9 Z-Z@BIZ "BBB@#R#XD^*IX+N[T&SD*(\@DN74\L"B@)]., MGUR/>O,JNZO>/]&LWMY/(K?Q->0:5#?
-8K(!#LL Z$8'\6PY&<]Z)S<6DOSL$*:DFW^5 MSRBBO2[[2;"Z\:)/]-K$C6NEB^U.VA.%,JCE>.F=M"60I/N M_8/LR^3M_N]_ K255R^%%.DH_$SCZ*]/T?3[>S^(MEW;YNQ2P]|[_)7/(]*
MZR;Q9?:#K.I6_A]\6WTV2Z9T58D8'MD%@>.,:/:MCQYXNUVW\0:CH\5]ML618 MS%Y2'AD&1G;GN>]7SSNE;?S_ . 1[.*VWMY2\$\[HKOM8UVX\$3)H>@K#;3 M0Q(;N[,2O)+(1DC+
C;R,#%5;Z[3Q;X4OM4NK>&/5]-,R3Q)L\^-SM^8#@L M#WI*H]';1@Z25U?5%T5U/CK_C\T?_L$V_\ (UF^&-*&L^(K.S?/DE]\Q(U
MY;]!^M6IKEYF2X/GY49%%=OXUEB\0Z79^)K6,*/-DLYU4?=VDF,GZJ17$40E MS*XIQY78****L@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** .F\%^*9O#FJJ)')L)V"SQ]E_VQ[C]17O M(90RD$$9!'>OF&OH'P5=O>^#=,F7G_<)7_V6O.QU-
TT>E@:C=X,WJ M**\\]$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M**
"BBB@ HHHH 56*G(ZT;@VJQ$?\^[_/H2TE-B_P"0E&?^F+_S2@"_7+_$ M&\2U\(W"_Q47$B0<Z>ME>3-.WVJ-C)"[?>V8X/KS0 Q_%UU_8UI,MB/[M1?4!8RVP.X;P3OVG([#
()X&>>+-8L[S^RII-"@U$#S9);BX:.")#]U> M2&9^I., <5]6?A=[&ZT?;.)8++SIIGY402G (9 M9&. #GN>,50TGQ=]$^NV=C=SZ'=1W;,JC3IV=X<*6^;/!Z8XJ>[\&RR>'$LX
M7L!>+&M7C\16>]:A_9,<<$G6-X*AM'F.KI#9 MZ<&C%B+.%L-YBG+>9D#+\=,9QW-;6O:3[5S>V6IZ/<6\5]:ATV7*DQR(V,@%X MY'0=*S-.):A'XD@U^^NK-[MBWVB&*$B-?
EPI0GG=ZL><'\P#K+F-YK6:*.0 MQNZ%5<=5)'!KSZWTW1=.TV+2/$GAZ.T>G8U M#/X4OAH4L<5[%/JLUVEY--<(1'*ZD$*0O(4 #IZ?D :NH:G=V3
M!)05.%0*6<@9]N.O6N,DN]8AL/%VJW/V003%K1#!OWF1<1KMS_#\QSWSFNEL M-$UF3Q%!J^LWEI*8;9XXX;9&58G8C..\G@=3Z].*JVOAO5SI-KI[!+8M'#J(MN7:
(N#)&&+G=DV^S_9]0@__=],YW]$& WT %)I_A M34X+'64EU&.\OG1XKBS!01[0,+MXP 0/C@'K@<[]N> EU1]+N;V_%[(IV=KF+R0VXEBNG]IC']*0^3&\1<1(M.@;D$D@<[.M '*>
(]1TO7YM;-QJ-JD>GVSP6<,DRJTD^,LX4G)Z!1^-=5J&N M3V7A"WU2T@$\DD41!)5 P&7;:"=HSDXI]OX/TX[5M*LI66,(9GMT+L)(SGO5&/0=>LM$TF.PU&!+[3U:-HY"YMYU/ #
8.0,Z=,6C!'5&5CNSCFH9-J)&\^4001%AN)* MYW,>>@R>?I\C-$P; M/'SN=\+Z#>Z//]4]]+;2RW8&7M)#^ZD_]E/O_.O7PF)Y MUR2W/(Q>&Y'SQV_(Q*['PEXM_L_;I^H.3:DXCD/_
"S]C_L_RKCJ*ZJE.-2/ M+(YJ525.7-$]Y5E=0RD,I&00<@BEKR[PQXMETAEM;PM+9$\=VB^GM[?E[^F6 MUS#=VZ3\)RQ.,JRG(-
>+6H2I.SV:HXUU5=;DM%%%8&P5YC\6/#2WT=OJL> MX2*/)=L9"CJ"?U'Y5Z=2,JNI5@&4C!!&0:J$Y0?-'/J.E/TR\ETK4%E18Y204>-NC*>"#52^AO[2&V
M@N8GC%N"BHRX*G.>16S:1VYM('6$.TW+.#AE;T^E;^TY:*:U3..5SH[71M=\ M0Q2VVE7$D=BF#L9IJKZ+GJ?I79^ ?"5_X=:[GU"5-\X"K&C;@ .Y-2_#J24Z M/RTQR(CQ),."WLOH/?
_)TITY3 M=D!:\4^U17T_3L,N?EEF4_=]A[^]<)117HPI["L@"MCP]HDFM7X0@BVCYE< M>GH/ 8'5Y".$7UKU;3M/M]+LDM;9<(O4GJQ[D^]95ZO(K+< M=R>*)(8DBC4(B *]CH *?
117GB"BBB@ HHHH **** .3\@\V)C-WJ M,N,2$A?+3YFW$*VFE2,17K2.6.-JE!@GQW<-[;V=I=>%/!C3VT,NZ^6,F2,-E"7)4 MY[' XKMKSPKH=_]:ZC=:=%)=EC]X2><=,C.#^(-.G\,:-
"=K>WA6RMYE!41E?F*H>#SW[5EM';6 MMAXXL]-V_P!FQPAD5&RB2E#O"_D..U=A]/A?1=6@@AOK!)E@4)&Q9@RJ.@W MYQ^-31:#I<&D2:5#9QQV4BE7B3(W
C!R1R3[YS0!RPTVTU/QCI$=Y D\3+C" M3RY!E6.X#D=#U[U0MM!TQM\7-)9Q2&UGN4M]XSY*A-P"?W>23Q7>QZ7917L M5XD.+B*#L[CICQ'D'&,XZ@<[::FCV"6]] L&
(KYW>X7>WSEAACUXR/3%% '%: M;8V^KZ_X?&H1+*[JVT;3[.X@G@M]DEO;"UB;>QVQ @[>3ST')YI4T>P2WOH%@Q%? M.[W"]V^O&1Z8H Y/19MVO\ AEYG^>70\ L?O-\I/XXR:HZI-
%<6?CUX M9%=,PKN4Y&0H! 4&NQO?"VBZCI]M8W=@DMO:J$A!9@4 &,!@<|AW[4]>&=&C MM+NUCL52"[55FC1F 8*,#H>./3% '-ZEH>FZ1-X6EL+2*WF%|'$9(U 9U*G.
MX]6SCO6:EAJNK^)]=,=KX?NI8KGR[F]*\DB1@#;M X"D'\\UZ%ZL9Q'<.(Q92M)'$O!V9/(P<\'-3>,_^1-U;_KV:M:SLK;3[2.ULX$A@ MC&%C08
HO:.WU"RFL[/S(D£*.F2,CZCF@#DT\&YTO9/^$E\1#,(;:+[Y?N] M.;>E<]3,Q@K>LP@=P"45]IO)&LS0M+T"Z\!:E=7T<#S(9Q),^"\)!.T*3RO4$ =2?>NWTC
MPQHV@O))IM@D$CC#/N9VQZ98D@>U87A_P-I_lG6\FM:3$U_%+(?F;((+DC<% M.UN#WS0!1:=;^/0+6;0XM5UV1O%6OVEO: MZ8B-:();R&Z$'/0@\9]>,?K78ZQX;T?7O*_M.R2M:
<'A/0[:VGMH;$)#/*LTB+(M^"ZG((YXP>PXJS=Z%IE[JEMJ5Q:AKRV_U4H9E(_(_CF@#BDTX:IX5N+87EK M;R_VU^\2W38CG82'$;#N#Z<]*N:#NTOQ3!::CX?
L;"]N89%BN=/DVQR*N"08 M\\?34\UT[>']*?3YK"2R1[6:1!7C73;!(9'& M"Y9G;'IEB2!0!2\;D_V' C?ZE[VW67_<\P?UQ5?QS+<7=M9Z#8F,W>HRXQ(2 M%\M/F;
<1SC@#\ZW]6TZ/5M*N;"4E5F3 8=5/4$?0@'\"KZ=8&1[:4M0MMFJQ MP&W=_,R,9Y*@'&"1G.,X.#CI0!R\/]MZ+XRLK_6O[.2'4%%BWV'?MW#0]0L&[MYXK0M/\
D8_&'_7.#_T4:Z+4=,L]5MU@O8O,C5UD4!BI##H00010FF6<=S>7 M"PXEO HG;NV+Z9KU_9.,&&=U'N,\\ ML5GUZQ\0_"%QJDUWK6GHTLT,@CFA49+($4AAZD9Y'I]*\GKVZ-
15(0H*O2= M.;3)K1@MY $$ "122>W-=3XN\3ZF?%6HC3]=N_I?F?N_L]VWEXP.F#C'TKD* M*MP3=V0IM1LC=\,ZU%INM22ZB))K2[B>WNL'+%'ZGZYP:T_^$.THR^>/%VD_ MV=]
[<7/G[?\ KEUS[9KCZ*3@[W3L,U:TE<]!L/$.G7?CB.6*1;;3;2P>TMF MG8)E1&P!.>Y)_6N=*:W'IE^UK?KYNDW@\]JA;I@_P 8]"O7/6L"BE[*-FA^
MUE=,T=:L(=,UF>UM[N&ZMU?,4T,@<,AZ\-7.B6-_%]%]?2(UU/ /W2(O(16_BYYS7(45*I6TOHBW5O= MVU?4] US1+?Q -+NK?Q%H, CT^&%X[B]"N&4"=.U:^AU;3KK5
M7"6UH;2990H;YF;!'08 Z8SQ7"T4O9.W*WH'M5?F2U.ITWQ7=-*/U31_$.I M0[9;8O:RS".)5E4Y R !S[UP5%%7&"C>Q$YN:7.%%%%%0%%%% !1110 4444 M %%%% !1110 4444
%%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7 MT)X/LGT_PCIEO(,.
(0[#T+$MC]:\L\"^$)M=U".]NHRNFP,&8L.)2#]T>H]: M]NKS<;43M!'IX&DU>;"BBBN] **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH MH **** "BBB@ HHHH *;% R$X \ KB__*$M2*I8>(_"-SI#O<6P::QSG<.6C M_P![V]Z];#8M3]V>YY6(PKA[T-CFJU-
%U^]T.XWV[[HF/SPM]UO+#[UET5UR MBI*S.:$G%W1[%HWB.PUN,"'"39C\+0OPP^GJ/I6O7A".T;JZ,5=3D,IP0:[+1 M?'L]LJPZHC7$8X$]_?'U[^?
UKS*V":UIZGI4L6GI,]%HJGI^]V.J1>99W"2 M@=5!PR_4=15RN%IV9V)IJZ"BBBD,X[Q9X&AUPRW=LVRZ;EHV/R2$#'X&O(- M3GNM!N/L:Z>+;2%N3)DG_"OI"J.H:+INJ[?
MUE#.5Z%UY_/TK2E-0?O*Z['G M8G 1J/GAH_S,_P &^6WA2QEC@$/FIO*^]Z_C6]341(T5$5511A548 'H*=6 M9W0CRQ4>P4444%A1110 4444 %%%075Y;6,)FNITBC'=SC/T]:$K[
3U1U/5 M[+28?,NY@I/W4'+-]!7*ZOX[!5HM*C.>GGR#^2_X_E7%SW$UU,TT\KR2-R68 MY)KJIX5O66A+EV-C7?$MWK+&/F&T!^6('K[L>]8E':BNZ,5%60@J_I.D76L7
M8@MUX'+R'[]#W_P]SHGAZ[UJ4%!Y=L#\\S#CZ#U->FZ?IUMI=HMM:QI4'4]V M/]3ZUA6KJ&BW*1'I.DVVCV0M[<>[N>KGU-7J**\]MMW8PHHHI %%%% !1110 M 4444 %%%%
!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 5++_7WW_7Q_P"R)7/Z M]\/-
"UZ5KAHGM+IN6EMR%W'U9<8/_>N@LO]???]?'_LB5;]BXE!WBR90C-6 MDKGE;.!A2QV:\0OH;3)_]#IO_"E_^H__.2?_P!G7JU%;?6]W?\)(P^]4>WY MGE/_ I?_]/_ /DG_P#9T?\
"E_^H_\ ^2?_ -G7JU%'UNMW_(/JE'M^9Y3_M_*7_P"H_P#^2?\ ]G1_PI?_ *C_ /Y)_P#V=>K44?6ZW?\ (/JE'M^9Y3_P MI?\ ZC__))__ 9T?*7_ .H__P"2?_V=>K44?6ZW?
\@^]4>WYGE/_"E_^H__ M .2?_P!G1_PI?_]/_P#DG_\ 9UZM11];K=_R#ZI1[?F>4_\ "E_^H_\ ^2?_ M -G1_P *7_ZC_P#Y)_\ V=>K44?6ZW?\@^]4>WYGE/\ PI?_ *C_ /Y)_P#V M='_"E_\ ]/\
_DG_ /9UZM11];K=_P @^]4> MWYGE/_"E_P#]/_\ DG_]G1_PI?\ ZC__))__ 9UZM11];K=_R#ZI1[?F>4_*7_ C_\ Y)__ &=>K44?6ZW?\@^]4>WYGE/_ I?_]/_ /DG M_P#9UZM11];K=_R#ZI1[?F>4_P#"E_\ ]/_DG_ /9T?*7_P"H_P#^2?\ M]G7JU%'UNMW_"#ZI1[?F>4_*7_ .H__P"2?_V='_"E_P#]/_\ DG_]G7JU
M%'UNMW_(/JE'M^9Y3_PI?_]/_P#DG_\ 9T?*7_ZC_\ Y)__ &=>K44?6ZW? M\@^]4>WYGE/_ I?_]/_ /DG_P#9T?\ "E_^H_\ ^2?_ -G7JU%'UNMW_(/J ME'M^9Y)\'MES##_ &[GS
QS]DZ8Q_M^]3?*7_ZC_\ Y)__ &=>ES_\A*T_MW9/Y"K='UNMW_(/JE'M^9Y3_ *7_P"H_P#^2?\ ]G1_PI?_ *C_ /Y)_P#V M=>K44?6ZW?\ (/JE'M^9Y3_PI?\ ZC__))__ 9T?*7_ .H__P"2?
V=>K44 M?6ZW?\@^]4>WYGE/"E_^H__ .2?_P!G1_PI?_]/_P#DG_\ 9UZM11];K=_R M#ZI1[?F>4_\ "E_^H_\ ^2?_ -G1_P *7_ZC_P#Y)_\ V=>K44?6ZW?\@^]4 M>WYGE/\ PI?_ *C_
/Y)_P#V='_"E_\ ]/_DG_ /9UZM11];K=_P @^]4> MWYGE/_"E_P#]/_\ DG_]G1_PI?\ ZC__))__ 9UZM11];K=_R#ZI1[?F>4_\ M*7_ZC_\ Y)__ &=' "E_^H__ .2?
P!G7JU%'UNMW(/JE'M^9Y3_P *7_ZC_P#Y)_\ V=' _I?_]/_ /DG_P#9UZM11];K=_R#ZI1[?F>4_P#"E_\ ]/_M_DG_ /9T?*7_P"H_P#^2?\ ]G7JU%'UNMW_"#ZI1[?F>4_*7_ .H__P"2
M?_V=' "E_P#]/_\ DG_]G7JU%'UNMW_(/JE'M^9Y3_PI?_]/_P#DG_\ 9T?\ M*7_ZC_\ Y)__ &=>K44?6ZW?\@^]4>WYGE/_ I?_]/_ /DG_P#9T?\ "E_^ MH_\ ^2?_ -
G7JU%'UNMW_(/JE'M^9Y3_ _*7_P"H_P#^2?\ ]G1_PI?_ *C_ M /Y)_P#V=>K44?6ZW?\ (/JE'M^9Y3_PI?\ ZC__))__ 9T?*7_ .H__P"2 M?_V=>K44?6ZW?\@^]4>WYGD=U\'OLUI-
/_;N[RT+;?LF,X'^_4W_I?_]/_ M /DG_P#9UZ7JO_(0N_\ KBW\]MT?6ZW?\@^]4>WYGE/_ I?_]/_ /DG_P#9 MT?\ "E_^H_\ ^2?_ -G7JU%'UNMW_(/JE'M^9Y3_ ,*7_P"H_P#^2?\ ]G1_ MPI?
_ *C_ /Y)_P#V=>K44?6ZW?\ (/JE'M^9Y3_PI?\ ZC__))__ 9UKZ7\) MM&LI%EO)YKU@/_ *X/_P"A+0!;HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "JFJ?\@N_ZYFK=5-4_P"07<_!U%% '$>(O Z3;[O25"2=6M^BM_N^GTZ?2N!F@EMIFAGC:.13AE<8(KW6L[5 M=#L-9AV7<(+ ?
+*O#K]#_2NZAC7'W9ZHXJV$4M8:,\8HKI-9\&:CIA:2W4W= MOUW1CYE^J_X5S?0UZ4*D9J\6<$H2@[21+#-+;RK+#(\ZC M;)>1I=(/XC\K_F./TKDZ*52G"?Q(N$Y0^%GK&G^,M'OP
T_V:0_P5/*SZ? MK6[')',@>-U=3T93D5X6*EM[JXM7WV\\L+>L;E3^E<4\#'[+.N.*?VD>XT5Y M3;>,];M@%-RLRCM*@/Z]:TX/B)>+CS[&"3_<8I_/-<\L'46VINL1!GH=%<6G
MQ$M2!OL)E/?:X\ A4Z_$+3#]ZUNQ]%4_P#LU0\/5[%JK!]3K:*Y)OB#I8'R MVUX3[H_]F])_B'9C.RQG/IE@*7U>KV'[2'<[*BN G^(=PV?L]A$GH9'+?RQ M6;<>-M:G!"S10@_\\XQ_7-
6L)4>XO:Q/4&954LQ ZDFL>^\4Z18 [[M97'\ M$/SG].!^)KRZYO[N];-SQV.H>/[J7*6%ND"_WY/F M;\N@_6N6NKRYOIC-=3/+(>[G/_ZJKTM=,*<8?"B>9O<7M11VK9TGPQJ.K%66
M,PVY_P"6T@P,>P]TY245=E(R%5G(502Q. .378:!X+DF*W.J]8X^]P=&;_> M]![=?I73Z/XN&KB6](&B0R**,&)8HD5(U&%51@ M4^BBN0H**** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M** "BBB@"I9?Z^^_P"OC_V1*MU#! 8I+AB0?-DWCV^51_2[J "BBB@
HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH]3_ /(2M/\ =D_D*MU#)"7NH9@1B,,"/7./*FH **** "BBB@ HHHH M **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ MIJO_ "":O_KBW\JMU#>0&YLIH%(!D0J">V14U !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444
%%%% !1110 4444 %5-/_U4 MW_7>3_T(U;J&VA,".I(.Z1GX]R30!-1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5&_Y"\?_7!__0EJ
MW4)A)O4GR,+&R8^1!_I0!-1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %5-4_P"07<_]9:EX#U*U+/;,EW'V ^5_P
CQ^1KFI[>:UE,5Q#) M%(.JNI4_K7N5075G;7L7EW4$C]#79#'27QJYRSPD7\+L>("BO3+SP%I4^ M3;--;-V"MN7\CS^M8-W\/M1BR;:X@G'HBJ,DUT.G^#-5O<-
+&MK&>\I^;_OD<_GBO1;/3K/3TV6EM"*.Y5>3]3U- M6JY9XMOX4:GJW,'2O"6FZ;M=H_M,X_Y:2C(!]AT%;U%%@I:**D84444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !

!1110 4444 %%% !1110 M 4444 %%% !1110 4444 %%% !1110 4444 %%% ! M1110 4444 %%% !1110 4444 %%% !1110 4444 %% M%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 444 M4 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 M 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% ! M1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% M%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 444 M4 %%% !1110 4444 %%% !1110 4444 %%% !1110 M 4444 %%% !1110 4444 %%% !1110 4444 %%% ! M1110 4444 %%% !1110 4444 %%% !1110 4444 %%% M%% !1110 4444 %%% !1110 4444 %%% !1110 444 M4 %%% !1110 4444

"BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@" MI?\ _+M_U\)_6K=5+_\ Y=O^OA/ZU;H **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JIG_ "#8/]W^ MM6ZJ:9_R#8/]W^M %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH *]#_)"[?]O6])"OYE8 M_J:KTCY^;O)LZ?P1#NU2>7LD./Q)'^!KNZY'P*@$5Z^.2R#^?^-==3/7PBM2 M04444'2%%%% !1110 4444 ,O"DOAW3:778|5O9|3\Y5FF>3N0>5[CD8ZGK6Y\0 M+A|SZ;6%S* KCCRM#NC"@Y^\W.<|ZY?P-K-Y]/A+6;*^E>: M6R1U61SD[2IX)
[X(-97A'3(=6^%^L03M(JIUB1@+9H6!+C)SGYF_V? M3K7#_"C0+6:-]=:2874$SPJ@(V%2@ZC&<_,>]2?#BX6TN?%5RX)6%A(0.X!D M- 'J%%>3>']!G^(GVO5]D45X_8Z3-KGQ&U[3Q?3VMJ[N|P8" TB MAL!<_4_I5OPU:S>%_B?)H5M,_B ?_&4UWU2U+:3?9[V"?_)YR*_Y'-14AK<\5;'T1UHJO82>;IUK)_?B1OS J MQ7,?0)W04444#.;\>?\
{GWGUC_]#6O.=$\/ZIXBMW2!BMK;!BI?[N\C,T>Y MXR>WY5Z5XUMY{KPK=PV\,DTK%,)&I9C\X["H/ 5K<6?AORKJWE@D\YSLE0[< M<=C6D7:)Q5:2J5TGM8POA{KIAD?0KS*,&)@W<$'^)/YG\Z[^YN8;.VDN+B01 MQ1J69CT KSSQKX;O(=9BU:2;>:1I6W.(+,D@_BP/7^?UI/%%SKFMZ+IJ)IM M^A8-]JA6W?[ZXP>G3J1_]:AI2=Q0J2I1<9*
[6QGSRWWC_P 2+%%NBLHNF>D: M=V/^T?\ /2O4+"QM]-LHK2UC"0Q#"C^!Z\RT74/$V@V9MK/PZQ#-N=WLY2S M'W({K;T_O/XLN-2M8;G0_+@DF1)'^R2C:I(!.2<#
HDF]A4*D8ZROS/R*GQ1 M_P!9I?TE_P#9:H7L?C'2]'BO&OV#9^6O,,F=BD<9XR*V/B/I|[?2:<;2SN+C M8)-WDQ,^W.W&<"NQLX ^C6]O/'D&W5)(W'^R 011S6BANDYU9ZM;'#>!=
(L-`M0N3K$\]W?1MN:JQ@HQ_B0).IV-;_B3QA'X=0(K=[-IS)'OW"3;CDC'3VKD_M(U;PEXL_3K*ZNK/.?W4;/NC/520.H_H#7I#VEG?+'-/:12$J_>=$"P'7'(
MR/I1*U[E45+D<(Z21D>&?%2>)&N0EHT'D!2+_ !@;0MI.E$R7-MK_(IISY>>PI6_E]:VM=5])T*ZDT:P NY $46T'SO5V.]\&>&9-#L9}G OK@#(_YYKV'
MU]_P#"FD2:WJLE@;F2"$Q%Y]G5E!"YD=:[SPQK7B+4-4>'5M/:WMQ$6#F MV>/YLC R?8FL*^TC6/"GB635=+M6NK64L=J*6PIY*L!R,'H?8?2FF[LSG&+C M!Q3Y5N0E)_
_C"VM;>YDDLKC861SU5B5.1TR,$YKTSI-_;K[284_;L\S:-V MWDXSZ<__7-O MY5-4-U_QYS_]A-,I'SIW/@=<:=Y^Q1+Y*H2^1MR-O7-4+??3IU?@\UB M;.X%WY#*R##$WF9\PG&W&:
[ZB@#SNVTV_7X-O8FRN1>;&'V&O#<6GCPY/=!T+6TJJV8MV3AU-)X)/7%>]44 <+X0\,WFB>$]2-X MI^W7J,S1#DK\IP..IY/YU%\/-)O8?!FI65W:36TLTT@5)XRA(,:C.#VKOZ* M/-?
ARVLZ+,^AWFA7444DSRM=LI"*=H&.F#G:..<]ZE^'VCW<5UXCCU"QN((;E M@JF6)D#J2^<9'/|_6O1:* /+=('B?P]U8KHDVK6,LA>)[C^\8Q_X^ MI_I3CN95OX'M.;UM(C_ ..'M"L_0
1X.#O44.JI*.|" 3QS5*$GT.>6+HQERN2N:5%1PRB520,8.*9=745I TTSA M47J342:BKLZ(^,;EUN2/+'E>ZKGIDT^N=/L<63#(K_?\ P_"N MA
P*Y\/7=:\DO=Z>9K5IJG97UZBT445TF04444 %%%% !1110 4444 %%%% M!7*_$)]OA5Q_>F0?KG^E=57#_$VXV:396^?]9.7_ .^5Q_[-51W,<0[4!'F%
M(:6GPQ&>>.,)>KL%'XG%;GAGO.EQ^5I%E'_<@1?R45;I%4(H4< # I:YCZ%*R ML%%%% PHJ"]NXK"QGNYVVQ01M(Y]@,UB^$]?NM;M;A-0@CM[Z!E+Q)G&QU#(M>2>H/Z4
=#152YU*R94UMY;RWCN7&8X7E4._T&HJM<:A96C%;F\MX6"&0B255(4'!;D],GK3[:ZM!R 3V MMQ%/$>DD3AE/XB@"B]MKJ=A>RR16E]:7$D?WTBE5ROU /%%WJ=AIY07M];6
MQ?[OG2JF[Z9/- %JBF--$D)F:1%B"[BY8!0/7/I6(_B%)M?TJSL)[6YM+M9C M)+&^_!0 @ @X[\T ;U%1YR[_^^%[Y6ZN+)_+FD7?;.2BJ#P&)Z,!U M]Z +]%5K/4++4$9I*\M[E4.&,,JN ?
0X-6: "BBB@ HHHH ****"BBB@ J& MZ_X\Y_\ KFW\JF]&Z_X\Y_\ KFW\J "U_P"/.#_KFO\ *IJI_:[> QTE+FZE6 M*&.)2SL>!Q7G&M_$N\FE:+2(UMX1D":10SMIX/
_6FHM|&52M"G\1ZG17@LO MBC7ICEM7O!_N2E?%8J/ (2'6_\ H;_A P"!+_XU?IV<:P<CV?|*\"_P"$ MAUO_*#&H?\ @2_^-' "0ZW _:C4\ P)?_ !H!FQ?7!HGCWVBO _P#A(=;_M
.@QJ'_@2_\ C1_PD.M_]!C4/_ E_P#&CV;#Z']L>^45X'_PD.M?!]!C4/_ E M_P#&E_X2'6O^@QJ'_@2_^-'LV'UZ/8]!HKP3_A(=:_Z#&H?^!+_XTO\ PD&M M?]!C4/\ P)?_
:!H|FP^O1!'O5%>"_P#"0:U_T&-0_P# E_\ &C_A(-:_Z"]_ M_P"!+_XT>S8?7H|CWJBO!?\ A(-:_P"@O?\ _@2_^-*/$&M?!|>__P# E_\ M&CV;#Z!'L>\T5X-_PD&M?!|>_P#_)?_&C_ (2#6O\
H+W_/X$O_C1[-A] M>CV/>:*\& X2#6O^@O?_/@2_P#C1_PD&M?!>__/ E_P#&CV;#Z!'L>\T5 MX/\ \)!K7_07O_\ P)?_ !H_X2#6O^@O?_\ @2_^-'LV'UZ/8]XHKP?_(2# M6O\ H+W_
/X$O_C2_P!OZS_T%[___,"7_P ;/9L7U^/8|WHKPC^W]9_Z"]__ M .!+_P"-+_;^L_\ 07O_/P)?_&CV;#Z_'L>]45X3_;^L_\ 07O_/P)?_&C M^W]9_P"@O?\ _@2_^-
'LV'U^/8|VHKPC^W]9_P"@O?\ _@2_^-'!OZS_-!: M_P#_)?_&CV;#Z_'L>U6_\ R$;S_@"\]MUX2-Q[I17A?]OZS_-!:_P#_)?_&C^W]9_Z"U_M_P"!+_XT_9,/K\>O[I17A8U_6?\ H+7_
/X$O_C4D?B36XCE=5NS_O2EOYT>_MR8?7X]CW"BO+|)^(-[#(L>ICSXCP9$^5U]\=#^E=_:WL=[;)<6T_F1.,JRGK M42BUN=5*O"K\)HT54WM_>/YT;V_O\'ZDU+=%5-[?
WC^=&|O[Q_.@"W153>W]X_G1O;^\?SH MT54WM_>/YT;V_O\'Z +=%5-[?WC^=&|O[Q_.@"W153>W]X_G1O;^\?SH MT54WM_>/YT;V_O\'Z +=%5-[?
WC^=&|O[Q_.@"W153>W]X_G1 MO;^\?SH MT54WM_>/YT;V_O\'Z +=%5-[?WC^=&|O[Q_.@ O_P#EV_Z^$_K5 MNJ3?/C=S@Y&>Q|:=O;^\?SH MT54WM_>/YT;V_O\'Z +=%5-[?
WC^=&|O[Q_.M.@"W153>W]X_G1O;^\?SH MT54WM_>/YT;V_O\'Z +=%5-[?WC^=&|O[Q_.@ M"W153>W]X_G1O;^\?SH MT54WM_>/YT;V_O\'Z +=%5-[?WC^=&|O[Q_.@"W
M153>W]X_G1O;^\?SH MT54WM_>/YT;V_O\'Z +=%5-[?WC^=&|O[Q_.@"W15 M3>W]X_G1O;^\?SH MT54WM_>/YT;V_O\'Z +=%5-[?WC^=&|O[Q_.@"W533/
M^0;!_N_UHWM_>/YTU?D4*GRJ.@'_% %VBJF|O[Q_.C>W]X_G0!;HJIO;^\?S MHWM_>/YT 6Z*J;V_O\'Z-[?WC^= %NBJF|O[Q_.C>W]X_G0!;HJIO;^\?SHW MM_>/YT 6Z*J;V_O\'Z-[?
WC^= %NBJF|O[Q_.C>W]X_G0!;HJIO;^\?SHW M_>/YT 6Z*J;V_O\'Z-[?WC^= %NBJF|O[Q_.C>W]X_G0!;HJIO;^\?SHWM_>/ MYT 6Z*J;V_O\'Z-[?WC^=
%NBJF|O[Q_.C>W]X_G0!;HJIO;^\?SI*X|Y^M M %JJ@_Y"[?\ 7 ?^A&ITE#\=#4 _Y"[?|>>+X?*U|WQ_K8U?!,?TK KLO'-O_QZ70'K&Q_4?UKC:1XF|CRU9&YX2F$/
MB"$$X$BLGZ9_I7HU>1VEPUK>0W"]8G#_)&O6U8.@93E2,@?STMXP,KP<1:*** M#N"BBB@ HHHH ****"BBB@ HHHH *S]3U:WTR,-*26/11]0.?3DBM UPWC?
M1+|JX7|3%/E)66%D9L8#' ^OS8-5&U]3CQU6K2I9@:[]QJ$-PUG(K MSJ6VQKT+C./UKG/AOKEU+]DD6I74QEE!#)*2-K ^G:G1PVVF-)LO$.TE@"WS M;0>N*YV.5K7Q"=3CN&F$\H?
D$.O3@YI>E4YR/)HTDZ(MG9)K827"+:R,$DA9,E^14FAZI#>QH\3#8XZ9Z&DUTO\ ;+ |H!$)E+&3DCGM M7G9I_N\O,^276M1%Q-'&%A&IRM=#:AC2*)4C4*BC 4# %24@I:ZXI)(;U"BD)
&2<"H MXIXYAN0Y&<9|:**=FP);***H HHHH **** "BBB@ HHHH *\R^)MR'U6RM@ M<^5"7(I-Q_\ L:]-KQ+Q9>_;_$\|*#E5D\M?HOR_TS^-7!:G'C96IVF[+6MX M8MOM?B?38L9_?
]Y'LOS'^59-=C\.+/S_ !#)=1 MCS5$CU:BBBN<|T*****,3\@V)C-WJ,N,2$A?+3YFW$5&.A&/TJK9O-;_ T#?(%+3:6QE;'5H2Y$@_ +G*Z^]*Z'J& MD]J%UIT4ETA!\PDC)'3< <-
^..:NVVEV=GI@TV" +9A"@B+%OE.YH YN MQNK>_P!4USQ%*S/86L)M8&0GE%&Z4KCU/&1Z5R.M6R'P:]U!XHV&E6.F: M1AI$1,@(.7<@9] 3Q]1C%
&5+IUIJWB0DOXN32C+LD&Y2V5'(/7J:SKV(M:7I_C:WT]3"DD!'1)M[';'QQR>>@ MY/-.CTRRBGO)E@?7>8^T;B6$F!M&0>.G% & FD^&=/O-%N;0I:3LVRV-J.;D M%>0^
=PQSDI/6N=2PU75_$^NF.U\/W4L5SY>S5%>21(P!MV@:[+3/" M6A:/>M>6&6G1PW!!&_N3K/J.GI-,HQO#.C$>Y4C/XT M<7):26OAS3=/U"[LIM;/6 DXLYF>&./D^62>0
W8GCBM>:PTK3?B+HR6$,%N M[6\[2Q0@*H&WAMHX!///?%=1_8VF_P!D_P!E_8H?L.W;Y&WY>N?SSSGKGFJ- MGX/T'3]GV33Q$4#]&65\X<8;G.3Q^7;% &#= S_#
[7]4;KJ/FSK]D]P_OE0 M?QJ!IV307O(82 ^]6$$EH/6? B(^O*&NUDTNRETDZ6\ -EY0A\H,1\@&,9!S M3)M&T^XFL99;8.]@VTF%(O4LJMC M!Y^PT+4=0\)I<9]JH1CTZUBU&?
4$BQ=3H MJ22;C\RKT&,X%9,G@CPU+?FI?283,6W'EMA/NF=I_*@#)NK"'X\4^%FOH;2Z MG>TE,TH4.LK*BD-DCD9R0?>]MRL&I:IJ\VG^'-+N!#,8[F^U.<$!U&#A2"54 M#TP*Z_5-
!TS63 =0M5F;W;=$VYE*'V*D'L*IWW@SP]J.H-?7>F1R7#'+-O90 MQ]2 <'\J ,,T?3QJGP\AM5O;*!UU)F@29CY$S!B1'@\E3UQR>*U=#4Z,XGAL MM3\,V%C=W<$B1W%@^(I57!
(,?]3S72KX9T9-,FTT:?%]CFD,K0G)7<>XY^7\ M,8|4FD>%|%*T5Y=-L$AD<8+EF=L>5]6)(% ^:%8Y:9X6\275S8PS7$L\+K"/ M+9TW *FX8(7)|<"LC7|66UMM,E?
0M%TD&ZA,7DRAKAN1T90 1ZDY_/%>A+X8 MT5+B]G6PCWWRE;G+,5D!.?NYP.><@52B\ ^%X594TE!N(.3(Y88.1@ELC*
M*T=A9GXG3R&T@,@TY)0QC&0_F$;L^N.,]:P)2I\+&&=RME-X@>.Z.<#RC(ZI;:E<6H:\MO]5*&92/K@_CFG)HNG)87%B+5&MKAVDEC3') #I^=1F.?_D#/_?
1HI8%'VS=W,9'ZB@"Y1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% &/XGM?M6@SX& M6BQ*/PZ_IFO-
.]@=%DC9'&58$$'N*\HU"T:QU">U;.8W(!/<=C^5!YN.AJIE M:O2_#5X+W0H^3EXAY3?AT_3%>:5U'@F^\J_ELV/RS+N7_>'_-;/Y4&.#GRU M+=SNJ***#V HHHH *****"BBB@ HHHH
***1F"]23@"@!LDBQKEF"_4UY\2 M/$E5F*Y/MQ@5Z'X=M(6'FW M\:)O&(MWIW-8/BC0+O\ X2:,\T[2&>U:$,[VZDEF!P=WQT^OX5+]6N1C5V@" MO'!!@ ,>;V6LKJ,<5]Z*6+
=.3[\5T[_JL5EJUOIT M5LTL\< GGEA!?);_ Y ^4\ \^M<6)?/5A3>]W:.K!1^K86I6]TG9)WQ]H|/ M0| NM4GCL9'A.Y@,YQR!W-3:-=S7-GYDDFY@2.,YC3=0%%9:+.SQM(,9Q@ >
MF*2X?4],BWVF]X&(=O+7/']*SQ4]JJJI&_+8>%Q'NVF]3J=6O!]C:&.-I97P M-J=AZU)IBS"U4W'WS^E<2GBF.75W,,3122+Y8#]_>NZTX.;.'SB^^WD^]9]] M:J!/,,-
'IM.MH%B6X2Y2=58G W;?NCWJ M!XA@T^^>PLK]IFM;R28O92Q]ED49ZX(Z$\'K69>W?B+PO;K>7U],ZK8+(JS M%H?)F4,P *[3M,,^E '7UFZ]JO\ 8FB76I>3YWD*#Y>
[;NR0.N#CKZ5ST^EV MWBCQ?JEKJSRRV=A"'(;42LB%ND):#N8GE=O48&#GWJOKVK?V)L,E]V'G; M'1=F_;G(=>N']B:'1$=#C.""^#61K'AJPL?!D&JPS3F!G M^SO/,TS-
]H+,I(8$XZG(P,\4 >E3O)';R/%%YLBJ2D>[;N..!GMGUKD)O%OB M*WO;:SE\(;,BZW>2G]H1G=M&6YQ@<>=M=G7-:S_R.WAKZ77_H H UM)NO4D0
MR:EIO|GSAR!#YZRY''.5X]>/:K]\,3R,X:56(#>KX4L'\(C7FN[O^US:?:O|0 M^TMO#;=V.N,=OIW]\LOB;6/#JZD)/+NM*:2XB5BGF?<.#CG&<'CT% '?T5% M;6T-G:Q6UN@2&)
B*.R@8]6@ HHHH ****"BBB@ HHHH ****"BBB@ HH MHH *****"BBB@]&Z_X\Y_\ KFW\]FJ&Z_X\Y_\ KFW\J /!-N>ZMR/T-4*]=\6>$SKVE6]U: ?;X(5"@G
D7&=OU]*\EEADMYGAFC:,1# MAD88(/O6\7='C5Z3IR\AE HH%48BT444Q"T444 ***!10 4M)2T %+24M !0 M**!0(6BBB@ HHHH 6BBB@ %+2"EH$%+24M !2BDI10 4444 +1110
4444Q M*6D%+0 5?T:R;4-9M+902'D&['91R3^6:I1QO-*L<:,[L<*]C())KT[PEX:.C MPM=70'VR48QU\M?3Z^M3*5D;X>BZD_(Z>BBBN8]P***** "BBB@ HHHH ***** M "BBB@ HHHH
***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHHH **** "BBB@ HHHH ****
"BBB@ HHHH ***** "BB MB@ HHHH ***** "D@)_M_]>GDY'XG_P"M4D<9<^WK35&-68"_)1Q_P"A&@"Y M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M%% !1110 4444 %%%% !7$>-K'9=07JCB0;'^HZ?I_*NWJEJVGKJ>FS6S8W,M,H3V8=*#&O3]H3<3RJI+:XDM+F.XB.'C8,*8ZLCLC AE."#V--H/$5T>N6=U
M'>V<5S$WM4]<9X*U0*7TV5NI+Q9_4?U,.NSH/+.@\/4M;W7U-2YO5M;27SF4A%)8 M!\''?FN1\;Z/]GM+35HA&(IB8VC0'*XZ%C757&C07L,BR2G]&R'&*C(Q_6L
MOPYO@H.M2E@[_M !6;I4WJR(L43,2ZEAGHA?PKKX?$UF'G:26-KIYB)FC3)7"C| M!69\,$C\1:G$;A(2K82-L$ 9,""'>N*YB%9TO;I+OFYCN91*3_$VXY/'O4PG
M>O*7;Q&*J/#X&%.VK;N_PL>E17@O9 86'E*QKNH);6=L+,F\8/# 5U*=M3S9)5(Z;E6+3IM7\0 P")1 M*0P&-H SG&/QKTF , !MP *XG2K2?^TY+VR=&6-MK9/WL]:[:V=GC!88/<5Q
MX1IU%S/4].@DD6****]@W"BBB@ HHHH ***** "FNZQ1M([!44%F)Z "G5QWQ M UM;+2O[.B;_ $BZ'S8/W8^_Y|/SH7=B*DU'+DSS[7]5;6=:N+PD[&;;&#V M0=/\?QK+I:2N@\&3
M,^W>)$F=W1DC1AT(&!R/>NEHH MQ-7\+66KWB7OGWEE>]NS[393&-RO!TGD$5&O@_2X!:NM(3SUCNSNGF\S=+(V M0=Q8@\\>E;!% &>-'MAJL^IL7:2>W6V=&(*% 2>F.O)
[UAM\/M*:(PF[U(VZ ML&A@:YW1P$'R @X].<\$\UUE% !5&ZT]"[U2QU'1Y!+9>9Y84C:=X ,>/;\Y] M]10!F:UH=IKMM'#7]HU$6&[=_9XNC|GSG/W>O7
MGK6VVD6S:M;;B"ZR6T+01HN FUL=L>P[U?HH ***** "BBB@ HHHH ***** "B MBB@ HHHH ***** "BBB@ HHHH ***** "H;K_CSG_ZYM_*IJANO^/.?_KFW\J
M"U_X\X/^N;_RJEJOA_2M: ^WV:2N!@2#*L/Q'-7K7_CTA_ZYK_*I:!-)JS.+ M?X8&9S$]\@\9D7'ZK3?^%7Z)_S]:A_W\3_XBNVHJN9F7U>E_+<3_P *OT3_M_\)^M0_[^)_\ $4?
*OT3_GZU#_OXG_Q%=M11S,/J]+^4XK_A6&B?_6H?]_$ M_P#B^/\ A6&B?_6H?\ ?Q/_(BNUHHYF'U>E_*<5_PK#1?^?K4/^_B?_$4? M*PT7_GZU#_OXG_Q%=K11S,/J]+^4XK_
(5AHO\ Sl:A_P!_$_\ B*7_ (5C MHO\ Sl:A_P!_$_\ B*!2BCF8?5Z7\IQ?_"L=%_Y^M0_[^)_\11_PK'1?^?]_M_P"_B?\ Q%=I11S,/J]+^4XO_A6.B_\ /U?_/?Q/_B*/^%9:+_Sl7___\3 M_P"
(KM**.9A]7I?RG%_*RT7_GZO_P#OXG_Q%'_'LM%_Y^K_/[^)_\ $5VE M%',P^KTOY3B_^%9:+_Sl7_\ W\3_.(H_P"%9:+_._5_P#]_$_^(KM**.9A M]7I?RG&?*RT7_GZO_\ OXG_.11_P
ST7_)^K_P#[^)_\179T4C?\/S?_/?Q/_B[.BCF8?5Z7\IQG_"ML]&_Y^;_/[^)_\ $4?*TT;_GYO_P#OXG_Q-=G11S,/J]+^4XS_(5IHW_/MS?\ _?Q/_B:7_A6FC?\/S?_/?Q/_B:[*BCF8?
5Z7\IQO\ PK31O^?F_P#^ M_B?_!-'_"M-&_Y^;_\[^)_\37944D/=7$1N+[;'MQATS MR/\ =]?_(5KHW_/S?_?Q/_B:Z>W'_!,+S_@'\]MT]8>AD7^BUV%%'/+N'U>E_*96G>'-+TH?Z';"-
B,% MR=S'\36AY"^]J6BI-5%15D1>00J:/(7U-2T4#(O(7U-'D+ZFI:* (O(7U-'D M+ZFI:* (O(7U-'D+ZFI:* (O(7U-'D+ZFI:* (O(7U-'D+ZFI:* (O(7U-'D M+ZFI:* (O(7U-'D+ZFI:* (O(7U-'D+ZFI:* (O(7U-'D+ZFI:* (O(7U-'D+ZFI:* (O(7U-'D+ZFI:* (
MO(7U-'D+ZFI:* (O(7U-'D+ZFI:* (O(7U-'D+ZFI:* (O(7U-'D+ZFI:* (

****** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH CN+>*Z@>"}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end EX-101.SCH 7 kzr-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Available-for-Sale Securities - Summary of Available-For-Sale Securities Recorded in Cash and Cash Equivalents or Marketable Securities (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100040 - Disclosure - Debt - Schedule of Long-term Debt Balance (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100080 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 100090 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100100 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Organization and Description of the Business link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Available-for-Sale Securities link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Lease link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Pre-Funded Warrants link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Everest Collaboration link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Restructuring and Impairment Charges link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Available-for-Sale Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Lease (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Pre-Funded Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Restructuring and Impairment Charges (Tables) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Organization and Description of the Business - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Fair Value Measurement - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Available-for-Sale Securities - Summary of Available-For-Sale Securities Recorded in Cash and Cash Equivalents or Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Available-for-Sale Securities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Available-for-Sale Securities - Summary of Gross Unrealized Losses and Fair Value by Major Security Type for Available-For-Sale Securities in Unrealized Loss Position (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Lease - Details of Right-of-Use Assets and Lease Liabilities (Details) 2 link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Available-for-Sale Securities - Summary of Amortized Cost and Estimated Fair Value of Available-for-sale Securities by Contractual Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Balance Sheet Components - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Balance Sheet Components - Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Balance Sheet Components - Accrued and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Lease - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Lease - Details of Right-of-Use Assets and Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Debt - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Debt - Schedule of Long-term Debt Balance (Details) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Debt - Schedule of Estimated Future Principal Payments (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Pre-Funded Warrants - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Stock-Based Compensation - Summary of Activity under Stock Option Plans and Related Information (Details) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense Recognized (Details) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options Granted is Calculated Using Black Scholes Option Pricing Model with Range of Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 995945 - Disclosure - Everest Collaboration - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995955 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995965 - Disclosure - Net Loss Per Share - Calculation of Basic and Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995975 - Disclosure - Net Loss Per Share - Anti-dilutive Outstanding Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995985 - Disclosure - Related Party Transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995995 - Disclosure - Subsequent Events - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996005 - Disclosure - Restructuring and Impairment Charges - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996015 - Disclosure - Restructuring and Impairment Charges - Schedule of Accrual Activity and Payments Relating to Restructuring and Impairment Charge (Details) link:presentationLink link:calculationLink link:definitionLink Statement [Line Items]Statement [Line Items]Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range LimitExercise prices, lower rangePlan Name [Domain]Plan NameSchedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]Summary of Pre-Funded Warrants OutstandingEntity Address, Postal Zip CodeEntity Address, Postal Zip CodeFair Value, Recurring and Nonrecurring [Table]Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]Entity Incorporation, State or Country CodeEntity Incorporation, State or Country CodeTwo thousand eighteen employee stock purchase plan.Two Thousand Eighteen Employee Stock Purchase Plan [Member]2018 Employee Stock Purchase PlanRestructuring Charges, TotalRestructuring ChargesOther comprehensive income (loss):Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]Interest Paid, Excluding Capitalized Interest, Operating ActivitiesCash paid for interestNumber of Operating SegmentsNumber of operating segmentsSchedule of right of use assets and lease liabilities table textblock.Schedule Of Right Of Use Assets And Lease Liabilities Table [Text Block]Details of Right-of-Use Assets and Lease LiabilitiesSouth san Francisco, California.South San Francisco California [Member]South San Francisco, California [Member]Shares, OutstandingBalance, sharesBalance, sharesFair Value Hierarchy and NAV [Axis]Level 2Fair Value, Inputs, Level 2 [Member]Level 2Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]Share Based Compensation Arrangement By Share Based Payment Award [Line Items]Long-Term Debt, Current Maturities, TotalLong-Term Debt, Current MaturitiesDebt, currentLessee, Operating Leases [Text Block]LeaseRestructuring Cost [Table]Product and Service [Axis]Depreciation, Depletion and AmortizationDepreciation and amortizationDepreciation, Depletion and Amortization, TotalBase Rate [Member]Floor RateCollaborative Arrangement and Arrangement Other than Collaborative [Domain]Collaborative Arrangement and Arrangement Other than CollaborativeNoncash Investing and Financing Items [Abstract]Supplemental disclosures of noncash investing and financing information:Related Party Transaction [Line Items]Share based compensation arrangement by share based payment award subsequently authorized additional period start.Share Based Compensation Arrangement By Share Based Payment Award Subsequently Authorized Additional Period StartAuthorized an additional offering beginning periodOxford Finance LLCOxford finance LLC.Oxford Finance L L C [Member]Equity [Text Block]Pre-Funded WarrantsOrganization and description of business.Organization And Description Of Business [Line Items]Organization And Description Of Business [Line Items]Title and Position [Axis]Title of IndividualSale of Stock [Domain]Sale of StockLong-Term Debt, GrossPrincipal loan balanceTwo thousand fifteen and two thousand eighteen equity incentive plan.Two Thousand Fifteen And Two Thousand Eighteen Equity Incentive Plan [Member]2015 and 2018 Equity Incentive PlanDebt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]Summary of Gross Unrealized Losses and Fair Value by Major Security Type for Available-For-Sale Securities in Unrealized Loss PositionEntity Central Index KeyEntity Central Index KeyAdvance for clinical related costs, noncurrentOther Assets Advance For Clinical Related Costs Non CurrentOther assets advance for clinical related costs non current.Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in PeriodNumber of options outstanding, Options cancelled/forfeitedIncrease (Decrease) in Operating Capital [Abstract]Changes in operating assets and liabilitiesCollaboration RevenueCollaboration Revenue [Member]Collaboration revenue.Common Stock, Shares, IssuedCommon stock, shares issuedCommon Stock, Shares, Issued, TotalCommon stock grantedTotal other assetsOther AssetsShare-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, MinimumRisk-free interest rate, MinimumIncrease (Decrease) in Prepaid Expense and Other AssetsIncrease (Decrease) in Prepaid Expense and Other Assets, TotalPrepaid expenses and other current assetsBusiness Description and Basis of Presentation [Text Block]Organization and Description of the BusinessIncome Statement [Abstract]Entity Address, State or ProvinceEntity Address, State or ProvinceClass of Warrant or Right [Table]Class Of Warrant Or Right [Table]Line of Credit Facility, Expiration DateLine of credit facility, Maturity periodInvestments Classified by Contractual Maturity Date [Table Text Block]Summary of Amortized Cost and Estimated Fair Value of Available-for-sale Securities by Contractual MaturityCover [Abstract]Subsequent Event [Line Items]Sublease incomeEstimated Future Sublease IncomeEstimated future sublease income.Net loss per common share, BasicEarnings Per Share, BasicEarnings Per Share, Basic, TotalOperating lease, option to extendLessee, Operating Lease, Option to ExtendDebt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]Available-for-sale securities maturing, Estimated Fair Value:Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before TaxUnrealized GainsOperating Expenses [Abstract]Operating expenses:Investments, Debt and Equity Securities [Abstract]Additional shares available for future issuanceCommon Stock Additional Shares Authorized For Future IssuanceCommon Stock Additional Shares Authorized For Future IssuanceStock-based compensation expenseShare-Based Payment Arrangement, ExpenseTotal stock-based compensation**

expenseLong-Term DebtTotalShare based compensation arrangement by share based payment award annual increase in number of common stock shares.Share Based Compensation Arrangement By Share Based Payment Award Annual Increase In Number Of Common Stock SharesAnnual increase in number of common stock sharesRetained Earnings (Accumulated Deficit)Accumulated deficitAccumulated deficitRetained Earnings (Accumulated Deficit), TotalRetained Earnings (Accumulated Deficit), Beginning BalanceRetained Earnings (Accumulated Deficit), Ending BalancePlan Name [Axis]Plan NameAsset Impairment MemberAsset Impairment [Member]Asset ImpairmentsShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, NumberNumber of options outstanding, Outstanding, Ending balanceNumber of options outstanding, Outstanding, Beginning balanceStock options shares outstandingAssets, Current [Abstract]Current assets:Common Stock, Capital Shares Reserved for Future IssuanceShares available for future issuancePayments of Ordinary Dividends, Common StockPayments of dividends of common stockDeferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]Prepaid Expenses and Other Current AssetsNet Cash Provided by (Used in) Operating ActivitiesNet cash used in operating activitiesProduct and Service [Domain]Accumulated Other Comprehensive Income (Loss), Net of TaxAccumulated other comprehensive lossAccumulated Other Comprehensive Income (Loss), Net of Tax, TotalContra research and development expense.Contra Research and Development ExpenseContra research and development expenseDebt Instrument [Line Items]Consulting expense for related party.Consulting Expense for Related PartyCompensation expenseProperty, Plant and Equipment, NetProperty and equipment, netProperty and equipment, netProperty, Plant and Equipment, Net, Beginning BalanceProperty, Plant and Equipment, Net, Ending BalanceNet Cash Provided by (Used in) Operating Activities [Abstract]Cash flows from operating activities:Type of Restructuring [Domain]Fair Value, Recurring [Member]Fair Value, Measurements, RecurringRestructuring and Related Activities [Abstract]Common Stock, Par or Stated Value Per ShareCommon stock, par valueStock options to purchase common stock [Member]OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after TaxUnrealized (loss) gain on marketable securitiesStatement of Cash Flows [Abstract]Counterparty Name [Axis]Counterparty NameConsulting agreement effective date.Consulting Agreement, Effective DateConsulting agreement, effective dateAntidilutive Securities, Name [Domain]Antidilutive Securities, NameClass of Warrant or Right, Number of Securities Called by Warrants or RightsNumber of shares underlying warrantsPre funded warrants to purchase shares of common stockEquity Components [Axis]Equity ComponentsEntity Address, Address Line OneEntity Address, Address Line OneCalculation of Basic and Diluted Net Loss Per ShareSchedule of Earnings Per Share, Basic and Diluted [Table Text Block]Employee-related Liabilities, CurrentAccrued employee-related costsEmployee-related Liabilities, Current, TotalEmployee Severance [Member]Severance and Related Benefit CostsRelated Party Transaction [Table]Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in PeriodNumber of shares, grantedComputer Equipment [Member]Computer EquipmentProperty, Plant and Equipment [Line Items]Property Plant And Equipment [Line Items]Line of Credit Facility, Frequency of PaymentsLine of credit facility frequency of paymentsSubsequent Event Type [Axis]Subsequent Event TypeAnti-dilutive Outstanding Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per ShareSchedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]Line of Credit Facility, Maximum Borrowing CapacityLine of credit facility, maximum borrowing capacityShare-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest RateRisk-free interest ratePercentage of bonus on annual base salaryPercentage of Bonus on Annual Base SalaryPercentage of bonus on annual base salary.Number of shares outstanding, beginning balanceShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, NumberNumber of shares outstanding, ending balanceRestructuring, Impairment, and Other Activities Disclosure [Text Block]Restructuring and Impairment ChargesAmendment FlagAmendment FlagOperating Loss Carryforwards [Table]Operating Lease, Liability, NoncurrentOperating lease liabilities, noncurrentDomestic Tax Jurisdiction [Member]U S [Member]Corporate Debt Securities [Member]Corporate debt securitiesAdditional Paid in Capital, Common StockAdditional paid-in capitalAdditional Paid in Capital, Common Stock, Beginning BalanceAdditional Paid in Capital, Common Stock, Ending BalanceSecured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]SOFRNet lossShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in PeriodNumber of options outstanding, Options exercisedShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, NumberMaximum number of shares issued upon exercise of incentive stock optionsVariable Rate [Domain]Variable RateResearch and Development Expense [Member]Research and Development ExpenseNumber of tranches.Number Of TranchesNumber of tranchesAdvance for clinical-related costs, currentPrepaid Advance For Clinical Related Costs CurrentPrepaid advance for clinical related costs current.Equity Component [Domain]Equity ComponentStatistical Measurement [Domain]Statistical MeasurementGeneral and Administrative ExpenseGeneral and administrativeGeneral and Administrative Expense, TotalProceeds from sale of equipmentProceeds from Sale of Property, Plant, and EquipmentProceeds from Sale of Property, Plant, and Equipment, TotalSupplemental Balance Sheet Disclosures [Text Block]Balance Sheet ComponentsInterest Expense, Debt, TotalInterest Expense, DebtInterest expenseShare-Based Compensation Arrangement by Share-Based Payment Award, Expiration PeriodOptions granted expiry periodCashless exercise of pre-funded warrantsStock Issued During Period Value Cashless Exercise of Prefunded WarrantsStock issued during period value cashless exercise of prefunded warrants.Organization and description of business.Organization And Description Of Business [Table]Organization And Description Of Business [Table]Net Income (Loss), Including Portion Attributable to Noncontrolling InterestNet lossNet Income (Loss), Including Portion Attributable to Noncontrolling Interest, TotalPreferred Stock, Shares IssuedPreferred stock, shares issuedPreferred Stock, Shares Issued, TotalOperating Lease, PaymentsCash paid for operating lease liabilitiesOperating lease liabilitiesDebt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]Available-for-sale securities maturing, Amortized Cost:Two thousand eighteen plan .Two Thousand Eighteen Plan [Member]2018 PlanShare based compensation arrangement by share based payment award initially authorized period end.Share Based Compensation Arrangement By Share Based Payment Award Initially Authorized Period EndAuthorized an offering ending periodShare based compensation arrangement by share based payment award number of shares increase automatically continuing through maximum period.Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Increase Automatically Continuing Through Maximum PeriodNumber of shares increase automatically continuing through maximum periodPrepaid Expense and Other Assets, CurrentPrepaid expenses and other current assetsTotal prepaid expenses and other current assetsShare-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, MaximumRisk-free interest rate, MaximumShare-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise PriceWeighted average exercise price, Options cancelled/forfeitedCollaborative Arrangement and Arrangement Other than Collaborative [Axis]Collaborative Arrangement and Arrangement Other than CollaborativeSeverance costsSeverance CostsRestructuring chargesPrepaid Expense, Current [Abstract]Everest CollaborationCollaborative Arrangement Disclosure [Text Block]Comprehensive Income (Loss), Net of Tax, Attributable to ParentComprehensive lossCommon Stock, Shares, OutstandingCommon stock, shares outstandingCommon Stock, Shares, Outstanding, Beginning BalanceCommon Stock, Shares, Outstanding, Ending BalanceFair Value Measurement, Policy [Policy Text Block]Fair Value MeasurementsLine of Credit Facility, Current Borrowing CapacityCurrent borrowing capacityNon-cash adjustmentsRestructuring Reserve, Accrual AdjustmentPreferred Stock, Par or Stated Value Per SharePreferred stock, par valueAntidilutive Securities [Axis]Antidilutive SecuritiesOptions to purchase of common stock outstanding.Options To Purchase Of Common Stock OutstandingOptions to purchase of common stock outstandingCashCashResearch and development activities amortize period.Research And Development Activities Amortize PeriodResearch and development activities amortize periodShare-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]Summary of RSU ActivityEntity Interactive Data CurrentEntity Interactive Data CurrentDebt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year OneIn one year or less, Estimated Fair ValueThe entire disclosure for available for sale securities.Available For Sale Securities Disclosure [Text Block]Available-for-Sale SecuritiesModified exercise price with respect to all outstanding stock options which are in the customized range of exercise prices.Share Based Payment Arrangement Option Exercise Price Range Outstanding Modified Exercise PriceModified exercise priceDocument Quarterly ReportDocument Quarterly ReportShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair ValueWeighted average exercise price, vestedCash, Cash Equivalents, Restricted Cash, and Restricted Cash EquivalentsCash and cash equivalents at the end of periodCash and cash equivalents at the beginning of periodCash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, TotalRelated Party Transactions Disclosure [Text Block]Related Party TransactionsStatistical Measurement [Axis]Statistical MeasurementOperating Lease, CostOperating lease costsJune OfferingJune Offering [Member]June offering.Share based compensation arrangement by share based payment award options vested and exercisable number.Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable NumberNumber of options outstanding, options vested and exercisableAssets, Fair Value Disclosure, TotalAssets, Fair Value DisclosureFinancial AssetsRelated and Nonrelated Parties [Domain]Issuance of common stock under equity incentive plansValue of issuance of shares under incentive and share based compensation plans.Value Of Issuance Of Shares Under Incentive And Share Based Compensation PlansEqual to the sum of (a).Equal To Sum Of A [Member]Equal To Sum Of ACommercial Paper [Member]Commercial paperShare-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for GrantShares grantedAdditional milestone payments on achievementAdditional Payments Receivable On Milestone AchievementsAdditional Payments Receivable On Milestone AchievementsShare-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for RecognitionEstimated weighted average amortization periodForeign Tax Jurisdiction [Member]Non - U S [Member]Furniture, laboratory and office equipment.Furniture Laboratory And Office Equipment [Member]Furniture, Laboratory and Office EquipmentEffect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing OperationsEffect of exchange rate changes on cash and cash equivalentsStatement of Income Location, Balance [Axis]Income Statement LocationShort-Term Debt [Table]AssetsTotal assetsShare-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected TermExpected term (years)Expected termRestructuring Type [Axis]2022 Stock Inducement PlanTwo Thousand Twenty Two Stock Incentive Plan [Member]Two thousand twenty two stock incentive plan member.Number of shares, vestedShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in PeriodNumber of shares, vestedNew Accounting Pronouncements, Policy [Policy Text Block]Recently Issued Accounting PronouncementsEntity Address, City or TownEntity Address, City or TownAccumulated Other Comprehensive Income (Loss)AOCI Attributable to Parent [Member]Equity [Abstract]Schedule of Maturities of Long-Term Debt [Table Text Block]Schedule of Estimated Future Principal PaymentsNumber of shares, forfeitedShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in PeriodNumber of shares, forfeitedPayments for RestructuringCash payments madeNon-cash chargesCash payments madePercentage of commission on gross sales proceeds of issuance of common stock.Percentage Of Commission On Gross Sale Proceeds Of Issuance Of Common StockPercentage of commission on gross sales proceeds of issuance of common stockRestructuring Cost and Reserve [Line Items]DepreciationDepreciation expenseDepreciation, TotalDebt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year OneIn one year or less, Amortized CostShare-Based Payment Arrangement [Text Block]Stock-Based CompensationShare-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares AuthorizedMaximum number of shares authorized available for issuanceRestructuring Reserve, Settled without CashNon-cash chargesFair Value Disclosures [Abstract]Schedule of accrued and other current liabilities.Schedule Of Accrued And Other Current Liabilities Table [Text Block]Accrued and Other Current LiabilitiesChief Executive Officer [Member]Chief Executive Officer [Member]Liabilities, Current [Abstract]Current liabilities:Document TypeDocument TypeUS Government Agencies Debt Securities [Member]U.S. government agency bondsTitle of 12(b) SecurityTitle of 12(b) SecurityCash and Cash Equivalents, at Carrying ValueCash and cash equivalentsCash and Cash Equivalents, at Carrying Value, TotalCash and Cash Equivalents, at Carrying Value, Beginning BalanceCash and Cash Equivalents, at Carrying Value, Ending BalanceNoncurrent unbilled receivable from collaborationNoncurrent Unbilled Receivable From CollaborationNoncurrent Unbilled Receivable From CollaborationStatement of Stockholders' Equity [Abstract]Document Fiscal Period FocusDocument Fiscal Period FocusShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic ValueAggregate intrinsic value, Options exercisedAggregate intrinsic value of exercised stock optionsResearch and Development ExpenseResearch and developmentResearch and Development Expense, TotalLong-Term Debt, Excluding Current MaturitiesLong-term debt, netDebt, noncurrentStock options shares grantedShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, GrossNumber of options outstanding, Options grantedUnderwritten public offering.Underwritten Public Offering [Member]Underwritten Public OfferingCowen and Company limited liability company.Cowen And Company Limited Liability Company [Member]Cowen and Company LLCAsset Class [Domain]Asset ClassProperty, Plant and Equipment, GrossTotal property and equipmentProperty, Plant and Equipment, Gross, TotalProperty, Plant and Equipment, Gross, Beginning BalanceProperty, Plant and Equipment, Gross, Ending BalanceSubsequent Event Type [Domain]Subsequent Event TypeDebt securities available for sale credit related losses.Debt Securities Available for Sale Credit Related LossesCredit-related losses related to marketable securitiesSchedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]Fair Value of Employee Stock Options Granted is Calculated Using Black Scholes Option Pricing Model with Range of AssumptionsSchedule of Restructuring Reserve by Type of Cost [Table Text Block]Schedule of Accrual Activity and Payments Relating to Restructuring and Impairment ChargeUnaudited condensed consolidated financial statements.Unaudited Condensed Consolidated Financial Statements Policy [Text Block]Unaudited Condensed Consolidated Financial StatementsFair Value, 12 months or greaterDebt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or LongerTranche, available period.Tranche Available PeriodTranche, available periodClass of Warrant or Right, Exercise Price of Warrants or RightsExercise PricePre funded warrants exercise priceFinancial Instruments [Domain]Class of Warrant or Right [Line Items]Class Of Warrant Or Right [Line Items]Sale of Stock [Axis]Sale of StockNet Cash Provided by (Used in) Investing Activities [Abstract]Cash flows from investing activities:Marketable Securities, CurrentMarketable securitiesMarketable Securities, Current, TotalCollaboration revenueRevenue from Contract with Customer, Excluding Assessed TaxStatement of Comprehensive Income [Abstract]Income Tax Disclosure [Text Block]Income TaxesAt-the-market agreement.At The Market Agreement [Member]ATM AgreementDiscount rate of cash flowDiscount Rate of Cash FlowDiscount rate of cash flowCredit Facility [Domain]Credit FacilityCollaborative agreement upfront payments collectedCollaborative agreement upfront payments collected.Collaborative agreement upfront payments collectedOther Accrued Liabilities, CurrentOthersEntity Address, Address Line TwoEntity Address, Address Line TwoLiabilities and Equity [Abstract]Liabilities and Stockholders' EquityUnvested Option Shares Cancelled Due To TerminationUnvested Option Shares Cancelled Due To TerminationUnvested option shares cancelled due to

terminationDocument Period End DateDocument Period End DateNet Cash Provided by (Used in) Financing ActivitiesNet cash provided by financing activitiesProceeds from issuance of common stock and warrants, net of issuance costs.Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance CostsProceeds from issuance of common stock and warrants, net of issuance costsStockholders' Equity Note [Abstract]Antidilutive Securities Excluded from Computation of Earnings Per Share, AmountAnti-dilutive securities excluded from computation of diluted net loss per shareDebt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through FiveIn one to two years, Estimated Fair ValueRestructuring Reserve, TotalRestructuring Reserve, Beginning BalanceRestructuring Reserve, Ending BalanceRestructuring ReserveSeverance and related benefit costsAPIC, Share-Based Payment Arrangement, Increase for Cost RecognitionStock-based compensation expenseAPIC, Share-based Payment Arrangement, Increase for Cost Recognition, TotalAccrued Liabilities, CurrentTotal accrued liabilitiesPrepayment fee percentage.Prepayment Fee PercentagePrepayment fee percentageIncome Tax Expense (Benefit)Provision for income taxesIncome Tax Expense (Benefit), TotalGain (Loss) on Disposition of Property Plant Equipment, TotalGain (Loss) on Disposition of Property Plant EquipmentLoss on disposition of fixed assetsTrading SymbolTrading SymbolVariable Rate [Axis]Variable RateEquity, Attributable to ParentBalanceBalanceTotal stockholders' equityRestructuring Costs and Asset Impairment Charges, TotalRestructuring Costs and Asset Impairment ChargesRestructuring and impairment chargesLong-Lived Tangible Asset [Axis]Long-Lived Tangible AssetClass of Warrant or Right, OutstandingPre-funded warrants outstandingRestricted Stock Units (RSUs) [Member]RSU MemberRelated Party Transactions [Abstract]Variable Lease, CostVariable lease costsProperty, Plant and Equipment [Table]Schedule Of Property Plant And Equipment [Table]Share based compensation expense plan modification incremental compensation cost of vested option shares.Share Based Compensation Expense Plan Modification Incremental Compensation Cost Of Vested Option SharesStock – based compensation expenseShare-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]Stock-Based Compensation Expense RecognizedAccrued Liabilities [Member]Accrued Liabilities [Member]Geographical [Axis]GeographicalDebt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before TaxUnrealized LossesShare-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, AmountUnrecognized stock-based compensation costLeases [Abstract]Use of Estimates, Policy [Policy Text Block]Use of EstimatesRemaining amount with sales agreementCommon Stock Aggregate Offering Price Remaining ValueCommon stock aggregate offering price remaining value.Sharebased compensation arrangement by sharebased payment award options vested and exercisable weighted average remaining contractual term.Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Exercisable Weighted Average Remaining Contractual TermWeighted average remaining contractual term, (Years) options vested and exercisableCumulative accretion of final fee.Cumulative Accretion of Final FeeCumulative accretion of final feeShare-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, MinimumExpected volatility, MinimumLessee Disclosure [Abstract]Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range LimitExercise prices, upper rangeShare-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend RateExpected dividend yieldShare based compensation arrangement by share based payment award options vested and exercisable weighted average exercise price.Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise PriceWeighted average exercise price, options vested and exercisableSecurity Exchange NameSecurity Exchange NameCounterparty Name [Domain]Counterparty NameOperating Loss Carryforwards [Line Items]Operating ExpensesTotal operating expensesCashless exercise of pre-funded warrants, sharesStock Issued During Period Shares Cashless Exercise of Prefunded WarrantsStock issued during period shares cashless exercise of prefunded warrants.Long-Lived Tangible Asset [Domain]Long-Lived Tangible AssetAccumulated Depreciation, Depletion and Amortization, Property, Plant, and EquipmentLess accumulated depreciation and amortizationAccumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, TotalAccumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning BalanceAccumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending BalanceFair Value Disclosures [Text Block]Fair Value Measurements25 – 36 monthsLessee, Operating Lease, Liability, to be Paid, Year ThreeShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair ValueWeighted average grant date fair value of options grantedIssuance of shares under incentive and share based compensation plans.Issuance Of Shares Under Incentive And Share Based Compensation PlansIssuance of common stock under equity incentive plans, sharesSubsequent Event [Member]Subsequent EventMaximum [Member]MaximumAnnual base salarySalary and Wage, NonOfficer, Excluding Cost of Good and Service SoldLiabilities and EquityTotal liabilities and stockholders' equityTranche three.Tranche Three [Member]Tranche ThreeOperating Lease, Right-of-Use AssetOperating lease right-of-use assetSupplemental Cash Flow Information [Abstract]Supplemental disclosuresNet loss per common share, DilutedEarnings Per Share, DilutedEarnings Per Share, Diluted, TotalLeasehold Improvements [Member]Leasehold ImprovementsEntity Ex Transition PeriodEntity Ex Transition PeriodLiabilitiesTotal liabilitiesFair Value Hierarchy and NAV [Domain]Fair Value Hierarchy and NAVOther AssetsSchedule of Other Assets [Table Text Block]Tranche one.Tranche One [Member]Tranche OneSign-on bonusSign on Bonus AmountSign on bonus amount.Assets, CurrentTotal current assetsNet Cash Provided by (Used in) Investing ActivitiesNet cash provided by investing activitiesStock Issued During Period, Shares, New IssuesIssuance of common stock net of offering costs, sharesIssuance of common stockOption grant vesting periodShare-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting PeriodEntity Filer CategoryEntity Filer CategoryIncrease in number of shares reserved for issuance as percentage of total number of shares of capital stock outstanding on last date of preceding calendar year.Increase In Number Of Shares Reserved For Issuance As Percentage Of Total Number Of Shares Of Capital Stock Outstanding On Last Date Of Preceding Calendar YearIncrease in number of shares reserved for issuance as percentage of total number of shares of capital stock outstanding on last date of preceding calendar yearPayments to Acquire Marketable SecuritiesPurchases of marketable securitiesPayments to Acquire Marketable Securities, TotalCurrent Fiscal Year End DateCurrent Fiscal Year End DateFair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]Lessee, Operating Lease, Liability, Undiscounted Excess AmountLess: imputed interestLicense, dues and subscriptionPrepaid License Dues And SubscriptionPrepaid license dues and subscription.Share-Based Payment Arrangement, Noncash ExpenseStock-based compensationShare-based Payment Arrangement, Noncash Expense, TotalTwo thousand eighteen equity incentive plan.Two Thousand Eighteen Equity Incentive Plan [Member]2018 Equity Incentive PlanShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic ValueAggregate intrinsic value, Outstanding balanceAggregate intrinsic value, Outstanding, Beginning balanceAggregate intrinsic value, Outstanding, Ending balanceLong term debt principal amount.Long Term Debt Principal AmountTotalAdjustments to additional paid in capital, share based compensation, vesting related to shares of common stock issued pursuant to early exercises.Adjustments To Additional Paid In Capital Share Based Compensation Vesting Related To Shares Of Common Stock Issued Pursuant To Early ExercisesVesting related to shares of common stock issued pursuant to early exercisesRelated and Nonrelated Parties [Axis]Incentive Stock Options [Member]Incentive stock options.Entity Registrant NameEntity Registrant NameSchedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]Earnings Per Share [Text Block]Net Loss Per ShareEntity Emerging Growth CompanyEntity Emerging Growth CompanyNet Income (Loss) Available to Common Stockholders, Basic [Abstract]Numerator:Line of credit facility, extension period.Line Of Credit Facility Extension PeriodLine of credit facility, extension periodMoney Market Funds [Member]U.S. Treasury Money Market FundsFinal payment fee percentage on principal.Final Payment Fee Percentage on PrincipalFinal payment fee percentageWeighted-average shares used to compute net loss per common share, BasicWeighted Average Number of Shares Outstanding, BasicWeighted Average Number of Shares Outstanding, Basic, TotalNon Rule 10b5-1 Arrangement ModifiedNon Rule 10b-51 Arr Modified [Flag]Non rule10b51 arrangement modified flag.Interest Income (Expense), NonoperatingInterest incomeShare-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, MaximumExpected volatility, MaximumCommon Stock, Shares AuthorizedCommon stock, shares authorizedSchedule of Long-Term Debt Instruments [Table Text Block]Schedule of Long-term Debt BalanceRoyaltyRoyalty [Member]Proceeds from Issuance of Common StockNet proceeds from the public offeringProceeds from Sale and Maturity of Marketable SecuritiesMaturities of marketable securitiesProceeds from Sale and Maturity of Marketable Securities, TotalFair Value, Inputs, Level 1 [Member]Level 1Existing stockholder, ventures, officers and directors.Existing Stockholder Ventures Officers And Directors [Member]Existing Stockholder, Morningside Ventures and certain officers and directorsIncrease (Decrease) in Accounts Payable and Accrued LiabilitiesAccounts payable, accrued liabilities and other current liabilitiesIncrease (Decrease) in Accounts Payable and Accrued Liabilities, TotalAccounts payable, accrued and other current liabilitiesDebt Disclosure [Abstract]Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option ExercisedProceeds from issuance of common stock under employee stock incentive plansSufficient cash and cash equivalents available period term.Sufficient Cash And Cash Equivalents Available Period TermSufficient cash and cash equivalents available period termShare-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise PriceWeighted average exercise price, Options grantedFinancial Instrument [Axis]Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual TermWeighted average remaining contractual term, (Years) Outstanding balanceAccrued preclinical and research costs, current.Accrued Preclinical And Research Costs CurrentAccrued preclinical and research costsGeneral and Administrative Expense [Member]General and Administrative ExpenseShare-Based Payment Arrangement [Abstract]Operating lease asset and liabilitiesIncrease Decrease In Operating Lease Asset And LiabilitiesIncrease decrease in operating lease asset and liabilities.Collaborative Arrangement and Arrangement Other than Collaborative [Table]Debt Securities, Available-for-SaleFair ValueTotal available-for-sale securities, Estimated Fair ValueAccounting Policies [Abstract]Share-Based Payment Arrangement, Option, Activity [Table Text Block]Summary of Activity under Stock Option Plans and Related InformationIncome Tax Disclosure [Abstract]Equity, Attributable to Parent [Abstract]Stockholders' equity:Share based compensation arrangement by share based payment award number of shares increase automatically through every year on specified date.Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Increase Automatically Through Every Year On Specified DateNumber of shares will increase automatically through every year on specified dateUnbilled receivable from Everest, noncurrent (Note 10)Other Unbilled ReceivableThe amount of unbilled receivable other.Common stock weighted average purchase price per share.Common Stock Weighted Average Purchase Price Per ShareWeighted average purchase price, per shareStatement [Table]Statement [Table]Property and Equipment, NetProperty, Plant and Equipment [Table Text Block]Existing stockholder, equal talent investments limited and directors.Existing Stockholder Equal Talent Investments Limited And Directors [Member]Existing Stockholder, Equal Talent Investments Limited, and one of the DirectorsSubsequent Event [Table]Preferred Stock, Shares Authorized Preferred stock, shares authorizedSecurities Act File NumberEntity File NumberCash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectNet decrease in cash and cash equivalentsTwo thousand fifteen equity incentive plan.Two Thousand Fifteen Equity Incentive Plan [Member]2015 Equity Incentive PlanEarnings Per Share [Abstract]Interest ReceivableInterest receivableWarrants and Rights Outstanding, TermPre-funded warrants, termStatement of Financial Position [Abstract]Interest Expense, TotalInterest Expense, Operating and NonoperatingInterest ExpenseInterest expenseLoss from operationsOperating Income (Loss)Loss from operations2024Long-Term Debt, Maturity, Year OneShare-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility RateExpected volatilityEntity Shell CompanyEntity Shell CompanyOther Assets [Abstract]Accrued Professional Fees, CurrentAccrued professional servicesDebt Instrument, Interest Rate, Effective PercentageEffective interest rate percentageEntity Tax Identification NumberEntity Tax Identification NumberAssets [Abstract]AssetsIncome tax refunds receivedProceeds from Income Tax RefundsEntity Current Reporting StatusEntity Current Reporting StatusLine of Credit Facility, Interest Rate During PeriodLine of credit facility, interest rateSubsequent Events [Abstract]Contract liabilityIncrease (Decrease) in Contract with Customer, LiabilityDeposits for operating leaseOther Assets Deposits For Operating LeaseOther assets deposits for operating lease.Geographical [Domain]GeographicalDocument Fiscal Year FocusDocument Fiscal Year FocusConsultant fee per monthConsultant Fee Per MonthConsultant fee per monthCash, Cash Equivalents, and Short-Term InvestmentsTotal cash, cash equivalent and marketable securitiesCertificates of Deposit [Member]Certificates Of DepositPreferred stock, $0.001 par value, 10,000,000 shares authorized; zero shares issued and outstanding as of June 30, 2024 (unaudited) and December 31, 2023Preferred Stock, Value, IssuedPreferred Stock, Value, Issued, TotalPreferred Stock, Value, Issued, Beginning BalancePreferred Stock, Value, Issued, Ending BalanceConsulting fee per monthConsulting Fee Per MonthConsulting fee per month.Capital Expenditures Incurred but Not yet PaidPurchases of property and equipment in accounts payableDebt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through FiveIn one to two years, Amortized CostShare based compensation expense plan modification unamortized incremental compensation cost of unvested option shares.Share Based Compensation Expense Plan Modification Unamortized Incremental Compensation Cost of Unvested Option SharesCompensation expense related to the unvested optionCity Area CodeCity Area CodeSign-on bonus of 2018 equity incentive planSign-On Bonus of 2018 Equity Incentive Plan [Member]Sign-on bonus of 2018 equity incentive plan member.Liabilities, CurrentTotal current liabilitiesDevelopment, Regulatory and Commercial MilestonesDevelopment Regulatory and Commercial Milestones [Member]Development regulatory and commercial milestones.Rule 10b5-1 Arrangement ModifiedRule 10b-51 Arr Modified [Flag]Rule10b51 arrangement modified flag.ESPPESPP RightsEmployee Stock Purchase Plan [Member]Employee stock purchase plan.Organization, Consolidation and Presentation of Financial Statements [Abstract]Local Phone NumberLocal Phone NumberReceivable from Everest, current (Note 10)Receivable from CollaborationReceivable from CollaborationReimbursement receivable from collaborationImpairment loss of right-of-use assetOperating Lease, Impairment LossImpairment chargePreferred Stock, Shares OutstandingPreferred stock, shares outstandingPreferred Stock, Shares Outstanding, Beginning BalancePreferred Stock, Shares Outstanding, Ending BalanceAntidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]Common stock aggregate offering price.Common Stock Aggregate Offering PriceCommon stock aggregate offering priceUnrealized Losses, Less than 12 monthsDebt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated LossIncome Tax Jurisdiction [Axis]Share based compensation arrangement by share based payment award annual increase in number of common stock shares percent.Share Based Compensation Arrangement By Share Based Payment Award Annual Increase In Number Of Common Stock Shares PercentPercentage of annual increase in number of common stock sharesEqual to the sum of (b).Equal To Sum Of B [Member]Equal To Sum Of BTotal available-for-sale securities, Amortized CostDebt Securities, Available-for-

~~Sale, Amortized CostOperating Lease, Liability, CurrentOperating lease liabilities, currentOther Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of TaxForeign currency translation adjustmentsOther Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, TotalIncome Tax Jurisdiction [Domain]Retained Earnings [Member]Accumulated DeficitAmortization of Debt Issuance Costs and Discounts, TotalAmortization of Debt Issuance Costs and DiscountsAmortization of debt discount and issuance costs and other non-cash interestPayments to Acquire Property, Plant, and EquipmentPurchases of property and equipmentPayments to Acquire Property, Plant, and Equipment, TotalDocument Transition ReportDocument Transition ReportNumber of stock options exercise price modifiedShare Based Compensation Arrangement By Share Based Payment Award Options Exercise Price ModifiedShare based compensation arrangement by share based payment award options exercise price modified.Increase (Decrease) in Other Operating Assets, TotalIncrease (Decrease) in Other Operating AssetsOther assetsShare-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, PercentOption price per share of common stock at fair market value13 - 24 monthsLessee, Operating Lease, Liability, to be Paid, Year Two13 – 24 monthsAntidilutive Security, Excluded EPS Calculation [Table]Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, TotalDebt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, NetUnamortized debt discount and issuance costsMinimum [Member]MinimumAccrued liabilities and other liabilities, current.Accrued Liabilities And Other Liabilities CurrentAccrued and other current liabilitiesTotal accrued and other current liabilitiesCommon Stock [Member]Common StockShare-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]Long-Term Debt, Maturity, Year Two2025Additional Paid-in Capital [Member]Additional Paid-in CapitalAdjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]Adjustments to reconcile net loss to net cash used in operating activities:Statement of Income Location, Balance [Domain]Income Statement LocationEverest License AgreementEverest License Agreement [Member]Everest License Agreement.Lessee, Operating Lease, Liability, to be Paid, Year OneLess than 12 monthsOther Assets, NoncurrentOther assetsOther Assets, Noncurrent, TotalOthersOther Prepaid Expense, CurrentProceeds from Sale of Debt Securities, Available-for-SaleSale of available-for-sale securitiesRestricted Stock Units Subject to Future Vesting [Member]Restricted Stock Units Subject To Future Vesting [Member]Restricted Stock Units Subject To Future Vesting [Member]Entity Common Stock, Shares OutstandingEntity Common Stock, Shares OutstandingFair Value, Less than 12 monthsDebt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 MonthsBasis of Presentation and ConsolidationBasis of Accounting, Policy [Policy Text Block]Title and Position [Domain]Title of IndividualAdjustments to Additional Paid in Capital, Stock Issued, Issuance CostsIssuance of common stock under the ATM Agreement, net of offering costsDebt Securities, Available-for-Sale, Allowance for Credit LossAllowance for credit losses on securities in unrealized loss positionDebt Securities, Available-for-sale, Allowance for Credit Loss, TotalDebt Securities, Available-for-sale, Allowance for Credit Loss, Beginning BalanceDebt Securities, Available-for-sale, Allowance for Credit Loss, Ending BalanceCommon stock, $0.001 par value, 250,000,000 and 250,000,000 shares authorized as of June 30, 2024 (unaudited) and December 31, 2023, respectively; 72,887,538 and 72,779,077 shares issued and outstanding as of June 30, 2024 (unaudited) and December 31, 2023, respectivelyCommon Stock, Value, IssuedCommon Stock, Value, Issued, TotalCommon Stock, Value, Issued, Beginning BalanceCommon Stock, Value, Issued, Ending BalanceCollaborative Arrangement and Arrangement Other than Collaborative [Line Items]Tranche two.Tranche Two [Member]Tranche TwoInsurancePrepaid InsuranceLoan and Security AgreementLoan and security agreement.Loan And Security Agreement [Member]Fair Value, Assets Measured on Recurring Basis [Table Text Block]Summary of Financial Assets Measured at Fair Value on a Recurring BasisSharebased compensation arrangement by sharebased payment award options vested and exercisable intrinsic value.Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Exercisable Intrinsic ValueAggregate intrinsic value, options vested and exercisableLong-Term Debt, Maturity, Year Three2026Operating lease liabilityOperating Lease, LiabilityTotal lease liabilitiesTotal operating lease liabilitiesAccrued clinical costs, current.Accrued Clinical Costs CurrentAccrued clinical costsDebt Securities, Available-for-Sale [Table Text Block]Summary of Available-For-Sale Securities Recorded in Cash and Cash Equivalents or Marketable SecuritiesMeasurement Frequency [Axis]Measurement FrequencyIncremental fair valueShare-Based Payment Arrangement, Plan Modification, Incremental CostUnrealized Losses, 12 months or greaterUnrealized Losses, 12 months or greaterDebt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated LossWeighted-average shares of common stock outstandingWeighted-average shares used to compute net loss per common share, DilutedWeighted Average Number of Shares Outstanding, DilutedWeighted Average Number of Shares Outstanding, Diluted, TotalSignificant Accounting Policies [Text Block]Summary of Significant Accounting PoliciesLessee, Operating Lease, Liability, to be PaidTotal undiscounted lease paymentsCollaborative arrangement right descriptionCollaborative Arrangement, Rights and ObligationsWeighted Average Number of Shares Outstanding, Diluted [Abstract]Denominator:February OfferingFebruary Offering [Member]February offering.Entity Small BusinessEntity Small BusinessDebt Instrument, Basis Spread on Variable RateLine of credit facility, additional interest rateDebt Disclosure [Text Block]DebtCollaboration revenueRevenues, TotalUS Treasury Securities [Member]U.S. Treasury SecuritiesCredit Facility [Axis]Credit FacilityOther Assets, MiscellaneousOther Assets, Miscellaneous, TotalOtherShare based compensation arrangement by share based payment award initially authorized period start.Share Based Compensation Arrangement By Share Based Payment Award Initially Authorized Period StartAuthorized an offering beginning periodInterest rate of sublease income per yearInterest Rate of Sublease Income Per YearInterest rate of sublease income per yearAccretion (Amortization) of Discounts and Premiums, InvestmentsAmortization of premiums and discounts on marketable securitiesNet Cash Provided by (Used in) Financing Activities [Abstract]Cash flows from financing activities:Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise PriceWeighted average exercise price, Outstanding, Ending balanceWeighted average exercise price, Outstanding, Beginning balanceStock options exercise priceAsset Class [Axis]Asset ClassMeasurement Frequency [Domain]Measurement FrequencyOther comprehensive gain (loss)Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to ParentTotal other comprehensive (loss) income, net of taxFair Value, Inputs, Level 3 [Member]Level 3Subsequent EventsSubsequent Events [Text Block]Accounts Payable, CurrentAccounts payableAccounts Payable, Current, TotalPar value of common stock upon cashless exercise of prefunded warrants.Par Value Of Common Stock Upon Cashless Exercise Of Prefunded WarrantsPar value of common stock upon cashless exercise of prefunded warrants XML 9 R1.htm IDEA: XBRL DOCUMENT~~

Document and Entity Information - shares	6 Months Ended Jun. 30, 2024	Aug. 09, 2024
Cover [Abstract]		
Document Type	10-Q	
Amendment Flag	false	
Document Period End Date	Jun. 30, 2024	
Document Fiscal Year Focus	2024	
Document Fiscal Period Focus	Q2	
Trading Symbol	KZR	
Entity Registrant Name	Kezar Life Sciences, Inc.	
Entity Central Index Key	0001645666	
Current Fiscal Year End Date	--12-31	
Entity Filer Category	Non-accelerated Filer	
Entity Small Business	true	
Entity Emerging Growth Company	false	
Entity Shell Company	false	
Entity Common Stock, Shares Outstanding		72,962,220
Entity Interactive Data Current	Yes	
Entity Current Reporting Status	Yes	
Entity File Number	001-38542	
Entity Tax Identification Number	47-3366145	
Entity Address, Address Line One	4000 Shoreline Court	
Entity Address, Address Line Two	Suite 300	
Entity Address, City or Town	South San Francisco	
Entity Address, State or Province	CA	
Entity Address, Postal Zip Code	94080	
City Area Code	650	
Local Phone Number	822-5600	
Document Quarterly Report	true	
Document Transition Report	false	
Title of 12(b) Security	Common Stock, $0.001 par value	
Security Exchange Name	NASDAQ	
Entity Incorporation, State or Country Code	DE	

~~XML 10 R2.htm IDEA: XBRL DOCUMENT~~

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:		
Cash and cash equivalents	$ 28,276	$ 35,493
Marketable securities	135,906	165,879
Prepaid expenses and other current assets	3,435	5,578
Total current assets	167,617	206,950
Property and equipment, net	3,391	3,912
Operating lease right-of-use asset	2,391	4,778
Other assets	6,522	5,595
Total assets	179,921	221,235
Current liabilities:		
Accounts payable	2,263	8,251
Accrued and other current liabilities	9,363	6,481
Operating lease liabilities, current	3,260	3,012
Debt, current	2,609	0
Total current liabilities	17,495	17,744
Operating lease liabilities, noncurrent	4,152	5,852
Debt, noncurrent	7,589	10,069

Total liabilities	29,236	33,665
Stockholders' equity:		
Common stock, $0.001 par value, 250,000,000 and 250,000,000 shares authorized as of June 30, 2024 (unaudited) and December 31, 2023, respectively; 72,887,538 and 72,779,077 shares issued and outstanding as of June 30, 2024 (unaudited) and December 31, 2023, respectively	73	73
Preferred stock, $0.001 par value, 10,000,000 shares authorized; zero shares issued and outstanding as of June 30, 2024 (unaudited) and December 31, 2023	0	0
Additional paid-in capital	544,965	538,390
Accumulated other comprehensive loss	(385)	(130)
Accumulated deficit	(393,968)	(350,763)
Total stockholders' equity	150,685	187,570
Total liabilities and stockholders' equity	$ 179,921	$ 221,235

~~XML 11 R3.htm IDEA: XBRL DOCUMENT~~

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]		
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	72,887,538	72,779,077
Common stock, shares outstanding	72,887,538	72,779,077
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

~~XML 12 R4.htm IDEA: XBRL DOCUMENT~~

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Operating expenses:				
Research and development	$ 16,298	$ 20,999	$ 33,470	$ 39,317
General and administrative	5,603	5,785	12,142	11,991
Restructuring and impairment charges	1,482	0	1,482	0
Total operating expenses	23,383	26,784	47,094	51,308
Loss from operations	(23,383)	(26,784)	(47,094)	(51,308)
Interest income	2,237	2,861	4,690	5,556
Interest expense	(401)	(385)	(801)	(755)
Net loss	$ (21,547)	$ (24,308)	$ (43,205)	$ (46,507)
Net loss per common share, Basic	$ (0.3)	$ (0.34)	$ (0.59)	$ (0.64)
Net loss per common share, Diluted	$ (0.3)	$ (0.34)	$ (0.59)	$ (0.64)
Weighted-average shares used to compute net loss per common share, Basic	72,845,869	72,461,850	72,822,890	72,395,410
Weighted-average shares used to compute net loss per common share, Diluted	72,845,869	72,461,850	72,822,890	72,395,410

~~XML 13 R5.htm IDEA: XBRL DOCUMENT~~

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statement of Comprehensive Income [Abstract]				
Net Income (Loss)	$ (21,547)	$ (24,308)	$ (43,205)	$ (46,507)
Other comprehensive income (loss):				
Foreign currency translation adjustments	14	(5)	(15)	(17)
Unrealized (loss) gain on marketable securities	(44)	(302)	(240)	110
Total other comprehensive (loss) income, net of tax	(30)	(307)	(255)	93
Comprehensive loss	$ (21,577)	$ (24,615)	$ (43,460)	$ (46,414)

~~XML 14 R6.htm IDEA: XBRL DOCUMENT~~

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Balance at Dec. 31, 2022	$ 269,872	$ 68	$ 519,620	$ (923)	$ (248,893)
Balance, shares at Dec. 31, 2022		68,493,429			
Cashless exercise of pre-funded warrants, shares		2,236,233			
Cashless exercise of pre-funded warrants		$ 2	(2)		
Issuance of common stock under equity incentive plans	154	$ 1	153		
Issuance of common stock under equity incentive plans, shares		86,338			
Stock-based compensation expense	4,263		4,263		
Other comprehensive gain (loss)	400			400	
Net Income (Loss)	(22,199)				(22,199)
Balance at Mar. 31, 2023	252,490	$ 71	524,034	(523)	(271,092)
Balance, shares at Mar. 31, 2023		70,816,000			
Balance at Dec. 31, 2022	269,872	$ 68	519,620	(923)	(248,893)
Balance, shares at Dec. 31, 2022		68,493,429			
Other comprehensive gain (loss)	93				
Net Income (Loss)	(46,507)				
Balance at Jun. 30, 2023	232,277	$ 73	528,434	(830)	(295,400)
Balance, shares at Jun. 30, 2023		72,532,814			
Balance at Mar. 31, 2023	252,490	$ 71	524,034	(523)	(271,092)
Balance, shares at Mar. 31, 2023		70,816,000			
Cashless exercise of pre-funded warrants, shares		1,556,643			
Cashless exercise of pre-funded warrants		$ 2	(2)		
Issuance of common stock under equity incentive plans	382		382		
Issuance of common stock under equity incentive plans, shares		160,171			
Stock-based compensation expense	4,020		4,020		
Other comprehensive gain (loss)	(307)			(307)	
Net Income (Loss)	(24,308)				(24,308)
Balance at Jun. 30, 2023	232,277	$ 73	528,434	(830)	(295,400)
Balance, shares at Jun. 30, 2023		72,532,814			
Balance at Dec. 31, 2023	187,570	$ 73	538,390	(130)	(350,763)
Balance, shares at Dec. 31, 2023		72,779,077			
Issuance of common stock under equity incentive plans	0		0		
Issuance of common stock under equity incentive plans,					

shares		22,282			
Stock-based compensation expense	3,434		3,434		
Other comprehensive gain (loss)	(225)			(225)	
Net Income (Loss)	(21,658)				(21,658)
Balance at Mar. 31, 2024	169,121	$ 73	541,824	(355)	(372,421)
Balance, shares at Mar. 31, 2024		72,801,359			
Balance at Dec. 31, 2023	187,570	$ 73	538,390	(130)	(350,763)
Balance, shares at Dec. 31, 2023		72,779,077			
Other comprehensive gain (loss)	(255)				
Net Income (Loss)	(43,205)				
Balance at Jun. 30, 2024	150,685	$ 73	544,965	(385)	(393,968)
Balance, shares at Jun. 30, 2024		72,887,538			
Balance at Mar. 31, 2024	169,121	$ 73	541,824	(355)	(372,421)
Balance, shares at Mar. 31, 2024		72,801,359			
Issuance of common stock under equity incentive plans	56		56		
Issuance of common stock under equity incentive plans, shares		86,179			
Stock-based compensation expense	3,085		3,085		
Other comprehensive gain (loss)	(30)			(30)	
Net Income (Loss)	(21,547)				(21,547)
Balance at Jun. 30, 2024	$ 150,685	$ 73	$ 544,965	$ (385)	$ (393,968)
Balance, shares at Jun. 30, 2024		72,887,538			

~~XML 15 R7.htm IDEA: XBRL DOCUMENT~~

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Cash flows from operating activities:			
Net loss	$ (43,205)	$ (46,507)	
Adjustments to reconcile net loss to net cash used in operating activities:			
Depreciation and amortization	521	508	
Stock-based compensation	6,519	8,283	
Amortization of premiums and discounts on marketable securities	(2,902)	(3,532)	
Amortization of debt discount and issuance costs and other non-cash interest	129	118	
Impairment loss of right-of-use asset	1,549	0	$ 2,700
Changes in operating assets and liabilities			
Prepaid expenses and other current assets	2,143	2,246	
Other assets	(927)	(5,888)	
Accounts payable, accrued and other current liabilities	(3,106)	2,453	
Operating lease asset and liabilities	(614)	(141)	
Net cash used in operating activities	(39,893)	(42,460)	
Cash flows from investing activities:			
Purchases of property and equipment	0	(1,673)	
Purchases of marketable securities	(52,126)	(95,233)	
Maturities of marketable securities	84,750	126,500	
Net cash provided by investing activities	32,624	29,594	
Cash flows from financing activities:			
Proceeds from issuance of common stock under employee stock incentive plans	56	536	
Net cash provided by financing activities	56	536	
Effect of exchange rate changes on cash and cash equivalents	(4)	(17)	
Net decrease in cash and cash equivalents	(7,217)	(12,347)	
Cash and cash equivalents at the beginning of period	35,493	40,456	40,456
Cash and cash equivalents at the end of period	28,276	28,109	$ 35,493
Supplemental disclosures of noncash investing and financing information:			
Purchases of property and equipment in accounts payable	0	117	
Par value of common stock upon cashless exercise of prefunded warrants	0	4	
Supplemental disclosures			
Cash paid for interest	$ 672	$ 637	

~~XML 16 R8.htm IDEA: XBRL DOCUMENT~~

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended			
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure						
Net Income (Loss)	$ (21,547)	$ (21,658)	$ (24,308)	$ (22,199)	$ (43,205)	$ (46,507)

~~XML 17 R9.htm IDEA: XBRL DOCUMENT~~

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Trading Arrangements, by Individual	
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Rule 10b5-1 Arrangement Modified	false
Non Rule 10b5-1 Arrangement Modified	false

~~XML 18 R10.htm IDEA: XBRL DOCUMENT~~

Organization and Description of the Business	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]	
Organization and Description of the Business	

1. Organization and Description of the Business

Description of Business

Kezar Life Sciences, Inc. (the “Company,” “we,” “us,” or “our”) was incorporated in the state of Delaware in February 2015 and commenced operations in June 2015. The Company is a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company’s principal operations are in South San Francisco, California, and it operates in one segment.

Liquidity

Since commencing operations in mid-2015, substantially all of the Company’s efforts have been focused on research, development, and the advancement of the Company’s product candidates, zetomipzomib (KZR-616) and KZR-261. The Company’s ultimate success depends on the outcome of these ongoing research and development activities. The Company has not yet generated product sales and as a result has experienced operating losses since inception and had an accumulated deficit of $394.0 million as of June 30, 2024. The Company expects to incur additional losses in the future to conduct research and development and will need to raise additional capital to fully implement management’s business plan. The Company intends to raise such capital through the issuance of additional equity, including through at-the-market (“ATM”) offerings, and potentially through borrowings, strategic alliances with partner companies and other licensing transactions, such as our collaboration with Everest Medicines II (HK) Limited (“Everest”). However, if such financing is not available at adequate levels, the Company may need to reevaluate its operating plans. Management believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund the Company’s cash requirements for at least 12 months following the issuance of these financial statements.

In December 2021, the Company entered into a Sales Agreement (the “ATM Agreement”) with Cowen and Company, LLC (“Cowen”), pursuant to which the Company can offer and sell, from time to time at

its sole discretion through Cowen, as its sales agent, shares of its common stock having an aggregate offering price of up to $200.0 million. Any shares of its common stock sold will be issued pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-261774). The Company will pay Cowen a commission up to 3.0% of the gross sales proceeds of any shares of its common stock sold through Cowen under the ATM Agreement and also has provided Cowen with indemnification and contribution rights. As of June 30, 2024, we have sold an aggregate of 11,986,003 shares of our common stock for gross proceeds of approximately $131.7 million at a weighted average purchase price of $10.98 per share pursuant to the ATM Agreement. As of June 30, 2024, approximately $68.3 million remains available under the ATM Agreement. No shares were sold under the ATM Agreement during the three months ended June 30, 2024.

~~XML 19 R11.htm IDEA: XBRL DOCUMENT~~

Summary of Significant Accounting Policies	6 Months Ended Jun. 30, 2024
Accounting Policies [Abstract]	
Summary of Significant Accounting Policies	

2. Summary of Significant Accounting Policies

Significant Accounting Policies

The Company's significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2023 and the notes thereto, which are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission ("SEC") on March 14, 2024 (the "Annual Report"), and there have been no material changes during the six months ended June 30, 2024.

Basis of Presentation and Consolidation

The condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and include the Company's accounts and those of its wholly owned Australian subsidiary, Kezar Life Sciences Australia Pty Ltd., which is a proprietary company limited by shares. All intercompany balances and transactions have been eliminated upon consolidation.

The condensed consolidated balance sheet as of December 31, 2023 has been derived from the audited consolidated financial statements at that date but does not include all information and footnotes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements included in the Annual Report.

Unaudited Condensed Consolidated Financial Statements

The accompanying financial information as of June 30, 2024 is unaudited. The interim condensed consolidated financial statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that our management considers

necessary for the fair statement of the results of operations for the interim periods covered and of our financial condition at the date of the interim balance sheet. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such judgments, estimates and assumptions include the valuation of marketable securities, impairment of long-lived assets, determining the fair-value of stock-based compensation, and evaluating the progress to completion of external research and development costs. Management bases its estimates on historical experience and on various other market-specific relevant assumptions that management believes to be reasonable under the circumstances. Actual results may differ from those estimates.

Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its judgments, estimates and assumptions or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company's condensed consolidated financial statements.

Recently Issued Accounting Pronouncements

In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2023-09 *Income Taxes (Topic 740) – Improvements to Income Tax Disclosures* ("ASU 2023-09"), which requires entities to disclose specific categories in the income tax rate reconciliation annually and provide additional information for reconciling items that meet a qualitative threshold. ASU 2023-09 also requires that entities disclose annually additional information about income taxes paid and disaggregated information for certain items. ASU 2023-09 is effective for the Company beginning on January 1, 2025. The Company is currently evaluating the impact of the adoption of ASU 2023-09 on its financial position, results of operations and cash flows.

In November 2023, the FASB issued Accounting Standards Update No. 2023-07 *Segment Reporting (Topic 280) – Improvements to Reportable Segment Disclosures* ("ASU 2023-07"), which requires entities to disclose incremental segment information on an annual and interim basis. ASU 2023-07 requires entities with a single reportable segment to provide all the disclosures required by the amendments in ASU 2023-07 and all existing segment disclosures in *Segment Reporting (Topic 280)*. ASU 2023-07 is effective for the Company beginning with the Form 10-K for the year ending December 31, 2024. The Company is currently evaluating the effect of adopting the update on its related disclosures.

There have been no other recent accounting pronouncements, changes in accounting pronouncements or recently adopted accounting guidance that are expected to have a material impact on the Company's condensed consolidated financial statements upon adoption.

~~XML 20 R12.htm IDEA: XBRL DOCUMENT~~

Fair Value Measurements	6 Months Ended Jun. 30, 2024
Fair Value Disclosures [Abstract]	
Fair Value Measurements	

3. Fair Value Measurements

Financial assets and liabilities are recorded at fair value. The carrying amount of certain financial instruments, including cash equivalents, other current assets, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. Assets and liabilities recorded at fair value on a recurring basis in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.

The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are required to be recognized or disclosed at fair value in the financial statements. The Company determines the fair value of Level 1 assets using quoted prices in active markets for identical assets. The Company reviews trading activity and pricing for Level 2 investments as of each measurement date. Level 2 inputs, which are obtained from various third-party data providers, represent quoted prices for similar assets in active markets and were derived from observable market data, or, if not directly observable, were derived from or corroborated by other observable market data.

In certain cases, where there is limited activity or less transparency around inputs to valuation, securities are classified as Level 3 within the valuation hierarchy. The Company did not have any financial assets or liabilities measured using Level 3 inputs as of June 30, 2024 or December 31, 2023.

The following table summarizes the Company's financial assets measured at fair value on a recurring basis and classified under the appropriate level of the fair value hierarchy as described above (in thousands):

	June 30, 2024			
	Total	Level 1	Level 2	Level 3
Financial Assets:				
Cash equivalents:				
U.S. Treasury money market funds	$ 28,158	$ 28,158	$ —	$ —
Marketable securities:				
Certificate of deposit	533	—	533	—
U.S. Treasury securities	51,889	51,889	—	—
Commercial paper	65,494	—	65,494	—
Corporate debt securities	10,990	—	10,990	—
U.S. government agency bonds	7,000	—	7,000	—
Total	$ 164,064	$ 80,047	$ 84,017	$ —

	December 31, 2023			
	Total	Level 1	Level 2	Level 3
Financial Assets:				
Cash equivalents:				
U.S. Treasury money market funds	$ 35,349	$ 35,349	$ —	$ —
Marketable securities:				
Certificate of deposit	544	—	544	—
U.S. Treasury securities	54,175	54,175	—	—
Commercial paper	65,070	—	65,070	—
U.S. government agency bonds	46,090	—	46,090	—
Total	$ 201,228	$ 89,524	$ 111,704	$ —

Nonrecurring Fair Value Measurements

The right-of-use ("ROU") asset associated with Suite 400 of the Company's headquarters in South San Francisco, California, is a separate asset group measured at fair value on a nonrecurring basis as of December 31, 2023 due to an impairment recognized on the ROU asset at that date (see Note 6). The fair value of this asset group calculated as the present value of the estimated future cash flows of sublease income attributable to the ROU asset associated with Suite 400, was classified in Level 3 of the fair value hierarchy. When calculating the present value of the estimated future cash flows, sublease income was estimated to increase at a rate of 3.5% per year, and the cash flows were discounted using a rate of 13.3%. In June 2024, the Company recognized an additional $1.5 million

impairment charge in relation to Suite 400 to write off the net book value of the ROU asset as of June 30, 2024 as the estimated future cash flow from sublease income is zero due to current market conditions.

~~XML 21 R13.htm IDEA: XBRL DOCUMENT~~

Available-for-Sale Securities

6 Months Ended
Jun. 30, 2024

Investments, Debt and Equity Securities [Abstract]

Available-for-Sale Securities

4. Available-for-Sale Securities

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in the Company's condensed consolidated balance sheets (in thousands):

	June 30, 2024			
	Amortized Cost	Unrealized Gains	Unrealized Losses	Fair Value
Cash equivalents:				
U.S. Treasury money market funds	$ 28,158	$ —	$ —	$ 28,158
Marketable securities:				
Certificate of deposit	533	—	—	533
U.S. Treasury securities	51,926	—	(37)	51,889
Commercial paper	65,572	3	(81)	65,494
Corporate debt securities	10,994	1	(5)	10,990
U.S. government agency bonds	7,005	—	(5)	7,000
Total	$ 164,188	$ 4	$ (128)	$ 164,064
Cash				118
Total cash, cash equivalent and marketable securities				$ 164,182

	December 31, 2023			
	Amortized Cost	Unrealized Gains	Unrealized Losses	Fair Value
Cash equivalents:				
U.S. Treasury money market funds	$ 35,349	$ —	$ —	$ 35,349
Marketable securities:				
Certificate of deposit	544	—	—	544
U.S. Treasury securities	54,066	151	(42)	54,175
Commercial paper	65,038	41	(9)	65,070
U.S. government agency bonds	46,115	27	(52)	46,090
Total	$ 201,112	$ 219	$ (103)	$ 201,228
Cash				144
Total cash, cash equivalent and marketable securities				$ 201,372

The Company has not recognized an allowance for credit losses on any securities in an unrealized loss position as of June 30, 2024 and December 31, 2023.

The following tables display additional information regarding gross unrealized losses and fair value by major security type for available-for-sale securities in an unrealized loss position as of June 30, 2024 and December 31, 2023 (in thousands):

	June 30, 2024	
	Less than 12 consecutive months	
	Fair Value	Unrealized Losses
U.S. Treasury securities	$ 48,463	$ (37)
Commercial paper	47,574	(81)
Corporate debt securities	7,814	(5)
U.S. government agency bonds	7,000	(5)
Total	$ 110,851	$ (128)

	December 31, 2023	
	Less than 12 consecutive months	
	Fair Value	Unrealized Losses
U.S. Treasury securities	$ 16,261	$ (42)
Commercial paper	20,789	(9)
U.S. government agency bonds	39,052	(52)
Total	$ 76,102	$ (103)

The Company believes that the individual unrealized losses represent temporary declines primarily resulting from interest rate changes and intends to hold these marketable securities to their maturities.

The Company currently does not intend to sell these securities prior to maturity, and it is not more likely than not that the Company will be required to sell these securities before recovery of their amortized cost basis, which may be at maturity. The Company evaluated securities with unrealized losses to determine whether such losses, if any, were due to credit-related factors and determined that there were no credit-related losses to be recognized as of June 30, 2024. There were no sales of available-for-sale securities in any of the periods presented.

As of June 30, 2024, the amortized cost and estimated fair value of the Company's available-for-sale securities by contractual maturity are shown below (in thousands):

	Amortized Cost	Estimated Fair Value
Available-for-sale securities maturing in:		
One year or less	$ 164,188	$ 164,064
Total available-for-sale securities	$ 164,188	$ 164,064

~~XML 22 R14.htm IDEA: XBRL DOCUMENT~~

Balance Sheet Components

6 Months Ended
Jun. 30, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Balance Sheet Components

5. Balance Sheet Components

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

	June 30, 2024	December 31, 2023
Receivable from Everest, current (Note 10)	$ 1,312	$ 1,596
Advance for clinical-related costs, current	773	1,818
Licenses, dues and subscriptions	662	506
Insurance	104	712
Interest receivable	374	695
Others	210	251
Total prepaid expenses and other current assets	$ 3,435	$ 5,578

Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):

	June 30, 2024	December 31, 2023
Leasehold improvements	$ 3,488	$ 3,488
Furniture, laboratory and office equipment	5,559	5,559
Computer equipment	285	285
Total property and equipment	9,332	9,332
Less: accumulated depreciation and amortization	(5,941)	(5,420)
Property and equipment, net	$ 3,391	$ 3,912

Depreciation expense was $0.3 million and $0.5 million for each of the three and six months ended June 30, 2024, respectively, compared to $0.2 million and $0.5 million for the three and six months ended June 30, 2023, respectively.

Other Assets

Other assets consisted of the following (in thousands):

	June 30, 2024	December 31, 2023
Advance for clinical related costs, noncurrent	$ 4,670	$ 4,787
Unbilled receivable from Everest, noncurrent (Note 10)	1,099	—
Deposits for operating lease	674	674
Other	79	134
Total other assets	$ 6,522	$ 5,595

Accrued and Other Current Liabilities

Accrued liabilities consisted of the following (in thousands):

	June 30, 2024	December 31, 2023
Accrued clinical costs	$ 5,909	$ 1,801
Accrued employee-related costs	1,802	3,708
Accrued preclinical and research costs	1,532	756
Accrued professional services	55	110
Others	65	106
Total accrued liabilities	$ 9,363	$ 6,481

~~XML 23 R15.htm IDEA: XBRL DOCUMENT~~

Lease

6 Months Ended
Jun. 30, 2024

Leases [Abstract]

Lease

6. Lease

In November 2022, the Company entered into an amendment to the lease agreement for its corporate headquarters in South San Francisco, California, which expanded the leased premises in the same building as its corporate headquarters and extended the lease term of the original premises to be coterminous with the expansion premises to July 31, 2026. The transaction was treated as a lease modification as of the effective date and resulted in the recognition of approximately $8.0 million in new lease liabilities and ROU assets.

In December 2023, the Company committed to a plan to sublease Suite 400 of its corporate headquarters in connection with a workforce reduction (see Note 14) and evaluated the recoverability of ROU asset by comparing the carrying amount of the asset to future net undiscounted cash flows associated with the asset. The ROU asset is considered to be impaired if the carrying amount of the assets exceeds the fair value of the assets. Consequently, the Company recognized a $2.7 million impairment charge in 2023. In June 2024, the Company recognized an additional $1.5 million impairment charge in relation to Suite 400 to write off the net book value of the ROU asset as of June 30, 2024 as the estimated future cash flow from sublease income is zero due to current market conditions.

Information related to the Company's lease liabilities were as follows (in thousands):

	Three months ended June 30, 2024	Six months ended June 30, 2024
Cash paid for operating lease liabilities	$ 741	$ 1,452
Operating lease costs	655	1,322
Variable lease costs	467	916
Maturities of lease liabilities as of June 30, 2024 were as follows:		
Less than 12 months		$ 3,957
13 - 24 months		4,095
25 - 36 months		347
Total undiscounted lease payments		8,399
Less: imputed interest		(987)
Total lease liabilities		$ 7,412
Operating lease liabilities, current		$ 3,260
Operating lease liabilities, noncurrent		4,152
Total operating lease liabilities		$ 7,412

~~XML 24 R16.htm IDEA: XBRL DOCUMENT~~

Debt

6 Months Ended
Jun. 30, 2024

Debt Disclosure [Abstract]

Debt

7. Debt

In November 2021, the Company entered into a loan agreement (the "Loan Agreement") with Oxford Finance, LLC ("Oxford Finance"), which provided the Company up to $50.0 million in borrowing capacity across five potential tranches (each a "Term Loan," and collectively "Term Loans"). The initial tranche of $10.0 million was funded at the closing of the Loan Agreement. The remaining tranches were dependent on achieving certain clinical trial milestones, and the Company declined these remaining tranches in borrowing capacity available to it under the Loan Agreement. The loan facility is secured by all assets except intellectual property, which is subject to a negative pledge, and will mature on November 1, 2026 (the "Maturity Date"). There are no warrants or financial covenants associated with the Loan Agreement.

Until June 30, 2023, the Term Loans bore interest at a floating per annum rate (based on the actual number of days elapsed divided by a year of 360 days) equal to the sum of (a) the greater of (i) 30-day U.S. LIBOR rate reported in the Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue and (ii) 0.08%, plus (b) 7.87%. A

LIBOR transition event occurred effective July 1, 2023 and Oxford Finance subsequently replaced the LIBOR rate with the 1-month CME term SOFR plus 0.1%. The rate change did not require contract remeasurement at the effective date of the change or a reassessment of any previous accounting determinations pertaining to the facility. The rate change did not have a material impact on the Company's financial statements. The Company is required to make monthly interest-only payments prior to the amortization date of January 1, 2025, subject to a potential one-year extension upon satisfaction of certain conditions.

All unpaid principal and accrued and unpaid interest with respect to each Term Loan is due and payable in full on the Maturity Date. The Company has the option to prepay the outstanding balance prior to maturity, subject to a prepayment fee of 1.0% to 2.0% depending upon when the prepayment occurs. Upon repayment of the Term Loans, the Company is required to make a final payment fee to the lenders equal to 6.5% of the original principal amount of the Term Loans funded which will be accrued by charges to interest expense over the term of the loans using the effective interest method.

The Loan Agreement also includes subjective acceleration clauses that permit the lenders to accelerate the Maturity Date under certain circumstances, including, but not limited to, material adverse effects on a Company's financial status or otherwise. As of June 30, 2024, the Company is in compliance with all covenants in the Loan Agreement.

Interest expense was $0.4 million and $0.8 million for the three and six months ended June 30, 2024, respectively, compared to $0.4 million and $0.8 million for the three and six months ended June 30, 2023, respectively. The initial effective interest rate on the Term Loans, including the amortization of the debt discount and issuance costs, and accretion of the final payment, was 11%. The components of the long-term debt balance are as follows:

	June 30, 2024	December 31, 2023
Principal loan balance	$ 10,000	$ 10,000
Unamortized debt discount and issuance costs	(189)	(243)
Cumulative accretion of final fee	387	312
	$ 10,198	$ 10,069
Debt, current	$ 2,609	$ —
Debt, noncurrent	7,589	10,069
Debt, net	$ 10,198	$ 10,069

As of June 30, 2024, the estimated future principal payments due were as follows:

Years Ending December 31,	
2024	$ —
2025	5,217
2026	4,783
Total	$ 10,000

~~XML 25 R17.htm IDEA: XBRL DOCUMENT~~

Pre-Funded Warrants

6 Months Ended
Jun. 30, 2024

Equity [Abstract]

Pre-Funded Warrants

8. Pre-Funded Warrants

In connection with the Company's previous underwritten public offerings, the Company issued pre-funded warrants to purchase an aggregate of 3,793,706 shares of the Company's common stock. Each pre-funded warrant entitled the holder to purchase shares of common stock at an exercise price of $0.001 per share and expired 20 years from the date of issuance. These warrants were recorded as a component of stockholders' equity within additional paid-in capital. The warrant holders exercised all the shares of outstanding pre-funded warrants in 2023 at an exercise price of $0.001 per share. As of June 30, 2024, there were no pre-funded warrants outstanding.

~~XML 26 R18.htm IDEA: XBRL DOCUMENT~~

Stock-Based Compensation

6 Months Ended
Jun. 30, 2024

Share-Based Payment Arrangement [Abstract]

Stock-Based Compensation

9. Stock-Based Compensation

Stock Incentive Plans

2022 Inducement Plan

In April 2022, the Company adopted the Kezar Life Sciences, Inc. 2022 Inducement Plan (the "Inducement Plan"), which is a non-stockholder approved stock plan adopted pursuant to the "inducement exception" provided under Nasdaq Listing Rule 5635(c)(4), for the award of nonstatutory stock options ("NSOs"), restricted stock units ("RSUs") and other equity awards as permitted by the Inducement Plan (collectively, "Inducement Awards") to persons not previously an employee or director of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company ("Eligible Recipients"). Under the Inducement Plan, the Company may grant up to 3,000,000 shares of Common Stock in

the form of Inducement Awards to Eligible Recipients in compliance with the requirements of Nasdaq Listing Rule 5635(c)(4). Awards must be approved by either a majority of the Company's independent directors or the Company's independent compensation committee. Consultants and directors are not eligible to received grants under the Inducement Plan.

As of June 30, 2024, options to purchase 1,247,708 shares of common stock were outstanding and 1,752,292 shares were available for future issuance under the Inducement Plan.

2018 Equity Incentive Plan

In June 2018, the Company's board of directors adopted and the stockholders approved the 2018 Equity Incentive Plan (the "2018 Plan"), which became effective as of June 20, 2018, at which point no further grants could be made under the 2015 Equity Incentive Plan (the "2015 Plan") described below. Under the 2018 Plan, the Company may grant incentive stock options ("ISOs"), NSOs, stock appreciation rights, restricted stock awards, RSUs and other stock-based awards. As of June 30, 2024, options to purchase 12,645,480 shares of common stock and 185,416 RSUs were outstanding, and 2,843,990 shares were available for future issuance under the 2018 Plan.

Initially, subject to adjustment as provided in the 2018 Plan, the aggregate number of shares of the Company's common stock authorized for issuance pursuant to stock awards under the 2018 Plan was 4,000,000 shares, which is the sum of (i) 1,600,692 shares plus (ii) the number of shares reserved and available for issuance under the 2015 Plan at the time the 2018 Plan became effective and (iii) the number of shares subject to stock options or other stock awards granted under the 2015 Plan that expire, terminate are forfeited or otherwise not issued, or are withheld to satisfy a tax withholding obligation in connection with an award or to satisfy a purchase or exercise price of an award (such as upon the expiration or termination of a stock award prior to vesting). The number of shares of the Company's common stock reserved for issuance under the 2018 Plan automatically increases on January 1 of each year, beginning on January 1, 2019 and continuing through and including January 1, 2028, by 5% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the Company's board of directors prior to such increase.

The maximum number of shares that may be issued upon the exercise of ISOs under the 2018 Plan is 12,500,000 shares.

2015 Equity Incentive Plan

The 2015 Plan provided for the granting of ISOs and NSOs to employees, directors and consultants at the discretion of the Company's board of directors. The 2015 Plan was terminated as to future awards in June 2018, although it continues to govern the terms of options that remain outstanding under the 2015 Plan.

No additional stock awards will be granted under the 2015 Plan, and all outstanding stock awards granted under the 2015 Plan that are repurchased, forfeited, expire or are cancelled will become available for grant under the 2018 Plan in accordance with its terms.

Options granted under the 2015 Plan expire no later than 10 years from the date of grant. Options granted under the 2015 Plan vest over periods determined by the Company's board of directors, generally over four years. The 2015 Plan allows for early exercise of certain options prior to vesting. Upon termination of employment, the unvested shares are subject to repurchase at the original exercise price. As of June 30, 2024, options to purchase 1,363,394 shares of common stock were outstanding under the 2015 Plan.

2018 Employee Stock Purchase Plan

In June 2018, the Company's board of directors adopted and the stockholders approved the 2018 Employee Stock Purchase Plan (the "ESPP"), which became effective as of June 20, 2018. The ESPP is intended to qualify as an "employee stock purchase plan" within the meaning of Section 423 of the U.S. Internal Revenue Code of 1986, as amended. The number of shares of common stock initially reserved for issuance under the ESPP was 200,000 shares. The ESPP provides for an annual increase on January 1 of each year, beginning on January 1, 2019 and continuing through and including January 1, 2028, equal to the lesser of (i) 1% of the shares of common stock outstanding on the last day of the prior fiscal year or (ii) 375,000 shares, or a lesser number of shares determined by the Company's board of directors prior to such increase. In December 2023, the Company's board of directors acted such that there was no increase of the number of shares of common stock reserved for issuance under the ESPP as of January 1, 2024. As of June 30, 2024, 676,129 shares of common stock had been issued under the ESPP and 657,095 shares remained available for future issuance under the ESPP.

The price per share of common stock to be paid by an ESPP participant on the applicable purchase date of an offering period shall be equal to 85% of the lesser of the fair market value of a share of common stock on (i) the applicable offering date or (ii) the applicable purchase date. The Company's board of directors authorized an initial six-month offering period beginning on November 16, 2018 and ending on May 15, 2019. The Company's board of directors has subsequently authorized additional six-month offering periods, with the most recent offering period beginning on May 16, 2024.

Option Repricing

In July 2023, the Compensation Committee of the Company's board of directors approved a stock option repricing (the "Option Repricing") in which the exercise price of certain outstanding options to purchase shares of the Company's common stock under the 2018 Plan was reduced to $2.28 per share, the closing price of the Common Stock on July 24, 2023. Outstanding options that were granted under the 2015 Plan and the Inducement Plan were not included in the Option Repricing. The Option Repricing included options granted pursuant to the 2018 Plan that were held by, among others, members of the Company's board of the directors (other than options granted in June 2023) and the Company's named executive officers and principal financial officer.

As a result of the Option Repricing, 9,904,755 shares of vested and unvested stock options outstanding as of July 24, 2023, with original exercise prices ranging from $2.44 to $22.85 per share, were repriced to $2.28 per share. The total incremental fair value to be recognized as a result of the repricing was approximately $4.7 million on the date of Option Repricing, of which $3.0 million related to the vested option shares had been recognized as stock-based compensation expense and $0.6 million related to the unvested option shares subsequently cancelled due to termination as of June 30, 2024. As of June 30, 2024, there was $1.1 million remaining related to the unvested option shares which will be amortized over the remaining requisite service periods through the end of 2026.

Stock Option Activity

The following table summarizes activity under the Company's stock option plans and related information (in thousands, except share and per share amounts):

	Number of Options Outstanding	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Outstanding as of December 31, 2023	13,110,717	$ 2.60	7.1	$ 118
Options granted	3,541,000	$ 0.90		
Options cancelled/forfeited	(1,395,135)	$ 2.84		
Outstanding as of June 30, 2024	15,256,582	$ 2.18	7.2	$ —
Vested and exercisable as of June 30, 2024	8,334,868	$ 2.58	5.7	$ —

The weighted average grant date fair value of options granted during the three and six months ended June 30, 2024 was $0.54 and $0.67 per share, respectively. There were no options exercised during the six months ended June 30, 2024. The aggregate intrinsic value is calculated as the difference between the exercise price and the estimated fair value of the Company's common stock at the date of exercise.

Restricted Stock Units Activity

There were no RSUs granted during the six months ended June 30, 2024. One-third of each RSU granted vests annually following the vesting commencement dates, over a vesting period of three years. RSUs are awards that entitle the holder to receive freely tradable shares of the Company's common stock upon vesting and are not forfeitable once fully vested. The valuations for these RSUs were based on the closing prices of the Company's common stock on the grant dates and recognized as stock-based compensation expenses over the respective vesting terms.

	Number of RSUs Outstanding	Weighted Average Grant-Date Fair Price
Outstanding as of December 31, 2023	219,609	$ 9.20
RSUs vested	(22,282)	$ 9.63
RSUs forfeited	(11,911)	$ 9.26
Outstanding as of June 30, 2024	185,416	$ 9.14

Stock-Based Compensation Expense

Total stock-based compensation expense recognized by function was as follows (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Research and development	$ 915	$ 2,013	$ 1,971	$ 4,281
General and administrative	2,170	2,007	4,548	4,002
Total stock-based compensation expense	$ 3,085	$ 4,020	$ 6,519	$ 8,283

As of June 30, 2024, the unrecognized stock-based compensation cost related to outstanding unvested stock options and RSUs that are expected to vest was $20.0 million with an estimated weighted average amortization period of 2.7 years.

The fair value of the stock options granted is calculated using the Black-Scholes option-pricing model with the following range of assumptions:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Expected term (years)	5.5 - 6.1	5.5 - 6.1	5.5 - 6.1	5.5 - 6.1
Expected volatility	86.8 - 87.7%	88.0 - 88.3%	86.8 - 87.9%	87.8 - 88.3%
Risk-free interest rate	4.3 - 4.6%	3.5 - 3.9%	4.0 - 4.6%	3.5 - 4.3%
Expected dividend yield	—	—	—	—

The expected term of options granted represents the period of time that options granted are expected to be outstanding and was determined by calculating the midpoint between the date of vesting and the contractual life of each option. The expected term of the ESPP rights is equal to the six-month look-back period. Since inception until March 2024, the volatility of the Company's stock price was based on the weighted average of the historical volatility of the Company's stock price and that of a peer group of public companies over the expected term due to the Company's limited public trading history of its common stock. The peer group was selected on the basis of operational and economic similarity with the Company's principal business operations. Effective as of the quarter-ended June 30, 2024, the expected volatility is based on the daily historical volatility of the Company's common stock covering the estimated expected term. The risk-free interest rate for the expected term of the options is based on the U.S. Treasury yield curve with a maturity equal to the expected term in effect at the time of grant. The Company has not paid, and does not anticipate paying, cash dividends on its shares of common stock; therefore, the expected dividend yield is zero.

Financial Statements [Abstract]

Everest Collaboration

10. Everest Collaboration

In September 2023, the Company entered into a Collaboration and License Agreement (the "Everest License Agreement") with Everest pursuant to which, among other things, the Company granted to Everest an exclusive license to develop and commercialize one or more products containing the Company's proprietary compound, zetomipzomib (the "Products"), in the licensed field in the Greater China region (Mainland China, Taiwan, Hong Kong and Macau), South Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam and the Philippines (the "Territory"). The licensed field includes all uses other than the diagnosis or treatment in humans of cancerous or pre-cancerous diseases or conditions. During the PALIZADE trial, Everest will contribute their local regulatory and clinical trial expertise and will be responsible for study costs in the Territory. Everest Medicines Limited is also a party to the Everest License Agreement solely for limited purposes, including to guarantee the performance by Everest of its obligations under the Everest License Agreement.

Under the terms of the Everest License Agreement, the Company received a one-time, irrecoverable, non-refundable and non-creditable upfront payment of $7.0 million in October 2023 and is entitled to receive certain variable payments for manufacturing supply services and milestone payments upon achievement of certain development, regulatory and commercial milestone events, for total potential milestone payments of up to $125.5 million. In addition, Everest will pay to the Company tiered royalties on the net sales of the Products in the Territory during the term of the Everest License Agreement ranging from the single digit to the low-teens, subject to certain reductions for patent expiration, generic competition and payments for licenses to third-party patents.

The term of the Everest License Agreement will continue on a market-by-market basis until expiration of the relevant royalty term of the Products, unless terminated earlier. Everest has the right to terminate the Everest License Agreement for convenience following completion, suspension or termination of the PALIZADE clinical trial. The Company may terminate the Everest License Agreement if Everest challenges the Company's patents or fails to perform any development or commercialization activities for a continuous period of more than twelve (12) months, subject to certain exceptions. In addition, either party may terminate the Everest License Agreement

for the other party's uncured breach or insolvency, and the Everest License Agreement will automatically terminate in the event of termination of the Company's exclusive license agreement with Onyx Therapeutics, Inc.

Under the terms of the Everest License Agreement, at the election of Everest, the Company may manufacture and provide clinical supply to Everest to use in development and commercialization in the Territory at the fully burdened manufacturing cost plus specified margins, as defined within the Everest License Agreement. Certain of these provisions were determined to be options to acquire additional goods or services at a price that approximates the stand-alone selling price for that good or service and therefore do not represent material rights, or separate performance obligations, within the context of the Everest License Agreement. The Company evaluated the Everest License Agreement and determined it was within the scope of ASC 606. The transaction price was determined to consist of the upfront payment of $7.0 million.

License of Intellectual Property. The license to the Company's intellectual property and associated know-how represents a distinct performance obligation. The license and associated know-how was transferred to Everest in the third quarter of 2023 to satisfy this performance obligation. The Company allocated the full transaction price to the license of the Company's intellectual property and accordingly recognized collaboration revenue of $7.0 million in 2023.

Milestone Payments. The potential development, regulatory and commercial milestone payments are paid upon achievement of certain milestones as defined in the Everest License Agreement. It was determined that their achievement is highly dependent on factors outside of the Company's control. These payments have been fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods and, as such, have been excluded from the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint and, if necessary, adjust its estimate of the overall transaction price. As of June 30, 2024, the Company has not recognized any revenue associated with development, regulatory and commercial milestones.

Royalties. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Everest and, therefore, have also been excluded from the transaction price. No royalty revenue was recognized as of June 30, 2024.

In July 2024, the Company amended the Everest License Agreement to modify a development milestone and adjust certain payment terms relating to Everest's responsibility for PALIZADE study costs in the Territory. As of June 30, 2024, the Company had a receivable of $1.3 million, representing the billed amounts related to Everest's share of the Territory-specific direct costs and pro rata portion of indirect costs incurred to conduct PALIZADE study under the Everest License Agreement, and a noncurrent unbilled receivable of $1.1 million representing reimbursement for payment is yet to be billed or due. The receivable amount was included in prepaid expenses and other current assets and the unbilled receivable was included in other assets in the Company's Condensed Consolidated Balance Sheet. In connection with the cost-sharing arrangement with Everest, $1.6 million and $2.4 million was recognized as contra research and development expense for each of the three and six months ended June 30, 2024, respectively.

~~XML 28 R20.htm IDEA: XBRL DOCUMENT~~

Income Taxes

6 Months Ended
Jun. 30, 2024

Income Tax Disclosure [Abstract]

Income Taxes

11. Income Taxes

No provision for income taxes was recorded for the three and six months ended June 30, 2024 and 2023, respectively. Deferred tax assets generated from the Company's net operating losses have been fully reserved, as the Company believes it is not more likely than not that the benefit will be realized.

Effective January 1, 2022, under the Tax Cuts and Jobs Act, for tax purposes the Company is required to capitalize and subsequently amortize all R&D expenditures over five years for research activities conducted in the U.S. and over fifteen years for research activities conducted outside of the U.S. Given the significant loss and credit carryforwards in the U.S., the Company does not anticipate having a change in valuation allowance assertion.

In March 2020, the Coronavirus Aid, Relief and Economic Security ("CARES") Act was signed into law. The CARES Act included several tax changes as part of its economic package. These changes principally related to expanded net operating loss carryback periods, increases to interest deductibility limitations, and accelerated alternative minimum tax refunds. The CARES Act enacted the Employee Retention Credit ("ERC") to incentivize companies to retain employees, which was subsequently modified by extension of the CARES Act. Under the provisions of the CARES Act and its subsequent extension, the Company was eligible for ERCs, subject to certain criteria. During the six months ended June 30, 2023, the Company received refunds of approximately $1.4 million related to ERCs that offset the related payroll expenses in the respective operating costs and expenses line item in the condensed consolidated statements of operations. During the six months ended June 30, 2024, no refund related to ERCs was received by the Company.

~~XML 29 R21.htm IDEA: XBRL DOCUMENT~~

Net Loss Per Share

6 Months Ended
Jun. 30, 2024

Earnings Per Share [Abstract]

Net Loss Per Share

12. Net Loss Per Share

Net Loss Per Share

The following table sets forth the calculation of basic and diluted net loss per share during the periods presented (in thousands, except share and per share data):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Numerator:				
Net loss	$ (21,547)	$ (24,308)	$ (43,205)	$ (46,507)
Denominator:				
Weighted-average shares of common stock outstanding	72,845,869	72,461,850	72,822,890	72,395,410
Net loss per share, basic and diluted	$ (0.30)	$ (0.34)	$ (0.59)	$ (0.64)

Basic net loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock and pre-funded warrants outstanding during the period, without consideration of common share equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock, pre-funded warrants and common share equivalents outstanding for the period. The pre-funded warrants were included in the computation of basic and diluted net loss per common share as the exercise price was negligible and the pre-funded warrants were fully vested and exercisable. Common share equivalents are only included in the calculation of diluted net loss per common share when their effect is dilutive.

Potential dilutive securities, which include, vested and unvested options to purchase common stock and RSUs subject to future vesting have been excluded from the computation of diluted net loss per share as the effect is antidilutive. Therefore, the denominator used to calculate both basic and diluted net loss per common share is the same in all periods presented.

The following outstanding shares of common stock equivalents were excluded from the computation of the diluted net loss per share for the periods presented because their effect would have been anti-dilutive:

	Three and Six Months Ended June 30,	
	2024	2023
Stock options to purchase common stock	15,256,582	12,962,005
Restricted stock units subject to future vesting	185,416	433,611
Total	15,441,998	13,395,616

~~XML 30 R22.htm IDEA: XBRL DOCUMENT~~

Related Party Transactions

6 Months Ended
Jun. 30, 2024

Related Party Transactions [Abstract]

Related Party Transactions

13. Related Party Transactions

In connection with the resignation of John Fowler from his role as Chief Executive Officer, the Company and Mr. Fowler entered into a Separation and Consulting Agreement, effective as of November 7, 2023 (the "Fowler Agreement"), pursuant to which Mr. Fowler provides consulting services to the Company at a rate of $5,000 per month for one year ending November 7, 2024. Pursuant to the Fowler Agreement, the Company recognized $15,000 and $30,000 of compensation expense within general and administrative expenses in the Condensed Consolidated Statement of Operations during the three and six months ended June 30, 2024, respectively.

~~XML 31 R23.htm IDEA: XBRL DOCUMENT~~

Restructuring and Impairment Charges

6 Months Ended
Jun. 30, 2024

Restructuring and Related Activities [Abstract]

Restructuring and

14. 2023 Restructuring and Impairment Charges

Impairment Charges

In October 2023, the Company announced a strategic restructuring and workforce reduction to prioritize its clinical-stage assets, extend its cash runway and reduce its total workforce. All employees affected by the workforce reduction separated from the company by December 31, 2023. In connection with the workforce reduction, the Company committed to a plan to sublease Suite 400 of its corporate headquarters which resulted in an impairment to the ROU asset and certain property and equipment no longer utilized under current or expected future operations.

The Company recognized cumulative restructuring charges of $6.2 million, comprised primarily of one-time employee termination benefits and long-lived assets impairment costs during the year ended December 31, 2023. The Company recognized an additional $1.5 million impairment charge in relation to Suite 400 to write off the net book value of the ROU asset as of June 30, 2024. The unpaid severance and related benefit costs included in accrued liabilities in the Condensed Consolidated Balance Sheets were $0.2 million and $1.4 million as of June 30, 2024 and December 31, 2023, respectively. The Company expects that substantially all of the remaining accrued restructuring liabilities will be paid in cash over next four months.

The following table illustrates the accrual activities and payments relating to restructuring and impairment charges (in thousands):

	Severance and related benefit costs	Asset impairments	Total
Balance as of January 1, 2023	$ —	$ —	$ —
Restructuring charges	3,279	2,908	6,187
Cash payments made	(1,858)	—	(1,858)
Non-cash charges	—	(2,908)	(2,908)
Balance as of December 31, 2023	$ 1,421	$ —	$ 1,421
Cash payments made	(775)	—	(775)
Balance as of March 31, 2024	$ 646	$ —	$ 646
Restructuring charges	(67)	1,549	1,482
Cash payments made	(344)	—	(344)
Non-cash charges	—	(1,549)	(1,549)
Balance as of June 30, 2024	$ 235	$ —	$ 235

~~XML 32 R24.htm IDEA: XBRL DOCUMENT~~

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract]

Basis of Presentation and Consolidation

Basis of Presentation and Consolidation

The condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and include the Company's accounts and those of its wholly owned Australian subsidiary, Kezar Life Sciences Australia Pty Ltd., which is a proprietary company limited by shares. All intercompany balances and transactions have been eliminated upon consolidation.

The condensed consolidated balance sheet as of December 31, 2023 has been derived from the audited consolidated financial statements at that date but does not include all information and footnotes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements included in the Annual Report.

Unaudited Condensed Consolidated Financial Statements

Unaudited Condensed Consolidated Financial Statements

The accompanying financial information as of June 30, 2024 is unaudited. The interim condensed consolidated financial statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that our management considers

necessary for the fair statement of the results of operations for the interim periods covered and of our financial condition at the date of the interim balance sheet. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such judgments, estimates and assumptions include the valuation of marketable securities, impairment of long-lived assets, determining the fair-value of stock-based compensation, and evaluating the progress to completion of external research and development costs. Management bases its estimates on historical experience and on various other market-specific relevant assumptions that management believes to be reasonable under the circumstances. Actual results may differ from those estimates.

Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its judgments, estimates and assumptions or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company's condensed consolidated financial statements.

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2023-09 *Income Taxes (Topic 740) – Improvements to Income Tax Disclosures* ("ASU 2023-09"), which requires entities to disclose specific categories in the income tax rate reconciliation annually and provide additional information for reconciling items that meet a qualitative threshold. ASU 2023-09 also requires that entities disclose annually additional information about income taxes paid and disaggregated information for certain items. ASU 2023-09 is effective for the Company beginning on January 1, 2025. The Company is currently evaluating the impact of the adoption of ASU 2023-09 on its financial position, results of operations and cash flows.

In November 2023, the FASB issued Accounting Standards Update No. 2023-07 *Segment Reporting (Topic 280) – Improvements to Reportable Segment Disclosures* ("ASU 2023-07"), which requires entities to disclose incremental segment information on an annual and interim basis. ASU 2023-07 requires entities with a single reportable segment to provide all the disclosures required by the amendments in ASU 2023-07 and all existing segment disclosures in *Segment Reporting (Topic 280)*. ASU 2023-07 is effective for the Company beginning with the Form 10-K for the year ending December 31, 2024. The Company is currently evaluating the effect of adopting the update on its related disclosures.
There have been no other recent accounting pronouncements, changes in accounting pronouncements or recently adopted accounting guidance that are expected to have a material impact on the Company's condensed consolidated financial statements upon adoption.

Fair Value Measurements

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.

The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are required to be recognized or disclosed at fair value in the financial statements. The Company determines the fair value of Level 1 assets using quoted prices in active markets for identical assets. The Company reviews trading activity and pricing for Level 2 investments as of each measurement date. Level 2 inputs, which are obtained from various third-party data providers, represent quoted prices for similar assets in active markets and were derived from observable market data, or, if not directly observable, were derived from or corroborated by other observable market data.

~~XML 33 R25.htm IDEA: XBRL DOCUMENT~~

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2024

Fair Value Disclosures [Abstract]

Summary of Financial Assets Measured at Fair Value on a Recurring Basis

The following table summarizes the Company's financial assets measured at fair value on a recurring basis and classified under the appropriate level of the fair value hierarchy as described above (in thousands):

	June 30, 2024			
	Total	Level 1	Level 2	Level 3
Financial Assets:				
Cash equivalents:				
U.S. Treasury money market funds	$ 28,158	$ 28,158	$ —	$ —
Marketable securities:				
Certificate of deposit	533	—	533	—
U.S. Treasury securities	51,889	51,889	—	—
Commercial paper	65,494	—	65,494	—
Corporate debt securities	10,990	—	10,990	—
U.S. government agency bonds	7,000	—	7,000	—
Total	$ 164,064	$ 80,047	$ 84,017	$ —

	December 31, 2023			
	Total	Level 1	Level 2	Level 3
Financial Assets:				
Cash equivalents:				
U.S. Treasury money market funds	$ 35,349	$ 35,349	$ —	$ —
Marketable securities:				
Certificate of deposit	544	—	544	—
U.S. Treasury securities	54,175	54,175	—	—
Commercial paper	65,070	—	65,070	—
U.S. government agency bonds	46,090	—	46,090	—

Total	$ 201,228	$ 89,524	$ 111,704	$ —

XML 34 R26.htm IDEA: XBRL DOCUMENT

Available-for-Sale Securities (Tables)

6 Months Ended
Jun. 30, 2024

Investments, Debt and Equity Securities [Abstract]

Summary of Available-For-Sale Securities Recorded in Cash and Cash Equivalents or Marketable Securities

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in the Company's condensed consolidated balance sheets (in thousands):

	June 30, 2024			
	Amortized Cost	Unrealized Gains	Unrealized Losses	Fair Value
Cash equivalents:				
U.S. Treasury money market funds	$ 28,158	$ —	$ —	$ 28,158
Marketable securities:				
Certificate of deposit	533	—	—	533
U.S. Treasury securities	51,926	—	(37)	51,889
Commercial paper	65,572	3	(81)	65,494
Corporate debt securities	10,994	1	(5)	10,990
U.S. government agency bonds	7,005	—	(5)	7,000
Total	$ 164,188	$ 4	$ (128)	$ 164,064
Cash				118
Total cash, cash equivalent and marketable securities				$ 164,182

	December 31, 2023			
	Amortized Cost	Unrealized Gains	Unrealized Losses	Fair Value
Cash equivalents:				
U.S. Treasury money market funds	$ 35,349	$ —	$ —	$ 35,349
Marketable securities:				
Certificate of deposit	544	—	—	544
U.S. Treasury securities	54,066	151	(42)	54,175
Commercial paper	65,038	41	(9)	65,070
U.S. government agency bonds	46,115	27	(52)	46,090
Total	$ 201,112	$ 219	$ (103)	$ 201,228
Cash				144
Total cash, cash equivalent and marketable securities				$ 201,372

Summary of Gross Unrealized Losses and Fair Value by Major Security Type for Available-For-Sale Securities in Unrealized Loss Position

The following tables display additional information regarding gross unrealized losses and fair value by major security type for available-for-sale securities in an unrealized loss position as of June 30, 2024 and December 31, 2023 (in thousands):

	June 30, 2024	
	Less than 12 consecutive months	
	Fair Value	Unrealized Losses
U.S. Treasury securities	$ 48,463	$ (37)
Commercial paper	47,574	(81)
Corporate debt securities	7,814	(5)
U.S. government agency bonds	7,000	(5)
Total	$ 110,851	$ (128)

	December 31, 2023	
	Less than 12 consecutive months	
	Fair Value	Unrealized Losses
U.S. Treasury securities	$ 16,261	$ (42)
Commercial paper	20,789	(9)
U.S. government agency bonds	39,052	(52)
Total	$ 76,102	$ (103)

Summary of Amortized Cost and Estimated Fair Value of Available-for-sale Securities by Contractual Maturity

As of June 30, 2024, the amortized cost and estimated fair value of the Company's available-for-sale securities by contractual maturity are shown below (in thousands):

	Amortized Cost	Estimated Fair Value
Available-for-sale securities maturing in:		
One year or less	$ 164,188	$ 164,064
Total available-for-sale securities	$ 164,188	$ 164,064

XML 35 R27.htm IDEA: XBRL DOCUMENT

Balance Sheet Components (Tables)

6 Months Ended
Jun. 30, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

	June 30, 2024	December 31, 2023
Receivable from Everest, current (Note 10)	$ 1,312	$ 1,596
Advance for clinical-related costs, current	773	1,818
Licenses, dues and subscriptions	662	506
Insurance	104	712
Interest receivable	374	695
Others	210	251
Total prepaid expenses and other current assets	$ 3,435	$ 5,578

Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):

	June 30, 2024	December 31, 2023
Leasehold improvements	$ 3,488	$ 3,488
Furniture, laboratory and office equipment	5,559	5,559
Computer equipment	285	285
Total property and equipment	9,332	9,332
Less: accumulated depreciation and amortization	(5,941)	(5,420)
Property and equipment, net	$ 3,391	$ 3,912

Depreciation expense was $0.3 million and $0.5 million for each of the three and six months ended June 30, 2024, respectively, compared to $0.2 million and $0.5 million for the three and six months ended June 30, 2023, respectively.

Other Assets

Other assets consisted of the following (in thousands):

	June 30, 2024	December 31, 2023
Advance for clinical related costs, noncurrent	$ 4,670	$ 4,787
Unbilled receivable from Everest, noncurrent (Note 10)	1,099	—
Deposits for operating lease	674	674
Other	79	134
Total other assets	$ 6,522	$ 5,595

Accrued and Other Current Liabilities

Accrued liabilities consisted of the following (in thousands):

	June 30, 2024	December 31, 2023
Accrued clinical costs	$ 5,909	$ 1,801
Accrued employee-related costs	1,802	3,708
Accrued preclinical and research costs	1,532	756
Accrued professional services	55	110
Others	65	106
Total accrued liabilities	$ 9,363	$ 6,481

~~XML 36 R28.htm IDEA: XBRL DOCUMENT~~

Lease (Tables)

6 Months Ended
Jun. 30, 2024

Leases [Abstract]

Details of Right-of-Use Assets and Lease Liabilities

Information related to the Company's lease liabilities were as follows (in thousands):

	Three months ended June 30, 2024	Six months ended June 30, 2024
Cash paid for operating lease liabilities	$ 741	$ 1,452
Operating lease costs	655	1,322
Variable lease costs	467	916
Maturities of lease liabilities as of June 30, 2024 were as follows:		
Less than 12 months		$ 3,957
13 - 24 months		4,095
25 - 36 months		347
Total undiscounted lease payments		8,399
Less: imputed interest		(987)
Total lease liabilities		$ 7,412
Operating lease liabilities, current		$ 3,260
Operating lease liabilities, noncurrent		4,152
Total operating lease liabilities		$ 7,412

~~XML 37 R29.htm IDEA: XBRL DOCUMENT~~

Debt (Tables)

6 Months Ended
Jun. 30, 2024

Debt Disclosure [Abstract]

Schedule of Long-term Debt Balance

The components of the long-term debt balance are as follows:

	June 30, 2024	December 31, 2023
Principal loan balance	$ 10,000	$ 10,000
Unamortized debt discount and issuance costs	(189)	(243)
Cumulative accretion of final fee	387	312
	$ 10,198	$ 10,069
Debt, current	$ 2,609	$ —
Debt, noncurrent	7,589	10,069
Debt, net	$ 10,198	$ 10,069

Schedule of Estimated Future Principal Payments

As of June 30, 2024, the estimated future principal payments due were as follows:

Years Ending December 31,	
2024	$ —
2025	5,217
2026	4,783
Total	$ 10,000

~~XML 38 R30.htm IDEA: XBRL DOCUMENT~~

Stock-Based Compensation (Tables)

6 Months Ended
Jun. 30, 2024

Share-Based Payment Arrangement [Abstract]

Summary of Activity under Stock Option Plans and Related Information

The following table summarizes activity under the Company's stock option plans and related information (in thousands, except share and per share amounts):

	Number of Options Outstanding	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Outstanding as of December 31, 2023	13,110,717	$ 2.60	7.1	$ 118
Options granted	3,541,000	$ 0.90		
Options cancelled/forfeited	(1,395,135)	$ 2.84		
Outstanding as of June 30, 2024	15,256,582	$ 2.18	7.2	$ —
Vested and exercisable as of June 30, 2024	8,334,868	$ 2.58	5.7	$ —

Summary of RSU Activity

	Number of RSUs Outstanding	Weighted Average Grant-Date Fair Price
Outstanding as of December 31, 2023	219,609	$ 9.20
RSUs vested	(22,282)	$ 9.63
RSUs forfeited	(11,911)	$ 9.26
Outstanding as of June 30, 2024	185,416	$ 9.14

Stock-Based Compensation Expense Recognized

Total stock-based compensation expense recognized by function was as follows (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Research and development	$ 915	$ 2,013	$ 1,971	$ 4,281
General and administrative	2,170	2,007	4,548	4,002
Total stock-based compensation expense	$ 3,085	$ 4,020	$ 6,519	$ 8,283

Fair Value of Employee Stock Options Granted is Calculated Using Black Scholes Option Pricing Model with Range of Assumptions

The fair value of the stock options granted is calculated using the Black-Scholes option-pricing model with the following range of assumptions:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Expected term (years)	5.5 - 6.1	5.5 - 6.1	5.5 - 6.1	5.5 - 6.1
Expected volatility	86.8 - 87.7%	88.0 - 88.3%	86.8 - 87.9%	87.8 - 88.3%
Risk-free interest rate	4.3 - 4.6%	3.5 - 3.9%	4.0 - 4.6%	3.5 - 4.3%
Expected dividend yield	—	—	—	—

~~XML 39 R31.htm IDEA: XBRL DOCUMENT~~

Net Loss Per Share (Tables)

6 Months Ended
Jun. 30, 2024

Earnings Per Share [Abstract]

Calculation of Basic and Diluted Net Loss Per Share

The following table sets forth the calculation of basic and diluted net loss per share during the periods presented (in thousands, except share and per share data):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Numerator:				
Net loss	$ (21,547)	$ (24,308)	$ (43,205)	$ (46,507)
Denominator:				
Weighted-average shares of common stock outstanding	72,845,869	72,461,850	72,822,890	72,395,410
Net loss per share, basic and diluted	$ (0.30)	$ (0.34)	$ (0.59)	$ (0.64)

Anti-dilutive Outstanding Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share

The following outstanding shares of common stock equivalents were excluded from the computation of the diluted net loss per share for the periods presented because their effect would have been anti-dilutive:

	Three and Six Months Ended June 30,	
	2024	2023
Stock options to purchase common stock	15,256,582	12,962,005
Restricted stock units subject to future vesting	185,416	433,611
Total	15,441,998	13,395,616

~~XML 40 R32.htm IDEA: XBRL DOCUMENT~~

Restructuring and

6 Months Ended

Impairment Charges (Tables) — **Jun. 30, 2024**

Restructuring and Related Activities [Abstract]

Schedule of Accrual Activity and Payments Relating to Restructuring and Impairment Charge

The following table illustrates the accrual activities and payments relating to restructuring and impairment charges (in thousands):

	Severance and related benefit costs	Asset impairments	Total
Balance as of January 1, 2023	$ —	$ —	$ —
Restructuring charges	3,279	2,908	6,187
Cash payments made	(1,858)	—	(1,858)
Non-cash charges	—	(2,908)	(2,908)
Balance as of December 31, 2023	$ 1,421	$ —	$ 1,421
Cash payments made	(775)	—	(775)
Balance as of March 31, 2024	$ 646	$ —	$ 646
Restructuring charges	(67)	1,549	1,482
Cash payments made	(344)	—	(344)
Non-cash charges	—	(1,549)	(1,549)
Balance as of June 30, 2024	$ 235	$ —	$ 235

~~XML 41 R33.htm IDEA: XBRL DOCUMENT~~

Organization and Description of the Business - Additional Information (Details) $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended	31 Months Ended	
	Dec. 31, 2021 USD ($)	Jun. 30, 2024 USD ($) Segment shares	Jun. 30, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($)
Organization And Description Of Business [Line Items]				
Number of operating segments | Segment		1		
Accumulated deficit		$ 393,968	$ 393,968	$ 350,763
ATM Agreement				
Organization And Description Of Business [Line Items]				
Issuance of common stock | shares		0		
ATM Agreement | Cowen and Company LLC				
Organization And Description Of Business [Line Items]				
Percentage of commission on gross sales proceeds of issuance of common stock	3.00%			
Weighted average purchase price, per share | $ / shares			$ 10.98	
Remaining amount with sales agreement		$ 68,300	$ 68,300	
Issuance of common stock | shares			11,986,003	
Net proceeds from the public offering			$ 131,700	
Minimum				
Organization And Description Of Business [Line Items]				
Sufficient cash and cash equivalents available period term		12 months		
Maximum | ATM Agreement | Cowen and Company LLC				
Organization And Description Of Business [Line Items]				
Common stock aggregate offering price	$ 200,000			

~~XML 42 R34.htm IDEA: XBRL DOCUMENT~~

Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	$ 164,064	$ 201,228
Level 1		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	80,047	89,524
Level 2		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	84,017	111,704
Level 3		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	0	0
U.S. Treasury Money Market Funds		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	28,158	35,349
U.S. Treasury Money Market Funds | Level 1		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	28,158	35,349
U.S. Treasury Money Market Funds | Level 2		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	0	0
U.S. Treasury Money Market Funds | Level 3		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	0	0
Certificates Of Deposit		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	533	544
Certificates Of Deposit | Level 1		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	0	0
Certificates Of Deposit | Level 2		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	533	544
Certificates Of Deposit | Level 3		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	0	0
U.S. Treasury Securities		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	51,889	54,175
U.S. Treasury Securities | Level 1		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	51,889	54,175
U.S. Treasury Securities | Level 2		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	0	0
U.S. Treasury Securities | Level 3		

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	0	0
Commercial paper		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	65,494	65,070
Commercial paper | Level 1		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	0	0
Commercial paper | Level 2		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	65,494	65,070
Commercial paper | Level 3		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	0	0
Corporate debt securities		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	10,990	
Corporate debt securities | Level 1		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	0	
Corporate debt securities | Level 2		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	10,990	
Corporate debt securities | Level 3		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	0	
U.S. government agency bonds		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	7,000	46,090
U.S. government agency bonds | Level 1		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	0	0
U.S. government agency bonds | Level 2		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	7,000	46,090
U.S. government agency bonds | Level 3		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Financial Assets	$ 0	$ 0

~~XML 43 R35.htm IDEA: XBRL DOCUMENT~~

Fair Value Measurement - Additional Information (Details) - USD ($) $ in Thousands	**6 Months Ended**		**12 Months Ended**
	Jun. 30, 2024	**Jun. 30, 2023**	**Dec. 31, 2023**
Fair Value Disclosures [Abstract]			
Interest rate of sublease income per year			3.50%
Discount rate of cash flow			13.30%
Impairment charge	$ 1,549	$ 0	$ 2,700
Sublease income	$ 0		

~~XML 44 R36.htm IDEA: XBRL DOCUMENT~~

Available-for-Sale Securities - Summary of Available-For-Sale Securities Recorded in Cash and Cash Equivalents or Marketable Securities (Details) - USD ($) $ in Thousands	**Jun. 30, 2024**	**Dec. 31, 2023**
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Total available-for-sale securities, Amortized Cost	$ 164,188	
Fair Value	164,064	
Fair Value, Measurements, Recurring		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Total available-for-sale securities, Amortized Cost	164,188	$ 201,112
Unrealized Gains	4	219
Unrealized Losses	(128)	(103)
Fair Value	164,064	201,228
Cash	118	144
Total cash, cash equivalent and marketable securities	164,182	201,372
Fair Value, Measurements, Recurring | U.S. Treasury Money Market Funds		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Total available-for-sale securities, Amortized Cost	28,158	35,349
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	28,158	35,349
Fair Value, Measurements, Recurring | Certificates Of Deposit		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Total available-for-sale securities, Amortized Cost	533	544
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	533	544
Fair Value, Measurements, Recurring | U.S. Treasury Securities		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Total available-for-sale securities, Amortized Cost	51,926	54,066
Unrealized Gains	0	151
Unrealized Losses	(37)	(42)
Fair Value	51,889	54,175
Fair Value, Measurements, Recurring | Commercial paper		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Total available-for-sale securities, Amortized Cost	65,572	65,038
Unrealized Gains	3	41
Unrealized Losses	(81)	(9)
Fair Value	65,494	65,070
Fair Value, Measurements, Recurring | Corporate debt securities		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Total available-for-sale securities, Amortized Cost	10,994	
Unrealized Gains	1	

Unrealized Losses	(5)	
Fair Value	10,990	
Fair Value, Measurements, Recurring | U.S. government agency bonds		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Total available-for-sale securities, Amortized Cost	7,005	46,115
Unrealized Gains	0	27
Unrealized Losses	(5)	(52)
Fair Value	$ 7,000	$ 46,090

~~XML 45 R37.htm IDEA: XBRL DOCUMENT~~

Available-for-Sale Securities - Additional Information (Details) - USD ($)	6 Months Ended	
	Jun. 30, 2024	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]		
Allowance for credit losses on securities in unrealized loss position	$ 0	$ 0
Credit-related losses related to marketable securities	0	
Sale of available-for-sale securities	$ 0	

~~XML 46 R38.htm IDEA: XBRL DOCUMENT~~

Available-for-Sale Securities - Summary of Gross Unrealized Losses and Fair Value by Major Security Type for Available-For-Sale Securities in Unrealized Loss Position (Details) - USD ($) $ in Thousands		
	Jun. 30, 2024	Dec. 31, 2023
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Fair Value, Less than 12 months	$ 110,851	$ 76,102
Unrealized Losses, Less than 12 months	(128)	(103)
U.S. Treasury Securities		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Fair Value, Less than 12 months	48,463	16,261
Unrealized Losses, Less than 12 months	(37)	(42)
Commercial paper		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Fair Value, Less than 12 months	47,574	20,789
Unrealized Losses, Less than 12 months	(81)	(9)
Corporate debt securities		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Fair Value, Less than 12 months	7,814	
Unrealized Losses, Less than 12 months	(5)	
U.S. government agency bonds		
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]		
Fair Value, Less than 12 months	7,000	39,052
Unrealized Losses, Less than 12 months	$ (5)	$ (52)

~~XML 47 R39.htm IDEA: XBRL DOCUMENT~~

Available-for-Sale Securities - Summary of Amortized Cost and Estimated Fair Value of Available-for-sale Securities by Contractual Maturity (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Available-for-sale securities maturing, Amortized Cost:	
In one year or less, Amortized Cost	$ 164,188
Total available-for-sale securities, Amortized Cost	164,188
Available-for-sale securities maturing, Estimated Fair Value:	
In one year or less, Estimated Fair Value	164,064
Total available-for-sale securities, Estimated Fair Value	$ 164,064

~~XML 48 R40.htm IDEA: XBRL DOCUMENT~~

Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands		
	Jun. 30, 2024	Dec. 31, 2023
Prepaid Expense, Current [Abstract]		
Receivable from Everest, current (Note 10)	$ 1,312	$ 1,596
Advance for clinical-related costs, current	773	1,818
License, dues and subscription	662	506
Insurance	104	712
Interest receivable	374	695
Others	210	251
Total prepaid expenses and other current assets	$ 3,435	$ 5,578

~~XML 49 R41.htm IDEA: XBRL DOCUMENT~~

Balance Sheet Components - Property and Equipment, Net (Details) - USD ($) $ in Thousands		
	Jun. 30, 2024	Dec. 31, 2023
Property Plant And Equipment [Line Items]		
Total property and equipment	$ 9,332	$ 9,332
Less accumulated depreciation and amortization	(5,941)	(5,420)
Property and equipment, net	3,391	3,912
Leasehold Improvements		
Property Plant And Equipment [Line Items]		
Total property and equipment	3,488	3,488
Furniture, Laboratory and Office Equipment		
Property Plant And Equipment [Line Items]		
Total property and equipment	5,559	5,559
Computer Equipment		
Property Plant And Equipment [Line Items]		
Total property and equipment	$ 285	$ 285

~~XML 50 R42.htm IDEA: XBRL DOCUMENT~~

Balance Sheet Components -	3 Months Ended	6 Months Ended

Additional Information (Details) - USD ($) $ in Millions	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]				
Depreciation expense	$ 0.3	$ 0.2	$ 0.5	$ 0.5

~~XML 51 R43.htm IDEA: XBRL DOCUMENT~~

Balance Sheet Components - Other Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Other Assets [Abstract]		
Advance for clinical related costs, noncurrent	$ 4,670	$ 4,787
Unbilled receivable from Everest, noncurrent (Note 10)	1,099	0
Deposits for operating lease	674	674
Other	79	134
Total other assets	$ 6,522	$ 5,595

~~XML 52 R44.htm IDEA: XBRL DOCUMENT~~

Balance Sheet Components - Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]		
Accrued clinical costs	$ 5,909	$ 1,801
Accrued employee-related costs	1,802	3,708
Accrued preclinical and research costs	1,532	756
Accrued professional services	55	110
Others	65	106
Total accrued liabilities	$ 9,363	$ 6,481

~~XML 53 R45.htm IDEA: XBRL DOCUMENT~~

Lease - Additional Information (Details) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Nov. 01, 2022
Operating lease liability	$ 7,412			
Impairment charge	1,549	$ 0	$ 2,700	
Sublease income	$ 0			
South San Francisco, California [Member]				
Operating lease, option to extend	July 31, 2026			
Operating lease liability				$ 8,000

~~XML 54 R46.htm IDEA: XBRL DOCUMENT~~

Lease - Details of Right-of-Use Assets and Lease Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2024	Dec. 31, 2023
Lessee Disclosure [Abstract]			
Cash paid for operating lease liabilities	$ 741	$ 1,452	
Operating lease costs	655	1,322	
Variable lease costs	467	916	
Less than 12 months	3,957	3,957	
13 - 24 months	4,095	4,095	
25 - 36 months	347	347	
Total undiscounted lease payments	8,399	8,399	
Less: imputed interest	(987)	(987)	
Total lease liabilities	7,412	7,412	
Operating lease liabilities, current	3,260	3,260	$ 3,012
Operating lease liabilities, noncurrent	4,152	4,152	$ 5,852
Total operating lease liabilities	$ 7,412	$ 7,412	

~~XML 55 R47.htm IDEA: XBRL DOCUMENT~~

Debt - Additional Information (Details) - Oxford Finance LLC $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended	
	Nov. 30, 2021 USD ($) Tranche	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)
SOFR					
Debt Instrument [Line Items]					
Line of credit facility, additional interest rate				0.10%	
Loan and Security Agreement					
Debt Instrument [Line Items]					
Line of credit facility, maximum borrowing capacity	$ 50.0				
Number of tranches | Tranche	5				
Line of credit facility, Maturity period	Nov. 01, 2026				
Line of credit facility frequency of payments				monthly interest-only payments	
Line of credit facility, extension period	1 year				
Final payment fee percentage	6.50%				
Interest expense		$ 0.4	$ 0.4	$ 0.8	$ 0.8
Effective interest rate percentage	11.00%				
Loan and Security Agreement | Minimum					
Debt Instrument [Line Items]					
Prepayment fee percentage	1.00%				
Loan and Security Agreement | Maximum					
Debt Instrument [Line Items]					
Prepayment fee percentage	2.00%				
Loan and Security Agreement | Tranche One					
Debt Instrument [Line Items]					
Current borrowing capacity	$ 10.0				
Loan and Security Agreement | Equal To Sum Of A | Floor Rate					
Debt Instrument [Line Items]					
Line of credit facility, additional interest rate	0.08%				
Loan and Security Agreement | Equal To Sum Of B					
Debt Instrument [Line Items]					
Line of credit facility, interest rate	7.87%				

~~XML 56 R48.htm IDEA: XBRL DOCUMENT~~

Debt - Schedule of Long-term Debt Balance (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]		

Principal loan balance	$ 10,000	$ 10,000
Unamortized debt discount and issuance costs	(189)	(243)
Cumulative accretion of final fee	387	312
Debt, current	2,609	0
Debt, noncurrent	7,589	10,069
Total	$ 10,198	$ 10,069

~~XML 57 R49.htm IDEA: XBRL DOCUMENT~~

Debt - Schedule of Estimated Future Principal Payments (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Debt Disclosure [Abstract]	
2024	$ 0
2025	5,217
2026	4,783
Total	$ 10,000

~~XML 58 R50.htm IDEA: XBRL DOCUMENT~~

Pre-Funded Warrants - Additional Information (Details) - $ / shares	Jun. 30, 2024	Dec. 31, 2023	Apr. 30, 2023	Dec. 31, 2022
Class Of Warrant Or Right [Line Items]				
Pre funded warrants exercise price		$ 0.001	$ 0.001	
Pre-funded warrants, term			20 years	
Pre-funded warrants outstanding	0			
Underwritten Public Offering				
Class Of Warrant Or Right [Line Items]				
Pre funded warrants to purchase shares of common stock				3,793,706

~~XML 59 R51.htm IDEA: XBRL DOCUMENT~~

Stock-Based Compensation - Additional Information (Details) - USD ($)	3 Months Ended			6 Months Ended		11 Months Ended		
	Jul. 24, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jan. 01, 2024	Dec. 31, 2023	Jun. 30, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]									
Stock options shares outstanding		15,256,582		15,256,582		15,256,582		13,110,717	
Common stock, shares issued		72,887,538		72,887,538		72,887,538		72,779,077	
Number of options outstanding, Options exercised				0					
Payments of dividends of common stock				$ 0					
Expected dividend yield		0.00%	0.00%	0.00%	0.00%				
Compensation expense related to the unvested option		$ 1,100,000		$ 1,100,000		$ 1,100,000			
Unvested option shares cancelled due to termination						600,000			
Maximum									
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]									
Expected term		6 years 1 month 6 days	6 years 1 month 6 days	6 years 1 month 6 days	6 years 1 month 6 days				
Minimum									
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]									
Expected term		5 years 6 months	5 years 6 months	5 years 6 months	5 years 6 months				
ESPP									
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]									
Expected term				6 months					
Employee Stock Option									
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]									
Unrecognized stock-based compensation cost		$ 20,000,000		$ 20,000,000		$ 20,000,000			
Estimated weighted average amortization period				2 years 8 months 12 days					
RSU Member									
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]									
Number of shares, granted				0					
2022 Stock Inducement Plan									
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]									
Stock options shares outstanding		1,247,708		1,247,708		1,247,708			
Shares granted		3,000,000		3,000,000		3,000,000			
Shares available for future issuance		1,752,292		1,752,292		1,752,292			
2018 Plan									
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]									
Number of stock options exercise price modified	9,904,755								
Modified exercise price	$ 2.28								
Exercise prices, lower range	2.44								
Exercise prices, upper range	$ 22.85								
Stock - based compensation expense						$ 3,000,000			
Incremental fair value	$ 4,700,000								
2018 Equity Incentive Plan									
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]									
Stock options shares outstanding		12,645,480		12,645,480		12,645,480			
Shares available for future issuance		2,843,990		2,843,990		2,843,990			
Number of shares will increase automatically through every year on specified date				--01-01					
Number of shares increase automatically continuing through maximum period				beginning on January 1, 2019 and continuing through and including January 1, 2028					
Weighted average grant date fair value of options granted		$ 0.54		$ 0.67					
2018 Equity Incentive Plan | Common Stock									
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]									

Maximum number of shares authorized available for issuance	1,600,692	1,600,692	1,600,692		
Increase in number of shares reserved for issuance as percentage of total number of shares of capital stock outstanding on last date of preceding calendar year		5.00%			
2018 Equity Incentive Plan | Maximum | Common Stock					
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]					
Maximum number of shares authorized available for issuance	4,000,000	4,000,000	4,000,000		
2018 Equity Incentive Plan | Incentive Stock Options | Maximum | Common Stock					
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]					
Maximum number of shares issued upon exercise of incentive stock options	12,500,000	12,500,000	12,500,000		
2018 Equity Incentive Plan | RSU Member					
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]					
Stock options shares outstanding	185,416	185,416	185,416		
Option grant vesting period		3 years			
2015 Equity Incentive Plan					
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]					
Option grant vesting period		4 years			
Options to purchase of common stock outstanding	1,363,394	1,363,394	1,363,394		
2015 Equity Incentive Plan | Maximum					
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]					
Options granted expiry period		10 years			
2018 Employee Stock Purchase Plan | Common Stock					
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]					
Shares available for future issuance	657,095	657,095	657,095		200,000
Additional shares available for future issuance				0	
Common stock, shares issued	676,129	676,129	676,129		
Authorized an offering beginning period		Nov. 16, 2018			
Authorized an offering ending period		May 15, 2019			
Authorized an additional offering beginning period		May 16, 2024			
2018 Employee Stock Purchase Plan | Maximum | Common Stock					
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]					
Percentage of annual increase in number of common stock shares		1.00%			
Annual increase in number of common stock shares		375,000			
Option price per share of common stock at fair market value		85.00%			

~~XML 60 R52.htm IDEA: XBRL DOCUMENT~~

Stock-Based Compensation - Summary of Activity under Stock Option Plans and Related Information (Details) - USD ($) $ / shares in Units, $ in Thousands	**6 Months Ended** **Jun. 30, 2024**	**12 Months Ended** **Dec. 31, 2023**
Share-Based Payment Arrangement [Abstract]		
Number of options outstanding, Outstanding, Beginning balance	13,110,717	
Number of options outstanding, Options granted	3,541,000	
Number of options outstanding, Options cancelled/forfeited	(1,395,135)	
Number of options outstanding, Outstanding, Ending balance	15,256,582	13,110,717
Number of options outstanding, options vested and exercisable	8,334,868	
Weighted average exercise price, Outstanding, Beginning balance	$ 2.60	
Weighted average exercise price, Options granted	0.9	
Weighted average exercise price, Options cancelled/forfeited	2.84	
Weighted average exercise price, Outstanding, Ending balance	2.18	$ 2.60
Weighted average exercise price, options vested and exercisable	$ 2.58	
Weighted average remaining contractual term, (Years) Outstanding balance	7 years 2 months 12 days	7 years 1 month 6 days
Weighted average remaining contractual term, (Years) options vested and exercisable	5 years 8 months 12 days	
Aggregate intrinsic value, Outstanding, Beginning balance	$ 118	
Aggregate intrinsic value, Outstanding, Ending balance	0	$ 118
Aggregate intrinsic value, options vested and exercisable	$ 0	

~~XML 61 R53.htm IDEA: XBRL DOCUMENT~~

Stock-Based Compensation - Summary of RSU Activity (Details)	**6 Months Ended** **Jun. 30, 2024** **$ / shares shares**
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]	
Weighted average exercise price, Outstanding, Beginning balance	$ 2.60
Weighted average exercise price, Options cancelled/forfeited	2.84
Weighted average exercise price, Outstanding, Ending balance	$ 2.18
RSU Member | 2018 Equity Incentive Plan	
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]	
Number of shares outstanding, beginning balance | shares	219,609
Number of shares, vested | shares	(22,282)
Number of shares, forfeited | shares	(11,911)
Number of shares outstanding, ending balance | shares	185,416
Weighted average exercise price, Outstanding, Beginning balance	$ 9.2
Weighted average exercise price, vested	9.63
Weighted average exercise price, Options cancelled/forfeited	9.26
Weighted average exercise price, Outstanding, Ending balance	$ 9.14

~~XML 62 R54.htm IDEA: XBRL DOCUMENT~~

Stock-Based Compensation - Stock-Based Compensation Expense Recognized (Details) - USD ($) $ in Thousands	**3 Months Ended**		**6 Months Ended**	
	Jun. 30, 2024	**Jun. 30, 2023**	**Jun. 30, 2024**	**Jun. 30, 2023**
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]				
Total stock-based compensation expense	$ 3,085	$ 4,020	$ 6,519	$ 8,283
Research and Development Expense				
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]				
Total stock-based compensation expense	915	2,013	1,971	4,281

General and Administrative Expense				
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]				
Total stock-based compensation expense	$ 2,170	$ 2,007	$ 4,548	$ 4,002

~~XML 63 R55.htm IDEA: XBRL DOCUMENT~~

Stock-Based Compensation - Fair Value of Stock Options Granted is Calculated Using Black Scholes Option Pricing Model with Range of Assumptions (Details)	**3 Months Ended**		**6 Months Ended**	
	Jun. 30, 2024	**Jun. 30, 2023**	**Jun. 30, 2024**	**Jun. 30, 2023**
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]				
Expected volatility, Minimum	86.80%	88.00%	86.80%	87.80%
Expected volatility, Maximum	87.70%	88.30%	87.90%	88.30%
Risk-free interest rate, Minimum	4.30%	3.50%	4.00%	3.50%
Risk-free interest rate, Maximum	4.60%	3.90%	4.60%	4.30%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Minimum				
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]				
Expected term (years)	5 years 6 months	5 years 6 months	5 years 6 months	5 years 6 months
Maximum				
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]				
Expected term (years)	6 years 1 month 6 days	6 years 1 month 6 days	6 years 1 month 6 days	6 years 1 month 6 days

~~XML 64 R56.htm IDEA: XBRL DOCUMENT~~

Everest Collaboration - Additional Information (Details) - USD ($) $ in Thousands	**1 Months Ended**	**3 Months Ended**		**6 Months Ended**	
	Oct. 31, 2023	**Sep. 30, 2023**	**Jun. 30, 2024**	**Sep. 30, 2023**	**Jun. 30, 2024**	**Dec. 31, 2023**
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]						
Reimbursement receivable from collaboration			$ 1,312		$ 1,312	$ 1,596
Everest License Agreement						
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]						
Collaborative arrangement right description		In September 2023, the Company entered into a Collaboration and License Agreement (the “Everest License Agreement”) with Everest pursuant to which, among other things, the Company granted to Everest an exclusive license to develop and commercialize one or more products containing the Company’s proprietary compound, zetomipzomib (the “Products”), in the licensed field in the Greater China region (Mainland China, Taiwan, Hong Kong and Macau), South Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam and the Philippines (the “Territory”).				
Collaborative agreement upfront payments collected	$ 7,000					
Additional milestone payments on achievement	$ 125,500					
Reimbursement receivable from collaboration			1,300		1,300	
Noncurrent unbilled receivable from collaboration			1,100		1,100	
Contra research and development expense			$ 1,600		2,400	
Collaboration Revenue | Everest License Agreement						
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]						
Collaboration revenue				$ 7,000		
Royalty | Everest License Agreement						
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]						
Collaboration revenue					0	
Development, Regulatory and Commercial Milestones | Everest License Agreement						
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]						
Collaboration revenue					$ 0	

~~XML 65 R57.htm IDEA: XBRL DOCUMENT~~

Income Taxes - Additional Information (Details) - USD ($)	**3 Months Ended**		**6 Months Ended**	
	Jun. 30, 2024	**Jun. 30, 2023**	**Jun. 30, 2024**	**Jun. 30, 2023**
Operating Loss Carryforwards [Line Items]				
Provision for income taxes	$ 0	$ 0	$ 0	$ 0
Income tax refunds received			$ 0	$ 1,400,000
U S [Member]				
Operating Loss Carryforwards [Line Items]				
Research and development activities amortize period			5 years	
Non - U S [Member]				

Operating Loss Carryforwards [Line Items]	
Research and development activities amortize period	15 years

~~XML 66 R58.htm IDEA: XBRL DOCUMENT~~

Net Loss Per Share - Calculation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended			
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Numerator:						
Net Income (Loss)	$ (21,547)	$ (21,658)	$ (24,308)	$ (22,199)	$ (43,205)	$ (46,507)
Denominator:						
Weighted-average shares of common stock outstanding	72,845,869		72,461,850		72,822,890	72,395,410
Net loss per common share, Basic	$ (0.3)		$ (0.34)		$ (0.59)	$ (0.64)
Net loss per common share, Diluted	$ (0.3)		$ (0.34)		$ (0.59)	$ (0.64)

~~XML 67 R59.htm IDEA: XBRL DOCUMENT~~

Net Loss Per Share - Anti-dilutive Outstanding Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended		6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]				
Anti-dilutive securities excluded from computation of diluted net loss per share	15,441,998	13,395,616	15,441,998	13,395,616
Stock options to purchase common stock [Member]				
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]				
Anti-dilutive securities excluded from computation of diluted net loss per share	15,256,582	12,962,005	15,256,582	12,962,005
Restricted Stock Units Subject to Future Vesting [Member]				
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]				
Anti-dilutive securities excluded from computation of diluted net loss per share	185,416	433,611	185,416	433,611

~~XML 68 R60.htm IDEA: XBRL DOCUMENT~~

Related Party Transactions - Additional Information (Details) - Chief Executive Officer [Member] - USD ($)	3 Months Ended	6 Months Ended
	Nov. 07, 2023	Jun. 30, 2024	Jun. 30, 2024
Related Party Transaction [Line Items]			
Consulting agreement, effective date	Nov. 07, 2023		
Consultant fee per month			$ 5,000
Compensation expense		$ 15,000	$ 30,000,000

~~XML 69 R61.htm IDEA: XBRL DOCUMENT~~

Restructuring and Impairment Charges - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Mar. 31, 2024	Dec. 31, 2022
Restructuring and Related Activities [Abstract]							
Restructuring and impairment charges	$ 1,482	$ 0	$ 1,482	$ 0	$ 6,200		
Severance and related benefit costs	$ 235		235		1,421	$ 646	$ 0
Impairment charge			$ 1,549	$ 0	$ 2,700		

~~XML 70 R62.htm IDEA: XBRL DOCUMENT~~

Restructuring and Impairement Charges - Schedule of Accrual Activity and Payments Relating to Restructuring and Impairment Charge (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Restructuring Cost and Reserve [Line Items]					
Restructuring Reserve, Beginning Balance	$ 646	$ 1,421	$ 1,421	$ 0	$ 0
Restructuring Charges	1,482				6,187
Impairment charge			1,549	0	2,700
Cash payments made	(344)	(775)			(1,858)
Non-cash charges	(1,549)				(2,908)
Restructuring Reserve, Ending Balance	235	646	235		1,421
Severance and Related Benefit Costs					
Restructuring Cost and Reserve [Line Items]					
Restructuring Reserve, Beginning Balance	646	1,421	1,421	0	0
Restructuring Charges	(67)				3,279
Cash payments made	(344)	(775)			(1,858)
Non-cash charges	0				0
Restructuring Reserve, Ending Balance	235	646	235		1,421
Asset Impairments					
Restructuring Cost and Reserve [Line Items]					
Restructuring Reserve, Beginning Balance	0	0	0	$ 0	0
Restructuring Charges	1,549				2,908
Cash payments made	0	0			0
Non-cash charges	(1,549)				(2,908)
Restructuring Reserve, Ending Balance	$ 0	$ 0	$ 0		$ 0

~~EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-1Y@8BS MXB]9E]\=#'HDR#,EDJH86I!$;?F?O50G8]? =5H*:%5 ORIPVG[!K0J*,V>5 M+2NPKIEBXY$4:R+UMR%-?RC.35$--%&JNW&J)!R-H$Z-KT600Z\HPM*0W*0J M4AMREY:7AS[-?9(MF.39R%+P:IK&"JKDJS*9MB1[Y+U(U2*#U)"'K^LM:&7= M5+IMZA5% W_+TU/BVB>$VG1@:(^/ET_R^2FQ+TSEKYKCUF?.+?+,R7A8OS;=(;*A($Y0=^A;
[(E"_AE#V!!C,L5[XU_^,[Q!]-->-\HI!7L MH(8=8.G-9?*T67(3*5[NV/V/)B2TJB/2L$8:HFV: $]8,-W&;&YBPNMG+,Y, M\)'RSI">364=U@_/7
9"7'U'AP3&!6.7X4GUW=9ZNZ'U'3G/:LZSPSAOHRO@ M,7G$F22WL-,X4.%9;?QHS4Y>^\YKO_'_Q5=W92HBG?:0F/K2F(!]%S7>!MNA) MLC!*YV2Z29Y%;"+"ZI]^?
C0AH44=D1R[>93::*.JQ^L49.M+@K)VTX*=HX/Y?RZP$'KQNWVQ/7[#NV[CA$4K>P*_MVFB-@XK$MD-OHQCTQ@>ZN9#FWL1S[D7:9T$ PBXA)"P#C;S'$!NG,1L'=Y.*
M=Y]P."97>0;',]/NXCE*YD8=P,NZXC66X^":4N'=)%S.]8C["R2H!?%%LF2I MN5\[>@]>UQ6T,1\'%Y9M/RY@2HCBX3'M>,?P':<1'@>WE.TX*Y($IF53)8{O
M)P"KYV;D0ZXR!1,XZ%\C\3H\E&G#(DV_)5B-S^B%1RFU1];*Q-A(CX-[-M2CW_5%R6\WLlO#)2C;U&-CSODW'FZN-57?NRD1\'MY=M7U;/E$>^%%(5.I28 M,@O>GL0VSF,
($6V$B!XD1'KD)_=Y\FP< Z_Va(4]-WSX<#HL'AM5\!&?NA! M\O/$7LA="%T9S:*@?&^"X.*1@L.^ZW]>,Q@:;>8\A0;21((I;2\4[*4-(!R>M M/H"JHQ\2(TBM"=R
-8'XYB07!^!\2V7IAO=QV.ZDC=61_^R(C/YTUH8R'\(M:1XI#E-LVXA[#"FBC131@Z2HQO7UEI#D2:O3(RH>-Q4Y,,>4I>06YD4!*+3I MA/EX2E?
H1I7H0:I40^O1F&OJ!RE6$(Z4[_^^I@S"3(8;RI),F+B M66WS,KRL(Z+;N)&++:TWS1AU&Q"PJI*&=<4]8ZZ0%K^L*V?B1B\O,4Z1__<2, M./3'YY_(E >YA#O22(@GO9[W?&^?@A:2)9-
DQ6)S_ ^^!2=$;57)QK]FRDIN7 M8,'2.6]I&;@GZ'XRO9X5T_PPJZ$.^M?!RG171H("==MX;TI#TTPN53)3>O NMNR?]^L.($VUR-I9-
]7O1XKEY(P$NN7E$F]J#MUZRGA0+M5;S]7*]^SW3KU&PO=V]R:W-H965T&ULM5AM;]LV$/XKA%=L+>#$(]G7-#'0)ABV <6"IMT^TQ(=$Y%$ MEZ22IK]^1]F1,)%24B#
!D)BT[X[/W9%\[GC^(-6=WG!NT/>JK/7%;&/,]FRQ MT/F&5TR?RBVOX9>U5!4S,%6W"[U5G!6M4E4N2!#$BX])>K8\;[^[5LMSV9A2 MU/Q:
(=U4%5./"WDI'RYF>/;TQ6=QNS=YU>?2C/M,N^0TW7[?"F:+SDHA*EYK M(6ND^/IBJ@&?79+$*K02_PC^H _&R+DJRDO+,3OXL+F:!1<+1+GAMK@L'';_D M96DM
8YO>Z.S;DVK>#A^LOY[ZSPXLV*:?\KR7U&8S<4LG:&"KUE3FL_RX0^^ M=RBR]G)9ZO8 >MC+!C.4-]K(:J\,""I1[S[9]WT@#A1P.*)]@KDI0ITKT!; M1W?(6K>NF&'+6EK
M("B\0C+0L M1<$,3#ZRDM4Y1S?6L$8GZ.O-%7K[YAUZ@T2-OFQDHUE=Z/:% 0S6TB+?K_=Q MMQX96>^OICY%-)@C$I#0HWXYK7[%Y]WKV3LR%?:^4]G MK"\OF=X@R!K*
[8!_,\0]*\%Y;O9WIN+6E+T*I5HE&8T4[]M"&?8X0PG<7YBZHX;MBHYTCOOE#""">S'NS$0!]V.;9<$0I$!"7>HXTG4 M7Z1AY0L OIZ8)3%.!A!=.,1+<$613X028:R.29T
)++*?/8AM3NTRWPAIFCFAL? MUL0-)LWP *E*,/$CS/M<*:3,A&E,R(^A:5')@$*4L9)W)]TL"DC:T/;NK& MS(7K"H7)6.ZS#FXV#;?=G.,YSYPUXXB0 3!7*(]RR \,!ST)!2_8EN/0]NI'
M^S'),C(,FT>,;$$SH&, #EL0OXHE2L)4HVQO)2Q9[,Z_$%]JE[=CIGAOQ)!TM M/^2Y;(?T)8]VNO8ZS#Q1#RFP[RX4BF)\$A6>D+#TXP& %4#U8I[]1[DR8N: M.G@RZ]\VI>
(P'4/=TQN>YK?AM7& =?!D@!>T2V24Q,$0M$)KN MKOC*3*-SZ0K 94-TKM0(6>"}TO#/<-ISF?^9#D!3W2!]SP!T22N)4F<'N%(86LZ1;@SW MY(;GV6VW"Y[+ODM?)"-T6#%ZQ"B-
XQ$6(3W-D6"216Z,S.\VLBRXTK^UE8UY M]/<]ZC>0:01O)NS82O6UJUA0"&M=WK07H$GFU M CIXZA3G'*QL>?MD4#Z^1PF9IVDRCVC:RL,T2;)YD"1/"PJM.V)IC#8PL(?V
M%1;WIAN])V=(1M,RQZDYZ'ZG&1Z;F#6' UV,9P=/),.]^L&5 #]BYHV26T0, MR6]2Y#A&?9%|GBDR"@]9 VWBVWX3D0-#?16P&WC!>G6#%$89O&08'QR-*79 M&-
R^NB#3U0741$W5E.TKSXFDA6KL'QI';>S42MVXXH:D#VR.%Z1CH MOKH@7]7%(>B"KT4NO Q#W.KAA&8TBL)&@%"3QV(GIBPWRDF#>RYR+V!/
M&1$%L1M6CUR:1,E88/MZ@TS7&PXKML?MQ? 3YWW'VW9YY+QMU^+@G=(^$G]B MZE;4&FJA-2@&IPD$0.W>77<3([?MT^5*&B.K=KCA#&!; ?A]+:5YFMC7T.[U M>_D?
4$L#!!0 (%F!#5FNSB35ZP(,L) 8 >&PO=V]R:W-H965T M&ULK99=;]HP%(;_BI5-TR9UY L(=!"H;JV29-0T;.+:1=N MCVZW>V[]D+ >AF11$P7+[M7/CG,]^S@BKB&X,-
WFH3F[ME'>V\RF=.IXE @Z)L184+VN8 >?6"3E^:9. M.Z<5;KX_KO,M29>"9%B@\%4H(M+3E+]<',)>54)$ 6UEB3 MW.J0)@,#$LH?T?>D]?$)3K#43UQ#7)8-
S=IYKRLYPSV/FY%#T2>FG43.NRFWCP MA",*1J-H$(X> 7<%1M'8BZ)NWF'+.SR=%SX*/ 0=M=#1 M0>@Y;@"@%'Z]CJGAZ*@:?BYJ!W34@HY. SV]C$=/ELWOKN(C
G>PQRWV^$78 M^^MX (3D,>NAB!U(W_NWH7DOPGRF?!O70['0VI:=VLGML>@+U2MF-"$PQ(U M7B]"L:I/%G7'R*+:G&^EP:V^:F9X&@-E _#^4DKST+'[?7N^B \"4$L#!!0 M (
%F!#5D;;<[].HP0 -<2 8 >&PO=V]R:W-H965T&ULK5AMDYLV$/XK&IKI)#.Y _%F<&W/Q"]ITVG:F[M<\UEG9)L)((]$??WW M70&';5@33WI?S(N??;3/KK2L-#F(XIO<<:[(2MR
MGL$ &U&D3,%CL35E7G 6549I8MJ6Y9LIBS-C-JG>W16SB2A5$F\KB"R3%-6 M #OGB3A,#6[\O+B/MSNE7YBS2S98GBE&7)/M)0G(;IAT 1U+"T1SSA:Z4I&%SV?,&31#.!` \TI$8I
MIC8\O7]A_UB)!S%/3/*%2+[&D=I-C< @$=^P,E'WXO ;;P15#JY%([JM?"@=,8.->.X#8&[K4C>(U! M)=VLM5>!6S+%9I-"$BAT<"F;ZKH5]80KSC3&^5!%?!O#'9]MA!9!&GG8I
M*9(X8@H>'A1<8#XH2<2&)7S@NF\2O+V,6-E% /F';DACP[+\O;-_*&Q!GY MLA.E9%DD)Z8"SS2_N6Z\F-=>V!>\<,AGD:F=)"OP)D+LE\/V_H"[*1%IPV*
MA&5N#Q+^7F;WO/'>$]NR7<2?Q?7F#B;G XV^^N'1SX+AM'/$]?B<"WQ_^K,M MX<^YGBQRC*6X)G%Q$EWPQC)G:SXUH\))7NRY,?OY)^L;OV#Q?4VRY6N2K5Z)
M[":P3;IL)=XA]=@^,K%CO""PS*(=[]/.Y7J58.FHFOV+2GXO]C/IV&$S,_6F< M^RC;"L/P'+7LHQS"5GGJ!6"""ATZ:E%GDKU6LC>P>Q+*L4L@@H82Z5G
MXYYCHFLN[\0%S[>RK(IRKMZ-&@Z"|" M099%K]1@0D>]P6W"";H1E#^*' [;OLHF-AA![7]HSSJ6 $N.6@E!X.2_Q!2 MDDTATA?9\(%Y ;]P6\PO1@,$8S
,,4(;$!RV$H.!R5_RA2*LJB@7UB+%%W" M83]MMC/]:$5 @4\[2OL@UP^!1:L/CS/QU52ZJA56=?I;*8QVA)92*:LCH@% MAG)ZU0I#!5VN%88:>=X%L2=>%K1.VC6/LJL026+
($YG,)N1T)-YN_)G,EXC0:AI@Q. MG;%NN^NW084=5'?]XC O[8 A?GN!?W'7I .-CA#^I=Q4BJT?9\WI-^+@'-= M!%!8/P(H[&(CCT8'6[ME:3Q[=L#U4[2VOY4M2ZEV4$CHH.
<2!9#\R4|S> M"AW9@>L%?MB-%89T?1IXW>\YSFG;0:\6HD@G]%QZX>-.CUT<'6[C7B%H0].K MWX==*AN&Q,.&3^G MXP5%WB_U]4UU,'"DKX]\/D/;&,,&/N$;&,]Z'8&
[17V*4C\HD57'1$1"*9%6 MMSO.(EYH /R_$4*]/.@<!VK.LV7]02P,$% @ 68$-62+G:RT P A@T M !@ !X;"]W;W)K)
[!)39L63:NQ&Q!.^405EY$8@N2E+++Y^$="S6Y:,EH1)RAD29#FUKMSQ?*3Q%>!?2G9RKXVT)PO.[W7G73:U M'+T@4I!4:08,?ULR(T6AB6 9WRH,JYU2&^ZW'!G?
5+Z#+PLLR8P77VBF\]DU MM%!&EGA3[$]\]Y8T_H2:+^6%K'[1KL$Z%DHW4O&R,885E)35 _BAT6'/ 'C, M!EYCX'4-@B<,_;; ?^X,06,0/'>&L#&H7++KWROA$JQP/!%\AX1&
YMN5.I7 MUJ 793I/;I6 KQ3L5#SC+(.HDPQ!2_*"9EA!YU;!'Z2+DH@OX5,)29CK[-@2 M](%+B<[N&-YD%+#GZ
+=W2;HI,4Y>H$H0Y|SOI&897)B*UBAGL=.FJ56T2_1!DR2G)Y8A,#W/29:1(1,'.YH!E>8$#UIEO <"TP6N*X5.LO_@9]NN%U-X:N9P+U7*+PH")($ M=*&*$]/_@^-5!5T!#!C?
\3H2&$!>X'0T. ;YKF/68-AJ,.S5X#-7N$#HM^@HQ4MTE"C^8=!B:?.SI!8,1T3K+$ /+",BX<@T.^6891*\,H5X;#*U)[M;O)R9#R-!]W3V 0+HFY&0)P98X =1-
^@F6!3L;;/:87NOL"R)6%45O828;IBJ MZX9VM'TT7%6U2D1H 'Q?.WJ"]ND5_P)02P,$% @ 68$- M654AR^;"'"0 B%8 !@ !X;"]W;W)KS>O?: $EP#.&N;9//;GPP.
M0E(C;+,W30))Z]!V _V@7\MP!UK57Y]54FWT=;/>-O>C5=L^OYM,FL5*;8KF M;?6LMOH_CU6]*5%)MGZ:-_^U*L;]09OUA,1Q.MD4Y7;T<+? Y\?ZX:[.M>MR MJS[64;//;
(KZ]_=]7;W>CY+1MS_\7#ZMVNX/DX>[Y^))?5+MK\\?:_UNCM^,X].3CF[@=>>OOZG+_<[KG?E<-&I6K?]7+MO5_2@; M14OU6.S6[<_5ZS_4<8=XH]>HULW^9_1ZC(U'T6+7M-
7F,%AOP;;<'GX77X^% M.!N0T L#R'$ Z3N '@=09P"97AC C@.8,X"E%P,PXP#N9KBTT^EQ0+JO_;%8 M^TK/B[9XN*NKUZCNHK5:]V)OUWZT+G"Y[8ZL3VVM_UOJ<>W#K-
HN]7&BEI%^ MU53KVX9>]+=; L%EXV*S:,/2Q MN=\X8/0\//K'Y,+LCNUB'7TLRN58[*L> "[A+1%7M!.+W6:WWE?NIW.E:EW, MC3[15]T9^**B#]M\M5'1FW]53>],]
("_[R\,58[DH6UMDHDT_,4].SL]*KN@ M^KY8%]N%BHI6BR[>1C3Y(2(Q(9!_!Z5TK]1=]UX>2)IG4QW[2X6ZGZDCXI&U2]]]//#7OR1L_'?HL#^(<:N,+*>,Y$XQ,,*3#&))&;YQT[^
ML:!_LZ)9K5731.JK[A=EH[I+F,XS?MSI:]TR>BW]NM!7MF\&0WX&,PSUDWE^_M$D)30IWC>8Z95&""220QRTY^LI.CV G9&%0>:B/W+X*.@=PS>NRS",PMDDAB
MEBWIR98T,.N'IMGM[Q_:C<7A3MQT=^*H22)\U+,,B2REU M)P*8*06FF$02LYS-3LYF06?WD[EQATK+SEY-CTVQ)S#UM7NM(,,RK]Z,I,ZQ M/PNF'5BA>9^,
C.C1!*S/,E/GN1!3PXS^H4UHW_2S!Z]65^8S[_/_0+%SA1W M%DPZU!%,,=%CZR520LN0)#;0&@[,HF?A7$.=0%43 MJ&KR>D5L/\Z:"$E?EOQW49]0B8*V)/\TF!.6N^?',>[\IC|U[_]
EI;*]3-_M$$#H^85 MJ&H22\VVT30&DEZ=@5X=@<2G>+!GLY3'4]HZH)5#6)I6:[9I@^"4/]V@]DDL-=M&]-)F*8'H8)/HC]_MY#U0P=>"4<&/@U !B JA
C%H2\)>PLJA"6"N;$N;8U+0]+(":5Z"]22PUVT9# MQ"1,O!B+4.$4@VWCUZ3;A/$V9>T- 32M0U2CCFN%X0\[8"2S_ND%*@D)9:.[99I
M%!!PLP!]$2N<;_)YG<2=&CBS2M0LPI4-8FE9CML^@@DW$>X93&+^(T$%KN- MKEDX\>!SKT].@9I38JG9UI@6 0FW"&YH\1"@84"]=D$X[V!G4-L%O?9 8N6T MG3%M -!)N
_1]WA"(LAF.,]<-S(7Q.;I;0%63URMB^V';#]17VZ%7NX'X#0*P M+7.,"[9E "VP+0/$ 6T9*"K4EB&&YTDOGA_4E@E+#KY3^RQ^H2V#FE>@JDDL M-?N15]-
VH+W;#NZ2#6@?]!1L$23;E4_NV!Q,H.V.XG2(L[5. B ;GJW0,M,5'U"3>$Y*XMO18M >T.$JRXEV6 "RFW#NHH:@I86>;9M?'.MT#,=O&A_O4ZHB_846K3/XH1R[]-TJ(OVJ&H22\VVT4
^[;UH?YUZ?!R'Z!:8 MM/<.H$,@<D2'S- S&]QH?[5.88?>:5'5!*]:Q%*S'31\S\)\WVM^Q("%<49) M[+F&"O"H:@)536*IV:X9UF>]GZL_[QV#LP/F@W?"XS3SS/.?J_=N+X 69RO/
M'2T!O(VIFU&"43G-TPNS3';V@?8P*E_IL<-U0ET-9SX$ZUF4OJU[G^M$S2M0 MU226FFVCP6H6QNHAL,!\&@5A@?F?
2OV7XG(7Y'+W+'LXW^'STX3U+DZEW,J*2.ZJ:Q%*S#3;DSL+D?DN7G?F<3&-_M@H7Z ?9>.05J3HFE9G^MC6D:\'#3X ;;Y-#ZMMM8":<=:@RJFNBS Q(KI>V+ MZ0+P@%T-
RB/L3SMQ'?<*Y!N!2OZH:O)Z16P_#-/SWE]4=Y5ZN/I8/$B' M0)PW,@08*H$X@ Z!*,"=,@-/?!!WU=WO4ZHB^'<)\+=(B:5Z"J22RU@XV3
ML^_D[+ZC59/,4[EMHK5ZU/+QVZFN5GWXVM/#F[9ZWGl-Y^>]:,O-_N5*%7H6 MU@7H_S[65?OM3??-GZ/G'Q56X)4>!;73%Y-=H]M;N83&2Q)366G_B.,/V?#1)C(G2"X MM$YU-
4%),IW4F++1\M+>NQ7+2[ZHBC)R*X!LZAJ+YQM2\:>K$1RlW/B#/FR5 MN3%97N[P]DCZLON5NAODWV4DM:$2QU]=T-'^-XWCX?5+!)\M> WF
M'DNRXM5 .::FV5Z/Y")1D@YM* -&^??B$=H-$W@E[5_PU-DF(U T4O&Z<]8C MJ"EK/_&WCH@#!QTG{ Z!^.QZ9"<[IR$\#[D(F4WS'9L
MMHZ.XTR4^1YE'DV;Z_)_NOZT14!Q7>0+S@I;$< Z^..NN2Y,=C6FAN@]\,;4 MRH=,K2&#K0<*=D3Z=$_Z-)I::Z*#%A2W39&5 -=<*/I_>R-$8QLN/TBD'$$G
MV0(VR=S)M.BPS@0!VX.>14'?*5Y\'9OV78*"'UUK3R)-X9QZ6:0X7#F#?:(IF MJ8,X.J8S$<_WB.=1Q-<'3]5T6/T3-6UJ;1!Y267!&]M!F>[UXBM1^%|/.TF*
M1M@)%)2)F[F$>HT6"'&8"5FF>.E;KZ.#/I&:QIV;Q+FI**MHQLZAG%D53YE80 MG3,E(-],@26'$T?7%6%2]>4YR"OR$@+|!+'?3)F""%LJF;.=9QGLM#KX5A5!LN M?
[>0(U!3OT8NT,R%&K#*YW.W2L3'9O;U'N00Y\.3E.%_,%5PP"=IFN!EXC^0CI M"7OM"6?O6AM3]IB5PQL6,' @=FQ-62T]5#!CCGMU2V,R|O;1A1;;'J,U;8F
ML]2SG5_DKX;NC&P),NJKT\1-JH" A=.95U\^0L'"7L+"N(8|PO]F!0|]V3G6 MBSGDE=B W2)'J4?"1TA4U$M4%)>HG[']P+Z+!>1+SWDVR|U$")AIIO+$K2[Q
M09Y+0BIG45341556SX)'6NI*>_\<+#%!*]", ,453Y+;,@:IE;Y(O,9>(CY"2] MY2="[ZJS&\KT(NX-=18-)!<[LH:,MAX]VC&GO91%<2EI*WA!2/G2N5[6O7]Z M%;RN!?
I9FIT5T+!2ZSQ2[RK^3$AWDVI+9EZZ@%V%63C_?(V;N\4H9).ZBC\. MXUR:>A6,7M^O]29A*/^")/B"UBQ"@+Z7A(#&G2$7XBID!E&:>51\A!1&O11&\7W8U2GH "N@UXK@GCQ0
MQLR<,,J.",I#+^MND+ _FN:9MT (F&5)YDZN]:MFQVA[D8KB(O55M,0LD:,X M?3&*YFCF58>0&4P6+LZYMZ%VS-HQSEZ,HD6T\=XUNUUE7^,BRFZD5EPVHE5E MC+-
NPW2O2#3HOC12[UAXMH)R%>_- $K,C:LAHZZ&B';]Q[>5O&I> ;U@#F7*# MG1V:X%O85W=C5P$3Z%7:^(C/9:37PFE<"]B ?04:P("9==UGXI(?L3$065 MI'LQLC'RI01/6
A\H@RGO@+V")/-7($<' ZY|/0".8T+Y%/S- AX4$T\:+3U M4-&..3PXZA#7Q+!:LVXUN7;JB;X*Z0(<%=SIS7YB%C%)O8@VJ;R<'QWEJ(A[L ML2@;))UH3[#L[^Z/7EW;
T?._1MXL6H/4/5AVO-4^A2R-1^C*F,54PML\FN381B9W93@O_?K;3AA;E M5<7ZI^'+\SSG\UU]%ZXH>^8I@$ O14[XP$B%^/NFR>,4"LPO: E$!LPI*[*0 M4[8P>"QG3,L,5B7)"B
\HP0QF^,;[L_]11> WYGL.(;8Z0\ M>:+T64UNDX%AJ0-!#K%0"EA^EG #>:Z$Y#'^-H&:U(1-\=K]8GV7?KRA#G< MT/Q/EHAT8%P:*($YKG)O3U??H/"'5WHQS;G^1:L:Z_L&BBLN:-
&0Y0F^C-1? M_-+0^CI8&0+

5K6@@2=MJ MEM!G!YK=45BWYXDH;K>$A^\D\\M(.K;Y;N;XZ5B/6G W9YRGVZDK)XSG|.-G M,$O8?-<8!S/'C6'!75V .'^RUKR+3QKKU5&STJ<6P;NOO_^:.+KL1@QHP#8P% MG4+D62W9-,R-7:,DF#+=] CCH?;FIE9OS]RENWR;$CSCMW?83 MV$7\\M,=C[//DL'*A1J1E(1\.35P/AXC>I^"/8)7\'FMH0;,V7"VR;RM$! M/*R_X("+& &0 'AL M+W=O,"1FB(@$* #'_A5BK7MK1E9LM#Z,VU^3.\& M,2DD1)X3(ZCQI>8Y;$4287 _=<'_G;8^,$+]&Y!?^S=3@[G0U84EFGBYH8&A12A5_^7/NA1W 9 M'R&8U 03KW<0Y+5\RQV_OS5ZS0R=!C=:>%,]-923BH+RZ S>2M"Y^W=<&O8K MSRO!W@MN*R/@<3+6=O1P[,Z<@H]1F!"8PF1QB=L _=:NG>+^GX3F)*/#:DZ' M{(@ !DXJKA+)<\;M%7C 5*$KY9A>LD08!XA@RY:W5/!{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{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|*-9\QXI:ZM_T^[M(#N&Q7)KG5ZWRGA>]R9\BC_; <^@I%/$+"FFKD'] @R'OY3OAQ,V5T3LR+ TT M7OA0O3;<4PTGY=X9O%70W#T+58E[+UTCPZWM12[]7Y=8HIZ2]&CF88,%1 MV<*]#7#I"W_3^DDW,F7!? 5/)ZG^^"YU_]4']ZF9P' M6TN*(LC2N,T/X.7 M=?%'B]| =^5'YD%:AZIR-]W#]H5IH':,SYYJMD$K\Y$T>'19'?0 _K&3L+=]$N-K9 (+.FJ&/ M*TD+7:.E5;,DQW*D+ (E#D'B"8!G!/B{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|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|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|!|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|_MBS&9&.TW(>UPZA\OUC)TD,NM0F#-=V7JAS#VQ">RX(&V")86.0',5 M^ F$O0A6T8BZ<+0:P(MPQ!?GS$/IMTUU3\-! MY.2$NO09DB"3\2I-E"5 !DS" !!8JA6*VA:ZU+E*4\>O 7%9<;ZAQ'"7$KFM:QT$@E'""%A4JB95O9LGR=:.!=+=3O"Y[# M5,BM,:M1&_.JXCP&#W()K&C2U3//#(Y"? S!ZGNIXJZHRG*=@EMV*9Y[\;H) MAF81[T(Y(8@(Y\]Y^\B6VC;@ZRK321IAE$UH'"-1@1I3"#DA!4>Y\G,J\3WR M(FMS'=UOV!#U4[FWSK?$#HX&&L#&BIN0H

*E4QZB,-1US,W8'!*EZ#? MQA^D6G>B?²|52%0XB<7CO%&QI0Z.B !RB*:WHEQX<0QW37]IR*\62-\XH[4* MHUBHA!NSN!WZ,TN- M+&%"EM$'21=F6I/]++VO{#"2Y>2\,,YY:^/G&Z /XJ MC4=3%\U$<0]J+8&O^C#>W M >,S_RR41%S3 CQ?6'"S=$$'=-]U+_X'4$1#!!0 (%F!#5G-5I"^/P4 M *P+ 9 >&PO=VIR:W-H965T)DQ>)2\[E MS.R9(<_WSM^%+5$4] [6QX6*PC;%Y,QX'M:5:AI%KR.*D!f\|=VTIVM('+T);U!(?KLBX_<5@.CANK/5F&WEC MO#QOY(9N*7Y]/GA\C7LKI.{)!NV\L%1=#"ZG;ZX6+)\$?M>T#R=KP9$4SMWQ MQ!OR8C!A&0+1(1;8@<;>C%1G#\A@#'BO9!+5L[\H7^L.NVKK#W!BO9+\=[9N WBQI94/M8? TD/9W.$1;-)-/:E?;%.i<:V#.BZTJ2:ET6(`H3XZTLA9XN++UOD M)GD3&JGH8H N".1W-%@^?S9].3E[N^BO[MXROHWR_&T]G0Z$J<6Q&].--[M M=&HA=+#0^32FT[T,Z"OE/&J73N,61UM/)*0M1=#WHL[E)2ZO0'&H+TX2P6(^ MA{W04.HNXC#B9 A4 QB0Y:\C.S&NSKY6;FZD?;P _-GKV?3561 6 M PBC!E+;;@0*%8!P*W;U36@^C6Y'R6%GH8J=$G"50 &?@&*;#OHC=655M+&5,'D M1R%>)%I) [P!PL>-2*=@AH^25#K*Y8,-K70#TC +F!-2*)1Q0ZR\DZ.5>;P; MW^O2*DI<\[S'32#>IR!0M\G1@7<6AGR+6FDP;.Y4J1+&$P3H;JW$+;G6ZW@0 M/S(O9Y.SU>7ZYC:MIV<_<8U3TW"<*:,HHY'ID?C(#E@TB:#)3,L-$'I)+TVB M1,8>F+B-])$SJ,$?.KK&2+G#+9AL!>K%&P]K2$-FOTD]!*_@@DP]^7G;Y$P7 M,">PKUT9AHP(!$^$= R;4.6(RXNKJ@MM.&2C;_"1\P<%SHI4"I=G;EMIH&-E M:@O<0KINZQ05KE T1?A_!LC*1!=._$W=&'? 3%E3!++NY9]M,B6.2;|:K/L4) MGV*Y'?-?)5KH#-O3Q"M#4&<0,/=;C2*GDIRV3^U*T!#^BP,R%;LG1,?9'N5(M?.K[N9^2X3.QE LNU8.+!Z./RN,+<)Q2B/%6#8LD$8]QI/%9YY/XCI:(%B&9/?3SUW M&%0>A*ZJ,)Z3W>-Y(P_>8<$.$Z3KU8<;?T$VYT(W 7$XPEM>1DB@6PT;I&%H?S^8S%8_^,3/!.OKYEU.L[\8%<^=Z9.F.M7~@=]M= M>_Z^Z4J?CS>]_4=N5@)5EE"@:#@\03,-/UR,W%ZI?4MG+6=/VPQ+\88.@ M[A<;Tf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{)4PA_J C!H2L$'-MW==HH#"Z@4I;,+I&$!8VE<0"WN\QZ[C=X'-1R S-Q!-M=-,*=0"A&%$GE-AXPE:8X(T--Z2,6DRJ$NY*@T@3P4T BP}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{AMM@LY(9 $LK,>%)%[/0$7V9"77J/'4/$,ZA=UW 1X^$$7<(5X(->BE6$3>B M-<;>>*&VCGIPI11@52NS0@I#% 5U#2(Z7\4(#C%R6 L;2Z:PIHK;LC90LOJ(M&58LPV@48VTRHW7;CI;2ERIA[M&J)7?I(A$$% K$>5P8;2O^A'D1 MTL$ 3-'$;6QMEf]4U*;O@[>K8-E*,2\,:,&16"26J[&ND%Q<B!]0B\5I2;'0$?>4NNREC<82QFI&S&+ M0$E&8"#!8;H>?-N)TV]F%CIB9*$*=:RI?S\ICZRM,XKTS":!A%JB4E$QUMY* M1\;T0 _>+5"O>932>>KI%-LD%TH+Z;"0 <|18L&0<%0=RJLAGW4>3KCB9<;20 M-RQ8IA4*"HW;VZ%6**(1+1E"V^^>!!J,#++3S,9%;,FBILFVG ,FISF5,L/E!,ZFNTY:5IAJTX, MN]29"GE;.%EF PV5%'-*> ^R6M-Q4+6FB.0\T(}3G#]Q\EE8ZK.MAY3[5#K9PZ?Y"]J\@\D9 MX0^[X_0]TY@FAVF,TG2/1IR_)R6=/+/4WLWB$[AF0TW]/,\T/OEO[.RL"`ML((/S:S_P!02P,$% @ 68$-6= 0<1U: M"P GB(!D !X;"]W;W)K&ULM5K;;(H&^]~G30SY?6?? 1+Y4*XG/;&/]BL@RA>[IVWZNE;J?2M9TR^&1N72L# M_G2+/=\Y)6N^U#9[A_OI3_9;] M33 XF^8UW>K$,],>>V?-.+M25"N^[2X>_]HJ46K?*>&V-<&K^8G)^\/3BE.IS M@3^T6OG1.T&>S*S]2'^]5],]LD@U;@]D 2)_Z[52]4T) AF?$HR)T4E71R_MSM)?L^_P92.]>FF;?^DZ+%],3B>B5G/9-^&=??U=)7|>D[S*-I[_%.MXIO'Q M1%2]#[9-EV%/]TW\7WY. <1A=,-V_Y\)ANG#(=D=%;.4K&>39O.T68A+V^A**R]^ MR*\>/=\+4$T"!]DYB*],:Q'S1/QU]PL)'4ZMZ_?X>3"YV'V:!+PZW"ORY M-[OB:\]#@R M4B\F:!:OW+6:G'W_W<&3_6=;K#TNUAYODWYV(;WVE++-DFV"C!5N:O'2&@_[M:WYGD]G?1+#X?:E$99%+XU5-K}G^&.NC325EHWPM*[0P,&+!;Q68J:4$8A& MJQW.:6K)RKH:IQ6]/BS%0AGE9-/{(VERR$OG-.1V#3*#NP$6O#>;SER1 M'M3G]]^=`A[N/_OI_/R27QX\>\2FXUK3UX]OO+1M)\T-?7YP\LQG^9X/A]7U MBKS7>&,UM&2)7?1FH.._^I$AHM#>!KYG6MT313\8OZA5KGQ]YXK<862@2-^.'NN MPXWX-=2I4\G2U5(GA\)>6#BB C5=%8T1C6J9D=F:\$L$Q^^^'Z:!W4&Y?&8F M&\GRV5 GC9>,:^/8*A)D. M]ARQ5XYSMD:DB[B0)<_J]4I=J9"#+B ?^B(F/5X8>&4L.&D2,+K<=[DZIM, M&W &)YWZU&L7@T69QD>.]DH'-RDDAU'7GLSLO+!E>N7MF^@30F:>51YN/.A M-W&H<-F. [:11O*LSG5[;DR/$^]49UW8W8('CPL>/-[.MN^+:R^+;R_'KKTN M9ET5LS:AP_]!#9<=M1G7,37RS*.U-'/1 =<5<%U$*>6*6F+!2 6Q ZXX67] X\;S/Y! {(1EUK&EX.AHRM,&5JG>./AA=>!1+VO8. MH[F R]"[;)=&IZ"ZT4G>4|=3L5(%S*5V@X4DG]Y%YX-,+5 2;6>6-0'=MGB);C1A[Y>L.;IEEB-B=RU;/]2)ZPP'T&I M9@VPC ":?9T*C? [1+B-L8\UBIV'>$H,S!8]WX$R9'0^G.7$(8B-[=*D\ 0Z M;X>Z(.6:>;>0@#4C#[K6(8X-]XQY8P#"P B"';O$Z3$D.SS3E44>>]36|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|-&8&U-GR MR.98\$5T3?$,L;>=FBH#*/ZM]5D(CI_8\VLU=EA?8;BC*C0S*QIW%]M],? M $_K.FDlJ52M/WV'Q_%QK&9*_YI!3)W6P9D6 -]MAU8Z.=Y)#@#!\ $FQ; >YV,1=Z&"^)5&8W#LX'S MJ

P$U1];6$";&B3=CB\UZ'ITP3N7S^@_UYV7G?FGDI8\/032}3Z8C 9D 26 MM$C5>[H[_^H.G1N\F*>R_$MV=5EW0.)'"H[5P;H%&//!AU M@'\0$(R/! 1U0' 0,#S6I&$=,'QJD\ JK@++K3M7WDKB0*CJ?",XCPI36;...B M9+ ^,UGRQW R4.R7TMTS'J?DJL:(Y^Y=6JN4)"4'&@FW*>[XD:@WDJI Z2DKR M*IE,$F:^HBFYSJMA:@J^#$%1ELI?R OB$+FF B1A.;? F8,R5?Z8?Z^L,,%U+7 M(&>,T@TWU3MQW0l,0O[/&CI\6'IOC U@!',]0 M[C_0?N5;$4.(STC@O2*^ZWODXUU(7K[XI:]C=I@_BUS#N"7,\ &&W,%*3V55 MZ]#7W1!W5/V*\#'T]%X' ;WNL!DT@S@H<8.G#.++@T\;MD.X+_?Z$|RK2"3 M_ 0-PZJ:87\U)F>_EAL:P(5\ )4>M^<_>2/W5#I,,%"3+' (,"<;R:;#1 M:FA#G{\MLGI0)K7HQ4YHR?(5D=6 E>2_A{';)XX5]U1Q*K#$S\LPLIMNY-W.V M^XQC5A8N?N>!0TQ3]\C!I>1G9>/MR0RY4 .#;@K.&G,H()%F*"14A@'0W& MC0;CY\G<8TRM,,%"3+ (";RCU;31;F*=+]=2%C2/P>3NF&>95DAO3^//.FL? MW1!<62%/U67R*&FI!PD%L[H(";Q#]K0A>_KTY*097O =5!OT!<\V-/]&WKQ9 M!%NA3V5<RP!.L0@+K;..YK6ERGR=MU?4@R86*9*B15AH7<7V;*YGG4^W M&{)D^BJ25],EB\[],]*<"V5I*FY-AO!8X!$FE+L2,+K%;*VV>Y^;)"F&@1%EI7(;]5R+$VEOA LAE=$VX5] MH='IL#6CO6)8:SIY5F&BA37:=-]YN&?JPRTO5]5=,5I#[5D]X/P!F)>,OIO1 MC!=Z!=HQM:ZG"+7MF>VX)U,?/-KYCR:!>[C]/ZU8A-6V+]>M\??LSO>'[D]V MS)/YQ$0+O1X3[4TG(_%:^UMP4]RF+M1!+ M$'JD|!*/:HI1T4+OL2OV F_\>-0CU=KEOC79GMUEW^@TDA59+[NH!AL5+41% MB[#0NA[T)MM(]I? MH=IL5+00%2W"0NLJUEIMS^ZU[XJF>5%GO%],Y;HT?N4% M?"G85B_#YFTIW5*6TOL4S-.(\80H$/T3#=6%?Z?IGD^R\|\EO2*A&G0LM*Y(MK47W}!]AGXU]4WSOV*P,JE]'18NPT+K_,FL=N_],CW!=>RH:"$] M6H2%UE6I=>R^W;$OIK?(=*5GUXHJ:+9KE2OL59]<_CCXCN9:+3%]Y.C-U2L6"Y)"DL= MZIZ-I>Y25(;DP%S9&8^?]02P,$ M% @ 68$-6>(2!RL\" (U, !D !X,"IW;W)K&ULS9QO;YM(S,;_RLI7G5JIC?FS"[B76&H31==3>ZV;MO?B=""^(O4Y0 M;? !3EKJ/OP!=CVL608H@\2;Q(YG'^_.C,G/^P#GCU"\-,F7,F7?-NLPN9C< MI^GVY72;+.[EQD_.HJT,LU=64;SQT^QI?#=-MK'TE\6@S7I]&88SW?A!.)F? M%W_[$,_/HUVZ#D+Y(6;);K/QX^^OY3IZO)8B?J2V CPR2(0A;+U<7DE?GRTN/Q=^B2R ?D\)CEB_E-HJ^YD_>M+"\F1CXCN9:+?;>A:)0fTX_2&"L@H:H4ROM M7>$8U;K#M32.BW>NTA"{419@FV6/JL-)B8|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v/$@YR"$=#]E.;ENY@F-|^\IT?WP5APM9RE8TQ MSG+.B?=W9-P_2;-M<5/#VRA-HTWQ\%[Z?QGG =GKJRA*?SS)[Y-XO"_F_']0 M2P,$% @ 68$-6:Z7:>$& P . H :D !X,"]W;W)K&ULK59,3]LP%/XK5H8F)W-K9>M:R.US="8A(3H8 _3'MSDM+%P M],QV6OCWLY,T%#'!A2'U?)#G?YW. ^X\N9[+BXE1F 0BXE1F QUEDU0 - ,S:RYKE'17;%Q9",!I!T,TQ84XT]<8N133AL:*$P:5 LLQS M+.[G0/ENZO.?N"*;#)E!MQH4N -+$%=%Y=*]]R6)24Y,$DX0P+64V?FC^.1 ML:\,;@CLY$$;F4A6G-^:SGDZ=3SC$%!(E&' ^K>%!5!JB+0;?QM.IUW2_; M>_;S*G8=RPI+6'#ZBZ0JFSJ?'93"&I=47?'==VCB&1B^A%-9?=&NL?4)OJGH#!.!;C M 5T Ej4 G5.%/]%9 MFA*3&S1.:NWG3:0P*$RH_,)/K98Q.3SZ@$T08]GQ4F*6RHf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fO5+1,F4G/17^DHDUZXU_@D&WB\V3<W4DK.(W7/H-_MNZ2//,.41H!6%JK,5H\LE\!.(VY2,_-E>_.N$QM_M@,$N2#9,EM/88!@E>H78#-CP^E4#O(#4#' .\8,&^*4!?DL##AX6SC;+G$)W7:H=":O8'Y3V!R|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|,@DRYC5FW)R(^]BL>]?$,@4)^BR<-\1D]>G\:,^P7RL M55]M8E_6L<,CL2-R*X7)-;D2&63[>!]YM&3"+9G+L-/AUTJZI"F,/;S%&M!0:0.3#NWX4? #XDP'|RMB?'L)5C MV.4]F7!L&52D0+"_2*H *XMP]35*@"6E7P5A@E0">O)GOR!S)]24VM7A(87] ML)$+:,]O6.@EB?[U+N\MBC\NHY3+JY#)UV?<4<&k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{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|"WBDN%9,8[!*YD(\V\-IM>6M(G;XQ?T:Z?=:,)D3A9>"?:.9SB?> MF0<9+DC%)U8?\%&$]##Bl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}I]=F9;403>U69K*$],QS"Q<>PKD![SHV1-WY+SJRGL@ MLI8+?NV"W\<>? 1&:)B1KE@+,DV*MC,%K*))K[O3>U-,Z$'@EI"@UIH MT"OT)3"32'.TSRA&I:XEM&.F-%RMT#=-!5CL[_%1)?TDC!LJ'H93@W1WM7 M5. YW>+#6GS8*W[1Z>\IX=!TP>U3I#YB,.^9.)$MR MEF)-;,#([%SJO3S[+H"!R%HI'14I'SW>-G TI L#D;5<&-TP7/\1*[6W:=G;B8'8VD[+<") M" &0 'AL+W=OJ MN_Y6JD>] C#DJ>[!"# [R5,67/IW6V@H+]CBO!X,M"JH(;O*JEKTL%-'>@@OMA M&%SZ!67"2_I.-E5)7ZX-9P*FBNAU45#U:P1<;@=>U|L)[MER9:S 3_HE7<(_MS&,Y57CS&Y:<%2 TDX(H6 R\8; M0V8L \7?!L-N25"-W[6G%YCT@+W5SVOU:Q<]QC*G&L:2?V.Y60V\X_DI*]K M;N[E@>J>"XL7R:Y=E^RK74#CV1K;611@|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|E+P)57Q7U.MQ.C*===N9--B[W7")MRLH&X#K&PO=V]R:W-H965T7&<";@6A&]]2]I?\#E]N9%WH/'3=L M71K;X6?3FJYA >9+?:VPY7=9"E.:I'$P*HF U\|{"T_G$QKN KPRV>N>9V$J6 M4M[9QH=BY@46"#CDQF:@^':?']}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|-OA'8R)W09)9Z^;]FO\]QU+@LL8&0-++!3!$F=4? >;.]U#FTS-\(;.9Q"R20UOI M, R9'98N)X5+]XA+']UQIF") A9!5(,?->,[;@.!K?,O1'"W(DS<1L;C%V@ MKG..7,?U;@*;_CN\6Y=/,WP&H89WCL*#9OA'OKY 3@%W&\3H5BNBF_-Y1_@^ M#2!"I=D*T?QM4((7A!+U%5?I@LK]4Q+6H_[?D=']L=Y5K\&?:827.L4AC"S=.MZ22(-5CC5R\ZOO.N3LLVR8*6R/9TIBF=O4;=:Y(4$Z%,KD;4Z*ZOOM*!H[M^C9ZWML#?;UG17#V+6;/+=R^5(K1>]O M64X;79RZSMHD'UHBVY/6KZ3UFZ75IX,8S3%#UP*SD,B0GZ,HD1W>48P^G$' MR0+$SSK-&YE/%&':)MFL3,*@);*|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|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|<-:C25M(DQ M H:F_OYK"@6MA28-A^!-(;/;.B?*M5LYP7+)\A^&3,/FT,@O70W':(SK-@<_MU):T@(HC:)HIHJU@>.^V<%1TX>K*-7SP%8AH68.E.9#<0&41E$T4^_;T?&Q MEHX+]72@-:|*"ZTBJ*9,M?&CFMW=FX$Z_"-9>96?QH"X.E$91 M-%.VLAQ[4[.@9Q<>',M0B))D1F4YD-I 91&433SM8': O(<:.

*M(KJN*JI^WP"7FY$?>D\O;MEB:>P+/QNNZ›F8.Y74X4]OV4I6 5",RF(@G+D M78=7X]3&NX!O#*9ZITVLD[F4#[;$]1AY@14$'')C&2@^UC &$BT1ROBUY?3;*
M*2UPM_W$_1%Y1R]SJF$L^7=6F.7(2SU20$EK;F[EYB-I_?0M7RZY=0]DT\0F MB4?R6AM9;<&HH&*B>=+';1YV &'O!4"T!42O!<1;0.R,-LJ@*N(&;RBG M(@=R.@%#&=?O,/Q^-
B&G)^_("6&"W"UEK;DH|- WJ,CR^OEV|IMF|NB%V3_7 MXH+$P1F)@JC7 1\?AT\@1WCHX/%SN(JY.),1M M;Z-PI_WLLM9PI,JYI.F[TBN:P\C#XZ5!K<'+WKX)!\'[+-J/_B>R9[,BU'1|C
MSZ:*B9RM"=<4H&GPBUXE^6&9^!X;'U89V& OZ&_WO7RKZAG(GMNR-Y1D?>" M5E(9]@<+*/*:X3@6NDZR%(;CU"-Z=KLTE1;L2&O;\CZCO,+ __+=P1%O;A; M>+\5WC\]?%O7-
.:>V6&'-RA6XZH7'K&0",UY"9Z+[!T+B--D3VQ$31MU:!ZW6 MP5&M]@"<8=E1"H3ITC4XF#,.!/M9/ QZ8>V35E;R"EE"BB/*DH-)D_[!^AX& MX&ULA53=;ILP%'X5BU53*VV%D$*]C"
US:IMTJ2H:;>+:.1<.G 2KQF;V(;1O M/]L0E*TTS47PL?W]88Z31]I'70 @>2]YT'.O0*QFO]^S DJ]+V4%PJQLI2HI MFE+M?%TIH+D#E=P/@R#V2\]$ER9N;I721-;
(F8"5(KHN2ZJ>%\!E,_=&WF'B MCNT*M\!-^FE1V!OAVJE3.7W++#DK06@F:5PG7O7HIDBMOO=AA\,>T(C;) M1LI'6WS-YUY@#0&'#" H #GELC8^=_
Q>KVD!1Z/#^RW+KO)LJ$:,B3_MR7(LYMZ51W+8TIKCG6R^0)A M"|"&KP#"#A ZWZV0<[FD2--$R88HN]NPV8&+ZM#&'|/\4-:HS"HS.$R7L$'R MD:S-8>DG.SR[^1?%-ICY8 MV
<+'>_X5+ ETQF7VH;X=;W1],Q\'O(8\LU&>:RC3'3%^ M?S>*@T\GG(Y|I^-3[*D-/N2I1<4.97MKGP:)OO\0FO1"D[>$HB&A%A4=*47A M:#JL%?5:T5M:\9!6|$)K,KT:#VO%O59\4NM>
(N5#8O&+-S@*S.|_-?^H> ^Q% M])VJ'1.:<-@:7' Y-6Y5V]QM@:)R#;61:-K3#0MS'X*R&|SZ5DH\%+9'^QLV M_0M02P,$% @ 68$-6?B8S7$P P V X !D !X,"[W;W)K&ULM9==;YLP%
(,_BL6F:9/:0"]ZQ^D-E"MTZ9&K;}>3+MP MX1'L F:V2=[_QL("AMAB>3=)\C. ^]A^CVTX\RUESSP&:@E33*^.&(A\@O3 MY$$,*>8#FD,FGT2415C0\EN;/&>
PU*4)J9M61,SQ20SW'EY,\7<.2U$0C)8 M,<2+-,7L]0H2NET80V-WXXZI8Z%NF.X\QVNX[_&0KYALF0TE)"EDG- .,8@6 MQN7PPI^1^#++@.X$MWI M&:B9/E#ZKQDVX,"PU($@@$(J
Y=\&EI D"B2'\;MF M&DV72KA_O:-?EW.722AB!?&S$ A1+A(Q!W=?H9Z/F/%"VC"RU^T MK6(G,C@HN*!I+98C2$E6_>.7VH<]P7!T0 OM8@5,+G&,%HUHP.E8PK@7E
MU;UJ[5Q\3:4IQ%2YJZ*-TOU=(ODJEU8 9^:,0@Y$X-U9->]Q^DRV6+B!"0H57QE)! MAO\%,8#F0&2 6QK
#JCTQ$(Q30-)5?H?*;'GN2E9O/Z1G+ MTA.8"I#/(TK%KJ%JCZ:8=7\#4$L#*!\0 (.%F!#5D9V5ZNV1$ ([U 9 M ->&PO=V]R:W-H965TM#V3C2MOOOBZKZ@[4[*&H,7<-
)9[8=?,"3ELG$9IL\JH|&, MG^IW;'+^4,6AB@^/>?&CO%>]C(_7:59^O+BOJLW[R\MR>;_6.%<_\PN_)W7W5O'!Y]6$3WZFOJOJVN2GJ9YSF?-UVG_C?1#V6>X)\U.^Y_F/YHE8?;R8--]
(I6I9-8BX_M^+ MNE9IVI#JJ_&/#GKQHMDTW"_3(/V|(^.=_C4EWGZ=*3577_\6)^05;J-MZF MU>_Y(U?=#_.(WC)/RIU_R6/WVMOL$%R&&>C$<: MN%T#JZ"!.SW18-
HUF YM,.I.:S X:G/P-7M? &ZK@=PW\PQ_MGV@0= V"H5MI MWC68#VVPZ!HLAC9P)L]_N9TE+|L_^=K7O-@9[I=^]HF M2=;4Q]>JJ-]-ZG;5U=R[@G9*?F29]5]26BV
M4]N>]M3>WC_7GMG;.XX%<%EOPY<-Z3YOR,^NE2BWZ3OBSMX0=^>).^S;(N>;9 M.S*=[)K/>]J[*PYOW]=-?4X]^39W|FCH_TSRNFT^XV)% M_N^O-9*(2]W+_^_Y/9],_5F_?G,\?
E]NXJ7Z>%$?<$M5/*B+]$_]E^-/_J?/-MU4A8B(11)"QPA@2QI$P@81)$,RHHME+%E2GCC,)G,I4E2!5PX?>BP\]PP_K/?BZWG>7C1W?//LP* MT08*W/D*:S
PLB5>E0U0BIRHI:JU'!5,4R*?M];548ZTLD+$3"J'_T]YP*U*H M-&ZL5^6DNE=DFSVHLGG>=CSZ+&@5&6O!Q=':K!X/-/<^! I2@>*1DA1-E"4 MT4%$B9!,,,ISD2?!)Y8W?O-
=.,SP&P99TN5ILW.]D(@QUH/7^*?R7]H|O6XM>5H MCR-I(91&H,0(2F-0&H?2!)0F432S$EQ=">XKOR_=%T 5%)(60FD42HN@-.;E M<2A-
0&D213,+2L>9CC7GT>/1IB_56P_0//+,M_']RD4W<3_Q^K>*GL M+040B*)<0VD"2I.HFNE'!4(ZJA3R2Y*=[%9!TT8H+832*)0606D, M2N-0FH#2)
(IF5H*.01WOM;M5T.P42@NA- JE15 :@[XE";@-(FBF06E0UW"_MGNJ>[U9!,]LSW\;K^AY^V_?H[U#],H+ ^.B+Z=02#;ED.I0DH3;)HIL=U=NO8 MPUOZ}>:FU|K0T?8OF',GD[YK Z&Z
M=+!N!-5E@W4Y5%= .1)%,PVLDVOW3')=5LEZ=SWKXVZ5A?I[_*'"^$Z1>)T7 M5?+/UL(.521Y[P76=H'1)HL,M872Z)E-Z7:G5>?=>(X[LF8&_K%&)3&H30!
MI4D4S:P6G76[!JS|lZ_?R!?53#7KK01HW VEA5 :A=(B*(U!.1Q*$U";1-', M8M!QM_O:<;<+C;NAM!!*HU!.!*4Q*(U#:0)*DRB:65 Z[G.'3F)NIV]\(7=U M(57]LY7MK-&U
9VO#*51]_R,9:@@@[(XE":@-(FBF8;7V;=KS[+=B>MVIVA% MMMHNVT/&31KWGZN%)N)06@BE42@M@M(8:.A- &E213-+ Z=B+NOG8B[T$0< M2@NA- JE15 :@[XE":@-
(FBF06E$W"7GO/^D>6RI,C1);(XZLDX|BP()H>+ M%4%EZ5#9""K+ALIR]*R TB2*9BZ3](/L]3W(_MJZU#(.L /&.G1Z/,UXVALA M0&7I4-D(*LN&RG*HK(#2)(IF.E1'RE/|K.K.H?
%#*G*3Q]U21V[P@M]MJ6W=*.MFC7@FM4&>GT+#8H[FK&O"3S771RN1 B5I4-E(Z@L&RK+H;("2I,HFNE;G=Q. M[UH977XX9NQXS
M=D%/[(K,V"69LG8R0=EQJ[*C%V6^J^1%$TIU3CRUV\]1[9_*-0>?S^J-D4R1+ M1=;Y*KE-3O3K9T2"^.5B,@L\SSS&7]N_RNAB@:,$4%H$I3$HC4-I DJ3*)I9 M##HGGMJ7A_[2N?S
_;VF;TF+_4NZWKGS0=#@UPHC4)I$93&H#0.I0DH3:)H MIN-UD#L]-V]YW^CE&Y+FC_7A8->7ZK5]BW-SV:'OH2ME;AM A*8U : MA|($E"91--
/W.L^=GIG+?.C[!69C]7UPO+MWW\V/>CC0]!9*HU!.!*4Q*(U# M:0)*DRB:Z7L=U4[MRU&WR=);TG/I?[=]<*_[H?$KE!9";11*BZ TUM'V9Q&<- MR
"@R2]4)E$TT_\Z69W:DU61+8O=2:(X);=Q4I"'- WV>_ YX4>=9T+.UK^V* MH^T,S5.AM A*8U :A|($E"91-//66S]9G=F3V5U^0/^Q3:HGA0N _G_RH$X& M*G;8V'T]E!9";11*BZ
T!J5Q*$U :1)%,WM##A*SUYYG(/&QU!:"*51*"V" MTAB4QJ$T :5)%,TL")U6S^Q!]1^ZU2,TQ.YHVM5<_LR;S0\O#8+JTL&Z$527 M#=;E4%T!I4D4S;2M#I9G]BFQ?
3B(#MVM'6G1W]*=SZ,+A9'SH4FP4-E(Z@L M&RK+H;("2I,HFNG;O1OK#L1YO6P<)FE*DF.86_=52+RM\N9&|^,WOD>U0_)TIGF=?#YFQ;=V!>JFC=WJ7'LN"$77MT MW4###9"B-
GMG*W15=DF7-QJOW-5+.MG&]_W">$'?B+$?=2C+*^S;O,W+]+|\CW3:|-M1K-1DJ/W5" T@H;2.)0HD5]"/HF3V" OOA:BZ[*02!8|'>*=K|&R9;
MYAC8M497G'^4^DW>>>;/#OA@TGN[5](/#CA@T=H;2.)0FH#2)HIE>U[^S[-PT MXE.G8LF_2'=S^J^G[H%L9X_V-C2JAM(HE!9!:0Q*XU":@-(DBF;6BHZJ9Z\]
M]W@&C;6AM!!*HU!.!*4Q*(U#:0)*DRB:65 Z^Y]9L^_NKJ(D.QSRU":_=^[S8 M+0QIGO^RGOB"SC>>]:^,%*^C MBV8 F]9E-
SZI/UG_N*7:O;..4Y6MXF)W8]VO9.R_;&S)0&DAE$8I6G,;Y.U1 MS.3@G,W+-/I++..8IZ/,N?',W;5T>4 #<;A-.JE 1M15 :@[XE";@-(FBF56C@W'OM6IE[4%C=."@MA-(IIE!9!:0Q*XU";@-
(DBF86 ME(IL/7MDCQW/\,5&%|QM#WK79T&*DN'RD906394ED-E!90F4333S3K(]^S1 MLK53I5_8OTU0..Z[!0WQH;002J-06@2E,2B-0VD"2I,HFEE/.MCW7GO-;P^: M[D-
I(91&H;0(2F-0&H?2!)0F432SH'1.]ES^]/=K;9751?/=K,.1-C-JZW? M3EX.6L;2(KVE!(WMO>-EN!W7Z^U!0;/[P;H15)<-UN5070&E213-M+>.YKU? MB.;M=U.QDT>
[%QK,0VD42HN@-.:E<2A-0&D213,K10?SWFL\QXTF(?20BB-_M0FD1E,;@-_ZE"2A-HFAF0>E@WL,O]VU'CBZ1GD!ZJLT<_["_!$W?!ZI&4%4V
M4)5#5064)E$TP["^SMV]>_;>GG[H+M1]4&75Q-^G+X.WT9Z%4H+H31Z9KM- MV_LN]NVZH=^#06D<2A-0FD315$K04;A_-&KW4J^M8(>-+@1HX@VE42@M@M(8 ME,;A-
&E213-+ Z=>/NOG7C[T,0;2@NA- JE15 :@[XE";@-(FBF06E$V_? MGGB/!7=!(VTH+832Z)GM-K/TNZ!!.)3&H30!I4D4S.P$G9;[!K3\.0"O'#OJRCE[?0F-G*"V$TBB4%D%I#$KC4)]
TB2*9I:)CIU] M_[4'$=#P&4H+H30*I450&H/2.)0FH#2)HID%I8-NWQYT_V:NHM'L^YP43[9A M!#3>AM)"*(V>V7+.Q#*.@&;94!J'T@24)E$TLQATENW;UT-OK_I8;]++\23U? M7'OS/*
8N"Z#*76)743:BB-0FD1E,;@- ZE"2A-HFAFR>BTVE^\=H+<,FFU# M:2&41$C"$IC4!J'T@24)E$THZ "G:8'@^Z8]KU@LCB8 MLQU"5>E-U0BJR@:J[5MH1@RET3/\&_YPSOB^&]
(LRAM[_]RT*_#H#0. MI0DH3:)H9G'HJ#BP1\4GBD.URSE9*@..#T-I(91&SVS + _$3<;RV,!:]A0'- ME[$T#J4)*$VB;&9AZ ZL ?09F'$NML_[@ "C:.AM!!*HVA<.K#/HOZ$] 5H\@REA5
.:#8YG04\#[WBE&J@J@[(XE":@-(FB M&<4PUYGR?-_,[4V1+%4S>&\]?U0)<=7>8FD=%S]4U=YJJ:\N[&ICZP)*'Z$T M.N]=N7Q^F$=#11F4Q]$T .5)%*TMB\OR7JDJC*OXZL-:%??
]6]5I65M'U?- MF&3O55*HV|ILG/>?W(O+H]>OG?>AT_/Z==Y\N3:[-L-UCM95HA#? MHKOU>[0P\4O5(WKH[#A1-._G3S%6:P.AQXIK;LKG&O>[SZ)8SM9+8TH60/)=W M-
7F#3Y[PEV10X6\E&Z&Q=X:(1R;H1^0BN:<"9'T9L#!N C2V%L9] 3**N@*T M$(*R'>@5]M#F$;7GK>BC?;PX4I&@C[]KE>A&02[_[@I997_2;=]4Y:4L: QS M1Y>=!'$)WKS
_;IGP>\FS3>38:T1Q_LJM7(] \"5R&"!Q!Q*@$5(IHWA#/U9 M*JDH2U"Y.T-+V*6,Z;$NA(RR&+K,0:3;DB_@?3_QU!>Y^M0'/V,,,*@F_&B M8;P89#1U? OY!@3Z1Y<,#M#U|]+4]
(V&8&9_1"L-U(4S[@-_KM*@P0Z^,9.H TBWT(IM;9ICDGA 2DAZ;5L_ 7TC3E(@R$7P)A'&+< T1.0.05 M*81GM3Y,2%X0XF ZP3T.*#YU.3S81K[&I£],#%[LX0B'SWXI\^?VA%,.9GZIE
MV(DW>;G+AR-_[+5^?8D_-z],3L3[FA-X8CTI?_4F_"W;4[X9?72N9\,0=9M M'5)S$#M[%->.I<]Q?5(?&ULS5A; MCYM&%/XK(Q15B=0LP|6WK8VT-K1-U*BK-=
(^5'V8A6.#%A@R,[8W^^?6=&<3 ! MS*)-2Z2\F+F<[SNWX3#'RQ-E#SP&$.@Q2W.^,F(ABFO3Y&$,&>%7M(!<[NPH MRXB04[8W><& 1!]4I::-\=3,2)(;WE*OW3)O20\B37*X98@?
LHRP3VM(Z6EE M6,9YX2[9QT(MF-ZR('O8@OA0W#(Y,VN6*,D@YPG-$8/=RKBQK@,+*X"6^#.! M$V^,D7+EGM('-7D3K0RL+((40]$HB'P<80-IJIBD'1\K4J/6J8#-\9G]%^V\ M=,:>
<-C0!*D$O*F!LH@ATJ1,*,GGZ#RJ&)X@MIRO4O.E6RVS#A@0N;56!H @M9;DY9,15H%H "1/\^N '87X#X[<"[\UP:,@5PGZMA4@&NTZ+3P3Q MEHRR>$%/2DDT-
=/0U6L8KR=5!V0HF=Q.)$]Y6I/#A]5J&.D(:FLGSQXG.X&OT MY%;P],. [B"D^SSY+/=?^B!(DO)7$O=AZZ.7+UZA%RC)T?N8'CC)(IXTA317
M*37#RK1U:9K]A&D.>D=S$7,4Y!%$/7A_&#\=P)LR3'6Ll'.LUO8@X=M#?H4< M_!.RL>WVV+-Y/MSI<^?_:0_^L_96,)SZX#B:SWF"+\B*E'X"0%M@QR24SY@P M0#W'Y29-
:5@._]@U#\TML(0]82XX>OMWJ0"]$9#Q?_K.2FF VV-^_?]?O"A MK Q9+[DT"0SOOQ^L*?Z\Y+U%CDOECD@4CD;52ZM8!8?8O?=4D!1Q _=K?ZSR& MS3Q"^=KW);:?
DG6I>]6DZ>@Z>3Y;FL1GT2R$7V[@MY%*32?6HBT47 K-[;E3 M"[6C_(06\IL HSM6NS^U!Q[]HV.2^6.2!2.1 MM=(RK=,R_:
[*S'3,E(^)YH])%HQ$UDKIK$|H[!N5F9)WTGCO%U:WRES*V-AR M.E7F4LA:S*Q.E;D4%9F;2-[G$BX847?EH3HS MR/FUAW),,GI,LF DLE9B%G5B%M]5G5F,F=(QR?
POR8*1R%HIM?"7W@9_HTI3 M$3>O&+8UZUQ6-GU2&,\ZQ;9'RIVX]TZUZ9/"V.Z4&[/1Z67]KK%YM*M0R[* MNWN]6K?Q-IIY[:ROK>N-U;/NJ[!9?=Y9?Z,0_#-
X1MD]RCE+82557X:B8K(RO; M\'(B;*'[S'LJ9->JAS&0")@2D/L[2L5YHA34?X9X_P)02P,$% @ 68$- M6?1$=I\F! O!4 !D !X;"]W;W)K&ULQ5A= M;^(X%/TK5E9:S4K3Y@L"
[0)2(9G=64TUJ-?,/JSVP4T,L9K$K&V@_/NUG320 MR E,.VE>(;'N.?:Y]^8FOI,]H<\L18B#ESPKV-1*,=_0.)$!9 M?,=HSTZN@93R1,BS"Q.H8C=X0R%')_<??
#BU0EDDFL8__*E*K?E,"3Z]? MV3\!4+,$V1H0;*_<<+3J36V0O6<)OO!!+_&U6"AI(O)AE3OV!?V3H6B+>. MDI[P"BQWDN"C_X4OEB!. YW< O K@70KP$*;%0 0:7 H850$FW2^W*
<2'D M<#:A9 ^HM!9L\D)Y7Z&%OWA+^614W7"QR?/7(2/U_-A:L3L""YR#\&502O MP">(?^@.LRT"9 64(?BZD3<9^(/"@@L(9F !LWB;03GZQG"Q!O,,"LO'."49 M8A4"+"F.Y[V$?
VV+;^_]'X'G>/-?A:7 MPWV=G/>M'KUY|88S_#K1?,7G=R5;"BD"FD2[HU0F@B@^',P/X-1N"0]^FX/
M:0+^^2(IPG>.RSZ&4C"KR(S(Z()QYE!\^@GM8TS516X65DD=YL=#1K*|_6RH=O4 Y?NI0/|:L8M93K MS<9^2WH'VTU+^EFVAO2@EA[T2G_[/E]11$"6-1\D50<4%'N>P,?
Z';B#%]Z M%GHS?]B2'^CRPQFTU)\E:Z@?U>I';U3?'?R17GW04J\W\UM1#2]CBSK,.H(_MKN6/+\O[!.]P@HH$'##*=&_7^5@3I9;B\R;A>9.HUZ2A\]96>=.KLB>3>X$_M^E8Q21:;)
(L,D36\ISK'CU#G)W\<5!LP%$>C,*%1ML@46S.4)^<)]F*"(8IE M#CX<$*0=`_/|$.@"H" N?HJUX,AW13A^RFB=U$TO>P=O>SU%ZSNET\,\H<+5K]/$'U
MK+OELRZ>^00>]*7+$%%HBB@R0%1ZWS[I1N6(KE4;D(&8; M>]@OJV;K5>*<: M;*WYN7N[<#7SH6Q-JN[7D;IL:]Y#NL8% QE:B;6&PO=V]R:W-H965T&-+OG(:2*RCV3;;
(&F[#KM]H"?&(B)16HIRDF(__YE6;026]6W4^3% MUC6_&7'^XC&V3N^E^]9%C&GRD,0B.VM%6]?'G4X61*RAV8%,F8 S=U(E5,.N MFG6R5+$:%D9)W+&]W6$GH5RTQ]?
%L6LU/I6YCKE@UXID>9)0]7C!8GE_UK): MRP,W?!9ITEW2MN M'FYF2C,VD?&?/-316>NP14)V1_-8W\C|ZR\H8'A!3+.BD]R7U[;9$@SI1, M2F.((.%B\4T?RH98,P#.9@.[-+"?
&&SUT"L->KMZZ)<&_:<&_2T&@])@L*N'-M86DPW-7#J#08%*M5G"6@YT> MNW.F6*8)I#*F4ZEH(9#?R'D89^_@DB^W#GG[^AUY
M3;@@GR.99U2$V6E'0U@&W@G*$"X6(=A;0K#(E10ZRH@K0A9NL'>.[7L_LO>:.MI8<-[AUHSJI-I66;7MB-P$-^/B-[JTWLKMW,$,^DY?R6I6#>W6KN-)O_GHO*.MO+_:W/TY]H|/>?
=;S1T6;&NZ6BIZE;Q[:.^WA;)>Q% ?W_9B0YSE(:L+,6#!494W/6&K]Y M90V[)YN4@0ES,&$N)LS#A/E(L)[^^I6^^DWT\0WCR317V4)#B@6,S^DT9N1. MR80$ZYW])NTTPO?
5#B;,6<"&!/0W7#0X&E87 MU7(X]'(X:,SA<@C\R .88D$O,5.LR.>FC#6B|LT8)LS!A+F8, \3YB/!:DH9 M5DH90O1H,L34%R;,P82YF# /$^8CP6KZ&E7Z&C7V1'6IT#4]*;.B@B56%BB>
M;AM-&N'[;&L#+#0DM GBPOS MK#$K;E;8__FU:%M=T^V]LC%>>OD'2R2=$26EZ4P .<4&.#L!)U"8TD6)& M9/D4H;S(9O#@CTMP@YDDC 5)*E(HE4C*1*AGF@,]A$P
D)@.MUAR9P.W22F>M2Q6$1I1X-+96Y"-OD M.X-U'D^_P\>TUA+7)79YXVVSUC+GRP!#]-&\'R':7E% YJ#@UN90]M^@)N"2V,A/F@*VVTX M*]/'C!OF(":
U,1]*4)HA.+@5[@I09,"94*YCGC,TQ1TD)7NZ#-3BFNI'[>W M=+"!L\&4LHL)\S!A/A*LUMD<5IW-X3Z=3?4@YBG,7>$[H8]F/RMFL2S0&Y?6 M%X?/)F2C;K=;G[5-&@/9=QS"A+F8,
\3YB/!:M(XJ]1QU"B-M>)/PF/H'\U/ M5^FA*"!&'+K%,9/DH^>S=>LP+'+QB#VE04FS,65>9@P'PE6DX75714+N|!R MN=M,WVW>&@DIS2M]@MOQ*ED7U:>WDT\?
RV<]YVL%8JLQYW](&>1*%4.#F'(8 M"\+_D?E&'WMG'1/FE+1:%JSGFWDT\?R6<^O;Z1?-;S MO:J56XVETG%]F78#F18Y(_^2O0IDS3[VSCQ01R5Y]+2/%2:CT6K*VE5%;?Z
M+UTHLU!KYZ@T!Y7FHM(5)]/1:OK,%6YMY1+]_4>2RUZK(U]0:W;H](<5)L; MTH7Y\ZJ3Q^+5E?]BIO-19EQS?RD<;Z<>^1"K76CDIS4&DN^LU#!?E8M+IV
M5A5W;_3B(Q5J7!Z5Y]#27%2:ALTSL6AUG:Y*K=,.U=8?C%285<0)*LU!,8V M-*^DK:^PGBVO?D5-U5H55:WFIJ[SG[W874UXV-J?@:@TEQ4FH=*\
/%H];\>KDJT=O>E!S0;M8R+2G-0:2XJS4.E^5BT MNLY696&[N2R\X#6S-E;+:BE7U2:BTKS2MJP84##(E@L6.EFGQ'.:IU%HFQ6;$:.B4N0#.WTFIESO&0?4JQ_@_4$L# M!!0 (
%F!#5D;_($SD@._(\2 9 >&PO=V]R:W-H965TD%-7N%#ENV>9%+%%WO^/=GZ)(CK="?E(K $WNBYRKB;?2NCSW M?96NH*#]1)3 \&Z]9:F%3NA/AD;N;9Q M,CR"'5!L$Q9|-
S"#/#0G[\4\- M]9J8QG'W^I^;TT>D[FC"B8?\\RO9IX9QJ)8$'7N;X6V]^@3FAH>*G(E?U/ MMI7M$(W3M=*B]}VQ!P7CU2^]KPNQXX"<=H=>[=#[TF'PA$._=N@_-*@=A@\-M-
*P=K"\^U7NMG QU30:2[$ETE@CS5S8ZEMOK:?C9]#<:(E&?KI,,Y340#Y MB]Z#(K=0BRQC1D':DSFOAJ&1\U4,FK)7@NN5[@G/(&QOCIO]1QW^/J;=\-
Y!S'W:ZP3^ON8GI[_\3'1!;]#2 MG(GSW?MMZ7Q;1.2KH^\5HI\;A+!E]9_@_5F"1+'YDKP32I$9E?(!!\"6RDR1 M#^_0FLPU%ICF_ 5>M"-G/=N2I"A,/)S,%<@-*>]/)%,
K>ME7=)2QV'4L< MP?;T&33Z#+KHT944&V:G9U2%L.JUU>;U;1.D8HTLRWPK-E$P]C>[53YH$1^T M2+HL]H(<-DD..Y.<-VF9C]"*X]"3D) ^2MKFBVDG[-AAYQ(6#P_6[O\6X2 P M?
^?5'#45'56\);$\@S7E!M<+:)>X]-75HA67/@2HH60 MFOT++!>5]:OK M11#L_-(HV9 MYSJ62VZTID%OO5C\"6>K 6A#+X^%X&'6W^?1ZI-LT2?9LD^RJ$^R M54]D9\D1-
,D1=!ZMVG6]1Y(fO(?;=T..WWPH'>"\Y5!$0!D3OR HA(6$CWY*_M-[HW3:Z1=J^.$PY;7E<[0 M":]J>;>D/|*#1;/":?UV&F*K@=5'!'E91LMU6YIQ.H8@Q/KQ;KWFV)T^GVM>)4
M9,.61Z^E3)\N(ZU+OY6'*ZU5X.DU"1M-PE_5I"Z\=:J$UZC2Z?BUJH17]=*G MRTCK\B=5M%8_J6*>=$M0+FI*1EC AA=45J5F.IOTVA_*%K,U/[-'2ULS'T%O
M7K72/^BKQAZ[f4U*!&PO M=V]R:W-H965TRH++)N;55[KJR;9EM28GE!:\(@S=K+DJL8"@VM[P$P;D!E87M.4VDEY@R
M*YZ9N7L1SWBM"LK(O4"R+DLL_KXA!=_/+==ZGGB@FZW2$W8\]_"&++(GZ6-T+ M&-D=2TY+PB3E# FRGEO7[E7].AI@)#Y1LI<'STB[LN++\40_>Y7/+T1:1@F1* M4V#XVY$%*0K-
!'9\;4FM3]<&'CX_L]\;Y\&9%99DP8L_;*ZV!2[#"'4SP/1);&MCT@XF^04.*-.%LE0" MWE+]?AWJ,7W7$IT3P1;,K$@Z VZ9HJ^R6E1ZR2B#[62"K.*G%]EIA4Q2 2C0IO!M0^U-"%*:%
M_!D.D$;-S%,@H;;3SEIO;AIOO%>\|=$=9VH+1C"P8 "?G,9')_V1+8+K_<< MWAOO).%O:,M OO,+\APO&+!G<3[<'W+G_VE/_[/V7C#\KM9\P^>_PJ?+JJNJ M\)UPQ'I8HQ8)!Y1U6RN?
W0(S>*5+*/X=JI+$B<+9=]XK6>&, MS"UHK9^(',*B'W]P(^??H02-29:,,29:.1+9=*E,CC%'O<(A'S))>FM_JR_ M^O-V]3-8_85>_17DU*SUH30V%H3& OV]V\5N& 3N=#J9V;O#%
T(^OXTC-RH M+YBP=@+6]B%+3P9MJ9,\DH'1"+%456+; O?.1TIW4ZE$?A\1\H5$8/% M?5+!UQ;WF&3)F&3I2&2]+$5=EJ+OHDJ%8Z9R3++)D3+)T)+)>*B^[5%Y^\SYU M.=!5O#
*)]Y1GQH0]*81;.G#HSYU+F-Z!F,O;),N;).387L@4@F:Z1@T++JC MH[U6]:KOV"#KQO7;:Uf*/%/(*CWA:LUH3>IUC$@;'.Z;%@%S@^Y'K'G6L M,_G2?^=K@F8?G&A+
(C;F*D&"SS53S8&CF+V=ZJ-(?UI_L;I6K@#\XF^WC G M2!?ZYF[D#HL+A=U9O=;@RKFX\&-%W0#!2OS'EZO16< MJ^>:%K&^<L3_ %!+ P04_ !9@0U923,U\>4 !R"0 &0
'AL+W=O M#*$:QBF]G.2__];$-8TA+63,F'8)M[']N\|/NX\6'+O*#, A58T M9W+H9$H59ZXKXPPHEAU>--O4BXH5GHJ9XL!.#$@FCN^IX7NA03YD0#NS81 MT8#/54X83 22+J

G"^`3M=9+]R06:,,@AL-"CR#6U!WQ43HF5NS)(0" MDX0S)" =.N?=LW%H[*W!3P)+N3%&)I(IYX]F<3KVE 6Z.U^R?;.PZEBF6,.+Y+Y*H,.A|<% "*9[GZH8O/T.53]_P MQ3R7]A\M*UO/0?%<*DXKL/. $E8^\;K280/0#7<_K@/P?T=P"""A"\%M"K-M #VK3!F*U6&,%8X&@B^1,-:;S0RLF!:MPR?,'/NM$OHMT3@5W4".%21H@H5Z M0C\$9A+;$Y'H//3I/$F+&.$=7K$PQ(OJ7,J/3-W^%;@*XY4YE$ERR!I $_M;L>'+7A7ZU2+Y;_%NO!;",_Q10=YIR?(I_R@*9YV^)4SC_#=-^*.M}IB//K!\P;Y'C^Z_.E-TI8#*AP8_+TK>7C-51GLL Q#!U=B22(!3C1NS?= MT/O8I-DAR<8'(MO2LU?KV6MCCT;ZH!\5AK 9PC.!H(NC.D&0IF!K&T[FVDU] MMK/.G+-)MS/K6@GV5?! 9%L*]FL%^Z]1$#.%4@!4Z#I"S1?$BR M<4D66C+3=1=1W_.\@;MH4":LE0G_H0S5C5Z6]1=69MR82ZTL^ZH2O@BDNQ5) M&>Y+]\ K?\|"=C>Z% 4QL]U>HIC/F2H;5KU;7RC,.]1U_YJ7MY%K+&9$MZ@< M4@WU.J=:.&%[W!0KW4'M,.-7(A#&0+|/.5?KB=F@OF9%?P!02P,$ M% @ 68$-67U@"FUO P X@X !D !X;"]W:W)K&ULK5=M;].P$/XK5I@02+"9Z.TE;JF78>$-&T;/B ^N.FUI4CL8CLM M_'OL),O;)@N=R)E85F!FF%!C/"SF;OEXR"9$@JW'(D\RS#_M%*:2D)E)A_*HXC=JE!NX M/!+/B[6KM2RQ@"E+OY%0B)B/CTD QK'"">RCNV6T"U'E_S12P5Q2.,5;,6@;)< M2)958!5!1FCYCW]7^['4#SM *<",,< {0F 6P'<4SUX%< [U8-? ?QC0/ , M(*@ P:D)>+BK Q:F RPIP6:A;RE%H&6*)QT/,=HAK;\6F'XJ$*-!*0D)UZMY+ MKMX2A9/C.0"2YV',.:%KA&E,;K(-)EQEIT33!/,U"/0>3>*8Z%S#*;JA9<'H-MS'L3@L0D%6^5R<-]B-Z@S MHS(1;$9CB%OP83<^^!=^WHVWG0X'4VUOO B1@MO/PJ^[X9\QK^%MP2].]^YT*.G6U>(6?.[) MU7(*980HXD^@U6}J&KY/EDJ*W4H_VA+_M*!U^Y ?Z@&8H,C&!GJ2R2 ;\$8 MOWYE!];'ML3HDRSLDVS6)]F\3[+K/LD6/9$=)*-7)Z/?Q=Z2C,3IZ(*HLM M TO6H-YOMV/8N575L$.K:60=6H2GT,S^23-O6@3]VG5H=-VY$2_5K">R M \W6C_,4[-[V +'-(}"+UX='DN@L")*-"9DJV1^0Y,2!;5D0:=D-\=%U290)\5+3_4^ MR<*@6;.^]^%(RJ;1<9DV+9R+1IGV&?BB)(}2N,&M"!4IAI5Q9YQ&PO=V]R:W-H965T8DF>.4.>&9-S%"Y../U.]@A1\"..$K)4]I0>,E25!'L40W*-#RAAWVQQ M&D/*;M.=2@XI@IO<*8Y40]-L-89AHJP6^,.'=+7 1QJ%"7I(3G&,4Q?UBC" MIZ6B*Z\/'L/=GF8/U-7B -'? H"=&OAX>4W:D5RB:,44)"G(4;92*K7[C&V;F MD%O\&:(3.,L&V52^8?P|N[G;+!4M&Q&*4$ S",@^GI&#HBA#8N/XMP15JIB9 MX_GU*[J?3YY-YALDR,'17^&&[I?*3 $;M(7'B# [BTQ=43FB2X04X(OE?<"IM M-04$1T)Q7#JS$<1A4GS"'R419PX,A^]@E Y&V\']Z<3!+!W-H!*MTL(9&F)0. MD[.#W>-@EPYVSGU!5LZT"RE<+5)\ FEFS=*RBSQ=N3N3"SY^^ 0^@# !M?^SQD3 ?LE IFVDV7C4H9{4N9F7TS,H$]SBA>P*\9(,V"]7[&!?\O?%_KHA M %!9BJH\&;]Y6AM"Q%^/R34PM<_ T R+,R!'[*X/4^;N!JJ[_R^Z-]S=Y+$I M=G=14 W>%'!I5C0YGCFH)W.*%Y,;+'*U&X,_?F#VXHR@F_|*KP"W^.#9 M3G!##C|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|!,D33V,TDQP!W=_.UM)7%VO?6T(0/7OISBJIF2+3 MD8KF2D7SI*+YLM":N:UUMSY[U^95IJAUI**Y4M$\J6B^+++1FUFN=K[!)Z]K M7KN:N;-W731Q+YMXI8GH3;80I?DOLE]\&V+Q/KAI+7'$KRI=<;2Q-2T5S9.* MYG/XZ'\E9=3RVA *N8%=:PDBJLK+)]YX**/IE:IWA<-ONXHCC:YSF6B>5#2?1XB@T&NU;(Q1RR-ZUA)7L% ZETW> *C>10% M++#A4S\JGO(A5:'9ZB(`Q-;_*N^>E+5GTGJ_U&T?G(/'U&Z\X?U3# M%\>A[MD/(DP(B-"6A=*NIRS?:7"']+BA^)"?B/F&*<5Q?KE';'5*,PV/_19C M^GJ3!.C.>;W^ U|+ P04 " !9@0U9=N>+#$0# #*% #0 'AL+W-T M>6QE+M[_G!?Z]EW@[FWN_$+"UR2 MT"MZ^1QH2[A{G>9QJ3[FU+V^'G1L@1SS%:X]&9+&LF M=!!RM^4E;U M,.S+9-C/"KFNEHBX@%&F.0N>J1B0$15\K#BP,HSL73A#@0F MA2A4H$V9FE1MB%0O#FZ['E1PK9-S62B;VV5PW^-Z^ ZPZH%|+D1CL$-<8-@O MJ=9,R3O3L8-M\!44U.W"96D<3A5=MCLW9$VP-Y-D7*B4J29-FZQ"P[Y@&=A1 M?#J#NR[*$$"MB]PT4DZGA:36PXI1-XSLA GQ (_WCVQ+>Y%M!)G=,=DTC:&Z MZ61V3<{CKK_RK+!K;)KV:NQ? F\V7B'[ZP#;TWT5@LT4KT1LIOA:_^)?-V DB7^W ML3$ P'8!QOW({|\#-7G1!'L*N8->X)Q)$DP!&K17Z-QC*Q.#!___F!,/210E MB1\!S.\@BC $GD8W'D?A;OW5+C^[^7P-U!+ P04 " !9 M@0U9EXJ[', 3 @ "P %)R96QS+RYR96QSG9*Y;L,P#$! Q="> ,.?0 M(8@S9?$6!/D!5J(/V|(%BD6=OZ ;I7&0"QEY/3P2W!Y10.TXI+ :+J1C|$%)I M6M6X 4BV)8|ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6 MFD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L# M!!0 (%F!#5FC00HB!@4 $,I / >&PO=V]R:VO.VLN>&ULQ9I+ M;lLX$(#_"N%}3]Z"U!7+,(Z0QLFN@:0QXFSVN& DVB8BD09))4U^_0H>DLU MJF O$YIL/4Q_&E'SD4.=/FOS^*#*U(_O>-LI.!FOG-B?#H:W6HN7Y=[T1"HXL MM6FY@TVS&MJ-$;RV:R%F/\31KU*H3F1<,#, MZ@!.!WFA52V4%36#;U8WL@:.FGWA#5>58!%DAD!F1X3)XLG#)L+DSXN7^B MI}6C;:=$1'B)P3Q$RWB3%E9"\/N#*\A4[-S8[A:^2?&V8CP,T+XF9;PQJRX MDJ_A0,CE4V$K(S=A6R_C/#["$OF(%G/1M2TW+T#$%G*E)/R,@WS.JTIW()\8 M$_4-L7"NN&3GC>=8%%]_WPUUN=8J9)B55S_L1EP^$_$_AYLN"-8 M1=48Z M*7J0F&E28M7L[!P&09!_VHU6OP81DTQ*;)EKN+%Q>DDQF:3$-IF*!Q>58,Y(MB:4Q-R*YZD <-?N;^T37OV>8*5)B52R4SS[<>=`V;CHFBHQ8%*CZV8<8$W-(M1NR00_+_$+?8BK.(AFQ1?Q@8"\49H^,V!Z'U/OVCN:8 M4/)W%\J^2..867)RL^S/VV*;N&-,3"\YL5]0&66_GH46M(CU5[7LC?QS3&]Y$?52Q)C8GK)B?6"8O:[)J.7G%@O.&9<(]PQW^3$ MOL$QXRIACADH)S;0P3%%PF#*NHEKUYB!"F(#H9BZAXE9J""V$(+!4U*,B5FH M(+80@GGCUO&PH\ L5!RIV.6C654FOD075MZCYO6?=+3B3;58%R^D%9B%"F(+ M!3"GPD%FLG[}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| 'AL+U]R M96QS+W=O XML 72 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none';Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}} XML 73 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 75 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html2192991false520false6 falsefalseR1.htm100000 - Document - Document and Entity InformationSheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformationDocumentAndEntityInformationCover1 falsefalseR2.htm100010 - Statement - Condensed Consolidated Balance SheetsSheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/RoleStatementCondensedConsolidatedBalanceSheetsCondensed Consolidated Balance SheetsStatements2 falsefalseR3.htm100050 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentheticalCondensed Consolidated Balance Sheets (Parenthetical)Statements3 falsefalseR4.htm100060 - Statement - Condensed Consolidated Statements of Operations (Unaudited)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnauditedCondensed Consolidated Statements of Operations (Unaudited)Statements4 falsefalseR5.htm100070 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLossUnauditedCondensed Consolidated Statements of Comprehensive Loss (Unaudited)Statements5 falsefalseR6.htm100080 - Statement - Condensed Consolidated Statements of Stockholders' EquitySheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityCondensed Consolidated Statements of Stockholders' EquityStatements6 falsefalseR7.htm100100 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnauditedCondensed Consolidated Statements of Cash Flows (Unaudited)Statements7 falsefalseR8.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes8 falsefalseR9.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes9 falsefalseR10.htm995455 - Disclosure - Organization and Description of the BusinessSheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessOrganization and Description of the BusinessNotes10 falsefalseR11.htm995465 - Disclosure - Summary of Significant Accounting PoliciesSheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummary of Significant Accounting PoliciesNotes11 falsefalseR12.htm995475 - Disclosure - Fair Value MeasurementsSheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFair Value MeasurementsNotes12 falsefalseR13.htm995485 - Disclosure - Available-for-Sale SecuritiesSheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureSecuritiesAvailable-for-Sale SecuritiesNotes13 falsefalseR14.htm995495 - Disclosure - Balance Sheet ComponentsSheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetComponentsBalance Sheet ComponentsNotes14 falsefalseR15.htm995505 - Disclosure - LeaseSheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseLeaseNotes15 falsefalseR16.htm995515 - Disclosure - DebtSheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/RoleDisclosureDebt1DebtNotes16 falsefalseR17.htm995525 - Disclosure - Pre-Funded WarrantsSheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosurePreFundedWarrantsPre-Funded WarrantsNotes17 falsefalseR18.htm995535 - Disclosure - Stock-Based CompensationSheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStock-Based CompensationNotes18 falsefalseR19.htm995545 - Disclosure - Everest CollaborationSheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureEverestCollaborationEverest CollaborationNotes19 falsefalseR20.htm995555 - Disclosure - Income TaxesSheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesIncome TaxesNotes20 falsefalseR21.htm995565 - Disclosure - Net Loss Per ShareSheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShare1Net Loss Per ShareNotes21 falsefalseR22.htm995575 - Disclosure - Related Party

TransactionsSheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRelatedPartyTransactionsRelated Party TransactionsNotes22 falsefalseR23.htm995585 - Disclosure - Restructuring and Impairment ChargesSheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentCharges1Restructuring and Impairment ChargesNotes23 falsefalseR24.htm995605 - Disclosure - Summary of Significant Accounting Policies (Policies)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPoliciesSummary of Significant Accounting Policies (Policies)Policieshttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies24 falsefalseR25.htm995615 - Disclosure - Fair Value Measurements (Tables)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsTablesFair Value Measurements (Tables)Tableshttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements25 falsefalseR26.htm995625 - Disclosure - Available-for-Sale Securities (Tables)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesTablesAvailable-for-Sale Securities (Tables)Tableshttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecurities26 falsefalseR27.htm995635 - Disclosure - Balance Sheet Components (Tables)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetComponentsTablesBalance Sheet Components (Tables)Tableshttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetComponents27 falsefalseR28.htm995645 - Disclosure - Lease (Tables)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseTablesLease (Tables)Tableshttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLease28 falsefalseR29.htm995655 - Disclosure - Debt (Tables)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtTablesDebt (Tables)Tableshttp://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebt129 falsefalseR30.htm995675 - Disclosure - Stock-Based Compensation (Tables)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTablesStock-Based Compensation (Tables)Tableshttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation30 falsefalseR31.htm995685 - Disclosure - Net Loss Per Share (Tables)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShareTablesNet Loss Per Share (Tables)Tableshttp://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShare131 falsefalseR32.htm995695 - Disclosure - Restructuring and Impairement Charges (Tables)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairementChargesTablesRestructuring and Impairement Charges (Tables)Tables32 falsefalseR33.htm995705 - Disclosure - Organization and Description of the Business - Additional Information (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetailsOrganization and Description of the Business - Additional Information (Details)Details33 falsefalseR34.htm995715 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetailsFair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details)Details34 falsefalseR35.htm995725 - Disclosure - Fair Value Measurement - Additional Information (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformationDetailsFair Value Measurement - Additional Information (Details)Details35 falsefalseR36.htm995735 - Disclosure - Available-for-Sale Securities - Summary of Available-For-Sale Securities Recorded in Cash and Cash Equivalents or Marketable Securities (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesRecordedInCashAndCashEquivalentsOrMarketableSecuritiesDetailsAvailable-for-Sale Securities - Summary of Available-For-Sale Securities Recorded in Cash and Cash Equivalents or Marketable Securities (Details)Details36 falsefalseR37.htm995745 - Disclosure - Available-for-Sale Securities - Additional Information (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetailsAvailable-for-Sale Securities - Additional Information (Details)Details37 falsefalseR38.htm995755 - Disclosure - Available-for-Sale Securities - Summary of Gross Unrealized Losses and Fair Value by Major Security Type for Available-For-Sale Securities in Unrealized Loss Position (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfGrossUnrealizedLossesAndFairValueByMajorSecurityTypeForAvailableForSaleSecuritiesInUnrealizedLossPositionDetailsAvailable-for-Sale Securities - Summary of Gross Unrealized Losses and Fair Value by Major Security Type for Available-For-Sale Securities in Unrealized Loss Position (Details)Details38 falsefalseR39.htm995775 - Disclosure - Available-for-Sale Securities - Summary of Amortized Cost and Estimated Fair Value of Available-for-sale Securities by Contractual Maturity (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndEstimatedFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetailsAvailable-for-Sale Securities - Summary of Amortized Cost and Estimated Fair Value of Available-for-sale Securities by Contractual Maturity (Details)Details39 falsefalseR40.htm995785 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetailsBalance Sheet Components - Prepaid Expenses and Other Current Assets (Details)Details40 falsefalseR41.htm995795 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetailsBalance Sheet Components - Property and Equipment, Net (Details)Details41 falsefalseR42.htm995805 - Disclosure - Balance Sheet Components - Additional Information (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetailsBalance Sheet Components - Additional Information (Details)Details42 falsefalseR43.htm995815 - Disclosure - Balance Sheet Components - Other Assets (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsOtherAssetsDetailsBalance Sheet Components - Other Assets (Details)Details43 falsefalseR44.htm995825 - Disclosure - Balance Sheet Components - Accrued and Other Current Liabilities (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetailsBalance Sheet Components - Accrued and Other Current Liabilities (Details)Details44 falsefalseR45.htm995835 - Disclosure - Lease - Additional Information (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseAdditionalInformationDetailsLease - Additional Information (Details)Details45 falsefalseR46.htm995845 - Disclosure - Lease - Details of Right-of-Use Assets and Lease Liabilities (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseDetailsOfRightOfUseAssetsAndLeaseLiabilitiesDetailsLease - Details of Right-of-Use Assets and Lease Liabilities (Details)Details46 falsefalseR47.htm995855 - Disclosure - Debt - Additional Information (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetailsDebt - Additional Information (Details)Details47 falsefalseR48.htm995865 - Disclosure - Debt - Schedule of Long-term Debt Balance (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtScheduleOfLongtermDebtBalanceDetailsDebt - Schedule of Long-term Debt Balance (Details)Details48 falsefalseR49.htm995875 - Disclosure - Debt - Schedule of Estimated Future Principal Payments (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetailsDebt - Schedule of Estimated Future Principal Payments (Details)Details49 falsefalseR50.htm995885 - Disclosure - Pre-Funded Warrants - Additional Information (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosurePreFundedWarrantsAdditionalInformationDetailsPre-Funded Warrants - Additional Information (Details)Details50 falsefalseR51.htm995895 - Disclosure - Stock-Based Compensation - Additional Information (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetailsStock-Based Compensation - Additional Information (Details)Details51 falsefalseR52.htm995905 - Disclosure - Stock-Based Compensation - Summary of Activity under Stock Option Plans and Related Information (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderStockOptionPlansAndRelatedInformationDetailsStock-Based Compensation - Summary of Activity under Stock Option Plans and Related Information (Details)Details52 falsefalseR53.htm995915 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetailsStock-Based Compensation - Summary of RSU Activity (Details)Details53 falsefalseR54.htm995925 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense Recognized (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetailsStock-Based Compensation - Stock-Based Compensation Expense Recognized (Details)Details54 falsefalseR55.htm995935 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options Granted is Calculated Using Black Scholes Option Pricing Model with Range of Assumptions (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedIsCalculatedUsingBlackScholesOptionPricingModelWithRangeOfAssumptionsDetailsStock-Based Compensation - Fair Value of Stock Options Granted is Calculated Using Black Scholes Option Pricing Model with Range of Assumptions (Details)Details55 falsefalseR56.htm995945 - Disclosure - Everest Collaboration - Additional Information (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureEverestCollaborationAdditionalInformationDetailsEverest Collaboration - Additional Information (Details)Details56 falsefalseR57.htm995955 - Disclosure - Income Taxes - Additional Information (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetailsIncome Taxes - Additional Information (Details)Details57 falsefalseR58.htm995965 - Disclosure - Net Loss Per Share - Calculation of Basic and Diluted Net Loss Per Share (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareDetailsNet Loss Per Share - Calculation of Basic and Diluted Net Loss Per Share (Details)Details58 falsefalseR59.htm995975 - Disclosure - Net Loss Per Share - Anti-dilutive Outstanding Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShareAntidilutiveOutstandingSharesOfCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareDetailsNet Loss Per Share - Anti-dilutive Outstanding Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share (Details)Details59 falsefalseR60.htm995985 - Disclosure - Related Party Transactions - Additional Information (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetailsRelated Party Transactions - Additional Information (Details)Details60 falsefalseR61.htm996005 - Disclosure - Restructuring and Impairment Charges - Additional Information (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentChargesAdditionalInformationDetailsRestructuring and Impairment Charges - Additional Information (Details)Details61 falsefalseR62.htm996015 - Disclosure - Restructuring and Impairement Charges - Schedule of Accrual Activity and Payments Relating to Restructuring and Impairment Charge (Details)Sheethttp://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairementChargesScheduleOfAccrualActivityAndPaymentsRelatingToRestructuringAndImpairmentChargeDetailsRestructuring and Impairement Charges - Schedule of Accrual Activity and Payments Relating to Restructuring and Impairment Charge (Details)Details62 falsefalseAll ReportsBookAll Reports kzr-20240630.htmkzr-20240630.xsd img40159629_0.jpg http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024falsefalse JSON 77 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "kzr-20240630.htm": { "nsprefix": "kzr", "nsuri": "http://www.kezarlifesciences.com/20240630", "dts": { "inline": { "local": ["kzr-20240630.htm"] }, "schema": { "local": ["kzr-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 236, "keyCustom": 63, "axisStandard": 20, "axisCustom": 0, "memberStandard": 29, "memberCustom": 22, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 219, "entityCount": 1, "segmentCount": 52, "elementCount": 600, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 654, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-

19e2-49f5-a983-aa6298898506", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "100050 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "longName": "100060 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_0df6afe8-eb4b-4efd-9b99-8ad8238e551a", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0df6afe8-eb4b-4efd-9b99-8ad8238e551a", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "longName": "100070 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_0df6afe8-eb4b-4efd-9b99-8ad8238e551a", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_0df6afe8-eb4b-4efd-9b99-8ad8238e551a", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "unique": true } }, "R6": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity", "longName": "100080 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_5e721df8-6d62-4b3c-8eb9-df753f4eece5", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_40e725d3-91ca-4a02-bd6f-36fdf298b3f2", "name": "kzr:StockIssuedDuringPeriodSharesCashlessExerciseOfPrefundedWarrants", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "unique": true } }, "R7": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "longName": "100100 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_0df6afe8-eb4b-4efd-9b99-8ad8238e551a", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_0df6afe8-eb4b-4efd-9b99-8ad8238e551a", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0df6afe8-eb4b-4efd-9b99-8ad8238e551a", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness", "longName": "995455 - Disclosure - Organization and Description of the Business", "shortName": "Organization and Description of the Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995465 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements", "longName": "995475 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecurities", "longName": "995485 - Disclosure - Available-for-Sale Securities", "shortName": "Available-for-Sale Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "kzr:AvailableForSaleSecuritiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "kzr:AvailableForSaleSecuritiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetComponents", "longName": "995495 - Disclosure - Balance Sheet Components", "shortName": "Balance Sheet Components", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLease", "longName": "995505 - Disclosure - Lease", "shortName": "Lease", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebt1", "longName": "995515 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosurePreFundedWarrants", "longName": "995525 - Disclosure - Pre-Funded Warrants", "shortName": "Pre-Funded Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation", "longName": "995535 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureEverestCollaboration", "longName": "995545 - Disclosure - Everest Collaboration", "shortName": "Everest Collaboration", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxes", "longName": "995555 - Disclosure - Income Taxes", "shortName": "Income Taxes",

```
"isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShare1", "longName": "995565 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRelatedPartyTransactions", "longName": "995575 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentCharges1", "longName": "995585 - Disclosure - Restructuring and Impairment Charges", "shortName": "Restructuring and Impairment Charges", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995605 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "longName": "995615 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesTables", "longName": "995625 - Disclosure - Available-for-Sale Securities (Tables)", "shortName": "Available-for-Sale Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "kzr:AvailableForSaleSecuritiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "kzr:AvailableForSaleSecuritiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables", "longName": "995635 - Disclosure - Balance Sheet Components (Tables)", "shortName": "Balance Sheet Components (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseTables", "longName": "995645 - Disclosure - Lease (Tables)", "shortName": "Lease (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "kzr:ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "kzr:ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtTables", "longName": "995655 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "longName": "995675 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShareTables", "longName": "995685 - Disclosure - Net Loss Per Share (Tables)", "shortName": "Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentChargesTables", "longName": "995695 - Disclosure - Restructuring and Impairment Charges (Tables)", "shortName": "Restructuring and Impairment Charges (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails", "longName": "995705 - Disclosure - Organization and Description of the Business - Additional Information (Details)", "shortName": "Organization and Description of the Business - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "U_Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "U_Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails", "longName": "995715 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details)", "shortName": "Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_206412a6-dcde-42a4-a588-cf49af9ae635", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_206412a6-dcde-42a4-a588-cf49af9ae635", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformationDetails", "longName": "995725 - Disclosure - Fair Value Measurement - Additional Information (Details)", "shortName": "Fair Value Measurement - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_3d87c4de-c3c5-4313-84ad-8cafd568412a", "name": "kzr:InterestRateOfSubleaseIncomePerYear", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3d87c4de-c3c5-4313-84ad-8cafd568412a", "name": "kzr:InterestRateOfSubleaseIncomePerYear", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesRecordedInCashAndCashEquivalen "longName": "995735 - Disclosure - Available-for-Sale Securities - Summary of Available-For-Sale Securities Recorded in Cash and Cash Equivalents or Marketable Securities
```

(Details)", "shortName": "Available-for-Sale Securities - Summary of Available-For-Sale Securities Recorded in Cash and Cash Equivalents or Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "div", "kzr:AvailableForSaleSecuritiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_206412a6-dcde-42a4-a588-cf49af9ae635", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div", "kzr:AvailableForSaleSecuritiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "unique": true } }, "R37": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetails", "longName": "995745 - Disclosure - Available-for-Sale Securities - Additional Information (Details)", "shortName": "Available-for-Sale Securities - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "kzr:AvailableForSaleSecuritiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "kzr:AvailableForSaleSecuritiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfGrossUnrealizedLossesAndFairValueByMajorSecurityTypeFor", "longName": "995755 - Disclosure - Available-for-Sale Securities - Summary of Gross Unrealized Losses and Fair Value by Major Security Type for Available-For-Sale Securities in Unrealized Loss Position (Details)", "shortName": "Available-for-Sale Securities - Summary of Gross Unrealized Losses and Fair Value by Major Security Type for Available-For-Sale Securities in Unrealized Loss Position (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "div", "kzr:AvailableForSaleSecuritiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "div", "kzr:AvailableForSaleSecuritiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndEstimatedFairValueOfAvailableForSaleSecu "longName": "995775 - Disclosure - Available-for-Sale Securities - Summary of Amortized Cost and Estimated Fair Value of Available-for-sale Securities by Contractual Maturity (Details)", "shortName": "Available-for-Sale Securities - Summary of Amortized Cost and Estimated Fair Value of Available-for-sale Securities by Contractual Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "div", "kzr:AvailableForSaleSecuritiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "div", "kzr:AvailableForSaleSecuritiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails", "longName": "995785 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)", "shortName": "Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "kzr:ReceivableFromCollaboration", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "kzr:PrepaidAdvanceForClinicalRelatedCostsCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "unique": true } }, "R41": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails", "longName": "995795 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details)", "shortName": "Balance Sheet Components - Property and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "longName": "995805 - Disclosure - Balance Sheet Components - Additional Information (Details)", "shortName": "Balance Sheet Components - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_0df6afe8-eb4b-4efd-9b99-8ad8238e551a", "name": "us-gaap:Depreciation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0df6afe8-eb4b-4efd-9b99-8ad8238e551a", "name": "us-gaap:Depreciation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsOtherAssetsDetails", "longName": "995815 - Disclosure - Balance Sheet Components - Other Assets (Details)", "shortName": "Balance Sheet Components - Other Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "kzr:OtherAssetsAdvanceForClinicalRelatedCostsNonCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "kzr:OtherAssetsAdvanceForClinicalRelatedCostsNonCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails", "longName": "995825 - Disclosure - Balance Sheet Components - Accrued and Other Current Liabilities (Details)", "shortName": "Balance Sheet Components - Accrued and Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "kzr:AccruedClinicalCostsCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "kzr:ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "kzr:AccruedClinicalCostsCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "kzr:ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseAdditionalInformationDetails", "longName": "995835 - Disclosure - Lease - Additional Information (Details)", "shortName": "Lease - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "kzr:ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_5e45da79-04a6-4218-b79a-412ce07df47e", "name": "us-gaap:LesseeOperatingLeaseOptionToExtend", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "unique": true } }, "R46": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseDetailsOfRightOfUseAssetsAndLeaseLiabilitiesDetails", "longName": "995845 - Disclosure - Lease - Details of Right-of-Use Assets and Lease Liabilities (Details)", "shortName": "Lease - Details of Right-of-Use Assets and Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_0df6afe8-eb4b-4efd-9b99-8ad8238e551a", "name": "us-gaap:OperatingLeasePayments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "kzr:ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0df6afe8-eb4b-4efd-9b99-8ad8238e551a", "name": "us-gaap:OperatingLeasePayments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "kzr:ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "longName": "995855 - Disclosure - Debt - Additional Information (Details)", "shortName": "Debt - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_d5ec09ce-9931-4f75-a42d-b992c7319450", "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d5ec09ce-9931-4f75-a42d-b992c7319450", "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtScheduleOfLongtermDebtBalanceDetails", "longName": "995865 - Disclosure - Debt - Schedule of Long-term Debt Balance (Details)", "shortName": "Debt - Schedule of Long-term Debt Balance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails", "longName": "995875 - Disclosure - Debt - Schedule of Estimated Future Principal Payments (Details)", "shortName": "Debt - Schedule of Estimated Future Principal Payments (Details)", "isDefault": "false",

```
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosurePreFundedWarrantsAdditionalInformationDetails", "longName": "995885 - Disclosure - Pre-Funded Warrants - Additional Information (Details)", "shortName": "Pre-Funded Warrants - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_83050768-cf70-4770-84c7-b7df9d3ad565", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83050768-cf70-4770-84c7-b7df9d3ad565", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "longName": "995895 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "shortName": "Stock-Based Compensation - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "unique": true } }, "R52": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderStockOptionPlansAndRelatedInformationDetails", "longName": "995905 - Disclosure - Stock-Based Compensation - Summary of Activity under Stock Option Plans and Related Information (Details)", "shortName": "Stock-Based Compensation - Summary of Activity under Stock Option Plans and Related Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_83050768-cf70-4770-84c7-b7df9d3ad565", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_1673a714-19e2-49f5-a983-aa6298898506", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "unique": true } }, "R53": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails", "longName": "995915 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)", "shortName": "Stock-Based Compensation - Summary of RSU Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_83050768-cf70-4770-84c7-b7df9d3ad565", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d0a4a4d8-f24c-488c-bdb7-f3ca0bba11d2", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "unique": true } }, "R54": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails", "longName": "995925 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense Recognized (Details)", "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense Recognized (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_0df6afe8-eb4b-4efd-9b99-8ad8238e551a", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0df6afe8-eb4b-4efd-9b99-8ad8238e551a", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedIsCalculatedUsingBlackScholesOptionPr
"longName": "995935 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options Granted is Calculated Using Black Scholes Option Pricing Model with Range of Assumptions (Details)", "shortName": "Stock-Based Compensation - Fair Value of Stock Options Granted is Calculated Using Black Scholes Option Pricing Model with Range of Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_0df6afe8-eb4b-4efd-9b99-8ad8238e551a", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0df6afe8-eb4b-4efd-9b99-8ad8238e551a", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureEverestCollaborationAdditionalInformationDetails", "longName": "995945 - Disclosure - Everest Collaboration - Additional Information (Details)", "shortName": "Everest Collaboration - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C_75eba55e-eb71-4385-acc5-ce7b8a83cd33", "name": "kzr:ReceivableFromCollaboration", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_ae15ef1b-995f-44a4-bc37-db5122ab6468", "name": "us-gaap:CollaborativeArrangementRightsAndObligations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "unique": true } }, "R57": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "longName": "995955 - Disclosure - Income Taxes - Additional Information (Details)", "shortName": "Income Taxes - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_0df6afe8-eb4b-4efd-9b99-8ad8238e551a", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0df6afe8-eb4b-4efd-9b99-8ad8238e551a", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareDetails", "longName": "995965 - Disclosure - Net Loss Per Share - Calculation of Basic and Diluted Net Loss Per Share (Details)", "shortName": "Net Loss Per Share - Calculation of Basic and Diluted Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_0df6afe8-eb4b-4efd-9b99-8ad8238e551a", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true }, "uniqueAnchor": null }, "R59": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShareAntidilutiveOutstandingSharesOfCommonStockEquivalentsExcludedFromComputationO
"longName": "995975 - Disclosure - Net Loss Per Share - Anti-dilutive Outstanding Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share (Details)", "shortName": "Net Loss Per Share - Anti-dilutive Outstanding Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_0df6afe8-eb4b-4efd-9b99-8ad8238e551a", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0df6afe8-eb4b-4efd-9b99-8ad8238e551a", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "longName": "995985 - Disclosure - Related Party Transactions - Additional Information (Details)", "shortName": "Related Party Transactions - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C_f8754889-65e3-42bb-a060-510ef73b3d34", "name": "kzr:ConsultingAgreementEffectiveDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "ix:continuation", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f8754889-65e3-42bb-a060-510ef73b3d34", "name": "kzr:ConsultingAgreementEffectiveDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "ix:continuation", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentChargesAdditionalInformationDetails", "longName": "996005 - Disclosure - Restructuring and Impairment Charges - Additional Information (Details)", "shortName": "Restructuring and Impairment Charges - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "C_0df6afe8-eb4b-4efd-9b99-8ad8238e551a", "name": "us-gaap:RestructuringCostsAndAssetImpairmentCharges", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3d87c4de-c3c5-4313-84ad-8cafd568412a", "name": "us-gaap:RestructuringCostsAndAssetImpairmentCharges", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "kzr-20240630.htm", "unique": true } },
```

"R62": { "role":
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentChargesScheduleOfAccrualActivityAndPaymentsRelatingToRestructuringA
"longName": "996015 - Disclosure - Restructuring and Impairment Charges - Schedule of Accrual Activity and Payments Relating to Restructuring and Impairment Charge
(Details)", "shortName": "Restructuring and Impairment Charges - Schedule of Accrual Activity and Payments Relating to Restructuring and Impairment Charge (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "C_4ad8b40a-910a-40ae-b033-
d4e5cac024d7", "name": "us-gaap:RestructuringReserve", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "div", "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "div", "body", "html"],
"reportCount": 1, "baseRef": "kzr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_0df6afe8-eb4b-4efd-9b99-8ad8238e551a", "name": "us-
gaap:RestructuringCharges", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "div", "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "div", "body", "html"],
"reportCount": 1, "baseRef": "kzr-20240630.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit",
"presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label":
"Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total", "documentation": "Carrying value as of the balance sheet date
of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to
reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r45", "r734"] }, "us-
gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label":
"Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Amortization of premiums and discounts on marketable securities", "documentation":
"The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the
security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash
provided by or used in operations using the indirect method." } } }, "auth_ref": ["r72"] }, "kzr_AccruedClinicalCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.kezarlifesciences.com/20240630", "localname": "AccruedClinicalCostsCurrent", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role":
{ "documentation": "Accrued clinical costs, current.", "label": "Accrued Clinical Costs Current", "terseLabel": "Accrued clinical costs" } } }, "auth_ref": [] },
"kzr_AccruedLiabilitiesAndOtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname":
"AccruedLiabilitiesAndOtherLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Accrued
liabilities and other liabilities, current.", "label": "Accrued Liabilities And Other Liabilities Current", "terseLabel": "Accrued and other current liabilities", "totalLabel": "Total
accrued and other current liabilities" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role":
{ "label": "Accrued Liabilities, Current", "totalLabel": "Total accrued liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and
payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or
will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal
operating cycle if longer)." } } }, "auth_ref": ["r48"] }, "us-gaap_AccruedLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AccruedLiabilitiesMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Accrued
Liabilities [Member]", "terseLabel": "Accrued Liabilities [Member]", "documentation": "This item represents obligations incurred and payable, pertaining to costs that are
statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered." } } },
"auth_ref": ["r48"] }, "kzr_AccruedPreclinicalAndResearchCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630",
"localname": "AccruedPreclinicalAndResearchCostsCurrent", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role":
{ "documentation": "Accrued preclinical and research costs, current.", "label": "Accrued Preclinical And Research Costs Current", "terseLabel": "Accrued preclinical and
research costs" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role":
{ "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional services", "documentation": "Carrying value as of the balance sheet date of obligations
incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due
within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r48"] }, "us-
gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label":
"Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation and amortization", "totalLabel":
"Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization,
Property, Plant, and Equipment, Beginning Balance", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending
Balance", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods
and services." } } }, "auth_ref": ["r30", "r115", "r562"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated Other
Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of
Tax, Total", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } }
}, "auth_ref": ["r16", "r17", "r63", "r120", "r558", "r587", "r588"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": {
"terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in
equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in
equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r1", "r10", "r17", "r408", "r411", "r466", "r583", "r584",
"r862", "r863", "r864", "r874", "r875", "r876", "r877"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v)
Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r798"] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional Paid in
Capital, Common Stock", "terseLabel": "Additional paid-in capital", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "periodEndLabel":
"Additional Paid in Capital, Common Stock, Ending Balance", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of
par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May
be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r58"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label":
"Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock
and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r598", "r874", "r875", "r876", "r877", "r949", "r1008"] },
"kzr_AdditionalPaymentsReceivableOnMilestoneAchievements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname":
"AdditionalPaymentsReceivableOnMilestoneAchievements", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureEverestCollaborationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel":
"Additional milestone payments on achievement", "label": "Additional Payments Receivable On Milestone Achievements", "documentation": "Additional Payments Receivable
On Milestone Achievements" } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel":
"Adjustment to Compensation, Amount" } } }, "auth_ref": ["r811"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]",
"terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r811"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": {
"label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r811"]
}, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To
PEO Compensation, Footnote" } } }, "auth_ref": ["r811"] },
"kzr_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingRelatedToSharesOfCommonStockIssuedPursuantToEarlyExercises": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname":
"AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingRelatedToSharesOfCommonStockIssuedPursuantToEarlyExercises", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": {
"documentation": "Adjustments to additional paid in capital, share based compensation, vesting related to shares of common stock issued pursuant to early exercises.",
"label": "Adjustments To Additional Paid In Capital Share Based Compensation Vesting Related To Shares Of Common Stock Issued Pursuant To Early Exercises", "terseLabel":
"Vesting related to shares of common stock issued pursuant to early exercises" } } }, "auth_ref": [] }, "us-
gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit",
"presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": {
"role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "totalLabel": "APIC, Share-
based Payment Arrangement, Increase for Cost Recognition, Total", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for
award under share-based payment arrangement." } } }, "auth_ref": ["r38", "r39", "r335"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit",
"presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical"], "lang":
{ "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "terseLabel": "Issuance of common stock under the ATM Agreement,
net of offering costs", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not

limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": { "r11", "r83" } }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r844"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r770", "r780", "r790", "r822"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r773", "r783", "r793", "r825"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r845"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r811"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r818"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r774", "r784", "r794", "r818", "r826", "r830", "r838"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r836"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "verboseLabel": "Total stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r364", "r370"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt discount and issuance costs and other non-cash interest", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r295", "r707", "r708", "r869", "r960"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShareAntidilutiveOutstandingSharesOfCommonStockEquivalentsExcludedFromComputationO], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive securities excluded from computation of diluted net loss per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r173"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShareAntidilutiveOutstandingSharesOfCommonStockEquivalentsExcludedFromComputationO], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r25"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShareAntidilutiveOutstandingSharesOfCommonStockEquivalentsExcludedFromComputationO], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShareAntidilutiveOutstandingSharesOfCommonStockEquivalentsExcludedFromComputationO], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r25"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureEverestCollaborationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r399"] }, "kzr_AssetImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "AssetImpairmentMember", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentChargesScheduleOfAccrualActivityAndPaymentsRelatingToRestructuringA], "lang": { "en-us": { "role": { "documentation": "Asset Impairment Member", "label": "Asset Impairment [Member]", "terseLabel": "Asset Impairments" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r89", "r96", "r117", "r146", "r177", "r179", "r187", "r188", "r227", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r401", "r405", "r441", "r553", "r626", "r699", "r700", "r734", "r761", "r912", "r913", "r965"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r111", "r121", "r146", "r227", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r401", "r405", "r441", "r734", "r912", "r913", "r965"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "totalLabel": "Assets, Fair Value Disclosure, Total", "label": "Assets, Fair Value Disclosure", "terseLabel": "Financial Assets", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r419", "r420", "r722"] }, "kzr_AtTheMarketAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "AtTheMarketAgreementMember", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical"], "lang": { "en-us": { "role": { "documentation": "At-the-market agreement.", "label": "At The Market Agreement [Member]", "terseLabel": "ATM Agreement" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesRecordedInCashAndCashEquivalen], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Gains", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r199"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesRecordedInCashAndCashEquivalen], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Unrealized Losses", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r200"] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndEstimatedFairValueOfAvailableForSaleSecu "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesRecordedInCashAndCashEquivalen], "lang": { "en-us": { "role": { "totalLabel": "Total available-for-sale securities, Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r196", "r235", "r551"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndEstimatedFairValueOfAvailableForSaleSecu

```
], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "terseLabel": "In one to two years, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r896" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndEstimatedFairValueOfAvailableForSaleSecu
], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "terseLabel": "In one to two years, Estimated Fair Value", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r204", "r548" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndEstimatedFairValueOfAvailableForSaleSecu
], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]", "terseLabel": "Available-for-sale securities maturing, Estimated Fair Value:" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndEstimatedFairValueOfAvailableForSaleSecu
], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]", "terseLabel": "Available-for-sale securities maturing, Amortized Cost:" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndEstimatedFairValueOfAvailableForSaleSecu
], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "In one year or less, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r895" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndEstimatedFairValueOfAvailableForSaleSecu
], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "In one year or less, Estimated Fair Value", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r203", "r547" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndEstimatedFairValueOfAvailableForSaleSecu
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesRecordedInCashAndCashEquivalen
], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale", "terseLabel": "Fair Value", "totalLabel": "Total available-for-sale securities, Estimated Fair Value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r197", "r235", "r419", "r543", "r722", "r725", "r886", "r953", "r954", "r955" ] }, "kzr_AvailableForSaleSecuritiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "AvailableForSaleSecuritiesDisclosureTextBlock", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecurities" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for available for sale securities.", "label": "Available For Sale Securities Disclosure [Text Block]", "terseLabel": "Available-for-Sale Securities" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r833" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r834" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r829" ] },
"ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r829" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r829" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r829" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r829" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r829" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r832" ] },
"ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r831" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r830" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r830" ] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BaseRateMember", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Base Rate [Member]", "terseLabel": "Floor Rate", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Consolidation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness" ], "lang": { "en-us": { "role": { "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Organization and Description of the Business", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r44", "r73", "r74" ] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property and equipment in accounts payable", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r22", "r23", "r24" ] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesRecordedInCashAndCashEquivalen
], "lang": { "en-us": { "role": { "label": "Cash", "terseLabel": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r100", "r555", "r599", "r621", "r734", "r761", "r857" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r20", "r113", "r690" ] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesRecordedInCashAndCashEquivalen
```

```
], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, and Short-Term Investments", "totalLabel": "Total cash, cash equivalent and marketable securities", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": [ "r861" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at the end of period", "periodStartLabel": "Cash and cash equivalents at the beginning of period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r20", "r70", "r142" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r70" ] }, "us-gaap_CertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CertificatesOfDepositMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesRecordedInCashAndCashEquivalen
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
], "lang": { "en-us": { "role": { "label": "Certificates of Deposit [Member]", "terseLabel": "Certificates Of Deposit", "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured." } } }, "auth_ref": [ "r9", "r755", "r756", "r757", "r758" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r809" ] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer [Member]" } } }, "auth_ref": [ "r885" ] },
"ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r806" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r804" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosurePreFundedWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Exercise Price", "terseLabel": "Pre funded warrants exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r320" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosurePreFundedWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Class Of Warrant Or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosurePreFundedWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "verboseLabel": "Number of shares underlying warrants", "terseLabel": "Pre funded warrants to purchase shares of common stock", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r320" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosurePreFundedWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Pre-funded warrants outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosurePreFundedWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "terseLabel": "Class Of Warrant Or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": [ "r34" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r810" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r810" ] },
"kzr_CollaborationRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "CollaborationRevenueMember", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureEverestCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration Revenue", "label": "Collaboration Revenue [Member]", "documentation": "Collaboration revenue." } } }, "auth_ref": [] },
"kzr_CollaborativeAgreementUpfrontPaymentsCollected": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "CollaborativeAgreementUpfrontPaymentsCollected", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureEverestCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative agreement upfront payments collected", "documentation": "Collaborative agreement upfront payments collected.", "terseLabel": "Collaborative agreement upfront payments collected" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureEverestCollaboration" ], "lang": { "en-us": { "role": { "terseLabel": "Everest Collaboration", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r101", "r103", "r108" ] }, "us-gaap_CollaborativeArrangementRightsAndObligations": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementRightsAndObligations", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureEverestCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement right description", "label": "Collaborative Arrangement, Rights and Obligations", "documentation": "Description of rights and obligations under the collaborative arrangements." } } }, "auth_ref": [ "r40" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureEverestCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r399" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesRecordedInCashAndCashEquivalen
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfGrossUnrealizedLossesAndFairValueByMajorSecurityTypeFor
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
], "lang": { "en-us": { "role": { "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r79", "r263", "r755", "r756", "r757", "r758" ] },
"kzr_CommonStockAdditionalSharesAuthorizedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "CommonStockAdditionalSharesAuthorizedForFutureIssuance", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional shares available for future issuance", "label": "Common Stock Additional Shares Authorized For Future Issuance", "documentation": "Common Stock Additional Shares Authorized For Future Issuance" } } }, "auth_ref": [] }, "kzr_CommonStockAggregateOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "CommonStockAggregateOfferingPrice", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Common stock aggregate offering price.", "label": "Common Stock Aggregate Offering Price", "terseLabel": "Common stock aggregate offering price" } } }, "auth_ref": [] }, "kzr_CommonStockAggregateOfferingPriceRemainingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "CommonStockAggregateOfferingPriceRemainingValue", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining amount with sales agreement", "label": "Common Stock Aggregate Offering Price Remaining Value", "documentation": "Common stock aggregate offering price remaining value." } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri":
```

"http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label":
"Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares available for future issuance", "documentation": "Aggregate number of common shares
reserved for future issuance." } } }, "auth_ref": ["r57"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommonStockMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label":
"Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r751", "r752",
"r753", "r755", "r756", "r757", "r758", "r874", "r875", "r877", "r949", "r1007", "r1008"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label":
"Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } },
"auth_ref": ["r57"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockSharesAuthorized", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label":
"Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by
an entity's charter and bylaws." } } }, "auth_ref": ["r57", "r613"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label":
"Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "totalLabel": "Common Stock, Shares, Issued, Total", "verboseLabel": "Common stock
granted", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued,
repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of
shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r57"] }, "us-gaap_CommonStockSharesOutstanding": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label":
"Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
"periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "documentation": "Number of shares of common stock outstanding. Common stock represent the
ownership interest in a corporation." } } }, "auth_ref": ["r11", "r57", "r613", "r632", "r1008", "r1009"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Common
stock, $0.001 par value, 250,000,000 and 250,000,000 shares authorized as of June 30, 2024 (unaudited) and December 31, 2023, respectively; 72,887,538 and 72,779,077
shares issued and outstanding as of June 30, 2024 (unaudited) and December 31, 2023, respectively", "label": "Common Stock, Value, Issued", "totalLabel": "Common Stock,
Value, Issued, Total", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
"documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes
treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within
stockholders' equity." } } }, "auth_ref": ["r57", "r557", "r734"] }, "kzr_CommonStockWeightedAveragePurchasePricePerShare": { "xbrltype": "perShareItemType", "nsuri":
"http://www.kezarlifesciences.com/20240630", "localname": "CommonStockWeightedAveragePurchasePricePerShare", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role":
{ "documentation": "Common stock weighted average purchase price per share.", "label": "Common Stock Weighted Average Purchase Price Per Share", "terseLabel":
"Weighted average purchase price, per share" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-
us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" }
} }, "auth_ref": ["r815"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid
vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r814"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation
Actually Paid vs. Other Measure" } } }, "auth_ref": ["r816"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-
us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } },
"auth_ref": ["r813"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited"], "lang": { "en-us": { "role": {
"label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in
equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity
resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r18", "r126", "r128", "r133", "r544", "r568", "r569"] }, "us-
gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label":
"Computer Equipment [Member]", "terseLabel": "Computer Equipment", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and
utilization of information systems." } } }, "auth_ref": [] }, "kzr_ConsultantFeePerMonth": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.kezarlifesciences.com/20240630", "localname": "ConsultantFeePerMonth", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation":
"Consultant fee per month", "label": "Consultant Fee Per Month", "terseLabel": "Consultant fee per month" } } }, "auth_ref": [] }, "kzr_ConsultingAgreementEffectiveDate": {
"xbrltype": "dateItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "ConsultingAgreementEffectiveDate", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation":
"Consulting agreement effective date.", "label": "Consulting Agreement, Effective Date", "terseLabel": "Consulting agreement, effective date" } } }, "auth_ref": [] },
"kzr_ConsultingExpenseForRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname":
"ConsultingExpenseForRelatedParty", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation":
"Consulting expense for related party.", "label": "Consulting Expense for Related Party", "terseLabel": "Compensation expense" } } }, "auth_ref": [] },
"kzr_ConsultingFeePerMonth": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "ConsultingFeePerMonth", "crdr":
"debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Consulting fee per month", "label": "Consulting Fee Per Month", "documentation": "Consulting fee per month." } } }, "auth_ref": [] },
"kzr_ContraResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname":
"ContraResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureEverestCollaborationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation":
"Contra research and development expense.", "label": "Contra Research and Development Expense", "terseLabel": "Contra research and development expense" } } },
"auth_ref": [] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CorporateDebtSecuritiesMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesRecordedInCashAndCashEquivalen
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfGrossUnrealizedLossesAndFairValueByMajorSecurityTypeFor
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
], "lang": { "en-us": { "role": { "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities", "documentation": "Debt securities issued by domestic
or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": ["r712", "r714", "r722", "r735", "r749", "r1004"] },
"srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role":
{ "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "auth_ref": ["r148", "r149", "r277", "r308", "r472", "r493", "r550", "r692", "r694"] },
"dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover
[Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "kzr_CowenAndCompanyLimitedLiabilityCompanyMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.kezarlifesciences.com/20240630", "localname": "CowenAndCompanyLimitedLiabilityCompanyMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role":
{ "documentation": "Cowen and Company limited liability company.", "label": "Cowen And Company Limited Liability Company [Member]", "terseLabel": "Cowen and Company
LLC" } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis",
"presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Credit
Facility [Axis]", "terseLabel": "Credit Facility", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to
structure a loan for each borrowing." } } }, "auth_ref": ["r263", "r910"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails"],
"lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility", "documentation": "Type of credit facility. Credit facilities provide capital to
borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r263", "r910", "r911"] }, "kzr_CumulativeAccretionOfFinalFee": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "CumulativeAccretionOfFinalFee", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtScheduleOfLongtermDebtBalanceDetails"], "lang": { "en-us": { "role": { "documentation":
"Cumulative accretion of final fee.", "label": "Cumulative Accretion of Final Fee", "terseLabel": "Cumulative accretion of final fee" } } }, "auth_ref": [] },
"dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End
Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-
gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": {
"label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DebtDisclosureTextBlock", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebt1"], "lang": { "en-us": { "role": { "label":
"Debt Disclosure [Text Block]", "terseLabel": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which
includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any
other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates,
collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial

statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": { "r78", "r144", "r244", "r245", "r246", "r247", "r248", "r262", "r263", "r273", "r279", "r280", "r281", "r282", "r283", "r284", "r289", "r296", "r297", "r299", "r452" } }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Line of credit facility, additional interest rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtScheduleOfLongtermDebtBalanceDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Gross", "terseLabel": "Principal loan balance", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": { "r15", "r90", "r300" } }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": ["r50", "r303", "r452", "r453", "r732"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r150", "r274", "r275", "r276", "r277", "r278", "r280", "r285", "r286", "r287", "r288", "r290", "r291", "r292", "r293", "r294", "r295", "r298", "r704", "r705", "r706", "r707", "r708", "r732", "r871", "r959", "r961"] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtScheduleOfLongtermDebtBalanceDetails"], "lang": { "en-us": { "role": { "totalLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedLabel": "Unamortized debt discount and issuance costs", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r285", "r301", "r451", "r452", "r453", "r705", "r706", "r732"] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "crdr": "credit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "terseLabel": "Allowance for credit losses on securities in unrealized loss position", "totalLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Total", "periodStartLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance", "periodEndLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance", "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r198", "r235", "r240", "r241"] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfGrossUnrealizedLossesAndFairValueByMajorSecurityTypeFor], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, 12 months or greater", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": ["r98", "r237", "r702"] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfGrossUnrealizedLossesAndFairValueByMajorSecurityTypeFor], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized Losses, 12 months or greater", "terseLabel": "Unrealized Losses, 12 months or greater", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": ["r98", "r237"] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfGrossUnrealizedLossesAndFairValueByMajorSecurityTypeFor], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Less than 12 months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": ["r98", "r237", "r702"] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfGrossUnrealizedLossesAndFairValueByMajorSecurityTypeFor], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized Losses, Less than 12 months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": ["r98", "r237"] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesTables"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Summary of Available-For-Sale Securities Recorded in Cash and Cash Equivalents or Marketable Securities", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899"] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesTables"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]", "terseLabel": "Summary of Gross Unrealized Losses and Fair Value by Major Security Type for Available-For-Sale Securities in Unrealized Loss Position", "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": ["r97", "r702", "r904"] }, "kzr_DebtSecuritiesAvailableForSaleCreditRelatedLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "DebtSecuritiesAvailableForSaleCreditRelatedLosses", "crdr": "credit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Debt securities available for sale credit related losses.", "label": "Debt Securities Available for Sale Credit Related Losses", "terseLabel": "Credit-related losses related to marketable securities" } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet, and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Depreciation", "verboseLabel": "Depreciation expense", "totalLabel": "Depreciation, Total", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r6", "r29"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Total", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r6", "r177", "r183", "r188", "r699", "r700"] }, "kzr_DevelopmentRegulatoryAndCommercialMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "DevelopmentRegulatoryAndCommercialMilestonesMember", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureEverestCollaborationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Development, Regulatory and Commercial Milestones", "label": "Development Regulatory and Commercial Milestones [Member]", "documentation": "Development regulatory and commercial milestones." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r333", "r337", "r365", "r366", "r369", "r716"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "kzr_DiscountRateOfCashFlow": { "xbrltype": "percentItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "DiscountRateOfCashFlow", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Discount rate of cash flow", "label": "Discount Rate of Cash Flow", "terseLabel": "Discount rate of cash flow" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "verboseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "verboseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event

reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r765"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r797"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "verboseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticCountryMember", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Domestic Tax Jurisdiction [Member]", "terseLabel": "U.S [Member]", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": ["r375"] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r808"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Net loss per common share, Basic", "label": "Earnings Per Share, Basic", "totalLabel": "Earnings Per Share, Basic, Total", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r134", "r156", "r157", "r158", "r159", "r160", "r161", "r166", "r168", "r170", "r171", "r172", "r176", "r395", "r398", "r416", "r417", "r545", "r570", "r696"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Net loss per common share, Diluted", "label": "Earnings Per Share, Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r134", "r156", "r157", "r158", "r159", "r160", "r161", "r168", "r170", "r171", "r172", "r176", "r395", "r398", "r416", "r417", "r545", "r570", "r696"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShare1"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r165", "r173", "r174", "r175"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r442"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued employee-related costs", "totalLabel": "Employee-related Liabilities, Current, Total", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r48"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Estimated weighted average amortization period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r368"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation cost", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r944"] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentChargesScheduleOfAccrualActivityAndPaymentsRelatingToRestructuringA], "lang": { "en-us": { "role": { "label": "Employee Severance [Member]", "terseLabel": "Severance and Related Benefit Costs", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShareAntidilutiveOutstandingSharesOfCommonStockEquivalentsExcludedFromComputationO "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Stock options to purchase common stock [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "kzr_EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "EmployeeStockPurchasePlanMember", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "ESPP", "terseLabel": "ESPP Rights", "label": "Employee Stock Purchase Plan [Member]", "documentation": "Employee stock purchase plan." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r763"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "verboseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [

```
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r763" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r848" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r763" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r847" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "verboseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r763" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r763" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r763" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r763" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r802" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r843" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r843" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r843" ] }, "kzr_EqualToSumOfAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "EqualToSumOfAMember", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Equal to the sum of (a).", "label": "Equal To Sum Of A [Member]", "terseLabel": "Equal To Sum Of A" } } }, "auth_ref": [] }, "kzr_EqualToSumOfBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "EqualToSumOfBMember", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Equal to the sum of (b).", "label": "Equal To Sum Of B [Member]", "terseLabel": "Equal To Sum Of B" } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "terseLabel": "Equity Component", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r11", "r109", "r129", "r130", "r131", "r151", "r152", "r153", "r155", "r160", "r162", "r164", "r178", "r228", "r229", "r242", "r321", "r385", "r386", "r392", "r393", "r394", "r396", "r397", "r398", "r407", "r408", "r409", "r410", "r411", "r412", "r415", "r443", "r444", "r445", "r446", "r447", "r448", "r454", "r456", "r466", "r566", "r583", "r584", "r585", "r598", "r656" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r812" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r770", "r780", "r790", "r822" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r767", "r777", "r787", "r819" ] }, "kzr_EstimatedFutureSubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "EstimatedFutureSubleaseIncome", "crdr": "credit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformationDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sublease income", "label": "Estimated Future Sublease Income", "documentation": "Estimated future sublease income." } } }, "auth_ref": [] }, "kzr_EverestLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "EverestLicenseAgreementMember", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureEverestCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Everest License Agreement", "label": "Everest License Agreement [Member]", "documentation": "Everest License Agreement." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r818" ] }, "kzr_ExistingStockholderEqualTalentInvestmentsLimitedAndDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "ExistingStockholderEqualTalentInvestmentsLimitedAndDirectorsMember", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Existing stockholder, equal talent investments limited and directors.", "label": "Existing Stockholder Equal Talent Investments Limited And Directors [Member]", "terseLabel": "Existing Stockholder, Equal Talent Investments Limited, and one of the Directors" } } }, "auth_ref": [] }, "kzr_ExistingStockholderVenturesOfficersAndDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "ExistingStockholderVenturesOfficersAndDirectorsMember", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Existing stockholder, ventures, officers and directors.", "label": "Existing Stockholder Ventures Officers And Directors [Member]", "terseLabel": "Existing Stockholder, Morningside Ventures and certain officers and directors" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesRecordedInCashAndCashEquivalen
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfGrossUnrealizedLossesAndFairValueByMajorSecurityTypeFor
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r419", "r420", "r433", "r722" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesRecordedInCashAndCashEquivalen
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfGrossUnrealizedLossesAndFairValueByMajorSecurityTypeFor
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } },
"auth_ref": [ "r419", "r420", "r433", "r722" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Financial Assets Measured at Fair Value on a Recurring Basis", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r951", "r952" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesRecordedInCashAndCashEquivalen
```

```
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfGrossUnrealizedLossesAndFairValueByMajorSecurityTypeFor
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "terseLabel": "Asset Class", "documentation": "Class of asset." } } }, "auth_ref": [ "r424", "r425", "r426", "r427",
"r428", "r429", "r434", "r723" ] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueByAssetClassAxis", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesRecordedInCashAndCashEquivalen
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfGrossUnrealizedLossesAndFairValueByMajorSecurityTypeFor
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "terseLabel": "Asset Class", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r424", "r425",
"r426", "r427", "r428", "r429", "r434", "r723" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Level 2", "documentation": "Information by level within fair value hierarchy and
fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r287", "r325", "r326", "r327", "r328", "r329", "r330", "r418", "r420", "r421",
"r422", "r423", "r432", "r433", "r435", "r480", "r481", "r482", "r705", "r706", "r712", "r713", "r714", "r722", "r725" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesRecordedInCashAndCashEquivalen
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency", "documentation": "Information by measurement frequency."
} } }, "auth_ref": [ "r419", "r420", "r421", "r423", "r722", "r954", "r957" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock",
"presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "lang": { "en-us": { "role": { "label": "Fair Value
Disclosures [Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including
financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial
assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their
carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair
value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of
credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed
to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the
nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a
recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for
which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings,
(c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the
balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r428", "r430", "r431", "r432", "r435",
"r436", "r437", "r438", "r439", "r542", "r722", "r726" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueInputsLevel1Member", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1", "documentation": "Quoted prices in active markets for identical assets or
liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r287", "r325", "r330", "r420", "r433", "r480", "r712", "r713", "r714", "r722" ] },
"us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member",
"presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2", "documentation": "Inputs other than quoted prices included within level
1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or
quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r287", "r325", "r330", "r420", "r421", "r433", "r481", "r705", "r706", "r712",
"r713", "r714", "r722" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueInputsLevel3Member", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3", "documentation": "Unobservable inputs that reflect the entity's own
assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r287", "r325", "r326", "r327", "r328", "r329", "r330", "r420", "r421", "r422",
"r423", "r433", "r482", "r705", "r706", "r712", "r713", "r714", "r722", "r725" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesRecordedInCashAndCashEquivalen
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency", "documentation": "Measurement frequency." } } },
"auth_ref": [ "r419", "r420", "r421", "r423", "r722", "r954", "r957" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair
Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "Disclosure of accounting policy for fair value measurements of
financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a
group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-
gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV", "documentation": "Categories used to
prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r287", "r325", "r326", "r327", "r328", "r329", "r330", "r418", "r420", "r421", "r422",
"r423", "r432", "r433", "r435", "r480", "r481", "r482", "r705", "r706", "r712", "r713", "r714", "r722", "r725" ] }, "us-gaap_FairValueMeasurementsRecurringMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesRecordedInCashAndCashEquivalen
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring", "documentation": "Frequent fair value
measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r722",
"r951", "r952", "r953", "r954", "r955", "r957" ] }, "kzr_FebruaryOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kezarlifesciences.com/20240630",
"localname": "FebruaryOfferingMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosurePreFundedWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"February Offering", "label": "February Offering [Member]", "documentation": "February offering." } } }, "auth_ref": [] }, "kzr_FinalPaymentFeePercentageOnPrincipal": {
"xbrltype": "percentItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "FinalPaymentFeePercentageOnPrincipal", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Final payment fee
percentage on principal.", "label": "Final Payment Fee Percentage on Principal", "terseLabel": "Final payment fee percentage" } } }, "auth_ref": [] }, "us-
gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202",
"r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224",
"r230", "r231", "r232", "r233", "r234", "r236", "r238", "r239", "r298", "r318", "r413", "r440", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486",
"r487", "r488", "r489", "r490", "r491", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r567", "r702",
"r722", "r723", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r735", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r899", "r900", "r901", "r902", "r950",
"r953", "r954", "r955", "r956", "r957" ] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ForeignCountryMember", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "label": "Foreign Tax Jurisdiction [Member]", "terseLabel": "Non - U.S [Member]", "documentation": "Designated foreign jurisdiction entitled to levy and
collect income tax outside country of domicile." } } }, "auth_ref": [ "r375", "r376" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel":
"Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r774", "r784", "r794", "r826" ] },
"ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone
Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r774", "r784", "r794", "r826"
] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone
Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r774", "r784",
"r794", "r826" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone
Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r774", "r784", "r794", "r826" ] },
"ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r774",
"r784", "r794", "r826" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet
Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet
Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r807" ] }, "kzr_FurnitureLaboratoryAndOfficeEquipmentMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "FurnitureLaboratoryAndOfficeEquipmentMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": {
"documentation": "Furniture, laboratory and office equipment.", "label": "Furniture Laboratory And Office Equipment [Member]", "terseLabel": "Furniture, Laboratory and
Office Equipment" } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
```

```
"localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": {
"totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on
disposition of fixed assets", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber
property." } } }, "auth_ref": [ "r6" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "label":
"General and Administrative Expense", "terseLabel": "General and administrative", "totalLabel": "General and Administrative Expense, Total", "documentation": "The
aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated
with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r65", "r636" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails" ], "lang": { "en-us":
{ "role": { "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative Expense", "documentation": "Primary financial statement
caption encompassing general and administrative expense." } } }, "auth_ref": [ "r65" ] }, "kzr_IncentiveStockOptionsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.kezarlifesciences.com/20240630", "localname": "IncentiveStockOptionsMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Incentive Stock Options", "label": "Incentive Stock Options [Member]", "documentation": "Incentive stock options." } } }, "auth_ref": [] }, "us-
gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role":
{ "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails" ], "lang": { "en-us":
{ "role": { "label": "Statement of Income Location, Balance [Axis]", "terseLabel": "Income Statement Location", "documentation": "Information by location in statement of
income where disaggregated amount has been reported." } } }, "auth_ref": [ "r243", "r249", "r252", "r425", "r429", "r434", "r580", "r582", "r641", "r687", "r724", "r977" ] },
"us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain",
"presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails" ],
"lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "terseLabel": "Income Statement Location", "documentation": "Location in statement
of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r249", "r252", "r425", "r429", "r434", "r580", "r582", "r641", "r687", "r724", "r977" ] }, "us-
gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax
Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r141", "r375", "r376", "r380", "r383", "r719", "r947" ] }, "us-
gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax
Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r141", "r375", "r376", "r380", "r383", "r719", "r947" ] }, "us-
gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": {
"role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]",
"terseLabel": "Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r147", "r373", "r375", "r377", "r378", "r379", "r381", "r382",
"r387", "r389", "r390", "r391", "r593", "r719" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax
Expense (Benefit)", "terseLabel": "Provision for income taxes", "totalLabel": "Income Tax Expense (Benefit), Total", "documentation": "Amount of current income tax expense
(benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r99", "r107", "r163", "r164", "r177", "r184", "r188", "r374",
"r375", "r388", "r571", "r719" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label":
"Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable, accrued liabilities and other current liabilities", "totalLabel": "Increase
(Decrease) in Accounts Payable and Accrued Liabilities, Total", "verboseLabel": "Accounts payable, accrued and other current liabilities", "documentation": "The increase
(decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
} } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Contract liability", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to
transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r510", "r868" ] }, "us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label":
"Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities" } } }, "auth_ref": [] },
"kzr_IncreaseDecreaseInOperatingLeaseAssetAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname":
"IncreaseDecreaseInOperatingLeaseAssetAndLiabilities", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": {
"negatedLabel": "Operating lease asset and liabilities", "label": "Increase Decrease In Operating Lease Asset And Liabilities", "documentation": "Increase decrease in
operating lease asset and liabilities." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": {
"totalLabel": "Increase (Decrease) in Other Operating Assets, Total", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets",
"documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r5" ] }, "us-
gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label":
"Increase (Decrease) in Prepaid Expense and Other Assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total", "negatedLabel": "Prepaid expenses
and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r5" ] },
"kzr_IncreaseInNumberOfSharesReservedForIssuanceAsPercentageOfTotalNumberOfSharesOfCapitalStockOutstandingOnLastDateOfPrecedingCalendarYear": { "xbrltype":
"percentItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname":
"IncreaseInNumberOfSharesReservedForIssuanceAsPercentageOfTotalNumberOfSharesOfCapitalStockOutstandingOnLastDateOfPrecedingCalendarYear", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Increase in number of shares reserved for issuance as percentage of total number of shares of capital stock outstanding on last date of preceding calendar
year.", "label": "Increase In Number Of Shares Reserved For Issuance As Percentage Of Total Number Of Shares Of Capital Stock Outstanding On Last Date Of Preceding
Calendar Year", "terseLabel": "Increase in number of shares reserved for issuance as percentage of total number of shares of capital stock outstanding on last date of
preceding calendar year" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel":
"Individual:" } } }, "auth_ref": [ "r774", "r784", "r794", "r818", "r826", "r830", "r838" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel":
"Insider Trading Arrangements:" } } }, "auth_ref": [ "r836" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line
Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r766", "r842" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel":
"Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r766", "r842" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
"terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r766", "r842" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": {
"totalLabel": "Interest Expense, Total", "label": "Interest Expense, Operating and Nonoperating", "terseLabel": "Interest Expense", "negatedLabel": "Interest expense",
"documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." }
} }, "auth_ref": [ "r177", "r179", "r182", "r185", "r188", "r450", "r699", "r700" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Interest Expense, Debt,
Total", "label": "Interest Expense, Debt", "terseLabel": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for
debt." } } }, "auth_ref": [ "r66", "r293", "r304", "r707", "r708" ] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "label":
"Interest Income (Expense), Nonoperating", "terseLabel": "Interest income", "documentation": "Amount of interest income (expense) classified as nonoperating." } } },
"auth_ref": [ "r699", "r866", "r881" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet",
"crdr": "credit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ],
"lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest", "documentation": "Amount of
cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest
of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt
discount." } } }, "auth_ref": [ "r136", "r139", "r140" ] }, "kzr_InterestRateOfSubleaseIncomePerYear": { "xbrltype": "percentItemType", "nsuri":
"http://www.kezarlifesciences.com/20240630", "localname": "InterestRateOfSubleaseIncomePerYear", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation":
"Interest rate of sublease income per year", "label": "Interest Rate of Sublease Income Per Year", "terseLabel": "Interest rate of sublease income per year" } } }, "auth_ref": []
```

```
}, "us-gaap_InterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestReceivable", "crdr": "debit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Interest Receivable", "terseLabel": "Interest receivable", "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable." } } }, "auth_ref": [ "r859", "r1010" ] }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesTables" ], "lang": { "en-us": { "role": { "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Summary of Amortized Cost and Estimated Fair Value of Available-for-sale Securities by Contractual Maturity", "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments." } } }, "auth_ref": [] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "kzr_IssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "xbrltype": "sharesItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "IssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Issuance of shares under incentive and share based compensation plans.", "label": "Issuance Of Shares Under Incentive And Share Based Compensation Plans", "terseLabel": "Issuance of common stock under equity incentive plans, shares" } } }, "auth_ref": [] }, "kzr_JuneOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "JuneOfferingMember", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosurePreFundedWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "June Offering", "label": "June Offering [Member]", "documentation": "June offering." } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r76", "r465" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Lessee Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseDetailsOfRightOfUseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total undiscounted lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r464" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseDetailsOfRightOfUseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Less than 12 months", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r464" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseDetailsOfRightOfUseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "25 - 36 months", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r464" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseDetailsOfRightOfUseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "13 - 24 months", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "verboseLabel": "13 - 24 months", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r464" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseDetailsOfRightOfUseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r464" ] }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseOptionToExtend", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, option to extend", "label": "Lessee, Operating Lease, Option to Extend", "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": [ "r460" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLease" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Lease", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r455" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r15", "r47", "r48", "r49", "r52", "r53", "r54", "r55", "r146", "r227", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r402", "r405", "r406", "r441", "r612", "r697", "r761", "r912", "r965", "r966" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r62", "r91", "r560", "r734", "r872", "r903", "r958" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r49", "r112", "r146", "r227", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r402", "r405", "r406", "r441", "r734", "r912", "r965", "r966" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Current Borrowing Capacity", "terseLabel": "Current borrowing capacity", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": [ "r46", "r51" ] }, "us-gaap_LineOfCreditFacilityExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityExpirationDate1", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Expiration Date", "terseLabel": "Line of credit facility, Maturity period", "documentation": "Date the credit facility terminates, in YYYY-MM-DD format." } } }, "auth_ref": [ "r46", "r51" ] }, "kzr_LineOfCreditFacilityExtensionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "LineOfCreditFacilityExtensionPeriod", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Line of credit facility, extension period.", "label": "Line Of Credit Facility Extension Period", "terseLabel": "Line of credit facility, extension period" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityFrequencyOfPayments": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityFrequencyOfPayments", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Frequency of Payments", "terseLabel": "Line of credit facility frequency of payments", "documentation": "Description of the frequency of periodic payments, which may be presented in a variety of ways (for example, monthly, quarterly, annually)." } } }, "auth_ref": [ "r46", "r51" ] }, "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityInterestRateDuringPeriod", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Interest Rate During Period", "terseLabel": "Line of credit facility, interest rate", "documentation": "The effective interest rate during the reporting period." } } }, "auth_ref": [ "r46", "r51" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit facility, maximum borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r46", "r51" ] }, "kzr_LoanAndSecurityAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "LoanAndSecurityAgreementMember", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan and Security Agreement", "documentation": "Loan and security agreement.", "label": "Loan And Security Agreement [Member]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtScheduleOfLongtermDebtBalanceDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt", "totalLabel": "Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r15", "r90", "r286", "r302", "r705", "r706", "r732", "r975" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtScheduleOfLongtermDebtBalanceDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Long-Term Debt, Current Maturities, Total", "label": "Long-Term Debt, Current Maturities", "terseLabel": "Debt, current", "documentation": "Amount, after deduction of unamortized
```

premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": { "r118" } }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r8", "r150", "r291" } }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2026", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r8", "r150", "r291" } }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2025", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r8", "r150", "r291" } }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtScheduleOfLongtermDebtBalanceDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Excluding Current Maturities", "totalLabel": "Long-term debt, net", "terseLabel": "Debt, noncurrent", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": { "r119" } }, "kzr_LongTermDebtPrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "LongTermDebtPrincipalAmount", "crdr": "credit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtScheduleOfEstimatedFuturePrincipalPaymentsDetails"], "lang": { "en-us": { "role": { "documentation": "Long-term debt principal amount.", "label": "Long-Term Debt Principal Amount", "totalLabel": "Total" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Marketable Securities, Current", "terseLabel": "Marketable securities", "totalLabel": "Marketable Securities, Current, Total", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": { "r858" } }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedIsCalculatedUsingBlackScholesOptionPr], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": { "r258", "r259", "r260", "r261", "r332", "r371", "r423", "r509", "r579", "r581", "r589", "r604", "r605", "r664", "r666", "r668", "r669", "r671", "r685", "r686", "r701", "r709", "r715", "r725", "r726", "r730", "r731", "r745", "r914", "r967", "r968", "r969", "r970", "r971", "r972" } }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": { "r810" } }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": { "r810" } }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedIsCalculatedUsingBlackScholesOptionPr], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": { "r258", "r259", "r260", "r261", "r332", "r371", "r423", "r509", "r579", "r581", "r589", "r604", "r605", "r664", "r666", "r668", "r669", "r671", "r685", "r686", "r701", "r709", "r715", "r725", "r726", "r730", "r745", "r914", "r967", "r968", "r969", "r970", "r971", "r972" } }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": { "r829" } }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesRecordedInCashAndCashEquivalen "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "terseLabel": "U.S. Treasury Money Market Funds", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": { "r917" } }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": { "r837" } }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": { "r811" } }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": { "r138" } }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": { "r138" } }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": { "r70", "r71", "r72" } }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": { "r64", "r72", "r92", "r110", "r124", "r127", "r131", "r146", "r154", "r156", "r157", "r158", "r159", "r160", "r163", "r164", "r169", "r227", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r395", "r398", "r417", "r441", "r565", "r634", "r654", "r655", "r759", "r912" } }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator:" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r810"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r774", "r784", "r794", "r810", "r826"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [

```
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r801" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r800" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r818" ] }, "kzr_NonRule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "NonRule10B51ArrModifiedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non Rule 10b5-1 Arrangement Modified", "label": "Non Rule 10b 51 Arr Modified [Flag]", "documentation": "Non rule10b51 arrangement modified flag." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r837" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r837" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental disclosures of noncash investing and financing information:" } } }, "auth_ref": [] }, "kzr_NoncurrentUnbilledReceivableFromCollaboration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "NoncurrentUnbilledReceivableFromCollaboration", "crdr": "debit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureEverestCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent unbilled receivable from collaboration", "label": "Noncurrent Unbilled Receivable From Collaboration", "documentation": "Noncurrent Unbilled Receivable From Collaboration" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r700", "r880" ] }, "kzr_NumberOfTranches": { "xbrltype": "integerItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "NumberOfTranches", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of tranches.", "label": "Number Of Tranches", "terseLabel": "Number of tranches" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "terseLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r95", "r698", "r879", "r881", "r882", "r883", "r884" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseDetailsOfRightOfUseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Operating lease costs", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r461", "r733" ] }, "us-gaap_OperatingLeaseImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentChargesScheduleOfAccrualActivityAndPaymentsRelatingToRestructuringA
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentChargesAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Impairment loss of right-of-use asset", "label": "Operating Lease, Impairment Loss", "terseLabel": "Impairment charge", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease." } } }, "auth_ref": [ "r962" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseDetailsOfRightOfUseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liability", "label": "Operating Lease, Liability", "terseLabel": "Total lease liabilities", "totalLabel": "Total operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r458" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseDetailsOfRightOfUseAssetsAndLeaseLiabilitiesDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r458" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseDetailsOfRightOfUseAssetsAndLeaseLiabilitiesDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r458" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseDetailsOfRightOfUseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Cash paid for operating lease liabilities", "negatedLabel": "Operating lease liabilities", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r459", "r463" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r457" ] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r384" ] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsTable", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Table]", "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization." } } }, "auth_ref": [ "r384" ] }, "kzr_OptionsToPurchaseOfCommonStockOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "OptionsToPurchaseOfCommonStockOutstanding", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Options to purchase of common stock outstanding.", "label": "Options To Purchase Of Common Stock Outstanding", "terseLabel": "Options to purchase of common stock outstanding" } } }, "auth_ref": [] }, "kzr_OrganizationAndDescriptionOfBusinessLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "OrganizationAndDescriptionOfBusinessLineItems", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Organization and description of business.", "label": "Organization And Description Of Business [Line Items]", "terseLabel": "Organization And Description Of Business [Line Items]" } } }, "auth_ref": [] }, "kzr_OrganizationAndDescriptionOfBusinessTable": { "xbrltype": "stringItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "OrganizationAndDescriptionOfBusinessTable", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Organization and description of business.", "label": "Organization And Description Of Business [Table]", "terseLabel": "Organization And Description Of Business [Table]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Others", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r48" ] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssets", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsOtherAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total other assets", "label": "Other Assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": [ "r88", "r116", "r552", "r700", "r761" ] }, "us-gaap_OtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsAbstract", "lang": { "en-us": { "role": { "label": "Other Assets [Abstract]" } } }, "auth_ref": [] }, "kzr_OtherAssetsAdvanceForClinicalRelatedCostsNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "OtherAssetsAdvanceForClinicalRelatedCostsNonCurrent", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advance for clinical related costs, noncurrent", "label": "Other Assets Advance For Clinical Related Costs Non Current", "documentation": "Other assets advance for clinical related costs
```

non current." } } }, "auth_ref": [] }, "kzr_OtherAssetsDepositsForOperatingLease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "OtherAssetsDepositsForOperatingLease", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deposits for operating lease", "label": "Other Assets Deposits For Operating Lease", "documentation": "Other assets deposits for operating lease." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsMiscellaneous": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsMiscellaneous", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsOtherAssetsDetails"], "lang": { "en-us": { "role": { "label": "Other Assets, Miscellaneous", "totalLabel": "Other Assets, Miscellaneous, Total", "terseLabel": "Other", "documentation": "Amount of other miscellaneous assets." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "totalLabel": "Other Assets, Noncurrent, Total", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r116"] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments", "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": ["r2", "r566"] },
"us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": {
"terseLabel": "Other comprehensive gain (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive (loss) income, net of tax", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": ["r4", "r10", "r87", "r125", "r128", "r160"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited"], "lang": { "en-us": { "role": {
"terseLabel": "Other comprehensive income (loss):", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] },
"us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited"], "lang": { "en-us": { "role": {
"label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized (loss) gain on marketable securities", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r122", "r123", "r226"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label":
"Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r810"] }, "us-gaap_OtherPrepaidExpenseCurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Others", "label": "Other Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r860", "r905"] }, "kzr_OtherUnbilledReceivableNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "OtherUnbilledReceivableNonCurrent", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unbilled receivable from Everest, noncurrent (Note 10)", "label": "Other Unbilled Receivable", "documentation": "The amount of unbilled receivable other." } } }, "auth_ref": [] },
"ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r772", "r782", "r792", "r824"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": {
"role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r775", "r785", "r795", "r827"] },
"ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [
"r775", "r785", "r795", "r827"] }, "kzr_OxfordFinanceLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname":
"OxfordFinanceLLCMember", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Oxford Finance LLC", "documentation": "Oxford finance LLC.", "label": "Oxford Finance L L C [Member]" } } }, "auth_ref": [] },
"kzr_ParValueOfCommonStockUponCashlessExerciseOfPrefundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630",
"localname": "ParValueOfCommonStockUponCashlessExerciseOfPrefundedWarrants", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": {
"documentation": "Par value of common stock upon cashless exercise of prefunded warrants.", "label": "Par Value Of Common Stock Upon Cashless Exercise Of Prefunded Warrants", "terseLabel": "Par value of common stock upon cashless exercise of prefunded warrants" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r799"] }, "us-gaap_PaymentsForRestructuring": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentChargesScheduleOfAccrualActivityAndPaymentsRelatingToRestructuringA"], "lang": { "en-us": { "role": { "label": "Payments for Restructuring", "terseLabel": "Cash payments made", "verboseLabel": "Non-cash charges", "negatedLabel": "Cash payments made", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r251", "r867"] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label":
"Payments of Ordinary Dividends, Common Stock", "terseLabel": "Payments of dividends of common stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": ["r69"] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label":
"Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities", "totalLabel": "Payments to Acquire Marketable Securities, Total",
"documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": ["r887"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label":
"Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r68"] },
"ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation":
["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote"
} } }, "auth_ref": ["r809"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r809"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": {
"en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r801"] },
"ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r818"] }, "ecd_PeoName": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"],
"lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r811"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r800"] }, "kzr_PercentageOfBonusOnAnnualBaseSalary": { "xbrltype":
"percentItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "PercentageOfBonusOnAnnualBaseSalary", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel":
"Percentage of bonus on annual base salary", "label": "Percentage of Bonus on Annual Base Salary", "documentation": "Percentage of bonus on annual base salary." } } },
"auth_ref": [] }, "kzr_PercentageOfCommissionOnGrossSaleProceedsOfIssuanceOfCommonStock": { "xbrltype": "percentItemType", "nsuri":
"http://www.kezarlifesciences.com/20240630", "localname": "PercentageOfCommissionOnGrossSaleProceedsOfIssuanceOfCommonStock", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role":
{ "documentation": "Percentage of commission on gross sales proceeds of issuance of common stock.", "label": "Percentage Of Commission On Gross Sale Proceeds Of Issuance Of Common Stock", "terseLabel": "Percentage of commission on gross sales proceeds of issuance of common stock" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label":
"Plan Name [Axis]", "terseLabel": "Plan Name", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r918", "r919", "r920",
"r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942",
"r943"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label":
"Plan Name [Domain]", "terseLabel": "Plan Name", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r918", "r919", "r920", "r921",
"r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943"] },
"ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments

{"Prior Service Cost" } } }, "auth_ref": { "r802" } }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": { "r846" } }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": { "r801" } }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": { "r56", "r306" } }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": { "r56", "r613" } }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "totalLabel": "Preferred Stock, Shares Issued, Total", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": { "r56", "r306" } }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": { "r56", "r613", "r632", "r1008", "r1009" } }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.001 par value, 10,000,000 shares authorized; zero shares issued and outstanding as of June 30, 2024 (unaudited) and December 31, 2023", "label": "Preferred Stock, Value, Issued", "totalLabel": "Preferred Stock, Value, Issued, Total", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": { "r56", "r556", "r734" } }, "kzr_PrepaidAdvanceForClinicalRelatedCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "PrepaidAdvanceForClinicalRelatedCostsCurrent", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Advance for clinical-related costs, current", "label": "Prepaid Advance For Clinical Related Costs Current", "documentation": "Prepaid advance for clinical related costs current." } } }, "auth_ref": {} }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r861" } }, "us-gaap_PrepaidExpenseCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrentAbstract", "lang": { "en-us": { "role": { "label": "Prepaid Expense, Current [Abstract]" } } }, "auth_ref": {} }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Insurance", "label": "Prepaid Insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r691", "r703", "r905" } }, "kzr_PrepaidLicenseDuesAndSubscription": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "PrepaidLicenseDuesAndSubscription", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "License, dues and subscription", "label": "Prepaid License Dues And Subscription", "documentation": "Prepaid license dues and subscription." } } }, "auth_ref": {} }, "kzr_PrepaymentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "PrepaymentFeePercentage", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Prepayment fee percentage.", "label": "Prepayment Fee Percentage", "terseLabel": "Prepayment fee percentage" } } }, "auth_ref": {} }, "us-gaap_ProceedsFromIncomeTaxRefunds": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIncomeTaxRefunds", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income tax refunds received", "label": "Proceeds from Income Tax Refunds", "documentation": "Amount of income tax refund received from tax jurisdiction." } } }, "auth_ref": { "r21", "r71", "r870", "r945", "r946" } }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Net proceeds from the public offering", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": { "r3" } }, "kzr_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock and warrants, net of issuance costs.", "label": "Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs", "terseLabel": "Proceeds from issuance of common stock and warrants, net of issuance costs" } } }, "auth_ref": {} }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised", "terseLabel": "Proceeds from issuance of common stock under employee stock incentive plans", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised." } } }, "auth_ref": { "r3", "r14" } }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Maturities of marketable securities", "totalLabel": "Proceeds from Sale and Maturity of Marketable Securities, Total", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": {} }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "terseLabel": "Sale of available-for-sale securities", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r19", "r135", "r194", "r225" } }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": { "r67" } }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureEverestCollaborationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": { "r189", "r511", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r688", "r710", "r744", "r745", "r746", "r748", "r750", "r908", "r909", "r915", "r976", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1005", "r1006" } }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureEverestCollaborationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": { "r189", "r511", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r688", "r710", "r744", "r745", "r746", "r748", "r750", "r908", "r909", "r915", "r976", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1005", "r1006" } }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": { "r110", "r124", "r127", "r137", "r146", "r154", "r160", "r163", "r164", "r227", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r395", "r398", "r400", "r403", "r404", "r417", "r441", "r546", "r564", "r597", "r634", "r654", "r655", "r720", "r721", "r760", "r864", "r912" } }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": { "r7", "r465" } }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property and equipment", "totalLabel": "Property, Plant and Equipment, Gross, Total", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": { "r76", "r114", "r563" } }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails"], "lang": { "en-us": {

```
"role": { "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },
"auth_ref": [ "r465" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and
Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "periodStartLabel": "Property, Plant and Equipment, Net,
Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "documentation": "Amount after accumulated depreciation, depletion and
amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to,
land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r7", "r465", "r549", "r563", "r734" ] }, "us-
gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ],
"lang": { "en-us": { "role": { "terseLabel": "Property and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure
of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion
expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r7" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label":
"Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct
of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and
equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r76", "r465" ] }, "ecd_PvpTable":
{ "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-
us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r799" ] }, "ecd_PvpTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r799" ] },
"srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedIsCalculatedUsingBlackScholesOptionPr
], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "auth_ref": [ "r258", "r259", "r260", "r261", "r324",
"r332", "r360", "r361", "r362", "r371", "r423", "r483", "r492", "r509", "r579", "r581", "r589", "r604", "r605", "r664", "r666", "r668", "r669", "r671", "r685", "r686", "r701",
"r709", "r715", "r725", "r726", "r730", "r731", "r745", "r753", "r906", "r914", "r954", "r968", "r969", "r970", "r971", "r972" ] }, "srt_RangeMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedIsCalculatedUsingBlackScholesOptionPr
], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "auth_ref": [ "r258", "r259", "r260", "r261", "r324",
"r332", "r360", "r361", "r362", "r371", "r423", "r483", "r492", "r509", "r579", "r581", "r589", "r604", "r605", "r664", "r666", "r668", "r669", "r671", "r685", "r686", "r701",
"r709", "r715", "r725", "r726", "r730", "r731", "r745", "r753", "r906", "r914", "r954", "r968", "r969", "r970", "r971", "r972" ] }, "kzr_ReceivableFromCollaboration": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "ReceivableFromCollaboration", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureEverestCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Receivable from Everest, current (Note 10)", "documentation": "Receivable from Collaboration", "label": "Receivable from Collaboration", "verboseLabel": "Reimbursement
receivable from collaboration" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
"terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r767", "r777", "r787", "r819" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related
and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment
is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented
from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r193", "r331", "r470", "r471", "r554", "r561", "r607",
"r608", "r609", "r610", "r611", "r631", "r633", "r663" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RelatedPartyTransactionLineItems", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related
Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r193", "r637", "r638", "r641" ] }, "us-gaap_RelatedPartyTransactionsAbstract":
{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party
Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related
and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which
investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be
prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r193", "r331", "r470", "r471", "r554", "r561",
"r607", "r608", "r609", "r610", "r611", "r631", "r633", "r663", "r964" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions
Disclosure [Text Block]", "terseLabel": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party
transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d)
affiliates." } } }, "auth_ref": [ "r467", "r468", "r469", "r471", "r473", "r594", "r595", "r596", "r639", "r640", "r641", "r660", "r662" ] },
"srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"RepurchaseAgreementCounterpartyNameDomain", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role":
{ "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "auth_ref": [ "r148", "r149", "r277", "r308", "r472", "r493", "r550", "r693", "r694" ] },
"kzr_ResearchAndDevelopmentActivitiesAmortizePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname":
"ResearchAndDevelopmentActivitiesAmortizePeriod", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation":
"Research and development activities amortize period." , "label": "Research And Development Activities Amortize Period", "terseLabel": "Research and development activities
amortize period" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "label":
"Research and Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total", "documentation": "Amount of
expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research
and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in
business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r372", "r687", "r699", "r973" ] }, "us-
gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ResearchAndDevelopmentExpenseMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails" ], "lang": { "en-us":
{ "role": { "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense", "documentation": "Primary financial statement
caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": {
"en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r768", "r778", "r788", "r820" ] },
"ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" }
} }, "auth_ref": [ "r769", "r779", "r789", "r821" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": {
"en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r776", "r786",
"r796", "r828" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestrictedStockUnitsRSUMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSU Member", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash,
after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "kzr_RestrictedStockUnitsSubjectToFutureVestingMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "RestrictedStockUnitsSubjectToFutureVestingMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShareAntidilutiveOutstandingSharesOfCommonStockEquivalentsExcludedFromComputationO
], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units Subject to Future Vesting [Member]", "documentation": "Restricted Stock Units Subject To Future Vesting
[Member]", "label": "Restricted Stock Units Subject To Future Vesting [Member]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and
Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestructuringCharges", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentChargesScheduleOfAccrualActivityAndPaymentsRelatingToRestructuringA
```

```
], "lang": { "en-us": { "role": { "totalLabel": "Restructuring Charges, Total", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r6", "r254", "r255", "r907" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentChargesScheduleOfAccrualActivityAndPaymentsRelatingToRestructuringA
], "lang": { "en-us": { "role": { "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r250", "r251", "r255", "r256" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentChargesScheduleOfAccrualActivityAndPaymentsRelatingToRestructuringA
], "lang": { "en-us": { "role": { "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r250", "r251", "r252", "r253", "r255", "r256", "r257" ] }, "us-gaap_RestructuringCostsAndAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostsAndAssetImpairmentCharges", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentChargesAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Restructuring Costs and Asset Impairment Charges, Total", "label": "Restructuring Costs and Asset Impairment Charges", "terseLabel": "Restructuring and impairment charges", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentCharges1" ], "lang": { "en-us": { "role": { "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]", "terseLabel": "Restructuring and Impairment Charges", "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentChargesScheduleOfAccrualActivityAndPaymentsRelatingToRestructuringA
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentChargesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Restructuring Reserve, Total", "periodStartLabel": "Restructuring Reserve, Beginning Balance", "periodEndLabel": "Restructuring Reserve, Ending Balance", "label": "Restructuring Reserve", "terseLabel": "Severance and related benefit costs", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r251", "r256" ] }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveAccrualAdjustment1", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentChargesScheduleOfAccrualActivityAndPaymentsRelatingToRestructuringA
], "lang": { "en-us": { "role": { "verboseLabel": "Non-cash adjustments", "label": "Restructuring Reserve, Accrual Adjustment", "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability." } } }, "auth_ref": [ "r251", "r256" ] }, "us-gaap_RestructuringReserveSettledWithoutCash2": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveSettledWithoutCash2", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentChargesScheduleOfAccrualActivityAndPaymentsRelatingToRestructuringA
], "lang": { "en-us": { "role": { "label": "Restructuring Reserve, Settled without Cash", "negatedLabel": "Non-cash charges", "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash." } } }, "auth_ref": [ "r251", "r256" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r59", "r83", "r559", "r586", "r588", "r592", "r614", "r734" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r109", "r151", "r152", "r153", "r155", "r160", "r162", "r164", "r228", "r229", "r242", "r385", "r386", "r392", "r393", "r394", "r396", "r397", "r398", "r407", "r409", "r410", "r412", "r415", "r454", "r456", "r583", "r585", "r598", "r1008" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r93", "r94", "r177", "r180", "r181", "r186", "r188", "r189", "r190", "r192", "r322", "r323", "r511" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureEverestCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration revenue", "label": "Revenues", "totalLabel": "Revenues, Total", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r93", "r94", "r132", "r146", "r177", "r180", "r181", "r186", "r188", "r189", "r190", "r192", "r227", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r441", "r546", "r699", "r912" ] }, "us-gaap_RoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureEverestCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty", "label": "Royalty [Member]", "documentation": "Money for usage-based right to asset." } } }, "auth_ref": [ "r916" ] }, "kzr_Rule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "Rule10B51ArrModifiedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Modified", "label": "Rule 10b-51 Arr Modified [Flag]", "documentation": "Rule10b51 arrangement modified flag." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r837" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r837" ] }, "us-gaap_SalariesAndWages": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalariesAndWages", "crdr": "debit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Annual base salary", "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold", "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": [ "r865" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosurePreFundedWarrantsAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "kzr_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "lang": { "en-us": { "role": { "documentation": "Schedule of accrued and other current liabilities.", "label": "Schedule Of Accrued And Other Current Liabilities Table [Text Block]", "terseLabel": "Accrued and Other Current Liabilities" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShareAntidilutiveOutstandingSharesOfCommonStockEquivalentsExcludedFromComputationO
], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive Outstanding Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureEverestCollaborationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r399" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt Balance", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r15", "r32", "r33", "r43", "r81", "r82", "r705", "r707", "r873", "r959" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Calculation of Basic and Diluted Net Loss Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted
```

earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r870"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r37"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Stock-Based Compensation Expense Recognized", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r37"] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtTables"], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of Estimated Future Principal Payments", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": ["r8"] }, "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherAssetsTableTextBlock", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Other Assets", "label": "Schedule of Other Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r7", "r465"] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": ["r41", "r42", "r637", "r638", "r641"] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentChargesScheduleOfAccrualActivityAndPaymentsRelatingToRestructuringA], "lang": { "en-us": { "role": { "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": ["r250", "r251", "r252", "r253", "r255", "r256", "r257"] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentChargesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of Accrual Activity and Payments Relating to Restructuring and Impairment Charge", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": ["r31", "r77"] }, "kzr_ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseTables"], "lang": { "en-us": { "role": { "documentation": "Schedule of right of use assets and lease liabilities table textblock.", "label": "Schedule Of Right Of Use Assets And Lease Liabilities Table [Text Block]", "terseLabel": "Details of Right-of-Use Assets and Lease Liabilities" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedIsCalculatedUsingBlackScholesOptionPr], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r334", "r336", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363"] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of RSU Activity", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": ["r84"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Activity under Stock Option Plans and Related Information", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r12", "r13", "r84"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Fair Value of Employee Stock Options Granted is Calculated Using Black Scholes Option Pricing Model with Range of Assumptions", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r86"] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShortTermDebtTable", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Table]", "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability." } } }, "auth_ref": ["r47"] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosurePreFundedWarrantsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Summary of Pre-Funded Warrants Outstanding", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r34"] }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "SOFR", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } }, "auth_ref": ["r948"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r762"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r764"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "auth_ref": ["r190", "r191", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r601", "r602", "r603", "r665", "r667", "r670", "r672", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r689", "r711", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r747", "r753", "r915", "r976", "r978", "r979", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1005", "r1006"] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentChargesScheduleOfAccrualActivityAndPaymentsRelatingToRestructuringA "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Severance costs", "label": "Severance Costs", "verboseLabel": "Restructuring charges", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r6"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r5"] },

```
"kzr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfCommonStockShares": { "xbrltype": "sharesItemType", "nsuri":
"http://www.kezarlifesciences.com/20240630", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfCommonStockShares", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Share based compensation arrangement by share based payment award annual increase in number of common stock shares.", "label": "Share Based
Compensation Arrangement By Share Based Payment Award Annual Increase In Number Of Common Stock Shares", "terseLabel": "Annual increase in number of common
stock shares" } } }, "auth_ref": [] }, "kzr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfCommonStockSharesPercent": {
"xbrltype": "percentItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfCommonStockSharesPercent", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Share based compensation arrangement by share based payment award annual increase in number of common stock shares percent.", "label": "Share Based
Compensation Arrangement By Share Based Payment Award Annual Increase In Number Of Common Stock Shares Percent", "terseLabel": "Percentage of annual increase in
number of common stock shares" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
"presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Option grant vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
"documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or
performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not
limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r716" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
"presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails" ], "lang": { "en-us": { "role": {
"negatedLabel": "Number of shares, forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options,
Forfeited in Period", "terseLabel": "Number of shares, forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that
were forfeited during the reporting period." } } }, "auth_ref": [ "r354" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
"presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": {
"role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Number
of shares, granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan,
stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r352" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails" ], "lang": { "en-us": { "role": {
"periodStartLabel": "Number of shares outstanding, beginning balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity
Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of shares outstanding, ending balance", "documentation": "The number of non-vested
equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r349", "r350" ] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
"presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails" ], "lang": { "en-us": { "role": {
"negatedLabel": "Number of shares, vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options,
Vested in Period", "terseLabel": "Number of shares, vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that
vested during the reporting period." } } }, "auth_ref": [ "r353" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
"presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails" ], "lang": { "en-us": { "role": {
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date
Fair Value", "terseLabel": "Weighted average exercise price, vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award
plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to
receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r353" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
"presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedIsCalculatedUsingBlackScholesOptionPr
], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
"terseLabel": "Expected dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the
underlying shares over the option's term." } } }, "auth_ref": [ "r361" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
"presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedIsCalculatedUsingBlackScholesOptionPr
], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
"terseLabel": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also
may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously
compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices
plus dividends, if any, over the period." } } }, "auth_ref": [ "r360" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
"presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedIsCalculatedUsingBlackScholesOptionPr
], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate,
Maximum", "terseLabel": "Expected volatility, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to
fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the
standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the
natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
"presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedIsCalculatedUsingBlackScholesOptionPr
], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
"terseLabel": "Expected volatility, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a
period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of
the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of
the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation":
[
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedIsCalculatedUsingBlackScholesOptionPr
], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
"terseLabel": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r362"
] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedIsCalculatedUsingBlackScholesOptionPr
], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
"terseLabel": "Risk-free interest rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } }
}, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype":
"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedIsCalculatedUsingBlackScholesOptionPr
], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
"terseLabel": "Risk-free interest rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } }
}, "auth_ref": [] }, "kzr_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitiallyAuthorizedPeriodEnd": { "xbrltype": "dateItemType", "nsuri":
"http://www.kezarlifesciences.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInitiallyAuthorizedPeriodEnd",
"presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": {
"role": { "documentation": "Share based compensation arrangement by share based payment award initially authorized period end.", "label": "Share Based Compensation
Arrangement By Share Based Payment Award Initially Authorized Period End", "terseLabel": "Authorized an offering ending period" } } }, "auth_ref": [] },
"kzr_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitiallyAuthorizedPeriodStart": { "xbrltype": "dateItemType", "nsuri":
"http://www.kezarlifesciences.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInitiallyAuthorizedPeriodStart",
"presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": {
"role": { "documentation": "Share based compensation arrangement by share based payment award initially authorized period start.", "label": "Share Based Compensation
Arrangement By Share Based Payment Award Initially Authorized Period Start", "terseLabel": "Authorized an offering beginning period" } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

```
"ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedIsCalculatedUsingBlackScholesOptionPr
], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation
Arrangement By Share Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r334", "r336", "r338", "r339", "r340", "r341", "r342",
"r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Maximum number of shares authorized available for
issuance", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r718" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares granted", "documentation": "The
difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments),
and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other
type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r35" ] },
"kzr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseAutomaticallyContinuingThroughMaximumPeriod": { "xbrltype":
"stringItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseAutomaticallyContinuingThroughMaximumPeriod", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Share based compensation arrangement by share based payment award number of shares increase automatically continuing through maximum period.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Increase Automatically Continuing Through Maximum Period",
"terseLabel": "Number of shares increase automatically continuing through maximum period" } } }, "auth_ref": [] },
"kzr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseAutomaticallyThroughEveryYearOnSpecifiedDate": { "xbrltype":
"gMonthDayItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseAutomaticallyThroughEveryYearOnSpecifiedDate", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Share based compensation arrangement by share based payment award number of shares increase automatically through every year on specified date.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Increase Automatically Through Every Year On Specified Date",
"terseLabel": "Number of shares will increase automatically through every year on specified date" } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Maximum number of shares issued upon exercise of
incentive stock options", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently
converted under the option plan." } } }, "auth_ref": [ "r343" ] }, "kzr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceModified": {
"xbrltype": "sharesItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceModified", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Number of stock options exercise price modified", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercise Price
Modified", "documentation": "Share based compensation arrangement by share based payment award options exercise price modified." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr":
"debit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate
intrinsic value, Options exercised", "verboseLabel": "Aggregate intrinsic value of exercised stock options", "documentation": "Amount of accumulated difference between fair
value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r356" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderStockOptionPlansAndRelatedInformationDetails"
], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of
options outstanding, Options cancelled/forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of
occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r347" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderStockOptionPlansAndRelatedInformationDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Stock options shares granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options,
Grants in Period, Gross", "verboseLabel": "Number of options outstanding, Options granted", "documentation": "Gross number of share options (or share units) granted during
the period." } } }, "auth_ref": [ "r345" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted
average grant date fair value of options granted", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated
by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r355" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderStockOptionPlansAndRelatedInformationDetails"
], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel":
"Aggregate intrinsic value, Outstanding balance", "periodStartLabel": "Aggregate intrinsic value, Outstanding, Beginning balance", "periodEndLabel": "Aggregate intrinsic
value, Outstanding, Ending balance", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } }
}, "auth_ref": [ "r35" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderStockOptionPlansAndRelatedInformationDetails"
], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number
of options outstanding, Outstanding, Ending balance", "periodStartLabel": "Number of options outstanding, Outstanding, Beginning balance", "terseLabel": "Stock options
shares outstanding", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r341", "r342" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderStockOptionPlansAndRelatedInformationDetails"
], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
"periodEndLabel": "Weighted average exercise price, Outstanding, Ending balance", "periodStartLabel": "Weighted average exercise price, Outstanding, Beginning balance",
"terseLabel": "Stock options exercise price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option
plan." } } }, "auth_ref": [ "r341", "r342" ] }, "kzr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber": { "xbrltype":
"sharesItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderStockOptionPlansAndRelatedInformationDetails"
], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options vested and exercisable number.", "label":
"Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Number", "verboseLabel": "Number of options outstanding, options
vested and exercisable" } } }, "auth_ref": [] },
"kzr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType",
"nsuri": "http://www.kezarlifesciences.com/20240630", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderStockOptionPlansAndRelatedInformationDetails"
], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options vested and exercisable weighted average
exercise price.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price",
"terseLabel": "Weighted average exercise price, options vested and exercisable" } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "crdr":
"debit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Incremental fair value", "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost", "documentation": "An excess of the
fair value of the modified award over the fair value of the award immediately before the modification." } } }, "auth_ref": [ "r367" ] },
"kzr_ShareBasedCompensationArrangementByShareBasedPaymentAwardSubsequentlyAuthorizedAdditionalPeriodStart": { "xbrltype": "dateItemType", "nsuri":
"http://www.kezarlifesciences.com/20240630", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardSubsequentlyAuthorizedAdditionalPeriodStart", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Share based compensation arrangement by share based payment award subsequently authorized additional period start.", "label": "Share Based
```

Compensation Arrangement By Share Based Payment Award Subsequently Authorized Additional Period Start", "terseLabel": "Authorized an additional offering beginning period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderStockOptionPlansAndRelatedInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Options cancelled/forfeited", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r347"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderStockOptionPlansAndRelatedInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Options granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r345"] }, "kzr_ShareBasedCompensationExpensePlanModificationIncrementalCompensationCostOfVestedOptionShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "ShareBasedCompensationExpensePlanModificationIncrementalCompensationCostOfVestedOptionShares", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Share based compensation expense plan modification incremental compensation cost of vested option shares.", "label": "Share Based Compensation Expense Plan Modification Incremental Compensation Cost Of Vested Option Shares", "terseLabel": "Stock - based compensation expense" } } }, "auth_ref": [] }, "kzr_ShareBasedCompensationExpensePlanModificationUnamortizedIncrementalCompensationCostOfUnvestedOptionShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "ShareBasedCompensationExpensePlanModificationUnamortizedIncrementalCompensationCostOfUnvestedOptionShares", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Share based compensation expense plan modification unamortized incremental compensation cost of unvested option shares.", "label": "Share Based Compensation Expense Plan Modification Unamortized Incremental Compensation Cost of Unvested Option Shares", "terseLabel": "Compensation expense related to the unvested option" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "terseLabel": "Exercise prices, lower range", "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": ["r36"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "terseLabel": "Exercise prices, upper range", "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": ["r36"] }, "kzr_ShareBasedPaymentArrangementOptionExercisePriceRangeOutstandingModifiedExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "ShareBasedPaymentArrangementOptionExercisePriceRangeOutstandingModifiedExercisePrice", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Modified exercise price with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Share Based Payment Arrangement Option Exercise Price Range Outstanding Modified Exercise Price", "terseLabel": "Modified exercise price" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Options granted expiry period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r717"] }, "us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedIsCalculatedUsingBlackScholesOptionPr], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (years)", "verboseLabel": "Expected term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r359"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderStockOptionPlansAndRelatedInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term, (Years) Outstanding balance", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r85"] }, "kzr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue", "crdr": "debit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderStockOptionPlansAndRelatedInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Sharebased compensation arrangement by sharebased payment award options vested and exercisable intrinsic value.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Exercisable Intrinsic Value", "terseLabel": "Aggregate intrinsic value, options vested and exercisable" } } }, "auth_ref": [] }, "kzr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderStockOptionPlansAndRelatedInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Sharebased compensation arrangement by sharebased payment award options vested and exercisable weighted average remaining contractual term.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Exercisable Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term, (Years) options vested and exercisable" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Option price per share of common stock at fair market value", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "kzr_SignOnBonusAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "SignOnBonusAmount", "crdr": "credit", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sign-on bonus", "label": "Sign-on Bonus Amount", "documentation": "Sign-on bonus amount." } } }, "auth_ref": [] }, "kzr_SignOnBonusOf2018EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "SignOnBonusOf2018EquityIncentivePlanMember", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sign-on bonus of 2018 equity incentive plan", "label": "Sign-On Bonus of 2018 Equity Incentive Plan [Member]", "documentation": "Sign-on bonus of 2018 equity incentive plan member." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r73", "r143"] }, "kzr_SouthSanFranciscoCaliforniaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "SouthSanFranciscoCaliforniaMember", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "South san Francisco, California.", "label": "South San Francisco California [Member]", "terseLabel": "South San Francisco, California [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "terseLabel": "Equity Components", "documentation": "Information by component of equity." } } }, "auth_ref": ["r11", "r57", "r60", "r61", "r109",

```
"r129", "r130", "r131", "r151", "r152", "r153", "r155", "r160", "r162", "r164", "r178", "r228", "r229", "r242", "r321", "r385", "r386", "r392", "r393", "r394", "r396", "r397", "r398", "r407", "r408", "r409", "r410", "r411", "r412", "r415", "r443", "r444", "r445", "r446", "r447", "r448", "r454", "r456", "r466", "r566", "r583", "r584", "r585", "r598", "r656" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical" } } }, "auth_ref": [ "r190", "r191", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r601", "r602", "r603", "r665", "r667", "r670", "r672", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r689", "r711", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r747", "r753", "r915", "r976", "r978", "r979", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1005", "r1006" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseAdditionalInformationDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r151", "r152", "r153", "r178", "r456", "r511", "r590", "r600", "r606", "r607", "r608", "r609", "r610", "r611", "r613", "r616", "r617", "r618", "r619", "r620", "r622", "r623", "r624", "r625", "r627", "r628", "r629", "r630", "r631", "r633", "r634", "r635", "r636", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r656", "r754" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseAdditionalInformationDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r151", "r152", "r153", "r178", "r193", "r456", "r511", "r590", "r600", "r606", "r607", "r608", "r609", "r610", "r611", "r613", "r616", "r617", "r618", "r619", "r620", "r622", "r623", "r624", "r625", "r627", "r628", "r629", "r630", "r631", "r633", "r635", "r636", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r656", "r754" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r771", "r781", "r791", "r823" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "kzr_StockIssuedDuringPeriodSharesCashlessExerciseOfPrefundedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "StockIssuedDuringPeriodSharesCashlessExerciseOfPrefundedWarrants", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Cashless exercise of pre-funded warrants, shares", "label": "Stock Issued During Period Shares Cashless Exercise of Prefunded Warrants", "documentation": "Stock issued during period shares cashless exercise of prefunded warrants." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock net of offering costs, shares", "verboseLabel": "Issuance of common stock", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r11", "r56", "r57", "r83", "r591", "r656", "r673" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Number of options outstanding, Options exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r11", "r56", "r57", "r83", "r346" ] }, "kzr_StockIssuedDuringPeriodValueCashlessExerciseOfPrefundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "StockIssuedDuringPeriodValueCashlessExerciseOfPrefundedWarrants", "crdr": "credit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Cashless exercise of pre-funded warrants", "label": "Stock Issued During Period Value Cashless Exercise of Prefunded Warrants", "documentation": "Stock issued during period value cashless exercise of prefunded warrants." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r57", "r60", "r61", "r75", "r615", "r632", "r657", "r658", "r734", "r761", "r872", "r903", "r958", "r1008" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosurePreFundedWarrants" ], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Pre-Funded Warrants", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r80", "r145", "r305", "r307", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r319", "r321", "r414", "r659", "r661", "r674" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r449", "r475" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r449", "r475" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r449", "r475" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r449", "r475" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r449", "r475" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureSubsequentEvents1" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r474", "r476" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosurePreFundedWarrantsAdditionalInformationDetails", "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "kzr_SufficientCashAndCashEquivalentsAvailablePeriodTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "SufficientCashAndCashEquivalentsAvailablePeriodTerm", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Sufficient cash and cash equivalents available period term.", "label": "Sufficient Cash And Cash Equivalents Available Period Term", "terseLabel": "Sufficient cash and cash equivalents available period term" } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetComponents" ], "lang": { "en-us": { "role": { "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Components", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r856" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype":
```

"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label":
"Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang":
{ "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r817"] }, "srt_TitleOfIndividualAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role":
{ "label": "Title and Position [Axis]", "terseLabel": "Title of Individual" } } }, "auth_ref": ["r885", "r963"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role":
{ "label": "Title and Position [Domain]", "terseLabel": "Title of Individual" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label":
"Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r809"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder
Return Vs Peer Group" } } }, "auth_ref": ["r816"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]",
"terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r836"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading
Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r838"] }, "dei_TradingSymbol": { "xbrltype":
"tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol",
"verboseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "kzr_TrancheAvailablePeriod": {
"xbrltype": "stringItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "TrancheAvailablePeriod", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Tranche, available
period.", "label": "Tranche Available Period", "terseLabel": "Tranche, available period" } } }, "auth_ref": [] }, "kzr_TrancheOneMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "TrancheOneMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Tranche one.",
"label": "Tranche One [Member]", "terseLabel": "Tranche One" } } }, "auth_ref": [] }, "kzr_TrancheThreeMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.kezarlifesciences.com/20240630", "localname": "TrancheThreeMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Tranche three.",
"label": "Tranche Three [Member]", "terseLabel": "Tranche Three" } } }, "auth_ref": [] }, "kzr_TrancheTwoMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.kezarlifesciences.com/20240630", "localname": "TrancheTwoMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Tranche two.",
"label": "Tranche Two [Member]", "terseLabel": "Tranche Two" } } }, "auth_ref": [] }, "us-
gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label":
"Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to
exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other
financial instruments on potentially favorable terms." } } }, "auth_ref": ["r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207",
"r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r298", "r318", "r413", "r440", "r477",
"r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501",
"r502", "r503", "r504", "r505", "r506", "r507", "r508", "r567", "r722", "r723", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r735", "r849", "r850", "r851", "r852",
"r853", "r854", "r855", "r899", "r900", "r901", "r902", "r950", "r953", "r954", "r955", "r956", "r957"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": {
"label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r839"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": {
"label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r840"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": {
"role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r840"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": {
"role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r838"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": {
"label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r838"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": {
"en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r841"] },
"ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" }
} }, "auth_ref": ["r839"] }, "kzr_TwoThousandEighteenEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.kezarlifesciences.com/20240630", "localname": "TwoThousandEighteenEmployeeStockPurchasePlanMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"documentation": "Two thousand eighteen employee stock purchase plan.", "label": "Two Thousand Eighteen Employee Stock Purchase Plan [Member]", "terseLabel": "2018
Employee Stock Purchase Plan" } } }, "auth_ref": [] }, "kzr_TwoThousandEighteenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.kezarlifesciences.com/20240630", "localname": "TwoThousandEighteenEquityIncentivePlanMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"documentation": "Two thousand eighteen equity incentive plan.", "label": "Two Thousand Eighteen Equity Incentive Plan [Member]", "terseLabel": "2018 Equity Incentive
Plan" } } }, "auth_ref": [] }, "kzr_TwoThousandEighteenPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname":
"TwoThousandEighteenPlanMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"documentation": "Two thousand eighteen plan .", "label": "Two Thousand Eighteen Plan [Member]", "terseLabel": "2018 Plan" } } }, "auth_ref": [] },
"kzr_TwoThousandFifteenAndTwoThousandEighteenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kezarlifesciences.com/20240630",
"localname": "TwoThousandFifteenAndTwoThousandEighteenEquityIncentivePlanMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"documentation": "Two thousand fifteen and two thousand eighteen equity incentive plan.", "label": "Two Thousand Fifteen And Two Thousand Eighteen Equity Incentive Plan
[Member]", "terseLabel": "2015 and 2018 Equity Incentive Plan" } } }, "auth_ref": [] }, "kzr_TwoThousandFifteenEquityIncentivePlanMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "TwoThousandFifteenEquityIncentivePlanMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"documentation": "Two thousand fifteen equity incentive plan.", "label": "Two Thousand Fifteen Equity Incentive Plan [Member]", "terseLabel": "2015 Equity Incentive Plan" }
} }, "auth_ref": [] }, "kzr_TwoThousandTwentyTwoStockIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kezarlifesciences.com/20240630",
"localname": "TwoThousandTwentyTwoStockIncentivePlanMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"terseLabel": "2022 Stock Inducement Plan", "label": "Two Thousand Twenty Two Stock Incentive Plan [Member]", "documentation": "Two thousand twenty two stock incentive
plan member." } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"TypeOfArrangementAxis", "presentation": ["http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureEverestCollaborationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Collaborative
Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "documentation":
"Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r399"] },
"us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureRestructuringAndImpairmentChargesScheduleOfAccrualActivityAndPaymentsRelatingToRestructuringA
], "lang": { "en-us": { "role": { "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": ["r250",
"r251", "r255", "r256"] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"USGovernmentAgenciesDebtSecuritiesMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesRecordedInCashAndCashEquivalen
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfGrossUnrealizedLossesAndFairValueByMajorSecurityTypeFor
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
], "lang": { "en-us": { "role": { "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government agency bonds", "documentation": "Debentures,
notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae).
Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation
(FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": ["r695", "r712", "r974"
] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember",
"presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesRecordedInCashAndCashEquivalen
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfGrossUnrealizedLossesAndFairValueByMajorSecurityTypeFor
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
], "lang": { "en-us": { "role": { "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury Securities", "documentation": "This category includes information
about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills
(short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } }
}, "auth_ref": ["r695", "r712", "r714", "r722", "r974"] }, "kzr_UnauditedCondensedConsolidatedFinancialStatementsPolicyTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "UnauditedCondensedConsolidatedFinancialStatementsPolicyTextBlock", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation":
"Unaudited condensed consolidated financial statements.", "label": "Unaudited Condensed Consolidated Financial Statements Policy [Text Block]", "terseLabel": "Unaudited

```
Condensed Consolidated Financial Statements" } } }, "auth_ref": [] }, "kzr_UnderwrittenPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.kezarlifesciences.com/20240630", "localname": "UnderwrittenPublicOfferingMember", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosurePreFundedWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation":
"Underwritten public offering.", "label": "Underwritten Public Offering [Member]", "terseLabel": "Underwritten Public Offering" } } }, "auth_ref": [] },
"ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent",
"terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r835" ] }, "kzr_UnvestedOptionSharesCancelledDueToTermination": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630", "localname": "UnvestedOptionSharesCancelledDueToTermination", "crdr": "debit",
"presentation": [ "http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": {
"role": { "documentation": "Unvested Option Shares Cancelled Due To Termination", "label": "Unvested Option Shares Cancelled Due To Termination", "terseLabel": "Unvested
option shares cancelled due to termination" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "UseOfEstimates", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of
Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of
financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r26", "r27", "r28", "r102", "r104", "r105", "r106" ] },
"kzr_ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kezarlifesciences.com/20240630",
"localname": "ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "crdr": "credit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": {
"terseLabel": "Issuance of common stock under equity incentive plans", "documentation": "Value of issuance of shares under incentive and share based compensation plans.",
"label": "Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans" } } }, "auth_ref": [] }, "us-gaap_VariableLeaseCost": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosureLeaseDetailsOfRightOfUseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label":
"Variable Lease, Cost", "terseLabel": "Variable lease costs", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for
payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r462", "r733" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]",
"terseLabel": "Variable Rate", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]",
"terseLabel": "Variable Rate", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] },
"ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date
Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } }
}, "auth_ref": [ "r805" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WarrantsAndRightsOutstandingTerm", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_DisclosurePreFundedWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Warrants and Rights Outstanding, Term", "terseLabel": "Pre-funded warrants, term", "documentation": "Period between issuance and expiration of outstanding warrant and
right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS'
format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r953", "r954", "r955" ] }, "us-
gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareDetails",
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": {
"verboseLabel": "Weighted-average shares of common stock outstanding", "terseLabel": "Weighted-average shares used to compute net loss per common share, Diluted",
"label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "documentation": "The
average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of
shares or units in the period." } } }, "auth_ref": [ "r167", "r172" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": {
"label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator:" } } }, "auth_ref": [] }, "us-
gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.kezarlifesciences.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Weighted-average shares used to compute net loss per common share, Basic", "label": "Weighted Average Number of Shares Outstanding, Basic", "totalLabel":
"Weighted Average Number of Shares Outstanding, Basic, Total", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or
units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been
outstanding to the total time in that period." } } }, "auth_ref": [ "r166", "r172" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and
Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r803" ] } } } },
"std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230",
"Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-
10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)",
"SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic":
"10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r9": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r12": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic":
"718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" },
"r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-
02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r18": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r21": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r23":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-
5" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph":
"1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r28": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r31":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
```

"Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "808", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480000/505-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting
```

Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r295": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r296": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-
50-1I" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r300": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r301": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r302": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r303": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r306": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-
50-13" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r310": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-
50-14" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r314": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-
50-18" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r318": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r321": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r322": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-
20-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r326": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r327": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r328": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r329": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r330": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r331": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards
Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r336": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-
10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r340": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r341": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r342": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r343": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r344": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r345": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r346": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r347": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r348": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r349": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r350": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r351": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r352": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r353": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r354": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r355": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r356": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r357": { "role":
```

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-2B" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",

"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A",

"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

```
"Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r609": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r610": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r611": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r612": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r613": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r614": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r615": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r616": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r617": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r618": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r619": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r620": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r621": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r622": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r623": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r624": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r625": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r626": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r627": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r628": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r629": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r630": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r631": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r632": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r633": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-
50-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r661": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-
45-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r665":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r666": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
```

"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r731": { "role":

```
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r734": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r736":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932",
"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r739": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932",
"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r742": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932",
"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r745": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-
40-55-9C" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r751": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r754": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)
(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r760": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "b" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "b-2" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "d1-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q",
"Number": "240", "Section": "308", "Subsection": "a" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section":
"16", "Subsection": "f", "Paragraph": "a" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6",
"Subsection": "F", "Paragraph": "1" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection":
"F", "Paragraph": "1", "Subparagraph": "i" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6",
"Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r772": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence":
"D" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1",
"Subparagraph": "i", "Sentence": "E" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6",
"Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F",
"Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F",
"Section": "19", "Paragraph": "a" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph":
"a", "Subparagraph": "1" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a",
"Subparagraph": "1", "Sentence": "i" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F",
"Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form
40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-
F", "Section": "19", "Paragraph": "b" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",
"Subparagraph": "1" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",
"Subparagraph": "1", "Sentence": "i" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR",
"Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form
N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r801": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "iii" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1",
"Subclause": "i" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1",
"Subclause": "iii" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1",
"Subclause": "v" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r810": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "vi" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "3" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "v", "Paragraph": "4" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r815": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5",
"Subparagraph": "iii" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
```

"Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/210/tableOfContent" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r892": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" } } } ZIP 78 0000950170-24-096213-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-096213-xbrl.zip M4$L#!!0 (%F!#5D0B\Z><^8 +H] 0 1 :6UG-# Q-3DV,CE?,"Y] M<&?LO =05,O6(]H)@B(PDC,H6:)(C@,B69+DK))!LN0P"

*I*S@J2)*O7_?JO;I7VK.1WY#S_MP"U%6059 T=_-!0_P#D%" -7,?"PL:Z=AT;&_O&C>LXN,1XN#=OXE(0$H&(*

*M:2CI:&DHJ:EO,W*QW*;G8*"F9A6\RW&/AX^/CXV%6%SHOA@7+[_]'R!H-V[<_MP+V)2XZ'1WI_#O6=^__UA6P!""ZC?\>6Q$"C!})T# (T)!M !UJGM?0?KN M?UYHZ!B8U["PK]_*

N8GJ4'D+0$?#P$#'Q+AV#1,3==<7=1_)+A&>(="'HM(M_2DVO1/Q_9?1'Z\S/"C]3/)X;(^1]YESP T<4C)R"DHF9A,6NVQ_*"0L(B MT@JE9.7D%10U-+6T=73U!$W-

S"TLK;QM'7%ZXNKE\>'H%OGH=%/$E;4A,;%Q\ MPKOWB4D5F59..EY^05EY1655+4UM75?6MO:.SJ[NGN&1T;'QB> ^?9[<6%Q: M7EE=6]_8W#\X/#H^.3TfO_@A%QJ

*@?:OZR_E(D#)A8Z)B8&)_4,N-'3W'QT(M,*_=X<$BE%+'?NI$1'__Y77B!]$?2S_?8.!]O$?RS'D(AY21;X%[_X=HOTGV MGPD6\+4F6>B/BAIZZ='8:FBUQ@I+9)?BU6NG-G@0)P>21*

*N7R,Y_YX[,:E MT71$,$(OL!)RI]U5&ONQ"6FPV+Z;@8V7[VX(GRWU6^Y,=[H6LGZ(2EKX$R/X MPVK#4"4*N]M\7>YU7E, UN*;^7SH\3V/Q,8*D=!(6ACA\D/,>9H09M5-94OE*

M13L;GU12PK$PG=XJ1YQ95FI'O-HVF$'-WU?V0N3XW?5(.11$00JO=:',L=-M%!?\-)Q:40M4(D.";/739U3PVTV\,P7VEY<5:QLG[F)O`I95G^(\ M$FBZ;$ZU59SK%.DU@=%2(

%8E@<2&'0R'"-)SI?.'2=.VG1W:[XU.F_TC6!S ML DBC>"OMURN[5'D>GRV,/9K5R!PMHW4WJfZ#T4Q-)-N:R7R@&1]5$>L-)YV MDHJ#CZ"-

*I36OA>J8A:7IFR2B\CY_YFT7UVPLLOE.)C 97*0/[DFZ(%++#B!% ;@I%%X4BL(*&N M3[I%9]"*'=B!5+G)WOE<67[OJ8]==@4KTV5.+"@YG/QF!$P!*ERTO1S9S&5*

*M$JHRD0,*E>O%N0K[[2OYNKL3V_>.9H6<$.#(-<-<&]9D!GYK^HPM;\ZG@;.O\ MSVOZC\]X'47RCQ@J#4I(*QIJ2E,L*Q,SHEZ8@]?X9] MH(.#-@Q)'/M%.C5M$L?594AZ[V6$L+_QZA@D!?O!./[/)YXL2+@:SQ MWR2MQ/;/"C4<1GBOT=:KLQFPSN)Y(77WP'2@7U_\W\R)1+L] M,?,=*]';90R6JB5)TKR.$(#U;U%\)D77-(&@!U<@K^TH^)%=3%*

MWK>NQBW2"[''^Y2@#Z/_Q,.S.C&Y.8KS*?%Z>QV!=&Q>MKL6MUDI&%,!$HE]-MEO!9;6lQIAZYH1UL,23@/N@]!B+VJ%+62QKNK7"[?>!%X=\OK+BI,=H1@%QN74K&%U?*

*1'9M]Y0PW/M4GCF;L\TFZ_J4?&&@HQ1-MLKJ*2E=Z@5Y 'M/;%HQ&UTGNEUPEZ'UYY?I?/ E>7G8@@47(,F$52KYIR$M M(Z+^VDY>H;4]FD+*

*[ALEOXT>YIZGQU/3ZO1]SUL*IJ#NW>?NG-C(QOu!M5*"HN"ZG MNH $R%1SXJH:./ES);TJ(<KJV\9O,?<-6V*EZ+N)P\@KOSD^$:(^_7&0/)_7-*

*MO:_/<[XXH.JT#DEQT4[/W15SCMZLT"1UCS*9S.ZK>+GH]FNZW+TN&4LZ/^4 M;=$L0P(FOBBBNZ37]LLW1S1=(IK)P\+7_RT;Z1\74[8;X9"/\#?)RG7=CCR*

MA@UB'NF08$=4WLSS@4%PI_O(E/?K[R.>LMNVSC)5[.,K$K($>#3!55Q>;H*\ M@*G?M3#/5C_M1"):' G$KGGJG@O:]TK&N.?!QT_<6NP%C+(9?/

ML0G'(9PE=)NJPTLFG(H'NPX8BGP!5-XSX-1(55VO(X%)5?U$O^ XL+/A\HXN'##%Z;Q"ST{"!X052,1-=9EM1C,-\4 [;.<;_MH(@'3V$!1=:.MRMFO!'IS=V8^H"B>G)65Y9%7.:!'J1L-*

G&X]=8FP:PTKQSNU[ZCSG9";X;)M%]=RH5!)RU-(FCJX^Z__@MRY#WIC!P=;,$7=L'1Y M,S]749V_[H@-M=(U\]U7J:K_7M[_UFPJ>,NKGU>2]-->3)+\`"70Q[R)JJ@\!

M736TD$"4\MR5D\.*]OJ_G\VU4,_VQU:360*W-DH\&4N#C6)N*3"& <1KV@^1-MP*L=)>LE{PWINK*W_1BU+$=LO)(T\22OBSVB7UCS'1L\=:P.DWS/),9X45]*

*MM3GSBOM$SIJD\&N).G.9;/&/?<_=6Y.E2Y?H"D/PG5(IE=Y,X>U953IYO,M= M+M'G&&G/U;"E_VW?\B&\8PW(A:?XB$%/L.R<-4>!PL&6%/D-L+GGM9R*1 MUA]%_J5';W?A:.:*

{IG=WU]LZ2L$"888_'FIJWDV,31=T!4_21HH MR=NGBI9V2@]J!2Z%+SZN38W %9)*(&C'A5@6;_,IK%GC31H,4<7B#] M%#_I-$:.)W/7['$6=T;$:UG;4CD] M B-

*YMM;,$8O^1+ ^!?!TIGK*CV_@M;I_&A;"I'4E'C3);L:];YZ04!^UR8]_.I$WI6$'-M;\WOCQL/>1V)%%LR[MWUOMA]0C)^I?K'48/?UR=(+/&"1OHL$<+,R' ,M]3'$Q MKON.0%^-=$*Y*

*M1R8HFE&*O>1> ^\W;>R)77[_@VQ138Y$2I<*0IN:,4$HV=^N3]NR,N=U BE5&1^UC-7=+<7-Z7$)>)C/!$QT]4&5$S R3PVHED MXT%&4AV&9>LDO(YI3M&;#*

{1KBLB<.Y_(EQ+346/<$_)(-M=U)UF,'_;0:,-6 MJB-%19/!=]? !WV-?]F5K[W$OB;;B]^DZ'HZL]HP?QZ_Z7#7PG-!2%)&7GDK M((TI&8M?*

EVSVF'N)V_=%1CQW1!V#R^!CA*D_C9^:1%SK8ID_/=M"!21*? MX-92V_&8RI6VQ9N>= M.OO\RR+CF?S0U^^7D"Q\+(S4;ICX:XPZZO,IS)?RPSMWF@)!HE>G,[V]9 =%*

MB3:TN/GL7!0F=ES%;]RIB8 EWHEZ&3B73W,.F_5G/=,P$(C9K+)^<>]F/=AP MLC,?6.GMTK4I=)+'%XG?O=@GX:N-0$ J1K7F&NZC(@

M/>S/"FL^4#]RN%AMOD#2\K1;WH>$.FP5%^=$= S<,0U;8J1V7Q(>$(+&<@U MU^X7)^9)8\%TU1_&.*@']ZR2QA,7*2K#;$Q-V\8@E+]J#$3N13VUF

*M66R%CGB9/F>EZDHQ^BKA.2B6*L#-BZ@+8OJ_::S'YM8ZY&D3\\F2UEB0R38/-MPP+8]%ZN6/E%DGWB(E5-)=;8+B;!)O/#Z@?*

DLO(=OOY'V$F]Y<, ^R:=86.ZL%6GH4_2,'/08:;ZW@$O>8T&'/[@]XRJ5.JO*I&.5;. M=L(P,/"8&"W]\R-T#;4?EIFL$5MI7:B= X;_@H)G8L]QJO]L?E!$;_FT8,:: MF&,\=4(IZ2K5$K?*

4DDTP585XI>;W#-C(URC.MM?-5U51,(JY;C.0RN@++ M2+:-A[=<<<7'4TS/TV8.J/"O&ZJ_[(3S$@9\S;#MPT(,2'.]VN7IT MOM^GYC$*CQ<UZNI(U>/09-)&MGB8A?P"73-*

UX+(:V M"1V.55I$+,7ELIF](OU2Q>M'4_&JG&4JS6<;4@10[9$V0-?HD\'EYB;$<':_M5K/N;H!R@>OA;5\[I1=JQ1MG:C+0F"_RE24;GF\AQ>.;3+H>,.\UF\GHN1T/*!?*

OI#"H#_\0A2F3JUF5%&_X"G_PAY M$$6/-)'.1AN_YH P-? M$_6GBLH4OZEG[K)K_FW)T=O]/$?I^%HE?#/H)\,PJ;'<&M%2^ HW/>1^,%@B M%['&G_ E^;N_*RPI[,Z3.>E-

&>1>=+38+:V3)R.DBV"L&"_W@X/MMOFFMK56 M$KQK+:[I#+I#D.]1ACX3 7H#.R2KF+DXBD0 4B6K[I.]X?K[*K279!Q[?. ^.[7 MYFD]&?$&AV_'3,B652>Z?)26^'E&+C)]H>

*<4(I\';YHO%N=Z4+95 M!R$E"#EN;X[_=[<2!-ZWZTWP$QKANE/MGO4I86<$]BT:1M$T?(M39$:KY4.C_L#\WK3 &X$XVXT,>?L-W):P.*6N/]0!^_MK/P<<<)"/3-:T@?'T5Z9>_T?*

#34K.Z0A,VG/H+IG5Z47V;-R)HV-HWWP;_8?C49YO'>Y;JQQ3R6]>HHX65G0P44["9!%>T6;P5D$S M5QJE@"$2\(@7OL)6[-T+[XQ=GO123FIO RK,^B|SN9G2$V; N'0?HV(+=0[

*M:X"Y"43/=6Q4= R_.CMW^:Q6'1UXYS.6O*36_(L MV.Y 2^FT=0G$&O1ZIUX0>N<[EP%!Y!.0JLKUXA1NTR&GE:8$%XO.;%\\ M/%:QfGN3(KM:6)@0.2517E%)UUQ[N(J>0&MGB8A?P"73=*

=",BW09?7.DGP%6-@Z\7K%%B&DG?_ MMW/=TE._&CZT3M!6:382L(+8HR2P]X7;^5B*"YH6BZZ1;*32C#*.\=U4JO6, MG\!W"HN29SDJMAB>ZYATS?*R:Q#((>|GG"^+*

*(1,7%@?/"Q>/?U.I&@!)Y?,.M.C14=E?BBS_O+O0H7&3E^&N%_&]XHP7C6LX[;)>1;)N*0A MV7?PQLXZESI<=ML%V_4MW_;6?!> "QAX:B\5(1C_H'9'?AI4O:"?)#X0@K=U*

*MSX92*ZRS>,,#V1U,/P!E^U?Q'17[_.^E(H. #HKX,"7RDK/I9FY8D7?_% M.6W9+X&'Z.P!1 *#X!4S#&U)E56O':QM%Z;ROW16L]"%5#>A'\%M_'9EXCLR*

M%Z8#73AWTN^U#X)JKC#552ZI6NJN1'"&,38R&'^_ "_M?!IZ;!NNL?5<4'9"1?#6QSI7ZJ60E6-KOL*;WJ{EH,:Y208?!<_*,<.EJV)$ MB|NKW49,-IJ[3/7)FE/T7#==.ULN5@*

MW)59.LS,O1_[H_@ZN@F%X5>:DZ33T@'F" U>1L;BU;4 9_'2 ;C"0O:@B>YA MA:^L!P.+ +X\KA-BW.6,EF>\BI_[3/Z6OD)NJP,'&G:;!1VT;TO1-K@$NX&.;M\Y>RIC7L&41U"6=K6Y-

*1K*XO^/*ZB,$[+MM-26Z^X\7&!7M,@-MH='D**=4-(S:;A+HO.\C)&]NZ$^TSB6;&-6'?T9$Y#<_>'$Y,_^3YY/U0NT M$O(57[OT:Q&FX^OW%#$=T -4,?(&:#JE.J&N?G>&#?*

2&&2LB3-@,@\!++G&K.F;]R'V-U56-&-T5%[HB=|)>@?.9W\L4V3_6A@1<6J;5X" MV5S-3XMTI6CFOK?@V>^0?62YG2](*>QP@#)NZ.= H,;MQT<7CJE,;W. @-.MH=&%UTWMZ%?*

*QCM)Z#'"'AA1/+%KJ=N^LWF=SG%RZ5/9'UEL;G6/'*S\4D@_? M.:APZBUZ9DC0[Q3;[U%@)2(.EQ!K<*)'7NT&*<;4CF?KY6NBU)/1'B(YR> M,V=ULB?6SBRA0?I$11#?R_4\7&_?+*

JE.DQ(O/+D,Q"5'T+5,BEF6O">N;._1 M=,\VO39)9> ^F[\PX5LOEDL 2,RMP&O\73'LWGJY1CEY,9"LJ:OP43:\KQ'0 M 8Q2/K1W^1NJ'Y!;&{R3QM,**'N@.%RE1--"?*

1&8&I2[K_(1[S2DN9R?:H2.M 3 MKXO8X>"SZ/NP(^"PBSJ"0\'!?9B[DE-)PDB4.,YPGEW-M.]W4M-3B;UW"(-M7{?R:()/E7/M,IFNV6W0]1B+BTZ

4[62IN8B1@87TZ;+01^Y'GW#^@-M",O[Y;H7ODUJ9$9Q8\GF2349D9Q-+%]8Z:Y- HO8:EXN1D&O?)0X1\M@Z)/D MU\^?2M[$V)(2\U4H:"(;VCW:-M5-W0%QL;\5?#@UND/U_D3,%?

*6 LJJJ(X;'MV3W*5]I>DK&P ,^R?XW!<_)1AK@^[6(5I79CX&4R%Y3>]0$&/^QTL6T[@A[1 M47HI7@_)Z:[!F.,0K>X,C'!.,"19V6C N>S+M5&=B3@ MY)U6DNU-*

&!-2+V8ET_V=,I5HK]66]RIGR:0T'!5UYP1?9DZ-3N33NU9Q)2;QVBDH&3_/4-#-1832Q-M;"2Y.M-@2% M^O">/+N(C_%;/N05/0/EG2!,OC9EF>0(RJGUM&(2?"-)%HG 7P<19$,,B;R4

*M,TUVPHBL[_9:7C85V!(VLG8K&\%'7'ZN0P*3#)1&(XAC[!U=)$ 8N7 1N7)4 M_*5!^T96=4V$U?NBZ$_F3[^%'/?1:41]CSRK>X0N2P.I:\TKYI"1T.EIF7%_MK&[8]OK7-,[_DD@XFB?*

*F(!.=B*YX^P(]2$D3$BB)O(IFF_G[D?,?V;'^'%@\ MH3AR]1T<|:>DZ'|%:#]GXS9_]@@'_W8!XK](D_VG]*?3N%]+ "O%@'PE,8*,< M@P1_S]&_67/1 ^E<^::.PNOP#2Q;6&]$U"G?*

0D.H^,0Q^-Y#9\V'E8VVE_!29Z M^=L+ 01&R8)M>%;=CDF/. D@C_03'V"8X2/!739M?4Q.RL&KS]\"FU$UB M>53KB,^;S5%=KE^[8'/4V31:

*!QM;0**@!%C.P'GR>!ZFY7U/'/[OL^A8'/N M('3PH')WYGN[9(\)N=(Z&,&H-"+8Z=S8_XUZFIUVJV):GB M?E,SY9B'(0(QLM??W.3E:0%'ZG$/K0\2GP9I$/AF83U!6Q*O*

M+4C"#BGRD7'RQDO6N3[^G%3Z?AYFC!PYRV6.O^!?E91R"ZR',))\[F+QJ7V@-M5^~;MET[T.SRNH1)\RG&YUJOO66=^P)!^.LE%##P(%2EP_L,2_ATJ2,]%'^Q 8(F%KAJ:*

M]4T&KARX4.SK^~4Q>-/05(%G:Y <#?72#B9V, QF2TT8D0VJW8_R%A0TK M-'MI.Q'8Z^S5&]%GSKC[LDGM8'Q3F^$]RIGC&LHQ41G[7DG+TTV OW\%-.*

*M&NV*9UQH"NPI$.?S$(TS':BV33)UFG17)O9C&_;\=7V)#[2QV5*6M*"$9E[0 MHNDHPM4KA'W-P-G=&J4W8MXA%%9^OGS:0GWB 2# MX4;0[I-*

]UZQ3HLSHN+;\D3OQYU(TGW>3@,$]YS.Y]7V&32^^:C?W>@.!DH- M:W(A@#KB#"\S/=_5A- C4&__T04HB/;Z1 \HQ845._KSY04.%1&BY G^C&Z'

*M1;JWVN_]\>./T[O_5J)'@8XRU-S>3W1,C*1&]Z">^>U+NHY<&[NT.0$+:)- M.'4-]#@+,.[P<5<-V68 0;N:VD=%2[>.T3>QSG:V%/9$7.<*@P9=]V1CACU[(*

M.V>?/+UR09FS\J1G_4=7IFTS=[>A8[N\A0O$R42]B4O;& 1N.!E!3,*N%M-C21$B%8TX4,/H?-.@L=A6S]/3N1+[!OHRJYX=#SH>N4!?Z&00 M!!8.\C2MLVDMCCG\Z9K'Y^JO#*

*X_(13KR9[2]2]M>Q9,5#RPA'[UY8;Y&7;[!*4-/&PP244G/O5ZOE-I8+6&C?NZ:>.()1UN8Z?4 M)B(;3>T R9.Z'FG>==|W$S)6.U;9WRATG$TQ2*1VU(!PUNOL0Y4(;DUU#)+#NZO&*

(46C&[^]1,$|HQS'I%H$ZE9_=D 5V0A\1^+6G M!#0[IW+?S5=SB".UE8(!""69Y.[3ITX$WJC:&C2!!S9O84E?6=:/46MR>;

M'CNJPU@_;JH5]/$]5#ZN_V:&G';;\O'UHI=6O3C)DL":.BX]!MZH$0\FVZE-M0)H/FA&38X]8F9,9<"nV<-)_ GT3XOS:)D+E8/_?)P_Y TG$G]?&5 M0>2R

IR]DWT0P6B$LKOEV+OUBJWK]\"),(!]LD6Z83XRU32IQ(VTXVO2W3W M5%(Y?$2)PWB8N@\-UOUV-P.6C'7L,:GV]%ISZGIKQ3:O;-XF!H(O@3>H'RM*

*MOH7%+M;A%A+I8EA%%IOV]$C;/K9D(VE)IO/]$P?'0EF=_X],*6_?318.'21K3V>OIU.RAGT<=:DU/MF-(9#U_]'!!/ MU5.)GKW22?ADV(_H(_<$30XA@HL0]P&Y*

W%"I9V2WUNTF32YWC/-=W#2.+ M,98Q=Z 9#03=?_AQ:O-;]SI;'S&.]N&C3Z-N5U4=DVI_,X>+.ITC]#D!LU2Z MVE0>ID%,Z]%Y:F"TQ^]2Q#M'X;QJ40K>N?]&->1X?

#C+H'P2&Z%AUG&A(77B MIU]R .V7%!E (U1AY$F]H,/&2?1T]K9:^GDXW/_/HD)E=)23]K^GMF9;.&H M5L/+KLO!S3.QY*@6)F6KJ[BT,9>Y5Z'2'Z"G+A%HG@P'. C-(W?GI?U<72*

*M@6\PN9TQFOT^]=H*H]-MAXJ"LL4",TVG/Z0>/3UKB7X8&Q>VZ$W;&P> -#\ M_R)RY3VN)\BW.A7X|O6^.7B6.G*\(:2QJB'4L/*2M-83(%>_PR8>R7#$/_$Z*

*M89^+"7]L'7&]X5(VZ(EI0G54'1SSX(<>](OJZ,R+IG%KIDZG,H;@WG+%]>R4Y !$X,X>=NYXXWC(QFN/ I\(P?/D\M;NT9,0[7-: MZVRX>M,HORTIRV!#=DT*_7W/(K>@)*

*)RGWA;)^Z*MIPXV!5)OCT#[,]*RF7) MG*@,V*;\(QS)XC=&-0MZ>|^_>JZ1L0)-T,,6.>QQH*S(RG&DBB='FZ'KZ3!5 ME,9/?]7L1GM(A> ^),A=.V.R!2IHB"-&VJ6S-&Q#>"-?*

7D6;11.K%A6MZ+]M:4GF'Z'BZ> !Y/4LLY4^-1Y ;((G8|"_2L[EX":8W+8;'G30\/_?U'I]? M&L?2L9K4\U9FLMPF7;/%=3\ML"67?2LJ,7!.PP6'\SA-:F MIOIQI**.ME(Z NKQ-*

*7&F*9>%7A#.]N2#RNZ6FL!2\CE]I1^H8W\]R?^%.?.R M[T+D LGZJ+;?Q+13UJ5[S3\'85D:3G45]1P56+ MPDK30$7D!^O.BX^SC0$A(S#*V1D.RV,[PF:#5*;]NY:0-VX;MDB*

#H^;GLOI M<$<(4D!0:.TK;$US#@(_K16/6J)+8V2V;6B9!INM\#%82#%5.PLVS9O4 M;#]PW+8V2>RIJS>#'[*RMJBH4:KVH$T3^IO9*3W%[OLGT*

MXB/G)].Y.:+^@>L&DS6[.+#PA<+OW 8RME-5"XS1(>=/CEL^+U^@SEO8NCX; MPUMM&_7&KPDD.T(]XT(E>!Y))M3ZFW6^J\G/%P_$RJ1C=(6>>+TTE(V%%/G<

*M&]WEW*T8KRE/CDPF+&BSQ(4&B-#*&<=OQVEVE.D8-L'6#?,4OA|Z?\U?(I0] M]%'=YVQL2^"VS&Y!3Q GX8T-D)SNG,HEL5S"))0HS+F>8:&. 8IWB4Q0]`JQ*

M);)F3@C]Rr(WGP3=;DM\-5V2%H)L4W+76?@)+/,D$*1?O!"_)?6]=0[E]L0$\ M<+WOZGK>]C.7HJZU)>57:Q?-2K32>5$4OOX.<:"D_FRZ+L$S;>YB;A'C

*M5M@35W8RJ4A<>5\C*2HEV\CA MD]R76T0C4ML@8/2[+8[TL0A MSWD)15=;RL;BKMV=F[BRID9JU<MBZ%W.0/[CRGHQNN:@MVI^CT GQ2 M1?*

>Y,FE6$*\SI)CC;7HI|=YRM+@DVQM/SV.$3 W#7:[M:MJ[GD/#+;$;C8DB> MKYRU8-.<@G)LHT+,RFT1M,E_ [$-SFP-4>@T>H?5N;1G7MO"'"$J719.3VSA*

M$F.,8UGA"DK"1H,=@<@Q=8:NH1F@6{&QQ9XA2U_1_\FMN]^%M6+= -V4?US X4#O-)=:F$?Z-G'M.D22 MS'0 _XR;8T[]^&)96|&PNK>M2].5817SZU%X$4+4(!)VG;23)

*[KCKE<@\.G M60XT;$RS)\N4?'045K?:1,85'*'+WMY.5%-DZ,H]//Z-%Z-MH$C4 N3H*8[M35:|CH8#9"B;LU")VMTKX$7F9T2'/6#$JE@YQ]R0}:U')/'0>!3O8&&G&*

*M)6(28A/"7]$$@RNNQ6<\FF[HB]-&;![4UWR&I7II7=W5]*'O$$+TQ2&!I2(; M[M>2(*Q]&GLSA)(D*9Q_Z3T_!']V4V]@B1?*

6'5S]'9ZJH\&U'_ONUB.!!LE|NP)Q=ZQY_TR;-8ASQM#HB4RI#=_MTJ|R6[R.R1)2WSF+:,$!C@RIV%[\0Q(KVKBZ_T_E>&K..L,5UGJ M6I81^RLUD=H!CCRKI8$[4D@

*G=VA)YS^MY?Y<:.S4H"$PR5&*2TT+40-KK(?WZ-2OEL;S=`T'YHV>6.OT#F08"0N\ MPW59+D40^H*Q_]UU^5X9[;<*]2NW||EC$?"|)?OZ_RUPT8V:G;H*EH+;N:M*

*M7NTHU%@1S7;V+N7KN7A15.13Z.XN#EHH>S:A!M&1.L= \$|/4.PM.&49-1>= MP>,@X6ZN\XLS,/D+;LK*ZXE))L$5C63;=-]/FE0G5;U#B M)Z:W[VRl,$|)-[12&@RFAEBMA;K$"US*

M]F#!2%-4/9.K-D>@?]^0S SFOI8?4EW6^-^TXC4Q6LJ;C?@6!-KR,KL:.4TKB M75XH),([I-J2COA?#F1CM%[HPW+U29OW>9$6'T*/K*[K.U4M1G)\+^_*R:> M;4,);U|6HW-X_ H*=*

|.7+K02&?,DZ+2SF)UICW=T^)E+B]T M M5GQ<'8Z\3%DRZC]W:OS@X)_Y:?(|-@OVJAA^;:%.$]WP,8W*E'I=Y2'7 M=ER]^]JJ<#H%B&OBQ!^7\BCP5TP3/E|@Q7@[ZV2E# 8O,"*

*I'X MC6RVW=H:\@I(@_FDZF66EU9JH:@MS**]/D!XP;ZTZ'-+,)ZJ]JO=LU:I\DOC M3' LUOR"EYG+\?TU%&T%/X'$GSKB6>,4XIO+,#OI"2>I*F11X%QUH8-B8F M*

ZSIGI77U!ZL/D,\>G0IJW4"(V27^KBIDD72&.(^&"M..(HS;[<$6C%U MUX%K^6!FT:C_4]'E M@P5OJOD_1=(DA1E48>GF.95FE#AUH1U4F/G-UNW9*

*MB'I@O_\JWP_?/6F$'X.WOI(9TN\8]P\/BD4\?MH6_~M <^X,#*Q.=M> \N<^X,#*Q.=M> \JW4M-3B;UW"(-M7{?R:()/E7/M,IFNV6W0]1B+BTZ*

K<1JD"#XP^0=8A_S'OV7A#6=:MAF&:O!"\"%_87XE^0F^;;>AG8JI- EB MV[I"L<6C.CW^&UJF'5^B:994S=M;^1N+U)O2X6E/?9.<|%;^T)Y8ZRC\"HY MX$AA]2W)-

[P9EPIJRSTHN_B# 37"#Z)OUG33OKJ%+6.U" TLLA7'+^)QZR>L M0^[T=4_DT(,)@4Q75.JJ&A4E[8V^FZ>/)>L5[;<>IEU])L$?OBLK-

ML\VF+/0Q%,55)67/0Q87K5*21QKQF+4SB9&ZX-\;=]K3EN+#F.G5"WZ78CK<V@+8+MF$G,Q7R'V@=MVZ<@3$0A79A*MI4)5-T^4CZP1,.$XL3>U5CW=C)$G5)BB2YX*

*HH=C^BM_) M[WK<%B)FQIEVC3YG4G:F27%_9FP\\.R9>WW+18K@8EK]@S,OSIJZL#AF*YL,XNXR8MW<:?3=N+ 9WMTX\5I*

*M'4'58]V5Z!&C.$=]T5M5#]NZ4\VGF1KG(:GY&]ANH4]\[9; 9^N%\2OBO:@C M..OO_]3_E\!?B?OX=.YX'PF4,1D4;/=`*~0L,+#1#R18" &>UMW\'3 3PH4 M[6"%:KV>/8MW=T"#^*H;6N2*!GCL*5SNU;=.$A S09\!BJF MA 2DN.$OZ5"QFOZ5L>FR9<60,3<2N#'W%K+.A+\)H#*APU0H)O-IM:SXB1)D[M B2PSX> WD-U5/^WCM:0!=%)EBO,Y@~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|=K/F/9@3AE3L'TGR_FGC!H9#>4_-S;_N:?IO,/$D M*\U_#4/X+YC'&0W!=)0PGBAC^6R:5EDL"(>.0I9'8W, ^(UF)T:Y\?38_"W@=BSO.2@A| [6Z%OD^C\QN4Y<+4[f,^1 MKO5;%IE_#(<^]G_1716B3[\ 2=(,?74A+MHDUT2QZ'.\] (]2'M?/,>#X+=Y MN:91@YU)@_^5+ ._B)1H;]HW!%VV&]+T2>63RQ_OW\-$&=R.@{M\DT'U95 MQ-@)4ST_U05S>6""5$OTTQ $OAIML='!M\4-]8[.2;]E3W6N5G=LC<^LDK23 M7GRTB"C/URI[*2B6%HSHA8ADFRG9G5.I]=&TW>7C*J",S<7QJ0]QLK,F]S0 MOC]KK,@0Q!.C"GFZ;?MJV*$$<CBM;. MZUYY==>03R>4\F"IZGG;&]+8V@R(Y?!W><]/]2>,[^/G%WY=;+RIVRQM9^[.WFKW M7)?UE:F+=+W (L]9IQ/P0MQ$=7DDIKW;J=:A1+W\^"SMRL_|<(?"V&R>D%^;O!-Q*7P4Q369>I'E1.5\C\[[?14Y.PYZX+YU3!%Z@KG[-_M4IN,'?_>W"[V6,)!!YLY[#'@DX M7D8>3M:S]8\? &1BYJWB+ILOMR]%?K4^5XZP5P;4G<>]OS#);&-2;]VJPQ7#% MIK,C)J#B)S"VI M@--U@#+JM,GB74;J0QPGCJ6K$BDC^Y2<[QO:H,;FZ-(X)^H3TZFKX:0+;B=W MU_T8/U9]>8A"-7=%HVF=&5K7.KJ@/MM,Y9SDJQBE.C]SG; !/;<9>NW M48$+*'+NRYQO^"//+S:W2G:FKO;AV'/9[&XW*VL'\>6+*3O7I/ONKTGPTG M^SDV1?:,V%VM%'NH)>!#BL&;7]43]E.C#Z MFC@AA4,0&,H0;%56+D%(9L[TQ464/#Y<05-3V+>1#F.TTPP)}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{3X1:Q)SSR6M/ MU0TCK6I3CPN&;-8I,9#-^N++?!)S4"QE!+>I3^4:T:L 59%?:$8! C2/3BN')E M23,K^U:IXC9T8'[3?DP_VG9*R2F_.0-(O*B:ET^]11>,2&F$B\\ MURD>5.4*L@SYCH^0F+$E>**1Y$#?-Z.;LPZ5[K-K,UJF M@4W$"^KGSK0=&X->0AO=K6<87/=&XB>>X)05APW#"H*%],(% M[IT7-P^BT0TS#!N;O39Y_B9U8QEBVLC(W%)NY-7!I6Y8F&*\,P& MF +N2WVYUG2)2<94XY&XK*_">$!T8DX[!? 2^:S^=G7+991]VLW^SU;Z9WY=T MT?MT(%(?\]8U2S3XQ16PE*VYA_/R%ELW_RT5G:)DYS 9FIH3+IO+Z.<"UO0 MVUNH"H5&7?[@]>)D:6+94UFM9@++VKQ?.,(2Z7BB;GER$%-R M@AYERVHJ1Y#&46>6Q*&L]5>[,8 9G_U**9T7?$&]

{H7LR7E?45.S!4(R.9:W/6G-M3)O8"BS#>E5@"(.-72&84PLVK%$W4A;TZ(?#MWDYR=YQHV19K33WHA5-IUG2-M!<">,//<$) 4$,6?

OF#+92^ES/ON\JL7\4&:TUC\!^ZC1[_#P4W0T!'$4TV<-M,JT_ZA[9@\3&;KGT^,6]_7.F5V"2\%ECM[S4YT[^EXH5M74)1RR6A/I2O2-MM-

J2P^/'O3.X9.*U'W=^>1$[FR|=7*E.*+G\9DR9W#PP8=3PRN_DGVE)^P6-M=4]F\3P'Q2!,_'FHSQOA7.7Z?6DTLY8/?-6[!]J6E08J0UIR^%C00DX{C@FECV^((00K;P\-MC:N)-*

*G5S\.3#Z'T/N?_(%)MPP%ZGY& 9C=:VZ)M@VFKGNYLN+-,R$O?;-MV1(21%NXF5%IX<^=OTF:^9@!*WB*'OM%*U/NI^CC"1 ,E1&WA7)W4E$0;0*K.:K3*^VKOH9'0?>.=*

*[TD7Q8D,[EW\QW":-T M6X_]'/I3KMYH:7DODGA?J9U73DW4C._IF+&X,+@%DY5S_G(.X_^>"T])PHY]-MO(&Y&(G@_.AG]/G$;['1L<9/W]K/Q0#M&NT].#*VU)V%=*&@8R,2X=C8J5AU'*

M-O",;%"%IO+[:GE19";?2U-_G$4]1T:O/^F'.I*R92"X2RB=2M52]?70JZO/-M0;I[4@CV;A%M14L?XR^X(02N"!VHSM)>D-%?1V[BL_7B7^9=$?[]>+^8#QK>>_-MT)5!:L4L+#2RV1/T;?

*7NG!?.&ST/36UIHH7O 23}^Z@B/@1.HQGZCB!^GG M.-0^2M?U8:V1\WL*4T8RIK><\R0-#2:K08A+6B)&7CD:.%U>"\,=YQ2-HMU-M%;]6GUG4JH_JAMX'?;R%]GRUPM(;I3-*

*/*TMQZ?IQ*\F!#G@NN<7^BH(. Z(T-M(=;KC#?8QL$Y36.7.(ER(^K-T&3;RUL"R"G@6 ;Z/@CN:70*C.D89B@'=4XL-M]KO.LDO5%&L3LZ\]6W1V'R6*

N/'G"HTG#%6;4ZM@'EC|>O^^#S#&&'VL.\ |.O!S;#X9M:XAI=%SN\U9J,_'T'O=@VV6S;B'3R=-MQ.JS5U>}BBG46)XW<^/ZW](DSEI.!"#^W7N!^NF QXE@1])?"9!$.'L<5G)*

*M,BC$,PLS\SW3K4WNJQWG8GP;[X\(5=LL23,FV9&]1_Z*?8K$-N:CI1=+&%*3-M>A.1'AA_^/KH/LA3"6U4;?5=M^Z5!3[\PKPU+"+B[T0?\57Q3D1Q*

M'0MI&2WM!E4:VL=HJ#wM95&=K%!&YD)#D&NY.3'!/:&V8:-6?2G+'O2N9-75E MG(45L&N.!39X@'J 2$N/A"[++%R:*Q9@G,*L= QJ^Q*KQ6_8%UM5&NMD'<-M//.NXM2IV/Z*#_)*

*{Z=O.=ME:^%*UHF#W4GCY3{@\E2DTSJ/MCU'5V!#A1I/&R=[1WM@-9WJ,SQ-M9_3Z.LWS5/=NL8"'C O(1_,"=,FDC9ZZ)+\;;Z.Z^B@D.Y?7<&7221PA'NPM MY8IKJZ.9IY,;SQ)GY*

*1E=&[#@4*V/B)SI,D//DSE+8JD#T1 KTP]JBSW55CS M^\^XMK8Q:7.+I_YWDQXLZ^:MLI>8-/YA0W4F5;\<9HW")1?:9)O.|^^FU-K]-MK>$?XY9C\.-HYT%MHU>>GQ"7"D:*

<"_A\5GBA/J2024[JP3.DF=+W;L=7V^H MAH)TY^T"0!PPUN'>4Y-\D]:BD#IJW9YXEBLT3-LJ334K9N(X6 'GT?-&E=) M1@G$&UO;T:,XYH';M.3,ZRHI,6F+1-&9C GUU\O.>.:.L53*;*

*LLZ)THD=8 ME@]_*%CKC\M@-=24S$5;\.4I97KXV=%WM*U";/(L$-O(HO@7ASPXN9_O<2C MU4Y69\$.*Q+.7^|$M^FG+O;EIA]!34G[+++RAJ919)FVX]L93;@*,,UH0":I**

M$0(LP3(C-9N--7_AAH?/3S!\NJ;87%4?ULC=@::/P"6:(>U2B M&JV]<|=LA M$R;RO;126'9D8WVJ-.C)AL$[L.,#T'V05--W:RR6O2>_,P@A$1]D\/W;$A'M(26.ZG

S+:!4HZN)L>YCO%W.G|O$16#Y(P8!UL1U!?#>X-#LSDI.V2HKT M4JZ>*2255-I-!F+.^>M[\NOD%M2U=L1^5DUHRG0.(/Z +@;9>99_R8YS!GVK&G+6]W+CLBNNM=1)7![%*

M\+&M7(\UF]IM+]7#M>P.$VH+PH1!_/5QEZC;;81GQP"T;:AM2;X[PMYKN2/-M'PYFN_1<9XGK.4.U<*+.^ZQ_])3U=6E1/XTNY.\C2!:RAO,_Z@>(^YY!AKV M*8MR6:VL'FEM.<]*

(483F!96K\1-Y#&]+F MU]=O'>_%SWY<6LBY.BNI9!VH2O'3HC9#SCF\XBIBVE#4M!+_>69XIY;^]7ZW

*MN"=>6S'^YOL(D@6LU^R^WK*WROERI,6%2F"QH<6^Q^:Q^.>.XPV9CROJK(!& M6=4D4I=-^"1UX3,;=6,ZL7H%/?0C>)E>"]#*P=BX>(Z$BZ+CX.J,-PBTC%VZQ0 MBQ\OI{KM+-M-*

352FS$ MC83/"LUZ/6 15[HN;R$'H]B]I"TO+W---]/$B\UV:.TV7B6$; 2TP6?" : MF6B[*TG8N88,>0/8*K'Z2(E2GN+F9I,IJLWCJF<[=NMELH(I&2;_EYV: MY&4'V S-4(I85'V*

*UZL/HNOG-OB#$G;O.44_KM97W2%ZGSGD2\D[i.]=2@=/-MHUTLDLTWAHF2B]=X3]==LD*NGW.RRCQH=3O!A(G3=|\@JV+2-1PU)ZIR&N&OR9UB3H?J.9QFW."#0I?*

*VZ3>0D3$&I1/KD498(EF@"SS"31K2:(7O|0.?ER MZ<,0WGJ:)"DL43UM.?-FKN7'|(P@6'!D=R;D6T& /1!^"/U:B|(7I5Z1*NO9H%GA68"_WJ:G66P]K8U"%-*

*&IKQ:FRPZ5;_@TBWX2L[A9W*CO5F\]'7N\YW2?LL M:@YRFF4|+](/>0,?C=^4NG=V$PC8>A13-&MH<)TO9I5^6G\QERC7A=@_@CI M>?*

O<7-.$4Z#5U%+0FCJE:RP.4MQM<.;J^4JM88W33!T^:_6DTS/J_60.$B M2TSF^.TM H>R;L&-MN!TAB_.62BCDQ4I1%<$3M\QPY!F"2Z7VYGCF@NOS&N MDQRY

^C'6F<'593[EFB7LOT%H/;K;&3-P0M*^0\X?1FX86,RNA>7"X&RA)=S;&;!F0PE|#-.M."MO3)K"TRWUG76B%X %(GQ&4 #,#AW[.6>06!K6>'9-%*

<=+RXR[F9>TT"R^CQ?1.4KO5?MEA$,EA3A2,;T]7AETGOV&7EZYX. M?>9K|X5ZC6=79I%G(E$^S" (GQR"4:9=97;+W)5YCYOZQW@^^AXZ'!4XB,Z= M9P0B=+F:.M])X6O$3.4-

P3>WF7T2>!)?6GU]3:DL/2FGL1D,6JB$ZHKCZ?#UEK=?T455YU M4\20KR'97C0]=W828'.RLW$27?I&U$. =8RZW|KOI6N/M=^EL TH8L;H3;D

M,$UBB+_TX./G17!9;6MB8U;\AG)9),(OGS"N=9TVN"J#LX (\7?TIHA&$3HA MM;IVZA!S,2D_GZ&!/6SF_'R7J@GWSVL+>./L7'4IHS@C#3\X8#L[^SB=2X;? MB(_1M$

5.FH+0PPV\!/^ID%2HWEG+7R 1Q)EYLJB;JQF7W1/#TV(#HO%9NIFW MG?KR5*)A;G5=O#N WE>.+4DS,2C.WZD"MRU\WT2S0'&H ^ZTP@e@GF]HPS8A401_$0Y!*Z"20 ^FI#V4Q(M[3-*

FG:M)@_]M#F?H:KK|_#VHSH?8E?QJ_ENX=4HSUF[\R16-1 MT0%TH8'GL$OI&K9IM?DP7RXXS$U!F96OX,Y)M[_N*))PQWZ3QD+69Q0TI'T*

M+U(W4T;/+=NGQ;#BHWX<7ZS[<.:,QE0N*8>HNMJ;DU[-56.O,1,E/HE$*GB M"#&?BV+;KUG\5 (]*2+PT(+62C=*KW%R L=PFM];K>B^%9\&--K2D_++|<#-01E9O*

M17>EWJ_ 4V?S3O!8S3,@]*7X'($\1'5/&O*89!++4FG-60H3-- !K,0COTM M'ZI,DF8*\%*!$Y=3H M'Y(U%>[B1JF^A@(68&O'HH_FJ2=+Y_Q=[:OT?9#,/,;,SIGWO+[GO/?|N=!=Q4!KV9)GWVKO9U?-T_,M5F#*

*{83:NZ^D3XO=XKX|0B'X@WZVQ_+ ;#NP5/9)T4"R,'VR :KU;76^_B+0 MSPJQ>*YZK>.^=\X>J$?_0-1XF\.1P1=MP\6*"B;<8? ,Z"*Q OO M%*T8FG{T"@=M8EJ3O@N/5]*NTN]1*

*^D+S"R>Z#67V?1OBZP>?65S;8GEVO.I MG0'.LD<,G0^5JI<'!&\?WMD623J7FNY.#,/YLF7*1O] $M'=%W+%3Q<[<[O: MG5(D3.*DN$AE]^DOQ.3>A.L!$,N)@H8=N6E.N?.\%*

*O">#2;[PD2[!NK8^M?B8RZ)MH?$VQB.)L0%Z+0^3R.*^%$)>3H M"

*MNACPU_^>0O/7X&Y05_JS1O2MTC",>-DV)I8=U,P[=_9?9L5"BF&L(M+-WU0{R#NM%?DK.B:PZK]2Q6%D1WSHS$O7?)T<>G:-5U>,|SR-C,[V% MH]*=M+F;<)6BT#AU{J4.O*/7U-2CT 5(1?FIP7D<24?2*OO5X=29 ZQA=&90 M$K"=(Q02SH6<7MIOO&_P$-_5=0NM0L/Q6A1F*1CA/B\79O# #KMP:#4R% B+ M2)M6[V)"[>6^9NF D51Z<[3I$X[NF>Z//*FLX+6J_1KK=^*$E,__Y^,M=:H_0XU F5-06 M[$4;!LT#XHJ,#ZM\BRK5(NEVD?U;6K,W|N$YG^:V(#=)&^1T.PL(CD@J 8.! M1"J?KA MPF[!M_#G,,,D;R^>D@65;P= =I'"7D)F$5Y"LZ&+Nf{80(Z="EW+ M8NE,QL5|SUQ;.AW5;;W3@"Z{IC-'?DE]+EZ-M3[5]DO+*+KJ4FWP@T3(TB!? K$Z,+,]KTVHHM&;BRF+^P+N!F8G7"IDAVI] 6 MDQCF>U0WCZ_2YFY%C-*Y7@,*3MF?3<,KR;[37?M!5Q)O_JEQSI+=KNPEC]JG MP" /%8985<5(P54(,+D5KQl,4BYEGWY)N;6>@@\;%>)=Q+W3QDMY%DB*'5F. MN@:6$$]T/Z$EB(*EC/4'-BZPO]^UN!{IY;.:\'Q_D/TH:\)/2B0}80/Y+F_U M@*=*NNOND=9@_LYN:NU\63339'},$"D&;;3f0!5R1CR;Y*TLK!RRTCUT;#A< M1M&Z+$<$VKP 2CH1$&QO7X Z#0\9 MU0$3'Z4?$5NU+.\K*E'[108GH& <59G[@GK(1^L+"G5RG/HD'Jl/.<#Y6OH$' M9""E,Y9FIV[V1W]TP&<1_,%^O ~>Y XRTQ>5P/=)*:G&$ES!-N|F_43=Z&/ MU(?=$[769]'T(l[4V@3&P33*'+JT? MKQ:E>Q8)6E:JN^Q "BH%OJ[2&N6#GCAG<4H!VM/,$873+[*]=B,F*?+.^:G' MJ]>Z[7#(CS(CA(YGF\R,,]ISY[J.O ?)XA)M9CF2"\R\DU[FNQZ!;,,:S;?3 M7A$*,,$7OU\FM}?V@ELT$F'O2&/OW &[?N ,'K$+0P#AN _2&$A,N%=(LI2X MI+ ^+=\,AK A@;QT!4-KK3W8N$*Z2&@T\|HG1=\D_IY$;Y/[&SN;$OU]W_Z9N MK?.-;%=LB:J&,;H1-WF(QE=#D2.C)H>!""R<9BGO^SA'FJ))]# (-9I1Y8?C M-BQ-I6[&NMBQ&'2U.#H GEF0*7/QV\>2%-QATC*;Y)#JO(>WI,U_X1QC1-M948[,?DZ>_FCH(@*_9AMG8<W6I3Q8?;BI@04H0Z8!B[!<-UD%6/R9 MN0=;YVVI#*BDLWO=9QZRD$D5E2EN|MZ48!VMPR/47@R%-U%X0&#WY_B4JX< MKX?%>7 0^L9$VR6W%"WH,D3.4V3+RQ;>O'F3S3;3[?XR!GYD5G"+=>)YSH,' MY.UK&3[ZSR;L1J6Z4:E+JW8 FC!/P8;;R.=U0_3ONFTHN8KXL=1]E@;N MPF-EZQ E6L-Q()-7Q"3E_,FG!B# G4DFA\!8'DF1)U_,)=[H6O&.J:I;#? M%M\.57M\XFJG@7*=0? N$DD'6=]N@4VM6 M+1OE;(&3;[-1'RV4|_1D<3X;$*2O?YT |#K69C4,O=I=P:"H47Y'-E,0(G MY,?M;[@6M-XL?!DA6$"TUPDWK"M|ON_?,6_N^?$DRXTAE9A YDW5JZ=| M*,^=R-'L\:UC!WJ]1#++VK>7SXMBY=&+-&!\4GW\|6_1YPLZ3!'FVSSU9F&IA-MA9=#&#T0F10^)9H4'39.]J MV@*K:=>E9@*8WDG[fO(.LRMC R9/[(5)Q5XP;L$;>=^KJY04[LHO]9(1,1! M&^"B?_N Q35+[;K^.Y\OX7QK2*W=)(FB[,EJQ@!;G:2=G3M/-[.'51I/A;D6 MX1(C_\7'ZV3%\I8KI@%6T_"3L>B73FC]6"ET+U?1]LE=CJA(&%O>!)15'ZAW M^VF0$MX6]#'F1MDDUHQQA8HE+S).GG@Y*-?P\N7//!3VJ6$)0%W29*E4X%GDVNM5AY*9,,3 MD[6UT^28N/<#FW2OE38TKG@@O %POJ^I8-V>4\Y[@GHU5Q]l;>VBPLON^ AK M_/TU315-R.E%^?"NW1G5$B@8 !D!>>8T'QR0/H:334M/)Y%[HUV.2CO@R-4_ MI)97G50X]9A@1 P>Q:X-_)O8)^$G,O@K'0HI>,'[-TOEZ?1S4^9FYSH!%-.M^]%VPUF[G]<;*%?W8 M);#;,AV+"VX=IP(+<;-4QH>KI>)LH9L0.[.%1N;-62WZH\3M6*Q$NXFQ*,>0 M-HWH'#W&\C#VD)^(XP\@"\MF)P>KC942%\=76.H 4;&SU!&^5]4%&@ M2.B@*'#OWICA:-E'MW0+L$/P[5)Z__B86CR6$P:F-[2K2U+K+F4OBNEL<U MPA]5C12\K!ZX]J^/)Y3^3I]F&8W"SXAZ(X3AE 0K*N)S(}?TF*E:98NE\A0K=Q5CEDT3[4M{CT(L8EADAD M>J?=EJ6DU$]*!WN/LUI.E:(]AR6K0=CBX6?_1 MT?$62UZ>T-J92NENV(fJZ"8HA6<#W\+,LZ17.%V5,(W:4,28RJZS\U*%)17|% M1779-B);2CK0\SE,'O+V?3C&6^+$ANTUD=G1V$4$0'Y'?%+QW,.XHD/!+|%] M#WP-N(':Y+CZ<1+6I@)E$WH@$DZX#D-JU*9,*T;EO5O%1_^J/=_6AWM>9L2 M(GO'VCUJ;^^JGMHN>P7)MXB3:/Z?;- XX%M8]C:CD7&. M>62G(7K-EPK)5XZ:2L|.]^>;@Y$(W? F9L;"&'H 4&T:(9+5J>7+UQW&4'1'J; M38KH5!5]50<+BI;'&Q+2FK|&']'OMS:7'=9,M7)(:4W.=-"-#1=X$1:KW9, MJ^>V)/)TE*)S);\?E()-HNG4[Z6ZPXQV;|%L'O;EL'\L4GV7[@!XP-Z]%#@66> M/,$<;[+K:$$+V-JV"GMTMORR5>?4.(_XG%*]@7^OX:O=FW-O6SHY>..3'R=: MM4,:D/S4|I1"HX& C>&K0LG5=AHS9!V\++DV[BU]-A*K6V6_SVU!GWX@/_)/_>YQ"Z>1+B3CP4LCCZQI U?\'1T/48RS'.3GW&2L:B(I3@SG8Q*FGTN=>)):G8>"#E===/|!=S>_+?$D] MWEHZ"&=OZ+ !;'0F!]^I_Y,)SW;+C">\@>?;0IZP@ISMVM_,^IC_@RI1:EEGF-IVQO4W MZM>4"AHBHH*D/+9C\U J4K;>8@G>YYZR M85OHGPL#+=LA@%)-FV$RU0D'>/_<.SVC;>3;0)TH>[&-(70#"?UEBN%JF_IW\!K MU\8K"& OM@>]TI58XMs.#*/8$]#UHU@RH3FC ME;QZIUXCJ1Q*. LT910:K;M^+0[!X#)ELULO%I? =IVGB G*(KQ\>@W/E0OJ MQG:LB93]!#W6*>1;X]L[E#O=&+-!&8 CM{I\DES7F%/E^\-9P3B*"+)8B<8! M,X9L5P==RHKPE\(C[P]F9Z3Z[DE]H>5 RXU6%%!&'R4ATA6-NV4]+%4]@TUO MXF.*FH..TZ9A!9$#IUI.)KVM8C1_X+5M=[M!WOQHWB'EI@EZVMPP'\-V.VJ=>]M MR /U>V)?K%G>P9KTCJZP8:X/O)3%@5P]ZR8:X/O)3%@5P]ZR8:X/O)3%@5P]ZR

J^T5I0K9#$.B(L$_"@YH"@79(A,D''7CB9S:,?]S$%F M'P.\[.O1J/3EY+=XZ. 5H82GK5;_;*[AO,ARZ7W;]D'P[L?\VZVO9?/L%Z"? M%SM@*

L1F\K;T.XM5_'=L!LKI^>7_F*6[P9I/6+#W45IG[ROMX%11OFG[UT ML.:/U;$=38Z_\;+G%[.\7$*1B.%."$4%;P&.B'%N$/ G@XQ@%H%$P]HB#E(*

MV9]BRL<(ZF0,'^"@CO>RIF9],T']>GSVR0R6&_1TB)=''M&&"$#H ; M*@6$@V(8.R6H9'W%C@<4P&CE)1&7%I@VAKT^>"]M-(9CT5OO?C; MEO7?

*[&B:";5IXF1{9)OVO+P%^@8&/'O%/MBC;W+HN[SYY,__A+W8V\1.KUG)F:'QS:ZJ5P]3-] MZ06LO9=:&CUV3BC 5940J2W2#R&I((0M%$R5C[=?2-[L]BV;=T;?!D3') M*/(\@#6<$DM026K Q^S6_/TON*W3@]|91]WYN(0 H@#A+$SP/G:!F9(BX@1#5K@%*-, MUO<-1-]).!_CQ);C&!8W%(_R-L&(P&F@&)'6565,0M8&@93"E"@+VI4C?8/C*

MS9KW^Z^]JL,L,#.^?;O=E73;S|>5#M'!Z-JN,8=\';B03IXCCB.$=D@.9)!$4-U!(GQOD%G-=*U%$+OXM7A;?7] M+|\.G8[&Y!:>BSWBCGADC4N@9H-

*S8UBTBX|+$#|KI6#OS!F=*QZN")QP9F@WP MM &+S.T(L@YK9*-GE2/* >?ZAKN#%_\F'DBR*QXF[2+R .X=%EN@0=&<I'PH MG\ (A3')VQ@<I%2:=0ZDNA*

*+0D_S'"%297@SWK9'Y<2.UD:OB=IXC"T*7@3$ M.9%N 6F2P(RB9&),F M1B32.]TA\|\3B/PY5ONU/3H D3PZY7N[U71RL&O'K[/]7S:.^VK:C$K30<6F7 M32}G%<#[00;D8*

*R9F7F",,,.6>P\DM81K7%6\WH;$);=':>>EXMZ7:N^@FC9V M#(9 FL0XGI'2&S)QCEJ,_]D7906*RD%PL!(>.!BG&F-#'<2"6!O)# PHLTZ M^#O6XO;R#]T_5V#!CUO[;A_4X#*

(VKZ;G$;Y/S7MNT-/D%6*\1#;U%"=XQ0- M*$O4(RPT92HJH_O'_== :^H20E9AJ;E"SB8*\ME8!,9^0-2I]F'G7'*?^2H'; M.+^S<'@]!<&<6E?*

*5=E+5QS:I+LEYPZQC#!1;S8U!/.J(C*8*$2;B M8BJ[R'NGYZ[R(GH%%YC6B92S@5%(W"%N: #5BH 0MT$)ISTWH;?&XJUR:>]C M3$;Q:$2-';$8.6=,X)H:XWJK^?*

MJ.C4VE]/F"F0%=77HY4(<"-0QYK WRYC5:4 CE+92!!&^*?!E&O*5%QC16E M$4E,=:Y>E9!+GB%!M.N9G\ZIWJKN??-9\| 2*0 B>L) MQUH1S*/L+3B_&8S:AN!D1??-*

*X1&HODMW8W>HO3K%&,' &Z41V_$(97EPU'"%)7$!< MTX TBQ%109FV-@&FAK[A8M^ON'OE.GHJOANGJ=$>I)L(!)AJ MU%&R.0\0I+ M# ^"ZZWJN6Z1VD/@R#*U ^,LH*M#-/&*

*<;>T!D1W!2&GK,+$Q.&;L4UMRYZL?34,,K^OJ,$-Q M.FKQ^//:[#;.5NJ$uQSMYEY\ONC/-7CU/*MMT1++!N#'-!N:"2H MQ@CGI"V+O?;HWE;MU*/D ?*

*6DT4>G(.CD24PT!:Y[M*W.O3^+YU3:Q=UDY7=B=R^IX>&)^U#&4D]?6MP[@_,_N/Z=VM%?M3@]A8(8&V2EMHA9[W)^<-2A=Q%B*W-OKTC*1 HGE\!BRUY" MSD5*

6C,'ZH;C6D09<>QM2GZ/\[<[#(G"6+D4>40ZY)#1F%D7(B(&<8P'*HA MOK<.F@]U!5N='&=1GX/5,J!:7]NOQY>SNM]&D# 'U2B\ 4V_^CSSN*_+12:F M4H&,ET!'KKW(!*

(T14([#\5R8+],32O=76^EH:(:0B&7,9W:"/FL,0!.9-S9#S M*YQR(NNF3),F0%\0I2&OF;2#^$HJ^!)&D!S]+Y'@/BF3LYT[$>Y'@/BF3LYT[$>Y'*

MP$ERJ;=;|G[$HZM@!!PV/,F)"JK[&X[R2&\L5A,'_M@(W'F)&$&,\5K:TWR&@1+++8H*H 23)N5Y M:SGJ8.@|.+;.$)&Y%D7'@>W&!":?.P9I&S1E.@!!ELYV[R"@5I#DAR/F6 %)*

M29)$/BF/;/0>,6LE]14;BIN0(@Z MHDGJGX-_-5?MM[GO_K6_]_KK>=5.L!9$)HJ|\$F"$&0RL326&N--@9A-*[?I' M!#[4/6X/)!5A)$JK.)(V=\|\5'"--;>Z>ZZ6/;,+0W_ZC?6AV<-

*Y]A3MR?O$F MO4[@.)"ZJ4OFI4 >/Z"=[U>O!!/2OO[\0I2AB?]?)$682 MI<0BX4*N(IB C\K<"YB[]$R0(2Z_R=IR/4-=W3$1(5.R,&,(QH,"(04R,5KD M*!%*^.=.=.,[2T5]:810*

_N"HE4S"K"$3&1 AS!T+5&,Y1-7.UT0(OW7>T)KQ! M.A#;H"@;GA+(#<&15CPBP9WWA%L*1EY?,;X?M?&7$^9"M.6!&X.4%@IQ:@+2 M%BOD.1;1)$*]ZJV79H6)#^=+G9U->*

[@7,$"QBB2 6."YN)"S'KG<^EIX YHP M\X.KWN8R]%,LK",.FYC@C0:#1,)LNL07BG<)$LKPP$+TI+|F MS1!GLV)GM271.IY^A'FB!.O>2K.^UX\Z&S?Z80[ZLVT>,Q4I

*M0"1.\AUG\&U1.PN"5VB-2.+&)F.C9.M0:/.IF!B4&"L,\.KH*0:Z=Q&9D#\(M8DM-#%]PU-L;ZGYX3WMP64 IX=F(@++)\F!L92.2B"BCH$"S.0KB_S5#ZFK7\ M9!@ 959R:\'T(ED5)[EC O.*

(DESWSPKI6&\-I4'P+QDWF.D]ROEN;42Z/42 M:98HBF"]!6XPMVH= F5ZQ5>&E@0/XP"B3(JHI4$F19\+OAODO*1(*:HU,Z"= MFMJF3.]!CN'*C MF(M9L!VUOCZ$G)FQ7D8%,M;/.*

I@XA[6QO;V3 M&.I>/J1 ,A'L6)(>.US_PR%')%|]193N6SZNIXK-""4Z@$UG M%=A?G ;-' &%RGL?M!#)#9X M[!*7N'+6!)M/?@0H4&$7""*!,6B#[*WFN_6 M%UN'RZ6@GDKY-*

*29UU,KDBEZ$@GD":.& ZF A/@6.I=5!,O75AXBJ.Y9@G3)KH M/1@E224P3!BSR'(> >K>Q62-.[JW]3<]NG\<$BE6EX[I5]bQ"/*X'O:G.WZ-Y"QOS.J?CT=AR>G2W=I!GK- M$^,,,,;MO#*F.@)%I3U.R6.6>G=-*

*T]NZ^\L"32 \.(82SX79!5CH8/1WT\%7001 MH*0XC#*3@!9AP/B=PT 0L1L/?6H1$>LOS>Y&^.J0(K 1K%6/*&V1HKMMK D0O@%U9>5C5@0B@! 1/"&F*

*MDT<\$(RLM@9IQD&6$ ^"3K++=W>#.ZV[-?MZ:3@ZJ-03LOM*HZEOOCUM%6+]M? MMAJ_JY!*&D\"(CI0Q"GCN?N+0*"_4QX#8UM/>'^U"GI@UCPS*

/_SS6&A1@Z1.887"0.8EP%:T4XE%G73QH4?.G7>-J M2_/<&QE=L,@(W/4; 1C1&(QN04SNY(T5OVT^:EMZ-3$;,;@>6Q:|>O< IKV?AJ MVXY*T%'&I7V<[JX Q>:!6R:(EL8%%*

M%9'2(5N=_[VN2T'(R2;0F MQB>G03M4N7DC=<@F2A#E6.E(&S|O?Y:-^8R^#D[XRL&1Q5RG:J@N#(5YA8G@1&6F92\UPB \8UPHI M0I.V# ^U->X+VM64TU)$*HJQ -*

V^K5>+#)>V5ROT1CF#9>QMS3.^T(^ZE%KE;CH&FJ% BY";]-@O#%#G2 MU(&!)GUT-HJD^]MC>]WB,7_?_7/U.=;C]B9U/XY\&9NE%_3LM>NR0ZU.,968 MQPH#?*

*3!A77(N=(1(9YJ[S(>]!8OM'Z/(-SF=8FZ@>0K$&,$L1&)B2HQ;G#H4).Y,X8 MP3++)=7)KX/P'12W55@@3@.:>(*D;GE:&!"[&9Z*ZRW^3>9JZV1/UP(K-\%*

*ME'*1*&FRT$PYF%,!K_()F*%C(M 8,;&]%2/|T+;&"D&K0-N@"9?$(XL#SAG0 M--?*,TAYQE@D1''?6_?9@#LK%K%1>)_;3@/?P_E.,M=;8!A)T-:,H4S$_K4K MZ[?FW'"%HO*

*L":V2,RF6%\U\2"\11+C<59/!IG:L;/GCAKRY!DR+'5&O$1109 M-!Y1+_ +U8L(^FD137'>]>;@+BWO(P>FXG('D]T]'P()/COQPQ)_F<\!?RXF M6#Q9?,XS7#%;#MW*45RSTIM;A[*

*;U_E1M!ULWM@$[PJE)\!*F>G>=%X792 MU1=74S85I5T0!%XZ;3F7?I^_?!7'U6$YOKE,^?'G534WS7MNBN)OG'%WAGY7SCA_]KTXL/OJTFRW!"%\+-^^*

M@&.HK6/S>SC0;2AI11X!"P X((.8K:@7N!-48Y?/CLS M[F@QZLB& !(,N6HRJ0Y?D/)RP0$@9KR7_$%P?#QT-;I,-6D.GJ!9\^2/2Q' MQR_V@!$TQ;OXI?*

*A8'=KQ8N!\)OS2534L;O&9;E)Q-"E"-76C^#)'3'+*C[#?!;=Q=/XLNMKXFSNY3/83=G>W?/[!9>[.S6VR]>U?L_,_V M?VZ[^_-,L;?W^M]_>[.Z^>?]NW4^&WO%D_GMK]S_?*

*O/OSWOMW&\6K[8)BP6#L1%@92?NE;B?GZDU92*2DLXXQ%/(US#)(L\ MQIL W?D/>2#9BCIH(]M]1S7V#S^-!._>S_'Y80+UX^^>R*6=]G%XL?C\?!*/"*

*M"7]TK^.,E/_IY;/GUSPV8E/)D^<_/9_4%U\VUX-;T?@%%HU<'>T?+!]I_H_S% MU;'YO)X%5;6'!F>@LF+],3=5\'8T1P3 HQ/JJ^?Z]VP@8,K=7[+TO0+7>_ VY(*QX_[$@XH?*

*P8_'^=;'WGSO% M&.W1.\/>VM[+CPE(*O.?$"\-_,AAZ @R]%[HK#W]=U<7D(;_7)!+,?-; M%7$<80B6MO6MMUI#!|#405!&4/2.(QX%048)C(0*.F$*HTDQ)1F1N)M8V1 MA<)(*H?*

AM#5/D74%A==E VSK[W"ZK^&;IA_GF^\RO\6=;Z<5/WX^\?[CH|'Q M;E;QI./1\#JV.FZGXVEN.=%<(OB7!JR:7(^*Y?'D7FIC3,&=&9)Y])?;=;F M]4I>LJ-FZ5H>[!.6UP-C

/K#V_NX]6[W3:O-#8K>PRAZDQ.:66AZJ:X.BT_G_M-BDFU85OG][DR|?)99-OHHO7)8@\(&T7ZQ=+4LJ,CI'Y'E9!662F+3.;4-88< MX59KB3U3Z;I&!W\Z;F>VE^>,,4%,"TX'C^-0

[@@ZH];35U%^-U@E&A* M+4/88HPX\P$!<;C<5S=%GK2+TG1#"A_C?ML@;CS),<*=DL,W-W\=(/\2_V7K MEVV98K'KRSCVL=DHWHS]YC?*

(HP=++]:]:O/.#O&=K]9/BHQ$196*4[0];%/L M'D6? Z:"48Z+MR^6B\WQ@;/V(J;A#P$BG>UM3 UO@&^SK,P]OL]!QO

*MIUG7EX%V\>T7+*H9N)=]3W*>/*ZY$;'4!1T38MYKL)9IKGF;&(<^]2HD1D7A+M;F1<+N!4@Y'+X]:Z'/[C$D\]JO/>9Y.'*+7(?^K.+)? M;(YSO),%W5O00)A!!2V$"$<(%@%9HY(*

*(B"J2F!6!IZ"Z >V>_?IF!EX[!K2 MF5I_'Z>*7*M?M'1;@"5?Y;I)Q3^F===F$LJU! M#PK'V4-?ZWV69WE5N!UZWX[!+?!62?^R2(ZS/F?SP9O/CYNYF,2^Y6__DZN>_ MG"?IXEVU>>7IW-*

*'UU7G%MQ>Y!5<<1+*H *5Y/'LPFO/.JEW6):7@B@ L4 MZ?8JF>=:.0K ;)BRA%'A.8_+0@C:#X38G<*+"H9Q_[%@]9Z!^V,<40I;*C R*

*ME.8T>@HL2#N'6.3$92^5X!VYI>;HM@U_OJ_WJB\]"4MHNS 6N[".DSZ_<>|\M9?$?ZKA0R8:<@&J__^3$^Z -4M%3;VT*FLE.L.%$ =_7'\ T S6IXT#B.]^1 M;#U=#,CYE$*ZA(P#8X|*

*[99"1B:/@"\>,B"_J./AQ4XU[=`M'6M*D9#?U&S7E+7<-6WGAID@V"A QA-\Z50\;_R"# @Q(W"CD,QB:-XE(%9 MC%MHGAUI@;#G0ZM4U"=W5/_GWS4EZF53'-4PN#RRHR(N.B;"R-*

*PRL1GNJCJX M]V1758ZSZ^8%WR2*_>F&LUE1\-8]+823LAA$_(IU#,71M&ZF^3)T4A4PHO58 M$'J#^S'C80Y-*

*VO*3%YT#$&DZG+,9AS]_*E,.QVI.TNF^BF$M'5)FU/-R3>,^%SZ9OO MC6!RJ=7VU;"L>\,&XXN%L?W")@1L6Z^-4?Y%J0!8@'F!:.^.94A72G[M_%/-MWN;>B63NAKN5>WX^F M-*

*P7^ @ZVA:0VBO\-!XQ) 0*T^>)S+@W44\+_6\&5*8!N505%0,$QMKG)KJ4&< M2J9<"LIJ>SL_YTQUM^6IW0'W+__OXP#!UY^2YT(HSU# N5.*D@"(Q"AR7"J= ME"< WJXH=&?.V-*

L8VTL!1YGMWS76Z%]!#$;%.IL$ ^\|%9\1>S$K+%V[?;=XA; MN?+V_+Q=(MCC,^;>C$...+XB%.R[\0813/,QE'[X7V5>XNS\|SW\/,/.N_$!G>W2 K/#<_0-VD,>W0^%'>17S>=K2]NTB

*MVD7:9E(87_1[W&RV;&4Y+F++C2}4(H>91#R7=W18.)2<#5PGS2GN**AP>UK7 ML.W0],^Q68*\^)[7W<6\!D2&!.MJ_[*TZ.T.)-,9$!? MA^5D A091T[=G=37.CF-*

*;SZS_6*_KKY,#A:/-T%OB>W:0DSEN,VU;3(+R3R; M ZY?WV)@5E;F@Z]9ZV)D.9ZQ0[*B$5VH7V=UKLT*O&L;0/\W\L)3MDF5N,D+ MOXEO\L$+LDG)33^_X1G%FYS=-/F-/]*

[$=!FN_YJD =V1?5Z'LF^O9A^]S)/I M>.M7NF!HK;K^KC*WS)(;"6UOQ\4)=NY7=760SKE+XZT/H= M:?VTFNL@-8===7HQZN\X>?PJ;!S^$KXNMUD90Z9#72>;\P8@<-

*SY788@T2D&C M$=W(K\8]?HTVY3@VS669Y:IJ%$'-7'5UZ6QK?NEZ3"S:.6#([VYVI76>P*X MT95V:P=9/_=-7*$K&[US,2#F#4$<)PTT"GI%GJ0CD5CB[E/+:&;<*YSX]#?N[>^V-*

M;T\N=OMY$HZ4=SS;C+=<_>8$ZZN MO+HLTU5!#FUH0PS%N&HC$Z,-[X0MCEKPW!%T=ZJ;M\U.LXQ_U+"J^&UQ1B6 M7643Y'/9M)Z)<<[0MZ-\7Y#+?,7AZ1,*

*[#K8..=.KRDTTKTG-83_8'Z^\'APN MINJR,=T2O$_N6, BKU"7-/[<'DJJC(TP;4;**K34[DVNF0M^P8_=#?!A|05N^V)G/M(MMUF&&=+*

*[$8VK$!>_@76=:3.=1O$K"F4]4TYR,,STO*7]*0(M"_#A:]YBCND%08VORS8\|[26WAT,9IVZ3_MU M'}2GA ?@F/GW;((EOK"C+_:XF4?IG(7,XMC;<[CZS%=RM"M%[BM:H#\8]JRH*

M5L=>&S4'$F'|[E7;;.B?%?}7 I'98A@)"_E)U'+B3GG87C M?:SD^,,+I5QZ>%?QS5NY*\[OCH?U%,YB|HR\6(&GGI2@*18KN_*XKMC;6I;?U;OO-UML";._W'W ;.RBWG3L[1=L NOL4+*

M3@EUF:?;OOT&%/S><[M3[8R\|\N\KQ=Y,XF%!'AFAP_X//\%/IY3>=A]IOL=<5N^[]!80P,8V 8 MZ\4P3A6+3]513M]8.L\XHVQ4]7C?OC0GA _.^9Q!8!\[X&'#)(7S41VQQ|

*M2@^MBCZLN@@7S[1,7 /0:NL1+N,XFL?DTJ3Y-%]<L.PU; ^D?+71Y[TH?X[TK_00_L_MS;2*4C9\V M35F-/\&WH^.F;+I4+GX[>=5)N[%7)V!LZU5NS=^:M8Q3%!%YR"S_+8_Y&)OI*

M:"'M[?OIUC!F8Q\J8!WN,S(-[^Z:.&RU\@I>?8_XP6OR=.OJZEH!WDU^4TI"U?32>+9@\?R^;/@3=|\^]%#;QA9,R!=|_&I+F/& // MYL6DKD;-

IZ.Z\C%DPNS42=%.WK!#RN;#B7[VSSU3*3/IAXH_-LR70\D MOCH2WWJ4-&X_U6 X?TK63ZJZ0_K.YGCQ>C;K0-H#:?>9M.5CI&SY*7X]*%W9 M9;[$SGS&@:"_ ??]W;_N[08R*&.?)[?*

*WY&GZT5]JX\MK#_Z/AT2I5V6WYJV-RZ M;FXH'':OZA[fW@T@Y5! ,*HA==-'-W< .[']W;.0ASOWN_M%!]W_KSU\=6;=W\N M7K__^-_P)WK[_OU?\N?=O:V]G=]VWNWMWJ?@9<<=K+|Z?*

*-'WZ[-MER+B?N6>8M M]\=Z]3EM:CXV+6^KVHQL7K[CXL"$9 ,6NHVG+<]KW_8D%7'575',/*TXL8 MXKNQRW=6,/HQGNDU?&L:EY,R7^O[-*

I.!&,8V"ML4]G:I6 M'?N'/&[>Y_;\\'E[VQ\WVGO"D]G)SA6SGRVX/"\-Q_8U9P>?OJ1M[5V./U>C MSVW3\5S>=)++#E{(K9797.1U[T"[A=/(I-XLW ++WJ,!;>-K'9(ZK^?R9*],"*

*M(8&PR6MLXME5<|>73C5K_\VL5SBL=KY %T=E_:PO{@P^M,<7O_I2CD87OXL@ MZ@[AG1>_SY MQ]-+W^=M^O+HBE^4&6_"Y7FFHTM?-@=7??OEJB^/JHR-<+*7*

M'M35/P#[E]X>V?&E/7X|NF)D$^,?%[^,:!W&|9AS>?6F!)*Q=0%3U<9Q+0Q1^/1M,:H#_#-8#C#%+5N1|N%GOMLQMHH1S[T32<0P,.!:1*

M2S;YI;D:C:HO63]NLGOY'7C@>LKF"QIH=]N@4=E,4!RU\&G??!3K$T/[;&1\ M+HBQ_G1> SUS(KDH^)6J)D"_GKQL=X,R&YL7#IC&J!S'2^=TNIYRU8D.?BF

*M$E12*14EA&G,3K==CO/*4;O|&!,;#Q_(IK0.^QFU\.1BYL595R.8[VDF>#MN MH[\#\-Y1==2R_%P1.I8YC\'7F+]HA=16F(&5\KGZ=H^&;A^PZKTX/6#9@V3DL*

*MRIR^\/(&T@96@.H!HFB\OY%\:C^+E!:C9[(-5);Z-% ZQWHLG5.!\UCTG0R MK4'Q@*UD7U' R $C;XV1=E8B.\QPVR-P?]GK+/)ON^RR9V<1B/KJGEV2:OV M3W(/OW2 V..9E\?*

E$?MH\K-9CB#EM.V\6 E -2WEJPSX1YBX>C\@\ SD%5 MA59XM^B5GP_G +N5?5Q 3A25Y]G\N4UTGU0- =\O <^GKA9"O@I<,9J/,NI_MJ:MC.P+F>62/9

*(9>%T$!)OYMA;X."I]%O"%!<5T)L0'Y!N0[_8Z8VO$S*7O MJ=IX 2]G.5JY;2UFMGW(3=H2GO!EZS$=.,.2 1-VH MD5GA;_G>EZIN/;C7FCS%W8'853:GT91S[XQ.Q?C)- Q_]@*

*#@GZ/K^CP:(8! M+;HM<,I-&UA5TQ2'58BC%BE/C9N9$S-;V>>&YD$#MQR0\1[(V/C[]!6]@$>3 M^67L%Y#58*FT_;. BY[:WQG?3DSSC(WY*G&4&R5/@10"#(!!P'G;@+CF1/B'*

M:7T.T_:-)-A$\U&^^A5K]JY:BI\,6#S@,VWP>8S'O'6_Y/7~ S3.7LGO'-MKL;9S%K;/M'YI]LJL%@=_|=,#_[^"G=%300_?-!:?R|6#.2.$N.8YF6?:.M\K_#+FHPHE0!ZVR&63Y@'OW-

*_WLX0=R[\D).#L@XIJX6WWB)@?*T(MOMS M1U(L#]VT;EI4&M!O0+^[&-ZV9\'N%K\NVBEY=I,?J9-G%)#PL*[,>\[_9+\U#5S./=*O0R5P@XB4OP:U'G,]S(<,D>Y.K)<CX))X$WA9*?*

ZK> MY -U.4\BTRQ?XRK+ ^-Y;LOL[S;,9>-|JLN,D<&A[?39A88/5?9%\1^4B/8 MSAQHPE"H'*IQDL82<9S-+K+@N*V.S^.]8S*LE9^?*\6F:QRS;*

M!_2Z_3KF5Q8APC&,Y$2>5K0T5]%;IY@E2-,'THC >WQ+'AAN?,HH1QW>0;S5Y Z\E22 MY[9 ,Z~F^P?YUF.>H34Q&SPJ;32+X5X8#C< M@V>M4TUSK-IC.W=&@S!\?*

*%HTE&HOE]=DLCH 1N+*YP9N&]KHHPG1GFTZ-L M;N>IZOBY.EL024WISN=Q768_B"V?..*]3.&TSY38W#C/#:?^-B_P(O!6,L9 MR+,+HG9)Z1PY#9B_]CW^/AfE2^0,@?;+KY-*

3\"PPJMEHGP.D#D_R&/\2_V7K MBPEY[9?%VS+%8K<-EH"?7LS9@XERNSQ N4L9A9>2%>7?@Y2Z"PC7B3\ 55F MJ0'O.\'2FU-AVQ]D6KAJR<6;L=\\T7"_"%19,H$!=+:RO(/8);!-'5-*

&4L M X5>,Y^R.HJLUKIK3N OGS]YMW6N^CM#^LO7VRI+D#ZC2MV"<%V<^A>.I4=4/,.Y+8B_Z.O4(@N>ZT&U^/P3EW0'8 MJQ),?IGY?UL?

*B[=O7N\4N]MO=MYM[^R"F?)N^UXVQ>I++74 GI;"KFR>&V*M\I.DT_-08Q]H;6KNB[V"(BPKE]GIU;LMJ?6H[6MWHH[&'WNA]:'44T;.Pf-*

*M1A%G'K[FH(W'SH&!L5Y\.]RFP!A_?!]>A=5YR2[NLJW#>M6-I9U.J!=SA3@O M(^O'N5 5#$=@NU53L,'*KS&\/+F1V\1_6OR@S6P_:N*+)H+F!QQL<1BSTK;M*

MW,\N5B/^7#;E+.;JQ>+W+R^7")^3LL-8]B?Y4K_%0/(]0W/;I&=W4FN'3 M?VXI5N?HQ;NZ)!]7:/+&&%WZ95+]SF"\6 M3.]^52_Q8+I38Z\[N?*

^:CF//!$9!,>5WPXT;#FU&:YCUXM@&8AF(Y7[$\BKZ M>.A @6.D)1@Y$,PMELJ0T /3Z8SH(@SNNF0[/ P^MM.0H)1_O!O<^W @ Y(_ M/B1_,)@^HLU^?P]K>?>!OQ\6_=1F-EY.3B?

_\BY(I_M =J M?0OE;G-@;X^'UVUX7/5KN^<1X+I|_N\.8=[/YKSW0/R?R[\ QO'KVLY])>80 MM->?L*:")D.1MYXC;BQ#V@J-M&))IY"P=?;9(LOJ8V[O?U)B>BLS!%%IPCB M3 MDO1?*

(1^6TU9|+;&(?IGYY3FMB;;MJZ/R_\^ MW^QH&I\5TW$Y>\OOGWI???6L+4H&1\!T(?KRTZ;GY\A^#0+?[Y6?EU\F(\ M/42AFI#YB-SF?*

H,J^=/S\QO^99WQO3M'EC7P+H>!^M2A@8K:41> L/BR5GD M@G-(1A6=B"P"]]K(NC3# BNID4]*(Z[@7YI[A9P*R01F@Y!BE:R+B0UNV!-G*

*M71U[.@9E^%K"^JTM&S.+"SUI7CM(DT=-78.0.2M$@.UIS#0[%#,&0D029+ 3 MF2-S$HBR0?,N]-I32COM$CWWIW8D.@C(#H.'M?=@5$\.E(^441&N)",)(L(P M.!W'(W+>*J2XM=*

I02 0676B[#\"HI-C0RCQQ1C5X?!]?R?U0QR-;AI.>L6>J MQ_ES-YN#/+DKQ7T[)'XM;/.P/ZNA(#")).$D9ZJ8! 642$N+4...X;\|#S' M) PQK@OE>4[!.S,"WAJ']YEZ9Z%RW:YI1TH|74>E*

M?J_*;4P'_?T)6%@.(A>@2EP@27AV:,L+OKO M.E@3Q7+#"/S$6=/2G=-W5%0[KY=^>7+3E;5MN_'-MFV)-HIQG PRX%'3S" # ^M5LH 110AG(%F^IQ"\-*

@^TL0RQ%+P5A.AK>W(-3RCMP\C.YYLCQ>Y\-MPLR0)RX0!C[UU$'Y2/E4P$D;;PWP'%|3N1<6@?H'7D3=|ZL2Q95AUXZM\ #YE M"'WB?&KI#MA'J[B^!_2<-ZU_M@IFL[F@&N3#

(A>^0 M"S(S$K(&7(\P|R 69"+(&%-(8?'!,.BUM)W'!)V3W-E/=Q[RW]^GW)K:^C:Y\ M&H,",.RBP3QZ4CY111;22)-8A;Q5%/(6(K.;96YD4-1-&8l:% OL0C(IOJ&6&

*M&:P%=.=^NUSMKL//&KD,HP!"S-L2I:?;<8H=0G1YU!0KB .$+.4T-TB1HH92T M3)E.]-W5+AW>GO]+1.0[BD1H82=B+F6G]KBU*4|\+O'_785*

*M*O,'JSRH432!818+Z$TL,*!%0ZL\#:LT%D;E0H*D1QLS#VGH*K;[/_VCA&*M4[HFL]XR;TO;-MPMY_4O=B>5_^,_?A'K MYC^*'(TT.?[.HMN/(Y;CVX73**

<^G^S>KEC'P_=@7PG&/KJ=/YG=#KUJ[MNK M9G0J[X:&-8]YG\/>UG-O WZN]=Z&\H4/)=&VO(=CG#3%D3W.93D'G^$;O?\- MS1XZ\O41@X.5PB--G$#

<$X<@'%A55^7_E/6*)H%H4A'Q?%=KK3:(4.68<(0:W4FE[J6R*KU!Q5// M&1KZT#R@CEM/8[BB,O<9/\X@31XUM0U"Y/S=MM0B2H.$3" 0J;(X."0"3HD M3I2,E\-0OT??_>-*

?)8LYU9VY&ES4D#WS5;=BQ6RP00,>>-83!^4CY5D4.T5I M"[" Z1H\XIP09@C$*)O'$]7")?\HA^A[%=T4\2VYP/;C"@[OW853ABW58SBC M&PNM>) JCYK8!JER3A-

*F.>0=$Z1MKG804.6A@#K]98HHA.62ZC$LI FQUW M<3ET'MEZ'RJ\+7'3C54P?E(<5422G#.B 5.Y.A%W\N)#"!,1<2>ETT[XJ$GWI5B6QIGP M4$UP<_ D-;!*6K)H-X.-0N&F<5WR@D-V'$;.%(^YIQ0)9&37")KA0XR8BKC MI89C=U&1WU;C ;U8'V9J[3HR0N(E=@1^-!4+!C8XL,&!#5[G*>#6&,83*, ^@ M>G-A(G*!>T2]<(I&%9/OI.],9VPPE5]C0/^*=9710%-*

"7PX\L% ^^Z%JRQ"* M,;AUGK1;QRBE XX>A GFB'L*?S&L$$\<4QZT, ^;26+F3=KVL"TRB-Q@RZX$] M9IP>V-.C >4C94[!8I84QOB;R!!W6",KC$.<$^.TX90$V8G6NT3VI#A XNQI*

*M:%RSE("\)4EIS4$F/&KZ&63"69D0:7#)\(B282 3N$W(&AF0MI(*TKS>B\H"W?(.*I7T8.SJ@_*1,JN@N0ZYX0 CP@/CD1@YBS&*)B0+O.+!>Z2Q@:^P MU%11RO!E3GC?>(C..2'!&U@.K+ ''N0A+.)<6,00#C%(ID$RW3%3/'';6/#,(M2YQ=/@$CR[!#TA+XGV-8QDLNGWN&5'05J&PV*).#.!HT\X'_#?SOSIF'04?0 MI -BC!K$K2#(*)&[!?*

+$9'(Z"=UQS$97:8%L0\JAM^30NV9YZO7YUC2Q;4TS MU/"_<9_]8),/5C;]B6UWP.)'"=9'M=TA5?ZAQ.-V=7A8Y8E 2FX4)_68EQM(/M9]5E(01$@[(":R:1-*

1ZC)+&1&@3^:48X[O8Z[.]M0K !UN_KWO? UO&\'@M_QM".:MZGK<-8 _!?5;.1K9OYZ%/=]LV[U!]0;]_>/,=<-M*"4H,A:5V86B=5$C3&4R-F&/(^M"65_QYO$FQE>5N;M&T^\(WV8>|MT8WB02!9>L638 %9D1+BS@CD"'* WIS&KEJXC,@:2'2;$TG!U4-[*6< M V7J/OP^>%&!-^ X\O?:!DBY.//#* Z\E$]#<.;+*,20TMQ9+3Y7I*

M)"#L44%GMLCB)U<_GW|S]M_V9&>%,8HJ%?\U'<>"X8V"8L]+'Z9C.PV9G?S8 MUN\^%7T]=+$N&&E'L(T")C^^*L/|/<73\\KK7/ SQ6]*5B@8QR03B,1>ZX$XA*

*MY8"B@S947V[!VPGQOI].F@D<3SG>OS=^7)-JB(7AVEMDO $YZUA$+C&'O,''' M:VDT29VD&E[:VINFF7;]8IN:*TV!-,K$B0/QJ.X()9B[!&.2F5(@2Q1T@#+ M$BX%0Z),>"D\JB-*

*(75?!3%9^BAYR-,0%HH#TR>6?-AR;K>#3<=-*Z8]FD!4BH ME-G 2[(''>S=LN&PA->MI<+]J.?^[AH'>BRT/US"\/J9ZR!HX%^:9'&-99Q>$ M -M)Q"(G%4,.!^-9%#BF2U;9/45E:XIU%>*

Y=$$8&-/3!N4C94Q:"H^9DL@D M.%RYB!YI:CP21AEA)'.:A(YUI{$Q]??B=O!D7TL_'^]88EW'\+#.;,&PELDI M%&:M1(T 4@7-(6'BP<#V+"C7A>9PLKV>^;,=T)IZV+\A"?

8OB486MIVBC902 M,&R)Z2]MOK]/R67-F,@7@C5B$GO 4(^(>N(1!H6XX%#$2TZ":D\#]7_G[TS M;V!K2!+\5T%XIW>ZO(#]N@lY9B-HBM[FM"U]17DF9OYQU)$EH1L$V#ADJ3_]

*MU@-(BB8HB@0?P$<@6&)(@G@U9&_O*HR6X^;?B4N)ES263NP*=?!!1,@E1,3 M8C'1\V-2;.4FPX8'Q^^*'6(O.0S£EOS!=C9GL-HFIO-XX3(H)GE%M9@C#*> M9;Y%,B5_>-*

*OZK14P@RFF9OT:%3[%T=?&57AQV5:*QM)D*ERJ!H UL=IZ@E!V20BO *V151?H0Z-=R4K<&1A\8 :?0 MPDX[8Q1:N$XN7AV4Y*OQ8P(K36@{9I0P+ B8I+,6+D!-2]{Z,)6"USO\H8FM-NW,4NXHFUQC3=G,@,GD]\G($D0F+ 3K?%11ZQ);"7L2FSH4^:0SO.N)T$&N M-FW=8&'8.P^#?!^]E\+Y8!:&I#-V6L1(9_SN$)54JKD'"4697.U9P2 8[;.] MC.*

*\;I%7*_^M8\]^;1T;=WN\DJXQ_;XWI.YFQO^6&7S^ M=F]*\[/YL$D"]\:S#$BIPG)67_4!1]//1^P-QU,JHK3;PK:O&ON6/VTFI.AZD MX1%DDQY7 IO$G;---F-BA+NBIQE8LZB^"?-+*

{\>%U,3X>5:G&GZHLO\,927D7 M/MU?74WKW->OOE6%Q.V6C?WI??"U)?\3H?$9K2FAL5MH%"$$5TUQ.,EA-<2U M@9"3 A1%1.NWRGL.LSED$:4-\"J@E(-0&?4MI% MHZM2R @L-

*#6_Z$\@<.1@)#?6HLVFG3X(;W$6!B/,1V$R&HS>3Z^QX-42!:U; M_U!VO;GMBOGF)? IBQ"2ET#D)?)VG[PR*2;9*F E5\V1<(284(/5EAFFE!2E MM.%]/ %Y-*

*>M;1$;@KM'WJTF%/2@=QB_(JX8WJL:0122.21GS09<*B"O<.DI=@&EM<"2D]TZ0"?'10*RY$O7+A9AU+?G,<;*KQV0uF!';&@]0^ M;;MV^K7V:8N;G62W.TY?B1>B0_0WW\Q09>=P-*

^USQ;UL^_\N/N. ^IZ# ^^;G??UX7ZCP0(&|\33K#/<4L5?M ME/%9_>3/32V9T7A67S@;]V8?L'=50Z:1X^HF39=?+=S4Q9&E,AB%41HLL@?U M&V?U3:=K9@I,&$SOX"G@%>\?*

*6J&6-_AY17I/FT:9[=+SM;0\ 1CVXX@\=|1 MO^ZCBS^;3??A*LBSV'/+R$THI5E?AN%OX?/T^^_^?+4|KWYSN;<6$W+[QGJ2 M_?.D$OQE2KN\C7Y.+E&L!E<;<_#7H_\Y>-O[Z?C'HI*

*IIX?'1Z\.CTW[O^/?A MB\?HC);?<0TE8AZO^Q=&]962_?6ZDOWDUBVK]=7R.DS#KQF(>7!D$A]=-@M-9 MAQ;S?$C;IIZ,VY"*G4$7E\E]GXWD5H$:S\64P MH7F.QF*J8VA^':HQ/YY?*

*%.CZ?ODIG+$7 _^?+TA-1?#S*;Z^NW]W$9_0(3_$(=Z2)W<.$Q+>*X>]F?$BTWCV)4W'Q_0JZ6%\-<Z(-)X-_ M[5IC'<#CZ1*-$SC:8I7U^^V'-:&%]#@21+ILS MK+=O[G-6M-LS1HJ;!*

(D$J3N'U 6U?\M\|"">46(-1^C 2!*;,,]=T6B(0D1'1 M$#U.B+[9C(R$B(2(A(@T$0D1'1%IHB<7HF]=^7V4_ C5NCX/<2R?^D3(U^,T MXA#;Z'T/(YTWI^>F+[^UX^X[']W=?1>,[S\'SE*

W+F1M0)_1/)#$D,20Q+0Q M#Q>18)(8VBDD,:1C2&)(8C;@*%(CB;8H*PIX'B.()QCF4D1A%EMLHR)Q:@M>&=+ MY:"0X+GE(-%CD$H;@[?

*TK=D!VB3K>^^);2TR.6=\S6>PUL2TEICFI,"VY&J8 M"5695BJ

*FJ^1E,Z.2QD9C+3<)+M=&"_)+LDNR2XM)CE[/_XJK"J9F0_" ME0*EHP"G@H44HS'"&ZWM2MNPAR20+FNL',2_S:>SL_HHTW?C@YP'S3.$X9LP MR,>CPW ^F(7APMF+-YV|M_B/^6!:!WJ*DX^#A,M+4&\QC=^/%N^R\"5;\@95 MGXD-UFO9:8DA_.W08I+ILE?+3;*[0XM)LKM7RTVRNT.+N2=NAS)>N(0*K%4"*

*M5$((COL"AFFKE,]&*OF0'!.Y'<)/@NCNUQ;24">S#5A9)*.F^*N]>9>UW|+MI6M=NRY=9$O2:BRY< MXL/K'Q'OJ#K(^%-UBU_C[*2|"Y_>C"?-DQW,9I-!G,]"",*f\9LP]<_?=IE-MR>QN18*H>Q+1E"PALH1(=KLRWL()+EX"=[>C$;@NPQ@LHS 5!L0)))E<0 M,5NS(\)2LF(65 P)HO,(.GE;DDQ~M6745I1/\:9U!B\|UW^%+]R=8FN8Y=I2^=4 ,$X9W --W!]=)AW8HX;GXM-^6\Q'"P_S5R?TA#!>= MX<*T:0[W'_,1]B3K}YH.5J3]6A(X\4(T$I?'\SC$?=1_MT] -S3@QC54]-55 M0".K9Q $*.L","%=53Z>1XM!) 0W-90MJ)APKCD$K4$QEL EC2S$DB)9%RGTGYJ,/.0BL1K.& V)B>687] MSZ.#1+0]{QL$[M)8F4C|U8("*P[@9=3@&"DAVA4L#Q4?"?*

*7)HGO%WMV)RSO'95>X9RE[**@D*"DB.)\2L*1#L$H5959:V5D3O6;*@F*A #NL%E"(ZM%O5)!9 B12\@Q"8PB>;'S|KDLOX-KK1FPF-A.;B M(=\N,MW!M(O9":@H\A|'GP>A|;S2>U1?.QKW9!ZR"%>;Y?G#3@[2YF+_L1CI:G/X)S;?+ M8!1&.!"&|:GK-Q:5TV_,7!X\[*5AF%89/_Q=4,CC)UDG8'XV^CX/IN?#\/EE\|/OST-NDM/7#B,-EF.[.+VS_$93Q'U0/E]^ MRN*E@*-<1?!3,U_U'5Y>2>,G3?/X]N7=VN[=V:VK?@>FNH\N_FPVW8>K8UV+ M/;<\K!5*?=:?8?A;^#S|_KL_7^W.]H]<[JW%A-R^L9YD_ZS#OG7G\];B7TYI M=[?1]9-J+/7AR]N\TF?Z!E[#U=/ MYEL?]>WE69AZ5YK@U^N:X-F'7TLW%O/P2F\=7M=;I[,.+>;EQ#5G M*_KW/5^'(Y_FW;H =?8;;N!@C_^9;&#*H/W_PZ5 M]/*^6]N 3YN^7"\49M>\'= MME|\G@<$00"_N##L;OD%_L*(NWY\U_$^>WG@N%LW MXNf*'1.ZIY7E/3&T X&.0_QF0^MKGSSDW_SGQWIPD>DP;"9[HL!?HQ^# M3!V?Z[\^3'M'U4[,#US\#LU*2|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f7!9O))227\/[=\/4FR$JKF]76QR@"}08K.^!+,2_F =@_H/-MI')MH]}OW<0.R4.NM*8

*>AT:7)6W_%^F%<|SB% F=[1N|]BP_7<;F|&?4)C09Q>;;K(,H?O>W7_|> M?B/OOFMLUGCY9^M[=AQ#\Z4WOFP^3F!(#<}/&-J-X;8?YE+?N M?7F[|[JYZA@^-';,\FA^B#Y>N3AL&#EK**:L M"7#/N&U@!#T89&|8BB'@YO9B /0+ ^7EY"C#KV6S'\ '\"E WXYB;/[2PF_R MN_,FTVQY*'GVY=6+48/2]9-^H16,*#\9%FV4W|ET3VSB:*

Q60;XJ3<8P2[AO M=-FD?ONE3&,4=;%1>D-?'L%=:!F/ASTWZ0\AMG<&?%#ZW/6?(%[^#YE<]N+0#OWES7GSOR[C8#Z53./G3,1L91IY-(L,8![P M^,!< /2VS?!ZT-J]\/8$CM^\-YXT|=+EWOH4[$L1(W)&180EX38P<*_I2H\^ M%C0XW2$B#[:CSDCN$& #TMZF(*3FA,Y/,?KM7\,W/V=S'&CS-Z#!K^GCE'__M%[K]-0[=*

[3#6U;F=3$[IV8FILMVYF-..3M_N+OH[G'HF^8:Q/4&YG<&0AH*.M4RT)PQ>@2A,R;DP&F6DFH\R.^|LKQED)82.0P58@2GIAQC)G59DBFREMNJGB,0?8*/QJX MN@\|#>,41+-N+0)?XN^]/ OBBX'IVRO>/;Z[M142#-LMX=]^;]NL99 ,;C[RCT M@)TS-=_"N"=7@W< >]=|> ,V? ON.G/WX&(I\ZO7#6F:+-5\(()]-=T,WM+ MN17%00#?__<\37C"VWD8X/=M^_]+(-,3?,AD6^_$WG_W';+\|WV.C.^3H3&-).2P0Q8'D-C?@)7@@LI'(P)%&KCJE@ M51?T^,%,D6B\LA0I.?)>%$ZIX<0A)2@W)@1+\=\!F&TS>KH:#ZC0&W+NDQ M@=MN@J=>.LE9D"@"TB'N$LE;31&P,R@+IA\5=J4\:)=@N8W@J29'AY8U>%IA ML\++FPS 7F0&[+P#"]1@0#RXAC5E 7EL1M.7.Z97TH$W W):#1^#8@GU[=&A6 M4U /(G@ZO&Z'N86)1%03CE .;"A)O3'?(+"YE%NRT'4XM?BHT.5FH%Z $'44L=_T<(T!U?P M26,OXL#?.*ZM1|%N0.H42 M3S2;X,+F6*SV2/M(41).$!5);GVZ4BT1,

<&69'+SX5.RMFG@YFRLAYX%$@QH3)F)FO48"97FGM ME?!)JK #S#RJM@,512N*5A0|3A>56Q96L.E00%SLC2U<\BER)$3(E(|+(YB MM>YWAZA\@+'E/07E&G^NZ%S1>SQHT2.O?-YL'T9TF,&~Y>J-B;L74BJDG@:F[B7UK M[QDC6"(IIYA1Y=54=V=-% X?_O'-^!9'VI9S0Z4=Z5#%8C*")4,52 J-M(U2!.&V!J+EM-;=M37<^Z1BP\10IEW/;O);*

(!-0E,%80B4+$6_"G<^^S;9<=M=;+38&?-6JO%V4_,6FL\U:O?+;M)5 MDZZ:=%4@JD!4@:;@"406B"D3=T*|;^KN. &#.M_*H.2#56==2.02TR@P'2Y@-M"(SSE0YMSXT Y/__.'>{1N\'&>.R!T@64WA."!1].AV=3MZI.A&M=61*H[+@.D2DHB MIW,B!TT[]28#MZM;FCM$MYJL7~B4-'MZ);T6-'-Z<@2HP@L-0I>:$S($1|UG.E!]',K1X==8(25Q7,LH)1*; @?4(T10M&*

*M,Q?(!1D1(=A]RKR,8L5\QL)3*9- 3/. N,4)6:U /?DG3=1>!+:.!XCMI+O ,RV&>E::=D MB)(E[/&>A$^E,,,5QU3P:PNZ?&#F4M,)]P84E%PQ)V-2%L*AK*W1C#,<"!F M!V"VT_*

*IK!'3BFYU28|\W783/26&^F0C1A30$7%%!')<410#D8S[R!U>*1#: M)5IN(WIZ?#UV:O"THF9%S8=13K)H#!,$!>)T#G]JY)*DB @L5>"&N+ 2/-T$*

*MRFTY>)H=6&V[#LU]#NI%"],<7,$GC;V(W_3N+8>H[ ]7O\T.N# MDP>7,(QXLLUQ2N&M?@<9%&X(=PC!$.!%]!#B(5LXIP1$#80-' M/U))OO_00#^%. ,|;^|:2)H M_^L<8!Y.XGJ*5#Y)*

*I9A9F'D?%$]JLYSU!A=-4;ZC)O1&UWU[T]@0"IEL'X2K M@Y4L2<-X88C|[|NAX3/K*WIIL#]/HB=C-N9G9F'.M HN=3:6R4, 9[60,3_\|AG?=FPC&Y_B;V0TPG[Z]'L6WHWAMAW8<9|\Q?*

G(ON MV6_NVQ_ZW\OU7&\/#/)V]HR'LC/+:P7[YMV;/WSE OK(|^2Q^_%+'_#"^XEY MT@,>V7C33T^.O9<;[U^3M9-C|>%%.)X2P3FDZ3FAVDK)Q M/.Y|CLT5?'*Y5A9'Q:6*2Q67-K3?*

*6W&HIUZ.G#0E=%(AJ$I-E9KU&81A6S^.M7"):E57AJ6O&^IA67@\^ ;U&D^%-S1S>X ,^R:2X'&GZB@V.8YPPHLD|Q%W. M0F%'(AN,D2X)%?C*EI8@BC'E#3(T%(IV8P)&)"J-*

*@A,;!*2O\$|>'/\#S>X-) M.QG=OIF57<=/X#D2^DOQ%3?5Q5F?<;GEUC\|DM2,6^/E|IBWAZW3!..Z&RE M(NIHRN=11\!0FD]J#3P1FBS3:?\P=*G%VOVY,,^"5+,;E Y[V5O8>*

{)%65WC= MJ;G_H;VZBD/?L_WFVE['855W!RAR)UC$L7&MQ)(-02N#-%-@V8,ACYR6'4G+ ML)>M8,:13D*CH%00GFL=Y1.3U5[+1E=G0FVYSOW8 MY:)"W=$MZ<%#W6X,^H@%-Y!&2\C&. MDZ-#T5B,BDX*)DG(<|P\YMV/8BZ,#T1JH/R2[MON3D7+0PS<%5:>|W$0?^IG'M(%33OO:DK3U!GZOO%8!M%Q"U%...$V@ND!W MH9A8CEXEA]V*DHLZ&H*

Q@X05'O'D045BRI#V'\M0ED11?B#N 5^Q|K>M+D1% MU{JH^^J&6.8Y!BT$TJ(;ZN0YB0AIISBA'"=5KN&OSY"'Z0.LJ=@?8A;$'03

*MK@HI1%>E=*6O&K2VS*PM,S>A_CA12COP2!BA)'?@DT@SCA'C*1$1I FK+3,W MWX'OE1P40O"9%EO>5#^RMIH58BO$5HA]38^%2R,,D1+%TC0U*HV/-3!*

*MO#_@.9$0[5'X"J.HK7AJ4Y';(FPS3456>L[6IB*U*5A%HHI$M5EAQ:6*2R>' M2[7M6FU66*6F2DUM5KC'^KL6/-9FA8>Q.I:W(?/:N&NM72C,*>_92MZS5&LC]/,/5KL\(C4'>UT'\#A?G"'*,8)1ZHKLB<"F8@#HDP+B9EEU^*^V-&'2 MJ^0|(C1[T$HT(*,X1S)%PX5-BOO#2 FF^$QII.&NIVU7W<BAU@#>KV?.UILDV%5ROP3Z_'*

*M_X'Z$Y](D%]A*")!G&**###!]>"M2HE$;5?]3VPD)!!O$#58(BX<08[*A)C3 M)'(KN3R0GB;,G&&QY5#5GM;)5Q^B0FJ%U(/P0SS"1<1H*

MY0P'$XK5=VO#]%;:FIRFFA]B)L/M:M)5:&UY+Z6W+ ^*SL7-H3D$",&7\1- M#=).@XLB673<<$KU2AQ,,RRPDAKYI###B"GYH#MK3J9!,8#8(>1@GJ2IY1O!.*

ME=X>E<57)Z4B;$78P_-8%&'&2.*0\@G05PB"#)461:YT$$(KKMG^(:6FIK@=M+9^#O;?H_4I-3:,/:T-OH:)(%?IN^X, LPR|SXWOVO'PUF6]B&C0ACB[^4WW M]8P,_?@[*KUA+*

*{R5NXY,K@;O0F|TW;.H-+I9\VEXWKJGWUWWP MC\IEWB\LWL[>46U$D+ES=+;'^UFI_9B[\YNZQ9E M08SMS"UA SZ;_UQFOZ7?Y\)X.0\;%/{L(@$VP4S>VOX7>S/*G5N6.7/&=H56*

*M]_/*H>_3*[BL.=GE|Q"|Z;=L."GR}A\;*_@O3>-B_U>_!Q+ M/X Q_(A-;P"S[X6)[8/VG9<6]DMI83,,,)!1WOX=QZM\=-WP)FOB?F\ 7UX/-M0=|.821PV6C2!\U_T:1A>P6//":-*

HW%3CKKSH/ OX'(!".6.08"WM\UEVP]V M./8P%-^B\/&4G/:(E\#7_>&\/5X^MGY,VV1#1"Q>2)8'3ZKP$(,X5~8MW#" MS8-V/%V^O#*<CV.]/5V]HR8 CVT^>KID-V?*

*=JL.=W0.NVF%L^KW?(CRU=*3(M'\Y9TDCQMW\-5_V-.M-FV'HQ#R;W'N0L3G.1$(5CH[$CG0#G#WYOM!^Z +\0K8 MM*.L_*\WSO^:@! P_'H#*(VV>)'F?14:[ZFF+*

*8DDY6(PY\@+\P@$JQ6^23# M2+R2XB@5LXIP1$"H$#2*)-C9C!$,'N6/EQ&|-\C_/%49S368@FW(M*JS8.S&<+RO\9?]O_1',>6!J:4Y9P,D0)%;PB$GEX[6Y1U98AQ+&PH4DC-!N*

*M$RSP\P ,O7%,WAM|R+WM+_5B^----#M+D50*I[Y>L OL!8.53)M0G>...?^W__M|4T3 3:O\P;/*8V3[C:QL|_<#-COP.BO<>,=\R88!+"6(8VF!M:C06X%VV7P:92VB_--^"*

*MA(POV\D(7C_Z[NWQ-8.5\MR81[NLGDOZTD:L]%QKAA?_'KUA[\>T3WW05FLL MCJ%336WSM&=KN\DF3N]G^/[\U=|'DE1VK^R^#KO_.+-=*KNOIS^?DQ_X8@7Z*

*MZAN6+\34KQ]HG94[N "W[VW%H-I9\=X.%J-Q;:98=7;5E!]_=^J4?ZUC?F88 M_M=!,&ZB'3;ML.G'4,U=/M[6 ;4-WWK9_<8QC(-`R1.5!Q\T60D6V;,,:S?*SXC>\DEW-5F_ M*

*ET%NKT".L44)3Y2)+%+B!.AD(Z 8=8(EK1.VMJ5,J;= 5VVGHOOO$<0PY)7 MD-M6?.V!G<1GV-3|;S27>MJO;R-7I?+ I*R4*4$O%GD.I6DGV8$*9 M$80J&Y'&N6<>#129X-*

1MMH!=2B6THN3N9FV.X/\=<\LG3X M%5_5!:@873%ZWS&:$QN3=@X18<$1<4(C^,L@KFSP0AA&B=Z^(]+X:P|<0#&%&&&X(48RY$ MBZ-6*]'0YV1C?*

YQ<7_=CSL.V_3_9OAWX^/$ROO%/O9'OMZ/),(V>E'VM7Z?> M,'FC< .YT.\F1*G*=0!|PQR1!>\.C?&HQH#RHM>DNS:|ZVP-F[?D' MZ?#?8;RV@-H_ GX=!Z-IC>>OI0;N0U<|V+P?*

C>+X5K#@?NDE=P;U[Q_@S6[8 M^_>SD1V,T @-D-CTDPE'F'A<$)-&'@+@U61P)09J0@)FC/HD5%^@Y(OQ#3!%F M57RAB[M+!6F0Q!^:@1[FE$)E&/%$_) M"

*,@%5<,*GE*Y]!=89R47CRCEF*,/8\!2@=LE@PI A.@[<0DK8O-7AG6Y*=,/[4 M#C],A7';J[';0NL$<5/G=[@MMHT+CQNOE[_F4Y#(^30. MFD7A_|FT.[SKCKDV:RI[CHV=O.%-*

!8;@;B4' 'L0 MPF$/EC;@E,.YD+I"EA."@J-*41$)4V0K8L $;S0-2+*H$8|*(ANQ C,^*:,3 ME/V*@(MD<5GDEMS6GK^;TW5G-6**951RB*RQ KF8,)+8NJ #$5,%O:@9JN^YD,.3*

MRNNK^%CQL>+C532<,26X,<@YZA%/6"+-G4:$"\V,%Q9;O(6/G&>>\9%B91 / M,B)#4D J2,6H,L1T.);^*JK,: NKKEM7S6@P.N#O;\Y1X1,8NU!8[P\5I"M(5Y ^$)!FR6:V_ ,I8"3B*

DP6@R5&T4<C==72@C"IZ%C@,%.S)@)HB M'2-#,B8FI"5;Y#6!8?ZQ>2$1R25' (8T7);K(W+1,I0;RU!1^U5.|EFB\/P-SC .,S M-|'ZXV4MU-GQ-*

,8R^>WP6W,")QRW31R&)IED:PF%\@;--/8GD9XCRIQ=#: M.3\)YM5,X:C8Y0+%A/!&<%(IQN5Q%5W2XJ 284LDFY!V&.1:PTK52%@41M.,, M!TZWW+D^6!EU8

@S9A&'F46.@BDK!"?]81-:2NAY7FAPPU0@6VBPM$&CZJE MTG>U;&W>,:+5RVEU[_*I1>+&[^K@5V#LG'9*!,8 ^P#\P51P209C@F4TA,"4Q MW$9C?

O3',JE:'-9\,@QA%)}AL>8^*IU?/7A/M5#SU8-2%\\37CQ]53I_O@NH5L"YTY[4 MF_#%CGTL=KD?# >/8*&&.QR M-?,41$"*0-DWIBFM*j;=@2S7&NF+P?U]*

*{(:C$1#C*9AMPR_%IYRFDY/F';Q: M;&?K5+EY^#!-Z;HHB, MIUZX\G)=_K9:EKUK$+ IA8=KL!5I_0Y)?EV ;ID0I<"#&'/#F.(P(T4D9Q M(FG:*I=^*T+#HA[.V>(IS)H&=*

MY:B/4>Z4617%LUE%55%LA_%3$HUU%I.7<38-K(I$E 9#" 9\E4?,9(_>X.4;-M_&DR_;!<@:55;4\D5RI>E45%KC[E3Q^Y5,J18,,*R*

ME(RY4X3$,C]D3;O\=CZ.!K9<9S,^ZK2]^[9VWN@]:PJ7;[6('Q?L(L"!>$ M2N#+.#C$j:1 N1/A&4,2B8LDU5;BW&T^?=PS,!)VSU3[22%C+7"^AIX_D[5D MR:JR:J&J6JBJER8<+I%

D4<"4=!6GH|>6];M>_^@:.^\AG;KPZ2$;_YT3S$KI2,'P&U_L\7I_9S1.)B,N3 M7VQ6FAG%;R@,I'(4ZY$,3|9OPI#|G1DSUE7U?>VA"&X)KIMXPZ>ZZ%==1]

*M8|Y.QNFL^5=RJDHC@-(U;?\KKEDQTK OMVW%-T<H?4&M7:N/QD(_VX/4[6% MX(W55FHY+?Y=E[^USZO5>+RRJHM(=[:R3? JK^SHJSUK3;1&NV?P\M*6DSS"N? X'^0;KY9$NMJ0QVU5A,P|HL/-M:84L9'9V/Q6;)L%JXJQ;N.OAGJH6[:N&NAZ@]=)MMR2=1 M>ZB/PETWV+([A.&KBZ2H-8BGQ)'6WB/CDE-:".?#G9.R[A^[R$#C>VZ:*

M^6BPJV9C|4)RX)GI:'(6(JH3%L5QK-91U5/,0.&:=+VOJ:XQ[CL\[ZG)>P>O)3>2!3L2\LOG.8P1& MND6<(N,Y!0)Y6D0(@9#[U1VGJKF6-<<1&.-K0HNZ1QBKS%#AN*$M,(*6R[<-*

.HGU^ZOYROPS3C\ MMEA_]^(L$:Q2YM[Q=4J? 8!A9QU+/B%I*=!8(+NY @!'BL=$M%?8"-&3?_?! M $P)6>&K^GK()+^3%-L6Y C8;QNG7X8^5L[!?)9151D;KEXEO,?,(4F)1CQZ

MC(#/6F0IT)\""8^*TEZ3[E=HX7WP_Q;Y=)>>TTR?NHQ7V'IR4_I$04LG&KRD M"1E'/.*8$A:|[O97A*K3+O>V=2@?M.5*(Z^D6.&Q MPF.%QZO@D5/GK8LH**

*(03U0B:YJ5!2%-;?NL0G7\&C#P[A%CP/;N6GQ0^/C[MN5:-S=?I*LW:[5(;57_5DH]UI&(OJ?TPTAL "1TH:8/A$Y\9]0B-K@[,P.G2VP6+E^Q&19"QDXN^[+(=R@R#B/1@.0.M.C MP_W^<7*

*(#KN\Y>?")8>7.8K2["S?N_!9./0S47+MW;^52|\OU6N,08\]PTPXQ-M0V&=T9B02]?WX^:7R9>NS!#%E Y*X<:WDQ-XDK.F*"\P/8?CV:2!1P/Q M&8>37(D4_IX'EM;?*

*C(]G>2BA\UQM.%?;C M9#XL:C["Q0!YQW!8^LF@>0O# *>.AW;0P)OZXR9^@P<(<.O57 4K*PLD01+0I MQ21CT\+C-&X^\,5"NXUMOW?GG.(XQTWK]G ;R?*

+:I43T+'"YN@^\(MP MQ7S4<#R9M\W7(3Q\/K@\7IX.WCAZ5UW+N^-!}-(DL"M0(^8A+BU%AAN#"%%. M*J+!ZMAJZB0B%\|$@C"WN5@JT.:R3O@P8?3K!P_3=Z5L=N+*

MB/[W?'262V!E^92K-7E1S6P/_,,\W5'3?)YF($PMPNV!5$<3:-)8D911B9/|Q1Z/HW18/G1G&+&,L5)H-R*@(FBE]PHDEAIBM"A.6X&@1*

*ML$KGLT_94HL,=@0E$V/2Q(A$MOW#&X*Z9(MGEY)$N4$2Q14D41]='I#Q\%+6 MP-&C,L3C9@Q'=O*U7GPWR\UO'WY?=*0Z.HP*NT]9;;Z]\^6J?)MJTT].3H:S MO("SVFQ.1_!X*G-*

]#_/V_?02BTKCRO=VFI5H/MC; MZ?2L:-23R1QT^@*GNJ/A-=)\-I]&$,,,9K+20%3@MEV/:X2:/)US8?._'# MG;(3S,L+'.=.7SM*"(?8RA[>I-PWE-?O&X M>= 1S,RXC?^,P^2-*

*SC;G:H&M_|Y8?7A8@A3/AB*2/)@/D?BD$U2H>BID10[MRI.[B*4L.:5Y;IG!0$ <+@$FMPU(>YO W-9 >SWL?1]F8%,Z'Z>M)>W@+D9 MH-(C=9" NGK7QA#U,2\ZO*2/FI@D9?*

*ZM;EN[>5" [H\A**;@3H>G EQA+A M*2!&-0B0!:O2&H0I#3RB'$@=LN_?1M;\@$$B!Q='LIR:)4:@CE7P'2SM$> M_O@ZS7],4@=/&4/=9/+/3= ZA\>.)2Z+*!=!S-*

\5VMC."@,,2SQ>P6^3H.3 MO6[C^,5?_AVGDT,2S "2!)+F%SU#@#_]$T0) M#NA0ZIP;|M^BP__M_-"7J=;O#E/@*9"S#3->^ MH[VL>4?MH%$[:#Q4!XWM174H-???!. AWG!'ML*

*[&,X^BS[_^CX>&W<+#P[M!O.V.*Q+]?\-&GB ;0">@D0|0BF]B^K>.M7'X;>Z1&HGC7U%\K[-QOF!:8G(M.Z23I;.DFWSW%:VTIR':=ZC:W]6B5[>_DTM(I)BB)P2E2#WB.F]D]2#*

*(!$T<.M-TZ(M\?Z@.D-L&1T7&'>$P!&6<,TC9HRG04@ESA[_[5GF7_75_-SA6OI>F? M@'!7+*M8=K>MEY"<QN|M.J$[3RYNV<]|(QE9.!%K1UY*

*M%PYPUTY5#>NJP6GLB60$*;5R$Z8@D3;*HIBLQM$'-MXO56Q;6[T|QU8A ?"Z%M M,A$'\T2(ZM7Q4D_D1>O+/=.;7NW9(WV&HZ0<-ZGQRKWP/KIGGI,6^9F?S.9?2 M,DF[4N9W9-*

==R'UY59&F%Z>Q28 MKD7H(F^B;F!H[GU)Z644T851BY9#$B.9I3&Z!U80$*EDNZ|>6_XO?L MO;H=:VMVTZNB6*E*

*NU'FOXNC.5T(>-53E8D]X_FN;_QDS/GJQMK8#@Q!<$=(#9DSU7SVL_^[T?&.(5*O/>=>I M+7=*;&=56U0^}(SGN[YQ|4Q5S\1?7MZR_<|-4Y85,5%8CH+5%'&/;7*$*F-[*

M06)M/#9L]]U.[QSM|S7?P+MO'@Y]4|KT]976K)^GM^MZD8T_5+:??/;]]:G'V M2N[]?-/1,;SQEIZH6=[MGU] MN0-_N9IM_XQ>N3H0>NUUL>9$&"P[-NIF=[2Y]G$-7+FOLS\2HX6Y

BD MJ_*CRH_]?-CU2 MJ\[62]JWO'IRWVU6#S30Y<#=4^MY\N6]=TV^+Q=Y;-GW73S,Y'+>=AU)?4)# M^O0#[IDCEERNOOO'I

MBQ5#'%$$IHX\1AQ%0DRBD58.RE8R.3VLI=&:3|&-_MQV/K1]U/XR>XV%]'M$__/%TV$)7*:M>%*T'ON7-[/4B'M-:NC,DD7,0K&Y.PD*I*%)B$GX?^"|(2D>!$G/%->)B*1<-XCS@-*

!CFN/_%4$ M-IPK;_A6=M)P'#^DMR 0P|E/UA>U^C?|;7@R/_GK9#]=?`6E^\;"FWQ/W7ZS+___MY:>-J4=M|\GZLX.HC>,?;?TG@+_&09OYTDC\+[:B9+5ZQ>1DM((7=.=\/\U0+

M$/T4IR=-1N#! D ;.RZNCE&$M%FELQ?B:2QNEP:N#@V(&+\4X ;[^XZ'\-)OLA@ED1XA-C:)N.\ M29X7TCH%'&#@SM>T.Z\X26JX8I=CK+MDQG$<)8+?*

0'CNNP|"M%'P%HAFT# MZ#C/1,S!E4:CQ69MG+5-_.8CV(;Y(D99ZG-X>"_N8 #/SI9$)I\|=_^.7YO" MX<;QL\V8T)R.8O@G.0F?C&/T!V7WXO=YDRD&+NR?Q02+"(/-HT! M*

*P;RTBR@W56B<4M(=%9 6H(P4F MXQ_M+)++--1'@*U3*W>8+H6#/T%FT4Y35T!Z6P(/)D!(4;L D(O6\=[6Z#KQ M7!1^/&ORP"YY?Y'BW-X1_C>>I^%/]>PNH @9U.FU28?*

*EYF'MYS7+X&<9I 5[FZ M2S$8=BR+YV"+_0!\8K31)9-UYMBYUL[0$E#G\ <8L+]WF!Z./!\W/[__ZX;?N M8;;Q=#+*M"@>5I_XG ^C'&0C6K/GOR7PZSOMMW4\C"V/]Y!EG*

"PP(6!5,%8^AABNW8,W^3W=GQVCP5?++7>3^>Q>.W4(3SOH9$< <M0|!*P2ED(DZ(.R=R*B5&%#-'F*;O:Q*UZ^LDYS*T5*,B,Z1+,!*.Q0CIY$A-- M@>LM,S[5MZ/%]ETGE?V7VT[,#_"*

(IOP8?QW"PH8E.1O'4BO$9O34$TKAH/H M.L7A5S -(#CZ@!C.'P>@>N=@/;C#X0+8M44Z2IR#Q71V0IY4B)%",W0AHI

MMCR.F'&AE4/648DX3@8Y)30!@OKB"9)T^NHZ/>+Q9+G_D=0*>//OX*>FX2^ MQ$ =?:? R1[$X&B/P/UFC^1A79/#; ""'>(QA,P MFQ;GO>A^7JZ04?R&PG :RQR^@N>>GXQ?AV%*

[,K)GK_*OKT_!(@,)6HO!&?:/ MM-A:Z,[XQ#R=#=/9\B[E5&!]X;6;?,NO"5=XM=]-^?;?6RIGFWU!V8K8P[L] MC,01LK$UU>TTK?:,>24{X8J=CK+MDQG$<)8+?

*KS\2K8J0AD%\%D$[S(*SOZ"O3D|8L_;0CF M4NK*4.T6N;U(UFVVN&[ODMK:#-P>ZZ?*X#O:N3|PS4Z(=E@4>OQ2W!V^1$^& M}J;4^0+!O@#FVIF6K)#1S2V8[*UH@77#V7*

.X!P:N6&61^P3$!5"':)18V1$H,AX3"S%4E!K+I;(*+'-MQD=D#,O1KTH@RVE SAC]%2.&"WS?_/-JD 1\1"JO641/9A|@ED|_,,>?(QB7*

*MH1E/9B#&_YH#7RB3FX3Q;N@D[2W;IVUNX+7<|-M\K&%Y[#9*1>+4W)X(ZT=1TPR;!0FD:5T<85+@@4.EB(ABO)S M9$ &S!S$B0Y.)FN]4=&:V@G!NXK7.FZ>[/=;P7BV,P]*

(*OKA9&N;3U6;I-M'B9N,Hl%2WYX$A67(!?,3^&?%[2I30LF_.*TVO29C$,A2NW1@5C#3Y45OQGE-MQC:G%C0;K'904Z>P6C/Sl#RBH7Q>'+#F,@56"9].%RN|+6O'.%9J82%,Q6P*

MK6RLP9RF^6CES-W8F.CTI%(C'=O.93LY+4(!5X?7A6CU0#8*>1C'<9^78W"3S$";&6C'PSGZ_+.;*1&D%VQ+73G%&,s:9,,(-M(#Y A)"-)"%*/*',6QP3?=!YI@5O&T'2;DF4?*

*TL65XG5GV>R8GBF, #3;\.6R!6;]IB-MI*U%++?-MD"MT^^1T-"QLJE'[O-M_'(@&RV)M_AD$?[R\NNASX=G :!D-1'I[A@-M"-*

L$(.V51%H;@HB,PGN=G$A;50"$PCQ%$Q'V(GM6A$,ZV80THPX+ZAC%6\E; MR|%XUPU&=]7V%.>(C_@!0?D]S#$;_[S]D^I)"/U6RGR4*?YB[%9>[;X;+/-6#)163*

*5I<8@9C@AJP)%&6M!S@16lP5$]<-M-BX:I(GB,.8D0V2(YGI*U$=;.6J):T6(5((IZ/$6P3(;.;IZ;/.YMAA%10BNW#. MK1O$*I*ZCO06P,#D"3'JS;'Y5AF38MO/")?*

VDG2W"|+-1$]=/V|"C!X58'=PJ M\B80!TL 2%1VUT2+G, 4)4*X2196A-_B5;=)W=OZZ M1[O?)<-(D9),C#FR'H,TX$%1T8SC)B.5FA&#*&J9&E_],2)K#T-.18JHP4!0"6SOB<5)"3@R:C*

MT>1K^^J#:AL.ZI'+#MYTOA>#:-<7[34'<*+Y\?HNT13 M1E8+B-4%=(C%40^X N,=;.+5?FV7\+X@^#V7W#N4W(K:SJ2V,!FF5\@*YU+2 M#!$;*

*N*I9"JDB((.1C(?.3=;F;BW*96XZ4AX:Z?3,S!!>^TJ3_`!J5V,ZD(M=NA36A&L1P3S-+EDF43!,X6X-P9IEPSBG##'X<5@B9C(S+AE<5#A0,RZZ2(7;T+_-=I/!G. M3]Z,0SETL=K?*

YL7^2^Q-76GSY'35I.C9#Q4Q^'<5L0\/,144C#MC$* S[NUV#=,R;/.#+/HP_W4*P-MN MJ>%;?6;346>-XQ;X/ 52[!O!EAF!+*)B141A/&79]>^7..3#'?XI+0?DBK_A7O MQ[_*

*O3Y]C:,O\6^3W*FS!GH=PF92#?0ZUQRB:HYGLUJJPM@(S"*>6^8PLB27 MIPA*@L)P 07,HE61NV3O5##N5@HCFY*?ODYZ* 27W7$WNT0A_-3+NJBID M514UVJU&N|\VV>Y?*

GWG)M2F(JZH1Y8ZA1SWDJ:H&.T_:N!ZZN9XVEN%/CY0 M^I[+9M=@N-O8+S48+E_GTV1F1U6+U4"/&NC12\9D2E(+"NHINAP(QSER@7-D MN?0D[

*<[5ENO*K]NSE>)Z=)WV\.IA@&8/P0l;(Y5? M:G>)'''<:O[''7&93?P_CRI 1B/?[<#M=/+0T.833STZ9N8+\N!K:9 M3>Z#W%SI/XVVM$HAK^>+85T<>#F%E1[,*>Q75>7[W_YZ;HJ[-EMX]87JHR'UXZF^Y%LECLDDH_.3F9Y$<"\#IJWEE_O$/.&KC4< 9C5B[1X>"& M)I?8_UZC4A4\R(.J ^$D7&;.T6@+Z;C$^O^;A6?VXDDJR-M2>;@8PP?9[#2X4)OBC*T/^8XNVG[.*

*<_"S206'V%,#DE.3T&RBC25!J_QV^EP M*F)W1WFYA#U(PSSW $;$<(TX,$UD28C(^"4\5#5@2O;7-<9M97\|HFW'HIO3# M?-,;*

*F*RP1^8XY0&_VK,)^>13O=BS5>*6T+Q+4O4G%60DC3-/)24&@L-!S MR_Z_1\VGXP@ LU*.)6IV&GVV+4(.GJ49F$XG8[A>/K%=XW,+*&QBX75%?P]! MGX8PS&NAQ,,, X*O@-*

*<-9W94;K9"QL5%5B '=QN-RD.>8^+D?+IWJG*X-L64 M/1ZXY%Q%%XU$6&F%N'4O[2&-X$+A<6,9X'3BO,HP/%S:/*

MFLM"SJ>+8/)#$R;&8W#&>-"!Z8.AQ#1Q/NQ20<\811;DU=HL2@Q&$'RJRAT-$>'ZW9\)Q>W.,J9'J4+ M:P&=OP)G#K\N=IV]I^ OYJ@I'A94!J99'IO'X4"XY7ATA^9;OGT\F7&!8N@--

\S>7CG,ZGF;#/LN]@[3;# M\]O$;SZ>YG6_N%>3+S;,>JQXS9I?;!OLO^!MVEEFT[_-1[$1DHF7_H>7"!X, M5'2YL@6U%S((@L<#K3>;SR;3L\4C3/OZ\.+B;J)%.KI?%0;MMF@P,(V4GV

(7&G94GVAKGG!R7?89?XNAL ML&/$WY1KK>Z5W2U@:.0"T]F*V_BZ*58#">GH\E9&MAV@2PF#V\|&6/SR#_ MUF41YI&$C0<DIDDPMOZP\ERM%!WK?P@<V(Y 4\]?

ZB#B&G\ZOL>4/78WD.U@^P[S+\QMPK-.A5H7+ESU]FM_+=.\8N$U! M/[%GS>=BB,U\S,=&KE-0%.URFY+'0/B,8'\(S!P"0N<5W 7>=@JY)2$H\)+ MCJR.!LAMJ,BFX)"BT1HG-

8V;&U0K&C%NO)\DZG?YS)V?SW;8AY%P%;>T4)X MWWRQPU'>L_II,OVO/*PW(L6[''*(PCM_=0]R?0W1_3P +[6WG)NW4^G"\Q]%8 MUY0P1P# HWF(73ZZSR;3?[XXM9\C&D]"7)*

*fW8C-=?2I_H0YU8&9STN_\9/PZ M#%O_K-7^=?7!HF=,OZ/%HHI!Y1$i9R*XCB|=I-O^35S M_O)IN_C;?>)GXiZW^?`1\N; MG`:-BZ>$W(@HG%8V*H%WO2/R30SUDNV!7/D(M"*

*(`+ZX(I1MLR#7WSO8KI&/ MLAF827 \@G/&[7PT*YZH3)O/+YKW>C*CCNG&7IINZWO/!T?YHS8*1XJ2DP3QO(!32@N1]3Y":,*2/8BLF MZ4$L_X=N$-=N3P:4JX'"EI?*

0VVOPPT9@0MD(6=^6RY!T:((4@G"" M&8D\81YQD^LW11 DBY/T/G$I0^A#D#I;I)@B;[LMSLX8_"VV<0H@#+;@3Z5& MT?O%=NN=!44),J"&'J"@=.66EE9P<2W\0A2W33 MA4E>

<%D_!Y7Y?MSRISP@YU\R4T6SLDU$K3PD&8<*L$#;P$*YPPN_W+YX&ZX M;LMANYRV+GI8_4U,J?,.7^9A_?4L73LE^<'!O.%H>?3H8@WN,)+(-IX8X+1N8G_M\U'(]/+$AO4U*

.:+ZSV>V'@\P(_63X MIQL>WNSO'2PCoL&!H 9E;?D2NI%EUAUS8?:^$ MZ3IZCA+-$O4,84$YX@JHDR$T9P,F(T(D!'-Z4<\Q F<%0I#-

*(262BP"7A^@=W0KE/$""1$0P8/705&M$[!SK!GBG+@& &S$%CHPA+%-D(,M!>Y28UQR+(@*G.BQ]\#=P\-*VF \W9P)A#1),, MT>J5NK\QH,Y9D=B#X8O#V=",\B9P.W?_ %:6M;4-*

*>3>DV!9I-WFY'SX<[V)$ MV\D?XU(O)<3UVF'_C9W/cB=3:(E09F8U)>O;]>M$:-=<-5_M]BVU?2YUAYD@ M26N4$]O8'F&5.P6VM%$A!E@,8?MT$*G09-X@0NH87_1C3%H"""LL-*

ZF1+#;.M3@_K.?=U-0]WSD3AA[OQNA8]4BR=>7&2OQS^<'CBDRSS,2:4E,@%M&5$!B@% M,C%II842$6\14P_B$;'3R,;X:.XL-SB)%"(@01G%V%+;'[^X-_$A PGB(P_2 M17,ZFH-E-

P1YR>$!7C3A7HMW&-3Y>S6-9T=FBW>_,4,GN8"LFU;S'!E>(#+ MGF -Q3?-T1R3*$4PUO,#@6BUZ;RQSON7BW\B><.MMSY$^7?+=;;_$LN7U0Y>"*

*<2M=MQ*M'R5?B,>VYPCFLD)RQ/CK++H9IA>$NXSO M*3W: 5\$@P2]@W8P=GSJRF8,\(K(K#U--*M=I@BU\@1TB+'1PQ;@ M1E>)&0.4LGB!9D!/4/-^,1HOUL?HT_%T,O\|_,Y+G)*

*fEZCD?QA|/ 5#2,(8? M06HW(2>G\"""8EMEQ?C@4[!G*8?1[P)7_MN.YG9XUY/#2GD"@8\[(S.E(@WN2 M.A%-,MI29!,GN5(%08ZGA&1*7$42I1=;O;T/2>K>3DHOC9Q*U\G?*

*W^RWX!4[Y@] P+;2>%-N9[\3F/,6>K 0,^J4Y_Z8%$O\8OA6V!HD;-*+8P;!LW"K&C M(^?!V[?8P5F1E,)TEG3A$<6G/$[O22:")QWB;T]DH<[YF\C%92F--?ZY(*LY*

*M0NOCA]U.C>'A^318("I@I9#W%G0O)0;1 "FO9,6)Q?\ME$]@V&*:0SZ.B>M M,S!IM0L282F4,1%,7*7Z=GHOTG2S\74MI_G9#'BXTF3D\3SK_:^$R"&P+*7B$F ME4 \P"K7R""^O]H*

KCD,=3&<(W%%S'?G+/M4F _@B#^1VYL^@^1S'M<5I5B]R3:2>58CXBH-""-7H<%)KR1%)FC.O3"4I.W",\Q&%j6-*'21NI[D MEA \P"DJ"":HQEBENU0FY-?LL_?^_\E'EG!K<')\\7.8HM*

*M34^+GH'G!=E:MJ[\G,X*K5A(^<5M@J/F!V+L;6XMK*C_/A.=2OLQFS MWEO;P3E7E$ON-9D.0=. !M[<[JBA?]?IAQUQXCA99(6.B$=8I89)AOQV#%OA*

*MI.%;99(M<5C'8',CL[Q!CQTH(^>1M(YH@(%<$7;=9,< P4^37Q>C4{JS+$-S M;EL ;->>>*9-LP P_/.OTZOR'/NCX$S9I=?-N66&A2]E>RM*SL6P?)*K].V.|*

*M$3W^]N.O0$XFKKU3+_GL[-D;YG?+YCD@Y+_F,,!U0D4%0C<9E558U'*9/D\ MI^=QZ]MR@?GA3[(=+XS[CXN!CC4?,^1UUGW?%;_!+!?(?!87$M*$;-*

E5V[CI#S3Y3O<&^MXN(P=NW)?N!ST(<9H46R% MU!Q:3[;#,94).$B,= GB]3X@&T1 ,1KED_<;6_DAZLL)\&2Q< M5!W%RH1K/(:5L-]^V-C O+ -=W?

*LNYR!7T>E*RV2)7>S.'&ALF*$>4^5REH(M%I*+!3O)""+.6TN\,H1M97G*'#T6N$8I*(6X8'#]3G.$36#)&@:GI5ZVS=^4 M6=S>JUQ, YWP+W8H^]M//*2BF*O]Q$O*

\|+V89SV'\9PL&%7G^2%9I$C#//I% M|+-GK,2>'9II,N^D9%PBI3E&)L:667 ,L9)4,JCE7$K6?3PY'N%=B5.$S, M?< M9V 9YWOAN;#P]?E:E_.6KU8\Q8NJL0?(&IRB3E.&

*<[U8,!PES9*N,(I2 M]F!<-X>VVK2A0+231R[HD/DV MD!WC8"M-N[HF(%E/R#4'-*RNF3Q'-N<_1S'JV"5"\OF +/!%.6)A!!02!A$@R4%'OR M% ,ST3#G%2<]B\:#9--*

*)H0;8'%)XW'F"0]Y,CQ>3&R[/I\NRL^',JV7^:IF_M^]\M9;7,7RWS]V!15UW*T7GWH(NJ%:PD%TLKEVQ@P1-V|B^;6U(.3W,(R\(% M8$]/1T-?*

*8'7E\V UN]|OOJE',LF@RW*T+VEGYK@Y-0WL2GYXB7$ MJ^P_.W6Y?,M;4^-KS$]Q,40KG$0;NB"%)>1MSPC2&+,0%YAQGGB1*L0R^NKU5V_[G+H(L+^3@#[+DR)R[!/>5 M&/?*

+Y$OG0R*RVSX[N'"1KD?,#"E L"6!"O&*FQ/#JF MMSVK^Q>O=^-PT,+U-WO6$-'M%AV<7%T;#0$_<[!0"\H?SLRI&-,@<2W]S)X MS,40EF5^3R;MK!2^+2WJ'AQ%G50R*

*=DB:ZZ%V-?[?R2AY, MS#^NC?&Y4))[91\+I!:IEYV,[_"D_I'$9-]IP$\7,=;\%K-1 8ONV<3W (!M M[A>M*GF_75;ROGZ^R7F S[*;0Q>1F$,]NW'=B.FY,.BKPI##\2+"9R-K;U5B*

*M8A4%NKZ;NR/T\08U(BXK;S2-N=YKB1X, MSH$*6,;MM&B#0_<&)2+V2!.30!F@Q7R'.>]-(1Z97?#]Q*;$Y&[F!Z-WIR_MY=-6XBQ_-@FE&,3&07UTZZ17!>(MVQ+9.?*

WXOV7L7@7^U&5$TOUF!?Y=)3][)]%BQ?.BRVWO8Y^7H(8@0B"4"P2 >&%Q]E9-6K2 M<&SA(WQ:'/!8=/>=NQ'8O,,\!V6@W]1&@YO\S3I9*-A"K U%TO!F"%M@"1S*

*MKYR"G[CW6\3Z]LA\IV3M#I*7.'WG8!PS,)@/E#@D!IL:#UCD?>25=9X$LEFP M.!U#P"*<> V&%;,)0DAP!=@I/.D3WKX!B#D-AH3A/RN?DR#RHARS&&"FB$ M5XC(DB;?*

<9DQX)@332%J2,PB%0#IQBS"QP6.7LB?N>KE4%^-H2K7O+B.C^!M<+I+)WZ> &IWGX9 2!^&/?" #2NDX1/8950HIJ8@8(!?B7'"DE?2(&B69C0!9 M?

>"RJ/OIZ8/+$CTZJ"V(=2I:Z%\GFQVHC1,[X8!8'IDD M-CIY8J$36U)6;9P]'!:^S86NF%2)8\QSE,ESWF#K=M:Z76&@(JY/X\YIN\TP MS]T5V0=0G!K?AKD/+C"!@ULB7%-

K4@R(.6%R7&Q$3@#WQ($9FQ<+W]IFUQ\0 M7X-P9BSN%HDO[P_GYCU*[V=M!< ^>./JX4AUQ<&$E>50CY2A[0PX.A1244> M;V3L;!LQ\&7G]SHX(5,68Q[,0MPYGL-

*!'3(,5#ZV2O#$)*72;!7:L]X2+5EN M?PP,P8.D.:HQPM@Y:[*77M&K+!9IWW_+'> ,A^I#^7IA]-[X[L@QN+UCLZ*#R M#):"-8VC4M!GX?*

18+W^O"^ED%FFY"WWI#FXU&CK$;]V(K'9PXAES5S.4@ M4DI5QCP0+0$F#=1.6,1,X)A=%,=@!0/M3U#B#C"/>Z_%TC%$(T8K" @&!M)*

*MY+\O#,1U,7JHK([SXSQ^FGPZ+S/0DWSAHX-J\7&)?*U,YTD)V[@5/:\C%#JE MNUZ3P1Y2V80+51R6 ?GGB3`)_U&$>ORIBO!N80"HQ8YJ32H<&$Y#0QKL16>*

MH$1T5HB(HBL]#K0 (NT%\E$Y,37S@;%;@_'O<-YD.LN8\EUEVHYY.B0 M\A#75DZ.W,Y,\GIKJ%/_RZI@JU"M"NQTU/3\@O^:#UMX_B.'PR|"(4LUGV7J M,=D|&Q>G-

*FG/^3+M\Z4\Y(O$3W)>O(_CQ11-AV9_"-6?3>;Q>E/:CW'3/ MJFF:Y!I'}4F^A6<V\Q-X5KAL2<4VBI;X,AQW.#DL M<:+9XIC,6SB@S97^:?#R=+<)*R^]2*G8:D&8^GK4_O'IH/(7|S<*

*Z%G7Y\\V? M%_/0/<;BJ?.3OLH=(5XO\@?RH^1T GB/?#@:V;/)? 97_Q:#Z^Y.!._C_,?E M"3Z[>$[.^*J-IW8*L[.]A#XR_ZA32&PAP1?;-K_/E/-ML^DN>5LDSF2EZZS_YV>@#^.*

*%LLQE?]>YVSE+/G/59>?DJ_8O4AWBRHPF-*_ M80$ '2CL@H0=L*,?/O/K!FDWLW"#%[!?%[QV M(=7@_D(O|:'-3??=55WM4R M-3 KG\EH&)HEQA_"[-^&&UX:/[,E?*

*^5F_YI60NV^WR^87/!V?G.@^:K%+.# M&-*ZH.]"ZF=!_4\)H:RAM[-J-C/L7O>]K8U9;NM+IFZI,J2NN.2^FW16BI_MY29;V9$VMZ*R=W9V-RIS*Z+VA[KF 89J\4D[K"7|&$KLG6M*

*>UH7W7H=<;S.X'P7UQZ^V,;=<7O|LN/)8;UROV!WQ93N7._W^<;%5=KC*K@D-MS)*&X*TD2#C)$;MI0,%/('1D.TNJMP&C-L,!*:N23PH@K^$=SKY!3(9G*

M,!!R=YN4.P3MKZWAOCJLL0$A>*#(Y1%3=6%4K#N05]Y<^)>|ZQ\JZ%TK<-1I M:S55B KC$$^6(,L(1M10899V*.K'MW>$|@||2=EV8K?<0B0OC_%[K.NF M0N&3@\)G1/MV!|?

DZF0N!8^L%3@'JB@&:;90"[H+B6Q=]M"+0M:>9|+73(O M&&>$?:9U"!+HDVOZ-B^,^:\3MOWBX;3_S6=M#T7(1H(`3KKJ;AJBNC

*IV[_+*E4[W686/F!P=)R$28X$$G'578KO5T'ZC7 MW@cVI[M^3>E6FJZE8^=RQ:Y#^G"4+I[A-V &3$@I/(BD/>]6E=XQ)Y8@C G7#O()11U$Q*0RE :#H(M/](.C-RW,XD>Z@\,*

*IOZSDI+RS(F E$P<\1 "LB(0A*FT+G L M.-WJ^:"3XK8'G(HH!E3(@=#T(3U%%X1KG[ZB2O"JB^@)<;;>H=`K0*)E#.72*

*MO;GN=^YZ+QCB.EICC3#\;G6_'V7"YE6>H1KE7W&R3ND!P>/N;$X>"67>2\0C MUXB[X)*&1B/E&$>LW5D>/6[#(N_GV V)ZW9G!7K'L>45D[8H[E,M$HL6A1P M*HVY#-+,*

7A2&S4-WG!G#XP3[!-68KNHW_'Z22O"DT)?5UIWAWWSNI MKLO;F%U?;75P|&:\[,Z;P: G=Z(\>,,8'6MZS?Z)Z>Y\INNY=[U9F?R=X%-H[M%15'(@H/&!:D<-

*R_RU=4EV\%RSJEAX.1NUV^GAO%A%!(M)9XWL3!'-L GJK5A*G>A=^0N+M\5P-W!W7L-@+O,[_L ,E^1^]Q7MV_%N*

I80]U8@G0R@J-#1$(M]4OV0PYZQL_I^:\KW"Y_S@._0 M#&'XY4 ,^W>]);=?+<'Y!IO=N7--M[-P-%W=SA?>)K;O&ON'?UU03X.V[&/-MKNI@$\"(:I(=3ILO>6%E9_5DLRQA

^RCM)R&B\R.I[`K -T.OS4G<(/C-G>-MAZ,6+N[|M8KOG.O-5|LV?!CU%#>X1?\5]D+@P>,4<_0,XDYII#.6*BH9ID9Y MGK88JTR4!C@48!9'Q"T07!=] +KI61&*"/ON<+=!,Y.?*

*OP1Y.4G\)<=,'Q? M!9[$Y2EZ#RI61?@3KZ"\MABR5%(.(!\<8.<$ PEJGR*A&$YW\@A.>-"TF1-M8!'EO-& ' 8Z$#25E#&EA<7/0KIDY1ULJB!?W';E%\U03.-[6F$|_H21V=' M#8#X-*

,,X_'-HXB>TMDE+@J+.!3Q-P,A9PQ$++B3F!?>8|1#-9OX?[YOVWD,M/Q:EU,E1F?VV,+B0LZ7O*9%&(JU#2*2=Z_,.'IQE_'DD&1CJ9GC\O76=?.6 M1MI?*

@VYL=Q?);>RRFV$S7'4Rf!C',%?A&?GYR!9VTI:7" <.40-+'/C8NSK[& M."Y?+U^:\.MV!A.;3]HD.OFW#%1V?%,XOGH-]Y](\"T-';6 MW2T %QR_O/S1#6GA30AOCZ1PO8OD#6:M.S3?

ZM5P!D_A+!YW'WV!@8:#SP);5 MU60,;ILW&9.&L[/',4IWILZ'BKI1]R'CY0A+ 68YT$ADI9$H<4HQIHH0LE5 MU#$LA,84>;P!J3F8\I+ 7!-92!!&^+[J\?

_[E!SD)+W8Q"B>2D0\0$6V_33 ML1WOI -78#5^3$C!V\??=QI0EYE-2ZC\;OH=CR@.AF,TFGQ=7CK_F#>]G@.O F4>|(%[.";. L!JJ.N2TC'>^Q1UE^L5N M!SU)WCG%.(Y*

*8\SDCOLP)^8R^!!LRN:ME+Q;&O^QA00M1J#N>,EX\FL6=3K*U>;9)Z0YGE-?"F^PXYS9!Y@.\8$1^>[',H#UIP MO+@?*

X=QR>S^:M&5I9&)QU4,MSCGWH+3ET>!%)Y_',+"%QI1#47<3OR:>P#+R MYWR3O"KSAT>AE]VH,-5WK!+T,%)#E3,,^1#++E@D

MB$:.>H>$!\$(VC/FMOIOW/Q7RVM<%H=;/BOED=%-?/WB3|\YAAP1>=4A5_W.CMB=KW$DZ5TO08_T ME6^.J%1258='ZYD4O=B[9W5-TY=;44VC/?O4+W^\+[JFD3@^^50_Q4"\;

*MO2XJ-FOKX5C/\1*D1F&MNVX--SKD "B.;@&2LQ;[)PE)/>++>BC7[2^3<>=[MZ2FIB1(SD-C4>*P*@(<^I34>M42M,O[>QPZ=1XU43/9M$\5P7T,/V+!)46YSTM-M*@T0^D*

4TMHR%'&@S#BGG#%[W?N^DMIWZ1>]M3&B=$#ONS+MWF&W]B=Z2KA. M&7Z/@)B88EYI@IB4 ?'H%7+1 LUGD89$I4QXB^$?,B >1-2Z.9+LR4%[]==/O MRP.HS4|K\|-

*[JDQ6FY_>6G,R1<4ZXC. 7=@*Y(A^"P\Q&TYU9GO\/2 MG#M\=<.6 ,IAD8 BI'5&KQ5$MCFIQ7)(8DY+A'NP,I%Y)=.D34PH+AHAG%'L!+4)>1U;LHS|IC>\[/(.^M*%[=;X3158P*

ZF'JLB'<0T-=#Z+?\S;V3"=+>]23D5Q'$%K?LOOFE-G5PKXVWU+T0TR2VZ0#=UK(<(] M92++=3>S(0%7RDDN_EV7O!?/]5XO+++"BTAVIK5-\"JO[.BK/6MSRNZZ:"[E

*MK@S6;J';BVSM=YGO&.U;5_F\6N ?;=VC4@\ %47=K"OSYEU7NN'>2B-$CIDD M-B$"O 1Q&1-R3AC4E"*NZ)[Z>9Y:HTPKN3T]'D+,;/$L2=-6D^*

*M[IA[+E)IVT4!GI9Y.RVW^T3*9W!!))BYLG_%E5=6 MIKCB=W,D,O69'LLSU0HDM79"C[439*V=L%7C,5=-:]NDE.5IMU&6*

MKQ9,J,NH+J/K+:./PV[U$=UWU8&^M/WVJ!W'"G[R,/4P+]ACK.3'#DS7#3OI M.QKT<0E,71':D5#LQ2B Q;9^+#+MW_1?!#K?KM;L=6TA$

*M#2VL0';H4U]K,]$3!LUHYH!%'G5)55]+2V2W$6BE>]8BZUFXT0JBK% CN1> MDC%99+P"7"/>&.8-EW$KG.E!@8P,*FU5RJ4'?R45BCK$\I4BC@S,84=!RA3 M$1E,"0H\,,F-8B)M-*

*5OD6F,2;$X,!19Q20.@:"(+1NBQDO)Q_<*961@U#W7 MTJA05]&L06M!OE1!01D)@DPQY#5\ )G#/@9X11I$7"PC*9H44H]RDDI9U#+$>G M4>OW"F5\0'6%LKLX)FU!B\'7@_E<*Y?*

*8O30J,DM%"!D^325I_%!T9*C.^Y ML]230LH'BU@M3S\C5BJEI[H@61 M][-I^8PK(POCH@A2(^L-!6;/$S+4&T1#,"84TK\5-XM#DC9%C:++%;=R!P#C MC$':!DV9CD*0_<;-*

*L@&H[5K;N-H#%3@K<-X3< 9MQT M("&]LRP(FU+<*W#] =7WG!GVQ(!S9Y>-6U>D?Z1%^;_Q9C#%=+GU_O#"%M,#1HU*Z?SC+ M)4L:&"]XT"Q:7Q?=FAK;M6MJL D$L/O?G1B?*

*EBX)>27<4>I>[&X9084V-@:; M8Z(9XBPD9*1R2$2>$F6:"KX5+,A$B"HJBU@2"G$N!#)!!,0((4&QZ,,#RD[7 M1N*GR73Q53Z;,@':J;_%>;3LVBG>T$R>]16@'U1.>U-(/-HM$?*

*[520/UQ-I M=YN56ZZ9_Y-]-V|N&TGV1?]_GP+1,^:>]@@6!TMAD)\$Y3IZW^US/=+?[VIXS M\>:?B=H@80P"""R2V)_^958!(^E0BR5*HJ[CJ09(+%59F;]<*BLS\X1B7D))*

MJKR(4,$423W@?V!|ZJ0"N5.TL8>UF9E=^>W3=C\'U9TIME*TW0+|\]D7-(@> MU%OE11H.7\|&R%A>.^= -$X70B5;#MJH_K5F)FJLW#F@7T1DSH6OO0.L"K_UPP M,"M@

:H"WFGN(DM@ ;Q@44E5&"3':TT;%OQ"]^K#%I+U(CQK.Y8GPI(C[L12 MSSW_#KT]_-LN@6OB\-;G1+?'W@#F6|]EV),=>;O-)^R@$MH_"H;0CL5QUQ%QE MNW.\H.X<5OD=M?

*<ST'14M= MCWO3JEXXW^O!G|_V;1;_Q&RR0ZO$%N'1FD#E+

*M(/^S1ZBL4%BA>$RAH%*YB0SQP**4A+I!1KC@D@1!Yj%T!&$\.5KQl}$**Q16 M*!XU?"=B\#%Y3*(@"L!\BB+'"%;.31C)V4R]DW@%ZK%8HGOSD[@OK)KB_1DD' MZ!+OH4,-M@126_42]VS2"ZA6\,H&;FAT6Y]UY{46WF)Z EZ]Y6J/0*ZV^@QB M0T'L&"@5OC,OX2*^&AL.#;V&%KE<5GG9PMWMA5*E_E"'C..!L1_.\"C\!.>$M@MJQPBGR3%^CF#CKAS9W=DX5]WS_^,??'(VR#;8!4O_&1\"@\;O'Z2T7)D)D M6.I"A+'>*P&SW L3 H#*/0[HF=*)KQlFB6*1\(@*O13N221)LE01%D416BU) MP.0S5U#V!.PR;]&)G.)K+SESYW->"LR8%$]3%C16 MFQ?.+ZP&=M7M/)QM.CZQA(#@XP@_[!RI35C.*9Q3-.P[/NEM"::/]:.5$=%) MX\;^(6@-1$Y>C C^(10,HEKFQIX<<%]I/G8HNWJN@+52Y$OX5:. M/=]4TZR?U\R=]V#1@2UT#@O3# L'<%D#G8G:ZGZRT99632M7(,YNL8QD0,P[M,<@XU$T*P2^P]H//>6+<0W6($0\9Z=\8RXMD.WNG?;BW]\/^V_PS/+56K.E@ MZ73@V1%=#?0Q[4P=&$;G*;ZE5;,?D9>.TG1U@, Q;ZU6X;=Y M0+=]G+;'7=OZ'W!]:.]PRFXQ*JRR.]"6N*VS9+F<;>&5%=Q25L -H"0.(%3 MEVP%G#X#8.,52N@@:HBE-O>)LOA1A92U"7!-M';6:G409^YA'':R;.BD[.;'K5JO*872}QQ$;@D]53D!PK\ #&)Q-R'W=]ANT]> MH6X_5QM+ <_F/>B*("A?;P#KG1\W3(W6P_L0?F[EPP>LZ-F;.!L*K]QM# [?SV M,>1XN_]4IJAJTD4EN6CS$\(SS+XPTN#4%(;"S%)16++"U7F<9*F80:LR2BR M9DPD#SW?9SRB6$SV;FSV23O<;TOY$@&4"WD3D8|%,OI0)'1;4,C&YT_S Q9N;\KD!T^N7O\ ??HL1Q_6.'B<_0Y,.O M^P%*)S.VC_GTO\&>!\H|fV#*S*G5*=+[^U!@/ 4.7W\|<[ZP_(*5,^?_((W^ M6O61]%^88!V\X'/5 6W_'I."2\'=/V5++;7K]P@]V:G*_PQ<'H;C_E!*((+^ M\'](4B ^8U#KMS-P@99+=,2V9O1%U>!5@+LX3&E^>&&/+[L(#*PAX796%$[7MI)G;.Q?KW<'~;.!V9]R*(>D88LZ[%[..*3=4'[@ MM0$+8%@>&;J06G-Z.=4@6\-M:*%*F&W1$6K7V^3K=+LU^1/S !W-=OHPO1U1!'X;O5KA"N1XS"V6% MHV=F:\&-H=#-A[@=>K>W5'ZT.#)RT2DJ!^0R,L ;Q* IR3V7)+R M.*4L\B.PP2?E@^(DB7T:$^:ZDM 0;DPRP"C.9215$)4N8\+3[\>$CR-V]P# M+*'-M(E8FVKK^89I%*9-M'C\LP9_Z0!.IM8)R(,^/WMSY\3P9E')/%MA6&,C MO'I%U#(&U&@#@#\%/LT&@X:W/ .Y?--K.8]*RL>LP_#PF.=R*

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`3[V;&0 MX]N> _+_I]):.#*UZ<(7NL89K6^U@RO@@#ZX=L?6QT3Z(O$X5TI50=?#M$7DI M=IET@X3$D0Q!M5)\TC2(B"<2WU69IQ2;,). $H4^]D&8D2- 9D1Z8&@E+L48IM#1//ERI(CXJ7,CRO_W+9Z4H^H&:K_P8!Z8^&;*30H=8TZ3NZ'@Y 8%VOX 58 MD[/99,OM#<%=-55|\^IP*!Z\+D_U\263[:9#4W@\7$=64;_K'9;CR@VZ8;MZ M+$KN#D2LJQ*(57>@W!]^[2F7OWGZJG@*B=O/Z8L!?;=<^]@%[AE"U!"_7R MOL(I6XX^ZN5]A5.Y\"W4RWMT4[Z?YW+CYM8U^5F[OOOB/)>;4G@QV_X*M'4M"AP/BNQX;%G=,.7MJ($_]S%L(*L.LQ"!7EVWKBU N;>UO\NQ#@,*]_f`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|U6V:\(.8ZWM1,DF.WQO@22G@SH-=IL&KM!7L MJ0:KN*SB>L&*2\G83=)4D3 #]*9QXI49PG) A,'01H$,MK+V=Y#55Q<^KXO M:$1"ZH(_&BA*4A&D))PHXSY 563WJ+[F^S*:Y=[=^MXK**RRHNJ[A>EN*B MD72]R(\(CP+PN-P@@)]D2%P944D]-V4T?8RFT(>BN!(:^A&GE/A^$A+,*&/B> M- I)Y([(<8|FB>|^QOR?1W&%N]*EK.*RBLLJ+]NX7I;B8G&8I)$/P!U[*8"P M#R L79=D'A=^P&.5)9-0X7UVS0Y5<874#V0:<7"Q?)?0R /OB441$32-D@R4 MF<ES[45R;^XOP,[8K'RFIVTWD GZ7^?F!:,*HK[[Q=3>8673;R^ZU:KIGAWYZPX',A\U48Y-3;NZ!#N=]4 J=O'& T457@*!*AZ\< M6.<<[_K7[\ V=U+GFS-[NK^)N#JWUU^#@ "#YP[/0+=,LJLML>SV/LO9SBGBU"\;[M;\ >0V)C]WON#/.QYXH7-2I2@Z_#@OI4UF1B-I)KO:.M-[*#-?H)ZE+5(F_PG;F VK*_I=]B?0&?]B<95>+,.I:HJ1Q_^ORW MQFDZ_B^D,5R9=6T'],=',!S)^T;S;@_3=VYX}2-3_@P@PN$*&%!=]FR*W YQY]DTHD)N7 M-V#>H0BRHNB!]$&9;]#7D%M2!+BY0X[\6R@X&]R].3%L[8>A%*ZKB,]Y2*@"M>S5AU"51%+LN4#,>N),"U/<)M'P69TIVA0(=.IL&KM!7L MJ0:KN*SB>L&*2\G83=)4D3 #]*9QXI49PG) A,'01H$,MK+V=Y#55Q<^KXO M:$1"ZH(_&BA*4A&D)) PHXSY 563WJ+[F^S*:Y=[=^MXK**RRHNJ[A>EN*B MD72]R(\(CP+PN-P@@)]D2%P944D]-V4T?8RFT(>BN!(:^A&GE/A^$A+,*&/B> M- I)Y([(<8|FB>|^QOR?1W&%N]*EK.*RBLLJ+]NX7I;B8G&8I)$/P!U[*8"P M#R L79=D'A=^P&.5)9-0X7UVS0Y5<874#V0:<7"Q?)?0R /OB441$32-D@R4 MF<ES[45R;^XOP,[8K'RFIVTWD GZ7^?F!:,*HK[[Q=3>8673;R^ZU:KIGAWYZPX',A\U48Y-3;NZ!#N=]4 J=O'& T457@*!*AZ\< M6.<<[_K7[\ V=U+GFS-[NK^)N#JWUU^#@ "#YP[/0+=,LJLML>SV/LO9SBGBU"\;[M;\ >0V)C]WON#/.QYXH7-2I2@Z_#@OI4UF1B-I)KO:.M-[*#-?H)ZE+5(F_PG;F VK*_I=]B?0&?]B<95>+,.I:HJ1Q_^ORW MQFDZ_B^D,5R9=6T'],=',!S)^T;S;@_3=VYX}2-3_@P@PN$*&%!=]FR*W YQY]DTHD)N7 M-V#>H0BRHNB!]$&9;]#7D%M2!+BY0X[\6R@X&]R].3%L[8>A%*ZKB,]Y2*@"M>S5AU"51%+LN4#,>N),"U/<)M'P69TIVA0(=.IL&KM!7L MJ0:KN*SB>L&*2\G83=)4D3 #]*9QXI49PG) A,'01H$,MK+V=Y#55Q<^KXO M:$1"ZH(_&BA*4A&D))PHXSY 563WJ+[F^S*:Y=[=^MXK**RRHNJ[A>EN*B MD72]R(\(CP+PN-P@@)]D2%P944D]-V4T?8RFT(>BN!(:^A&GE/A^$A+,*&/B> M- I)Y([(<8|FB>|^QOR?1W&%N]*EK.*RBLLJ+]NX7I;B8G&8I)$/P!U[*8"P M#R L79=D'A=^P&.5)9-0X7UVS0Y5<874#V0:<7"Q?)?0R /OB441$32-D@R4 MF<ES[45R;^XOP,[8K'RFIVTWD GZ7^?F!:,*HK[[Q=3>8673;R^ZU:KIGAWYZPX',A\U48Y-3;NZ!#N=]4 J=O'& T457@*!*AZ\< M6.<<[_K7[\ V=U+GFS-[NK^)N#JWUU^#@ "#YP[/0+=,LJLML>SV/LO9SBGBU"\;[M;\ >0V)C]WON#/.QYXH7-2I2@Z_#@OI4UF1B-I)KO:.M-[*#-?H)ZE+5(F_PG;F VK*_I=]B?0&?]B<95>+,.I:HJ1Q_^ORW MQFDZ_B^D,5R9=6T'],=',!S)^T;S;@_3=VYX}2-3_@P@PN$*&%!=]FR*W YQY]DTHD)N7 M-V#>H0BRHNB!]$&9;]#7D%M2!+BY0X[\6R@X&]R].3%L[8>A%*ZKB,]Y2*@"M>S5AU"51%+LN4#,>N),"U/<)M'P69TIVA0(=.IL&KM!7L MJ0:KN*SB>L&*2\G83=)4D3 #]*9QXI49PG) A,'01H$,MK+V=Y#55Q<^KXO M:$1"ZH(_&BA*4A&D)) PHXSY 563WJ+[F^S*:Y=[=^MXK**RRHNJ[A>EN*B MD72]R(\(CP+PN-P@@)]D2%P944D]-V4T?8RFT(>BN!(:^A&GE/A^$A+,*&/B> M- I)Y([(<8|FB>|^QOR?1W&%N]*EK.*RBLLJ+]NX7I;B8G&8I)$/P!U[*8"P M#R L79=D'A=^P&.5)9-0X7UVS0Y5<874#V0:<7"Q?)?0R /OB441$32-D@R4 MF<ES[45R;^XOP,[8K'RFIVTWD GZ7^?F!:,*HK[[Q=3>8673;R^ZU:KIGAWYZPX',A\U48Y-3;NZ!#N=]4 J=O'& T457@*!*AZ\< M6.<<[_K7[\ V=U+GFS-[NK^)N#JWUU^#@ "#YP[/0+=,LJLML>SV/LO9SBGBU"\;[M;\ >0V)C]WON#/.QYXH7-2I2@Z_#@OI4UF1B-I)KO:.M-[*#-?H)ZE+5(F_PG;F VK*_I=]B?0&?]B<95>+,.I:HJ1Q_^ORW MQFDZ_B^D,5R9=6T'],=',!S)^T;S;@_3=VYX}2-3_@P@PN$*&%!=]FR*W YQY]DTHD)N7 M-V#>H0BRHNB!]$&9;]#7D%M2!+BY0X[\6R@X&]R].3%L[8>A%*ZKB,]Y2*@"M>S5AU"51%+LN4#,>N),"U/<)M'P69TIVA0(=.IL&KM!7L MJ0:KN*SB>L&*2\G83=)4D3 #]*9QXI49PG) A,'01H$,MK+V=Y#55Q<^KXO M:$1"ZH(_&BA*4A&D))

*B0XBU>_V^]!KKVO4&/P@^RV]^-<\%,!*Y"HT,:)8<"91QM=%AT[8,BA9W-M0S<A#W>#,#&]&C)=J <+!5&F5A,&8'G?6<0/P')EA44AG/#R3BK"<, MOME8F\",0*Y-0FU[YB/V]D-J-CK*>G7GM;5!5HX\,"F]\IS8+#7(M$W&E5: M@UX,$]S7,*'Vf85+OVPOK>*\6AWH>H"?55H5W1+70#_ 3,*#,)4%ZR6VY;C MU((&X[/7"7/GU\]f^+]Z!ZD/*<"#UBA?<9T.1+92KDQ #U+;$,#]Y899N&D. MJMX;U:ITL,B!H#HV(C9#W\LVJ0XTZ!>\$M;ZG",Y=)RK6BR0-L,B(MRL0_BS-MD<5@K2O$A:,C {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|$\/2>1SZD1]%L>]Y0>(&ZVGG)8ZT%/F'9[K7GWJ\\CD6@R!J:ORM$*NUKC6L_0-T<:UIME6WY;)+)-M M,1EHXZ\Z6&9X:15>+I)8#\\2>JL$3S7ESAN%.W#^;K9D5?RRICWMX[7;@UM] M.>_Z/5]-L9L-=64\Q+4'O;6_MV9CS?@r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{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f^FQ87]UPY]Z<1X3M2-M*WH>8CT,;3X"KYQN4(-M4V-$&91_^!CX*H=YP!N0T9;J;JJR5(61@=E&'_*-.M-N7KGN);31M%'8;MWS1W_M[+J.[,#.2"-YFACY,#;,+U0:T568 5K-$CF%0IG@$9F#I7N MN5[5K;[EM*XNVK/A)H[=NX%*5HBW.BVW-6"'VW1G,ZM5(-M\8? 2^2C.BH.RQ@K@1W6398:#L3\T=RF3G.!\G.%:!=5_14D2:"\T*C^_\=!\@#P+@%#5(/(X,"H@{GVF@-66C4*/PB>&M8LV194W#2E!5O-S%MQ,/C-><C"\MP@N 6]:!7A#W3^"O@;)4Z!YJY5"2@[$&A4E7#7CV"E++)L@3?3I)L[']U"C UB8VR]R$,)K MGJW)C!HY;_'Y0 SF+ O6BS+8$(/XG[,>%(L*@ _,'IRJ_AKHD64 4@-> CV M1\!\,#8))^)^CBG?R-6?#PW6/>)0N4F6D@Y=\WZ_5IX]_&]=&D]{8*L;:0:0% MQ&X-1JI_=[FQ3$]P\ZKR%(C0M3"&W^&E70E.D;,;'IZ--5?<6*4[!V(_X(-V(MC4;$6HGJM$0>V!YK48%MJ*T="'"K]V*!`262CL_2W-TH6C6KX%&@JL5PWG M"6B/(ZZGAGB--E+;P9-EWBRK)C=F4;T&V?IZ<27G2H5A*M53#Y8 7^/6 2X6Z)#*O#?=AE_EN4,[!B15L=8+?OEFBSBE/-U@cC[?CZV@_L-K0H>PUE\AKD]#:/YVPFY MP$C]G\AU9V->B68ZDRS",ACL"2L >IN^=_TF_PW,I2FRF[.>A8'N$VNX+U%W M1%@&DAZK_5"@#]^>,.8/3@M7U2IL'"[@P-/ K)3S:P7^]$>U[XXJO,(<(&,> MESH!RT!Z7K(2W5,,&K0*E8"Q]C<,Y4W#O3)OG%HE&TI$&%/:FKZ;!AY(;=. MC!6P/]0KL7+15\V'F>=ZYH,KI^,O5[]3K"[1PBI'HW-FC VT? MHYLQ5W<]HJQ*8GBQ_TP_4P=/C7W/1']@=7@*0FOA+-E*@V*F_1^,=2SP97TP M4(=H83!@,]$[CX*"9_D3=/IN&X?C6F."F.;)Z$!)S&SQ70]^UIK31LF\|_ M7@62^L@47HFT@2'P:/XM3HWIA,X3MfQ"\P-D0AP530&?1P=HQ0^6A'3^TI7*'5SMA5/-UM=ZF[1]=E:0@*:) MUZQKJV&C$L>"IC<,'2\GX!96';AW^:62;\RK/~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|_

(7?":$CD.'*>D#5N@,4A|~%;WF)3#4Y2,T,3#T"0|JRG?TKK_H*%&,",YT?^=Y5?_;\[=NQ[G^_OC#[]&;-^1$ M'3Y_]_M_O_IPFZ(+;WY[_>[#K|>_OWGWVXT;^\,@ZBTQOH-_%^"S%1S@HPK2 MVQ3A.YA%;W%XMRF\)]]f-U!<8SI=1,(-+]RVT^&LJ(."0!:..X'\M7GH.;OR2 M$DA5<<8!#)*GR),G"\>1Z$;%$0+$CJ1@+C4V(ZC06DHS:O&)A-?1PHHXJ2CI M-1M/WWB=38[I,Y+SA/,.>']1O:]B#8?'#CPA4@4TWM(E)PDF!BDFJA>5C;E MT#Z'J4N++@K#^OHM\3"_8*#>[.,]_HL40?)O3!3^6^J4,I,2.)XA*.\6]8!/-MT6N>12]8M6=77[2,5 %\Z2XU[,>6[M{& O+V<)K}4#=2;:RN"E MC*.[2U6':G<6'D)9-$5!/HOFURCKXL*(XZL15QPU]:V8<82GH1U/'[?T:RRS.l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|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|H&|EK#F75T.\H2&1WSEO3* M:0(7![PATR:9-LE.F^1MGB(Z!)V$!9'U%5A$WG%0%K,@ZXC;W-H6NXIG38U6 M)[@"-.GSP>06FOLD-IDXO*@AL!YF/;@KA#U",(J6QX0:.,$;88TF20 MO4CGQKMR_1GKJ6$F3 =C@_/C39G.0%.DX&T5=-=Q1:,!0FY|&W3:6-/&VI&L M9\ DDO0*5R=K(3*2+E%U62LL N@H^3(7:I$##T6]NJ7&@BCENRPM;5]!AO8=C MT1P88@XQ"P?DO*X29A?72!O=QEA';(!CT;74T8Z>-79 +FB,49*9_U"']JNL6 M$S!E!?). '-/P.'1A5 +4X6C=%(:8=M[.E'0L]%1$JFY77E)!,FP#:>=&==0 M49B!+BW?T_$P">FE8F72R7*$>@Z]BM2Y(AM]";2KVB+@]A-URK!\'X79:FN4< MX)K\'(_+0S7)DK$H:=WEK8>8[*M3? 5)ZZ[WTC#@0WZ8"EZ2(0X-0^[N€@S(A MN:;=<0GCR>\;6VO[08Q3)<4:>[=)0|M5-R^PR@XI8)(:78=:FYB01:-_[\[% M9KLY^W#!76@-68$C124+\YBL?GPUF MN*\&.[D1AE("5=U.ID!F!?S@.AEB6L-U!'BOMB_U9!%&BM^,R>X.6> 73AA? MN@O)ZW=-:??,,5_>*M&WF=8N2>9.B\O=0DO0U?AO:C3Z MX\'^P>R9[5V]2[0&4R.B_FW12Y.2+1X=\5#?I"- :K\|?'LT.-VYK\L_:7!UO M[C5<&NST3[_W=N]?FC8E2[-R4?]\>C9P[F^OHPX6*4C>! 9M3+HS8!K/D!\M7NKY26'CW65S%O56P4UZ9LXJ'&M(^D(4LN(+1;[9F@PR+- BBGO2XU:+VM.1SK]HK64L)*/BRIUN#5338A5@0#<33 HG]

]#V0&T%^S66@EMD)CD'KX];@?\ M%G0 8I_E%/_JGNWBN!X3+"${RI-JR/8*[X$U3E9*K6C=;%>&(8R1=?49;8'U MQO1;[R@G6&*OP:!ZY\$>)H:-=N^4K-*
,U$W>M,IOI%XN\V#R<\)&,CJ5L^AO MTGJ'^F<2(9J0JH -33K$D;XRR5WBM(1)S5>B1'24B!1!JQ>%YNP1:2# MS;CNEZO-;3"\Y7NF'(J_FD+.*^'=RF(JT 8:-*
;SPMLW&/JCWW)%+6S^MN|SN MU,3W8'/;HW#SI12)(,$="':,\M(;G@OOK\,1H8|-"2*30-4$?!!.K(;&>:6Y MT@,OXYYUB[S$X;J05Y%$Z(=@;1+QT#C=^6_&4=*Z3I3YG*
(4.^FLQ=]0%NY-MQ:DK;X4 S!4WG8&6I&]-4[CD1&>HA[95T587N9!P!]0(QU)9U\ CU1MC)Y+R> M-$/:!$/41<&>2=#YPM.P 8:20S;POC!0$,$F,IAJ:'%TCCF&/>K'V!#--KI
*M+,GKOG3:>*PVE;1QJ4$BWP&_D$JHL:|.\"?^+#^\&N]K084*)&XXR,H;%]2Q9 MWYY>-A-X?@+/WPQX_O$$GI]:2US]DfT.2(/G3TSP^89U0WY'(?>*_^PU1[L[D92OQOOQI_?B@0Y8U-*
*/O> M_9!1?VC.#PE1=^9T 3#@F)GVM2 VRFR/9*6XMABF13K1[FLEV&2CSQ_M(;ZF!G';57!@O5UWQ 8>WW!T#T$;6[0_?67WC EIFS)Y46Y"?HG#NP+C@*Z M0=TGO2Q0K),N0?*
I?8RY 81MB $Y:!L.IN%.G)VJ7.2(8IUMB $-SLQ3/Z M[9;<6!LO@/,]$5Q01[HD2\C_%K>)DSX22M6$N-WI#88T06@512,SS4+K?O:Z M&^##?WWS\>,=[_UMSDQU7!/*
WK"'Y]fJ/N21'[HX$A(HLOUI[0H\VLSKSM$ MJ&VD>M*fJM-0\@]CC:OKQIE>^0 ;MOON(G-.$WI-]Y&-A'[D=* ``1FR2%I M1]/@B@-MR&6^]I(.!?RAP87$]0(//9YSH\6# M+A?*
*H@C4N^^(B.U[?T'Z+3PDZW_VXS,W]G0M=NZ^F=;C[M<4A9!ZVEQ948*0> M4L$V].VP>,DT*/<4O//:1V@XSW:%[2]\3W3&PH*A9/>]:9D!NZ<;5W5>U4(-MD=?*
>;R;;Z@E1O_/&4!O7R[0TG?1CV9+&W\PT;S3Q:38M98GX^C1LO;0WV:;Z MJK(51]V:,B"M#^L![5TW7I] +UQ.B7YTI-@%Z+]D]>:]L:;, DV90I7=>@; MD/S%ZM=AGJN YO^4RI?*
0V#2=L5-^6@O?2?#B60W-YQIY.DGQTHVJIP!4R MB? DPI<5X1HLY%T$N4%9M(<@64"W=F& %5/1Q'2\7W"\6P0)*E+,4O_LU2).(>1)O'8$*
*M:"5L*NAIVR+,O"Q^;?!,=@X,!;W.8#CL$JH8)99/+AB5AC1)V&X\5R]C@@I-XGIY<:7XP@A<%?4I$LS& MG/4B8%RLE%@A6P@%"RQ#JNFITY(0UX&^U? +O*"F$E8&"-M
JZCLG8^Is%|>/7KQTG6)UG?635[&I6(T46KH@A:PP&+MUB-.LR0V@&"-&V1 MF,1:O9,$3A)X"0ED;^?4%%E4Y$K#QC%/HB,64@/&E>V6IKUEXC5E=[Z5@/DM
*MC9(E#QI;\+T057#[30\%A-Y=^NB5MAU98X_7Z(,C>(L=^$YGA M/A>IQ^3YYK>7?#57I%H>5Y\!A7B\;DHBQ5[;2T142;5.R+1F:03K6X8,*G4:*
MEUQ+!8AMD!$R&&TV":;!T3]#G2Y'Q0IWE'E?5._(A<0[)=73=[#BQ]$<^\9%] M'R7!?()f"IS9M@3:Z/$J;Q$A'-+N5:SC5U+BWLE7'QW2/YNG-$6Z>9<=G +*
*M_R>U!ZU(_DS+T94BN[\$]IO5G=L602 I0L5BLE[Z43!![=_5!T,%Q=HV]A7" M02+(&&HVZS:!Q\^+7<2\Q\;;;8*2O<:TW#"I);K0,1.2K5#4Z#+W*FTW("WQ M5BJ10EF5CE*8*
M]R2O7_B>4R9\7&"3'%#9_#?=,_W":SR'__ZL'?X*>:== NBEV_M)BXL@I; M2RM"[CEPMN,9G57A!D2Q)L[+(91!{;>-]WBPM8:2%B2#0:84G,-%ZCV0I_GY;/:pG.G\SG/FE ;,$-R-*
*^@@V8)$4EJW*>T!=4 M*]B/"+/@\S.ACBI>]SG;KQ89(CVD0WO:1T4X<4B3NN8#F>(S]$'P+VF52VD= MZB!IY,AWB1U:++UA0M0^$"G3D0,(GD6[A5YU4Q'*XH8^\!M=H%W3-6*
*>W;XF? MN"'^*XY^VV0YRJ8H5ZQ^@&UM?F<3D/,/0MQRRIX_?OOG7_OLZJ[!-8 "&LVRZFQJ7U+5EV!NF@;<]W*IZN(6;!=)M>CY91\/1QA?A*
*MR],$)A(DM@>:4SG.FZ8++^D%L!@^Q'7S)=,3/P/G1#I$#LY'8&R/?K;78%$H M"]?!;/"WQX%=/$+SJ1"9RH/C>=T.'"$9+!^,,N,2IT6NHWIRZCY@;1C _)L\4=*W3,+?Y*
*MCGT7R53>.+I$NH/^YR!G9:6]@2.DHN^';\@,O5-=9?&VPGB%7REX44SPMS4@(TX\$7 ,[F]+64H ZBI=[J+LK(-+'R1U.#P85B2?@%9!2O92-

*MM,#NMSK*ENCA441&T8KS!0G<10\FO-SQ+3$3+G-9_^8BI,$3>N0\KV7$KE?T-MI29=%G7Q1G=1=GJCD'*-=`E&3S?HAMFZ3SW2"83I)L#)D)&6,<_:*_7KW06S-M[G,,NQ??G]$LUX:%G_M$NKTC-@OLH_"/# D,Y#:<3-M8,*"O&7)CY->(&*)W==C<-_QF3-*8HJHFN<J1K9-I7,VT%-(1U&]C:&,X">/%WO1W=5-$&A:"+TH&C:,LQ@3[.^3]=B% MLQ*XPZ#T#6=W<1VYJ!*>L>=>]{L,_)CO?C-MU";SO*1^R;-@[T_^46Y>K-/-.[RUGB03_4-M!&'!J_%F-U!3^(=,Z0+8NBM:40?,&>_[0NUH)8)AO]W]54]NKBY6SS:G\5YG-M(0-\!\R',4*9*#;PE-S_%6530(BA)21+N%&2M,=V0#=D]B6U#J1Q.%&&EE-MIOX4>'+!*M-PS'C1N\3I%TX5W=E39G0-1G2'1B'?!7L#:6GJ&C^ZXC4W(3\1B'?!7L#:6JB4CW5X%&I=J(_Q<8)U%W%*#)P*5DE/<9C@:.1-.[&NT=E2B3ZR%&(/VC6KWMb%#92_JUM\]PS1S1CN1\3I%TX5W=E39G0-1G2'

M&3MB=MY2+O%1X#?W\BC>!!C<@7"Q6)D$.7E,#G9ABJ"^4B3U'1&ZLM4X"NY8 M$)W#FC,T?95 T_4=#U#L6G:W()?>|-_4>6S-4/BF0?IW+HA#M)@V9/*XN M.U\5C^%2.@ZB1]R :I"7MQ(/PPZ.AG-.CL"$5,.[UWRU*>Z-INDD!KJE\B:4 MO>W].0"UG;@<%UO949Z8OWPPLV=/')E&[A=&G43]KO'A/UIP80MF+"W?^1U M494ALI'&KAPC,6'Q"GQ|AF)'WZ(X($-#@]188U7B;9&#H,#,WW"ZAR\/L+Y; MU1;Z,SW4MMF4%,5$!'R)DN27CMM0<@?S'H-4/(V4FS+9Q<$$7WX-!|VNV*)*-MBM7+HJ1-7:M,_G)+:,C*O,/5OZ#%@%$I=9O4K('K>-->1D&-8/-2T4 ML'M:.?;^?3+@U/,5=1%[UQ-1V!&; GBN6>(LAF@>2[&F5YK|:1L4|TPA>BI< M2EA>DT]?'4B%AU%F.QXE8XB'L,!2"%.>>J5H4]Z.3-]?N*'>>/*SR7JF&|H- MB8B(1I6'0U\W:.GE'0],/LLU5ZB$'^E4$(&&)""X-JP?N%F]DA3UY'C)AFQR MM"\K I>=F28&(XG<*E0>9\L5)+U6$N>D%;*"3PSMVP!(U\14/)EA;B|LPU.] M[^:,PP>U<;JBK^,&U^:7^93->X]KZH|C &?^@MIUPQ82,*.]GUIA*4>A!H*#+ M4!+EKS) QFV$^Q f2GRC2D82$\/&/##YM'G YDR<;4'C'E)F@D"RFQ#7NQ M1U L@[H8BS1:T8B/:93@0/T$Z(&+TF\@. B4,3K+NGM|QEU<7$)PWJ%=)(@)> M8-E7]RDWI#$V6|5WMZR:YAMF3@I-=:=NH107+A'N M54Z2\$7]9#1%K-I#IE=0,HTSO9N^@GU)AP%*A1RY@KI+]O#MK6G<;XG .!,?3SS"& OMQ<25R++#PW,W4>U8<]"FE{CI%&B2<;7;G M]#B/I6P8E;9 A,]'C1SJN2MBG&W&E?=IP\)1S8H?2:W7OW1#?CJQ(D,&P-YQ M/KBOYH!6#O^(LA\:/)\|VGF5K M@B@,|I_0!XHA.)V/;(R, @EO@3"3-? AS3FO3@+ZYP.9X,#=A$L8M%A-S^D< MO]FD5FL7Z(,7UV1_3!;U<8DD_K O'%"D$?')R"CH#Y^+95(D%PG_IW7K(L4;6/A*.8GP/ZM.> 0"FLGHOQ>$GVM[K7 MWN8%41<*>X[?%$M=@I>$;OQ<=#00<.16!QU,(=? H6QLB<##7N(22XN M#B(^8G105]^[4|CA@6D) 2YW$C@&,L>E.#5'1]#'KL43"#LM)/G)63)X_VK M;Z;9B OT$-@,W7$\)XPGA<9Q0$H-!-2I"D5VV(C8/$J;!3FW|CP' M:#(Y-NZ*;^-=*$S-65V(>0A5@80H.D"V.0GOG6SO]L!0X]"V4L MAI5W#YW*P_%'KK?$_E_"RC.RAPFM!7B'/<")N>(.0|+'/<1M?@B^+_7]AW<1 M/B;_X=XG%YM79P|B6[D|"{'01',D'R,D+5;?N(Q9@|V_JT1.(@CRA"#'&I* MO-)V*Y.'PLG#8"2.=C7*F]4S,OFM<(ND.02622<@^T|!60^]GOE\B|M2,%K|-MXE%-P9AC->R\NZV6;FG=R|5Y N#CNE<,F8H,|0# .FJ=V3MN.HLR:E_-^WC>Y#N%,.5[+W1'8T66QJIC1@0|KFP Z7P/ M|RB$WIPQT$:!|-]-MUCA-EBL6N6,_6>V+

*[VLGA,+#MG|RV[5B2G,M/ S*N%$2 MA(0IS+P3/!>Z+|E]-N46Y6KWWDO3@(TC*!C?3Q,/BA*6')K8K2$AOX0CWV>865HVC>M?1$ M S>G4(F@N--ZJB,0N 'TDQJ8$!ZNM"O4^N@UG4P@%VZTA^/ MJ_@<6AS.$L?^#=''1XJHAU%^@V1YG&6FI&1Q%HN:0!D)!1?G<78&]Wf5ZBF9) M\$Y&\Q;:FJ2SZ8G_8J8)-*

GT%!21U)R7U>Q_B,T5L_3=GEW&H1$HABJBF=BD/ M/-P=VPMM<,8]"S=G;DQ4,,](@O}3; 9O-*10[UQ|_Q1W%=($XSV D3WMI M+4@%1G]-V$*ZOX,K\UYP.]*

*(,W.YXU9&CRS3V!R|ZWB@FBP:(!WG>] MXI*4AK^3%)M.1M4B]-(^7:3[WG6M7.J0LP1<\G*8KX+?45[++$2@VJ^NZ-@'\HZ MK5AN$2@:43UA*

=]/<%9VOV!L!B@,ZV5H9,J8J9.XF';,P5Q,WA=:/;$[A=A*G M%I'NAMVGN3^8,[Y B\(,'-:,!JK2:/3[^Q(D.H,K$.YCWK#751FI,/1W?<:1 M\ -XN+KW5,F3*-)KDKR4*

SVND@4=,OP)!Q5E5HM/^\|F3DX1_%,&#^GQX(YV M2#9=;.2VSE%ONS'8Y]]V:ANSI?H:Y?]C]V6Q@I,M6!!N4? MWIHVT;4[\EBL0!X7]/U= B8)]22Q3Q >U15G<*(UH@@/,@M$B MN"E<,,^):!{,_OVS+W*$,U&U"R*N/6O)!;+2SA$SH#:,AQQCTL0=GXKY0[.E M.M@^9G7E=2/Y $P!:K\$BY,]2Y&[\+|KPJ79P70QN\=&2U@G7RY:(P@OJ!!G M'F,=^23?

Q^^T:.D$,_!O=:A<:BM!K%X1Z^W6DM6+V]OFMU"GIF/ M<"_A/-;'])\'#T:2&_+ST$8&")CXHHDBDP2(PW.]685O:=4&D)MS56$>QFS MJD!=S8L=M]B4N60>SJED:*P;&NONI[%N-C36#3]fGP)^).T.*"Z|+O3I:IV) M7.62{GQ^\4@7L/'!:,#0(8;//0L=?U\4%'11V:-<^9ESN-85A$DY!'RV-8V8 MPNDJ5]R209L7ZZ5C:[T]BV783-1[YG93'[QIF*RFJ*1_2Y3ZNR>4WK0S?

*BFD ML],< G7(E2:F)N=*DPLE<)-[Y,9>O58'U_%[.J-%M9=0?CS#?|=36@9UY LL M-&/XM(P2@"^D14+51CVW(TZ^)OI4O3$968YT_'P^XU9@2$WQJ3U;3$[MY L, M0[54 '-E,Z'@R?,*^ *,!Q MH'F +P?^])3(B4B&@<=JZ3?XM(.,0MNN>ZY"N#%$FD&,Q;;>'$=VHA@@[LD#5H$P.Y>51W1GQ#B5U/41Z/415 0S&6%TH78F3 MN0(F1!VX5T4YE\'!Y1,2-I'7)<^\>HHW$G"8C73L.XV0":\#<77=$FZ91%K M=_IXEMV]>[T7<'K*Z]*J@KK2(EY*=OW/"U\447U0,)2E"R8M%%Q<*

.X,$ZUR{#.J1'ZV5],N";WCH3L=C:)EUU;. M0RD2J4>5:@7?@4?UWT]^+2R)I%D:XH989&EB$%#@'?%+I%;CP1 E,,5$("14 M42DZ;GN-RX(0B<65*@4!DE<+A=5B'37';D2*?

<T65[\"N#>W!,.NMH0[DT .562\"[0=4M,?EDR1%S@;:HU.E/%Y4BL(S1?! MD%6<1D;?#4D1!)>"%B+:H/4NCS@YF&(ESZ>^;K;EO#_BD:[3EQ6,!-8+477 MX"A-]0713%T-DV/F",F

5PH1++1BEYU!:P;@2PSG4LDJ372:VA59L%1+64<M#X/|[BZ]O[-T[MW5_4-PT2PAA(=!);@LC@=@-PE%4$C^\E)H M*

+1.5E1@"+3+1Q5$D+F/39#08"%"8.*FEMR95NP'T%$#HI(O\;ML0,B;*$|_'Y8N>&=QLZ\^L#S8.15OIF<'AWAN!?4PS!SH.]18RD\N

MI=;&0#6XN3@3JN(H\^:W$A0*3^F6ATL9"2(+5+!?O2$?TKOW@.5;@9H!?=[MZ3X."L=@K/(QT79RD5$2NR*PO[_50[FHPG@9Z1#,O- M^O3>H///66^MJFU'",XE,=T<%Z4G(1\

{#0[ZDK FYL)?R\T5YWB!W NGI^G>= M3MR[.NCV50%3BF9<[>[,C>":KE)S-UN!$9;A^!D\NF&X/&LRL_A3=']J#7P7 MO5?%A&[UH10FGK>O78J1-/ 1Y!E0 M<:M/ M0>P6\WS?C.]|*

*[QM82X-XV='WWZ@5^T1$5)9G>GS&,2BE> MQZ;MP!E]>7K87'D&'GDF'[U@#G#;8&-W#%W>H:+V*WYN5%7"]%E_8Y>@-("_M+6T;,OR8H$5=;|-6KTK@(HF:+D;4>3X>])Q;A5:*

3.^(09%%72*8^ZFE M;-*5"DS"%3=< 3+N6UG90-6;*,\L_HH=8N6!9424F>C%0FY':Y/)D7<$,.E M0;AH!YDI[:@(0:OZ0?3 P=O5,#:BR7K7-^JE^2'G),3)C JP1XL7:>

M@]_$6#GO8[7M"_ NQ0AE>'?B,:?N?,%KJ;(G0<;R2:.)2X,7ZZ4W0M\/2], MOR 0&KZ9;3-ES[4"Z $CUOIWMK\75PI9^K5#R13AG%>8[^@>//09HV -^]JA M80<#-&R AMW]E>5*

08VL%9 ;(>,P\9^ET^S;*VN7L$Y49,_"'NA|PQ M8';YW0,&W%$2@9K<;CM^/)'OO6<>?K6!@]F%R"X<+RE5)8&O-&!"?;EWM>O M(-FH_X>+E|SCTRY8-*

*I5+P3)73H%;.DKIWND(R#|\XSOO^6S[:'Y ^,*6Z@3/PROE1A9SU2=)\EZ$,PQ"#=-8AU M2W0A&"2#P'B]R1 1MS9@@A;.IE4>]+ M)0YRE,*

(8I3$M4Z[,Q3ML@VX7"#2@M9HBR_KVO-@D(-![F:0-HSB%GT3LWF[M=QSE$@Q8^S1H=33 P>8&F[OUM@PP$1T1ZDT70FFO;M>(/L1*E KH<;+_13*

MSQ4CEZ&X1U5]/:M;B3T(PR%R&].5H3!9PIV^]%-^TXYQ@.Z\[EWU51X]B3Y M-8H5HR!I /<#%8VDSU2E3+=,YU!BCHVF6N>,IO]V5:,.L$E=8?JA!ML=:/<6*

M^SVTB1#=8;>DM*",@':.^ZT(A;$F0W=0:V=|JY/+N 0M6EMR)14)/6AU0[AYXD 6E-$ M .$7J1V77HFS!L=79^2PXXA05-B3P(S<"@K&W(7@0Y^PTK TD'LJ<'UKHAT_M%Z4J$!

(UMQV^D]&MC:N!6(_B%1U0_@ ;$L9+;34FNH/BIOW=QMS!0L]YHV@(HG(0RR=S8DE M#(%B#9W)(^;>ZV%^,T^22N&-$WQ2 QR M %PI'(:I15XD#

*(1GE9=T^&A;1=''BO*D;#!;>*@0;WNU!FJ'#'L3]8PRO!]0/ M-+3 Q@8@4EITUA>QF4+/#9V782K0C:4HTK!=+2/&5AET*R43A/XSO$5#U@CDD

MM2EBURP@EA1#U^43#IFT(H_;+NK $R@9[59<>ZPT_\/H5D#OYVK^@HB;T<@ MRL>TN(4I[IZY%'@2O8K)ES*#92,]YX3 MK!0 >Z"G=\(8!GE) -. 6 MAO/;33K)*

#G"3C)&2.6&CP.6S O@8>L-H3_:AEEBR%M<TI6B;&=@4]ISF M% "B'|AC%L$B31]I=0'S>U-0!L,.#.M.AJ6-)%79O3D*>Z+<=)SW1#^AC7WP

MRQ<$;2Y3A&'25HM'V+ ^]^(F)66X=-G#LU?M#RCT.AC\8 JT-W]^IL6JA#[KZ M9G6(7?;;=NY#B\)9(MZ'2L@0.0DFYXG5VST?HQZJ"<,IOUP?+JT+6SE|)<

*M!/PF40H<=D53@T90Y-F7=_Y=^ M=LDN;E@AAT' M2-&/!&I09)'#O?Z#! H1GL,HURU)1U%(8W_I\H&U> M-Z6=FTF"61PSH->A2 M%1*BF25?!-E4^-)\0:Q/>/?'D:BY9D@L<[#[0.7

E@CTSSC@=#]HL$* M%,!6F7 =RB2?H<04U1)-Y16TI%)M 2]TV'*3CK,H9Q9WH..]R*7@VC>&|HE";,92^3PY+V < MF4G*0I?5:$63QL&3W:->

*",PA.K]8Z\+)S[5A<" ^^&T<< M<(^SLC\PIVV<7HSF):**:LG\7:O;@-#;?/8&U%_=>./Z*Y_^)]NXJ; RT%1: M0W1<%,#ZL;1]!(=_K\E2*+7X3!GA5W).44<7OG(9?PXUOZ2XH%>UL:CE?E_=T ??H6%:?!8P0"OW$?C;]!*, MQJ Z;@69?R:6=Q_<)=O5>EE[\JM:36I7AB,'N2WL6FQ#(:AH>WQR8=XEK^HM M*%.-+>:U=3>N%J?*

D*NTE$")E8A'K<>5_=CUVTP@^7=H;ES[3J@BFOE1F@#+3 M4! SS;5=\AS'@"=PI?\'*>!+$/AGC8OE.A&B%?!%[>JLV88',9W!)@B9&N)W MR62L,#KJ9K],0A_]\]?

<#+1F$>X@U6; 9"C0#]QSZ]?2<3S'O5NN+5WL#%PT$ M>*0\'2F6CIXFC$#/E;>\AD[@MJ[W3S1],0NS$sL^C[!#XEC.9C,%"'B M9^S'57@?O!0-!TTMYURYHU%@?[

[]Q*FT+0&'A48SD%XR3^9JK9;..]#KW9', M5WCWBE#D";_?\@@FKXN%2K$B/]3%8M4UUX:L!H8R-XH@D,G'(K/@#YJAH&K0S7%X($Z=I<4<1&Z@@WS?*E<-HF2W@

MLG'1^N*57;%@7N"FZ6H?75OK"9,ABO4(6C94PP>&8^4@5:XA0 [_/-F\/MS] M' ,'UZ63]2WQ0O<$;.0\^>&YESTN__XZ?'>C4O6[YC .K/)O < M&D;=3";=OC5_URR%]7RI

/83HHJ4W/;XQ,K"U"5;=(U^LFO_)A)39%K:PG% M/:3K>0(KUHN<CSZ=4VfDOI]F=', MRD^+X*"8TH.?/(+,"'>_ VE:+(,,KA^1BW%:G>_P>UBRO3!<GY1K+((G9L

BO1>'L0F8'[J_5.N&YX3CQ MNST+[.B=$C]@DQE.5161[*3/86O EMH]1KI3&OE-M!+'1^.]+?+$]*/!< M!W:E -.WO%3EB))H#!D8A.:'#!'|@\^>5(Y\%2915B(9C>Q-$/-#UTV?68A.M M0I

!ZVMFC-O)N$%"'#<\'51MJGM-P^F,"%7U>W.YJ^D?TZ*]=0%O_6A-AZ<% M67=,)HT@>00#NMD%LE]GYTQOD\-M$E7_J?'1';6+>>V1ZQ8/;\M'D\I-KN-;

MX9XCB./3V5(AL;K]E"50P++#()--GUX&JV@\1!&Q<8=H!E%+/@#.:[6$]"$W& M]&VWG:A,G)C 9KQ[/GCC)^,FC\7W&\H/Q_(I MI+0O?::A\;AZ(^,:PF0Q'V4-M]*E%[Q4Z8;5#:=

[':/H.8D%Z0&73D>U@*E:C M7*<'W3ID-X2,28%&F$0B+]B,;T* "\?"0ZJMCW-UA5O(!T>'%(2H>7:PC?iG!3,@<3&]M(C!R%,:^L^E!E)"L!%*1I2A9V0AC M-ZLB?

X<1G%"8*YI,+T'<+KLU?G2LS)G+!+0@C=5&THI">??3Q.2Z^YVRK2T@X3!\>70^M*3*+9?4IJEFE2^1M4MIU>B11S+*?7IVJVO,5?= M>K+A_\RT.W! K/R*4H5ME0XI?FQ(TKP/+;

DW>VWCX%7(6'F_S[9C*OE<1LL MNJ5F,Q*D.@M/,WGR4!*%4J,0Y&UW;$7&3;F&;O"GVH%^$,HS"]8A/N6&_97 MER_GYXR[X?*T?&X

!50(0@A7@4'.L(B]/!0,JH9*OU+R4$5U!5:E<[N9K#R MG5%+8>EIXGP*,@!"F/XX9O6O<(IK'IFY.S.U(;$4=W<-)9=ZE3\[O9)=,9 M&OSC^K:S,=(4HJ0RL!.,,5\W'1IW2=1#2>A?

S.+2_/LA(-=RR9NK,]#V=%PA> MZC;!I-!HNB1*]-!S$<7NENW5N@4K-!K9+9N9])^>0OJ$OFN>#L&+2%##P!=?D M%/A,+YXT0?(K@'WNU#F(!V^#&4!\&0:%]NK3CV:

<7<%OSU=7A"-\[<=0%C> M):W< XWMCR]/J@GF\)< .(4P":QURQ;#4*G=Y@%,>-]&$57 %UIOWIKE,]LE M1<@/S!I37CA$;R^7VWG8,=4*?\)4K8/VQ4A=SFPB!^[VI(A&

9OD!#?7ZQM$Y!#KIG92C9T)PHTNIL"%-.PQW8RF! L#2T#W@THX3-U"8 FF<;$B<=T2F]_ER~3>@:E5B;2=N-:((CYRZXL"/1"M- M+3*VJ!X{V5YP_,?

72=L*.'$GJ,8]148N9;5)$6LQH8::+3I5[D9AUV3/58LNO_)8 \8Y?3^=.*H1GGT-D=RT< M;EWK:5TV],/!<0$2V.A"!I_Y+'0_9RF]!QK(FXQI-MW"=_Y9\&?

4)5)KE4MYFX]EA+S'VN5=PRX"!@%P[+@*LB,&UL^2IRGQNIQ8W5A]+6^=#T:GC&=_"D(BT!!7;MQE78(.633 M$ {'#'-:GWU= MVW1Z>8_ATPIST5@EF

^68.0@1_F4#^O6SQ.X_8Q3Z/Q-SMN'(N$.A>O-B T-M-'4#IZ.U?C*@RY;"!H??>(M.LEO(?NK@:ZH/V;E:W"!VG(\OL6>W0"S13-M4U!67#NPI&CI%.;]>[V?.6L.H+V7M_?J&NOPI??

L%YL=V=YM8I34^MQP9ZZ-M)ER79EB(D""[Z#Y(Q8XL%)5+Z#=)")#)+?!]<6*&W3]'U*]B>=%'=5=>U M5/PP^K.QO+<9Z^K;FS5;,YGXQ,;QDHC%8=4@!BQ-!'H M/E N7.'& V'=;D<;

!45MW">;*13LQ-7Z/K5=*BH@4_W7!, ^ M3'RGV9]3TWC4.<9\A)L*)&5G\HY%9/!=FLD_C,;8 ME<%NV0/P_O5^A#K,_%TIC=_8[6] MZ!KJY7ULW'Y-

7XSZ4%]P%1Y>)$4>_H4=TP0M'5C%GXROYV!(+1MD@K%2^,]&9 M$%N@-W6+G5+K'EC;:PB/VWL"\@4#Y$E9$[7/?B]BDI7.ZYW76-]\%3+BJ/3H MY,<-C$G@#+F0$59=Y3=?

VZX]3Y]G%/$5_&)TU>#\[E_9>&Y+. M0*):HJLR 2L?TX 1'_F CX90]$.HS$#QSM='45X?'L!BU_Q9]=IU\]6,UM%L M@,GRZ.ZM&F7GSZ?,'@:] L(LH0YG>[FUA@]FL+5KX%(49ZX(*]

[W+EE[(,'I MD<<[*V9-7\P(7OK@&AUZGI#>-N>\UT2^(PBU?_M_MV.VNC"]{C0G'HTHTXK9J8\^.R]"A41J N5F5GST6JL-C^C2XDO()@?2/@_M5E %DX[IB@$??F"'TR>P0AL?

_'RC&0)\M%SS'3[4,2)E73(=#*TF/ ,&Y22$ MZ4+XI%[VTD.)SB4YOW&S536=<,O1-657C'.(7Z]E(^-Y+OP):QR4VFPL,8LK=D]^DQ1;*8RYHA5[6<+MM*28K(JO_=RK)D$>0S

MBEC *_\+DR_O7ZCW3#\'?KRH15@81'. ^.#K?A45G3Q8.9%=/N-M3SVH^O2]HQ_F'=1Y/&8V0.U51<2&5+D-CJRBCV MHX7T--QKU<,\)ZR/D^+ /E:7?F*W-71/&O(LMR"[.*>)]++8&>

2U>[WCYS.-N\EL(,LU M$V16/A4NZDNFE,"]& E(>AY5UBLXY[^#,06U!0G?? M.9+&.]4/HD[?F(51 M! 5M"N<*0D"8-'46.)785N]?=8%/KM:?/GS\RS#NEP,^G@,V;+,.=I*+AJ#-]

M#ME, ;KL;^D35*L(PCVD(P3,+03%6]YGUV,,,/!KJKGV)#(J$P>D-X^>VUP= MIB##+?\+CFP;F-&W:MB^F,TJ&3Y8O2I3 6QYXKF.)\B5,R(C@VLIJ$:+C)G7F

MM0)HQ1Z%/#ZA*:9C2\[FPW;PI4VLU*3<7=YZK,$XY 2(5P)W-;2&>GK/%/JV5]N= MY8.R/PE%U<5%6?$S00+Z$X'!"'HGXUG=#'(D8'$.R:ORD5YBY>(<2"W8^X@;,[M1)[&8@#

=0LON!ATL %\(A M-69\!,%]CRN"801G<)=L5^O3>K&KHM5L5/?"Z5*59D3(!;B=MY*9B3B0VN:; M-,*6CZ;UWL,1">D&T,&>;194PU:"JV4C|%641R9I(O_\OBI2@$ROU"F^[-+ MI2D

8/S.9G3C-M8;J6T^([>DKQ]W#G9W>E1\)?R1$++IDK)S)6"ZH&.IQG%8)BR=F7H,Z0?""5 M&:0D#S0;=,NT'Z63F80K*CXE^>C>A'3K)EMXAJ&I0%"'I]D>,W,H5:,A*Y]=

MO[G>.:^O.F!:\B5.\09N]<)-/DCB/QHN65ZA-J.KVGN@1%XS9O_F9"5I3Z&K=1 MV"]-[-(>[?A]450W,9.6T:F!;=++6.KB:V/*1NQ6MQ6CN8'^]^&=>,^8SAQ]+-}]++8&>

2U>[WCYS.-N\EL(,LU M$V16/A4NZDNFE,"]& E(>AY5UBLXY[^#,06U!0G?? M.9+&.]4/HD[?F(51 M! 5M"N<*0D"8-'46.)785NJ

*^V(U7ZU\ML;?H?;ZIGH(PC"P4&*68 C2LE4:1.EC?1G]9B8 MBF"5&)7MKX++!'#);2.DZ84^Q0U|D>0>]$=?_EJ0=DJQ'@Z_'^]>A ME*FZ|H*7B">ON2GS5MJ/-G0$R?+GU)"3,3.3IB/SD<;LF ML+>/R8OBUVY>($,>[5OZ3/U$I {Z>)8 ?>LLB>)@2\,TAAP"/IC_<^ZMUV&Q M1$JZ(EYYU\!C^+,B9[X/2+!XN9WV9L:ER\|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kZ74E%?&^?1+ M$_ W\%5 ;@)=@\!+VDBDSCNMAY8K)RB +1P9U48C!LL2Z&&-[(@ VD&X3Y8V05R.4AZ8WIO|6)S)1RB3=!"\:%!]^A MH6*J .)7E*L&AN6'W8[&N)/U^ZV=SY4JY% {VH0*A>"PXP7!08ARR3B,/|(4 MYD^(6CV-W2P)S@Q.Y%'>(>0Q+T*@HY[?J8B*E&:(A<|P?_%J;V#FOEC;WKM-D"*2%@%BY>"_M-7N:2DDR"Q'S^S7-@WR\T(W&^R6\8PG_G<+2BTFZ4"8I{3Y%!OZ:Y]8HTN,< MN7R.'#Y'/*,X@["OWDB%?:1--F_-^(-\OT$/:D,NHZ&261IXFT4VHQ*S=D[9 MGK%=W';L9P_-])!XNPW"V/T=?U\[#?W#:-/H/K7_)4E'P#.1E3&L2"'K9I%/ MN_GJ[IP:< 4.O*5,GZ.,!22*$4@;QUE2WU+5=X^TPMH(N(&:,L+O^C!K E<]5EX+%%?\(N/U#BPJ.X U.2?<7 M'S%Q2:$0+LIF;VR"!0<, NK/?"'7RZ' E$_@33ID#4[;&*$J-'JRKWS 6H70(^IGF)T<_4I.^4,CI"?08=&6%%>??XU$9U7C3(MWM;,>VRO6PKZ_ECG)%?&H*[K$]PS'/E.V#NX. MW=:,Z]!Y*B,V M;UQ3/{GT')K\DM@L2,9,*.PD3.EU3@1*>_Y,/U"L%A@V9> MT#"2:CMHO.HD"T+;-P=3;T)>Z/97:R#4V]+W(2@:KG1(R;%"[9B%0T!*,O$$PO)7;_O/J9K4>)1BRT?&S-E M#Y=7X,LDHB8IP"#96\HZBW]+H.'5"4(DA@H:I6.A@[=["TY9*2D_?8=9^CJ M?98;OSD7/&C#'!)P_1!1=%_=[YS%1O}G@3K$T@/->+Z&}4M=7$RWCC062A9 M2]@__+!.LW26[G2?A@ZQH<^D%+U?^.@BW7%L=6)M3H%R.]?-# MC2%'%%Z%((M<;.%H-[=<#WH4XI$)6E,PQR1H9R_OI(KG5&7%WZ,,9<(8HKU M-;@%L>_!07),@+R 906%I/08NT{T1)'<;XB M4:X_&.06'HT5*6%+M-U@352.#.)**CKKRA_73A#X1JP$O8==L!% 7.#%H+> MPZZR#S!B6D-CW2=_Y9\&?A)QW+1!:A8C=L*>[D<@-^M1>]F H>894M(,'#?* MN(N1Q6+|..$"M4I[D#"_R 86M$4.YFK8#AER672R.2'-5?'DX)G&#V81K*+I M4.=T_Q!1Y\J_0FA!IFPN[=A]'B+!@DD!C4"R'XCP>_>]$-?_EJ0=D:RGX^59 M74U@'$+OR4YAW$W9M8ROVYB@\(6^X)_&3]$U0;39.61]!9'RFIGH|!T<.6 M(KUA^0!cWGXM?.#A>HXGVU%%?|/+_RX\)GX,,B(E3_.B!UARBF0 MYWQX[!Y/7A>C,69,NG0|&IY9,7T*PMZE,,D)"4D126OF0Z\P@9D9/X9D07D*-MM@>N_"\)Z"HR-.N61C1\ILYE$,KK9!EEU=E7;Q2!\M^LUJ*" D>SR2J"K?QK M*\)P2,RJLRG\|LSRJ.]8(<3>#HT&%$Q D*F/0U+B D/!":\Z+]J&*U+**PD-K M% C*7|,5RID2KX=2Z Q$;H\QQL,P>:H>YXU]PYDC>|:=WCC#HUQ <5S3A;OR M"1^:*$KLH.2",!9*:;4MTJLB%8ZVY+%[ZFOTDF!$0MPH{3)LFP!./,<9"2'+A M)%,8$OZV.HT"UKQ/G?9$4I&NK,? 1A[=U#P0)9<1MU$M_7Q5(<0C,9_%K8*J(VL MP9< 2COP?S(OWAV.HY)YDQ;230&^)#5\4XX$+N%T+-SCI(R&X'",0J[..G\U M+CDQA\NZ.5RI<[B? B80M @Y^+59DT'F=R[9.BI71+>IZ&]+GIG MHA8&X">H6PY!0DRD8GN*ZJO)A(H$PAWELO.B0WH/.<)CY-.'B,[=-&",BBN MAE-=$">1T=$*Y:-B2\IDG"X1A E0YOE4Q\I808N6#']"P"2<*$(R7ZO'SFNE659&1_Y+<+\)DH@=@@O,OZ4^ MSQU)]V^XD<<WA52-S)=5MX 9(S]S5FQ(U M$.PV(C.E$=RXUXZ TBB6!]&'0?3$2P/ (.N?.EO]3RIPG%^2Q$%N[#Y(G319 M@4,> 7*3A. 8B>^#"ROT|A)Z=*@XBC)RL#A;Z=@)ZG>N+YTKBUJ E$4;-Q%R M+H"0XIQ1XVD$HNE,,.M*;"3HICJ!5HYHG42AU%=G_N 9&-&-"KPA:.:>RSJH M%AF;(<8.9!2_IUK94P1\21:@)3*1XO!JC=.]HL519:A?1MS\Nf4%,4.W .2. M>5,0K\BD@-.]^I<^]>S%=!5[!++7R\W\"61=+,3/26A6T5%E2.V(/U\+UYA=YIT!'XIF-@AO .4*^R!KT'9=0]S'\/ATS^.]+Q/?&.98 M(3$1I4F0G#&HFW'X4)?HX;N[!\AIB(%GC*D2:SIW']:=%/++=):5**+N?FH\'M7B+815K^=$U+LK_W&+5.3R20NT0OC[B9$8SP24PQ2;4&WPW'<-03XN7G(T# M\'"7-Y*&!)P?INCY5OU??9@W$/+T)?!OF1+_\/SAY&,NT$/V<21L>66.R_(4\>#_L&6&B @NIE]_1<5?T;NUR;,8;2G;)H^?:*4B420[O+]J87VV M8L@*WZ_68P(+Y!B%GC"L1_8%"SL-SH!N_O-ECV)!93K(->W]O #/1?=$%1] M*H%>^;LDC]H,_4^#K]\U41V3G1!D"SY:.Q&'I&K/%X|LJ'3M'#QZF+TH^^W M_(6)(PF&7V+|*D@\/?=#)LH'X3@!7[)/M882Q"#S;A=P#V/\'N'$=V;56<[Z1 M:?"D7B385SKCL\"CGOE!@L2F!F+G*);1+S'}=02S!=8XPG#(ZQ*NUV#% T.3HKSU W>) MH2??S+SD UKKM\ND6P0T\:QP__2#Q0-D 1 4'P $&AN6Z^EN 2 R 202^?BE M+;Z)@K3\/O ;BB5O=T&T1SPROU(T>5#4_PN>1]_#C#!,3O@/Y!/_P:P?VD1 M>$=#FL"\UQ57/_\BQ0R3/],CI+U<-/'076'?Z**/]6;+.3Y#8D=RQ(.!*[.7@0\Q M5]T'=+G1+#H%2Y\+RA\'1W2$_/1!#?.P$F)I?5_;7:ZOC8#-536_A%!.3 ZXU'-MHL!E7@!R[+-KB"NU$YC/?"9,?=_KX8A60WLJXYQS"X%S<(]\F/T1P$B3/XV) MX$+2M^D+":"C\4_^P@OP;0L{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`8/X>)"?)\CL!J3GX0V73QL4!+W4BB,CC5[#$&##BS=QBR MY"F[ FT)BN_\Q3AX60700V[OR*W!8$S+RP9UR6L]/@+F=&{)(9C^^9>$,DQ' M37=)AN3$^;GY!UP'PQ=C*N3AL_?M;@GFRY6_((=:)\U:DXJ0^% >=32/6D_T M2$3]Z$3EXJ4/B3^^K.\TZY(0)"."@`,X(>$5CZ.CV"V&LUQ;LGI],Q&^_(MB'<=20[X;.$4E_D:,%AAS_@[%/%+[PHIM$Y^/5U'#+GL:+,Q9_F@,SKJL5 C MD59CDY2_QR454,4K]#H#D/_NA5ZC6J'7BNXPHU\:N.CK&&0;58 M:1 CQWIU MQORHQ'N->4W5HQ\X\M0O?KJYRI(42[B8HSYT>C+R@7,HA\$?C ,3E[LJ$#(M:,GO/E1,9Q_ID -Z#$9]GO]"%8=K+ $3/TUNHf@,Z=%E+?F@LU445T$[CHTN MF4T@IP^/7@5G.3;Z*IYEZ/TKG4K.-@@3E)G/[ZA-8PIY]0M(ZW092_]XC M0*4[&']JK&&CVWW2HP81GKP240.^*T894OJ[9EKCU$_PEL-K?XG\Y&)R%C3;C MPU$O !GP"&@H0[->/3PI-Z]3<1$+]7NV:>&CB#*7%OC\.M617RV9>CF'!%Y1EU$31AL034'3^%P&\G)$[T"%,H1GD,.0 *'SH>$FN0QHM M"/65P%U"NY427U\TZ^1\?__SQXZ?9#E!5;f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};T78+-02]X(L?X%L$;¥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

*VI=;O"D@M@2L?)JSNM*ITZ@H?>"?#A+L3KY@5B 1!Z4=R4D9\&^\CQLBZ/H:62C6%F8!+Q MNRR%!V=_D/#\,,.'XGD31]EZPUSG=7W&{DRU_043F+R\@N'6-N.+\$/MR-(BQY^ $XVDVI4"D*MI, MVM)$O+H96(EE(*]5IHX,>VR##0 8l%V<((DH53!&Q*VBF%D2(ONCI:,2P+4 M)0YJFKM"3ADOK*%.M*Z]$P3)C<6CI!9-D:TR8'W:RG$T1V#-V^W,L'-M4.DQ WI, ^K.8Z;'/T4,6+S: [RR"0"K$>;N.3NP8,(5++/R3\|J;70!Y,("!< M,-N:W)S0KK<3JU$D8<@?4$3> ^HN4R:*7T$\3BEM*J=JWR33MY1/6HXAIBC!Y MBWL\2=^3F$N:VC|Q_J9FYE_|=..'\Q#|$^_P7+O)8KB6CVA= FBFKW\'M<JG-MG=2Z.:1XM=$[I63Q(+$EPFWR)5]2\B-*T\Q0=$[1AD_:]31NO N-M+.:ZC!P?-MT2Z*:X=?TO@ 9U@B0H+P#B)R;B{&\%^,NRC_ DG%GX 33\9SPBRYL MS+Z6M;-^6&ZS."3A)_?4BQ{>PBM6JWPXFF@K5IV=6*=*+SI?'7S;,$!&0?Q M3/.P]W?N)]Q@GV5*MOW4$(.+@R%STS3W ER1/[%*>\B)P!)&"]O1,$T7>" M^@7AQ"0/3N.1!2A"5!.<%E@+>0C78%|S@IFEJ 2X,ZD,(<$)BE/9T,7Z=21$ MWS^_X]78XW^@&4[\ 604N=_8UXGU&\O@;-/8|02COZ+WB\4"]"](CXNC$/IQ M0=5VM8B=8=Q?=B)C5_B/_@Y>B^99S3-G%@W@Z)6:Z7;N+,.3I>)CI0OE M+:=P8M%\%ZM1ON1HHL_]:&.5_KWBJ2#$R0|93NLC+&@ 9:[>1?B5]66WD:ZY JSKDZ0 M6VPEBM5;&K^B=_"17^8UMD'DH<8"\C[_TX6CY*EX/8TOB.ZQ:T? MH/C^2]$ZBO=RM:+4Q+I\)/&{F+]W8;F6$,O/A*KTW.YQD8AUV4AT6KD/(+'0 MQ$?BAR[2$>;AO9<0RQ QN"\0_.,5%%%8>C'8Z&JF%B=FY<0AS,MB11<+ _)2. MD0Q)2^H,,.EH_=BP&XS6+@"F*[A5.V<6*,*"O5%6 YRKF%2XP9?HS N053? MZWR0O7["99I+?@O^'Q2@*>TO/FV (.>}+3 00-9%[LD5}C'J{@-_+^QU1LUF MV6NRB/V=#.ZEL8.3JH-9_'MST.6@&I*6/D"Q&=^;'@## M+1IPN \9RKH.A7<=ON!*<+(WWU+ 7);YMPRI.+&Z7Z(0|:G9XC8+EQJOH[RE M|;4AZ4X/$E"H>9BK?]7%,>GCQ.14HK\J5K="72?'1,9HK0.POI9?H_ 1WV2?.M/E[^\ E?6Q0$ 2UO V]=74)-4R=6|@Y"]+&F3.4="P7'DXZX%>6K/+3$I)\3 M\(Z16T<#SG\]ZK;^NA/,%B[(:E,:C#N:YDZ04ZBL\$H7B\:8.>]5O9P@[C': M>Ts]J30I;>#$E!M!A*7.CZ9.SI$&P!H7X9*!O^[G*V,]"9W6D'&=R M#X6(/ZFWI::Y=<7@qIM/C$[*$^%G?/C6SM8;O^M:D>K:C[$>.@09Q8 M2>ZKO4; <9WNQ("Z7!%]ML/,@XZ8&_2-7+PX9R0DF@-_WRVV7MW2""+G0{)8X MT??8UD_[4P,'T8=45R^!&NKP'_#SO$'D0)I4B@l*(43:#^'$_CC2/;1, M)K?P>2? 8+:E.J#+Y*YHI20497P!S!$&"(D_-9N7O&G89U6<4N2PANPK\0L+IP M"3%4N/^&H E*(DQ;=71BA_V$0KP0,.6+Y19%ZY4N$F8@4*M51U=(+$0E.@ MKQBA& #QZ)$EJ6U? +0l;MQ&M;^VZKE@. 2*!4N4X*56088LAG-@+A:FA7'!- MN Al_-="\;/H%#;PW/7U%2>8IR^]HG]HF_9U@U#Z=(((:2B WE"$5MW:"6*: MW,AB3 #+*%- BW2;@Y=%0GF'.I2]i;.0S0U)A15^S/X?)^!fL!RHXP?DU=9&D$ M6:Y8&0OVK\)+4##=9)Q -/0^:?=FA!O$S5ZG&+0 &^=#"29{B7$5WB H$P2PL|L M?(;QS:50?AL[6"=)L&-7WB(/# (^+O&)YY$F5P);='9$*#'L;K;"46C@Q;34> MD^Y::NYE?0-*&K-5XEOC92PQ8-&F/[(@$99*@^+6W?[<KI)T3 M! >&L)2;FGLS]7W<"38#9+NZ%TFCW K?G=B%< @7#$*%\)5QF-&X_]"2VK> MK+]NH0@G0?ZCT),01G"S6B&Y7C7N#*P+-"%WX]9?'9KVT=35B;U5*[JT:Y5 M;9T@A$=W%+RA+U&8;N0X.5T&=((E(X09'N2&[?Y91Y3&IPT* FUBA-C" MB3TA(?iA*VBF1/3_V.T0HE"4GZNT4F5;,5/9P@JAP0FNLCN?(+]*T]/1! M SAR=IZ\W=+T/GrH=A=ZTO1V(G5:SX,#IZC4K05M_<_$'J3SYNBLZGM'-A0[MT? B"!O!N.!3A2SN1[R=Y6R=6YEZ2>B6>:!$3ZJfVM.CO!,$52Y?V)*G:.D%(MW9S!XWU^\=/+59:D^-C$.?2(PO769@CK5A%!3:C&9PD_QI+;*"Y24BI)PU] MK$-)/Z%UM8RGO,*)LJ%UJ7@=+*8@Z4" BW>)_]0E$13/K6PMO_"0+4H_G.))W M5=U1)6GDA#"0F$=)W#*^;,^!1*?@K#(VKBMYN$(MBIH!,@(!U>]H.DUS)\)@I M.RR4@#629JZ<&&O:OT=]0+4LAO67C(&4 +0LAO67C(&4 +*VO,Q8:5L >&>?&;,_ M3A"[CQOOKS$T7*ZRYS4/$8BAN\4L.1'3'*M30,$SIFZ//#UC?U[T]SK^$'I^\ MMQC\"RNFW%NI^RX? MJXN7$%D%%8ZKZ)E'5M1^,W^7BCPF.>KSQ__=W8$6?> MTPD9(805:^Q:]5;65^@:DB\C$!'RB-90:BN*]Y#%%&VWD$/C!5_|.)^ *$2* M8(_V(U@GVA3ZP4G>R&KXP9*3Q3X2X_5 M>,/:6P+RN2@[33R*N9=1;QJO8V#K(O\^PB^^APT^-1'+;,_5WZUNT<-&#'5)(M.ZC#H6J:NK$U2_.:N^W.\V/8'8UN5TE[)PB217D)X0?-#ZA;%R?(NL';P1** MJ0"P8*9#WWR#2"4N,G>VNXR?MRK\3#W.M#FOL:Y?BZ%>.&+]3\&:P*9CM<6 M+,VRTL^-'9Q8^W+23O5%!999/\RB+'D)L6X<@-H/IY'I #N]//&"S]\IB$! M0MU1U2$?] (-.L#3W';$ 4#5(J;RE]:U^>$F*,,P@4J1:MZ"&=L0\M68OT0$^ M;)W%-*P[>LJV\]6E0OFL-W%B>U>/;.5 BS85 KEO8KEI&L,)PA7P^IIWJ]Z'-M&T2!IPI.6XPV 'WYAHJ8- [PXR%^5A)^%'*,,GP#D;P$]H#E2]5>4SE=8GBG# M;7K_DA-,K,MQ=24W55LG"E$*9X*6G(U3 .1)FWI!!%B9?/\<0K %$E*X;-H M,0RY8#+LZP2AM>(VK6K$F_>V_HCG_MNB%"6- ;E'Y>;OMK%_W7>L>L^'IYN$6M M-^U)IQ$G-KH$I (ND_QZI9$69LS$FLIY.$'DP-D\i7I6D\TK4I,&_Y>0SM061 MN.2I$H@?\/DIDCH=V@WA!-D%F$:'NXL!(DH? 7W"":>7(8L'!R6_[AQAM_6P+ M]S\1Y9_MH.CI D5/:"/8CY]!2Z97G2%8(NE!;\T+0VIR, M ;FC!-/L'-O\ST[T$U&%T4'ZU<8H :A)&5E+2_6,2*S5)B%=8V=6!U3Q=DH M0?7 L9Q@A) % !"[&CNQK*$!)+"RJRPB4&?O5K9V@IA]D0#\AM%&D,K]^>W& ML"Y<"GP2HA&^A'Z;/&6O_T*+]#FZS2"&F-6+E,N;MOVM&PM9]EO5\Z>(TS#K MX<3V!==S/KQOW@FF$? SNQ)H:5<8MJMR6K"N->G+++\9Q@B/[F+K!1Z(?LRR,Y 03%$:9%G%PU@\(_]0<'\U03=C59NLJXD(&_ZP2#N]DZ MN(UC'H,$1_'@B0\-'W2"I8I2YM<0) (^61NE2+8=P@FQ(N2;,'I^$6@49?>T5 MHtYY.$&GJB.GBQ'$"4-6+F8(-0W5(;^"QJ7FLS8M:UM\@A5'KG;6=)fMF-8 MU_QNT6N<>?&>)^3')'[;RL5HYX;)ZV7A!<9HD?HD0! 5AJXL1F*P?&D??RTPI?-M=_@5_,,7^W A H#?I^;@.G5?9P@M;DLUJMZ2IDZ0\8C>4)C)*\'QWYR8Z,O3 MLK46SDQ>2&8X0O>U0A?AR&*.GG&OZ*MJ?OA MX&?078@W$U0$*ZJ_T-C"I]2+^TMXU7_&.OM$,%:L!F18--/:)}$6P-C D%5E MA4$7)[8W&((06:52]EB>&4;142"X.VD 0#QL)"}>8\!6ELK!/%_.+#ZQ_2A. M$-\USTI=1++M[]? =^/NTS!FP5+';DAK@(O20S,>N7&;I$B,SFJHU8-NCE

MVS1\GK7J;G:#'AF^#SZT,#"\%469RIVH;.X" T'B-#V0T-Y/,TGC #[EN36V4:+Y^A=G'3_3;-%]-0 MW&VZ<">1%C;TWM4PMM_L,=??L\04=#HNW'P3W# JM=;793-[655\6V@S9TJ-^K5%O$49>GFR0MO(3\=,R:Z\K H-MC>+0]Y1)(T&'&NX4TZ:2.:;74BFB-MOR+_)\$@^:67;Q_U/CMI[ABI8]S88W!MGS2SVLEOI58PA+51%;KH I>4>1HR-M/D[%'O(!JKJ99.PI^H99:?CF<6=(0 M>H1^KI'4CI!?/WURY+G3QHBGTAXG88$YG%$3JL/3ADD2S7@2!H8V/#I<%9]$ M<-80K,R5^DD$8 W&0?I.F 12]Q \',1^Q18IWI2,#[^>.+@58>K)W4WT=_/-MQ[7P,<88|H\SP\P??%P1/C\7#'Z),:,?Z?31!.#ZKP+F_6&/-3HNEW=#!(KC5-M:WH7XF.8F42.]UK;,^GB*%MY45Q5<W6WBCb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fR*)!X-OGHH7X:198>22*.'0M97[HW]^)ZJ7/Z(N^M4.=#& 2-N M(<5>.W4VZ=P[?#6[>UTF(7U4_AM9=H5XCYWJECDH+B.OH:+P0TUB)^E]6?*2 MS#*I=:H[]JEM5BHC*A59I\X;@Z>9W.$WB8PXI_=$1P?C27.RZ?E1=DZ>-"O: MJI#J]_\0;'))*+70'@7?\B0V3T=3FMJA/8GLW;:O-YGF.2CCO7PB>$&D]A MANJ2*A)B*$GG=:0I9_4$\N.[8A)XU.4G!Z"6RX=E(^[7!V_-@C"AFO;K"/W!$%Q MO4)[' #'CC,/R)6H$K8*<2$-%0&/*&A@Y#+(+$7.I91PF MY]\(9AEW$$@* [>P^"M)1'+4:8OE+7OEQ?$>*W);U&)M%T<(-M>0F]+=;]_=.\]\K|F^K<>MGVXMP29HF208[CI0U_HK,;&T_;]\AJU?9-@L\ MD")0A!7!<:#E6Z%ZL"367M_>7HH(/O? \4:8'7Y:U=&+;C3#+BL9.3-Y@R@Y=-MO69!-'HQ=HXXTC#K %'9JS?77>3'9HX:2.7)N-X,149EPG\RKI/V/)+@.YZ^-MW;L]FZ92?%[UEJI43LM-&3GP\? EA95'C^N*ED&'HH^21F^B2^2I?1+O0M.13 MIS&/@Q4-I9\&>]{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|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|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|<'^>1-'V7IS\X;B/:2YS..G'5]0 MAPB@S/:YZ.EA-M8."+Z*4_Q(PV]LLM@OH9\FCT\O6E&F[W.T.^0JPIL\S."] M2E>'F<64Q7TM3J9O:4 F6)R:H9?Q^O4@$+++S5,^0IE?O.5URS(I*B<#C, MPWLO26%S0\896J E*5X0H'#IQ7 $Y(+'A8D=WVU5-KO HW%0OU+].P,=>O[M M8F9T!B7[C;"PO, [4VE1MKCW.-G'-L[5;6"1.<(USKH.$F=S/OH'<7I3_[6 M;V?HZ.F3I\'(E]UN;$96/VF7D;_-4N:U*F6*>@#2]C_\1W;.P,"F/S/SU@/ MR_&U5;E'O7[B^:C%WZ0OKAKY_$89O+15%4AATE2>,K6Q3_6*]>/G&56>.6$]9L] MV/";0VGY4;4^Z!+OLV@-Q73D'>!,/F9&>&#;AR4N]!/?7BD%[H8%==/]1?W*DD: MON0X.V[#

*__"//@*AQ^21H@%:@8G6N&DO2O,UX>Y%;?QNCRJ#*'""0K857-MOP9OPO;WG6%&CY6>$¦ ,77B^SHD*SS#.@@B>&&.?YL5Y=&:-=66X)0#\,=Y& MFU3V0B/*Q%7-G78KJ:UVK3]=&K/4=&+%MIZN-.P:SEF>;IZHT*X12G^M0ZQ0^F5WOZ9@.XT'EQ_OGNZMBH[67$+90(#3,/9F7UT;4$+//]! Wl,M<:.$I M[O1)Y//+17H?F\AS1.@(=(G%Y2GT*L;>M-EW6]W04B8>^1Z M$Q!ZQ6O%E)!W%D1%KRJ\+.,+PUD'$>D0M8OYZA^5L!W0;^P-CF^X16IJ1=V63 M(]VI3M2U-8^@2!I@G@7=:C;5"A;K(2'(*T+D)\^R_+)S8WOR.@CA>/NICTH7MEE[GH\9D-M_7AE18U,%>>3M>0DP2E!^XO#(OOQUT2(H:PPUQ@:;'M8]@#KSH@ZB*A5A^:'@H D$ZQEY)2$ L.Z^&05ZBFBX&R14L()GE*8160T: MHILX2Z^#9/-C#T;"F^T4>*4BN_HM2U(X#M$]UYSL;,BRCS8L*I!3*INGX03N MKUXW:S 4:JO+2-(I>5)I4=Q^9&V-T6DD:)8O:9DGW>=<|N:CS!|_RTB5S"/&D M;$FG%&8V^4K^"Z[W$VQ#HE%X3GX@T7P%!DCDY;'&+=@3E07DN6M^*#+D5I7G M/OJA2!%;;)X_CV12C'-M/L\?/36)'Y}:##RLPRB);S!/7[HASU]^IQ2DX4% M96*Z,D[?,%)'(4K,&6N@@@$R_,&H907J:EMEGO2G)-,ZD=)=_93=8Y)MLU+-M_X-Z9:X\DD/[_K*?OE.G_(MZ[*?2#(+Z62_"_??Z|%Y.#Q%I=;N*(IC?)-M,V9XX-7>#ODEB,_SX_^$M?844#.N:6]MQ&:6LL>"* ?UF7(E8%,) D "54OP.OC{@#D$$;+&^4EQ&HKJ!RAW?N6Y?4 UB5|/=+ M0'Y'*;"@0[/M-C/R$XYTV7^GTI;*TKN\W2#B&3 >@"YF TW"?D)P)BO7Q+$ M9M2=-*Z#J,>4#AU 'H-P=8^O@UV8!E%-"?8)9N7%I6)G1^$LNKN4M,RW:.KP MN@BLGLHD8,PR8)T^7"Z,AT/D")R?W=-\ZXNE]DV8Y%/!C$\=T'0!D)"[RA_M\!.*$'8=.D(VG37-<6%PCU/&L@2?U7 M7&!D,\S6,/3R.#7VVGNZ(R35<3)ID%-[CCW6]N% XK-9]42;G$KM)A)Q+N5, M1\BNZPOJP\;L |-W^O!AX(ZUJ8[T<2(]+1>]IC3A@7>&[Y&S¦_LD,45N2\VGP4+6KA0N%QLL1NHE4KEIM6AR'[V'H01Z"OKF"1!?6UY!G\6V<_7XB%/ M: E^<*:,5>(:-G//#TH:+._D<7TK=@PVUKC)KRFYBD0*/W^:!WE.77\%*\2.W"0Z,.+ZFAW]Q.R|<[$|>APZ8R8UN.N.6[\?OX#77,">V-2F2KZ\U)UN]10E MY^,'XZUGLH)*$F.@F]9>7!EEA9S,53.7^&7Y*9-?TYY#N MO%ZM*$M9"AV %+S)*!AP MV%130E1@ %>E2UW'$>5;,0D:Q^QZ\'+@,=_C%!$J%0\HX$8O3PAB-JHYM|W/ M_NJB=N2F.X??8KZ7$.FX/WM-'V/C,JXOVJUDCFV2J?%P&7T";,Y'5<-UZL9&/7+U&G;ON:.E-(IG]U^3^;N|H34Y=9GCV=B^MQPDVZ$T;(41H\&EI2&?#CF&M/|453]52UC2:4M:P(:[_'#[\P\|2H:I@)H-QE:MQ*##4.Y<#]WTG.2,OT"%C#OT2C+VYE@>06QR87G4=?S#S'%3) .\+'^:AW4,^Y^;!]9OCXG$.5J%G&&=00}/. M\JJ)LOSZ%KE=1^OL_3_H9NI7<3$HS[U#(-(%9;+-U:]H_>L/GF+OW@X1IBO!C M]AJ%25['4X|S\;(4)OLB+K6R!O75$KLJ<:X_P:@;UT"ZETXZ^0/]7]AEY:?K M..D!\Q1)]RHKK/|/?\1\Q_7A|RY29R/1Y0F}(YRAMK@2CW 3(O!WE3Y*1E!5M1+UP_M88WJH-VSTV(QU#:>B(!UJN^.8,@:8'YEZUK&IBL3O..!40YSI%(5 MBGEQ+ZB=?=C?CP6$!7GIM!5XTSIOK=(31 5J^L1R.)M5,E3):I8M: QU5;&L MN/LJHRNEIV:4-Y8M@*!0=0(.Q3'!)WES:&S\M\"@%R9+DM,<)7,4QG@6F/=_M//9Z!0PHER'K33W'[/DS>,WQD<1+A%9)/3FCIH56971'K^,F?OXGPXAOA/!^M<9%CWV4$AU#?]Y!?U#R+<X)I:AZQZWE4>HSQ468J29'#0)@.8RX7B@T">7& MOU$NM(CS:D=0-CIGVG^>B]#7[V*>.8MS]P3%X 2T_Q M&C+3Q7.>K7[+BIS)15P+/P?AZAZ7-8]2!(>=99105P*PI M]=\&)-J7ZG=ELEO=@C/*Q'@%RO>4 X50\7#(,S"9R:!:WC$G>^FT+3Pf%15V M_U(?>$B5\C=$[-J$!?H#-45FA4^BQFLCK.-&IP;VJ"7:.\&E_+6;[#H@/|:S#)8QML0_N,.C"DW#9J$>=XDN^!:4R&;O07_8TS_D^H86J6G,<9'66)^,KHOB(%D$ M/[NI_)O7>&[Q\1U?Y[(IDR9^-LO53Z_C1.W0; IGX152>;>"[@JE^O*967? MY:=]H/*!F.3>D9(@>'T0^LQV+9Y=-VUSI_8AQ6Z.JT+!!<3Y*^T=OK!!^0'@&66AY&GO1*=1L$MAW5D.NN%&&4?43H%<3 MG/>%A07O'U9-Y#O.K^X26L.B:ML&E(STFN7&^E&1Y"C...,8&!8,G2 M$F_A40((]C2I7FNH@Z1>]'!\")<0I;!)6'$+5/B4N4<-#5D^T)=CA;XI5.H4 MH B<*XI!+MHX',>^EO??==NM?!8E3RN NNZ[*/XH 1+!>F*6F\03D?M_QTQ#M*K_@FEY:\5)X?{Q

MEPQ1:H178_0C'DGWG97[>)LC'N7YZ4><_!L0=,8AZS.%K]U4+=U_,%UT>D: MEU_=_Y$K79/CSB6Y6P"*0N."0(NW,K9J-7V5K>V]#CGZ8K+2RMB!//RG@C@M_"Z2F62PLF$5(142)&D?Z=,TB'5&Z$*!7!PA8@)=)UR"HS#AETO]_=1%&3F M7>JGDBD&:W7&?HC%@**6K_2P?5RK5Q!.$ 9GA!)4UA/>OQ[ENU[B],Y,^+M M@[D@J,C*ZX,!T2@6B4Q8.H1VB&.@-CJHZ4\[?> CD.$TIAL!NR"HJ["[^V(M4%2>BU2?9(>>]K2_O8 J$(OD"= TA# ^,7E;05>A>6K] 48#2!HD4+${BBZ# M@/E@!,%]HM^P1)}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{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end XML_79 kzr-20240630_htm.xml IDEA: XBRL DOCUMENT 0001645666 2024-01-012024-03-31 0001645666 2023-12-31 0001645666 us-gaap:RoyaltyMemberkzr:EverestLicenseAgreementMember 2024-01-012024-06-30 0001645666 srt:ChiefExecutiveOfficerMember 2024-04-012024-06-30 0001645666 kzr:RestrictedStockUnitsSubjectToFutureVestingMember 2024-04-012024-06-30 0001645666 kzr:EverestLicenseAgreementMember 2024-01-012024-06-30 0001645666 us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 2023-04-012023-06-30 0001645666 us-gaap:CommonStockMember 2024-01-012024-03-31 0001645666 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001645666 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001645666 kzr:CowenAndCompanyLimitedLiabilityCompanyMemberkzr:AtTheMarketAgreementMember 2024-06-30 0001645666 us-gaap:ComputerEquipmentMember 2023-12-31 0001645666 us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 us-gaap:CommonStockMember 2024-06-30 0001645666 srt:MinimumMember 2024-01-012024-06-30 0001645666 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001645666 kzr:OxfordFinanceLLCMemberkzr:TrancheOneMemberkzr:LoanAndSecurityAgreementMember 2021-11-30 0001645666 us-gaap:ComputerEquipmentMember 2024-06-30 0001645666 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001645666 us-gaap:EmployeeSeveranceMember 2022-12-31 0001645666 kzr:OxfordFinanceLLCMemberkzr:LoanAndSecurityAgreementMember 2023-01-012023-06-30 0001645666 us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 kzr:CowenAndCompanyLimitedLiabilityCompanyMemberkzr:AtTheMarketAgreementMember 2021-12-012024-06-30 0001645666 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001645666 us-gaap:CommonStockMember 2023-03-31 0001645666 kzr:SouthSanFranciscoCaliforniaMember 2022-11-01 0001645666 kzr:TwoThousandFifteenEquityIncentivePlanMember 2024-06-30 0001645666 us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001645666 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001645666 kzr:FurnitureLaboratoryAndOfficeEquipmentMember 2024-06-30 0001645666 srt:MinimumMember 2024-04-012024-06-30 0001645666 us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 us-gaap:EmployeeStockOptionMember 2024-04-012024-06-30 0001645666 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0001645666 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001645666 kzr:EverestLicenseAgreementMember 2023-09-012023-09-30 0001645666 us-gaap:RestrictedStockUnitsRSUMemberkzr:TwoThousandEighteenEquityIncentivePlanMember 2024-01-012024-06-30 0001645666 us-gaap:CommonStockMember 2024-03-31 0001645666 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-06-30 0001645666 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0001645666 kzr:AssetImpairmentMember 2023-12-31 0001645666 kzr:OxfordFinanceLLCMembersrt:MaximumMemberkzr:LoanAndSecurityAgreementMember 2021-11-012021-11-30 0001645666 us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001645666 kzr:OxfordFinanceLLCMemberkzr:LoanAndSecurityAgreementMember 2023-04-012023-06-30 0001645666 us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001645666 us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001645666 us-gaap:DomesticCountryMember 2024-01-012024-06-30 0001645666 kzr:TwoThousandEighteenEquityIncentivePlanMemberus-gaap:CommonStockMember 2024-06-30 0001645666 2024-08-09 0001645666 us-gaap:CommercialPaperMember 2024-06-30 0001645666 us-gaap:RetainedEarningsMember 2022-12-31 0001645666 kzr:OxfordFinanceLLCMemberkzr:LoanAndSecurityAgreementMember 2021-11-30 0001645666 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001645666 kzr:AssetImpairmentMember 2024-06-30 0001645666 us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 us-gaap:EmployeeSeveranceMember 2024-04-012024-06-30 0001645666 kzr:EverestLicenseAgreementMember 2024-06-30 0001645666 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 us-gaap:EmployeeSeveranceMember 2023-01-012023-12-31 0001645666 kzr:AssetImpairmentMember 2023-01-012023-12-31 0001645666 us-gaap:RetainedEarningsMember 2024-03-31 0001645666 2023-01-012023-06-30 0001645666 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001645666 us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 kzr:EverestLicenseAgreementMember 2023-10-012023-10-31 0001645666 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-06-30 0001645666 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001645666 us-gaap:RestrictedStockUnitsRSUMemberkzr:TwoThousandEighteenEquityIncentivePlanMember 2023-12-31 0001645666 us-gaap:RetainedEarningsMember 2023-03-31 0001645666 kzr:OxfordFinanceLLCMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-01-012024-06-30 0001645666 kzr:AssetImpairmentMember 2024-04-012024-06-30 0001645666 2023-07-242024-06-30 0001645666 us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 us-gaap:CommonStockMember 2024-04-012024-06-30 0001645666 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001645666 us-gaap:CommonStockMember 2022-12-31 0001645666 2023-06-30 0001645666 2023-03-31 0001645666 srt:MaximumMember 2024-01-012024-06-30 0001645666 us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 us-gaap:EmployeeSeveranceMember 2024-03-31 0001645666 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-06-30 0001645666 2023-04-30 0001645666 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-012024-06-30 0001645666 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001645666 us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001645666 kzr:CowenAndCompanyLimitedLiabilityCompanyMembersrt:MaximumMemberkzr:AtTheMarketAgreementMember 2021-12-012021-12-31 0001645666 us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-012023-06-30 0001645666 kzr:DevelopmentRegulatoryAndCommercialMilestonesMemberkzr:EverestLicenseAgreementMember 2024-01-012024-06-30 0001645666 kzr:TwoThousandEighteenEquityIncentivePlanMemberus-gaap:CommonStockMember 2024-01-012024-06-30 0001645666 kzr:TwoThousandTwentyTwoStockIncentivePlanMember 2024-06-30 0001645666 srt:ChiefExecutiveOfficerMember 2023-11-072023-11-07 0001645666 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-03-31 0001645666 us-gaap:EmployeeStockOptionMember 2023-04-012023-06-30 0001645666 kzr:TwoThousandEighteenPlanMember 2023-07-242024-06-30 0001645666 kzr:OxfordFinanceLLCMemberkzr:EqualToSumOfAMemberkzr:LoanAndSecurityAgreementMemberus-gaap:BaseRateMember 2021-11-012021-11-30 0001645666 srt:MaximumMember 2023-04-012023-06-30 0001645666 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001645666 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001645666 us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001645666 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001645666 us-gaap:EmployeeSeveranceMember 2024-01-012024-03-31 0001645666 us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-06-30 0001645666 us-gaap:EmployeeStockOptionMember 2024-01-012024-06-30 0001645666 srt:MinimumMember 2023-01-012023-06-30 0001645666 us-gaap:LeaseholdImprovementsMember 2024-06-30 0001645666 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 2024-04-012024-06-30 0001645666 us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 kzr:OxfordFinanceLLCMemberkzr:EqualToSumOfBMemberkzr:LoanAndSecurityAgreementMember 2021-11-012021-11-30 0001645666 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001645666 kzr:EverestLicenseAgreementMember 2023-10-31 0001645666 us-gaap:CommercialPaperMember 2023-12-31 0001645666 kzr:RestrictedStockUnitsSubjectToFutureVestingMember 2024-01-012024-06-30 0001645666 2023-01-012023-03-31 0001645666 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0001645666 2024-01-012024-06-30 0001645666 kzr:AssetImpairmentMember 2024-03-31 0001645666 kzr:TwoThousandEighteenPlanMember 2023-07-24 0001645666 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0001645666 kzr:FurnitureLaboratoryAndOfficeEquipmentMember 2023-12-31 0001645666 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 kzr:UnderwrittenPublicOfferingMember 2022-12-31 0001645666 us-gaap:EmployeeSeveranceMember 2023-12-31 0001645666 us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001645666 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0001645666 us-gaap:CommonStockMember 2023-04-012023-06-30 0001645666 kzr:TwoThousandEighteenEmployeeStockPurchasePlanMemberus-gaap:CommonStockMember 2024-01-012024-06-30 0001645666 us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 kzr:AssetImpairmentMember 2024-01-012024-03-31 0001645666 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 kzr:TwoThousandEighteenEmployeeStockPurchasePlanMemberus-gaap:CommonStockMember 2024-06-30 0001645666 us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001645666 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-06-30 0001645666 kzr:RestrictedStockUnitsSubjectToFutureVestingMember 2023-04-012023-06-30 0001645666 kzr:OxfordFinanceLLCMemberkzr:LoanAndSecurityAgreementMember 2021-11-012021-11-30 0001645666 srt:MaximumMemberkzr:TwoThousandFifteenEquityIncentivePlanMember 2024-01-012024-06-30 0001645666 kzr:RestrictedStockUnitsSubjectToFutureVestingMember 2023-01-012023-06-30 0001645666 srt:MaximumMember 2023-01-012023-06-30 0001645666 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001645666 us-gaap:EmployeeStockOptionMember 2023-01-012023-06-30 0001645666 us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 kzr:AtTheMarketAgreementMember 2024-01-012024-06-30 0001645666 kzr:TwoThousandEighteenEquityIncentivePlanMember 2024-06-30 0001645666 kzr:TwoThousandEighteenPlanMember 2023-07-242023-07-24 0001645666 us-gaap:EmployeeStockOptionMember 2024-01-012024-06-30 0001645666 kzr:AssetImpairmentMember 2022-12-31 0001645666 us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 kzr:TwoThousandEighteenEmployeeStockPurchasePlanMember 2018-06-30 0001645666 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 kzr:CollaborationRevenueMemberkzr:EverestLicenseAgreementMember 2023-07-012023-09-30 0001645666 us-gaap:EmployeeSeveranceMember 2024-06-30 0001645666 kzr:TwoThousandFifteenEquityIncentivePlanMember 2024-01-012024-06-30 0001645666 srt:MinimumMember 2023-04-012023-06-30 0001645666 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001645666 kzr:OxfordFinanceLLCMembersrt:MinimumMemberkzr:LoanAndSecurityAgreementMember 2021-11-012021-11-30 0001645666 2023-01-012023-12-31 0001645666 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-06-30 0001645666 us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 us-gaap:CommonStockMember 2023-01-012023-03-31 0001645666 us-gaap:EmployeeStockOptionMember 2024-06-30 0001645666 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001645666 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001645666 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001645666 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-06-30 0001645666 kzr:CowenAndCompanyLimitedLiabilityCompanyMemberkzr:AtTheMarketAgreementMember 2021-12-012021-12-31 0001645666 2024-03-31 0001645666 us-

gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 us-gaap:RetainedEarningsMember 2024-06-30 0001645666 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001645666 us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001645666 us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001645666 us-gaap:USTreasurySecuritiesMember 2024-06-30 0001645666 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-012024-06-30 0001645666 srt:MaximumMember 2024-04-012024-06-30 0001645666 us-gaap:ForeignCountryMember 2024-01-012024-06-30 0001645666 kzr:TwoThousandEighteenEmployeeStockPurchasePlanMemberus-gaap:CommonStockMember 2024-01-01 0001645666 kzr:OxfordFinanceLLCMemberkzr:LoanAndSecurityAgreementMember 2024-04-012024-06-30 0001645666 kzr:TwoThousandEighteenEquityIncentivePlanMember 2024-01-012024-06-30 0001645666 us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001645666 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-012024-06-30 0001645666 kzr:SouthSanFranciscoCaliforniaMember 2024-01-012024-06-30 0001645666 2022-12-31 0001645666 kzr:EmployeeStockPurchasePlanMember 2024-01-012024-06-30 0001645666 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001645666 kzr:EverestLicenseAgreementMember 2024-04-012024-06-30 0001645666 kzr:OxfordFinanceLLCMemberkzr:LoanAndSecurityAgreementMember 2024-01-012024-06-30 0001645666 srt:ChiefExecutiveOfficerMember 2024-01-012024-06-30 0001645666 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001645666 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001645666 us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001645666 srt:MaximumMemberkzr:TwoThousandEighteenEmployeeStockPurchasePlanMemberus-gaap:CommonStockMember 2024-01-012024-06-30 0001645666 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001645666 us-gaap:RestrictedStockUnitsRSUMemberkzr:TwoThousandEighteenEquityIncentivePlanMember 2024-06-30 0001645666 srt:MaximumMemberkzr:IncentiveStockOptionsMemberkzr:TwoThousandEighteenEquityIncentivePlanMemberus-gaap:CommonStockMember 2024-06-30 0001645666 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001645666 kzr:TwoThousandEighteenEquityIncentivePlanMember 2024-04-012024-06-30 0001645666 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-03-31 0001645666 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-012023-06-30 0001645666 us-gaap:CommonStockMember 2023-12-31 0001645666 us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 2024-06-30 0001645666 us-gaap:RetainedEarningsMember 2023-06-30 0001645666 us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001645666 srt:MaximumMemberkzr:TwoThousandEighteenEquityIncentivePlanMemberus-gaap:CommonStockMember 2024-06-30 0001645666 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001645666 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001645666 us-gaap:RetainedEarningsMember 2023-12-31 0001645666 us-gaap:USTreasurySecuritiesMember 2023-12-31 0001645666 us-gaap:CommonStockMember 2023-06-30 pure iso4217:USD shares shares kzr:Tranche kzr:Segment iso4217:USD0001645666Q2false--12-3110-Qtrue2024-06-302024false001-38542Kezar Life Sciences, Inc.DE47-3366145400000 Shoreline CourtSuite 300South San FranciscoCA940806508222-5600Common Stock, $0.01 par valueKZRNASDAQYesYesNon-accelerated Filertruefalsefalse729622202827600035493000135906000165879000343500055780001676170002069500003391000391200023910004778000652200055950001799210002213850000-130000-393968000-350763000150685000187570000179921000221235000162980002099900033470000393170005603000578500012142000119910001482000014820000233830002678400047095000-23383000-26784000-47094000-513080002237000286100046900005556000401000385000801000755000-21547000-24308000-43205000-46507000-0.3-0.3-0.34-0.34-0.59-0.59-0.64-0.64728458697284586972461850724618507282280972822809723954107239541021547000-24308000-43205000-46507000140005000-15000-17000-44000-302000-240000110000-30000-307000-25500093000-21577000-24615000-43460000-46414000727790773000538390000-130000-350763000187570000222820034340003434000-225000-225000-21658000-216580007280135973000541824000-355000-372421000169121000861795600056000308500030850000-30000-30000-21547000-215470007288753873000544965000-385000-393968000150685000684934296800051962000092300024889300026987200022362332000-2000863381000153000154000426300042600004000004000000-22199000-22199000070816000710005240340000-523000-271092000252490000155664320000-200016017138200038200040200004020000-307000-307000-24308000-24308000072532814730005284340000-830000-295400000232277000-43205000-46507000521000500800651900082830002902000353200012900011800015490000-2143000-22460000927000588800031060000245300061400014100039893000-42460000016730005212600095233000847500001265000003262400029594000560005360005600053600040000-17000-7217000-123470003549300040456000282760002810900001170000400067200063700000 1. Organization and Description of the Business Description of Business Kezar Life Sciences, Inc. (the "Company," "we," "us," or "our") was incorporated in the state of Delaware in February 2015 and commenced operations in June 2015. The Company is a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's principal operations are in South San Francisco, California, and it operates in one segment. Liquidity Since commencing operations in mid-2015, substantially all of the Company's efforts have been focused on research, development, and the advancement of the Company's product candidates, zetomipzomib (KZR-616) and KZR-261. The Company's ultimate success depends on the outcome of these ongoing research and development activities. The Company has not yet generated product sales and as a result has experienced operating losses since inception and had an accumulated deficit of $394.0 million as of June 30, 2024. The Company expects to incur additional losses in the future to conduct research and development and will need to raise additional capital to fully implement management's business plan. The Company intends to raise such capital through the issuance of additional equity, including through at-the-market ("ATM") offerings, and potentially through borrowings, strategic alliances with partner companies and other licensing transactions, such as our collaboration with Everest Medicines II (HK) Limited ("Everest"). However, if such financing is not available at adequate levels, the Company may need to reevaluate its operating plans. Management believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund the Company's cash requirements for at least 12 months following the issuance of these financial statements. In December 2021, the Company entered into a Sales Agreement (the "ATM Agreement") with Cowen and Company, LLC ("Cowen"), pursuant to which the Company can offer and sell, from time to time at its sole discretion through Cowen, as its sales agent, shares of its common stock having an aggregate offering price of up to $200.0 million. Any shares of its common stock sold will be issued pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-261774). The Company will pay Cowen a commission up to 3.0% of the gross sales proceeds of any shares of its common stock sold through Cowen under the ATM Agreement and also has provided Cowen with indemnification and contribution rights. As of June 30, 2024, we have sold an aggregate of 11,986,003 shares of our common stock for gross proceeds of approximately $131.7 million at a weighted average purchase price of $10.98 per share pursuant to the ATM Agreement. As of June 30, 2024, approximately $68.3 million remains available under the ATM Agreement. No shares were sold under the ATM Agreement during the three months ended June 30, 2024. 1-394000000P12M2000000000.031198600313170000010.98683000000 2. Summary of Significant Accounting Policies Significant Accounting Policies The Company's significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2023 and the notes thereto, which are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission ("SEC") on March 14, 2024 (the "Annual Report"), and there have been no material changes during the six months ended June 30, 2024. Basis of Presentation and Consolidation The condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and include the Company's accounts and those of its wholly owned Australian subsidiary. Kezar Life Sciences Australia Pty Ltd., which is a proprietary company limited by shares. All intercompany balances and transactions have been eliminated upon consolidation. <span style="color:#000000;white-space:pre-

wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The condensed consolidated balance sheet as of December 31, 2023 has been derived from the audited consolidated financial statements at that date but does not include all information and footnotes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements included in the Annual Report. Unaudited Condensed Consolidated Financial Statements The accompanying financial information as of June 30, 2024 is unaudited. The interim condensed consolidated financial statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that our management considers necessary for the fair statement of the results of operations for the interim periods covered and of our financial condition at the date of the interim balance sheet. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such judgments, estimates and assumptions include the valuation of marketable securities, impairment of long-lived assets, determining the fair-value of stock-based compensation, and evaluating the progress to completion of external research and development costs. Management bases its estimates on historical experience and on various other market-specific relevant assumptions that management believes to be reasonable under the circumstances. Actual results may differ from those estimates. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its judgments, estimates and assumptions or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company's condensed consolidated financial statements. Recently Issued Accounting Pronouncements In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2023-09 Income Taxes (Topic 740) – Improvements to Income Tax Disclosures ("ASU 2023-09"), which requires entities to disclose specific categories in the income tax rate reconciliation annually and provide additional information for reconciling items that meet a qualitative threshold. ASU 2023-09 also requires that entities disclose annually additional information about income taxes paid and disaggregated information for certain items. ASU 2023-09 is effective for the Company beginning on January 1, 2025. The Company is currently evaluating the impact of the adoption of ASU 2023-09 on its financial position, results of operations and cash flows. In November 2023, the FASB issued Accounting Standards Update No. 2023-07 Segment Reporting (Topic 280) – Improvements to Reportable Segment Disclosures ("ASU 2023-07"), which requires entities to disclose incremental segment information on an annual and interim basis. ASU 2023-07 requires entities with a single reportable segment to provide all the disclosures required by the amendments in ASU 2023-07 and all existing segment disclosures in Segment Reporting (Topic 280). ASU 2023-07 is effective for the Company beginning with the Form 10-K for the year ending December 31, 2024. The Company is currently evaluating the effect of adopting the update on its related disclosures. There have been no other recent accounting pronouncements, changes in accounting pronouncements or recently adopted accounting guidance that are expected to have a material impact on the Company's condensed consolidated financial statements upon adoption. Basis of Presentation and Consolidation The condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and include the Company's accounts and those of its wholly owned Australian subsidiary, Kezar Life Sciences Australia Pty Ltd., which is a proprietary company limited by shares. All intercompany balances and transactions have been eliminated upon consolidation. The condensed consolidated balance sheet as of December 31, 2023 has been derived from the audited consolidated financial statements at that date but does not include all information and footnotes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements included in the Annual Report. Unaudited Condensed Consolidated Financial Statements The accompanying financial information as of June 30, 2024 is unaudited. The interim condensed consolidated financial statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that our management considers necessary for the fair statement of the results of operations for the interim periods covered and of our financial condition at the date of the interim balance sheet. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such judgments, estimates and assumptions include the valuation of marketable securities, impairment of long-lived assets, determining the fair-value of stock-based compensation, and evaluating the progress to completion of external research and development costs. Management bases its estimates on historical experience and on various other market-specific relevant assumptions that management believes to be reasonable under the circumstances. Actual results may differ from those estimates. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its judgments, estimates and assumptions or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company's condensed consolidated financial statements. Recently Issued Accounting Pronouncements In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2023-09 Income Taxes (Topic 740) - Improvements to Income Tax Disclosures ("ASU 2023-09"), which requires entities to disclose specific categories in the income tax rate reconciliation annually and provide additional information for reconciling items that meet a qualitative threshold. ASU 2023-09 also requires that entities disclose annually additional information about income taxes paid and disaggregated information for certain items. ASU 2023-09 is effective for the Company beginning on January 1, 2025. The Company is currently evaluating the impact of the adoption of ASU 2023-09 on its financial position, results of operations and cash flows. In November 2023, the FASB issued Accounting Standards Update No. 2023-07 Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures ("ASU 2023-07"), which requires entities to disclose incremental segment information on an annual and interim basis. ASU 2023-07 requires entities with a single reportable segment to provide all the disclosures required by the amendments in ASU 2023-07 and all existing segment disclosures in Segment Reporting (Topic 280). ASU 2023-07 is effective for the Company beginning with the Form 10-K for the year ending December 31, 2024. The Company is currently evaluating the effect of adopting the update on its related disclosures. There have been no other recent accounting pronouncements, changes in accounting pronouncements or recently adopted accounting guidance that are expected to have a material impact on the Company's condensed consolidated financial statements upon

adoption. 3. Fair Value Measurements Financial assets and liabilities are recorded at fair value. The carrying amount of certain financial instruments, including cash equivalents, other current assets, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. Assets and liabilities recorded at fair value on a recurring basis in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are required to be recognized or disclosed at fair value in the financial statements. The Company determines the fair value of Level 1 assets using quoted prices in active markets for identical assets. The Company reviews trading activity and pricing for Level 2 investments as of each measurement date. Level 2 inputs, which are obtained from various third-party data providers, represent quoted prices for similar assets in active markets and were derived from observable market data, or, if not directly observable, were derived from or corroborated by other observable market data. In certain cases, where there is limited activity or less transparency around inputs to valuation, securities are classified as Level 3 within the valuation hierarchy. The Company did not have any financial assets or liabilities measured using Level 3 inputs as of June 30, 2024 or December 31, 2023. The following table summarizes the Company's financial assets measured at fair value on a recurring basis and classified under the appropriate level of the fair value hierarchy as described above (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Financial Assets: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:5pt;vertical-align:top;"> Cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28,158 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">28,158</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:5pt;vertical-align:top;"> Marketable securities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Certificate of deposit </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 533 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 51,889 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 51,889 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,494 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,494 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;">Corporate debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,990 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,990 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. government agency bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 7,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">164,064</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 80,047 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">84,017</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-

space:pre-wrap;"> <td style="vertical-align:top;"> Financial Assets: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:5pt;vertical-align:top;"> Cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">35,349</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,349 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 544 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 544 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 54,175 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 54,175 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,070 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,070 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. government agency bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 46,090 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 46,090 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">201,228</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 89,524 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">111,704</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>   Nonrecurring Fair Value Measurements   The right-of-use (“ROU”) asset associated with Suite 400 of the Company's headquarters in South San Francisco, California, is a separate asset group measured at fair value on a nonrecurring basis as of December 31, 2023 due to an impairment recognized on the ROU asset at that date (see Note 6). The fair value of this asset group calculated as the present value of the estimated future cash flows of sublease income attributable to the ROU asset associated with Suite 400, was classified in Level 3 of the fair value hierarchy. When calculating the present value of the estimated future cash flows, sublease income was estimated to increase at a rate of 3.5% per year, and the cash flows were discounted using a rate of 13.3

%. In June 2024, the Company recognized an additional $1.5 million impairment charge in relation to Suite 400 to write off the net book value of the ROU asset as of June 30, 2024 as the estimated future cash flow from sublease income is zero due to current market conditions. Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are required to be recognized or disclosed at fair value in the financial statements. The Company determines the fair value of Level 1 assets using quoted prices in active markets for identical assets. The Company reviews trading activity and pricing for Level 2 investments as of each measurement date. Level 2 inputs, which are obtained from various third-party data providers, represent quoted prices for similar assets in active markets and were derived from observable market data, or, if not directly observable, were derived from or corroborated by other observable market data. The following table summarizes the Company's financial assets measured at fair value on a recurring basis and classified under the appropriate level of the fair value hierarchy as described above (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Financial Assets: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:5pt;vertical-align:top;"> Cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td>

style="color:#000000;min-width:fit-content;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">28,158</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:5pt;vertical-align:top;"> Marketable securities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Certificate of deposit </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 533 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 533 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 51,889 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 51,889 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,494 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,494 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,494 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,990 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,990 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. government agency bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 7,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">164,064</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 80,047 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">84,017</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Financial Assets: </td> <td style="vertical-align:bottom;"> </td> <td

colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td>

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 54,175 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,070 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,070 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. government agency bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 46,090 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 46,090 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">201,228</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 89,524 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">111,704</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>2815800028158000005330000533000051889000518890000065494000065494000010990000010990000070000000700000001640640008004700084017000035349000
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">4. Available-for-Sale Securities The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in the Company's condensed consolidated balance sheets (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-

bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">28,158</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28,158 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Marketable securities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Certificate of deposit </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 533 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 533 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 51,926 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (37 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 51,889 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,572 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (81 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,494 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,994 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (5 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,990 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. government agency bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 7,005 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (5 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 7,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 164,188 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (128 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">164,064</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">118</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total cash, cash equivalent and marketable securities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 164,182 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.56%;"></td> <td style="width:1.12%;"></td> <td style="width:1%;"></td> <td style="width:9.24%;"></td> <td style="width:1%;"></td> <td style="width:1.12%;"></td> <td style="width:1%;"></td> <td style="width:9.24%;"></td> <td style="width:1%;"></td> <td style="width:1.12%;"></td> <td style="width:1%;"></td> <td style="width:9.24%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Cash equivalents; </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-

align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">35,349</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,349 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Marketable securities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Certificate of deposit </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 544 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 544 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 54,066 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 151 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (42 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 54,175 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,038 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 41 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (9 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,070 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. government agency bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 46,115 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (52 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 46,090 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">201,112</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 219 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(103</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 201,228 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 144 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total cash, cash equivalent and marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 201,372 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> </table> <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-

family:Times New Roman;min-width:fit-content;">The Company has not recognized an allowance for credit losses on any securities in an unrealized loss position as of June 30, 2024 and December 31, 2023. The following tables display additional information regarding gross unrealized losses and fair value by major security type for available-for-sale securities in an unrealized loss position as of June 30, 2024 and December 31, 2023 (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:53%;"></td> <td style="width:2%;"></td> <td style="width:1%;"></td> <td style="width:20%;"></td> <td style="width:1%;"></td> <td style="width:2%;"></td> <td style="width:1%;"></td> <td style="width:19%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#fffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Less than 12 consecutive months </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">48,463</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (37 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 47,574 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (81 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,814 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (5 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. government agency bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 7,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">110,851</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (128 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">

<tr style="visibility:collapse;"> <td style="width:53.08%;"></td> <td style="width:2.3%;"></td> <td style="width:1%;"></td> <td style="width:19.16%;"></td> <td style="width:1%;"></td> <td style="width:2.3%;"></td> <td style="width:1%;"></td> <td style="width:19.16%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Less than 12 consecutive months </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16,261</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (42 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 20,789 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (9 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. government agency bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 39,052 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (52 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">76,102</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (103 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table> The Company believes that the individual unrealized losses represent temporary declines primarily resulting from interest rate changes and intends to hold these marketable securities to their maturities. The Company currently does not intend to sell these securities prior to maturity, and it is not more likely than not that the Company will be required to sell these securities before recovery of their amortized cost basis, which may be at maturity. The Company evaluated securities with unrealized losses to determine whether such losses, if any, were due to credit-related factors and determined that there were no credit-related losses to be recognized as of June 30, 2024. There were no sales of available-for-sale securities in any of the periods presented. As of June 30, 2024, the amortized cost and estimated fair value of the Company's available-for-sale securities by contractual maturity are shown below (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Amortized </td> <td style="vertical-align:bottom;text-align:left;"> <span style="white-

space:pre-wrap;min-width:fit-content;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Estimated </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Available-for-sale securities maturing in: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> One year or less </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">164,188</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 164,064 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total available-for-sale securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">164,188</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 164,064 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in the Company's condensed consolidated balance sheets (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.38%;"></td><td style="width:1.22%;"></td><td style="width:1%;"></td><td style="width:9.184000000000001%;"></td><td style="width:1%;"></td><td style="width:1.22%;"></td><td style="width:1%;"></td><td style="width:9.184000000000001%;"></td><td style="width:1%;"></td><td style="width:1.22%;"></td><td style="width:1%;"></td><td style="width:9.184000000000001%;"></td><td style="width:1%;"></td><td style="width:1.22%;"></td><td style="width:1%;"></td><td style="width:9.184000000000001%;"></td><td style="width:1%;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Gains </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair
Value </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"> Cash equivalents: </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;">

wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28,158 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Marketable securities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Certificate of deposit </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 533 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 533 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 51,926 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (37 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 51,889 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,572 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (81 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,494 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;">

</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,994 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (5) </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">164,188</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(128</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 164,064 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 118 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total cash, cash equivalent and marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-

wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 164,182 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.56%;"></td> <td style="width:1.12%;"></td> <td style="width:1%;"></td> <td style="width:9.24%;"></td> <td style="width:1%;"></td> <td style="width:1.12%;"></td> <td style="width:1%;"></td> <td style="width:9.24%;"></td> <td style="width:1%;"></td> <td style="width:1.12%;"></td> <td style="width:1%;"></td> <td style="width:9.24%;"></td> <td style="width:1%;"></td> <td style="width:1.12%;"></td> <td style="width:1%;"></td> <td style="width:9.24%;"></td> <td style="width:1%;"></td> <td style="width:1.12%;"></td> <td style="width:1%;"></td> <td style="width:9.24%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left

top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">544 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 544 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 54,066 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 151 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (42 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 54,175 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,038 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 41 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (9 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,070 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. government agency bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 46,115 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (52 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 46,090 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">201,112</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 219 </td> <td style="white-space:nowrap;vertical-

align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(103</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 201,228 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="color:#000000;white-

space:pre-wrap;min-width:fit-content;">47,574 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (81 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,814 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (5 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. government agency bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 7,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (5 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">110,851</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (128 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:53.08%;"></td> <td style="width:2.3%;"></td> <td style="width:1%;"></td> <td style="width:19.16%;"></td> <td style="width:1%;"></td> <td style="width:2.3%;"></td> <td style="width:1%;"></td> <td style="width:19.16%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Less than 12 consecutive months </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16,261</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (42 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 20,789 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (9 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">U.S. government agency bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 39,052 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (52 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">76,102</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (103 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table> 48463000370004757400081000781400050007000000500011085100012800016261000420002078900090003905200052000761020001030000 As of June 30, 2024, the amortized cost and estimated fair value of the Company's available-for-sale securities by contractual maturity are shown below (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Amortized </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Estimated </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Available-for-sale securities maturing in: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> One year or less </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">164,188</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 164,064 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total available-for-sale securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">164,188</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 164,064 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>16418800016406400016418800016406400 5. Balance Sheet Components Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.353%;"></td> <td style="width:1.5%;"></td> <td style="width:1%;"></td> <td style="width:12.963000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:12.963000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> June 30,
2024 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,
2023 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;">Receivable from Everest, current (Note 10) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,312</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,596 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Advance for clinical-related costs, current </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 773 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,818 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Licenses, dues and subscriptions </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 662 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 506 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Insurance </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 104 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 712 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Interest receivable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 374 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 695 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Others </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 210 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 251 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total prepaid expenses and other current assets </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,435</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,578 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30,
2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> <span style="white-

space:pre-wrap;min-width:fit-content;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,
2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Leasehold improvements </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,488</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,488 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Furniture, laboratory and office equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,559 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,559 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Computer equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 285 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,559 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,332 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,332 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Less: accumulated depreciation and amortization </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (5,941 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (5,420 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,391</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,912 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Depreciation expense was $0.3 million and $0.5 million for each of the three and six months ended June 30, 2024, respectively, compared to $0.2 million and $0.5 million for the three and six months ended June 30, 2023, respectively. Other Assets Other assets consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;border-

bottom:0.5pt solid #0000000;text-align:left;"> June 30,
2024 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,
2023 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Advance for clinical related costs, noncurrent </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,670</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,787 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Unbilled receivable from Everest, noncurrent (Note 10) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,099 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Deposits for operating lease </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 674 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 674 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 79 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 134 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total other assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,522</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,595 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Accrued and Other Current Liabilities Accrued liabilities consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30,
2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,
2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued clinical costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,909</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,801 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued employee-related costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,802 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,708 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued preclinical and research costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,532 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 756 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued professional services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 55 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 110 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Others </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 65 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 106 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total accrued liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,363</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Prepaid expenses and other current assets consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.353%;"></td> <td style="width:1.5%;"></td> <td style="width:1%;"></td> <td style="width:12.963000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:12.963000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> June 30,
2024 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,
2023 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Receivable from Everest, current (Note 10) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,312</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,596 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Advance for clinical-related costs, current </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 773 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:right;">1,818 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Licenses, dues and subscriptions </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 662 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 506 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Insurance </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 104 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 712 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Interest receivable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 374 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 695 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Others </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 210 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 251 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total prepaid expenses and other current assets </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,435</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,578 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>1312000159600077300018180006620005060001040007120003740006950002100002510003435000055780000 Property and equipment, net consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30,
2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,
2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Leasehold improvements </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,488</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,488 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Furniture, laboratory and office equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,559 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,559 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Computer equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 285 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 285 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,332 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,332 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Less: accumulated depreciation and amortization </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (5,941) </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (5,420 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,391</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,912 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Depreciation expense was $0.3 million and $0.5 million for each of the three and six months ended June 30, 2024, respectively, compared to $0.2 million and $0.5 million for the three and six months ended June 30, 2023, respectively.</p>348800034880000555900055590002850002850009332000933200059410005420000339100039120003000005000002000005000000<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:9pt;text-align:left;">Other assets consisted of the following (in thousands): </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30,
2024</p></td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31,
2023</p></td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Advance for clinical related costs, noncurrent</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,670 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,787 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Unbilled receivable from Everest, noncurrent (Note 10) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,099 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Deposits for operating lease </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 674 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 674 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 79 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 134 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total other assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,522</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,595 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 467000047870001099000067400067400079000134000652200059500 Accrued liabilities consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30,
2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,
2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued clinical costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,909</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,801 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued employee-related costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,802 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,708 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued preclinical and research costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,532 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 756 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued professional services </td> <td style="white-space:pre-wrap;vertical-align:bottom;">

  </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 55 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 110 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Others </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 65 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 106 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total accrued liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,363</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,481 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>590900018010001802000370800015320007560005500011000650001060009363000064810000 6. Lease In November 2022, the Company entered into an amendment to the lease agreement for its corporate headquarters in South San Francisco, California, which expanded the leased premises in the same building as its corporate headquarters and extended the lease term of the original premises to be coterminous with the expansion premises to July 31, 2026. The transaction was treated as a lease modification as of the effective date and resulted in the recognition of approximately $8.0 million in new lease liabilities and ROU assets. In December 2023, the Company committed to a plan to sublease Suite 400 of its corporate headquarters in connection with a workforce reduction (see Note 14) and evaluated the recoverability of ROU asset by comparing the carrying amount of the asset to future net undiscounted cash flows associated with the asset. The ROU asset is considered to be impaired if the carrying amount of the assets exceeds the fair value of the assets. Consequently, the Company recognized a $2.7 million impairment charge in 2023. In June 2024, the Company recognized an additional $1.5 million impairment charge in relation to Suite 400 to write off the net book value of the ROU asset as of June 30, 2024 as the estimated future cash flow from sublease income is zero due to current market conditions.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:9pt;text-align:left;">Information related to the Company's lease liabilities were as follows (in thousands):</p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three months ended
June 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Six months ended
June 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:1pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash paid for operating lease liabilities</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 741 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,452 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Operating lease costs </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 655 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,322 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Variable lease costs </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="color:#000000;white-

space:pre-wrap;min-width:fit-content;">467 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 916 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Maturities of lease liabilities as of June 30, 2024 were as follows: </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Less than 12 months </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,957</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">13 - 24 months</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,095</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">25 - 36 months</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">347</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total undiscounted lease payments</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,399</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: imputed interest</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(987</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total lease liabilities</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7,412 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;">

</td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Operating lease liabilities, current </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,260</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating lease liabilities, noncurrent</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,152</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total operating lease liabilities</p></td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7,412 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> July 31, 2026000000027000001500000000 Information related to the Company's lease liabilities were as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Three months ended
June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Six months ended
June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash paid for operating lease liabilities </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">741</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,452 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Operating lease costs </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 655 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,322 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Variable lease costs </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 467 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 916 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Maturities of lease liabilities as of June 30, 2024 were as follows: </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td></tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Less than 12 months </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,957</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">13 - 24 months</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,095</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">25 - 36 months</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">347</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total undiscounted lease payments</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,399</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: imputed interest</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(987</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total lease liabilities</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7,412 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Operating lease liabilities, current </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,260 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Operating lease liabilities, noncurrent </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,152 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt

solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total operating lease liabilities </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td colspan="2" style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7,412 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>7410001452000655000132200046700091600039570004095000347000839900098700074120003260000415200074120002p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:left;">7. Debt In November 2021, the Company entered into a loan agreement (the “Loan Agreement”) with Oxford Finance, LLC (“Oxford Finance”), which provided the Company up to $50.0 million in borrowing capacity across five potential tranches (each a “Term Loan,” and collectively “Term Loans”). The initial tranche of $10.0 million was funded at the closing of the Loan Agreement. The remaining tranches were dependent on achieving certain clinical trial milestones, and the Company declined these remaining tranches in borrowing capacity available to it under the Loan Agreement. The loan facility is secured by all assets except intellectual property, which is subject to a negative pledge, and will mature on November 1, 2026 (the “Maturity Date”). There are no warrants or financial covenants associated with the Loan Agreement. Until June 30, 2023, the Term Loans bore interest at a floating per annum rate (based on the actual number of days elapsed divided by a year of 360 days) equal to the sum of (a) the greater of (i) 30-day U.S. LIBOR rate reported in the Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue and (ii) 0.08%, plus (b) 7.87%. A LIBOR transition event occurred effective July 1, 2023 and Oxford Finance subsequently replaced the LIBOR rate with the 1-month CME term SOFR plus 0.1%. The rate change did not require contract remeasurement at the effective date of the change or a reassessment of any previous accounting determinations pertaining to the facility. The rate change did not have a material impact on the Company’s financial statements. The Company is required to make monthly interest-only payments prior to the amortization date of January 1, 2025, subject to a potential one-year extension upon satisfaction of certain conditions. All unpaid principal and accrued and unpaid interest with respect to each Term Loan is due and payable in full on the Maturity Date. The Company has the option to prepay the outstanding balance prior to maturity, subject to a prepayment fee of 1.0% to 2.0% depending upon when the prepayment occurs. Upon repayment of the Term Loans, the Company is required to make a final payment fee to the lenders equal to 6.5% of the original principal amount of the Term Loans funded which will be accrued by charges to interest expense over the term of the loans using the effective interest method. The Loan Agreement also includes subjective acceleration clauses that permit the lenders to accelerate the Maturity Date under certain circumstances, including, but not limited to, material adverse effects on a Company’s financial status or otherwise. As of June 30, 2024, the Company is in compliance with all covenants in the Loan Agreement. Interest expense was $0.4 million and $0.8 million for the three and six months ended June 30, 2024, respectively, compared to $0.4 million and $0.8 million for the three and six months ended June 30, 2023, respectively. The initial effective interest rate on the Term Loans, including the amortization of the debt discount and issuance costs, and accretion of the final payment, was 11%. The components of the long-term debt balance are as follows:</p><div style="font-size:10pt;font-family:Times New Roman;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30,
2024</p></td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31,
2023</p></td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Principal loan balance</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Unamortized debt discount and issuance costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td

style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (189 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (243 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cumulative accretion of final fee </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 387 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 312 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,198</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,069 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Debt, current </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,609</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Debt, noncurrent </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 7,589 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 10,069 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Debt, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,198</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,069 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> As of June 30, 2024, the estimated future principal payments due were as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Years Ending December 31, </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">

2025 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,217 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2026 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,783 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div>5000000051000000020026-11-010.00080.07870.001monthly interest-only paymentsP1Y0.010.020.065400000800000400000080000000.11The components of the long-term debt balance are as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30,
2024</p></td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31,
2023</p></td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Principal loan balance</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Unamortized debt discount and issuance costs</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(189</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">243</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cumulative accretion of final fee</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">387</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">312</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,198 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,069 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Debt, current </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span

style="color:#000000;min-width:fit-content;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,609</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Debt, noncurrent </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 7,589 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 10,069 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Debt, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,198</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,069 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>10000000100000001890002430003870003120001019800010069000260900007589000100690001019800010069000 As of June 30, 2024, the estimated future principal payments due were as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Years Ending December 31, </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2025</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,217</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2026</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,783</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>05217000478300010000000 8. Pre-Funded Warrants In connection with the Company's previous underwritten public offerings, the Company issued pre-funded warrants to purchase an aggregate of 3,793,706 shares of the Company's common stock. Each pre-funded warrant entitled the holder to purchase shares of common stock at an exercise price of $0.001 per share and expired 20 years from the date of issuance. These warrants were recorded as a component of stockholders' equity within additional paid-in capital. The warrant holders exercised all the shares of outstanding pre-funded warrants in 2023 at an exercise price of $0.001 per share. As of June 30, 2024, there were no pre-funded warrants outstanding. 37937060.001P20Y0.0010 9. Stock-Based Compensation Stock Incentive Plans 2022 Inducement Plan In April 2022, the Company adopted the Kezar Life Sciences, Inc. 2022 Inducement Plan (the "Inducement Plan"), which is a non-stockholder approved stock plan adopted pursuant to the "inducement exception" provided under Nasdaq Listing Rule 5635(c)(4), for the award of nonstatutory stock options ("NSOs"), restricted stock units ("RSUs") and other equity awards as permitted by the Inducement Plan (collectively, "Inducement Awards") to persons not previously an employee or director of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company ("Eligible Recipients"). Under the Inducement Plan, the Company may grant up to 3,000,000 shares of Common Stock in<span

style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the form of Inducement Awards to Eligible Recipients in compliance with the requirements of Nasdaq Listing Rule 5635(c)(4). Awards must be approved by either a majority of the Company's independent directors or the Company's independent compensation committee. Consultants and directors are not eligible to received grants under the Inducement Plan. As of June 30, 2024, options to purchase 1,247,708 shares of common stock were outstanding and 1,752,292 shares were available for future issuance under the Inducement Plan. 2018 Equity Incentive Plan In June 2018, the Company's board of directors adopted and the stockholders approved the 2018 Equity Incentive Plan (the "2018 Plan"), which became effective as of June 20, 2018, at which point no further grants could be made under the 2015 Equity Incentive Plan (the "2015 Plan") described below. Under the 2018 Plan, the Company may grant incentive stock options ("ISOs"), NSOs, stock appreciation rights, restricted stock awards, RSUs and other stock-based awards. As of June 30, 2024, options to purchase 12,645,480 shares of common stock and 185,416 RSUs were outstanding, and 2,843,990 shares were available for future issuance under the 2018 Plan. Initially, subject to adjustment as provided in the 2018 Plan, the aggregate number of shares of the Company's common stock authorized for issuance pursuant to stock awards under the 2018 Plan was 4,000,000 shares, which is the sum of (i) 1,600,692 shares plus (ii) the number of shares reserved and available for issuance under the 2015 Plan at the time the 2018 Plan became effective and (iii) the number of shares subject to stock options or other stock awards granted under the 2015 Plan that expire, terminate are forfeited or otherwise not issued, or are withheld to satisfy a tax withholding obligation in connection with an award or to satisfy a purchase or exercise price of an award (such as upon the expiration or termination of a stock award prior to vesting). The number of shares of the Company's common stock reserved for issuance under the 2018 Plan automatically increases on January 1 of each year, beginning on January 1, 2019 and continuing through and including January 1, 2028, by 5% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the Company's board of directors prior to such increase. The maximum number of shares that may be issued upon the exercise of ISOs under the 2018 Plan is 12,500,000 shares. 2015 Equity Incentive Plan The 2015 Plan provided for the granting of ISOs and NSOs to employees, directors and consultants at the discretion of the Company's board of directors. The 2015 Plan was terminated as to future awards in June 2018, although it continues to govern the terms of options that remain outstanding under the 2015 Plan. No additional stock awards will be granted under the 2015 Plan, and all outstanding stock awards granted under the 2015 Plan that are repurchased, forfeited, expire or are cancelled will become available for grant under the 2018 Plan in accordance with its terms. Options granted under the 2015 Plan expire no later than 10 years from the date of grant. Options granted under the 2015 Plan vest over periods determined by the Company's board of directors, generally over four years. The 2015 Plan allows for early exercise of certain options prior to vesting. Upon termination of employment, the unvested shares are subject to repurchase at the original exercise price. As of June 30, 2024, options to purchase 1,363,394 shares of common stock were outstanding under the 2015 Plan. 2018 Employee Stock Purchase Plan In June 2018, the Company's board of directors adopted and the stockholders approved the 2018 Employee Stock Purchase Plan (the "ESPP"), which became effective as of June 20, 2018. The ESPP is intended to qualify as an "employee stock purchase plan" within the meaning of Section 423 of the U.S. Internal Revenue Code of 1986, as amended. The number of shares of common stock initially reserved for issuance under the ESPP was 200,000 shares. The ESPP provides for an annual increase on January 1 of each year, beginning on January 1, 2019 and continuing through and including January 1, 2028, equal to the lesser of (i) 1% of the shares of common stock outstanding on the last day of the prior fiscal year or (ii) 375,000 shares, or a lesser number of shares determined by the Company's board of directors prior to such increase. In December 2023, the Company's board of directors acted such that there was no increase of the number of shares of common stock reserved for issuance under the ESPP as of January 1, 2024. As of June 30, 2024, 676,129 shares of common stock had been issued under the ESPP and 657,095 shares remained available for future issuance under the ESPP. The price per share of common stock to be paid by an ESPP participant on the applicable purchase date of an offering period shall be equal to 85% of the lesser of the fair market value of a share of common stock on (i) the applicable offering date or (ii) the applicable purchase date. The Company's board of directors authorized an initial six-month offering period beginning on November 16, 2018 and ending on May 15, 2019. The Company's board of directors has subsequently authorized additional six-month offering periods, with the most recent offering period beginning on May 16, 2024. Option Repricing In July 2023, the Compensation Committee of the Company's board of directors approved a stock option repricing (the "Option Repricing") in which the exercise price of certain outstanding options to purchase shares of the Company's common stock under the 2018 Plan was reduced to $2.28 per share, the closing price of the Common Stock on July 24, 2023. Outstanding options that were granted under the 2015 Plan and the Inducement Plan were not included in the Option Repricing. The Option Repricing included options granted pursuant to the 2018 Plan that were held by, among others, members of the Company's board of the directors (other than options granted in June 2023) and the Company's named executive officers and principal financial officer. As a result of the Option Repricing, 9,904,755 shares of vested and unvested stock options outstanding as of July 24, 2023, with original exercise prices ranging from $2.44 to $<span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-

content;">22.85 per share, were repriced to $2.28 per share. The total incremental fair value to be recognized as a result of the repricing was approximately $4.7 million on the date of Option Repricing, of which $3.0 million related to the vested option shares had been recognized as stock-based compensation expense and $0.6 million related to the unvested option shares subsequently cancelled due to termination as of June 30, 2024. As of June 30, 2024, there was $1.1 million remaining related to the unvested option shares which will be amortized over the remaining requisite service periods through the end of 2026. </p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Stock Option Activity</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table summarizes activity under the Company's stock option plans and related information (in thousands, except share and per share amounts):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9.662%;"></td><td style="width:1%;"></td><td style="width:1.22%;"></td><td style="width:1%;"></td><td style="width:8.942%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9.662%;"></td><td style="width:1%;"></td><td style="width:1.22%;"></td><td style="width:1%;"></td><td style="width:9.182%;"></td><td style="width:1%;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Number of
Options
Outstanding</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Weighted
Average
Exercise Price</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Weighted
Average
Remaining
Contractual
Term (Years)</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Outstanding as of December 31, 2023</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">13,110,717</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.60 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.1 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">118</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Options granted</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,541,000</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.90 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Options cancelled/forfeited </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,395,135 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.84 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:right;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding as of June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 15,256,582 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2.18</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.2</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Vested and exercisable as of June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,334,868 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2.58</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.7</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> The weighted average grant date fair value of options granted during the three and six months ended June 30, 2024 was $0.54 and $0.67 per share, respectively. There were no options exercised during the six months ended June 30, 2024. The aggregate intrinsic value is calculated as the difference between the exercise price and the estimated fair value of the Company's common stock at the date of exercise.</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:left;">Restricted Stock Units Activity</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:left;">There were no RSUs granted during the six months ended June 30, 2024. One-third of each RSU granted vests annually following the vesting commencement dates, over a vesting period of three years. RSUs are awards that entitle the holder to receive freely tradable shares of the Company's common stock upon vesting and are not forfeitable once fully vested. The valuations for these RSUs were based on the closing prices of the Company's common stock on the grant dates and recognized as stock-based compensation expenses over the respective vesting terms. </p><div style="font-size:12pt;font-family:Times New Roman;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.98%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.36%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.88%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Number of RSUs Outstanding</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Weighted Average Grant-Date Fair Price</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Outstanding as of December 31, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">219,609</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9.20 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> RSUs vested </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (<span style="color:#000000;white-

space:pre-wrap;min-width:fit-content;">22,282 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9.63</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">RSUs forfeited</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(11,911</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9.26 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding as of June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 185,416 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9.14 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table>
Stock-Based Compensation Expense Total stock-based compensation expense recognized by function was as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48.539%;"></td> <td style="width:1.261%;"></td> <td style="width:1%;"></td> <td style="width:9.604000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.261%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.604000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.261%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.604000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.261%;"></td> <td style="width:1%;"></td> <td style="width:9.604000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">915</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,013 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,971</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,281 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,170 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid

#ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,007 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,548 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,002 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total stock-based compensation expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,085</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,020 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,519</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,283 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> As of June 30, 2024, the unrecognized stock-based compensation cost related to outstanding unvested stock options and RSUs that are expected to vest was $20.0 million with an estimated weighted average amortization period of 2.7 years. The fair value of the stock options granted is calculated using the Black-Scholes option-pricing model with the following range of assumptions: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.121%;"></td> <td style="width:1.22%;"></td> <td style="width:11.275%;"></td> <td style="width:1.639%;"></td> <td style="width:11.275%;"></td> <td style="width:1.639%;"></td> <td style="width:11.275%;"></td> <td style="width:1.639%;"></td> <td style="width:11.275%;"></td> <td style="width:1.639%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Expected term (years) </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> 5.5 - 6.1 </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> 5.5 - 6.1 </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> 5.5 - 6.1 </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Expected volatility </td> <td style="vertical-align:bottom;"> <span style="white-space:pre-

wrap;min-width:fit-content;"> </td> <td style="vertical-align:bottom;text-align:center;"> 86.8 - 87.7 </td> <td style="vertical-align:bottom;"> % </td> <td style="vertical-align:bottom;text-align:center;"> 88.0 - 88.3 </td> <td style="vertical-align:bottom;"> % </td> <td style="vertical-align:bottom;text-align:center;"> 86.8 - 87.9 </td> <td style="vertical-align:bottom;"> % </td> <td style="vertical-align:bottom;text-align:center;"> 87.8 - 88.3 </td> <td style="vertical-align:bottom;"> % </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Risk-free interest rate </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> 4.3 - 4.6 </td> <td style="vertical-align:bottom;"> % </td> <td style="vertical-align:bottom;text-align:center;"> 3.5 - 3.9 </td> <td style="vertical-align:bottom;"> % </td> <td style="vertical-align:bottom;text-align:center;"> 4.0 - 4.6 </td> <td style="vertical-align:bottom;"> % </td> <td style="vertical-align:bottom;text-align:center;"> 3.5 - 4.3 </td> <td style="vertical-align:bottom;"> % </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Expected dividend yield </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> — </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> — </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> — </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> — </td> <td style="vertical-align:bottom;"> </td> </tr> </table> The expected term of options granted represents the period of time that options granted are expected to be outstanding and was determined by calculating the midpoint between the date of vesting and the contractual life of each option. The expected term of the ESPP rights is equal to the six-month look-back period. Since inception until March 2024, the volatility of the Company's stock price was based on the weighted average of the historical volatility of the Company's stock price and that of a peer group of public companies over the expected term due to the Company's limited public trading history of its common stock. The peer group was selected on the basis of operational and economic similarity with the Company's principal business operations. Effective as of the quarter-ended June 30, 2024, the expected volatility is based on the daily historical volatility of the Company's common stock covering the estimated expected term. The risk-free interest rate for the expected term of the options is based on the U.S. Treasury yield curve with a maturity equal to the expected term in effect at the time of grant. The Company has not paid, and does not anticipate paying, cash dividends on its shares of common stock; therefore, the expected dividend yield is zero.
3000000124770817522921264548018541628439904000001600692--01-01beginning on January 1, 2019 and continuing through and including January 1, 20280.0512500000P10YP4Y13633942000000.013750000676129657095 0.852018-11-162019-05-152024-05-162.2899047552.4422.852.2847000003000000600000110000 0 The following table summarizes activity under the Company's stock option plans and related information (in thousands, except share and per share amounts): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.11%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.662%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:8.942%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.662%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of
Options
Outstanding </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Exercise Price </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Remaining
Contractual
Term (Years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Aggregate
Intrinsic Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding as of December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,110,717 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.60 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.1 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">118</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Options granted</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,541,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.90 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Options cancelled/forfeited </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,395,135 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2.84</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Outstanding as of June 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">15,256,582</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.18 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.2 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Vested and exercisable as of June 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,334,868</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.58 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr>
</table><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.98%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.36%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.88%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;">

 </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of RSUs Outstanding </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted Average Grant-Date Fair Price </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding as of December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 219,609 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9.20</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">RSUs vested</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(22,282</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9.63 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> RSUs forfeited </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (11,911 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9.26</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Outstanding as of June 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">185,416</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9.14 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> 2196099.2222829.63119119.261854169.14 Total stock-based compensation expense recognized by function was as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48.539%;"></td> <td style="width:1.261%;"></td> <td style="width:1%;"></td> <td style="width:9.604000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.261%;"></td> <td style="width:1%;"></td> <td style="width:9.604000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.261%;"></td> <td style="width:1%;"></td> <td style="width:9.604000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.261%;"></td> <td style="width:1%;"></td> <td style="width:9.604000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-

align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">915</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,013 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,971</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,281 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,170 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,007 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,548 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,002 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total stock-based compensation expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,085</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,020 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,519</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,283 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>9150002013000197100042810002170000200700045480004002000308500040200006519000828300020000000P2Y8M12D The fair value of the stock options granted is calculated using the Black-Scholes option-pricing model with the following range of assumptions: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.121%;"></td> <td style="width:1.22%;"></td> <td style="width:11.275%;"></td> <td style="width:1.639%;"></td> <td style="width:11.275%;"></td> <td style="width:1.639%;"></td> <td style="width:11.275%;"></td> <td style="width:1.639%;"></td> <td style="width:11.275%;"></td> <td style="width:1.639%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> <span

style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (years) </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> 5.5 - 6.1 </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> 5.5 - 6.1 </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> 5.5 - 6.1 </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Expected volatility </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> 86.8 - 87.7 </td> <td style="vertical-align:bottom;"> % </td> <td style="vertical-align:bottom;text-align:center;"> 88.0 - 88.3 </td> <td style="vertical-align:bottom;"> % </td> <td style="vertical-align:bottom;text-align:center;"> 86.8 - 87.9 </td> <td style="vertical-align:bottom;"> % </td> <td style="vertical-align:bottom;text-align:center;"> 87.8 - 88.3 </td> <td style="vertical-align:bottom;"> % </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Risk-free interest rate </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> 4.3 - 4.6 </td> <td style="vertical-align:bottom;"> % </td> <td style="vertical-align:bottom;text-align:center;"> 3.5 - 3.9 </td> <td style="vertical-align:bottom;"> % </td> <td style="vertical-align:bottom;text-align:center;"> 4.0 - 4.6 </td> <td style="vertical-align:bottom;"> % </td> <td style="vertical-align:bottom;text-align:center;"> 3.5 - 4.3 </td> <td style="vertical-align:bottom;"> % </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Expected dividend yield </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> — </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> — </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> — </td> <td style="vertical-align:bottom;"> </td> </tr>
</table>P5Y6MP6Y1M6DP5Y6MP6Y1M6DP5Y6MP6Y1M6DP5Y6MP6Y1M6D0.8680.8770.880.8830.8680.8790.8780.8830.0430.0460.0350.0390.040.0460.0350.0430000P6M00<
style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">10. Everest Collaboration In September 2023, the Company entered into a Collaboration and License Agreement (the “Everest License Agreement”) with Everest pursuant to which, among other things, the Company granted to Everest an exclusive license to develop and commercialize one or more products containing the Company’s proprietary compound, zetomipzomib (the “Products”), in the licensed field in the Greater China region (Mainland China, Taiwan, Hong Kong and Macau), South Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam and the Philippines (the “Territory”). The licensed field includes all uses other than the diagnosis or treatment in humans of cancerous or pre-cancerous diseases or conditions. During the PALIZADE trial, Everest will contribute their local regulatory and clinical trial expertise and will be responsible for study costs in the Territory. Everest Medicines Limited is also a party to the Everest License Agreement solely for limited purposes, including to guarantee the performance by Everest of its obligations under the Everest License Agreement. Under the terms of the Everest License Agreement, the Company received a one-time, irrecoverable, non-refundable and non-creditable upfront payment of $7.0 million in October 2023 and is entitled to receive certain variable payments for manufacturing supply services and milestone payments upon achievement of certain development, regulatory and commercial milestone events, for total potential milestone payments of up to $125.5 million. In addition, Everest will pay to the Company tiered royalties on the net sales of the Products in the Territory during the term of the Everest License Agreement ranging from the single digit to the low-teens, subject to certain reductions for patent expiration, generic competition and payments for licenses to third-party patents. The term of the Everest License Agreement will continue on a market-by-market basis until expiration of the relevant royalty term of the Products, unless terminated earlier. Everest has the right to terminate the Everest License Agreement for convenience following completion, suspension or termination of the PALIZADE clinical trial. The Company may terminate the Everest License Agreement if Everest challenges the Company’s patents or fails to perform any development or commercialization activities for a continuous period of more than twelve (12) months, subject to certain exceptions. In addition, either party may terminate the Everest License Agreement for the other party’s uncured breach or insolvency, and the Everest License Agreement will automatically terminate in the event of termination of the Company’s exclusive license agreement with Onyx Therapeutics, Inc. Under the terms of the Everest License Agreement, at the election of Everest, the Company may manufacture and provide clinical supply to Everest to use in development and commercialization in the Territory at the fully burdened manufacturing cost plus specified margins, as defined within the Everest License Agreement. Certain of these provisions were determined to be options to acquire additional goods or services at a price that approximates the stand-alone selling price for that good or service and therefore do not represent material rights, or separate performance obligations, within the context of the Everest License Agreement. The Company evaluated the Everest License Agreement and determined it was within the scope of ASC 606. The transaction price was determined to consist of the upfront payment of $7.0 million. License of Intellectual Property:

The license to the Company's intellectual property and associated know-how represents a distinct performance obligation. The license and associated know-how was transferred to Everest in the third quarter of 2023 to satisfy this performance obligation. The Company allocated the full transaction price to the license of the Company's intellectual property and accordingly recognized collaboration revenue of $7.0 million in 2023. Milestone Payments. The potential development, regulatory and commercial milestone payments are paid upon achievement of certain milestones as defined in the Everest License Agreement. It was determined that their achievement is highly dependent on factors outside of the Company's control. These payments have been fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods and, as such, have been excluded from the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint and, if necessary, adjust its estimate of the overall transaction price. As of June 30, 2024, the Company has not recognized any revenue associated with development, regulatory and commercial milestones. Royalties. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Everest and, therefore, have also been excluded from the transaction price. No royalty revenue was recognized as of June 30, 2024. In July 2024, the Company amended the Everest License Agreement to modify a development milestone and adjust certain payment terms relating to Everest's responsibility for PALIZADE study costs in the Territory. As of June 30, 2024, the Company had a receivable of $1.3 million, representing the billed amounts related to Everest's share of the Territory-specific direct costs and pro rata portion of indirect costs incurred to conduct PALIZADE study under the Everest License Agreement, and a noncurrent unbilled receivable of $1.1 million representing reimbursement for payment is yet to be billed or due. The receivable amount was included in prepaid expenses and other current assets and the unbilled receivable was included in other assets in the Company's Condensed Consolidated Balance Sheet. In connection with the cost-sharing arrangement with Everest, <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$1.6 million and $2.4 million was recognized as contra research and development expense for each of the three and six months ended June 30, 2024, respectively. In September 2023, the Company entered into a Collaboration and License Agreement (the "Everest License Agreement") with Everest pursuant to which, among other things, the Company granted to Everest an exclusive license to develop and commercialize one or more products containing the Company's proprietary compound, zetomipzomib (the "Products"), in the licensed field in the Greater China region (Mainland China, Taiwan, Hong Kong and Macau), South Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam and the Philippines (the "Territory").70000001255000007000000700000000130000011000001600000024000000 11. Income Taxes No provision for income taxes was recorded for the three and six months ended June 30, 2024 and 2023, respectively. Deferred tax assets generated from the Company's net operating losses have been fully reserved, as the Company believes it is not more likely than not that the benefit will be realized. Effective January 1, 2022, under the Tax Cuts and Jobs Act, for tax purposes the Company is required to capitalize and subsequently amortize all R&D expenditures over five years for research activities conducted in the U.S. and over fifteen years for research activities conducted outside of the U.S. Given the significant loss and credit carryforwards in the U.S., the Company does not anticipate having a change in valuation allowance assertion. In March 2020, the Coronavirus Aid, Relief and Economic Security ("CARES") Act was signed into law. The CARES Act included several tax changes as part of its economic package. These changes principally related to expanded net operating loss carryback periods, increases to interest deductibility limitations, and accelerated alternative minimum tax refunds. The CARES Act enacted the Employee Retention Credit ("ERC") to incentivize companies to retain employees, which was subsequently modified by extension of the CARES Act. Under the provisions of the CARES Act and its subsequent extension, the Company was eligible for ERCs, subject to certain criteria. During the six months ended June 30, 2023, the Company received refunds of approximately $1.4 million related to ERCs that offset the related payroll expenses in the respective operating costs and expenses line item in the condensed consolidated statements of operations. During the six months ended June 30, 2024, no refund related to ERCs was received by the Company. 0000P5YP15Y14000000 12. Net Loss Per Share Net Loss Per Share The following table sets forth the calculation of basic and diluted net loss per share during the periods presented (in thousands, except share and per share data):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.38%;"></td><td style="width:1.22%;"></td><td style="width:1%;"></td><td style="width:9.184000000000001%;"></td><td style="width:1%;"></td><td style="width:1.22%;"></td><td style="width:1%;"></td><td style="width:9.184000000000001%;"></td><td style="width:1%;"></td><td style="width:1.22%;"></td><td style="width:1%;"></td><td style="width:9.184000000000001%;"></td><td style="width:1%;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Numerator: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net loss </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(21,547</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (24,308 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(43,205</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (46,507 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Denominator: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted-average shares of common stock outstanding </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 72,845,869 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 72,461,850 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 72,822,890 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 72,395,410 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net loss per share, basic and diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(0.30</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (0.34 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(0.59</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (0.64 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr></table> Basic net loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock and pre-funded warrants outstanding during the period, without consideration of common share equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock, pre-funded warrants and common share equivalents outstanding for the period. The pre-funded warrants were included in the computation of basic and diluted net loss per common share as the exercise price was negligible and the pre-funded warrants were fully vested and exercisable. Common share equivalents are only included in the calculation of diluted net loss per common share when their effect is dilutive. Potential dilutive securities, which include, vested and unvested options to purchase common stock and RSUs subject to future vesting have been excluded from the computation of diluted net loss per share as the effect is antidilutive. Therefore, the denominator used to calculate both basic and diluted net loss per common share is the same in all periods presented. The following outstanding shares of common stock equivalents were excluded from the computation of the diluted net loss per share for the periods presented because their effect would have been anti-dilutive: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.967%;"></td><td style="width:1.16%;"></td><td style="width:1%;"></td><td style="width:13.357%;"></td><td style="width:1%;"></td><td style="width:1.16%;"></td><td style="width:1%;"></td><td style="width:13.357%;"></td><td style="width:1%;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three and Six Months Ended
June 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Stock options to purchase common stock </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,256,582 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,962,005 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units subject to future vesting </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 185,416 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 433,611 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 15,441,998 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 13,395,616 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td></tr></table> The following table sets forth the calculation of basic and diluted net loss per share during the periods presented (in thousands, except share and per share data): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.38%;"></td><td style="width:1.22%;"></td><td style="width:1%;"></td><td style="width:9.184000000000001%;"></td><td style="width:1%;"></td><td style="width:1.22%;"></td><td style="width:1%;"></td><td style="width:9.184000000000001%;"></td><td style="width:1%;"></td><td style="width:1.22%;"></td><td style="width:1%;"></td><td style="width:9.184000000000001%;"></td><td style="width:1%;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">

Six Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Numerator: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net loss </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(21,547</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (24,308 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(43,205</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (46,507 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Denominator: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted-average shares of common stock outstanding </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 72,845,869 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 72,461,850 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 72,822,890 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 72,395,410 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net loss per share, basic and diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(0.30</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (0.34 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(0.59</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (0.64 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table>-21547000-24308000-43205000-46507000728458697246185072822890972395410-0.3-0.3-0.34-0.34-0.59-0.59-0.64-0.64 The following outstanding shares of common stock equivalents were excluded from the computation of the diluted net loss per share for the periods presented because their effect would have been anti-dilutive: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.967%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.357%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.357%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three and Six Months Ended
June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Stock options to purchase common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> 15,256,582 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,962,005 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units subject to future vesting </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 185,416 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 433,611 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 15,441,998 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 13,395,616 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>1525658215256582129620051296200518541618541643361143361115441998154419981339561613395616 13. Related Party Transactions In connection with the resignation of John Fowler from his role as Chief Executive Officer, the Company and Mr. Fowler entered into a Separation and Consulting Agreement, effective as of November 7, 2023 (the “Fowler Agreement”), pursuant to which Mr. Fowler provides consulting services to the Company at a

rate of $5,000 per month for one year ending November 7, 2024. Pursuant to the Fowler Agreement, the Company recognized $15,000 and $30,000 of compensation expense within general and administrative expenses in the Condensed Consolidated Statement of Operations during the three and six months ended June 30, 2024, respectively.2023-11-07500015000300000000 14. 2023 Restructuring and Impairment Charges In October 2023, the Company announced a strategic restructuring and workforce reduction to prioritize its clinical-stage assets, extend its cash runway and reduce its total workforce. All employees affected by the workforce reduction separated from the company by December 31, 2023. In connection with the workforce reduction, the Company committed to a plan to sublease Suite 400 of its corporate headquarters which resulted in an impairment to the ROU asset and certain property and equipment no longer utilized under current or expected future operations. The Company recognized cumulative restructuring charges of $6.2 million, comprised primarily of one-time employee termination benefits and long-lived assets impairment costs during the year ended December 31, 2023. The Company recognized an additional $1.5 million impairment charge in relation to Suite 400 to write off the net book value of the ROU asset as of June 30, 2024. The unpaid severance and related benefit costs included in accrued liabilities in the Condensed Consolidated Balance Sheets were $0.2 million and $1.4 million as of June 30, 2024 and December 31, 2023, respectively. The Company expects that substantially all of the remaining accrued restructuring liabilities will be paid in cash over next four months.</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table illustrates the accrual activities and payments relating to restructuring and impairment charges (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:46.889%;"></td><td style="width:1.74%;"></td><td style="width:1%;"></td><td style="width:13.963000000000001%;"></td><td style="width:1%;"></td><td style="width:1.74%;"></td><td style="width:1%;"></td><td style="width:13.963000000000001%;"></td><td style="width:1%;"></td><td style="width:1.74%;"></td><td style="width:1%;"></td><td style="width:13.963000000000001%;"></td><td style="width:1%;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Severance and related benefit costs</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Asset impairments</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance as of January 1, 2023</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Restructuring charges </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,279 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,908 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,187 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Cash payments made </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,858 </td><td style="white-space:nowrap;vertical-align:bottom;">) </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,858 </td><td style="white-space:nowrap;vertical-align:bottom;">) </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Non-cash charges </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,908 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance as of December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,421</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,421</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash payments made</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(775</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 646 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 646 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restructuring charges </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (67 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,549 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,482 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash payments made </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (344 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="min-width:fit-

content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (344 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Non-cash charges </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,549 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,549 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance as of June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">235</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">235</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div>62000001500000200000140000<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table illustrates the accrual activities and payments relating to restructuring and impairment charges (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:46.889%;"></td><td style="width:1.74%;"></td><td style="width:1%;"></td><td style="width:13.963000000000001%;"></td><td style="width:1%;"></td><td style="width:1.74%;"></td><td style="width:1%;"></td><td style="width:13.963000000000001%;"></td><td style="width:1%;"></td><td style="width:1.74%;"></td><td style="width:1%;"></td><td style="width:13.963000000000001%;"></td><td style="width:1%;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Severance and related benefit costs</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Asset impairments</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance as of January 1, 2023</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Restructuring charges </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,279 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,908 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,187 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> <span

style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash payments made </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,858 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,858 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Non-cash charges </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,908 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,908 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance as of December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,421</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,421 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash payments made </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (775 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (775 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance as of March 31, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">646</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 646 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restructuring charges </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (67 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="min-width:fit-

content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,549 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,482 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash payments made </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (344 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (344 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Non-cash charges </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,549 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,549 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance as of June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">235</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 235 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table>0003279000290800061870001858000018580000290800029080001421000014210007750000775000646000006460000-6700015490001482000344000034400001549000154900023500002350005falsefalsefalsefalsefalsefalse